USPatent applicationPatented

Substituted dihydropyrrolopyrazole compound

Granted 6 Apr 2021 · 3 office actions

Life of the application

13 dated events
⤢ drag to zoom20182020202220242026202820302032203420362038ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: [structure] wherein L 1 is an optionally substituted C 1-6 alkylene group or the like, L 2 is a single bond or the like, L 3 is a single bond or the like, R 1 , R 2 , and R 3 are each independently an optionally substituted C 1-4 alkyl group or the like, R 4 is a hydrogen atom or the like, and R 5 is a hydrogen atom or the like.

Description

153 parts
›This application is a divisional of application Ser…

This application is a divisional of application Ser. No. 15/522,592 filed Apr. 27, 2017, which is a National Stage Application of PCT/JP2015/080727 filed Oct. 30, 2015 and claims the benefit of Japanese Application No. 2014-223221 filed Oct. 31, 2014. The entire disclosures of the prior applications are hereby incorporated by reference herein their entirety.

›TECHNICAL FIELD

The present invention relates to a substituted dihydropyrrolopyrazole compound or a pharmacologically acceptable salt thereof which has excellent CDK7 inhibitory activity and is useful as a medicament (e.g., a medicament for the treatment or prevention of cancers or inflammatory diseases), or a prodrug thereof.

›BACKGROUND ART

CDKs (cyclin-dependent kinases) are cell growth control factors that are involved in entry to DNA synthesis (S phase) of the cell cycle and a mitotic phase (M phase), etc., and many types of CDKs are known. Also, the activation of CDK is controlled in multiple stages through the phosphorylation or dephosphorylation of the threonine residue of active loop (T loop) in its three-dimensional structure. When the particular threonine residue of CDK is phosphorylated, it forms a complex with a particular cyclin and is activated. This complex, which is important for cell cycle control, includes CDK1, CDK2/cyclin A, CDK1/cyclins B1 to B3 and CDK2, CDK4, CDK5, CDK6/cyclin D1 to D3, and CDK2/cyclin E, which are respectively involved in the particular periods of the cell cycle. CDK7 forms a CDK-activating kinase (CAK) together with cyclin H and MAT1 in metazoans and participates in the phosphorylation of CDKs (e.g., CDK1, CDK2, CDK4, and CDK6) necessary for the progression of the cell cycle (see Non Patent Literature 1).

Cell overgrowth by the abnormal activation of CDKs is a common feature in many cancers, and it is known that this is associated with a loss of checkpoint functions involved in the cell cycle control of cancer cells (see Non Patent Literature 2). Also, CDKs are known to have functions other than cell cycle control, and CDK7 is known to promote the binding of RNA polymerase II (RNAPII) to DNA and elongation thereof to positively control the transcription through the phosphorylation of serine in the COOH-terminal domain of the RNAPII (see Non Patent Literature 3).

CDK7 inhibitors exhibit effects in cell growth tests of various cancer cells and cancer-bearing mouse models, and the inhibition is expected to be useful as anticancer agents (see Non Patent Literatures 4 and 5).

Furthermore, it has been reported that in collagen-induced rheumatism mouse models, amelioration of clinical scores or tissue damage, decrease in the levels of inflammation-induced cytokines such as IL-6, IL-1β, and IL-17, and anti-CII-IgG2α, and decrease in the proportion of Th17 cells are attained by inhibiting CDK7 (see Non Patent Literature 6).

The CDK7 inhibitors, which play an important role in the progression of the cell cycle, are further expected to also have effects on the suppression of infection by viruses such as HIV, EBV, and HCV, and cardiomegaly (see Non Patent Literatures 7 and 8). Examples of diseases for which the CDK7 inhibitors seem to be useful, in addition to those described above, include autoimmune diseases typified by psoriasis and multiple sclerosis, neurodegenerative diseases typified by Alzheimer's disease, etc., allergic diseases typified by atopic dermatitis, etc., chronic respiratory diseases typified by chronic obstructive pulmonary disease (COPD), etc., and fibrosis typified by idiopathic pulmonary fibrosis, etc. (see Non Patent Literatures 9 to 11 and Non Patent Literatures 16 to 18).

Although the development of many CDK inhibitors is currently underway, there are not many compounds having an excellent CDK7 inhibitory effect (see Non Patent Literature 15).

›CITATION LIST

Patent Literature

Patent Literature 1: WO 2002/012242

Patent Literature 2: WO 2004/056827

Patent Literature 3: WO 2004/080457

Patent Literature 4: WO 2007/068637

Patent Literature 5: WO 2007/072153

Patent Literature 6: WO 2007/099171

Patent Literature 7: WO 2008/043745

Patent Literature 8: WO 2008/125945

Patent Literature 9: WO 2011/044264

Patent Literature 10: WO 2008/151304

Patent Literature 11: WO 2013/128028

Patent Literature 12: WO 2013/128029

Patent Literature 13: WO 2014/063068

Patent Literature 14: WO 2015/058126

Patent Literature 15: WO 2015/058140

Patent Literature 16: WO 2015/058163

Patent Literature 17: WO 2015/124941

Patent Literature 18: WO 2015/154022

Patent Literature 19: WO 2015/154038

Patent Literature 20: WO 2015/154039

Non Patent Literature

Non Patent Literature 1: Journal of Cell Science 2005, 118 (20), 5171-5180

Non Patent Literature 2: Nature Reviews Cancer 2009, 9, 153-166

Non Patent Literature 3: Biochim Biophys Acta 2004, 1677, 64-73

Non Patent Literature 4: Nature 2014, 511, 616-620

Non Patent Literature 5: Cancer Res 2009, 69, 6208-6215

Non Patent Literature 6: Clinical and Experimental Medicine, 2015, 15, 269-275

Non Patent Literature 7: Curr HIV Res 2003, 1 (2), 131-152

Non Patent Literature 8: Mol Cell Biol 1998, 18 (11), 6729-6736

Non Patent Literature 9: Br J Dermatol 2000, 143 (5), 950-956

Non Patent Literature 10: Biochem Biophys Res Commun 2013, 435 (3), 378-384

Non Patent Literature 11: Neurobiol Aging 2000, 6, 807-813

Non Patent Literature 12: Journal of Medicinal Chemistry 2012, 55 (10), 4728-4739

Non Patent Literature 13: Bioorganic & Medicinal Chemistry 2010, 18 (5), 1844-1853

Non Patent Literature 14: ChemMedChem 2007, 2, 841-852

Non Patent Literature 15: Current Drug Targets, 2010, 11, 291-302

Non Patent Literature 16: Clinical & Experimental Allergy, 2011, 41, 673-687

Non Patent Literature 17: Cell Death and Differentiation, 2012, 19, 1950-1961

Non Patent Literature 18: Am. J. Physiol. Lung Cell Mol, 2004, 286, 727-733

›SUMMARY OF INVENTION · 1 of 5

Technical Problem

The present inventors have conducted studies on novel substituted dihydropyrrolopyrazole compounds with the aim of developing excellent CDK7 inhibitors and completed the present invention by finding that a novel substituted dihydropyrrolopyrazole compound having a particular structure or a pharmacologically acceptable salt thereof has excellent CDK7 inhibitory activity and is useful as a medicament (e.g., a medicament for the treatment or prevention of cancers or inflammatory diseases), and further finding even a compound that can serve as a prodrug of the compound.

Patent Literatures 1 to 9 and Non Patent Literatures 12 to 14 describe a compound having a 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole skeleton, but do not disclose the compound according to the present invention or the pharmacologically acceptable salt thereof.

As compounds inhibiting CDK7, pyrazolopyrimidine derivatives are disclosed in Patent Literature 10, pyrazolotriazine derivatives are disclosed in Patent Literatures 11 and 12, phenyl derivatives are disclosed in Patent Literature 13 and Non Patent Literature 4, and heterocyclic compounds are disclosed in Patent Literatures 14 to 20; however, a compound having a 4,6-dihydropyrrolo[3,4-c]pyrazole skeleton is not disclosed.

Solution to Problem

The present invention provides a novel substituted dihydropyrrolopyrazole compound or a pharmacologically acceptable salt thereof which has excellent CDK7 inhibitory activity, or a prodrug thereof;

a pharmaceutical composition, preferably a pharmaceutical composition for the treatment or prevention of cancers, inflammatory diseases (e.g., autoimmune diseases), infection by viruses (HIV, EBV, HCV, etc.), neurodegenerative diseases (e.g., Alzheimer's disease), allergic diseases (e.g., atopic dermatitis), chronic respiratory diseases (e.g., chronic obstructive pulmonary disease (COPD)), fibrosis (e.g., idiopathic pulmonary fibrosis), circulatory diseases such as cardiomegaly, or impotence, comprising the substituted dihydropyrrolopyrazole compound or the pharmacologically acceptable salt thereof, or the prodrug thereof as an active ingredient;

use of the substituted dihydropyrrolopyrazole compound or the pharmacologically acceptable salt thereof, or the prodrug thereof for the production of a pharmaceutical composition for the treatment or prevention (preferably, treatment) of diseases (preferably, the diseases described above);

a method for treating or preventing (preferably, treating) diseases (preferably, the diseases described above) by administering a pharmaceutically effective amount of the substituted dihydropyrrolopyrazole compound or the pharmacologically acceptable salt thereof, or the prodrug thereof to a warm-blooded animal (preferably, a human); and a method for producing the substituted dihydropyrrolopyrazole compound or the pharmacologically acceptable salt thereof, or the prodrug thereof, or an intermediate thereof.

Examples of the cancers include urinary bladder cancer, breast cancer, large intestine cancer (e.g., colorectal cancer, for example, colon adenocarcinoma and colon adenoma), gastrointestinal stromal tumor, kidney cancer, epidermal cancer, liver cancer, lung cancer (e.g., adenocarcinoma, small-cell lung cancer, and non-small cell lung cancer), esophageal cancer, gallbladder cancer, ovary cancer, pancreatic cancer (e.g., exocrine pancreatic tumor), gastric cancer, cervical cancer, endometrial cancer, thyroid gland cancer, cancer of the nose, head and neck cancer, prostate cancer, skin cancer (e.g., squamous cell cancer), hematopoietic organ tumors of the lymphatic system (e.g., leukemia, acute lymphatic leukemia, chronic lymphatic leukemia, B cell lymphoma (e.g., diffuse large B cell lymphoma), T cell lymphoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, and Burkitt's lymphoma), hematopoietic organ tumors of the myeloid system (e.g., acute or chronic myeloid leukemia, myelodysplastic syndrome, and promyelocytic leukemia), follicular carcinoma of thyroid, mesenchymal tumors (e.g., fibrosarcoma, Ewing's sarcoma, and rhabdomyosarcoma), tumors of the central or peripheral nervous system (e.g., astrocytoma, neuroblastoma, glioma, brain tumor, and schwannoma), melanoma, seminoma, teratoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, follicular carcinoma of thyroid, and Kaposi's sarcoma.

Examples of the autoimmune diseases include multiple sclerosis, Guillain-Barre syndrome, myasthenia gravis, chronic atrophic gastritis, autoimmune hepatitis, primary biliary cirrhosis, ulcerative colitis, Crohn's disease, primary sclerosing cholangitis, autoimmune pancreatitis, aortitis syndrome, Goodpasture's syndrome, rapidly progressive glomerulonephritis, megaloblastic anemia, autoimmune hemolytic anemia, autoimmune neutropenia, idiopathic thrombocytopenic purpura, Graves' disease, Hashimoto disease, primary hypothyroidism, idiopathic Addison's disease, type 1 diabetes mellitus, circumscribed scleroderma, epidermolysis bullosa acquisita, vitiligo vulgaris, autoimmune optic neuropathy, autoimmune inner ear disorder, idiopathic azoospermia, rheumatoid arthritis, systemic lupus erythematosus, drug-induced lupus erythematosus, Sjogren's syndrome, polymyositis, psoriasis, dermatomyositis, scleroderma, vasculitis syndrome, mixed connective-tissue disease, and inflammatory bowel disease. In this context, the inflammatory bowel disease (IBD) is a generic name for diseases that cause chronic inflammation or ulcer in the large intestinal or small intestinal mucosa, and examples thereof include Crohn disease and ulcerative colitis.

In one aspect, the present invention provides the following [1] to [24]:

[1] A compound represented by formula (I) or a pharmacologically acceptable salt thereof:

wherein

L 1 is an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

›SUMMARY OF INVENTION · 2 of 5

L 2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

L 3 is a single bond, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group, an optionally substituted linear or branched C 2-4 alkenyl group, an optionally substituted linear or branched C 2-4 alkynyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group,

R 4 is a hydrogen atom, an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted linear or branched C 2-6 alkenyl group, an optionally substituted linear or branched C 2-6 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and

R 5 is a hydrogen atom, an optionally substituted linear or branched C 1-16 alkyl group, an optionally substituted linear or branched C 2-16 alkenyl group, an optionally substituted linear or branched C 2-16 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group.

[2] The compound or a pharmacologically acceptable salt thereof according to [1], wherein L 1 is an optionally substituted linear or branched C 1-6 alkylene group or an optionally substituted C 3-6 cycloalkylene group.

[3] A compound represented by formula (II) or a pharmacologically acceptable salt thereof:

wherein

L 2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

L 3 is a single bond, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group, an optionally substituted linear or branched C 2-4 alkenyl group, an optionally substituted linear or branched C 2-4 alkynyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group,

R 4 is a hydrogen atom, an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted linear or branched C 2-6 alkenyl group, an optionally substituted linear or branched C 2-6 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and

R 5 is a hydrogen atom, an optionally substituted linear or branched C 1-16 alkyl group, an optionally substituted linear or branched C 2-16 alkenyl group, an optionally substituted linear or branched C 2-16 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group.

[4] The compound or a pharmacologically acceptable salt thereof according to [3], wherein R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group.

[5] A compound represented by formula (III) or a pharmacologically acceptable salt thereof:

wherein

L 2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

L 3 is a single bond, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group, an optionally substituted linear or branched C 2-4 alkenyl group, an optionally substituted linear or branched C 2-4 alkynyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group,

R 4 is a hydrogen atom, an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted linear or branched C 2-6 alkenyl group, an optionally substituted linear or branched C 2-6 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and

R 5 is a hydrogen atom, an optionally substituted linear or branched C 1-16 alkyl group, an optionally substituted linear or branched C 2-16 alkenyl group, an optionally substituted linear or branched C 2-16 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group.

›SUMMARY OF INVENTION · 3 of 5

[6] The compound or a pharmacologically acceptable salt thereof according to [5], wherein R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group.

[7] A compound represented by formula (IV) or a pharmacologically acceptable salt thereof:

wherein

L 2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

L 3 is a single bond, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group, an optionally substituted linear or branched C 2-4 alkenyl group, an optionally substituted linear or branched C 2-4 alkynyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group,

R 4 is a hydrogen atom, an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted linear or branched C 2-6 alkenyl group, an optionally substituted linear or branched C 2-6 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and

R 5 is a hydrogen atom, an optionally substituted linear or branched C 1-16 alkyl group, an optionally substituted linear or branched C 2-16 alkenyl group, an optionally substituted linear or branched C 2-16 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group.

[8] The compound or a pharmacologically acceptable salt thereof according to [7], wherein R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group.

[9] A compound represented by formula (V) or (VI) or a pharmacologically acceptable salt thereof:

wherein

L 1 is an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

L 2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

L 3 is a single bond, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group, an optionally substituted linear or branched C 2-4 alkenyl group, an optionally substituted linear or branched C 2-4 alkynyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group,

R 4 is a hydrogen atom, an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted linear or branched C 2-6 alkenyl group, an optionally substituted linear or branched C 2-6 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and

R 6 is a hydrogen atom, an optionally substituted linear or branched C 1-16 alkyl group, an optionally substituted linear or branched C 2-16 alkenyl group, an optionally substituted linear or branched C 2-16 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted linear or branched C 1-6 alkoxy group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group,

R 7 is an optionally substituted linear or branched C 1-16 alkyl group, an optionally substituted linear or branched C 2-16 alkenyl group, an optionally substituted linear or branched C 2-16 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and

R 8 and R 9 are each independently a hydrogen atom or a C 1-4 alkyl group.

[10] The compound or a pharmacologically acceptable salt thereof according to [9], wherein L 1 is an optionally substituted linear or branched C 1-6 alkylene group or an optionally substituted C 3-6 cycloalkylene group, and R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group.

[11] A compound selected from a compound group consisting of

(S)—N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-3-[2-methyl-2-(trimethylsilyl)propaneamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)-3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)-3-[2-(ethyldimethylsilyl)-2-methylpropaneamido]-N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-1-phenylethyl)-N,6,6-trimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)-2-[(2-m ethoxypropan-2-yl)oxy]-1-phenylethyl6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, (S)-2-hydroxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, 2-Methoxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, N-[5-(4-hydroxy-3-phenylbutanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-hydroxy-3-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-(3-hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(4-hydroxy-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(5-hydroxy-1-phenylpentyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-2-methyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-2-methyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-hydroxy-3-methyl-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-methoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[2-(difluoromethoxy)-1-phenylethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-ethoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-methoxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, Sodium (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate, (R)—N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(2-fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[1-(3-fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[1-(4-fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[2-hydroxy-1-(pyridin-2-yl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[2-hydroxy-1-(pyridin-3-yl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(benzo[d][1,3]dioxol-4-yl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(1-cyclohexyl-2-hydroxyethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(1-hydroxy-3-methylbutan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(1-hydroxypropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-hydroxyethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-hydroxypropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(2S)-1-hydroxy-3-methyl-1-phenylbutan-2-yl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(4-hydroxy-1-phenyl-2-butyn-1-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl acetate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl propionate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl butanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl pentanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl octanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl dodecanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl palmitate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl isobutanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl pivalate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl 3-methyl butanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl benzoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl ethyl carbonate, Sodium (S)-4-(2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethoxy)-4-oxobutanoate, (S)-(2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethoxy)methyl pivalate, (S)-2-acetoxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, (S)-benzyl 2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate, (S)-methyl 2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate, N-(2,2-difluoro-3-hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-isopropoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 6,6-Dimethyl-N-(2-phenoxy-1-phenylethyl)-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[1-(2-chlorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[2-hydroxy-1-(o-tolyl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(1-hydroxy-3-phenylpropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-hydroxy-3-methylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(1-hydroxy-3-phenylpropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 2-Hydroxy-2-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, (R)—N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (S)—N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[6,6-dimethyl-5-(2-phenoxyacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide, N-{5-[3-(benzyloxy)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-hydroxy-2-phenoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(4-chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(2-chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(cyclohexyloxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(3-chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(2-methoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-methoxy-2-phenoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-{6,6-dimethyl-5-[2-(pyridin-3-yloxy)propanoyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[3-(dimethylamino)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-[6,6-dimethyl-5-(2-phenoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[3-(3,3-difluoropyrrolidin-1-yl)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (S)—N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (R)—N-{5-[3-(benzyloxy)-2-phenylpropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (R)—N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (S)—N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-methoxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(4-methoxy-2-phenylbutanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (S)—N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide, (R)—N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide, (R)—N-{5-[2-(difluoromethoxy)-2-phenylacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[5-(2-ethoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (R)-1-(ethyldimethylsilyl)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]cyclobutanecarboxamide, (R)—N-[5-(2-cyclopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsiyl)cyclobutanecarboxamide, (R)—N-[5-(2-isopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsiyl)cyclobutanecarboxamide, (R)—N-{6,6-dimethyl-5-[2-phenyl-2-(trifluoromethoxy)acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[6,6-dimethyl-5-(2-phenyl-2-propoxyacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(4-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(3-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-{5-[2-(2-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (−)-N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (+)-N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{[1-(hydroxymethyl)cyclobutyl](phenyl)methyl}-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[2-(1-hydroxycyclopropyl)-1-phenylethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-ethyl-3-hydroxy-1-phenylpentyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[1-(4-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[1-(3-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[1-(2-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(5-hydroxy-2,5-dimethylhexan-3-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(4-fluorophenyl)-3-hydroxy2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (−)-N-[1-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (+)-N-[1-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(2-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(1-hydroxy-2,2,4-trimethylpentan-3-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-hydroxy-3-methyl-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (−)-N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (+)-N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[5-(2-butoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, and N-(3-methoxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

›SUMMARY OF INVENTION · 4 of 5

[12] (R)—N-[1-(4-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

[13] (−)-N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropane-1-carboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

[14] (R)—N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[15] (R)—N-[6,6-dimethyl-5-(2-phenyl-2-propoxyacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[16] (R)—N-{5-[2-(2-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[17] (R)—N-[5-(2-ethoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[18] (R)—N-[5-(2-cyclopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[19] (R)—N-[5-(2-isopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[20] (+)-N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutane carboxamide or a pharmacologically acceptable salt thereof.

[21] (−)-N-[1-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

[22] N-{5-[2-(3-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[23] N-[1-(4-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

[24] (R)—N-[1-(3-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

[25] (R)—N-{6,6-dimethyl-5-[2-phenyl-2-(trifluoromethoxy)acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[26] (R)—N-[2-(1-hydroxycyclopropyl)-1-phenylethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

[27] (R)—N-(3-hydroxy-3-methyl-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

[28] (R)—N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide or a pharmacologically acceptable salt thereof.

[29] (R)—N-{5-[2-(difluoromethoxy)-2-phenylacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[30] (R)-1-(ethyldimethylsilyl)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]cyclobutanecarboxamide or a pharmacologically acceptable salt thereof.

[31] N-{[1-(hydroxymethyl)cyclobutyl](phenyl)methyl}-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide or a pharmacologically acceptable salt thereof.

[32] A pharmaceutical composition comprising the compound or a pharmacologically acceptable salt thereof according to any of [1] to [31].

[33] The pharmaceutical composition according to [32], wherein the pharmaceutical composition is a CDK7 inhibitor or a prophylactic agent.

[34] The pharmaceutical composition according to [32] or [33], wherein the pharmaceutical composition is for treating or preventing a cancer or an inflammatory disease.

[35] The pharmaceutical composition according to [34], wherein the inflammatory disease is an autoimmune disease.

[36] The pharmaceutical composition according to [35], wherein the autoimmune disease is rheumatoid arthritis or psoriasis.

[37] A method for treating or preventing a cancer or an inflammatory disease, comprising administering the compound or the pharmacologically acceptable salt thereof according to any of [1] to [31] to a subject in need thereof.

[38] The method according to [37], wherein the inflammatory disease is an autoimmune disease.

[39] The method according to [38], wherein the autoimmune disease is rheumatoid arthritis or psoriasis.

[40] Use of the compound or the pharmacologically acceptable salt thereof according to any of [1] to [31] for the production of a pharmaceutical composition which is a CDK7 inhibitor or a prophylactic agent.

[41] Use of the compound or the pharmacologically acceptable salt thereof according to any of [1] to [31] for inhibiting CDK7.

[42] Use of the compound or the pharmacologically acceptable salt thereof according to any of [1] to [31] for treating or preventing a cancer or an inflammatory disease.

[43] Use according to [42], wherein the inflammatory disease is an autoimmune disease.

[44] Use according to [43], wherein the autoimmune disease is rheumatoid arthritis or psoriasis.

[45] The compound or the pharmacologically acceptable salt thereof according to any of [1] to [31] for use as an active ingredient for a pharmaceutical composition.

[46] The compound or the pharmacologically acceptable salt thereof according to [45], wherein the pharmaceutical composition is a pharmaceutical composition for the treatment of a cancer or an inflammatory disease.

›SUMMARY OF INVENTION · 5 of 5

[47] The compound or the pharmacologically acceptable salt thereof according to [46], wherein the inflammatory disease is an autoimmune disease.

[48] The compound or the pharmacologically acceptable salt thereof according to [47], wherein the autoimmune disease is rheumatoid arthritis or psoriasis.

Specific examples of the compound represented by formula (I) of the present invention can include compounds as shown in Tables 1 to 164 described below. In Tables 1 to 164 described below, Me represents a methyl group, Et represents an ethyl group, nPr represents a n-propyl group, iPr represents an isopropyl group, cPr represents a cyclopropyl group, nBu represents a n-butyl group, iBu represents an isobutyl group, tBu represents a tert-butyl group, cHex represents a cyclohexyl group, Ph represents a phenyl group, 2-F-Ph represents a 2-fluorophenyl group, 3-F-Ph represents a 3-fluorophenyl group, 4-F-Ph represents a 4-fluorophenyl group, 2-Cl-Ph represents a 2-chlorophenyl group, 3-Cl-Ph represents a 3-chlorophenyl group, 4-Cl-Ph represents a 4-chlorophenyl group, 2-Me-Ph represents a 2-methylphenyl group, 3-Me-Ph represents a 3-methylphenyl group, 4-Me-Ph represents a 4-methylphenyl group, 2-Py represents a 2-pyridyl group, 3-Py represents a 3-pyridyl group, 4-Py represents a 4-pyridyl group, Bn represents a benzyl group, “—” represents a single bond, “(R)—” and “(S)—” each represent the configuration of a carbon atom with “*” in the following formulas (I), (II), (III), (IV), (Va), (Vb), (Vc), (VIa), (VIb), and (VIc), “racemic” represents being a racemate, “(+)” represents being a dextrorotatory optically active form, and “(−)” represents being a levorotatory optically active form. As for each chemical structure described as L 1 , L 2 , or L 3 in the tables, the atom positioned on the left side of the chemical structure binds to a silicon atom, a carbonyl group, or a carbon atom with “*” in the corresponding formula. In the case of, for example, a compound of compound No. 1-21, CH 2 —C(Me) 2 corresponding to L 1 means that the methylene carbon atom (CH 2 ) binds to a silicon atom and the quaternary carbon atom (C) binds to a carbonyl group, and C≡CCH 2 corresponding to L 3 means that the quaternary carbon atom (C) binds to a carbon atom with “*” and the methylene carbon atom (CH 2 ) binds to an oxygen atom adjacent to R 5 .

Advantageous Effects of Invention

As for a novel substituted dihydropyrrolopyrazole compound having a particular structure represented by formula (I) of the present invention or a pharmacologically acceptable salt thereof, the compound itself or a metabolite thereof has excellent CDK7 inhibitory activity, high selectivity for a kinase inhibitory effect, and excellent safety. Thus, the compound represented by formula (I) or the pharmacologically acceptable salt thereof is pharmaceutically useful as a therapeutic agent and/or a prophylactic agent for cancers or inflammatory diseases.

›DESCRIPTION OF EMBODIMENTS · 1 of 9

One embodiment of the present invention will be described below. In the present specification, each “compound represented by formula (I)”, etc. is also referred to as “compound (I)”, etc. for the sake of convenience. Various substituents defined or illustrated below can be arbitrarily selected and combined.

In the present specification, the “prodrug” means a compound or a salt thereof which forms a compound having a CDK7 inhibitory effect by undergoing metabolic reaction when administered into an animal body.

One embodiment of the present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

In formula (I),

L 1 is an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

L 2 is a single bond, an oxygen atom, an optionally substituted nitrogen atom, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

L 3 is a single bond, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenyl group, an optionally substituted linear or branched C 2-6 alkynyl group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group,

R 1 , R 2 , and R 3 each independently are an optionally substituted linear or branched C 1-4 alkyl group, an optionally substituted linear or branched C 2-4 alkenyl group, an optionally substituted linear or branched C 2-4 alkynyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group,

R 4 is a hydrogen atom, an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted linear or branched C 2-6 alkenyl group, an optionally substituted linear or branched C 2-6 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and

R 5 is a hydrogen atom, an optionally substituted linear or branched C 1-16 alkyl group, an optionally substituted linear or branched C 2-16 alkenyl group, an optionally substituted linear or branched C 2-16 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group.

In the present specification, the term “optionally substituted” means that the group concerned may be unsubstituted or may be further substituted by a substituent.

The substituent means a monovalent group, and examples thereof include linear or branched C 1-6 alkyl groups, C 3-6 cycloalkyl groups, linear or branched C 2-6 alkenyl groups, C 3-6 cycloalkenyl groups, linear or branched C 2-6 alkynyl groups, C 1-6 alkoxy groups, halogen atoms, a hydroxy group, a cyano group, an oxo group (═O), an amino group, C 1-6 alkylamino groups, a nitro group, a carboxy group (—COOH), a carbamoyl group (—CONH 2 ), N-mono-C 1-6 alkylcarbamoyl groups, N,N-di-C 1-6 alkylcarbamoyl groups, C 1-6 alkanoyloxy groups (—OCOR; R is a C 1-6 alkyl group), C 6-10 aryl groups, heterocyclic groups, C 6-10 aryloxy groups, C 7-12 aralkyl groups, and C 7-12 aralkyloxy groups. The substituent may be further substituted by a halogen atom, a hydroxy group, an amino group, a cyano group, an oxo group (═O), a linear or branched C 1-6 alkyl group, or the like. In the case where the substituent is an amino group or a carboxy group, the form may be a salt thereof.

In the case where the group concerned has two or more substituents, two substituents may be bonded to each other to form a cyclic structure. Examples of the case where two substituents are bonded to each other to form a cyclic structure include a cyclopropyl group, a cyclobutyl group, and a methylenedioxy group. Specifically, in the case where a methylenedioxy group is bonded to a benzene ring, the substituent becomes a 1,3-benzodioxole group; in the case where the same carbon atom of a 1,2-ethylene group has two methyl groups which are bonded to each other, the group becomes a group represented by the following formula (M-1) or (M-2); and in the case where the same carbon atom of a 1,2-ethylene group has a methyl group and an ethyl group and 2-position of the ethyl group is bonded to the methyl group, the group becomes a group represented by the following formula (N-1) or (N-2).

The linear or branched C 1-6 alkyl group described in the present specification means a linear or branched alkyl group having 1 to 6 carbon atoms. Examples of the linear or branched C 1-6 alkyl group include C 1-6 alkyl groups such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a 1-ethylpropyl group, a 1-methylbutyl group, a 2-methylbutyl group, a 1,2-dimethylpropyl group, a hexyl group, a 1-methylpentyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 4-methylpentyl group, a 1-ethylbutyl group, a 2-ethylbutyl group, a 1,1-dimethylbutyl group, a 2,2-dimethylbutyl group, a 3,3-dimethylbutyl group, a 1,2-dimethylbutyl group, a 1,3-dimethylbutyl group, and a 2,3-dimethylbutyl group. The substituent is preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, or a tert-butyl group.

Examples of a C 1-6 alkyl group substituted by a halogen atom include a chloromethyl group, a bromomethyl group, an iodomethyl group, a difluoromethyl group, a dichloromethyl group, a dibromomethyl group, a diiodomethyl group, a trifluoromethyl group, a trichloromethyl group, a 1-fluoroethyl group, a 2-fluoroethyl group, a 2-chloroethyl group, a 2-bromoethyl group, a 2,2-difluoroethyl group, a 2,2,2-trifluoroethyl group, a pentafluoroethyl group, a 2,2-dichloroethyl group, a 2,2,2-trichloroethyl group, a 1-fluoropropyl group, a 2-fluoropropyl group, a 3-fluoropropyl group, a 3,3,3-trifluoropropyl group, a perfluoropropyl group, a 1-fluoromethylethyl group, a 1-difluoromethylethyl group, a 1-trifluoromethylethyl group, a 1-fluoro-1-methylethyl group, a 4-fluorobutyl group, a perfluorobutyl group, a 5-fluoropentyl group, a perfluoropentyl group, a 6-fluorohexyl group, and a perfluorohexyl group.

›DESCRIPTION OF EMBODIMENTS · 2 of 9

A C 1-6 alkyl group substituted by an aryl group may be, for example, a C 7-11 aralkyl group. The C 7-11 aralkyl group means an alkyl group having an aryl group and having a total of 7 to 11 carbon atoms, and examples thereof include a benzyl group, a phenylethyl group, and a naphthylmethyl group.

The C 3-6 cycloalkyl group described in the present specification means a cyclic alkyl group having 3 to 6 carbon atoms. Examples of the C 3-6 cycloalkyl group include: monocyclic rings such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group; condensed rings such as a bicyclo[3.1.0]hexyl group; and spiro rings such as a spiro[2.3]hexyl group. The substituent is preferably a cyclopropyl group or a cyclobutyl group.

The linear or branched C 2-6 alkenyl group described in the present specification means a linear or branched alkenyl group having 2 to 6 carbon atoms. Examples of the linear or branched C 2-6 alkenyl group include alkenyl groups such as a vinyl group, a propen-1-yl group, a propen-2-yl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 1-methyl-1-propenyl group, a 2-methyl-1-propenyl group, a 1-pentenyl group, a 2-pentenyl group, a 3-pentenyl group, a 4-pentenyl group, a 5-pentenyl group, a 1-methyl-1-butenyl group, a 2-methyl-1-butenyl group, a 3-methyl-1-butenyl group, a 4-methyl-1-butenyl group, a 1-methyl-2-butenyl group, a 2-methyl-2-butenyl group, a 3-methyl-2-butenyl group, a 4-methyl-2-butenyl group, a 1-methyl-3-butenyl group, a 2-methyl-3-butenyl group, a 3-methyl-3-butenyl group, a 4-methyl-3-butenyl group, a 1,2-dimethyl-1-propenyl group, a 1-hexenyl group, a 2-hexenyl group, a 3-hexenyl group, a 4-hexenyl group, a 5-hexenyl group, a 6-hexenyl group, and structural isomers thereof.

The C 3-6 cycloalkenyl group described in the present specification means a cycloalkenyl group having 3 to 6 carbon atoms. Examples of the C 3-6 cycloalkenyl group include a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, and a cyclohexenyl group.

The C 2-6 alkynyl group described in the present specification means an alkynyl group having 2 to 6 carbon atoms. Examples of the C 2-6 alkynyl group include an ethynyl group, a propargyl group, a butynyl group, a pentynyl group, and a hexynyl group.

The C 1-6 alkoxy group described in the present specification means a group consisting of an oxy group (—O—) and a linear or branched C 1-6 alkyl group or a C 3-6 cycloalkyl group bonded to the oxy group. Examples of the C 1-6 alkoxy group include a methoxy group, an ethoxy group, a propyloxy group, an isopropyloxy group, a cyclopropyloxy group, a butoxy group, a cyclobutyloxy group, a pentyloxy group, a cyclopentyloxy group, a hexyloxy group, and a cyclohexyloxy group.

The C 1-6 alkylamino group described in the present specification means an amino group substituted by one or two independently selected aforementioned linear or branched C 1-6 alkyl groups or C 3-6 cycloalkyl groups. Examples of the C 1-6 alkylamino group include a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a cyclopropylamino group, a butoxy group, a cyclobutylamino group, a pentylamino group, a cyclopentylamino group, a hexylamino group, a cyclohexylamino group, a dimethylamino group, a diethylamino group, an ethylmethylamino group, an isopropylmethylamino group, and a cyclopropylmethylamino group.

The halogen atom described in the present specification means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.

The C 6-10 aryl group described in the present specification means an aryl group having 6 to 10 carbon atoms. Examples of the C 6-10 aryl group include a phenyl group and a naphthyl group.

The heterocyclic group described in the present specification means a cyclic group having at least one nitrogen atom, oxygen atom, or sulfur atom and may be an aromatic heterocyclic group or may be a nonaromatic heterocyclic group. Examples of the aromatic heterocyclic group include a pyridine group, a pyrimidine group, a pyridazine group, a pyrazine group, a triazine group, a pyrrole group, an imidazole group, a pyrazole group, an indole group, an indazole group, a furan group, a benzofuran group, a thiophene group, a benzothiophene group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, and an oxadiazole group. Examples of the nonaromatic heterocyclic group include a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a morpholinyl group, and a thiomorpholinyl group.

The C 6-10 aryloxy group described in the present specification means a group consisting of an oxy group (—O—) and the aforementioned C 6-10 aryl group bonded to the oxy group. Examples of the C 6-10 aryloxy group include a phenyloxy group, a 1-naphthyloxy group, and a 2-naphthyloxy group.

The C 7-12 aralkyl group described in the present specification means the aforementioned C 1-6 alkyl group substituted by the aforementioned C 6-10 aryl group. Examples of the C 7-12 aralkyl group include a benzyl group, a phenylethyl group, a naphthylmethyl group, and a naphthylethyl group.

The C 7-12 aralkyloxy group described in the present specification means a group consisting of an oxy group (—O—) and the aforementioned C 7-12 aralkyl group bonded to the oxy group. Examples of the C 7-12 aralkyloxy group include a benzyloxy group, a phenylethyloxy group, a naphthylmethyloxy group, and a naphthylethyloxy group.

The linear or branched C 1-6 alkylene group as L 1 , L 2 , or L 3 means a divalent group prepared by further removing one hydrogen atom from the aforementioned C 1-6 alkyl group. Examples of the C 1-6 alkylene group include a methylene group, a 1,1-ethylene group, a 1,2-ethylene group, a 1,1-propylene group, a 1,2-propylene group, a 2,2-propylene group, and a 1,3-propylene group.

The linear or branched C 2-6 alkenylene group as L 1 , L 2 , or L 3 means a divalent group prepared by further removing one hydrogen atom from the aforementioned C 2-6 alkenyl group. Examples of the C 2-6 alkenylene group include a vinylene group and a propenylene group.

›DESCRIPTION OF EMBODIMENTS · 3 of 9

The linear or branched C 2-6 alkynylene group as L 1 , L 2 , or L 3 means a divalent group prepared by further removing one hydrogen atom from the aforementioned C 2-6 alkynyl group. Examples of the C 2-6 alkynylene group include an ethynylene group and a propynylene group.

The C 3-6 cycloalkylene group as L 1 , L 2 , or L 3 means a divalent group prepared by further removing one hydrogen atom from the aforementioned C 3-6 cycloalkyl group, and examples thereof include a 1,1-cyclopropylene group, a 1,2-cyclopropylene group, a 1,1-cyclobutylene group, a 1,2-cyclobutylene group, a 1,3-cyclobutylene group, a 1,4-cyclobutylene group, a 1,1-cyclopentylene group, a 1,2-cyclopentylene group, a 1,3-cyclopentylene group, a 1,1-cyclohexylene group, a 1,2-cyclohexylene group, a 1,3-cyclohexylene group, a 1,4-cyclohexylene group, a 5,5-spiro[2.3]hexylene group, and a 6,6-bicyclo[3.1.0]hexylene group.

The C 3-6 cycloalkenylene group as L 1 , L 2 , or L 3 means a divalent group prepared by further removing one hydrogen atom from the aforementioned C 3-6 cycloalkenyl group, and examples thereof include a 1,2-cyclopropenylene group, a 1,2-cyclobutenylene group, a 1,3-cyclobutenylene group, a 3,3-cyclobutenylene group, a 1,2-cyclopentenylene group, a 1,2-cyclopentenylene group, a 1,3-cyclopentenylene group, a 3,3-cyclopentenylene group, a 4,4-cyclopentenylene group, a 1,2-cyclohexenylene group, a 1,3-cyclohexenylene group, a 1,3-cyclohexenylene group, a 1,3-cyclohexenylene group, a 3,3-cyclohexenylene group, and a 4,4-cyclohexenylene group.

The optionally substituted nitrogen atom as L 2 may be an unsubstituted nitrogen atom (divalent amino group represented by —NH—) or may be a divalent amino group having the aforementioned substituent bonded to the nitrogen atom.

The linear or branched C 1-4 alkyl group as R 1 , R 2 , or R 3 is a linear or branched alkyl group having 1 to 4 carbon atoms and corresponds to one having 1 to 4 carbon atoms among the C 1-6 alkyl groups described above.

The linear or branched C 2-4 alkenyl group as R 1 , R 2 , or R 3 is a linear or branched alkenyl group having 2 to 4 carbon atoms and corresponds to one having 2 to 4 carbon atoms among the C 2-6 alkenyl groups described above.

The linear or branched C 2-4 alkynyl group as R 1 , R 2 , or R 3 is a linear or branched alkynyl group having 2 to 4 carbon atoms and corresponds to one having 2 to 4 carbon atoms among the C 2-6 alkynyl groups described above.

The linear or branched C 1-6 alkyl group, the linear or branched C 2-6 alkenyl group, the linear or branched C 2-6 alkynyl group, the C 6-10 aryl group, and the heterocyclic group as R 4 are defined as in the substituents described above.

The linear or branched C 1-16 alkyl group as R 5 means an alkyl group having 1 to 16 carbon atoms. Examples of the linear or branched C 1-16 alkyl group include C 1-16 alkyl groups such as a methyl group, an ethyl group, a propyl group, a butyl group, an isobutyl group, a pentyl group, an isopentyl group, a neopentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group, a decyl group, an undecyl group, a dodecyl group, a tridecyl group, a tetradecyl group, a pentadecyl group, and a hexadecyl group.

The linear or branched C 2-16 alkenyl group as R 5 means a monovalent linear or branched alkenyl group having 2 to 16 carbon atoms, and the linear or branched C 2-16 alkynyl group means a monovalent linear or branched alkynyl group having 2 to 16 carbon atoms. The C 3-6 cycloalkyl group, the C 3-6 cycloalkenyl group, the C 6-10 aryl group, and the heterocyclic group as R 5 are defined as in the substituents described above and L 1 , etc.

The compound according to the present embodiment may be a compound represented by any chemical formula of formula (II), formula (III), or formula (IV).

In formula (II), formula (III), and formula (IV), L 2 , L 3 , R 1 , R 2 , R 3 , R 4 , and R 5 are defined as in formula (I).

In the formulas (I) to (IV), L 2 may be an oxygen atom, an unsubstituted nitrogen atom, or a methylene group. L 3 may be a single bond, or an optionally substituted linear or branched C 1-6 alkylene group or C 2-6 alkynylene group, or may be a linear or branched C 1-6 alkylene group, C 2-6 alkenylene group, or C 2-6 alkynylene group substituted by an oxo group which forms an ester group together with the oxygen atom bonded to R 5 .

In the formulas (I) to (IV), R 1 , R 2 , and R 3 may each independently be an optionally substituted linear or branched C 1-4 alkyl group. R 4 may be a hydrogen atom, an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group. R 5 may be a hydrogen atom, an optionally substituted linear or branched C 1-16 alkyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group.

In the formulas (I) to (IV), preferably, L 2 is a single bond or an unsubstituted nitrogen atom, L 3 is a single bond or an optionally substituted linear or branched C 1-6 alkylene group, R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group, R 4 is an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and R 5 is a hydrogen atom, an optionally substituted linear or branched C 1-16 alkyl group, or an optionally substituted C 3-6 cycloalkyl group.

In the formulas (I) to (IV), more preferably, L 2 is a single bond or an unsubstituted nitrogen atom, L 3 is a single bond or an optionally substituted linear or branched C 1-6 alkylene group, R 1 , R 2 , and R 3 are each independently a linear or branched C 1-4 alkyl group, R 4 is an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and R 5 is a hydrogen atom, a linear or branched C 1-16 alkyl group, a linear or branched C 1-16 alkyl group substituted by a halogen atom, an oxo group, or a linear or branched C 1-6 alkyl group, or a C 3-6 cycloalkyl group optionally substituted by a halogen atom.

›DESCRIPTION OF EMBODIMENTS · 4 of 9

In the formulas (I) to (IV), particularly preferably, L 2 is a single bond or an unsubstituted nitrogen atom, L 3 is a single bond or a group represented by the following formula (O-1), (O-2), (O-3), or (O-4), R 1 , R 2 , and R 3 are each independently a linear or branched C 1-4 alkyl group, R 4 is an optionally substituted phenyl group or thienyl group, and R 5 is a hydrogen atom, a linear or branched C 1-16 alkyl group, a linear or branched C 1-16 alkyl group substituted by a halogen atom, or a C 3-6 cycloalkyl group. In the present specification, the chemical formula represented by formula (O-1) is also referred to as “C(Me) 2 CH 2 ”, the chemical formula represented by formula (O-2) is also referred to as “CH 2 C(Me) 2 ”, the chemical formula represented by formula (M-2) is also referred to as “CH 2 -1,1-cyclopropylene”, and the chemical formula represented by formula (N-1) is also referred to as “1,1-cyclobutylene-CH 2 ”.

Among compounds (I) according to the present embodiment or pharmacologically acceptable salts thereof, a compound as represented by formula (V) wherein R 5 is substituted by an oxo group, and the oxo group and the oxygen atom bonded to R 5 form an ester bond, or a compound as represented by formula (VI) wherein R 5 is an alkylene group substituted by a substituent containing an oxygen atom, and an acetal group containing the oxygen atom and the oxygen atom bonded to R 5 is formed can be a compound that acts as a prodrug. The compound (V) or the compound (VI) tends to have better oral absorbability and skin penetration and can form compound (I) (wherein R 5 is a hydrogen atom) by metabolism.

In formula (V) and formula (VI), R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , and L 3 are defined as in formula (I). R 6 is a hydrogen atom, an optionally substituted linear or branched C 1-15 alkyl group, an optionally substituted linear or branched C 2-15 alkenyl group, an optionally substituted linear or branched C 2-15 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, an optionally substituted C 3-6 cycloalkenyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and R 8 and R 9 are each independently a hydrogen atom or a C 1-4 alkyl group. R 7 is a linear or branched C 1-15 alkyl group optionally having a substituent, an optionally substituted linear or branched C 2-15 alkenyl group, an optionally substituted linear or branched C 2-15 alkynyl group, an optionally substituted C 3-6 cycloalkyl group, or an optionally substituted C 3-6 cycloalkenyl group. The linear or branched C 1-15 alkyl group, the linear or branched C 2-15 alkenyl group, the linear or branched C 2-15 alkynyl group, the C 3-6 cycloalkyl group, the C 3-6 cycloalkenyl group, the C 6-10 aryl group, and the heterocyclic group as R 6 or R 7 , and substituents added to these are defined as in the groups in the formulas (I) to (IV).

R 6 may be an optionally substituted linear or branched C 1-15 alkyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted C 1-15 alkoxy group. R 7 may be an optionally substituted linear or branched C 1-16 alkyl group.

In formula (V), preferably, L 1 is a cyclopropylene group or a cyclobutylene group, L 2 is a single bond or an unsubstituted nitrogen atom, L 3 is a single bond or an optionally substituted linear or branched C 1-6 alkylene group, R 1 , R 2 , and R 3 are each independently an optionally substituted linear or branched C 1-4 alkyl group, R 4 is an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and R 6 is an optionally substituted linear or branched C 1-15 alkyl group.

In formula (V), more preferably, L 1 is a cyclobutylene group, L 2 is a single bond or an unsubstituted nitrogen atom, L 3 is a single bond or an optionally substituted linear or branched C 1-6 alkylene group, R 1 , R 2 , and R 3 are each independently a linear or branched C 1-4 alkyl group, R 4 is an optionally substituted linear or branched C 1-6 alkyl group, an optionally substituted C 6-10 aryl group, or an optionally substituted heterocyclic group, and R 6 is an optionally substituted linear or branched C 1-15 alkyl group.

The compound according to the present embodiment or a pharmacologically acceptable salt thereof is specifically a compound selected from a compound group shown below or a pharmacologically acceptable salt thereof.

(S)—N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-3-[2-methyl-2-(trimethylsilyl)propaneamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)-3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)-3-[2-(ethyldimethylsilyl)-2-methylpropaneamido]-N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-1-phenylethyl)-N,6,6-trimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5 (1H)-carboxamide, (S)-2-[(2-methoxypropan-2-yl)oxy]-1-phenylethyl6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, (S)-2-hydroxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, 2-Methoxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, N-[5-(4-hydroxy-3-phenylbutanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-hydroxy-3-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-(3-hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5 (1H)-carboxamide, (R)—N-(3-hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5 (1H)-carboxamide, (R)—N-(4-hydroxy-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5 (1H)-carboxamide, (R)—N-(5-hydroxy-1-phenylpentyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-2-methyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-2-methyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-hydroxy-3-methyl-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-methoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[2-(difluoromethoxy)-1-phenylethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-ethoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-methoxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, Sodium (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate, (R)—N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(2-fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[1-(3-fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[1-(4-fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[2-hydroxy-1-(pyridin-2-yl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[2-hydroxy-1-(pyridin-3-yl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(benzo[d][1,3]dioxol-4-yl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(1-cyclohexyl-2-hydroxyethyl)-6,6-dimethyl-3-[1-(trimethylsilyl) cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(1-hydroxy-3-methylbutan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(1-hydroxypropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-hydroxyethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-hydroxypropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(2S)-1-hydroxy-3-methyl-1-phenylbutan-2-yl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(4-hydroxy-1-phenyl-2-butyn-1-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl acetate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl propionate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl butanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl pentanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl octanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl dodecanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl palmitate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl isobutanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl pivalate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl 3-methylbutanoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl benzoate, (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl ethylcarbonate, Sodium (S)-4-(2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethoxy)-4-oxobutanoate, (S)-(2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethoxy) methyl pivalate, (S)-2-acetoxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, (S)-benzyl 2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate, (S)-methyl 2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate, N-(2,2-difluoro-3-hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-isopropoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 6,6-Dimethyl-N-(2-phenoxy-1-phenylethyl)-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[1-(2-chlorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-[2-hydroxy-1-(o-tolyl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(1-hydroxy-3-phenylpropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-hydroxy-3-methylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(1-hydroxy-3-phenylpropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (S)—N-(2-hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 2-Hydroxy-2-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate, (R)—N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (S)—N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[6,6-dimethyl-5-(2-phenoxyacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[6,6-dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide, N-{5-[3-(benzyloxy)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-hydroxy-2-phenoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(4-chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(2-chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(cyclohexyloxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(3-chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(2-methoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-methoxy-2-phenoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydro pyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-{6,6-dimethyl-5-[2-(pyridin-3-yloxy)propanoyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[3-(dimethylamino)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-[6,6-dimethyl-5-(2-phenoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[3-(3,3-difluoropyrrolidin-1-yl)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (S)—N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (R)—N-{5-[3-(benzyloxy)-2-phenylpropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (R)—N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (S)—N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(3-methoxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-[5-(4-methoxy-2-phenylbutanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (S)—N-[5-(3-hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide, (R)—N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide, (R)—N-{5-[2-(difluoromethoxy)-2-phenylacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[5-(2-ethoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (R)-1-(ethyldimethylsilyl)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimeth yl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]cyclobutanecarboxamide, (R)—N-[5-(2-cyclopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[5-(2-isopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-{6,6-dimethyl-5-[2-phenyl-2-(trifluoromethoxy)acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-[6,6-dimethyl-5-(2-phenyl-2-propoxyacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(4-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-(3-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (R)—N-{5-[2-(2-fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (−)-N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, (+)-N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide, N-{[1-(hydroxymethyl)cyclobutyl](phenyl)methyl}-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[2-(1-hydroxycyclopropyl)-1-phenylethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-ethyl-3-hydroxy-1-phenylpentyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[1-(4-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[1-(3-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[1-(2-fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(5-hydroxy-2,5-dimethylhexan-3-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(4-fluorophenyl)-3-hydroxy2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (−)-N-[1-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (+)-N-[1-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[1-(2-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(1-hydroxy-2,2,4-trimethylpentan-3-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-(3-hydroxy-3-methyl-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (−)-N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (+)-N-(3-hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, (R)—N-[5-(2-butoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide, and N-(3-methoxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide.

›DESCRIPTION OF EMBODIMENTS · 5 of 9

The compound or the pharmacologically acceptable salt thereof according to the present embodiment may be a single optically active form or may be a mixture of a plurality of optically active forms.

In the case where geometric isomers or rotational isomers are present in the compound according to the present embodiment, these isomers are also included in the scope of the present invention, and in the case where proton tautomers are present, these tautomers are also encompassed in the present invention.

The “pharmacologically acceptable salt” according to the present embodiment is not particularly limited as long as being a salt acceptable as a drug, and examples thereof include: salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, and phosphoric acid; salts with organic carboxylic acids such as acetic acid, fumaric acid, maleic acid, succinic acid, citric acid, tartaric acid, adipic acid, lactic acid, and trifluoroacetic acid; salts with organic sulfonic acids such as methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and naphthalenesulfonic acid; salts with alkali metals such as lithium, sodium, and potassium; salts with alkaline earth metals such as calcium and magnesium; and quaternary ammonium salts such as ammonia, morpholine, glucosamine, ethylenediamine, guanidine, diethylamine, triethylamine, dicyclohexylamine, diethanolamine, and piperazine.

The compound or the pharmacologically acceptable salt thereof according to the present embodiment can form a hydrate or a solvate, and each one or a mixture thereof is encompassed in the present invention.

The compound according to the present embodiment may contain a non-natural ratio of an atomic isotope for one or more of the constituting atoms. Examples of the atomic isotope include deuterium ( 2 H), tritium ( 3 H), carbon-14 ( 14 C), fluorine-18 ( 18 F), sulfur-35 ( 35 S), and iodine-125 ( 125 I). These compounds are useful as therapeutic or prophylactic agents, research reagents, for example, assay reagents, and diagnostic agents, for example, in vivo diagnostic imaging agents. All isotopic variants of the compound according to the present embodiment are encompassed in the present invention, regardless of whether to be radioactive.

The compound or the pharmacologically acceptable salt thereof according to the present embodiment can be used as a pharmaceutical composition, if necessary, by adding an excipient, a lubricant, a binder, a disintegrant, a coating agent, a stabilizer, a tonicity agent, a buffer, a pH adjuster, a solubilizer, a thickener, a preservative, an antioxidant, a sweetener, a colorant, a flavor, and the like. The pharmaceutical composition can be appropriately prepared according to a purpose by a known method described in, for example, General Rules for Preparations, Japanese Pharmacopoeia 16th edition.

In the pharmaceutical composition, the content of the compound or the pharmacologically acceptable salt thereof according to the present embodiment can be appropriately adjusted.

The pharmaceutical composition can be in a dosage form described in General Rules for Preparations, Japanese Pharmacopoeia 16th edition, for example, a preparation for oral administration such as tablets, capsules, granules, or powders, or a preparation for parenteral administration such as injections (e.g., intravenous administration, subcutaneous administration, intramuscular administration, and intraperitoneal administration), eye drops, nasal drops, suppositories, ointments, lotions, creams, gels, sprays, patches, inhalants, or percutaneous absorption preparations.

Examples of the excipient include lactose, mannitol, starch, crystalline cellulose, light anhydrous silicic acid, calcium carbonate, and calcium hydrogen phosphate, and examples of the lubricant include stearic acid, magnesium stearate, and talc. Examples of the binder include starch, hydroxypropylcellulose, hydroxypropylmethylcellulose, and polyvinylpyrrolidone, and examples of the disintegrant include carboxymethylcellulose, low-substituted hydroxypropylmethylcellulose, and calcium citrate. Examples of the coating agent include hydroxypropylmethylcellulose, macrogol, and silicone resins, and examples of the stabilizer include ethyl p-hydroxybenzoate and benzyl alcohol.

Examples of the tonicity agent include glycerin, propylene glycol, sodium chloride, potassium chloride, sorbitol, and mannitol, examples of the buffer include boric acid, boric acid salts, phosphoric acid, phosphoric acid salts, citric acid, citric acid salts, acetic acid, acetic acid salts, ε-aminocaproic acid, and trometamol, and examples of the pH adjuster include hydrochloric acid, citric acid, phosphoric acid, glacial acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium bicarbonate. Examples of the solubilizer include polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, purified soybean lecithin, and polyoxyethylene (160) polyoxypropylene (30) glycol, and examples of the thickener include cellulose polymers such as hydroxypropylmethylcellulose and hydroxypropylcellulose, polyvinyl alcohol, and polyvinylpyrrolidone. Examples of the stabilizer include edetic acid and sodium edetate, and examples of the preservative include sorbic acid, potassium sorbate, benzalkonium chloride, benzethonium chloride, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, and chlorobutanol.

Examples of ingredients that may be contained in pharmaceutical compositions for percutaneous administration such as ointments, lotions, creams, gels, patches, and sprays include: absorption promoters such as lauryl alcohol, myristyl alcohol, salicylic acid ethylene glycol, and pyrrothiodecane; fatty acid esters such as diisopropyl adipate, isopropyl myristate, cetyl lactate, myristyl lactate, isopropyl palmitate, diethyl sebacate, hexyl laurate, and cetyl isooctanoate; aliphatic alcohols such as cetyl alcohol, stearyl alcohol, oleyl alcohol, hexadecyl alcohol, and behenyl alcohol; glycols such as propylene glycol, propylenediol, polyethylene glycol, and dipropylene glycol; and surfactants such as sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyethylene glycol fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene castor oil, and polyoxyethylene hydrogenated castor oil.

›DESCRIPTION OF EMBODIMENTS · 6 of 9

The dose of the compound or the pharmacologically acceptable salt thereof according to the present embodiment can be appropriately varied according to symptoms, age, a dosage form, etc. In the case of, for example, oral administration, it can usually be administered in one portion or several divided portions of 0.01 to 2000 mg, preferably 1 to 500 mg per day.

As for ointments, lotions, creams, or gels, one having a concentration of 0.00001% (w/v) to 10% (w/v), preferably 0.001% (w/v) to 5% (w/v) can usually be administered in one portion or several divided portions.

Next, a method for producing the compound or the pharmacologically acceptable salt thereof according to the present embodiment will be described. The compound or the pharmacologically acceptable salt thereof according to the present invention is not limited to compounds or pharmacologically acceptable salts thereof produced by production methods described below.

In the production methods given below, in the case where partial structures that inhibit the desired reactions or receive side reactions (e.g., a hydroxy group, an amino group, a carbonyl group, a carboxyl group, an amide group, a thiol group and the like) are present in compounds, the compounds of interest can be obtained by introducing protective groups to these partial structures, performing the desired reactions, and then removing the protective groups.

The introduction reaction and removal reaction of a protective group can be carried out according to a method routinely used in organic synthetic chemistry (e.g., a method described in, for example, Protective Groups in Organic Synthesis, 4th ed., T. W. Greene, P. G. M. Wuts, John Wiley & Sons Inc. (2006)).

Specific methods for producing the individual compounds of the present invention will be described in detail in Examples mentioned later.

Compound (I) can be produced, for example, by methods of production methods 1 to 4 given below with compound (A) as a starting material. A method for producing the compound (A) will be mentioned later.

<Production Method 1 for Compound (I)>

Production method 1 is a method for producing compound (I) through steps 1 to 3 with compound (A) as a starting material. Production method 1 is a suitable production method in the case where L 2 is an oxygen atom or an optionally substituted nitrogen atom. In production method 1, R 1 , R 2 , R 3 , R 4 , R 5 , L 1 , L 2 , and L 3 are defined as in formula (I). P 1 group is a protective group for the amino group, and X is a leaving group. The P 1 group can substitute an acidic proton of pyrazole in the 4,6-dihydropyrrolo[3,4-c]pyrazole skeleton. Thus, the P 1 group may be added to position 1 of the 4,6-dihydropyrrolo[3,4-c]pyrazole skeleton or may be added to 2-position. Compound (A) will be described by using a chemical formula wherein it is added to 1-position of the 4,6-dihydropyrrolo[3,4-c]pyrazole skeleton, for the sake of convenience.

The P 1 group is not particularly limited as long as being a substituent known as a protective group for the amino group to those skilled in the art. Examples of the P 1 group include: optionally substituted C 7-11 aralkyl groups such as a benzyl group, a p-methoxyphenylmethyl group, and a o-nitrophenylmethyl group; optionally substituted acyl groups such as an acetyl group, a trifluoroacetyl group, and a benzoyl group; optionally substituted C 1-6 alkoxycarbonyl groups such as a methoxycarbonyl group, an ethoxycarbonyl group, a Boc group (tert-butoxycarbonyl group), a Cbz group (benzyloxycarbonyl group), a Fmoc group (fluorenylmethyloxycarbonyl group), and a Teoc group (trimethylsilylethyloxycarbonyl group); alkenyloxycarbonyl groups such as an Alloc group (allyloxycarbonyl group); alkylsulfonyl groups such as a methanesulfonyl group; and C 6-10 arylsulfonyl groups such as a p-toluenesulfonyl group.

The X group is not particularly limited as long as being a substituent known as a leaving group to those skilled in the art. Examples of X include: halogen atoms; an imidazolyl group; aminooxy groups such as a succinyl-N-oxy group and a benzotriazolyl-N-oxy group; and acyloxy groups such as a pivaloyloxy group and a benzoyloxy group. Alternatively, X may be a hydroxy group.

(Step 1)

Step 1 is the step of reacting compound (A) with an acylating agent to obtain compound (B).

As the acylating agent, for example, phosgene, diphosgene, triphosgene, carbonyldiimidazole (CDI), N,N′-disuccinimidyl carbonate, or carbonic acid ester can be used.

The amount of the acylating agent used is preferably 0.4 to 3.0 mol, more preferably 0.7 to 1.5 mol, with respect to 1 mol of the compound (A).

The reaction of step 1 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include dichloromethane, 1,2-dichloroethane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), and dimethyl sulfoxide (DMSO).

In step 1, a base can be further added in order to accelerate the reaction. Examples of the base include organic amines such as triethylamine, diisopropylethylamine (DIPEA), 1,5-diazabicyclo[4.3.0]nonene (DBN), 1,8-diazabicyclo[5.4.0]undecene (DBU), pyridine, and 4-dimethylaminopyridine (DMAP).

The amount of the base added is preferably 1 to 10 mol, more preferably 3 to 6 mol, with respect to 1 mol of the compound (A).

The reaction temperature of step 1 can be appropriately set by those skilled in the art. The reaction temperature is usually −100 to −20° C., preferably −80 to −60° C.

(Step 2)

Step 2 is the step of reacting compound (B) with compound (C) to obtain compound (D).

In step 2, the L 2 group is an oxygen atom or an optionally substituted nitrogen atom. Specifically, the compound (C) is an alcohol or an amine.

The amount of the compound (C) used is preferably 1 to 20 mol, more preferably 2 to 5 mol, with respect to 1 mol of the compound (B). The compound (C) and the compound (B) may be dissolved in an organic solvent and added to the reaction solution.

›DESCRIPTION OF EMBODIMENTS · 7 of 9

The reaction of step 2 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include dichloromethane, 1,2-dichloroethane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran (THF), 1,4-dioxane, N,N-dimethylformamide (DMF), and dimethyl sulfoxide (DMSO).

In step 2, a base can be further added in order to accelerate the reaction. Examples of the base include: organic amines such as triethylamine, diisopropylethylamine (DIPEA), 1,5-diazabicyclo[4.3.0]nonene (DBN), 1,8-diazabicyclo[5.4.0]undecene (DBU), pyridine, and 4-dimethylaminopyridine (DMAP); and inorganic bases such as potassium carbonate and sodium carbonate.

The amount of the base added is preferably 1 to 20 mol, more preferably 2 to 5 mol, with respect to 1 mol of the compound (A).

The reaction temperature of step 2 can be appropriately set by those skilled in the art. The reaction temperature is usually 0 to 120° C., preferably 25 to 100° C.

(Step 3)

Step 3 is the step of removing the P 1 group of compound (D) to produce compound (I).

The reaction conditions of step 3 can be appropriately selected by those skilled in the art according to the type of the P 1 group used. In the case where the P 1 group is, for example, an aralkyl group, it may be performed by hydrogenolysis or may be performed by using protonic acid or Lewis acid. In the case where the P 1 group is a Boc group, it can be performed by treatment with protonic acid or Lewis acid; in the case where the P 1 group is a Cbz group, it can be performed by hydrogenolysis or treatment with a base; and in the case where the P 1 group is a Teoc group, a reagent that forms a fluoride ion such as tetrabutylammonium fluoride can be used. In the case where the P 1 group is an alkoxycarbonyl group such as a methoxycarbonyl group or an ethoxycarbonyl group, it may be performed by heating in the presence of an organic amine such as triethylamine or diisopropylethylamine (DIPEA), or an inorganic base such as potassium carbonate or sodium carbonate.

The compound (I) obtained by step 3 can be converted to a pharmacologically acceptable salt thereof by a method well known to those skilled in the art.

<Production Method 2 for Compound (I)>

Production method 2 is a method for obtaining compound (D) through steps 4 and 5 with compound (C) as a starting material, followed by conversion to compound (1) according to step 3 of production method 1 described above. Production method 2 is a suitable production method in the case where L 2 is an oxygen atom or an optionally substituted nitrogen atom. In production method 2, R 1 , R 2 , R 3 , R 4 , R 5 , L 1 , L 2 , L 3 , P 1 , and X are defined as in production method 1 described above.

(Step 4)

Step 4 is the step of reacting compound (C) with an acylating agent to obtain compound (E).

In step 4, the L 2 group is an oxygen atom or an optionally substituted nitrogen atom. Specifically, the compound (C) is an alcohol or an amine.

As the acylating agent, for example, phosgene, diphosgene, triphosgene, carbonyldiimidazole (CDI), N,N′-disuccinimidyl carbonate, or carbonic acid ester can be used.

The amount of the acylating agent used is preferably 1 to 5 mol, more preferably 1 to 2 mol, with respect to 1 mol of the compound (C).

The reaction of step 4 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include acetonitrile, dichloromethane, diethyl ether, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), and dimethyl sulfoxide (DMSO).

In step 4, a base can be further added in order to accelerate the reaction. Examples of the base include organic amines such as triethylamine, diisopropylethylamine (DIPEA), 1,5-diazabicyclo[4.3.0]nonene (DBN), 1,8-diazabicyclo[5.4.0]undecene (DBU), pyridine, and 4-dimethylaminopyridine (DMAP).

The amount of the base added is preferably 1 to 5 mol, more preferably 1 to 2 mol, with respect to 1 mol of the compound (C).

The reaction temperature of step 4 can be appropriately set by those skilled in the art. The reaction temperature is usually 0 to 100° C., preferably 20 to 40° C.

(Step 5)

Step 5 is the step of reacting compound (E) with compound (A) to obtain compound (D).

The amount of the compound (E) used is preferably 1 to 5 mol, more preferably 1 to 2 mol, with respect to 1 mol of the compound (A). The compound (E) and the compound (A) may be dissolved in an organic solvent and added to the reaction solution.

The reaction of step 5 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include dichloromethane, diethyl ether, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), and dimethyl sulfoxide (DMSO).

In step 5, a base can be further added in order to accelerate the reaction. Examples of the base include organic amines such as triethylamine, diisopropylethylamine (DIPEA), 1,5-diazabicyclo[4.3.0]nonene (DBN), 1,8-diazabicyclo[5.4.0]undecene (DBU), pyridine, and 4-dimethylaminopyridine (DMAP).

The amount of the base added is preferably 1 to 10 mol, more preferably 1 to 5 mol, with respect to 1 mol of the compound (A).

The reaction temperature of step 5 can be appropriately set by those skilled in the art. The reaction temperature is usually 0 to 100° C., preferably 20 to 40° C.

<Production Method 3 for Compound (I)>

Production method 3 is a method for reacting compound (A) with compound (F) to obtain compound (D), followed by conversion to compound (I) according to step 3 of production method 1 described above. Production method 3 is a suitable production method in the case where L 2 is a single bond, an optionally substituted linear or branched C 1-6 alkylene group, an optionally substituted linear or branched C 2-6 alkenylene group, an optionally substituted linear or branched C 2-6 alkynylene group, an optionally substituted C 3-6 cycloalkylene group, or an optionally substituted C 3-6 cycloalkenylene group. In production method 3, R 1 , R 2 , R 3 , R 4 , R 5 , L 1 , L 3 , and P 1 are defined as in production method 1 described above.

›DESCRIPTION OF EMBODIMENTS · 8 of 9

(Step 6)

Step 6 is the step of condensing compound (A) with compound (F) to obtain compound (D). The condensation reaction involves converting the compound (F) to an acid halide, a carboxylic anhydride, an acid azide, or an active ester by using a reagent used in amide bond formation reaction, followed by reaction with the compound (A). The reagent used in amide bond formation reaction is not particularly limited as long as being a reagent known as a reagent used in amide bond formation reaction to those skilled in the art.

The amount of the compound (F) used is preferably 1 to 10 mol, more preferably 1 to 5 mol, with respect to 1 mol of the compound (A). The compound (F) may be dissolved in an organic solvent and added to the reaction solution.

The reaction of step 6 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include dichloromethane, 1,2-dichloroethane, diethyl ether, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), and dimethyl sulfoxide (DMSO).

In step 6, a base can be further added in order to accelerate the reaction. Examples of the base include organic amines such as triethylamine, diisopropylethylamine (DIPEA), 1,5-diazabicyclo[4.3.0]nonene (DBN), 1,8-diazabicyclo[5.4.0]undecene (DBU), pyridine, and 4-dimethylaminopyridine (DMAP).

The amount of the base added is preferably 1 to 10 mol, more preferably 1 to 5 mol, with respect to 1 mol of the compound (A).

The reaction temperature of step 6 can be appropriately set by those skilled in the art. The reaction temperature is usually 0 to 100° C., preferably 20 to 40° C.

<Production Method 4 for Compound (I)>

Production method 4 is a method for obtaining compound (D) through step 7 and step 8 with compound (H) as a starting material, followed by conversion to compound (I) according to step 3 of production method 1 described above. In production method 4, R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , and L 3 are defined as in formula (I). P 1 group is a protective group for the amino group, and P 2 is a protective group for the hydroxy group. The P 1 group is defined as in production method 1 described above.

The P 2 group is not particularly limited as long as being a substituent known as a protective group for the hydroxy group to those skilled in the art. Examples of the P 2 group include: optionally substituted C 7-11 aralkyl groups such as a benzyl group, a p-methoxyphenylmethyl group, and a o-nitrophenylmethyl group; optionally substituted acyl groups such as an acetyl group, a trifluoroacetyl group, and a benzoyl group; and substituted silyl groups such as a trimethylsilyl group, a tert-butyldimethylsilyl group, a triethylsilyl group, a triisopropylsilyl group, and a tert-butyldiphenylsilyl group.

(Step 7)

Step 7 is the step of performing the deprotection reaction of compound (H) to obtain compound (J). The removal reaction of the P 2 group can also be performed by a method well known to those skilled in the art (e.g., a method described in, for example, Protective Groups in Organic Synthesis, 4th ed., T. W. Greene, P. G. M. Wuts, John Wiley & Sons Inc. (2006)).

(Step 8)

Step 8 is the step of reacting compound (J) with an acid halide, an acid anhydride, or an alkyl halide to obtain compound (D).

The amount of the acid halide, the acid anhydride, or the alkyl halide used is preferably 1 to 10 mol, more preferably 1 to 2 mol, with respect to 1 mol of the compound (J).

The reaction of step 7 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include dichloromethane, diethyl ether, tetrahydrofuran (THF), 1,4-dioxane, N,N-dimethylformamide (DMF), and dimethyl sulfoxide (DMSO).

In step 8, a base can be further added in order to accelerate the reaction. Examples of the base include organic amines such as triethylamine, diisopropylethylamine (DIPEA), 1,5-diazabicyclo[4.3.0]nonene (DBN), 1,8-diazabicyclo[5.4.0]undecene (DBU), pyridine, and 4-dimethylaminopyridine (DMAP).

The amount of the base added is preferably 1 to 20 mol, more preferably 1 to 5 mol, with respect to 1 mol of the compound (J).

The reaction temperature of step 8 can be appropriately set by those skilled in the art. The reaction temperature is usually −20 to 120° C., preferably 15 to 100° C.

<Method for Producing Compound (A)>

The compound (A) can be produced, for example, by the following method with compound (A1) as a starting material. Compound (A1) can be produced, for example, with reference to WO2007/72153 or through the following steps 11 to 15.

The compound (A1) is 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole in which the nitrogen atom on the pyrazole skeleton may be substituted by P 1 group, and the nitrogen atom at 5-position may be substituted by P 3 group. The P 1 group can substitute an acidic proton of pyrazole in the 4,6-dihydropyrrolo[3,4-c]pyrazole skeleton. Thus, the P 1 group may be added to position 1 of the 4,6-dihydropyrrolo[3,4-c]pyrazole skeleton or may be added to 2-position. Compound (A1) and compound (A2) will be described by using a chemical formula wherein it is added to 1-position of the 4,6-dihydropyrrolo[3,4-c]pyrazole skeleton, for the sake of convenience.

In the compound (A1), P 1 has the same meaning as defined in compound (A). The P 3 group is not particularly limited as long as being a substituent known as a protective group for the amino group to those skilled in the art. Examples of the P 3 group include: optionally substituted C 7-11 aralkyl groups such as a benzyl group, a p-methoxyphenylmethyl group, and a o-nitrophenylmethyl group; optionally substituted C 1-6 alkylcarbonyl groups such as an acetyl group and a trifluoroacetyl group; optionally substituted C 6-10 arylcarbonyl groups such as a benzoyl group; optionally substituted C 1-6 alkoxycarbonyl groups such as a methoxycarbonyl group, an ethoxycarbonyl group, a Boc group (tert-butoxycarbonyl group), a Cbz group (benzyloxycarbonyl group), a Fmoc group (fluorenylmethyloxycarbonyl group), and a Teoc group (trimethylsilylethyloxycarbonyl group); alkenyloxycarbonyl groups such as an Alloc group (allyloxycarbonyl group); alkylsulfonyl groups such as a methanesulfonyl group; and optionally substituted C 6-10 arylsulfonyl groups such as a p-toluenesulfonyl group.

›DESCRIPTION OF EMBODIMENTS · 9 of 9

In the formulas (A2) and (A3), R 1 , R 2 , R 3 , and L 1 have the same meanings as defined in compound (I). The group X is not particularly limited as long as being a substituent known as a leaving group to those skilled in the art. Examples of X include: halogen atoms; an imidazolyl group; aminooxy groups such as a succinyl-N-oxy group and a benzotriazolyl-N-oxy group; and acyloxy groups such as a pivaloyloxy group and a benzoyloxy group. Alternatively, X may be a hydroxy group.

In the case where the compound (A2) is a carboxylic acid (i.e., X is a hydroxy group), it may be converted to an acid anhydride by a method well known to those skilled in the art and then reacted with the compound (A1), or may be reacted with the compound (A1) by using a reagent known as a condensing agent used in amide bond formation reaction to those skilled in the art.

(Step 9)

Step 9 is the step of reacting compound (A1) with compound (A2) to obtain compound (A3).

The amount of the compound (A2) used is preferably 1 to 10 mol, more preferably 1 to 3 mol, with respect to 1 mol of the compound (A1).

The reaction of step 9 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include dichloromethane, diethyl ether, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), and dimethyl sulfoxide (DMSO).

In step 9, a base can be further added in order to accelerate the reaction. Examples of the base include organic amines such as triethylamine, diisopropylethylamine (DIPEA), 1,5-diazabicyclo[4.3.0]nonene (DBN), 1,8-diazabicyclo[5.4.0]undecene (DBU), pyridine, and 4-dimethylaminopyridine (DMAP).

The amount of the base added is preferably 1 to 20 mol, more preferably 1 to 5 mol, with respect to 1 mol of the compound (A1).

The reaction temperature of step 9 can be appropriately set by those skilled in the art. The reaction temperature is usually −40 to 100° C., preferably −20 to 20° C.

(Step 10)

Step 10 is the step of performing the deprotection reaction of compound (A3) to obtain compound (A). The removal reaction of the P 3 group can also be performed by a method well known to those skilled in the art (e.g., a method described in, for example, Protective Groups in Organic Synthesis, 4th ed., T. W. Greene, P. G. M. Wuts, John Wiley & Sons Inc. (2006)).

<Method for Producing Compound (A1)>

In the formulas (A6), (A7), and (A8), P 3 has the same meaning as defined in compound (A1).

(Step 11)

Step 11 is the step of reacting compound (A4) with acrylonitrile to obtain compound (A5).

The amount of the acrylonitrile used is preferably 1 to 10 mol, more preferably 1 to 3 mol, with respect to 1 mol of the compound (A4).

In step 11, there is no limitation as long as a solvent does not have influence on the reaction, and an aqueous solvent is preferred.

In step 11, a base can be further added in order to accelerate the reaction. Examples of the base include inorganic bases such as potassium hydroxide. The amount of the base added is preferably 0.8 to 2 mol, with respect to 1 mol of the compound (A1).

The reaction temperature of step 11 can be appropriately set by those skilled in the art. The reaction temperature is usually 0 to 100° C., preferably 50 to 90° C.

(Step 12)

Step 12 is the step of protecting the amino group of compound (A5) with P 3 group to obtain compound (A6). The protection reaction of the amino group with the P 3 group can be performed by a method well known to those skilled in the art (e.g., a method described in, for example, Protective Groups in Organic Synthesis, 4th ed., T. W. Greene, P. G. M. Wuts, John Wiley & Sons Inc. (2006)).

(Step 13)

Step 13 is the step of performing the cyclization reaction of compound (A6) to obtain compound (A7).

The reaction of step 13 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include diethyl ether, tetrahydrofuran (THF), 1,4-dioxane, N,N-dimethylformamide (DMF) toluene.

In step 13, a base can be further added in order to accelerate the reaction. Examples of the base include sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, n-butyllithium, and tert-butoxy potassium. The amount of the base added is preferably 1 to 3 mol with respect to 1 mol of the compound (A6).

The reaction temperature of step 13 can be appropriately set by those skilled in the art. The reaction temperature is usually 20 to 150° C., preferably 50 to 100° C.

(Step 14)

Step 14 is the step of reacting compound (A7) with hydrazine to obtain compound (A8).

The reaction of step 14 may be performed in a solvent or may be performed without a solvent. In the case of using a solvent, there is no limitation as long as the solvent does not have influence on the reaction, and an organic solvent is preferred. Examples of the organic solvent include ethanol, n-propanol, and n-butanol.

In step 14, an acid can be further added in order to accelerate the reaction. Examples of the acid include acetic acid, hydrochloric acid, and sulfuric acid. The amount of the acid added is preferably 1 to 10 mol with respect to 1 mol of the compound (A7).

The reaction temperature of step 14 can be appropriately set by those skilled in the art. The reaction temperature is usually 20 to 150° C., preferably 50 to 120° C.

(Step 15)

Step 15 is the step of protecting the amino group of compound (A7) with P 1 group to obtain compound (A1). The protection reaction of the amino group with the P 1 group can be performed by a method well known to those skilled in the art (e.g., a method described in, for example, Protective Groups in Organic Synthesis, 4th ed., T. W. Greene, P. G. M. Wuts, John Wiley & Sons Inc. (2006)).

›EXAMPLE

Hereinafter, the present invention will be described further specifically as to the compound according to the present embodiment or the pharmaceutically acceptable salt thereof by showing Examples (Examples 1 to 125), Reference Examples (Reference Examples 1 to 137), and Test Examples (Test Examples 1 to 12); however, these examples are given for more understanding the present invention and does not limit the scope of the present invention.

DIOL silica gel in silica gel column chromatography represents CHROMATOREX (trade name) DIOL MB 100-40/75 manufactured by Fuji Silysia Chemical Ltd.

DNH silica gel in silica gel column chromatography represents CHROMATOREX (trade name) DNH MB 100-40/75 manufactured by Fuji Silysia Chemical Ltd.

In the case where a plurality of values of mass spectra are observed due to the presence of isotopes, only one having minimum m/z was described. DUIS in an ionization mode of a mass spectrum is a mixed mode of ESI and APCI.

1 H-NMR is indicated by chemical shift (δ) with tetramethylsilane as an internal standard (0 ppm), and a coupling constant (J value) is indicated by Hz unit, unless otherwise specified. An abbreviation for the split pattern of each peak has the following meaning: s: singlet, d: doublet, t: triplet, q: quartet, and br: broad.

Abbreviations described in Examples and Reference Examples are usually used as meanings generally used in the fields of organic chemistry and pharmacy. Each abbreviation is specifically understood by those skilled in the art as follows.

ATP: adenosine triphosphate

Boc: tert-butyloxycarbonyl

DIPEA: N,N-diisopropylethylamine

DMF: N,N-dimethylformamide

DMSO: dimethyl sulfoxide

DTT: dithiothreitol

Et: ethyl

FBS: fetal bovine serum

HEPES: N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid

MBP: myelin basic protein

n-: normal

NADPH: nicotinamide adenine dinucleotide phosphate

PBMC: peripheral blood mononuclear cell

PBS: aqueous solution of phosphate-buffered sodium chloride

TBME: tert-butyl methyl ether

TB S: tert-butyldimethylsilyl

tert-: tertiary

THF: tetrahydrofuran

Tris: trishydroxyaminomethane

›Examples134
›Example 1

(S)—N-(2-Hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-114)

To a solution of 308 mg (0.698 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 6 ml of THF, 0.23 ml (1.4 mmol) of DIPEA and 472 mg (3.44 mmol) of (S)-(+)-2-phenylglycinol were added at room temperature, then applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour. Subsequently, 2.7 ml (67 mmol) of methanol and 2.7 ml (19 mmol) of triethylamine were added to the reaction solution, then applied to a microwave reaction apparatus, and reacted at 80° C. for 0.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/diethyl ether, and the obtained solid was collected by filtration. 20 ml of water was added to the obtained solid and stirred, and then, insoluble matter was collected by filtration and dried under reduced pressure to obtain 152 mg of the title compound (yield: 46%) as a white solid.

Mass spectrum (DUIS, m/z): 470 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.65 (br s, total 1H), 9.66-9.46 (m, 1H), 7.41-7.25 (m, 4H), 7.22-7.15 (m, 1H), 6.18 & 6.06 (d, J=7.7 Hz, total 1H), 4.88 (t, J=5.9 Hz, 1H), 4.83-4.71 (m, 1H), 4.62-4.41 (m, 2H), 3.69-3.52 (m, 2H), 2.49-2.41 (m, 2H), 2.30-2.12 (m, 2H), 1.93-1.73 (m, 2H), 1.68-1.44 (m, 6H), 0.17-0.04 (m, 9H).

›Example 2

(S)—N-(2-Hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. III-114)

To a solution of 433 mg (1.08 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate hydrochloride synthesized in the similar manner as in Reference Example 7 in 7.5 ml of dehydrated dichloromethane, 0.90 ml (5.2 mmol) of DIPEA was added at room temperature in a nitrogen atmosphere, and then, a solution of 275 mg (0.928 mmol) of bis(trichloromethyl)carbonate in 2.5 ml of dehydrated dichloromethane was added dropwise at −78° C. and stirred at the same temperature as above for 2.5 hours.

After the completion of the reaction, 10 ml of a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred while the temperature was raised to room temperature for a while. The organic layer and the aqueous layer were separated, and then, the aqueous layer was subjected to extraction with dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 80:20 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain a concentration residue.

To a solution of 457 mg of the obtained concentration residue in 4 ml of dehydrated THF, 0.40 ml (2.2 mmol) of DIPEA and 528 mg (3.85 mmol) of (S)-(+)-2-phenylglycinol were added at room temperature in a nitrogen atmosphere and then stirred for 3.75 hours while heated to reflux. Subsequently, 0.90 ml (6.5 mmol) of triethylamine and 0.90 ml (22 mmol) of methanol were added to the reaction solution and then stirred for 1 hour while heated to reflux.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: dichloromethane:methanol=100:0 to 97:3 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/diisopropyl ether/n-hexane, and the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 388 mg of the title compound (yield: 79% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 456 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.02 & 11.54 (br s, total 1H), 9.44 & 9.25 (br s, total 1H), 7.40-7.33 (m, 2H), 7.33-7.24 (m, 2H), 7.23-7.16 (m, 1H), 5.88-5.69 (m, 1H), 4.86-4.79 (m, 1H), 4.61 (t, J=5.6 Hz, 1H), 4.55-4.37 (m, 2H), 3.71-3.64 (m, 2H), 1.63 (s, 3H), 1.57 (s, 3H), 1.08-1.01 (m, 2H), 0.83-0.60 (m, 2H), 0.07 (s, 9H).

›Example 3

(S)—N-(2-Hydroxy-1-phenylethyl)-6,6-dimethyl-3-[2-methyl-2-(trimethylsilyl)propanamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. II-114)

To a solution of 337 mg (0.714 mmol) of 5-tert-butyl 1-ethyl 6,6-dimethyl-3-[2-methyl-2-(trimethylsilyl)propanamido]pyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 9 in 3 ml of dehydrated dichloromethane, 0.25 ml (2.2 mmol) of 2,6-lutidine and 0.39 ml (2.2 mmol) of trimethylsilyl trifluoromethanesulfonate were added in this order at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 1.5 hours.

After the completion of the reaction, the reaction solution was diluted with dichloromethane and subsequently washed with a saturated aqueous solution of sodium bicarbonate. The organic layer and the aqueous layer were separated, and then, the aqueous layer was subjected to extraction with dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The operation of adding 25 ml of toluene to the obtained concentration residue and concentrating it under reduced pressure was repeated three times, followed by drying under reduced pressure to obtain a concentration residue.

To a solution of 292 mg of the obtained concentration residue in 5 ml of dehydrated dichloromethane, 0.38 ml (2.2 mmol) of DIPEA was added at room temperature in a nitrogen atmosphere, and then, 149 mg (0.502 mmol) of bis(trichloromethyl)carbonate was added at −78° C. and stirred at the same temperature as above for 2.5 hours.

After the completion of the reaction, 7 ml of a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred while the temperature was raised to room temperature for a while. The organic layer and the aqueous layer were separated, and then, the aqueous layer was subjected to extraction with dichloromethane once. All of the organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 85:15 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain a concentration residue.

To a solution of 262 mg of the obtained concentration residue in 3 ml of dehydrated THF, 0.27 ml (1.6 mmol) of DIPEA and 255 mg (1.86 mmol) of (S)-(+)-2-phenylglycinol were added at room temperature in a nitrogen atmosphere and then stirred for 2.5 hours while heated to reflux. Subsequently, 1.0 ml (7.2 mmol) of triethylamine and 1.0 ml (25 mmol) of methanol were added to the reaction solution and then stirred for 5.5 hours while heated to reflux.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 0.10 ml of acetic acid was added to the obtained concentration residue and then subjected to silica gel column chromatography (DIOL silica gel, elution solvent: dichloromethane:methanol=100:0 to 97:3 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/n-hexane, and the obtained solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 206 mg of the title compound (yield: 63% [3 steps]) as a pale yellow solid.

Mass spectrum (CI, m/z): 458 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.25 & 11.64 (br s, total 1H), 9.42-9.11 (m, 1H), 7.38-7.25 (m, 4H), 7.23-7.15 (m, 1H), 6.21-6.05 (m, 1H), 4.87 (t, J=5.9 Hz, 1H), 4.81-4.73 (m, 1H), 4.57-4.41 (m, 2H), 3.70-3.54 (m, 2H), 1.66-1.47 (m, 6H), 1.25 (s, 6H), 0.04 (s, 9H).

›Example 4

(S)-3-[1-(Ethyldimethylsilyl)cyclobutanecarboxamido]-N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-117)

To a solution of 454 mg (0.997 mmol) of ethyl 5-(chlorocarbonyl)-3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 13 in 10 ml of dehydrated THF, 700 mg (5.10 mmol) of (S)-(+)-2-phenylglycinol and 0.35 ml (2.0 mmol) of DIPEA were added at room temperature in an argon atmosphere and then stirred at 60° C. for 4 hours. Subsequently, 6 ml of methanol and 2 ml of triethylamine were added to the reaction solution and stirred at 60° C. for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, a saturated aqueous solution of sodium bicarbonate was added to the obtained concentration residue, and the mixed solution was subjected to extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the concentration residue, crystallization was performed with dichloromethane/diisopropyl ether, and the deposited solid was collected by filtration and subsequently dried under reduced pressure to obtain 404 mg of the title compound (yield: 84%) as a white solid.

Mass spectrum (DUIS, m/z): 484 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.66 (br s, total 1H), 9.64-9.47 (m, 1H), 7.40-7.14 (m, 5H), 6.26-6.01 (m, 1H), 4.88 (t, J=5.8 Hz, 1H), 4.83-4.71 (m, 1H), 4.60-4.43 (m, 2H), 3.66-3.54 (m, 2H), 2.48-2.42 (m, 2H), 2.33-2.14 (m, 2H), 1.93-1.72 (m, 2H), 1.67-1.45 (m, 6H), 0.92 (t, J=7.9 Hz, 3H), 0.60 (q, J=7.9 Hz, 2H), 0.08 (s, 6H).

›Example 5

(S)-3-[2-(Ethyldimethylsilyl)-2-methylpropanamido]-N-(2-hydroxy-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. II-116)

To a solution of 2.44 g (6.41 mmol) of ethyl 3-[2-(ethyldimethylsilyl)-2-methylpropanamido]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate synthesized in the similar manner as in Reference Example 16 in 30 ml of dehydrated dichloromethane, 5.6 ml (32 mmol) of DIPEA and a solution of 1.33 g (4.48 mmol) of bis(trichloromethyl)carbonate in 10 ml of dehydrated dichloromethane were added in this order at −78° C. in a nitrogen atmosphere and stirred at the same temperature as above for 1 hour.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the temperature was raised to room temperature for a while with stirring. After separation into an aqueous layer and an organic layer, the aqueous layer was subjected to extraction with dichloromethane. All of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=95:5 to 70:30 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 2.51 g of a concentration residue.

To a solution of 474 mg of the obtained concentration residue in ml of dehydrated THF, 700 mg (5.10 mmol) of (S)-2-amino-2-phenylethanol and 0.35 ml (2.0 mmol) of DIPEA were added at room temperature in an argon atmosphere, then applied to a microwave reaction apparatus, and reacted at 100° C. for 2 hours. After standing to cool, 6 ml of methanol and 2 ml of triethylamine were added, applied to a microwave reaction apparatus, and reacted at 80° C. for 3 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, a saturated aqueous solution of sodium bicarbonate was added to the obtained concentration residue, and the mixed solution was subjected to extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the concentration residue, crystallization was performed with dichloromethane/diisopropyl ether, and the deposited solid was collected by filtration and subsequently dried under reduced pressure to obtain 321 mg of the title compound (yield: 56% [2 steps]) as a white solid.

Mass spectrum (DUIS, m/z): 472 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.26 & 11.67 (br s, total 1H), 9.42-9.16 (m, 1H), 7.38-7.25 (m, 4H), 7.25-7.14 (m, 1H), 6.20-6.04 (m, 1H), 4.88 (t, J=5.8 Hz, 1H), 4.82-4.72 (m, 1H), 4.55-4.42 (m, 2H), 3.66-3.55 (m, 2H), 1.64-1.48 (m, 6H), 1.26 (s, 6H), 0.90 (t, J=7.9 Hz, 3H), 0.56 (q, J=7.9 Hz, 2H), 0.02 (s, 6H).

›Example 6

(S)—N-(2-Hydroxy-1-phenylethyl)-N,6,6-trimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-119)

To a solution of 210 mg (1.39 mmol) of (S)-2-(methylamino)-2-phenylethanol [synthesized according to the method described in J. Org. Chem., 1992, 57, 5383-5394] in 3 ml of dehydrated 1,4-dioxane, 0.24 ml (1.37 mmol) of DIPEA and 200 mg (0.454 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 were added in an argon atmosphere and stirred at 100° C. for 3 hours. Subsequently, 1 ml of triethylamine and 1 ml of methanol were added to the reaction solution and stirred at room temperature for 16 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was repulp-washed in hexane, and the solid was collected by filtration and then dried under reduced pressure to obtain 105 mg of the title compound (yield: 48%) as a white solid.

Mass spectrum (CI, m/z): 484 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.84 (br s, total 1H), 9.75-9.42 (m, 1H), 7.41-7.21 (m, 5H), 4.85 (t, J=5.2 Hz, 1H), 4.82-4.76 (m, 1H), 4.58-4.35 (m, 2H), 3.96-3.78 (m, 2H), 2.52 (s, 3H), 2.47-2.38 (m, 2H), 2.23-2.11 (m, 2H), 1.87-1.72 (m, 2H), 1.71-1.52 (m, 6H), 0.05 (s, 9H).

›Example 7

(S)-2-[(2-Methoxypropan-2-yl)oxy]-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (Compound No. VI-360)

To 205 mg of crude ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate [containing impurities] obtained through the same reaction as in Reference Example 5 from 225 mg (0.470 mmol) of 5-tert-butyl 1-ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 4, a solution of 187 mg (0.533 mmol) of (S)-2,5-dioxopyrrolidin-1-yl {2-[(2-methoxypropan-2-yl)oxy]-1-phenylethyl}carbonate synthesized in the similar manner as in Reference Example 18 in 3 ml of THF and 0.28 ml (1.6 mmol) of DIPEA were added at room temperature in a nitrogen atmosphere and stirred at the same temperature as above for 15 hours. Subsequently, 1.0 ml (7.2 mmol) of triethylamine and 0.70 ml (17 mmol) of methanol were added to the reaction solution and stirred at room temperature 4.5 hours and for 2 hours while heated to reflux, and then, 247 mg (1.80 mmol) of (S)-2-amino-2-phenylethanol was added to the reaction solution and stirred for 4.5 hours while heated to reflux.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=80:20 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/n-hexane, and the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 22.7 mg of the title compound (yield: 9% [2 steps]) as a white solid. The filtrate was further concentrated under reduced pressure and dried under reduced pressure to obtain 178 mg of the title compound (yield: 70% [2 steps]) as a white foam.

Mass spectrum (ESI, m/z): 565 [M+23(Na)] + , 541 [M−1] − .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.35-12.19 & 11.96-11.80 (m, total 1H), 9.85-9.44 (m, 1H), 7.45-7.26 (m, 5H), 5.81-5.68 (m, 1H), 4.63-4.18 (m, 2H), 3.72-3.50 (m, 2H), 3.08-2.94 (m, 3H), 2.56-2.38 (m, 2H), 2.30-2.10 (m, 2H), 1.94-1.75 (m, 2H), 1.73-1.45 (m, 6H), 1.32-1.18 (m, 6H), 0.13-0.02 (m, 9H).

›Example 8

(S)-2-Hydroxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (Compound No. IV-2)

To a solution of 175 mg (0.322 mmol) of (S)-2-[(2-methoxypropan-2-yl)oxy]-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate synthesized in the similar manner as in Example 7 in 2.5 ml of methanol, 9.6 mg (0.038 mmol) of pyridinium p-toluenesulfonate was added at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 70 minutes.

After the completion of the reaction, 0.1 ml of triethylamine was added to the reaction solution and then concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=65:35 to 25:75 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/n-hexane, and the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 124 mg of the title compound (yield: 82%) as a white solid.

Mass spectrum (CI, m/z): 471 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.35-12.11 & 11.97-11.79 (m, total 1H), 9.84-9.46 (m, 1H), 7.46-7.20 (m, 5H), 5.71-5.58 (m, 1H), 5.12-4.95 (m, 1H), 4.72-4.18 (m, 2H), 3.80-3.54 (m, 2H), 2.60-2.38 (m, 2H), 2.30-2.10 (m, 2H), 1.93-1.74 (m, 2H), 1.74-1.43 (m, 6H), 0.16-0.02 (m, 9H).

›Example 9

2-Methoxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (Compound No. III-5)

To a solution of 2.15 g (5.36 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate hydrochloride synthesized in the similar manner as in Reference Example 7 in 72 ml of dehydrated dichloromethane, 3.6 ml (21 mmol) of DIPEA was added at room temperature and subsequently cooled in a dry ice/acetone coolant, and then, a solution of 1.17 g (3.94 mmol) of bis(trichloromethyl)carbonate in 12 ml of dehydrated dichloromethane was added dropwise over 30 minutes and stirred at the same temperature as above for 6 hours. During this reaction, 3.6 ml (21 mmol) of DIPEA 4 times and DIPEA (1.0 ml, 5.7 mmol) once were added in this order.

After the completion of the reaction, 46 ml of a saturated aqueous solution of sodium bicarbonate was added at −78° C., and then, the temperature was raised to room temperature for a while. The reaction solution was separated into an aqueous layer and an organic layer, then the aqueous layer was subjected to extraction with 50 ml of dichloromethane twice, all of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=78:22 to 57:43 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. 20 ml of n-hexane was added to the concentration residue and cooled in ice, and then, the deposited solid was collected by filtration and dried under reduced pressure to obtain 1.96 g of white solid.

To 40.4 mg (0.0946 mmol) of the obtained white solid, 224 mg (1.48 mmol) of 2-methoxy-1-phenylethanol [synthesized according to the method described in WO 2012/138648], 26.0 mg (0.188 mmol) of potassium carbonate, 0.8 ml of 1,2-dimethoxyethane, and 80 mg of molecular sieve 4 A (powder) were added at room temperature and then stirred at 80° C. for 26 hours.

After the completion of the reaction, insoluble matter was filtered, and 10 ml of ethyl acetate, 5 ml of water, and 5 ml of a saturated aqueous solution of sodium chloride were added to the filtrate and then the aqueous layer and the organic layer were separated. The obtained organic layer was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography four times (silica gel (1st run), elution solvent: 1,2-dichloroethane:methanol=100:0 to 93:7 (V/V); silica gel (2nd run), elution solvent: ethyl acetate:methanol=98:2 to 95:5 (V/V); silica gel (3rd run), elution solvent: 1,2-dichloroethane:methanol=98:2 to 95:5 (V/V); and DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=98:2 to 95:5 (V/V)) and preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: 0.1% aqueous formic acid solution: 0.1% formic acid:acetonitrile=50:50 to 5:95 (V/V))), and a fraction containing the compound of interest was neutralized with dilute aqueous ammonia solution and then concentrated under reduced pressure. The obtained concentration residue was dissolved by adding acetonitrile and water and then freeze-dried to obtain 4.1 mg of the title compound (yield: 8% [2 steps]) as a white foam.

Mass spectrum (DUIS, m/z): 471 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.40-11.86 (m, 1H), 10.11-9.61 (m, 1H), 7.49-7.22 (m, 5H), 5.90-5.71 (m, 1H), 4.63-4.14 (m, 2H), 3.77-3.51 (m, 2H), 3.30-3.29 (m, 3H), 1.78-1.40 (m, 6H), 1.11-0.92 (m, 2H), 0.81-0.59 (m, 2H), 0.11-0.04 (m, 9H).

›Example 10

N-[5-(4-Hydroxy-3-phenylbutanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-558)

To a solution of 160 mg (0.536 mmol) of ethyl 4-(benzyloxy)-3-phenylbutanoate synthesized in the similar manner as in Reference Example 19 in a mixture of 3 ml of THF/1.5 ml of water, 48 mg (1.1 mmol) of lithium hydroxide monohydrate was added at room temperature in an argon atmosphere, stirred at the same temperature as above for 2 hours, and then stirred at 60° C. for 3 hours. The reaction solution was concentrated under reduced pressure, and 3 ml of ethanol and 1.0 ml (2.0 mmol) of a 2 N aqueous sodium hydroxide solution were added to the obtained concentration residue at room temperature and heated and stirred at 60° C. for 1 hour.

After the completion of the reaction, 1 N hydrochloric acid was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 50:50 (V/V)), and a fraction containing 4-(benzyloxy)-3-phenylbutanoic acid was concentrated under reduced pressure and dried under reduced pressure to obtain a concentration residue.

To a solution of 137 mg of the obtained concentration residue, 165 mg (0.436 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate synthesized in the similar manner as in Reference Example 5, and 201 mg (0.529 mmol) of O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate in 3 ml of dehydrated dichloromethane, 0.185 ml (1.06 mmol) of DIPEA was added at room temperature in an argon atmosphere and stirred at room temperature for 16 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=70:30 to 0:100 (V/V)), and a fraction containing ethyl 5-[4-(benzyloxy)-3-phenylbutanoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1 (4H)-carboxylate was concentrated under reduced pressure and dried under reduced pressure to obtain a concentration residue.

To a solution of 256 mg of the obtained concentration residue in a mixture of 2 ml of THF/2 ml of methanol, 2 ml of triethylamine was added at room temperature in an argon atmosphere and stirred at the same temperature as above for 16 hours. Subsequently, 0.20 ml (3.3 mmol) of 2-aminoethanol was added at room temperature and stirred at the same temperature as above for 30 minutes.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a concentration residue.

To a solution of 250 mg of the obtained concentration residue in 3 ml of ethanol, 25 mg of 20% palladium hydroxide/carbon (containing 50% water) was added in an argon atmosphere and after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 2 hours.

After the completion of the reaction, replacement with an argon atmosphere was performed, and the reaction solution was filtered through celite. The solid on the celite was washed with ethanol, and all of the filtrates were concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 93 mg of the title compound (yield: 45% [3 steps]) as a white solid.

Mass spectrum (CI, m/z): 469 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.19 & 11.83 (br s, total 1H), 9.84-9.47 (m, 1H), 7.27-7.21 (m, 4H), 7.18-7.12 (m, 1H), 4.72 (t, J=5.3 Hz, 1H), 4.57 (d, J=12.4 Hz, 1H), 4.44 (d, J=12.4 Hz, 1H), 3.60-3.52 (m, 2H), 3.27-3.19 (m, 1H), 2.75 (dd, J=6.0, 15.9 Hz, 1H), 2.58-2.52 (m, 1H), 2.48-2.40 (m, 2H), 2.25-2.12 (m, 2H), 1.89-1.72 (m, 2H), 1.61 (s, 3H), 1.49 (s, 3H), 0.08 (s, 9H).

›Example 11

N-[5-(3-Hydroxy-3-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-562)

To a solution of 285 mg (0.543 mmol) of a mixture of ethyl 6,6-dimethyl-5-(3-oxo-3-phenylpropanoyl)-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylat e synthesized in the similar manner as in Reference Example 20 and (Z)-ethyl 5-(3-hydroxy-3-phenylacryloyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate as a tautomer in 5 ml of methanol, 9.2 mg (0.24 mmol) of sodium borohydride was added at 0° C. in a nitrogen atmosphere and stirred for 1.5 hours after the temperature was raised to room temperature.

After the completion of the reaction, 10 ml of a saturated aqueous solution of ammonium chloride and dichloromethane were added to the reaction solution and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with dichloromethane, all of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with dichloromethane/n-hexane, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 88 mg of the title compound (yield: 35%) as a white solid.

Mass spectrum (DUIS, m/z): 455 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.23 & 11.85 (br s, total 1H), 9.75-9.43 (m, 1H), 7.44-7.13 (m, 5H), 5.35 (d, J=4.1 Hz, 1H), 5.05-4.98 (m, 1H), 4.57 (d, J=11.7 Hz, 1H), 4.35 (d, J=11.7 Hz, 1H), 2.65 (dd, J=8.9, 15.1 Hz, 1H), 2.57-2.35 (m, 3H), 2.25-2.09 (m, 2H), 1.89-1.72 (m, 2H), 1.65 (s, 3H), 1.61 (s, 3H), 0.06 (s, 9H).

›Example 12

(R)—N-(3-Hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-227)

To a solution of 216 mg (0.489 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 4.5 ml of 1,4-dioxane, 379 mg (2.51 mmol) of (R)-3-amino-3-phenylpropan-1-ol [purchased from Ark Pharm, Inc.] and 0.17 ml (0.99 mmol) of DIPEA were added at room temperature in an argon atmosphere, then applied to a microwave reaction apparatus, and reacted at 100° C. for 1 hour. After standing to cool, 1.0 ml of methanol and 0.5 ml of triethylamine were added, applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and ethyl acetate, water, and a saturated aqueous solution of sodium chloride were added thereto and then the aqueous layer and the organic layer were separated. The organic layer was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=99:1 to 96:4 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/diisopropyl ether, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 173 mg of the title compound (yield: 73%) as a white solid.

Mass spectrum (CI, m/z): 484 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.19 & 11.66 (s, total 1H), 9.61-9.47 (m, 1H), 7.39-7.13 (m, 5H), 6.46 & 6.38 (d, J=8.0 Hz, total 1H), 4.92-4.83 (m, 1H), 4.66-4.33 (m, 3H), 3.46-3.34 (m, 2H), 2.50-2.41 (m, 2H), 2.26-2.13 (m, 2H), 2.01-1.72 (m, 4H), 1.65-1.47 (m, 6H), 0.12-0.06 (m, 9H).

›Example 13

(R)—N-(3-Hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. III-226)

To a solution of 468 mg (1.17 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate hydrochloride synthesized in the similar manner as in Reference Example 7 in 10 ml of dehydrated dichloromethane, 0.72 ml (4.1 mmol) of DIPEA was added at room temperature in a nitrogen atmosphere, and then, 235 mg (0.791 mmol) of bis(trichloromethyl)carbonate was added at −78° C. and stirred at the same temperature as above for 3 hours.

After the completion of the reaction, 20 ml of a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred while the temperature was raised to room temperature for a while. The organic layer and the aqueous layer were separated, and then, the aqueous layer was subjected to extraction with dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 75:25 (V/V)), and a fraction containing ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate was concentrated under reduced pressure and dried under reduced pressure to obtain 490 mg of a concentration residue.

To a solution of 113 mg of the obtained concentration residue in 2 ml of dehydrated THF, 0.14 ml (0.80 mmol) of DIPEA and 105 mg (0.692 mmol) of (R)-3-amino-3-phenylpropan-1-ol [purchased from Ark Pharm, Inc.] were added at room temperature in a nitrogen atmosphere and then stirred for 2.5 hours while heated to reflux. Subsequently, 0.10 ml (1.7 mmol) of 2-aminoethanol was added and then stirred for 2 hours while heated to reflux.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 0.1 ml of acetic acid was added to the obtained concentration residue and then subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 15:85 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (elution solvent: dichloromethane:methanol=99:1 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/n-hexane, and the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 49 mg of the title compound (yield: 39% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 470 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.22 & 11.84 (br s, total 1H), 9.91-9.66 (m, 1H), 7.37-7.26 (m, 4H), 7.21-7.14 (m, 1H), 6.50-6.28 (m, 1H), 4.92-4.80 (m, 1H), 4.65-4.52 (m, 1H), 4.49-4.31 (m, 2H), 3.44-3.36 (m, 2H), 2.00-1.77 (m, 2H), 1.59 (br s, 3H), 1.51 (br s, 3H), 1.06-0.93 (m, 2H), 0.81-0.61 (m, 2H), 0.03 (s, 9H).

›Example 14

(R)—N-(4-Hydroxy-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-283)

To a solution of 100 mg (0.227 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 138 mg (0.684 mmol) of (R)-4-amino-4-phenylbutan-1-ol hydrochloride [purchased from NetChem, Inc.] in 2 ml of dehydrated 1,4-dioxane, 0.24 ml (1.4 mmol) of DIPEA was added at room temperature in an argon atmosphere and stirred at 100° C. for 3 hours. Subsequently, 1 ml of triethylamine and 1 ml of ethanol were added to the reaction solution and heated and stirred at 80° C. for 5 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, dried by adding anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 91.3 mg of the title compound (yield: 81%) as a white solid.

Mass spectrum (CI, m/z): 498 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.18 & 11.73 (s, total 1H), 9.66-9.40 (m, 1H), 7.38-7.33 (m, 2H), 7.33-7.26 (m, 2H), 7.21-7.13 (m, 1H), 6.43-6.16 (m, 1H), 4.75-4.66 (m, 1H), 4.47 (br s, 2H), 4.38 (t, J=5.2 Hz, 1H), 3.45-3.35 (m, 2H), 2.49-2.42 (m, 2H), 2.25-2.14 (m, 2H), 1.88-1.64 (m, 4H), 1.60 (br s, 3H), 1.55-1.28 (m, 5H), 0.09 (s, 9H).

›Example 15

(R)—N-(5-Hydroxy-1-phenylpentyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-291)

To a solution of 9.50 ml (9.50 mmol) of 1 M lithium aluminum hydride/THF solution in 40 ml of dehydrated THF, a solution of 2.02 g (6.28 mmol) of (R)-ethyl 5-[(tert-butoxycarbonyl)amino]-5-phenylpentanoate [synthesized according to the method described in Tetrahedron Lett., 1998, 39, 5951-5954] in 20 ml of dehydrated THF was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, 50 ml of THF was added, and then, 0.4 ml of water and 1.6 ml (1.6 mmol) of a 1 N aqueous sodium hydroxide solution were added and stirred at the same temperature as above for 30 minutes. The deposited solid was filtered using a celite filter, and the solid was washed with ethyl acetate. The obtained filtrate was concentrated under reduced pressure and dried under reduced pressure to obtain a concentration residue.

To a solution of 1.68 g of the obtained concentration residue in 20 ml of dichloromethane, 2 ml of trifluoroacetic acid was added at room temperature in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure and dried under reduced pressure to obtain 1.35 g of a concentration residue.

To a solution of 905 mg of the obtained concentration residue in 3 ml of dehydrated THF, 0.60 ml (3.4 mmol) of DIPEA was added with stirring in an argon atmosphere, and then, 205 mg (0.465 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 was added at room temperature and stirred at 60° C. for 4 hours. Subsequently, 0.5 ml of triethylamine and 1 ml of methanol were added to the reaction solution, heated and stirred at 60° C. for 3 hours, and subsequently stirred at room temperature for 15 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: dichloromethane:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure. The obtained concentration residue was further subjected to silica gel chromatography (DNH silica gel, elution solvent: dichloromethane:methanol=100:0 to 93:7 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 131 mg of the title compound (yield: 55%) as a white solid.

Mass spectrum (CI, m/z): 512 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.18 & 11.64 (br s, total 1H), 9.58-9.47 (m, 1H), 7.38-7.33 (m, 2H), 7.32-7.25 (m, 2H), 7.21-7.14 (m, 1H), 6.38-6.15 (m, 1H), 4.75-4.65 (m, 1H), 4.52-4.38 (m, 2H), 4.33 (t, J=5.2 Hz, 1H), 3.39-3.33 (m, 2H), 2.49-2.42 (m, 2H), 2.26-2.14 (m, 2H), 1.88-1.72 (m, 3H), 1.72-1.30 (m, 10H), 1.27-1.14 (m, 1H), 0.13-0.06 (m, 9H).

›Example 16

(S)—N-(2-Hydroxy-2-methyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-171)

To a solution of 200 mg (0.454 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 3 ml of dehydrated THF, 0.16 ml (0.92 mmol) of DIPEA and 385 mg (2.33 mmol) of (S)-1-amino-2-methyl-1-phenylpropan-2-ol [purchased from IS Chemical Technology Ltd.] were added at room temperature in an argon atmosphere and stirred at 60° C. for 4 hours. Subsequently, 1 ml of methanol and 1 ml of triethylamine were added at room temperature and stirred at the same temperature as above for 15 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, dried by adding anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: dichloromethane:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure. The obtained concentration residue was subjected again to silica gel chromatography (DIOL silica gel, elution solvent: dichloromethane:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 182 mg of the title compound (yield: 81%) as a white solid.

Mass spectrum (DUIS, m/z): 498 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.22 & 11.78 (br s, total 1H), 9.74-9.49 (m, 1H), 7.38-7.16 (m, 5H), 5.90-5.74 (m, 1H), 4.85 (s, 1H), 4.65-4.35 (m, 3H), 2.49-2.41 (m, 2H), 2.28-2.15 (m, 2H), 1.91-1.73 (m, 2H), 1.67-1.44 (m, 6H), 1.22 (s, 3H), 0.91 (s, 3H), 0.09 (s, 9H).

›Example 17

(S)—N-(2-Hydroxy-2-methyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. III-170)

To a solution of 468 mg (1.17 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate hydrochloride synthesized in the similar manner as in Reference Example 7 in 10 ml of dehydrated dichloromethane, 0.72 ml (4.1 mmol) of DIPEA was added at room temperature in a nitrogen atmosphere, and then, 235 mg (0.791 mmol) of bis(trichloromethyl)carbonate was added at −78° C. and stirred at the same temperature as above for 3 hours.

After the completion of the reaction, 20 ml of a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred while the temperature was raised to room temperature for a while. The organic layer and the aqueous layer were separated, and then, the aqueous layer was subjected to extraction with dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 75:25 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 490 mg of a concentration residue.

To a solution of 112 mg of the obtained concentration residue in 2 ml of dehydrated THF, 0.14 ml (0.80 mmol) of DIPEA and 109 mg (0.660 mmol) of (S)-1-amino-2-methyl-1-phenylpropan-2-ol [purchased from IS Chemical Technology Ltd.] were added in this order at room temperature in a nitrogen atmosphere and then stirred for 3 hours while heated to reflux. Subsequently, 0.10 ml (1.7 mmol) of 2-aminoethanol was added and then stirred for 2.5 hours while heated to reflux.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 0.1 ml of acetic acid was added to the obtained concentration residue and then subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 20:80 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/n-hexane, and the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 100 mg of the title compound (yield: 77% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 484 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.24 & 11.90 (br s, total 1H), 10.02-9.68 (m, 1H), 7.38-7.16 (m, 5H), 5.89-5.71 (m, 1H), 4.82 (s, 1H), 4.59 (d, J=8.4 Hz, 1H), 4.56-4.31 (m, 2H), 1.66-1.43 (m, 6H), 1.21 (s, 3H), 1.06-0.97 (m, 2H), 0.91 (s, 3H), 0.81-0.61 (m, 2H), 0.04 (s, 9H).

›Example 18

N-(3-Hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-354)

To a solution of 152 mg (0.346 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 201 mg (1.12 mmol) of 3-amino-2,2-dimethyl-3-phenylpropan-1-ol [synthesized according to the method described in Synthetic Communications 1994, 24 (7), 899-906] in 4 ml of 1,4-dioxane, 0.18 ml (1.0 mmol) of DIPEA was added at room temperature in an argon atmosphere, then applied to a microwave reaction apparatus, and reacted at 100° C. for 1 hour. After standing to cool, the reaction solution was concentrated under reduced pressure, and 4 ml of methanol and 1 ml of triethylamine were added to the obtained concentration residue and stirred at room temperature for 15 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, the obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=99:1 to 97:3 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=99:1 to 92:8 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with dichloromethane/n-hexane, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 55 mg of the title compound (yield: 31%) as a white solid.

Mass spectrum (DUIS, m/z): 512 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.95 (br s, total 1H), 9.89-9.36 (m, 1H), 7.36-7.17 (m, 5H), 6.85 (d, J=8.1 Hz, 1H), 5.50-5.39 (m, 1H), 4.64 (d, J=8.1 Hz, 1H), 4.47-4.28 (m, 2H), 3.30-3.22 (m, 1H), 3.03 (dd, J=4.1, 10.4 Hz, 1H), 2.49-2.40 (m, 2H), 2.28-2.13 (m, 2H), 1.92-1.71 (m, 2H), 1.60 (br s, 3H), 1.53 (s, 3H), 1.06 (s, 3H), 0.64 (s, 3H), 0.09 (s, 9H).

›Example 19

(R)—N-(3-Hydroxy-3-methyl-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-299)

To a solution of 132 mg (0.300 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 155 mg (0.865 mmol) of (R)-4-amino-2-methyl-4-phenylbutan-2-ol synthesized in the similar manner as in Reference Example 23 in 4 ml of 1,4-dioxane, 0.15 ml (0.86 mmol) of DIPEA was added at room temperature in an argon atmosphere and then stirred at 100° C. for 2 hours. After standing to cool, the reaction solution was concentrated under reduced pressure, and 4 ml of methanol and 1 ml of triethylamine were added to the obtained concentration residue and stirred at room temperature for 18 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and ethyl acetate, water, and a saturated aqueous solution of sodium chloride were added to the obtained concentration residue and then the aqueous layer and the organic layer were separated. The obtained organic layer was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=98:2 to 91:9 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with dichloromethane/diethyl ether/n-hexane, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 104 mg of the title compound (yield: 68%) as a white solid.

Mass spectrum (DUIS, m/z): 512 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.73 (br s, 1H), 9.66-9.40 (m, 1H), 7.37-7.25 (m, 4H), 7.19-7.13 (m, 1H), 6.54 (d, J=5.3 Hz, 1H), 4.95-4.84 (m, 1H), 4.75-4.57 (m, 1H), 4.45 (br s, 2H), 2.47-2.42 (m, 2H), 2.25-2.14 (m, 2H), 2.02-1.74 (m, 3H), 1.65 (dd, J=3.3, 14.3 Hz, 1H), 1.58 (s, 3H), 1.53 (s, 3H), 1.16 (s, 3H), 1.13 (s, 3H), 0.09 (s, 9H).

›Example 20

(S)—N-(2-Methoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-123)

To a solution of 201 mg (0.456 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 4.5 ml of 1,4-dioxane, 0.16 ml (0.91 mmol) of DIPEA and 213 mg (1.41 mmol) of (S)-2-methoxy-1-phenylamine [synthesized according to the method described in J. Chem. Soc., Perkin Transactions 1, 2002, 20, 2237-2242] were added at room temperature, then applied to a microwave reaction apparatus, and reacted at 100° C. for 1 hour. Subsequently, 1 ml of methanol and 0.5 ml of triethylamine were added and then reacted at 80° C. for 1 hour in a microwave reaction apparatus again.

After the completion of the reaction, 8 ml of ethyl acetate, 0.4 ml of water, and 8 ml of a saturated aqueous solution of sodium chloride were added to the reaction solution and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 10 ml of dichloromethane. All of the obtained organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Diethyl ether was added to the obtained concentration residue and ultrasonicated, and then, the deposited insoluble matter was collected by filtration and dried under reduced pressure to obtain 180 mg of the title compound (yield: 82%) as a white solid.

Mass spectrum (CI, m/z): 484 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.67 (br s, total 1H), 9.68-9.41 (m, 1H), 7.41-7.35 (m, 2H), 7.34-7.27 (m, 2H), 7.25-7.17 (m, 1H), 6.44-6.13 (m, 1H), 5.02-4.92 (m, 1H), 4.57-4.39 (m, 2H), 3.63 (dd, J=7.9, 9.9 Hz, 1H), 3.50 (dd, J=6.0, 9.9 Hz, 1H), 3.26 (s, 3H), 2.49-2.42 (m, 2H), 2.26-2.15 (m, 2H), 1.92-1.73 (m, 2H), 1.60 (br s, 3H), 1.53 (br s, 3H), 0.09 (s, 9H).

›Example 21

(S)—N-[2-(Difluoromethoxy)-1-phenylethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-131)

To a solution of 210 mg (0.697 mmol) of (S)-2-(difluoromethoxy)-1-phenylethanamine trifluoroacetate synthesized in the similar manner as in Reference Example 25 and 0.425 ml (2.43 mmol) of DIPEA in 3 ml of dehydrated 1,4-dioxane, 107 mg (0.243 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 was added at room temperature in an argon atmosphere and heated and stirred at 100° C. for 1 hour. Subsequently, 1 ml of triethylamine and 1 ml of methanol were added to the reaction solution and heated and stirred at 80° C. for 1 hour.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, dried by adding anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 40.5 mg of the title compound (yield: 32%) as a white solid.

Mass spectrum (CI, m/z): 520 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 (br s, 1H), 10.12-9.41 (m, 1H), 7.43-7.38 (m, 2H), 7.38-7.32 (m, 2H), 7.28-7.23 (m, 1H), 6.70 (t, J=76.0 Hz, 1H), 6.59-6.46 (m, 1H), 5.10-5.01 (m, 1H), 4.52-4.43 (m, 2H), 4.13 (dd, J=8.3, 10.4 Hz, 1H), 4.05-3.99 (m, 1H), 2.48-2.42 (m, 2H), 2.24-2.15 (m, 2H), 1.88-1.75 (m, 2H), 1.60 (s, 3H), 1.53 (s, 3H), 0.09 (s, 9H).

›Example 22

(S)—N-(2-Ethoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-139)

To a solution of 136 mg (0.308 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 162 mg (0.979 mmol) of (S)-2-ethoxy-1-phenylethanamine synthesized in the similar manner as in Reference Example 26 in 4 ml of 1,4-dioxane, 0.16 ml (0.92 mmol) of DIPEA was added at room temperature in an argon atmosphere and then stirred at 100° C. for 2 hours. After standing to cool, the reaction solution was concentrated under reduced pressure, and 4 ml of methanol and 1 ml of triethylamine were added to the obtained concentration residue, applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the obtained concentration residue, then the organic layer obtained by washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=98:2 to 91:9 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with dichloromethane/diethyl ether/n-hexane, and the deposited solid was collected by filtration. The obtained solid was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 93:7 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 67:33 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Diethyl ether and n-hexane were added to the obtained concentration residue, and after ultrasonication, the deposited solid was collected by filtration and dried under reduced pressure to obtain 81 mg of the title compound (yield: 53%) as a white solid.

Mass spectrum (DUIS, m/z): 498 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.71 (br s, total 1H), 9.67-9.47 (m, 1H), 7.41-7.34 (m, 2H), 7.34-7.27 (m, 2H), 7.25-7.17 (m, 1H), 6.38-6.11 (m, 1H), 4.99-4.91 (m, 1H), 4.56-4.38 (m, 2H), 3.65 (dd, J=8.0, 9.9 Hz, 1H), 3.54 (dd, J=6.0, 9.9 Hz, 1H), 3.51-3.41 (m, 2H), 2.49-2.41 (m, 2H), 2.28-2.14 (m, 2H), 1.91-1.71 (m, 2H), 1.61 (br s, 3H), 1.54 (br s, 3H), 1.08 (t, J=7.0 Hz, 3H), 0.09 (s, 9H).

›Example 23

(R)—N-(3-Methoxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-235)

To a solution of 138 mg (0.314 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 163 mg (0.987 mmol) of (R)-3-methoxy-1-phenylpropan-1-amine synthesized in the similar manner as in Reference Example 27 in 4 ml of 1,4-dioxane, 0.16 ml (0.92 mmol) of DIPEA was added at room temperature in an argon atmosphere and then stirred at 100° C. for 2 hours. After standing to cool, the reaction solution was concentrated under reduced pressure, and 4 ml of methanol and 1 ml of triethylamine were added to the obtained residue and stirred at room temperature for 18 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the obtained concentration residue, then the organic layer obtained by washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=95:5 to 88:12 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Diethyl ether and n-hexane were added to the obtained concentration residue and ultrasonicated, and then, the deposited solid was collected by filtration and dried under reduced pressure to obtain 88 mg of the title compound (yield: 56%) as a white solid.

Mass spectrum (DUIS, m/z): 498 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.18 & 11.73 (br s, total 1H), 9.54 (br s, 1H), 7.35-7.28 (m, 4H), 7.22-7.16 (m, 1H), 6.41 (br s, 1H), 4.91-4.79 (m, 1H), 4.53-4.40 (m, 2H), 3.32-3.27 (m, 2H), 3.23 (s, 3H), 2.50-2.42 (m, 2H), 2.26-2.15 (m, 2H), 2.08-1.70 (m, 4H), 1.60 (s, 3H), 1.52 (s, 3H), 0.09 (s, 9H).

›Example 24

Sodium (S)-2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate (sodium salt of Compound No. IV-403)

To a solution of 98.0 mg (0.171 mmol) of (S)-benzyl 2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate synthesized in the similar manner as in Example 55 in 15 ml of ethanol, 19.9 mg of palladium/carbon [ASCA2 (trade name), manufactured by N.E. Chemcat Corp., containing 52% water] was added in a nitrogen atmosphere and then, after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 50 minutes.

After the completion of the reaction, replacement with an argon atmosphere was performed, and the reaction solution was filtered through celite. 14.8 mg (0.176 mmol) of sodium bicarbonate was added to the obtained filtrate and concentrated under reduced pressure. Purified water and diethyl ether were added to the obtained concentration residue and then dried under reduced pressure to obtain 82 mg of the title compound (yield: 95%) as a white solid.

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.41 (br s, 1H), 9.95 (br. s, 1H), 7.38-7.30 (m, 2H), 7.24-7.17 (m, 2H), 7.14-7.08 (m, 1H), 6.42 (d, J=4.6 Hz, 1H), 4.68 (d, J=4.6 Hz, 1H), 4.48 (d, J=11.3 Hz, 1H), 4.45 (d, J=11.3 Hz, 1H), 2.51-2.41 (m, 2H), 2.28-2.14 (m, 2H), 1.90-1.74 (m, 2H), 1.59 (s, 3H), 1.55 (s, 3H), 0.08 (s, 9H).

›Example 25

(R)—N-(2-Hydroxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-115)

To a solution of 127 mg (0.287 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 203 mg (1.48 mmol) of (R)-2-amino-2-phenylethanol in 3 ml of THF, 0.15 ml (0.86 mmol) of DIPEA was added at room temperature in an argon atmosphere and then stirred at 60° C. for 3 hours.

After the completion of the reaction, ethyl acetate, water, and a saturated aqueous solution of sodium chloride were added to the reaction solution and then the aqueous layer and the organic layer were separated. The obtained organic layer was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (elution solvent: ethyl acetate:a mixed solution of 28% aqueous ammonia solution/ethanol [1:5 (V/V)]=98:2 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 82 mg of the title compound (yield: 61%) as a white foam.

Mass spectrum (DUIS, m/z): 470 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.79 (br s, total 1H), 9.73-9.49 (m, 1H), 7.44-7.11 (m, 5H), 6.25-6.00 (m, 1H), 4.95-4.70 (m, 2H), 4.62-4.41 (m, 2H), 3.71-3.52 (m, 2H), 2.48-2.41 (m, 2H), 2.27-2.13 (m, 2H), 1.93-1.73 (m, 2H), 1.71-1.43 (m, 6H), 0.09 (br s, 9H).

›Example 26

N-[1-(2-Fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-510)

To a solution of 201 mg (0.456 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 5 ml of 1,4-dioxane, 0.23 ml (1.4 mmol) of DIPEA and 212 mg (1.37 mmol) of 2-amino-2-(2-fluorophenyl)ethanol [purchased from Amatek Chemical Co., Ltd.] were added at room temperature in an argon atmosphere and then reacted at 100° C. for 1 hour. The reaction solution was concentrated under reduced pressure, and then, 4 ml of methanol and 1 ml of triethylamine were added to the concentration residue and reacted at 65° C. for 4.5 hours and further at 70° C. for 1.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and the obtained concentration residue was dissolved in 5 ml of ethyl acetate and washed with 10 ml of a 5% aqueous potassium bisulfate solution twice. All of the obtained organic layers were washed with 10 ml of a saturated aqueous solution of sodium bicarbonate, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 131 mg of the title compound (yield: 59%) as a white foam.

Mass spectrum (CI, m/z): 488 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.41-11.66 (m, 1H), 9.94-9.30 (m, 1H), 7.51-7.42 (m, 1H), 7.31-7.06 (m, 3H), 6.19 (br s, 1H), 5.15-5.04 (m, 1H), 4.98 (t, J=6.0 Hz, 1H), 4.54 (br s, 2H), 3.64-3.54 (m, 2H), 2.49-2.42 (m, 2H), 2.26-2.15 (m, 2H), 1.87-1.76 (m, 2H), 1.60 (s, 3H), 1.51 (s, 3H), 0.10 (s, 9H).

›Example 27

(S)—N-[1-(3-Fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-519)

To a solution of 201 mg (0.456 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 5.0 ml of 1,4-dioxane, 0.23 ml (1.4 mmol) of DIPEA and 212 mg (1.37 mmol) of (S)-2-amino-2-(3-fluorophenyl)ethanol [purchased from Amatek Chemical Co., Ltd.] were added at room temperature in an argon atmosphere and then reacted at 100° C. for 1 hour. The reaction solution was concentrated under reduced pressure, and then, 4 ml of methanol and 1 ml of triethylamine were added to the concentration residue and reacted at room temperature for 17 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and the obtained concentration residue was dissolved in 5 ml of ethyl acetate, washed with 10 ml of a 5% aqueous potassium dihydrogen phosphate solution twice and 10 ml of a saturated aqueous solution of sodium bicarbonate once, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 128 mg of the title compound (yield: 58%) as a white foam.

Mass spectrum (CI, m/z): 488 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.35-11.70 (m, 1H), 9.84-9.41 (m, 1H), 7.38-7.29 (m, 1H), 7.21-7.15 (m, 2H), 7.05-6.98 (m, 1H), 6.21 (br s, 1H), 4.92 (t, J=5.8 Hz, 1H), 4.83-4.74 (m, 1H), 4.58-4.45 (m, 2H), 3.67-3.55 (m, 2H), 2.49-2.42 (m, 2H), 2.26-2.15 (m, 2H), 1.89-1.73 (m, 2H), 1.60 (s, 3H), 1.53 (s, 3H), 0.09 (s, 9H).

›Example 28

(S)—N-[1-(4-Fluorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-527)

To a solution of 201 mg (0.456 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 5.0 ml of 1,4-dioxane, 0.23 ml (1.4 mmol) of DIPEA and 212 mg (1.37 mmol) of (S)-2-amino-2-(4-fluorophenyl)ethanol [purchased from Amatek Chemical Co., Ltd.] were added at room temperature in an argon atmosphere and then reacted at 100° C. for 1 hour. The reaction solution was concentrated under reduced pressure, and then, 4 ml of methanol and 1 ml of triethylamine were added to the concentration residue and reacted at room temperature for 15 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and the obtained concentration residue was dissolved in 5 ml of ethyl acetate, washed with 10 ml of a 5% aqueous potassium dihydrogen phosphate solution twice and 10 ml of a saturated aqueous solution of sodium bicarbonate once, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 139 mg of the title compound (yield: 63%) as a pale yellow foam.

Mass spectrum (CI, m/z): 488 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.71 (br s, total 1H), 9.75-9.43 (m, 1H), 7.42-7.33 (m, 2H), 7.15-7.06 (m, 2H), 6.28-6.02 (m, 1H), 4.89 (t, J=5.8 Hz, 1H), 4.81-4.72 (m, 1H), 4.51 (br s, 2H), 3.66-3.53 (m, 2H), 2.49-2.42 (m, 2H), 2.26-2.15 (m, 2H), 1.90-1.74 (m, 2H), 1.60 (br s, 3H), 1.53 (br s, 3H), 0.09 (s, 9H).

›Example 29

N-[2-Hydroxy-1-(pyridin-2-yl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-534)

To a solution of 152 mg (0.344 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 223 mg (1.06 mmol) of 2-amino-2-(pyridin-2-yl)ethanol dihydrochloride [purchased from J&W PharmLab, LLC] in 4 ml of 1,4-dioxane, 0.60 ml (3.4 mmol) of DIPEA was added at room temperature in an argon atmosphere, then applied to a microwave reaction apparatus, and reacted at 100° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and a saturated aqueous solution of sodium bicarbonate was added to the concentration residue, followed by extraction with dichloromethane. The obtained organic layer was dried over anhydrous sodium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 93:7 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=100:0 to 78:22 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 78 mg of the title compound (yield: 48%) as a white foam.

Mass spectrum (DUIS, m/z): 469 [M−1] − .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.22 & 11.78 (br s, total 1H), 9.79-9.45 (m, 1H), 8.54-8.49 (m, 1H), 7.74 (dt, J=1.7, 7.7 Hz, 1H), 7.42-7.36 (m, 1H), 7.28-7.21 (m, 1H), 6.19-6.00 (m, 1H), 4.92-4.82 (m, 2H), 4.62-4.43 (m, 2H), 3.76-3.65 (m, 2H), 2.49-2.42 (m, 2H), 2.27-2.15 (m, 2H), 1.92-1.72 (m, 2H), 1.68-1.50 (m, 6H), 0.10 (s, 9H).

›Example 30

N-[2-Hydroxy-1-(pyridin-3-yl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-542)

To a solution of 150 mg (0.341 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 218 mg (1.03 mmol) of 2-amino-2-(pyridin-3-yl)ethanol dihydrochloride [purchased from J&W PharmLab, LLC] in 4 ml of 1,4-dioxane, 0.60 ml (3.4 mmol) of DIPEA was added at room temperature in an argon atmosphere and then stirred at 100° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and a saturated aqueous solution of sodium bicarbonate was added to the concentration residue, followed by extraction with dichloromethane. The obtained organic layer was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. 4 ml of methanol and 1 ml of triethylamine were added to the obtained concentration residue, applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, the obtained concentration residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=95:5 to 88:12 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained residue was subjected again to silica gel column chromatography (DNH silica gel, elution solvent: ethyl acetate:methanol=96:4 to 70:30 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=99:1 to 73:27 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 27 mg of the title compound (yield: 17%) as a white foam.

Mass spectrum (DUIS, m/z): 471 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.77 (br s, total 1H), 9.75-9.47 (m, 1H), 8.54 (d, J=2.0 Hz, 1H), 8.41 (dd, J=2.0, 4.7 Hz, 1H), 7.75 (ddd, J=2.0, 2.0, 7.6 Hz, 1H), 7.32 (dd, J=4.7, 7.6 Hz, 1H), 6.39-6.13 (m, 1H), 4.97 (t, J=5.8 Hz, 1H), 4.84-4.76 (m, 1H), 4.61-4.42 (m, 2H), 3.71-3.59 (m, 2H), 2.49-2.42 (m, 2H), 2.27-2.14 (m, 2H), 1.89-1.72 (m, 2H), 1.60 (br s, 3H), 1.52 (br s, 3H), 0.09 (s, 9H).

›Example 31

N-[1-(Benzo[d][1,3]dioxol-4-yl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-502)

To a solution of 240 mg (0.815 mmol) of 1-(benzo[d][1,3]dioxol-4-yl)-2-[(tert-butyldimethylsilyl)oxy]ethanamin e synthesized in the similar manner as in Reference Example 32 in 10 ml of dichloromethane, 1 ml (4 mmol) of 4 N hydrogen chloride/1,4-dioxane solution was added at room temperature and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and 3 ml of THF, 0.210 ml (1.24 mmol) of DIPEA, and 93.0 mg (0.211 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 were added to the obtained residue at room temperature and stirred at 60° C. for 8 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and ethyl acetate, a saturated aqueous solution of sodium chloride, and water were added thereto and then the aqueous layer and the organic layer were separated. The obtained organic layer was dried over anhydrous magnesium sulfate, filtered, and then concentrated under reduced pressure. 2 ml of methanol and 2 ml of triethylamine were added to the obtained concentration residue, applied to a microwave reaction apparatus, and reacted at 80° C. for 30 minutes.

After the completion of the reaction, the concentration residue obtained by concentration under reduced pressure was subjected to silica gel column chromatography (elution solvent: ethyl acetate:a mixed solution of 28% aqueous ammonia solution/ethanol [1:5 (V/V)]=98:2 to 95:5 (V/V)), and a fraction containing N-{1-(benzo[d][1,3]dioxol-4-yl)-2-[(tert-butyldimethylsilyl)oxy]ethyl}-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 119 mg (0.190 mmol) of the obtained concentration residue in 3.5 ml of dehydrated dichloromethane, 0.18 ml (1.0 mmol) of trimethylsilyl trifluoromethanesulfonate was added at 0° C. and stirred at the same temperature as above for 5 minutes, and then, 0.17 ml (1.5 mmol) of 2,6-lutidine and 0.18 ml (1.0 mmol) of trimethylsilyl trifluoromethanesulfonate were added at 0° C. and stirred at the same temperature as above for 5 minutes. Subsequently, 1 ml of methanol and 0.17 ml (1.5 mmol) of 2,6-lutidine were added, and then, the reaction solution was concentrated under reduced pressure. To a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane, 0.18 ml (1.0 mmol) of trimethylsilyl trifluoromethanesulfonate was added at 0° C. and stirred at the same temperature as above for 5 minutes, and then, 1.0 ml of dehydrated acetonitrile was added at 0° C. and stirred at the same temperature as above for 10 minutes.

After the completion of the reaction, 1 ml of methanol and 0.17 ml (1.5 mmol) of 2,6-lutidine were added to the reaction solution and then concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: ethyl acetate:a mixed solution of 28% aqueous ammonia solution/ethanol [1:5 (V/V)]=98:2 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 52 mg of the title compound (yield: 48%) as a white solid.

Mass spectrum (DUIS, m/z): 514 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.72 (br s, total 1H), 9.69-9.50 (m, 1H), 6.89-6.83 (m, 1H), 6.81-6.76 (m, 2H), 6.12-5.94 (m, 3H), 4.96-4.90 (m, 2H), 4.59-4.43 (m, 2H), 3.62-3.56 (m, 2H), 2.49-2.42 (m, 2H), 2.26-2.15 (m, 2H), 1.90-1.74 (m, 2H), 1.60 (br s, 3H), 1.54 (br s, 3H), 0.10 (s, 9H).

›Example 32

(S)—N-(1-Cyclohexyl-2-hydroxyethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-495)

To a solution of 326 mg (0.739 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 4 ml of dehydrated THF, 0.33 ml (1.9 mmol) of DIPEA and 304 mg (2.12 mmol) of (S)-2-amino-2-cyclohexylethanol [synthesized according to the method described in Bioorg. Med. Chem. Lett., 2009, 19, 926-929] were added at room temperature in a nitrogen atmosphere and then stirred for 1.5 hours while heated to reflux. Subsequently, 0.90 ml (6.5 mmol) of triethylamine and 0.90 ml (22 mmol) of methanol were added to the reaction solution and then stirred for 1.5 hours while heated to reflux.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 85 μl of acetic acid was added to the obtained concentration residue and then subjected to silica gel column chromatography (DIOL silica gel, elution solvent: dichloromethane:methanol=100:0 to 97:3 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with dichloromethane/n-hexane, and the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 295 mg of the title compound (yield: 84%) as a white solid.

Mass spectrum (CI, m/z): 476 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.71 (br s, total 1H), 9.70-9.44 (m, 1H), 5.46-5.15 (m, 1H), 4.54 (t, J=5.0 Hz, 1H), 4.49-4.21 (m, 2H), 3.53-3.40 (m, 3H), 2.48-2.40 (m, 2H), 2.27-2.10 (m, 2H), 1.88-1.45 (m, 14H), 1.28-1.03 (m, 3H), 1.03-0.83 (m, 2H), 0.08 (s, 9H).

›Example 33

(S)—N-(1-Hydroxy-3-methylbutan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-475)

To a solution of 201 mg (0.456 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 4.5 ml of 1,4-dioxane, 235 mg (2.27 mmol) of (S)-2-amino-3-methylbutan-1-ol and 0.16 ml (0.91 mmol) of DIPEA were added at room temperature in a nitrogen atmosphere and then stirred at 100° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and ethyl acetate, water, and a saturated aqueous solution of sodium chloride were added to the concentration residue and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with ethyl acetate, all of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=99:1 to 96:4 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Acetone was added to the obtained concentration residue and then ultrasonicated, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 129 mg of the title compound (yield: 65%) as a white solid.

Mass spectrum (CI, m/z): 436 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.67 (br s, total 1H), 9.60-9.48 (m, 1H), 5.45-5.20 (m, 1H), 4.62-4.24 (m, 3H), 3.52-3.39 (m, 3H), 2.49-2.41 (m, 2H), 2.24-2.13 (m, 2H), 1.91-1.73 (m, 3H), 1.60 (br s, 6H), 0.92-0.82 (m, 6H), 0.08 (s, 9H).

›Example 34

(S)—N-(1-Hydroxypropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-455)

To a solution of 200 mg (0.454 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 4.5 ml of 1,4-dioxane, 170 mg (2.26 mmol) of (S)-2-aminopropan-1-ol and 0.16 ml (0.91 mmol) of DIPEA were added at room temperature, then applied to a microwave reaction apparatus, and reacted at 100° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and ethyl acetate, water, and a saturated aqueous solution of sodium chloride were added to the concentration residue and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with ethyl acetate, all of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=99:1 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Ethyl acetate was added to the obtained concentration residue and ultrasonicated, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 145 mg of the title compound (yield: 78%) as a white solid.

Mass spectrum (CI, m/z): 408 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.18 & 11.64 (br s, total 1H), 9.52 (s, 1H), 5.70-5.32 (m, 1H), 4.65 (t, J=5.6 Hz, 1H), 4.44-4.28 (m, 2H), 3.77-3.64 (m, 1H), 3.41-3.34 (m, 1H), 3.30-3.23 (m, 1H), 2.49-2.40 (m, 2H), 2.24-2.13 (m, 2H), 1.88-1.72 (m, 2H), 1.60 (s, 6H), 1.05 (d, J=6.7 Hz, 3H), 0.08 (s, 9H).

›Example 35

N-(2-Hydroxyethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-438)

To a solution of 200 mg (0.454 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 3 ml of dehydrated THF, 0.16 ml (0.92 mmol) of DIPEA and 0.14 ml (2.3 mmol) of 2-aminoethanol were added at room temperature in an argon atmosphere and stirred at 60° C. for 3 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried by adding anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=90:10 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 135 mg of the title compound (yield: 76%) as a white solid.

Mass spectrum (DUIS, m/z): 394 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.19 & 11.60 (br s, total 1H), 9.54 (s, 1H), 6.05-5.85 (m, 1H), 4.66 (t, J=5.5 Hz, 1H), 4.42-4.28 (m, 2H), 3.45-3.36 (m 2H), 3.17-3.02 (m, 2H), 2.48-2.39 (m, 2H), 2.25-2.12 (m, 2H), 1.91-1.71 (m, 2H), 1.67-1.52 (m, 6H), 0.08 (s, 9H).

›Example 36

N-(2-Hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-450)

To a solution of 100 mg (0.227 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 2 ml of dehydrated 1,4-dioxane, 0.20 ml (1.1 mmol) of DIPEA and 160 mg (1.17 mmol) of 2-amino-1-phenylethanol were added at room temperature in an argon atmosphere and stirred at the same temperature as above for 1 hour.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried by adding anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 82.0 mg of the title compound (yield: 77%) as a white solid.

Mass spectrum (CI, m/z): 470 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.38-11.74 (m, 1H), 9.59 (br s, 1H), 7.36-7.29 (m, 4H), 7.26-7.20 (m, 1H), 6.14-5.98 (m, 1H), 5.58 (d, J=4.0 Hz, 1H), 4.70-4.62 (m, 1H), 4.42-4.28 (m, 2H), 3.29-3.23 (m, 1H), 3.10 (ddd, J=4.8, 8.0, 13.2 Hz, 1H), 2.48-2.40 (m, 2H), 2.23-2.14 (m, 2H), 1.88-1.74 (m, 2H), 1.60 (s, 6H), 0.08 (s, 9H).

›Example 37

N-(2-Hydroxypropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-442)

To a solution of 100 mg (0.227 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 85 μl (1.1 mmol) of 1-amino-2-propanol in 2 ml of dehydrated 1,4-dioxane, 0.20 ml (1.1 mmol) of DIPEA was added at room temperature in an argon atmosphere and stirred at the same temperature as above for 1.5 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried by adding anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 61.1 mg of the title compound (yield: 66%) as a white solid.

Mass spectrum (CI, m/z): 408 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.19 & 11.78 (br s, total 1H), 9.71-9.46 (m, 1H), 6.05-5.78 (m, 1H), 4.76 (d, J=4.4 Hz, 1H), 4.38 (br s, 2H), 3.71-3.61 (m, 1H), 3.09-2.99 (m, 1H), 2.97-2.88 (m, 1H), 2.49-2.39 (m, 2H), 2.25-2.13 (m, 2H), 1.88-1.71 (m, 2H), 1.60 (br s, 6H), 1.01 (d, J=6.3 Hz, 3H), 0.08 (s, 9H).

›Example 38

N-[(2S)-1-Hydroxy-3-methyl-1-phenylbutan-2-yl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-487)

To a solution of 1.25 g (6.21 mmol) of (S)-tert-butyl (3-methyl-1-oxobutan-2-yl)carbamate [synthesized according to the method described in J. Am. Chem. Soc., 2004, 126, 11440-11441] in 15 ml of dehydrated THF, 6.60 ml (6.60 mmol) of 1 M phenyl magnesium bromide/THF solution was added dropwise at an internal temperature of 15° C. or lower in an argon atmosphere and, after the completion of the dropwise addition, stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution was cooled in ice water, and 20 ml of a saturated aqueous solution of ammonium chloride was added and stirred at room temperature. Ethyl acetate and a saturated aqueous solution of sodium chloride were further added thereto and then the aqueous layer and the organic layer were separated. The obtained organic layer was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 70:30 (V/V)), and a fraction containing tert-butyl [(2 S)-1-hydroxy-3-methyl-1-phenylbutan-2-yl]carbamate was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 0.90 g of the obtained concentration residue in 10 ml of dichloromethane, 1.2 ml (10 mmol) of 2,6-lutidine and 1.8 ml (10 mmol) of trimethylsilyl trifluoromethanesulfonate were added dropwise at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, 50 ml of a saturated aqueous solution of sodium bicarbonate was added thereto, stirred, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with dichloromethane, all of the obtained organic layers were dried over anhydrous sodium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The operation of adding toluene to the obtained concentration residue and concentrating the resultant under reduced pressure was repeated several times. The obtained concentration residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing (2S)-2-amino-3-methyl-1-phenylbutan-1-ol was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing (2 S)-2-amino-3-methyl-1-phenylbutan-1-ol was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 111 mg (0.251 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 4.0 ml of 1,4-dioxane, 97 mg of the concentration residue of (2S)-2-amino-3-methyl-1-phenylbutan-1-ol described above and 0.11 ml (0.63 mmol) of DIPEA were added at room temperature, then applied to a microwave reaction apparatus, and reacted at 100° C. for 1 hour. After the reaction, the reaction solution was concentrated under reduced pressure, and 4 ml of methanol and 1 ml of triethylamine were added to the obtained concentration residue, applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, the obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Diethyl ether and n-hexane were added to the obtained concentration residue and ultrasonicated, and the deposited solid was collected by filtration. The obtained solid was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with acetone/n-heptane, and the deposited solid was collected by filtration. The obtained solid was subjected again to silica gel column chromatography (elution solvent: hexane:ethyl acetate=38:62 to 17:83 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. n-Hexane was added to the obtained concentration residue, and after ultrasonication, the deposited solid was collected by filtration and dried under reduced pressure to obtain 55 mg of the title compound (yield: 42%) as a white solid.

Mass spectrum (CI, m/z): 512 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.15 & 11.74 (br s, total 1H), 9.85-9.20 (m, 1H), 7.33-7.19 (m, 4H), 7.17-7.10 (m, 1H), 5.68 (d, J=5.8 Hz, 1H), 5.32-5.16 (m, 1H), 4.82 (dd, J=2.6, 5.8 Hz, 1H), 4.37-4.23 (m, 2H), 3.52 (ddd, J=2.6, 8.7, 8.7 Hz, 1H), 2.49-2.39 (m, 2H), 2.26-2.13 (m, 2H), 2.00-1.72 (m, 3H), 1.52 (br s, 3H), 1.31 (br s, 3H), 1.03 (d, J=6.7 Hz, 3H), 0.90 (d, J=6.7 Hz, 3H), 0.09 (s, 9H).

›Example 39

N-(4-Hydroxy-1-phenyl-2-butyn-1-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-378)

To a solution of 106 mg (0.240 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 3 ml of dehydrated 1,4-dioxane, 0.24 ml (1.4 mmol) of DIPEA and 146 mg (0.739 mmol) of 4-amino-4-phenyl-2-butyn-1-ol hydrochloride synthesized in the similar manner as in Reference Example 33 were added in an argon atmosphere and stirred at 100° C. for 2 hours. Subsequently, 1 ml of triethylamine and 1 ml of methanol were added to the reaction solution and stirred at 80° C. for 1 hour.

After the completion of the reaction, water was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (DIOL column, elution solvent: dichloromethane:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel chromatography (elution solvent: dichloromethane:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 79.6 mg of the title compound (yield: 67%) as a light brown solid.

Mass spectrum (CI, m/z): 494 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.70 (br s, total 1H), 9.54 (br s, 1H), 7.53-7.47 (m, 2H), 7.38-7.32 (m, 2H), 7.29-7.23 (m, 1H), 7.20-6.97 (m, 1H), 5.89-5.84 (m, 1H), 5.20 (t, J=5.9 Hz, 1H), 4.45 (br s, 2H), 4.15 (dd, J=1.9, 5.9 Hz, 2H), 2.48-2.40 (m, 2H), 2.24-2.12 (m, 2H), 1.87-1.73 (m, 2H), 1.63 (s, 3H), 1.59 (s, 3H), 0.08 (s, 9H).

›Example 40

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl acetate (Compound No. V-1442)

To a solution of 360 mg (0.816 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 10 ml of THF, 883 mg (4.09 mmol) of (S)-2-amino-2-phenylethyl acetate hydrochloride synthesized in the similar manner as in Reference Example 35 and 2.0 ml (12 mmol) of DIPEA were added at room temperature, applied to a microwave reaction apparatus, and reacted at 100° C. for 2 hours. Subsequently, 1.1 ml (27 mmol) of methanol was added, then applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour. 2.0 ml (49 mmol) of methanol and 1.0 ml (7.2 mmol) of triethylamine were further added, then applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and 15 ml of ethyl acetate and 15 ml of a saturated aqueous solution of sodium chloride were added to the obtained concentration residue and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 15 ml of dichloromethane. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Ethyl acetate and diethyl ether were added in small amounts to the obtained concentration residue, then ultrasonicated, cooled in ice water, and then filtered. The obtained solid was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=100:0 to 99:1 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Ethyl acetate and diethyl ether were added in small amounts to the obtained concentration residue, then ultrasonicated, cooled in ice water, and then filtered to obtain white solid A. The filtrate was concentrated under reduced pressure, the obtained concentration residue was subjected to silica gel column chromatography (elution solvent: ethyl acetate:methanol=100:0 to 99:1 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Ethyl acetate and diethyl ether were added in small amounts to the obtained concentration residue, then ultrasonicated, cooled in ice water, and then filtered to obtain white solid B. The white solids A and B were dissolved in ethyl acetate, then diethyl ether was added, and the deposited solid was filtered and dried under reduced pressure to obtain 142 mg of the title compound (yield: 34%) as a white solid.

Mass spectrum (DUIS, m/z): 512 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.71 (br s, total 1H), 9.76-9.33 (m, 1H), 7.43-7.37 (m, 2H), 7.37-7.31 (m, 2H), 7.28-7.22 (m, 1H), 6.65-6.38 (m, 1H), 5.12-5.03 (m, 1H), 4.49 (br s, 2H), 4.30-4.19 (m, 2H), 2.49-2.41 (m, 2H), 2.25-2.14 (m, 2H), 1.98 (s, 3H), 1.89-1.74 (m, 2H), 1.61 (br s, 3H), 1.53 (br s, 3H), 0.09 (s, 9H).

›Example 41

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl propionate (Compound No. V-1446)

To a solution of 200 mg (0.369 mmol) of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 and 0.10 ml (0.74 mmol) of triethylamine in 3 ml of dehydrated dichloromethane, 0.071 ml (0.55 mmol) of propionic anhydride and 9.7 mg (0.079 mmol) of 4-dimethylaminopyridine were added in this order at room temperature in an argon atmosphere and then reacted at room temperature for 5 hours. Subsequently, 1 ml of methanol and 0.5 ml of triethylamine were added and reacted at room temperature for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and 10 ml of ethyl acetate, 0.5 ml of water, and 10 ml of a saturated aqueous solution of sodium chloride were added to the obtained concentration residue, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 10 ml of dichloromethane twice, and all of the obtained organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Diethyl ether was added to the obtained concentration residue, and after ultrasonication, insoluble matter was filtered and dried under reduced pressure to obtain 138 mg of the title compound (yield: 71%) as a white solid.

Mass spectrum (CI, m/z): 526 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.66 (br s, total 1H), 9.70-9.39 (m, 1H), 7.45-7.30 (m, 4H), 7.28-7.21 (m, 1H), 6.64-6.39 (m, 1H), 5.16-5.03 (m, 1H), 4.57-4.39 (m, 2H), 4.32-4.19 (m, 2H), 2.49-2.41 (m, 2H), 2.27 (q, J=7.5 Hz, 2H), 2.24-2.14 (m, 2H), 1.91-1.72 (m, 2H), 1.67-1.47 (m, 6H), 0.99 (t, J=7.5 Hz, 3H), 0.09 (s, 9H).

›Example 42

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl butanoate (Compound No. V-1450)

To a solution of 250 mg (0.461 mmol) of a mixture of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 and (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate and 0.10 ml (0.74 mmol) of triethylamine in 4.5 ml of 1,4-dioxane, 0.09 ml (0.6 mmol) of butyric anhydride and 9.0 mg (0.074 mmol) of 4-dimethylaminopyridine were added in this order at room temperature in an argon atmosphere and then reacted at 100° C. for 1.5 hours. Subsequently, 1.5 ml (37 mmol) of methanol and 0.75 ml (5.4 mmol) of triethylamine were added, applied to a microwave reaction apparatus, and reacted at 80° C. for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and 8 ml of ethyl acetate, 0.4 ml of water, and 8 ml of a saturated aqueous solution of sodium chloride were added to the obtained concentration residue, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 10 ml of dichloromethane twice, and all of the obtained organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, then the obtained concentration residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 51:49 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Water was added to the concentration residue, and after ultrasonication, insoluble matter was filtered and dried under reduced pressure to obtain 80 mg of the title compound (yield: 32%) as a white solid.

Mass spectrum (CI, m/z): 540 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.65 (br s, total 1H), 9.69-9.40 (m, 1H), 7.45-7.37 (m, 2H), 7.37-7.29 (m, 2H), 7.28-7.21 (m, 1H), 6.64-6.39 (m, 1H), 5.15-5.04 (m, 1H), 4.57-4.38 (m, 2H), 4.31-4.20 (m, 2H), 2.49-2.41 (m, 2H), 2.28-2.14 (m, 4H), 1.92-1.73 (m, 2H), 1.64-1.44 (m, 8H), 0.83 (t, J=7.4 Hz, 3H), 0.09 (s, 9H).

›Example 43

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl pentanoate (Compound No. V-1458)

To a solution of 200 mg (0.369 mmol) of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 and 0.10 ml (0.74 mmol) of triethylamine in 3 ml of 1,4-dioxane, 0.09 ml (0.5 mmol) of valeric anhydride and 9.0 mg (0.074 mmol) of 4-dimethylaminopyridine were added at room temperature in an argon atmosphere and then reacted at 100° C. for 1 hour. Subsequently, 1 ml of methanol and 0.5 ml of triethylamine were added, applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and 10 ml of ethyl acetate and 10 ml of 10% potassium dihydrogen phosphate were added to the obtained concentration residue, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 10 ml of dichloromethane twice, and all of the obtained organic layers were washed with 10 ml of water, 10 ml of a saturated aqueous solution of sodium bicarbonate, and 10 ml of a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 51:49 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Purified water was added to the obtained concentration residue, and after ultrasonication, insoluble matter was filtered and dried under reduced pressure to obtain 39 mg of the title compound (yield: 19%) as a white solid.

Mass spectrum (CI, m/z): 554 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.63 (br s, total 1H), 9.54 (s, 1H), 7.44-7.37 (m, 2H), 7.36-7.30 (m, 2H), 7.28-7.21 (m, 1H), 6.66-6.39 (m, 1H), 5.14-5.04 (m, 1H), 4.59-4.40 (m, 2H), 4.25 (d, J=7.5 Hz, 2H), 2.49-2.41 (m, 2H), 2.29-2.14 (m, 4H), 1.92-1.73 (m, 2H), 1.61 (br s, 3H), 1.56-1.41 (m, 5H), 1.29-1.18 (m, 2H), 0.80 (t, J=7.3 Hz, 3H), 0.09 (s, 9H).

›Example 44

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl octanoate (Compound No. V-1470)

To a solution of 183 mg (0.329 mmol) of a mixture of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 and (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate in a 3 ml of dehydrated dichloromethane, 0.10 ml (0.72 mmol) of triethylamine, 0.15 ml (0.51 mmol) of n-octanoic anhydride, and 10.6 mg (0.087 mmol) of 4-dimethylaminopyridine were added in this order at room temperature in a nitrogen atmosphere and then stirred at the same temperature as above for 2 hours. Subsequently, 1.0 ml (7.2 mmol) of triethylamine and 1.0 ml (25 mmol) of methanol were added to the reaction solution and then stirred at room temperature for 20.5 hours. 1.0 ml (7.2 mmol) of triethylamine and 1.0 ml (25 mmol) of methanol were added to the reaction solution, stirred at 50° C. for 2 hours, and then stirred for 4 hours after the temperature was raised to 60° C.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: dichloromethane:methanol=100:0 to 97:3 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. n-Hexane was added to the obtained concentration residue, and after ultrasonication, the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 115 mg of the title compound (yield: 58%) as a white solid.

Mass spectrum (CI, m/z): 596 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.16 & 11.77 (br s, total 1H), 9.55 (br s, 1H), 7.47-7.37 (m, 2H), 7.37-7.29 (m, 2H), 7.29-7.20 (m, 1H), 6.64-6.43 (m, 1H), 5.16-5.02 (m, 1H), 4.49 (s, 2H), 4.34-4.18 (m, 2H), 2.49-2.41 (m, 2H), 2.28-2.14 (m, 4H), 1.89-1.73 (m, 2H), 1.60 (s, 3H), 1.53 (s, 3H), 1.50-1.43 (m, 2H), 1.24-1.13 (m, 8H), 0.83-0.75 (m, 3H), 0.09 (s, 9H).

›Example 45

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl dodecanoate (Compound No. V-1474)

To a solution of 202 mg (0.373 mmol) of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 38, 0.11 ml (0.79 mmol) of triethylamine, and 10 mg (0.082 mmol) of 4-dimethylaminopyridine in 2 ml of dehydrated dichloromethane, 224 mg (0.585 mmol) of dodecanoic anhydride was added at room temperature in an argon atmosphere and stirred at room temperature for 1 hour. Subsequently, 1 ml of triethylamine and 1 ml of methanol were added to the reaction solution and stirred at room temperature for 16 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=95:5 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 139 mg of the title compound (yield: 57%) as a white solid.

Mass spectrum (CI, m/z): 652 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.18 & 11.66 (br s, total 1H), 9.83-9.28 (m, 1H), 7.42-7.37 (m, 2H), 7.37-7.30 (m, 2H), 7.28-7.21 (m, 1H), 6.67-6.35 (m, 1H), 5.14-5.03 (m, 1H), 4.56-4.42 (m, 2H), 4.30-4.20 (m, 2H), 2.49-2.42 (m, 2H), 2.28-2.13 (m, 4H), 1.89-1.73 (m, 2H), 1.60 (br s, 3H), 1.57-1.43 (m, 5H), 1.30-1.14 (m, 16H), 0.85 (t, J=6.9 Hz, 3H), 0.09 (s, 9H).

›Example 46

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl palmitate (Compound No. V-1478)

To a solution of 220 mg (0.406 mmol) of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 38, 0.115 ml (0.825 mmol) of triethylamine, and 300 mg (0.606 mmol) of palmitic anhydride in 3 ml of dichloromethane, 10 mg (0.082 mmol) of 4-dimethylaminopyridine was added at room temperature in an argon atmosphere and stirred at the same temperature as above for 1.5 hours. Subsequently, 1.0 ml of methanol and 0.5 ml of triethylamine were added to the reaction solution and stirred at room temperature for 15 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 195 mg of the title compound (yield: 68%) as a white solid.

Mass spectrum (DUIS, m/z): 708 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.18 & 11.64 (br s, total 1H), 9.64-9.50 (m, 1H), 7.43-7.38 (m, 2H), 7.36-7.30 (m, 2H), 7.27-7.21 (m, 1H), 6.63-6.39 (m, 1H), 5.13-5.04 (m, 1H), 4.55-4.42 (m, 2H), 4.30-4.20 (m, 2H), 2.48-2.40 (m, 2H), 2.29-2.14 (m, 4H), 1.89-1.74 (m, 2H), 1.60 (br s, 3H), 1.57-1.43 (m, 5H), 1.29-1.14 (m, 24H), 0.89-0.81 (m, 3H), 0.09 (s, 9H).

›Example 47

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl isobutanoate (Compound No. V-1454)

To a solution of 247 mg (0.456 mmol) of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 in 3 ml of dehydrated dichloromethane, 0.15 ml (1.1 mmol) of triethylamine and 0.060 ml (0.57 mmol) of isobutyryl chloride were added in this order at room temperature in a nitrogen atmosphere and then stirred at the same temperature as above for 100 minutes. Subsequently, 1.0 ml (7.2 mmol) of triethylamine and 1.0 ml (25 mmol) of methanol were added to the reaction solution and then stirred at room temperature for 4.5 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: dichloromethane:methanol=100:0 to 99:1 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/n-hexane, and the obtained solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 202 mg of the title compound (yield: 82%) as a white solid.

Mass spectrum (CI, m/z): 540 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.61 (br s, total 1H), 9.53 (s, 1H), 7.47-7.38 (m, 2H), 7.38-7.29 (m, 2H), 7.29-7.20 (m, 1H), 6.71-6.34 (m, 1H), 5.20-5.03 (m, 1H), 4.57-4.38 (m, 2H), 4.33-4.15 (m, 2H), 2.48-2.42 (m, 3H), 2.27-2.13 (m, 2H), 1.92-1.73 (m, 2H), 1.65-1.47 (m, 6H), 1.08-0.99 (m, 6H), 0.14-0.05 (m, 9H).

›Example 48

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl pivalate (Compound No. V-1462)

To a solution of 210 mg (0.387 mmol) of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 and 0.11 ml (0.79 mmol) of triethylamine in 3 ml of dehydrated dichloromethane, 0.12 ml (0.59 mmol) of pivalic anhydride and 10.5 mg (0.086 mmol) of 4-dimethylaminopyridine were added in an argon atmosphere and stirred at room temperature for 4.5 hours. Subsequently, 0.5 ml of triethylamine and 1 ml of methanol were added to the reaction solution and reacted at room temperature for 14 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure. Diisopropyl ether was added to the obtained concentration residue, and after ultrasonication, insoluble matter was collected by filtration and dried under reduced pressure to obtain 144 mg of the title compound (yield: 67%) as a white solid.

Mass spectrum (CI, m/z): 554 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.66 (br s, total 1H), 9.55 (s, 1H), 7.45-7.38 (m, 2H), 7.37-7.31 (m, 2H), 7.28-7.22 (m, 1H), 6.68-6.40 (m, 1H), 5.20-5.09 (m, 1H), 4.48 (br s, 2H), 4.29-4.19 (m, 2H), 2.49-2.41 (m, 2H), 2.26-2.14 (m, 2H), 1.90-1.74 (m, 2H), 1.59 (s, 3H), 1.55 (s, 3H), 1.08 (s, 9H), 0.09 (s, 9H).

›Example 49

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl 3-methylbutanoate (Compound No. V-1466)

To a solution of 201 mg (0.371 mmol) of a mixture of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 and (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate and 0.10 ml (0.74 mmol) of triethylamine in 3 ml of dichloromethane, 0.11 ml (0.56 mmol) of isovaleric anhydride and 10.6 mg (0.087 mmol) of 4-dimethylaminopyridine were added at room temperature in an argon atmosphere and then reacted at the same temperature as above for 3 hours. Subsequently, 1.0 ml of methanol and 0.5 ml of triethylamine were added and reacted at room temperature for 15.5 hours, then the reaction solution was concentrated under reduced pressure, and 1.0 ml of methanol and 0.5 ml of triethylamine were added again to the obtained concentration residue and reacted at 40° C. for 6 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and 8 ml of ethyl acetate, 0.4 ml of water, and 8 ml of a saturated aqueous solution of sodium chloride were added to the obtained concentration residue, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 10 ml of dichloromethane twice, and all of the obtained organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. Diethyl ether was added to the obtained concentration residue, ultrasonicated, and then concentrated under reduced pressure. Water was added to the obtained concentration residue, ultrasonicated, and left standing overnight, and then, insoluble matter was filtered and dried under reduced pressure to obtain 97 mg of the title compound (yield: 47%) as a white solid.

Mass spectrum (CI, m/z): 554 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.50-11.49 (m, 1H), 9.55 (s, 1H), 7.44-7.38 (m, 2H), 7.37-7.30 (m, 2H), 7.29-7.22 (m, 1H), 6.84-6.25 (m, 1H), 5.13-5.06 (m, 1H), 4.55-4.41 (m, 2H), 4.31-4.21 (m, 2H), 2.49-2.42 (m, 2H), 2.26-2.11 (m, 4H), 2.01-1.87 (m, 1H), 1.87-1.74 (m, 2H), 1.59 (s, 3H), 1.53 (s, 3H), 0.87-0.82 (m, 6H), 0.09 (s, 9H).

›Example 50

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl benzoate (Compound No. V-1482)

To a solution of 132 mg (0.244 mmol) of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 and 0.068 ml (0.49 mmol) of triethylamine in 2.5 ml of dehydrated dichloromethane, 0.042 ml (0.36 mmol) of benzoyl chloride was added at room temperature in an argon atmosphere and stirred at the same temperature as above for 1 hour. Subsequently, 0.5 ml of triethylamine and 0.5 ml of methanol were added to the reaction solution and stirred at room temperature for 20 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 94 mg of the title compound (yield: 67%) as a white solid.

Mass spectrum (CI, m/z): 574 [M+1] +

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.19 & 11.71 (br s, total 1H), 9.55 (br s, 1H), 7.95-7.91 (m, 2H), 7.66-7.60 (m, 1H), 7.52-7.46 (m, 4H), 7.39-7.33 (m, 2H), 7.30-7.24 (m, 1H), 6.73-6.59 (m, 1H), 5.35-5.26 (m, 1H), 4.57-4.44 (m, 4H), 2.48-2.42 (m, 2H), 2.23-2.15 (m, 2H), 1.87-1.73 (m, 2H), 1.57 (s, 3H), 1.55 (s, 3H), 0.08 (s, 9H).

›Example 51

(S)-2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl ethyl carbonate (Compound No. V-1486)

To a solution of 265 mg (0.490 mmol) of (S)-ethyl 5-[(2-hydroxy-1-phenylethyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 38 in 4 ml of dehydrated dichloromethane, 0.14 ml (1.0 mmol) of triethylamine and 0.060 ml (0.63 mmol) of ethyl chloroformate were added in this order at room temperature in a nitrogen atmosphere and then stirred at the same temperature as above for 2 hours. Then, 0.20 ml (1.4 mmol) of triethylamine and 0.10 ml (1.1 mmol) of ethyl chloroformate were added at room temperature and stirred at the same temperature as above for 1.5 hours. 0.20 ml (1.4 mmol) of triethylamine and 0.10 ml (1.1 mmol) of ethyl chloroformate were further added again at room temperature and stirred at the same temperature as above for 1 hour. Subsequently, 1.0 ml (7.2 mmol) of triethylamine and 1.0 ml (25 mmol) of methanol were added to the reaction solution and then stirred at room temperature for 4 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: dichloromethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous dipotassium hydrogen phosphate solution=45:55 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, and acetonitrile was distilled off. The deposited solid was collected by filtration, washed by sousing with pure water, and then dried under reduced pressure to obtain 60 mg of the title compound (yield: 23%) as a white solid.

Mass spectrum (ESI, m/z): 542 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.65 (br s, total 1H), 9.62-9.49 (m, 1H), 7.44-7.31 (m, 4H), 7.28-7.21 (m, 1H), 6.68-6.45 (m, 1H), 5.21-4.99 (m, 1H), 4.59-4.40 (m, 2H), 4.38-4.22 (m, 2H), 4.10 (q, J=7.0 Hz, 2H), 2.56-2.42 (m, 2H), 2.27-2.14 (m, 2H), 1.93-1.73 (m, 2H), 1.69-1.45 (m, 6H), 1.18 (t, J=7.0 Hz, 3H), 0.17-0.04 (m, 9H).

›Example 52

Sodium (S)-4-(2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethoxy)-4-oxobutanoate (sodium salt of Compound No. V-1490)

To a solution of 201 mg (0.456 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 7.0 ml of 1,4-dioxane, 628 mg of (S)-2-amino-2-phenylethyl benzyl succinate trifluoroacetate (containing impurities) synthesized in the similar manner as in Reference Example 40 and 1.0 ml (5.7 mmol) of DIPEA were added, applied to a microwave reaction apparatus, and reacted at 100° C. for 1 hour. Subsequently, 1 ml of methanol and 1 ml of triethylamine were added, applied to a microwave reaction apparatus, and reacted at 80° C. for 3 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the obtained concentration residue, washed with a 10% aqueous potassium dihydrogen phosphate solution, water, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous magnesium sulfate, and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 70:30 (V/V)), and a fraction containing (S)-benzyl (2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethyl)succinate was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 171 mg of the obtained concentration residue in 20 ml of ethanol, 25.4 mg of palladium/carbon (ASCA2 (trade name), manufactured by N.E. Chemcat Corp., containing 52% water) was added in a nitrogen atmosphere and then, after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 2 hours.

After the completion of the reaction, replacement with an argon atmosphere was performed, and the reaction solution was filtered through celite. 0.26 ml (0.26 mmol) of a 1 N aqueous sodium hydroxide solution was added to the filtrate and concentrated under reduced pressure. Diethyl ether was added to the obtained residue and then ultrasonicated, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 147 mg of the title compound (yield: 54% [2 steps]) as a white solid.

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 13.32 (br s, 1H), 10.75 (br s, 1H), 7.44-7.38 (m, 2H), 7.36-7.29 (m, 2H), 7.28-7.19 (m, 1H), 6.47 (d, J=7.3 Hz, 1H), 5.11-5.02 (m, 1H), 4.57-4.41 (m, 2H), 4.28 (dd, J=5.6, 10.8 Hz, 1H), 4.17 (dd, J=8.0, 10.8 Hz, 1H), 2.49-2.42 (m, 2H), 2.35 (t, J=7.2 Hz, 2H), 2.25-2.16 (m, 2H), 2.11 (t, J=7.2 Hz, 2H), 1.87-1.71 (m, 2H), 1.58 (s, 3H), 1.51 (s, 3H), 0.08 (s, 9H).

›Example 53

(S)-(2-{6,6-Dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylethoxy)methyl pivalate (Compound No. VI-474)

To a solution of 272 mg (1.08 mmol) of (S)-(2-amino-2-phenylethoxy)methyl pivalate synthesized in the similar manner as in Reference Example 42 in 2 ml of dehydrated THF, 0.15 ml (0.86 mmol) of DIPEA and 162 mg (0.368 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 were added in this order at room temperature in a nitrogen atmosphere and then stirred for 130 minutes while heated to reflux. Subsequently, 1.0 ml of triethylamine and 0.8 ml of methanol were added to the reaction solution and then stirred for 70 minutes while heated to reflux.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: dichloromethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/n-hexane, and the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 176 mg of the title compound (yield: 82%) as a white solid.

Mass spectrum (CI, m/z): 584 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.64 (br s, total 1H), 9.59-9.49 (m, 1H), 7.41-7.35 (m, 2H), 7.35-7.27 (m, 2H), 7.25-7.19 (m, 1H), 6.42 & 6.28 (d, J=8.0 Hz, total 1H), 5.29 (d, J=6.2 Hz, 1H), 5.22 (d, J=6.2 Hz, 1H), 5.02-4.94 (m, 1H), 4.57-4.37 (m, 2H), 3.91-3.83 (m, 1H), 3.79 (dd, J=6.0, 10.0 Hz, 1H), 2.49-2.40 (m, 2H), 2.28-2.13 (m, 2H), 1.92-1.73 (m, 2H), 1.67-1.45 (m, 6H), 1.13 (s, 9H), 0.14-0.06 (m, 9H).

›Example 54

(S)-2-Acetoxy-1-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (Compound No. V-1250)

To a solution of 412 mg of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate (containing impurities) synthesized in the similar manner as in Reference Example 3 by using 506 mg (1.06 mmol) of 5-tert-butyl 2-ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 84 in 4 ml of dehydrated THF, 0.70 ml (4.0 mmol) of DIPEA and 1.30 g (3.84 mmol) of (S)-2-({[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}oxy)-2-phenylethyl acetate synthesized in the similar manner as in Reference Example 43 were added in this order at room temperature in a nitrogen atmosphere and then stirred for 1.5 hours while heated to reflux. Subsequently, 2.0 ml (14 mmol) of triethylamine and 1.5 ml (37 mmol) of methanol were added to the reaction solution and then stirred for 3.5 hours while heated to reflux.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=80:20 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 225 mg of a concentration residue.

Approximately 50 mg of the obtained concentration residue was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous dipotassium hydrogen phosphate solution=50:50 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, and acetonitrile was distilled off. The concentration residue was subjected to extraction with ethyl acetate twice, and all of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. For the obtained concentration residue, crystallization was performed with ethyl acetate/diisopropyl ether/n-hexane, and the deposited solid was collected by filtration, washed by sousing with n-hexane, and then dried under reduced pressure to obtain 11.6 mg of the title compound (yield: 2% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 513 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.35-12.21 & 11.97-11.83 (m, total 1H), 9.87-9.45 (m, 1H), 7.47-7.24 (m, 5H), 5.99-5.85 (m, 1H), 4.65-4.17 (m, 4H), 2.48-2.36 (m, 2H), 2.28-2.10 (m, 2H), 2.05-1.95 (m, 3H), 1.92-1.72 (m, 2H), 1.71-1.43 (m, 6H), 0.16-0.02 (m, 9H).

›Example 55

(S)-Benzyl 2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate (Compound No. IV-411)

To a solution of 195 mg (0.442 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 7 ml of 1,4-dioxane, 565 mg of (S)-benzyl 2-amino-2-phenylacetate trifluoroacetate (containing impurities) synthesized in the similar manner as in Reference Example 45 and 0.50 ml (2.9 mmol) of DIPEA were added at room temperature in an argon atmosphere, then applied to a microwave reaction apparatus, and stirred at 100° C. for 1 hour. After the reaction, the reaction solution was concentrated under reduced pressure, and 4 ml of methanol and 1 ml of triethylamine were added to the obtained concentration residue, applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the obtained concentration residue, the organic layer after washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 55:45 (V/V)), and a fraction composed mainly of the title compound and a fraction composed mainly of a by-product [(S)-methyl 2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate] were each concentrated under reduced pressure. The concentration residue of the fraction composed mainly of the title compound was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 55:45 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 99 mg of the title compound (yield: 39%) as a white foam.

Mass spectrum (DUIS, m/z): 574 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.70 (br s, total 1H), 9.63-9.44 (m, 1H), 7.51-7.41 (m, 2H), 7.38-7.23 (m, 8H), 6.81-6.47 (m, 1H), 5.42 (d, J=7.2 Hz, 1H), 5.17 (d, J=12.7 Hz, 1H), 5.11 (d, J=12.7 Hz, 1H), 4.61-4.39 (m, 2H), 2.49-2.38 (m, 2H), 2.25-2.12 (m, 2H), 1.91-1.72 (m, 2H), 1.68-1.52 (m, 6H), 0.07 (s, 9H).

›Example 56

(S)-Methyl 2-{6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carboxamido}-2-phenylacetate (Compound No. IV-419)

The concentration residue of the fraction composed mainly of the title compound collected at the time of the first purification of silica gel column chromatography in the operational steps of Example 55 was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 55:45 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 29 mg of the title compound (yield: 13%) as a white foam.

Mass spectrum (DUIS, m/z): 498 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.71 (br s, total 1H), 9.63-9.46 (m, 1H), 7.48-7.41 (m, 2H), 7.40-7.28 (m, 3H), 6.73-6.56 (m, 1H), 5.36 (d, J=7.2 Hz, 1H), 4.61-4.38 (m, 2H), 3.62 (s, 3H), 2.49-2.38 (m, 2H), 2.27-2.10 (m, 2H), 1.92-1.71 (m, 2H), 1.67-1.51 (m, 6H), 0.08 (s, 9H).

›Example 57

N-(2,2-Difluoro-3-hydroxy-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-362)

To a solution of 249 mg (1.33 mmol) of 3-amino-2,2-difluoro-3-phenylpropan-1-ol synthesized in the similar manner as in Reference Example 48 in 2 ml of dehydrated 1,4-dioxane, 0.30 ml (1.7 mmol) of DIPEA and 178 mg (0.403 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 were added in this order at room temperature in a nitrogen atmosphere and then stirred at 80° C. for 7 hours. Subsequently, 0.10 ml (1.7 mmol) of 2-aminoethanol was added to the reaction solution allowed to cool to room temperature, and then stirred at room temperature for 1.5 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with dichloromethane three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 155 mg of the title compound (yield: 74%) as a white solid.

Mass spectrum (CI, m/z): 520 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.43-11.84 (m, 1H), 10.02-9.36 (m, 1H), 7.56-7.50 (m, 2H), 7.40-7.27 (m, 3H), 6.61 (br s, 1H), 5.71 (br s, 1H), 5.49-5.34 (m, 1H), 4.70-4.56 (m, 1H), 4.47 (br d, J=12.0 Hz, 1H), 3.73-3.45 (m, 2H), 2.57-2.42 (m, 2H), 2.26-2.15 (m, 2H), 1.90-1.74 (m, 2H), 1.61 (s, 3H), 1.51 (s, 3H), 0.09 (s, 9H).

›Example 58

N-(2-Isopropoxy-1-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-146)

To a solution of 0.102 g (0.231 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 0.127 g (0.709 mmol) of 2-isopropoxy-1-phenylethanamine synthesized in the similar manner as in Reference Example 50 in 2.5 ml of dehydrated 1,4-dioxane, 0.200 ml (1.15 mmol) of DIPEA was added at room temperature in a nitrogen atmosphere and then heated and stirred at 100° C. for 1 hour. After standing to cool, 0.50 ml (12 mmol) of methanol and 0.070 ml (1.2 mmol) of 2-aminoethanol were added to the reaction solution and stirred at room temperature for 1 hour.

After the completion of the reaction, ethyl acetate was added to the residue obtained by concentration under reduced pressure, the organic layer after washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 50:50 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, the residue was dissolved in a small amount of dichloromethane, and after addition of n-hexane and ultrasonication, the deposited solid was collected by filtration and dried under reduced pressure to obtain 0.106 g of the title compound (yield: 90%) as a white solid.

Mass spectrum (CI, m/z): 512 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.76 (br s, total 1H), 9.68-9.50 (m, 1H), 7.42-7.16 (m, 5H), 6.31-6.08 (m, 1H), 4.94-4.84 (m, 1H), 4.56-4.37 (m, 2H), 3.67-3.51 (m, 3H), 2.51-2.40 (m, 2H), 2.27-2.13 (m, 2H), 1.92-1.71 (m, 2H), 1.65-1.48 (m, 6H), 1.08-1.03 (m, 6H), 0.09 (s, 9H).

›Example 59

6,6-Dimethyl-N-(2-phenoxy-1-phenylethyl)-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-162)

To a solution of 0.101 g (0.230 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 0.145 g (0.681 mmol) of 2-phenoxy-1-phenylethanamine synthesized in the similar manner as in Reference Example 52 in 2.5 ml of dehydrated 1,4-dioxane, 0.200 ml (1.15 mmol) of DIPEA was added at room temperature in a nitrogen atmosphere and then stirred at 100° C. for 1 hour. After standing to cool, 0.50 ml (12 mmol) of methanol and 0.070 ml (1.2 mmol) of 2-aminoethanol were added and stirred at room temperature for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added, the organic layer after washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 67:33 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, the residue was dissolved in a small amount of dichloromethane, and after addition of n-hexane and ultrasonication, the deposited solid was collected by filtration and dried under reduced pressure to obtain 0.112 g of the title compound (yield: 89%) as a white solid.

Mass spectrum (CI, m/z): 546 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.70 (br s, total 1H), 9.57 (br s, 1H), 7.51-7.18 (m, 7H), 7.03-6.86 (m, 3H), 6.68-6.40 (m, 1H), 5.23-5.11 (m, 1H), 4.57-4.38 (m, 2H), 4.34-4.22 (m, 1H), 4.16 (dd, J=5.9, 9.8 Hz, 1H), 2.57-2.39 (m, 2H), 2.25-2.11 (m, 2H), 1.90-1.71 (m, 2H), 1.62 (br s, 3H), 1.54 (br s, 3H), 0.08 (s, 9H).

›Example 60

(S)—N-[1-(2-Chlorophenyl)-2-hydroxyethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-959)

To a solution of 0.105 g (0.238 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 0.124 g (0.723 mmol) of (S)-2-amino-2-(2-chlorophenyl)ethanol [purchased from Amatek Chemical Co., Ltd.] in 2.5 ml of dehydrated 1,4-dioxane, 0.200 ml (1.15 mmol) of DIPEA was added at room temperature in a nitrogen atmosphere and then stirred at 100° C. for 1 hour. After standing to cool, 0.50 ml (12 mmol) of methanol and 0.070 ml (1.2 mmol) of 2-aminoethanol were added and stirred at room temperature for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the residue, the organic layer after washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=84:16 to 33:67 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, the residue was dissolved in a small amount of dichloromethane, and after addition of n-hexane and ultrasonication, the deposited solid was collected by filtration and dried under reduced pressure to obtain 0.0958 g of the title compound (yield: 80%) as a white solid.

Mass spectrum (DUIS, m/z): 504 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.75 (br s, total 1H), 9.71-9.52 (m, 1H), 7.51 (dd, J=1.6, 7.7 Hz, 1H), 7.38 (dd, J=1.2, 7.8 Hz, 1H), 7.33-7.20 (m, 2H), 6.36-6.14 (m, 1H), 5.21-5.12 (m, 1H), 5.04 (t, J=6.0 Hz, 1H), 4.66-4.45 (m, 2H), 3.64-3.48 (m, 2H), 2.57-2.41 (m, 2H), 2.28-2.13 (m, 2H), 1.91-1.72 (m, 2H), 1.66-1.42 (m, 6H), 0.10 (s, 9H).

›Example 61

(S)—N-[2-Hydroxy-1-(o-tolyl)ethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-1067)

To a solution of 0.104 g (0.235 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 0.131 g (0.696 mmol) of (S)-2-amino-2-(o-tolyl)ethanol hydrochloride [purchased from Acesys Pharmatech Ltd.] in 2.5 ml of dehydrated 1,4-dioxane, 0.400 ml (2.30 mmol) of DIPEA was added at room temperature in a nitrogen atmosphere and then heated and stirred at 100° C. for 1 hour. After standing to cool, 0.50 ml (12 mmol) of methanol and 0.070 ml (1.2 mmol) of 2-aminoethanol were added and stirred at room temperature for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added, the organic layer after washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=84:16 to 33:67 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, the residue was dissolved in a small amount of dichloromethane, and after addition of n-hexane and ultrasonication, the deposited solid was collected by filtration and dried under reduced pressure to obtain 0.0738 g of the title compound (yield: 65%) as a white solid.

Mass spectrum (CI, m/z): 484 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.66 (br s, total 1H), 9.63-9.50 (m, 1H), 7.40 (d, J=7.4 Hz, 1H), 7.18-7.03 (m, 3H), 6.28-6.05 (m, 1H), 5.04-4.95 (m, 1H), 4.89 (t, J=6.0 Hz, 1H), 4.58-4.41 (m, 2H), 3.61-3.43 (m, 2H), 2.56-2.41 (m, 2H), 2.36 (s, 3H), 2.27-2.11 (m, 2H), 1.93-1.70 (m, 2H), 1.69-1.41 (m, 6H), 0.10 (s, 9H).

›Example 62

(S)—N-(1-Hydroxy-3-phenylpropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-862)

To a solution of 101 mg (0.229 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 3 ml of 1,4-dioxane, 0.115 ml (0.673 mmol) of DIPEA and 102 mg (0.675 mmol) of (S)-2-amino-3-phenylpropan-1-ol were added in this order in an argon atmosphere and then stirred at 100° C. for 1 hour. Subsequently, the reaction solution was concentrated under reduced pressure, and 2 ml of methanol and 0.5 ml of triethylamine were added in this order at room temperature and stirred at 80° C. for 1 hour in a microwave reaction apparatus.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, the concentration residue was dissolved in 5 ml of ethyl acetate and washed with a 5% aqueous potassium dihydrogen phosphate solution twice, and then, the organic layer was washed with 5 ml of a saturated aqueous solution of sodium bicarbonate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=100:0 to 86:14 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and subsequently dried under reduced pressure at 50° C. to obtain 88.5 mg of the title compound (yield: 80%) as a white solid.

Mass spectrum (CI, m/z): 484 [M+1]+.

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.19 & 11.71 (br s, total 1H), 9.54 (br s, 1H), 7.28-7.18 (m, 4H), 7.18-7.12 (m, 1H), 5.72-5.45 (m, 1H), 4.77 (t, J=5.5 Hz, 1H), 4.46-4.17 (m, 2H), 3.90-3.77 (m, 1H), 3.44-3.28 (m, 2H), 2.87-2.70 (m, 2H), 2.54-2.40 (m, 2H), 2.25-2.13 (m, 2H), 1.92-1.70 (m, 2H), 1.58 (br s, 3H), 1.50 (br s, 3H), 0.09 (s, 9H).

›Example 63

N-(2-Hydroxy-3-methylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-446)

To a solution of 103 mg (0.234 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 3 ml of 1,4-dioxane, 69.8 mg (0.677 mmol) of 1-amino-3-methylbutan-2-ol [purchased from Life Chemicals Inc.] and 0.115 ml (0.673 mmol) of DIPEA were added in this order at room temperature in an argon atmosphere and then stirred at 100° C. for 2.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, the concentration residue was dissolved in 5 ml of ethyl acetate and washed with a 5% aqueous potassium dihydrogen phosphate solution twice, and then, the organic layer was washed with 5 ml of a saturated aqueous solution of sodium bicarbonate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=100:0 to 86:14 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in dichloromethane, n-hexane was added, and then, the deposited solid was collected by filtration and dried under reduced pressure to obtain 71.9 mg of the title compound (yield: 71%) as a white solid.

Mass spectrum (CI, m/z): 436 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.72 (br s, total 1H), 9.56 (br s, 1H), 6.03-5.75 (m, 1H), 4.79 (d, J=4.5 Hz, 1H), 4.48-4.27 (m, 2H), 3.29-3.17 (m, 2H), 2.96-2.85 (m, 1H), 2.56-2.39 (m, 2H), 2.25-2.12 (m, 2H), 1.91-1.72 (m, 2H), 1.68-1.50 (m, 7H), 0.86 (d, J=6.8 Hz, 6H), 0.08 (s, 9H).

›Example 64

(R)—N-(1-Hydroxy-3-phenylpropan-2-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-861)

To a solution of 0.102 g (0.232 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 and 0.110 g (0.729 mmol) of (R)-2-amino-3-phenylpropan-1-ol in 2.5 ml of dehydrated 1,4-dioxane, 0.20 ml (1.1 mmol) of DIPEA was added at room temperature in an argon atmosphere and then heated and stirred at 100° C. for 1.5 hours. After standing to cool, the resultant was concentrated under reduced pressure, and 4 ml of methanol and 1 ml of triethylamine were added to the residue, applied to a microwave reaction apparatus, and reacted at 80° C. for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added, the organic layer after washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=100:0 to 90:10 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, small amounts of dichloromethane and n-hexane were added to the residue, and after ultrasonication, the deposited solid was collected by filtration and dried under reduced pressure to obtain 0.0454 g of the title compound (yield: 40%) as a white solid.

Mass spectrum (CI, m/z): 484 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.19 & 11.65 (br s, total 1H), 9.54 (s, 1H), 7.28-7.18 (m, 4H), 7.18-7.12 (m, 1H), 5.70-5.47 (m, 1H), 4.77 (t, J=5.5 Hz, 1H), 4.45-4.19 (m, 2H), 3.90-3.77 (m, 1H), 3.46-3.29 (m, 2H), 2.87-2.70 (m, 2H), 2.56-2.38 (m, 2H), 2.26-2.11 (m, 2H), 1.92-1.71 (m, 2H), 1.65-1.40 (m, 6H), 0.09 (s, 9H).

›Example 65

(R)—N-(2-Hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-786)

To a solution of 101 mg (0.229 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 2 ml of dehydrated THF, 0.20 ml (1.1 mmol) of DIPEA and 151 mg (1.10 mmol) of (R)-2-amino-1-phenylethanol were added in this order at room temperature in a nitrogen atmosphere and then stirred for 3 hours then with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with dichloromethane three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 20:80 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous dipotassium hydrogen phosphate solution=40:60 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, and acetonitrile was distilled off. The solid deposited in the course of concentration was collected by filtration, washed with pure water, and then dried under reduced pressure to obtain 55 mg of the title compound (yield: 51%) as a white solid.

Mass spectrum (EI, m/z): 469 [M] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.67 (br s, total 1H), 9.56 (s, 1H), 7.36-7.28 (m, 4H), 7.27-7.19 (m, 1H), 6.19-5.94 (m, 1H), 5.59 (d, J=4.0 Hz, 1H), 4.66 (td, J=4.0, 8.0 Hz, 1H), 4.48-4.24 (m, 2H), 3.44-3.22 (m, 1H), 3.09 (ddd, J=4.8, 8.0, 13.2 Hz, 1H), 2.56-2.38 (m, 2H), 2.26-2.12 (m, 2H), 1.90-1.72 (m, 2H), 1.60 (br s, 6H), 0.08 (s, 9H).

›Example 66

(S)—N-(2-Hydroxy-2-phenylethyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-787)

To a solution of 102 mg (0.231 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 2 ml of dehydrated THF, 0.20 ml (1.1 mmol) of DIPEA and 129 mg (0.943 mmol) of (S)-2-amino-1-phenylethanol were added in this order at room temperature in a nitrogen atmosphere and then stirred for 4 hours with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with dichloromethane three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: dichloromethane:methanol=100:0 to 98:2 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous dipotassium hydrogen phosphate solution=45:55 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, and acetonitrile was distilled off. The solid deposited in the course of concentration was collected by filtration, washed with pure water, and then dried under reduced pressure. Ethyl acetate was added to the obtained solid, then insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 52 mg of the title compound (yield: 48%) as a white solid.

Mass spectrum (EI, m/z): 469 [M] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.70 (br s, total 1H), 9.63-9.53 (m, 1H), 7.36-7.28 (m, 4H), 7.27-7.19 (m, 1H), 6.19-5.94 (m, 1H), 5.59 (d, J=4.0 Hz, 1H), 4.66 (td, J=4.0, 8.0 Hz, 1H), 4.48-4.24 (m, 2H), 3.44-3.22 (m, 1H), 3.15-3.04 (m, 1H), 2.56-2.38 (m, 2H), 2.26-2.12 (m, 2H), 1.90-1.72 (m, 2H), 1.60 (br s, 6H), 0.08 (s, 9H).

›Example 67

2-Hydroxy-2-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (Compound No. IV-670)

To a solution of 0.125 g of 2-[(2-methoxypropan-2-yl)oxy]-2-phenylethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (containing impurities) synthesized in Reference Example 56 in 3 ml of methanol, 0.0077 g (0.031 mmol) of pyridinium p-toluenesulfonate was added at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 3.5 hours, and then, 0.020 ml of triethylamine was added and concentrated under reduced pressure.

The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=77:23 to 26:74 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 0.0837 g of the title compound (yield: 66% [2 steps]) as a white foam.

Mass spectrum (CI, m/z): 471 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.25 & 12.19 & 11.83 (br s, total 1H), 9.73-9.49 (m, 1H), 7.47-7.19 (m, 5H), 5.58 (d, J=4.5 Hz, 1H), 4.89-4.74 (m, 1H), 4.50-4.23 (m, 2H), 4.21-3.91 (m, 2H), 2.57-2.35 (m, 2H), 2.27-2.09 (m, 2H), 1.93-1.68 (m, 2H), 1.66-1.30 (m, 6H), 0.17-0.01 (m, 9H).

›Example 68

(R)—N-[6,6-Dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1258)

To a solution of 58.3 mg (0.351 mmol) of (R)-2-phenoxypropanoic acid in 2 ml of dehydrated DMF, 0.12 ml (0.69 mmol) of DIPEA and 152 mg (0.354 mmol) of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate [COMU (trade name)] were added in this order at 0° C. in a nitrogen atmosphere and then stirred for 20 minutes with the temperature unchanged. Subsequently, 104 mg (0.274 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate synthesized in the similar manner as in Reference Example 5 was added at 0° C. and then stirred at room temperature for 15.5 hours. Subsequently, 0.10 ml (1.7 mmol) of 2-aminoethanol was added to the reaction solution at room temperature and then stirred for 2.5 hours with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The operation of adding toluene to the obtained concentration residue, followed by concentration under reduced pressure again was repeated twice, then the resultant was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=75:25 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 75 mg of the title compound (yield: 60%) as a white solid.

Mass spectrum (EI, m/z): 454 [M] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.53-11.80 (m, 1H), 9.69 (br s, 1H), 7.30-7.21 (m, 2H), 6.94-6.87 (m, 1H), 6.85-6.78 (m, 2H), 4.90 (q, J=6.5 Hz, 1H), 4.87-4.78 (m, 1H), 4.67-4.57 (m, 1H), 2.56-2.38 (m, 2H), 2.25-2.12 (m, 2H), 1.87-1.74 (m, 2H), 1.67-1.58 (m, 6H), 1.46 (d, J=6.5 Hz, 3H), 0.06 (s, 9H).

›Example 69

(S)—N-[6,6-Dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1259)

To a solution of 58.6 mg (0.353 mmol) of (S)-2-phenoxypropanoic acid in 2 ml of dehydrated DMF, 0.12 ml (0.69 mmol) of DIPEA and 153 mg (0.356 mmol) of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate [COMU (trade name)] were added in this order at 0° C. in a nitrogen atmosphere and then stirred for 20 minutes with the temperature unchanged. Subsequently, 104 mg (0.275 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate synthesized in the similar manner as in Reference Example 5 was added at 0° C. and then stirred at room temperature for 3 hours. Subsequently, 0.10 ml (1.7 mmol) of 2-aminoethanol was added to the reaction solution at room temperature and then stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The operation of adding toluene to the obtained concentration residue, followed by concentration under reduced pressure again was repeated twice, then the resultant was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=75:25 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 75 mg of the title compound (yield: 60%) as a white solid.

Mass spectrum (EI, m/z): 454 [M] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.32 & 11.92 (br s, total 1H), 9.81-9.55 (m, 1H), 7.30-7.21 (m, 2H), 6.94-6.87 (m, 1H), 6.85-6.78 (m, 2H), 4.96-4.74 (m, 2H), 4.71-4.54 (m, 1H), 2.56-2.38 (m, 2H), 2.26-2.10 (m, 2H), 1.91-1.72 (m, 2H), 1.69-1.54 (m, 6H), 1.46 (d, J=6.5 Hz, 3H), 0.06 (br s, 9H).

›Example 70

N-[6,6-Dimethyl-5-(2-phenoxyacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1238)

To a solution of 0.143 g (0.279 mmol) of ethyl 6,6-dimethyl-5-(2-phenoxyacetyl)-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 57 in 3 ml of methanol, 0.150 ml (1.38 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in a nitrogen atmosphere and then stirred at room temperature for 30 minutes.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the residue, the organic layer after washing with a 10% aqueous potassium dihydrogen phosphate solution, a saturated aqueous solution of sodium bicarbonate, and a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 62:38 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, the residue was dissolved in a small amount of dichloromethane, and after addition of n-hexane and ultrasonication, the deposited solid was collected by filtration and dried under reduced pressure to obtain 0.0876 g of the title compound (yield: 71%) as a white solid.

Mass spectrum (CI, m/z): 441 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.29 & 11.89 (br s, total 1H), 9.84-9.56 (m, 1H), 7.30-7.24 (m, 2H), 6.95-6.89 (m, 3H), 4.78 (s, 2H), 4.73-4.56 (m, 2H), 2.56-2.35 (m, 2H), 2.27-2.08 (m, 2H), 1.93-1.54 (m, 8H), 0.08 (s, 9H).

›Example 71

(R)—N-[6,6-Dimethyl-5-(2-phenoxypropanoyl)-1,4,5,6-tetrahydropyrrol o[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide (Compound No. III-1140)

To a solution of 143 mg (0.861 mmol) of (R)-2-phenoxypropanoic acid in 3 ml of dehydrated dichloromethane, 0.12 ml (1.4 mmol) of oxalyl chloride and 0.0050 ml (0.065 mmol) of dehydrated DMF were added in this order at 0° C. in a nitrogen atmosphere and then stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 154 mg (0.424 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 46 and 0.38 ml (2.2 mmol) of DIPEA in 2 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added at 0° C. in a nitrogen atmosphere and then stirred for 1.5 hours with the temperature unchanged. Subsequently, 0.24 ml (2.2 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at 0° C. and then stirred at room temperature for 2 hours.

After the completion of the reaction, the reaction solution diluted with dichloromethane was washed with a 5% aqueous potassium bisulfate solution and then separated into an aqueous layer and an organic layer. The aqueous layer was subjected to extraction with dichloromethane twice, and then, all of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=80:20 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 155 mg of the title compound (yield: 83%) as a white solid.

Mass spectrum (CI, m/z): 441 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.33 & 12.02 (br s, total 1H), 10.03-9.76 (m, 1H), 7.30-7.22 (m, 2H), 6.94-6.87 (m, 1H), 6.85-6.78 (m, 2H), 4.95-4.70 (m, 2H), 4.67-4.51 (m, 1H), 1.70-1.52 (m, 6H), 1.45 (d, J=6.4 Hz, 3H), 0.98 (br s, 2H), 0.80-0.59 (m, 2H), 0.01 (br s, 9H).

›Example 72

N-{5-[3-(Benzyloxy)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1354)

To a solution of 340 mg of 3-(benzyloxy)-2-phenoxypropanoic acid (containing impurities) synthesized in the similar manner as in Reference Example 60 in 3 ml of dehydrated dichloromethane, 0.005 ml (0.07 mmol) of DMF and 0.140 ml (1.63 mmol) of oxalyl chloride were added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 236 mg (0.625 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.550 ml (3.16 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 1 hour. Subsequently, 0.340 ml (3.12 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 16 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 90:10), and some fractions containing the compound of interest at high purity were concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 11.7 mg of the title compound (yield: 3.3%) as a white solid. Also, the remaining fractions containing the compound of interest obtained by silica gel column chromatography were combined, concentrated under reduced pressure, and dried under reduced pressure to obtain 162 mg of the title compound (yield: 46%) as a white solid.

Mass spectrum (CI, m/z): 561 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.30 & 11.92 (br s, total 1H), 9.82-9.54 (m, 1H), 7.38-7.20 (m, 7H), 6.97-6.88 (m, 1H), 6.88-6.80 (m, 2H), 5.03-4.66 (m, 3H), 4.60 (s, 2H), 3.93-3.81 (m, 2H), 2.57-2.39 (m, 2H), 2.29-2.11 (m, 2H), 1.91-1.71 (m, 2H), 1.70-1.50 (m, 6H), 0.07 (s, 9H).

›Example 73

N-[5-(3-Hydroxy-2-phenoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1330)

To a solution of 162 mg (0.289 mmol) of N-{5-[3-(benzyloxy)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide synthesized in the similar manner as in Example 72 in 5 ml of ethanol, 30 mg of 20% palladium hydroxide/carbon (containing 50 wt % water) was added in an argon atmosphere and after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 5 hours.

After the completion of the reaction, replacement with an argon atmosphere was performed, and the reaction solution was filtered through celite. The solid on the celite was washed with ethanol, and all of the filtrates were concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 61 mg of the title compound (yield: 45%) as a white solid.

Mass spectrum (CI, m/z): 471 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.39-11.82 (m, 1H), 9.70 (br s, 1H), 7.32-7.22 (m, 2H), 6.95-6.88 (m, 1H), 6.85-6.78 (m, 2H), 5.34-5.23 (m, 1H), 4.92-4.82 (m, 1H), 4.81-4.69 (m, 2H), 3.85-3.71 (m, 2H), 2.60-2.39 (m, 2H), 2.26-2.12 (m, 2H), 1.89-1.71 (m, 2H), 1.62 (s, 3H), 1.60 (s, 3H), 0.08 (s, 9H).

›Example 74

N-{5-[2-(4-Chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1270)

To a solution of 150 mg (0.748 mmol) of 2-(4-chlorophenoxy)propanoic acid [purchased from AK Scientific, Inc.] in 3 ml of dehydrated dichloromethane, 0.080 ml (0.93 mmol) of oxalyl chloride and 0.004 ml (0.05 mmol) of DMF were added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 129 mg (0.341 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.300 ml (1.72 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 3 hours. Subsequently, 0.200 ml (1.84 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 16 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain a solid. The obtained solid was subjected again to silica gel column chromatography (DNH silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 39 mg of the title compound (yield: 23%) as a white solid.

Mass spectrum (CI, m/z): 489 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.32 & 11.89 (br s, total 1H), 9.79-9.53 (m, 1H), 7.34-7.24 (m, 2H), 6.90-6.77 (m, 2H), 4.93 (q, J=6.4 Hz, 1H), 4.90-4.72 (m, 1H), 4.70-4.50 (m, 1H), 2.60-2.36 (m, 2H), 2.28-2.10 (m, 2H), 1.93-1.70 (m, 2H), 1.70-1.53 (m, 6H), 1.46 (d, J=6.4 Hz, 3H), 0.06 (s, 9H).

›Example 75

N-{5-[2-(2-Chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1266)

To a solution of 150 mg (0.748 mmol) of 2-(2-chlorophenoxy)propanoic acid in 3 ml of dehydrated dichloromethane, 0.080 ml (0.93 mmol) of oxalyl chloride and 0.004 ml (0.05 mmol) of DMF were added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 129 mg (0.341 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.300 ml (1.72 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 3 hours. Subsequently, 0.200 ml (1.84 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 16 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain a solid. The obtained solid was subjected again to silica gel column chromatography (DNH silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 16 mg of the title compound (yield: 10%) as a white solid.

Mass spectrum (CI, m/z): 489 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.32 & 11.92 (br s, total 1H), 9.80-9.54 (m, 1H), 7.45-7.38 (m, 1H), 7.29-7.20 (m, 1H), 6.96-6.89 (m, 1H), 6.89-6.83 (m, 1H), 5.01 (q, J=6.5 Hz, 1H), 4.92-4.74 (m, 1H), 4.72-4.52 (m, 1H), 2.58-2.37 (m, 2H), 2.27-2.10 (m, 2H), 1.93-1.71 (m, 2H), 1.71-1.55 (m, 6H), 1.51 (d, J=6.5 Hz, 3H), 0.06 (s, 9H).

›Example 76

N-{5-[2-(Cyclohexyloxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1255)

To a solution of 120 mg (0.697 mmol) of 2-(cyclohexyloxy)propanoic acid [purchased from Enamine Ltd.] in 3 ml of dehydrated dichloromethane, 0.080 ml (0.93 mmol) of oxalyl chloride and 0.005 ml (0.07 mmol) of DMF were added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 129 mg (0.341 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.300 ml (1.72 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours. Subsequently, 0.200 ml (1.84 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 16 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 37 mg of the title compound (yield: 24%) as a white solid.

Mass spectrum (CI, m/z): 461 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.39-11.73 (m, 1H), 9.63 (br s, 1H), 4.78-4.55 (m, 2H), 4.23 (q, J=6.5 Hz, 1H), 3.41-3.26 (m, 1H), 2.58-2.37 (m, 2H), 2.25-2.12 (m, 2H), 1.90-1.72 (m, 4H), 1.71-1.55 (m, 8H), 1.50-1.39 (m, 1H), 1.28-1.05 (m, 8H), 0.07 (s, 9H).

›Example 77

N-{5-[2-(3-Chlorophenoxy)propanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1268)

To a solution of 150 mg (0.748 mmol) of 2-(3-chlorophenoxy)propanoic acid [purchased from Combi-Blocks Inc.] in 3 ml of dehydrated dichloromethane, 0.080 ml (0.93 mmol) of oxalyl chloride and 0.005 ml (0.07 mmol) of DMF were added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 129 mg (0.341 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.300 ml (1.72 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours. Subsequently, 0.200 ml (1.84 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 16 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure. The obtained solid was subjected again to silica gel column chromatography (DNH silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 30 mg of the title compound (yield: 18%) as a white solid.

Mass spectrum (CI, m/z): 489 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.32 & 11.93 (br s, total 1H), 9.79-9.56 (m, 1H), 7.29 (t, J=8.3 Hz, 1H), 7.00-6.94 (m, 1H), 6.86 (t, J=2.1 Hz, 1H), 6.83-6.77 (m, 1H), 5.00 (q, J=6.4 Hz, 1H), 4.90-4.73 (m, 1H), 4.71-4.51 (m, 1H), 2.57-2.37 (m, 2H), 2.27-2.10 (m, 2H), 1.92-1.71 (m, 2H), 1.70-1.53 (m, 6H), 1.47 (d, J=6.4 Hz, 3H), 0.06 (s, 9H).

›Example 78

N-[5-(2-Methoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1241)

To a solution of 65.0 mg (0.624 mmol) of 2-methoxypropanoic acid [purchased from Combi-Blocks Inc.] in 3 ml of dehydrated dichloromethane, 0.200 ml (1.15 mmol) of DIPEA and 220 mg (0.514 mmol) of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate [COMU (trade name)] were added in this order with stirring at 0° C. in an argon atmosphere and then stirred at the same temperature as above for 15 minutes. Subsequently, 129 mg (0.341 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 was added at 0° C. and stirred at room temperature for 16 hours. Subsequently, 0.220 ml (2.02 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 4 hours.

The reaction solution was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 61 mg of the title compound (yield: 46%) as a white solid.

Mass spectrum (CI, m/z): 393 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.28 & 11.86 (br s, total 1H), 9.80-9.53 (m, 1H), 4.82-4.44 (m, 2H), 4.06 (q, J=6.4 Hz, 1H), 3.20 (s, 3H), 2.57-2.37 (m, 2H), 2.29-2.10 (m, 2H), 1.93-1.55 (m, 8H), 1.21 (d, J=6.4 Hz, 3H), 0.08 (s, 9H).

›Example 79

N-[5-(3-Methoxy-2-phenoxypropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1348)

To a solution of 116 mg of 3-methoxy-2-phenoxypropanoic acid (containing impurities) synthesized in the similar manner as in Reference Example 63 in 3 ml of dehydrated dichloromethane, 0.004 ml (0.05 mmol) of DMF and 0.070 ml (0.82 mmol) of oxalyl chloride were added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 124 mg (0.329 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.300 ml (1.72 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours. Subsequently, 0.200 ml (1.84 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 16 hours.

The reaction solution was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 75 mg of the title compound (yield: 47%) as a white solid.

Mass spectrum (CI, m/z): 485 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.32 & 11.94 (br s, total 1H), 9.85-9.57 (m, 1H), 7.34-7.21 (m, 2H), 6.97-6.89 (m, 1H), 6.88-6.78 (m, 2H), 4.98-4.79 (m, 2H), 4.78-4.59 (m, 1H), 3.83-3.68 (m, 2H), 3.34 (s, 3H), 2.58-2.37 (m, 2H), 2.28-2.10 (m, 2H), 1.92-1.71 (m, 2H), 1.69-1.49 (m, 6H), 0.08 (s, 9H).

›Example 80

N-{6,6-Dimethyl-5-[2-(pyridin-3-yloxy)propanoyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1274)

To a solution of 114 mg (0.682 mmol) of 2-(pyridin-3-yloxy)propanoic acid [purchased from Enamine Ltd.] in 3 ml of dehydrated dichloromethane, 0.200 ml (1.15 mmol) of DIPEA and 250 mg (0.584 mmol) of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate [COMU (trade name)] were added in this order with stirring at 0° C. in an argon atmosphere and then stirred at the same temperature as above for 15 minutes. Subsequently, 172 mg (0.454 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 was added at 0° C. and stirred at room temperature for 16 hours. Subsequently, 0.250 ml (2.30 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 4 hours.

The reaction solution was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 89 mg of the title compound (yield: 43%) as a white solid.

Mass spectrum (CI, m/z): 456 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.32 & 11.88 (s, total 1H), 9.76-9.60 (m, 1H), 8.24-8.17 (m, 1H), 8.17-8.09 (m, 1H), 7.33-7.27 (m, 1H), 7.25-7.20 (m, 1H), 5.06 (q, J=6.3 Hz, 1H), 4.93-4.79 (m, 1H), 4.70-4.54 (m, 1H), 2.57-2.38 (m, 2H), 2.27-2.13 (m, 2H), 1.91-1.71 (m, 2H), 1.69-1.54 (m, 6H), 1.50 (d, J=6.3 Hz, 3H), 0.13-0.02 (m, 9H).

›Example 81

N-{5-[3-(Dimethylamino)-2-phenoxypropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1372)

To a solution of 70.0 mg (0.335 mmol) of 3-(dimethylamino)-2-phenoxypropanoic acid synthesized in the similar manner as in Reference Example 66 in 3 ml of dehydrated DMF, 0.150 ml (0.861 mmol) of DIPEA and 200 mg (0.467 mmol) of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate [COMU (trade name)] were added in this order with stirring at 0° C. in an argon atmosphere and then stirred at the same temperature as above for 15 minutes. Subsequently, 115 mg (0.304 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 was added at 0° C. and stirred at room temperature for 3 hours. Subsequently, 0.200 ml (1.84 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 16 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: 1,2-dichloroethane:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 57 mg of the title compound (yield: 38%) as a white solid.

Mass spectrum (CI, m/z): 498 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.48-11.69 (m, 1H), 9.67 (br s, 1H), 7.32-7.23 (m, 2H), 6.96-6.88 (m, 1H), 6.84-6.77 (m, 2H), 4.87 (br d, J=12.0 Hz, 1H), 4.81 (dd, J=4.5, 6.6 Hz, 1H), 4.66 (br d, J=12.0 Hz, 1H), 2.82-2.70 (m, 2H), 2.57-2.39 (m, 2H), 2.26 (s, 6H), 2.24-2.12 (m, 2H), 1.89-1.73 (m, 2H), 1.62 (s, 3H), 1.61 (s, 3H), 0.07 (s, 9H).

›Example 82

N-[6,6-Dimethyl-5-(2-phenoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1211)

To a solution of 140 mg (0.613 mmol) of 2-phenoxy-2-phenylacetic acid [purchased from Enamine Ltd.] in 3 ml of dehydrated dichloromethane, 0.080 ml (0.93 mmol) of oxalyl chloride and 0.005 ml (0.07 mmol) of DMF were added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 129 mg (0.341 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.300 ml (1.72 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at the same temperature as above for 3 hours. Subsequently, 0.200 ml (1.84 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 16 hours.

The reaction solution was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 94 mg of the title compound (yield: 53%) as a white solid.

Mass spectrum (CI, m/z): 517 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.30 & 11.91 (br s, total 1H), 9.57 (br s, 1H), 7.57-7.50 (m, 2H), 7.48-7.36 (m, 3H), 7.31-7.23 (m, 2H), 6.97-6.88 (m, 3H), 5.91 (s, 1H), 4.98-4.72 (m, 1H), 4.40-4.21 (m, 1H), 2.48-2.35 (m, 2H), 2.27-2.08 (m, 2H), 1.91-1.73 (m, 2H), 1.67 (s, 3H), 1.60 (s, 3H), 0.04 (s, 9H).

›Example 83

N-{5-[3-(3,3-Difluoropyrrolidin-1-yl)-2-phenoxypropanoyl]-6,6-dimeth yl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1378)

To a solution of 170 mg of 3-(3,3-difluoropyrrolidin-1-yl)-2-phenoxypropanoic acid (containing impurities) synthesized in the similar manner as in Reference Example 69 in 3 ml of dehydrated DMF, 0.250 ml (1.44 mmol) of DIPEA and 300 mg (0.700 mmol) of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate [COMU (trade name)] were added in this order with stirring at 0° C. in an argon atmosphere and then stirred at the same temperature as above for 15 minutes. Subsequently, 129 mg (0.341 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 was added at 0° C. and stirred at room temperature for 16 hours. Subsequently, 0.200 ml (1.84 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then reacted with stirring at room temperature for 64 hours.

The reaction solution was subjected to silica gel column chromatography (elution solvent: 1,2-dichloroethane:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous potassium dihydrogen phosphate solution=50:50 (V/V)), and ethyl acetate and water were added to a fraction containing the compound of interest, then an organic layer and an aqueous layer were separated. The obtained organic layer was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 49 mg of the title compound (yield: 26%) as a white solid.

Mass spectrum (CI, m/z): 560 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.32 & 11.94 (br s, total 1H), 9.84-9.59 (m, 1H), 7.32-7.23 (m, 2H), 6.97-6.89 (m, 1H), 6.85-6.78 (m, 2H), 4.97-4.80 (m, 2H), 4.74-4.57 (m, 1H), 3.14-2.80 (m, 6H), 2.58-2.37 (m, 2H), 2.29-2.10 (m, 4H), 1.92-1.72 (m, 2H), 1.70-1.52 (m, 6H), 0.14-0.03 (m, 9H).

›Example 84

N-[5-(3-Hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-632)

To a solution of 139 mg (0.540 mmol) of 3-(benzyloxy)-2-phenylpropanoic acid synthesized according to the method described in Tetrahedron Lett., 2002 (43), 9691-9693] in 3 ml of dehydrated DMF, 0.18 ml (1.0 mmol) of DIPEA and 233 mg (0.544 mmol) of (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate [COMU (trade name)] were added in this order at 0° C. in a nitrogen atmosphere and then stirred for 15 minutes with the temperature unchanged. Subsequently, 158 mg (0.418 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate synthesized in the similar manner as in Reference Example 5 was added at 0° C. and then stirred at room temperature for 3.5 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 4 ml of THF, 0.25 ml (1.8 mmol) of triethylamine and 0.10 ml (1.7 mmol) of 2-aminoethanol were added in this order at room temperature in a nitrogen atmosphere and then stirred for 1.5 hours with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with dichloromethane three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 50:50 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of ethanol, 25.4 mg of 20% palladium hydroxide/carbon [containing 50 wt % water] was added at room temperature in a nitrogen atmosphere and then, after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 1.5 hours. The inside of the reaction container was replaced with a nitrogen atmosphere under reduced pressure, and subsequently, 68.3 mg of 20% palladium hydroxide/carbon [containing 50 wt % water] was added at room temperature and then, after replacement with a hydrogen atmosphere again under reduced pressure, stirred at room temperature for 3.5 hours.

After the completion of the reaction, the inside of the reaction container was replaced with a nitrogen atmosphere under reduced pressure. The reaction solution was filtered using a celite filter, subsequently the removed solid was washed with ethanol, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 104 mg of the title compound (yield: 55% [2 steps]) as a white solid.

Mass spectrum (EI, m/z): 454 [M] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.45-11.70 (m, 1H), 9.58 (br s, 1H), 7.35-7.20 (m, 5H), 4.81-4.64 (m, 2H), 4.23 (d, J=12.0 Hz, 1H), 3.98-3.89 (m, 1H), 3.84 (dd, J=5.4, 8.2 Hz, 1H), 3.52-3.44 (m, 1H), 2.58-2.37 (m, 2H), 2.24-2.12 (m, 2H), 1.87-1.73 (m, 2H), 1.69 (s, 3H), 1.58 (s, 3H), 0.05 (s, 9H).

›Example 85

(S)—N-[5-(3-Hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-633)

To a solution of 139 mg (0.256 mmol) of (S)—N-{5-[3-(benzyloxy)-2-phenylpropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide synthesized in the similar manner as in Reference Example 70 in 2 ml of ethanol, 58.4 mg of 20% palladium hydroxide/carbon [containing 50 wt % water] was added at room temperature in a nitrogen atmosphere and then, after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 3 hours.

After the completion of the reaction, the inside of the reaction container was replaced with a nitrogen atmosphere under reduced pressure. The reaction solution was filtered using a celite filter, subsequently the removed solid was washed with ethyl acetate, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=85:15 to 35:65 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 55 mg of the title compound (yield: 47%) as a white solid.

Mass spectrum (CI, m/z): 455 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.24 & 11.85 (br s, total 1H), 9.73-9.44 (m, 1H), 7.35-7.20 (m, 5H), 4.81-4.63 (m, 2H), 4.33-4.11 (m, 1H), 3.98-3.89 (m, 1H), 3.88-3.80 (m, 1H), 3.52-3.44 (m, 1H), 2.60-2.36 (m, 2H), 2.26-2.10 (m, 2H), 1.89-1.64 (m, 5H), 1.58 (br s, 3H), 0.05 (s, 9H).

›Example 86

(R)—N-{5-[3-(Benzyloxy)-2-phenylpropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1221)

To a solution of 1.22 g (4.76 mmol) of (R)-3-(benzyloxy)-2-phenylpropanoic acid [synthesized according to the method described in Tetrahedron Lett., 2002, 43, 9691-9693] in 20 ml of dehydrated dichloromethane, 0.55 ml (6.4 mmol) of oxalyl chloride and 0.030 ml (0.39 mmol) of dehydrated DMF were added in this order at 0° C. in a nitrogen atmosphere and then stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 903 mg (2.39 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 1.70 ml (9.76 mmol) of DIPEA in 15 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 5 ml of dehydrated dichloromethane was added at 0° C. in a nitrogen atmosphere and then stirred for 2 hours with the temperature unchanged. Subsequently, 1.0 ml (9.2 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at 0° C. and then stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution diluted with dichloromethane was washed with a 5% aqueous potassium bisulfate solution and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with dichloromethane twice, and then, all of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=85:15 to 50:50 (V/V)), and some fractions containing the compound of interest at high purity were concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 43 mg of the title compound (yield: 3%) as a white solid. Also, the remaining fractions containing the compound of interest obtained by silica gel column chromatography were concentrated under reduced pressure and dried under reduced pressure to obtain 1.10 g of the title compound (yield: 85%) as a pale yellow foam.

Mass spectrum (CI, m/z): 545 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.25 & 11.85 (s, total 1H), 9.65-9.47 (m, 1H), 7.38-7.20 (m, 10H), 4.79-4.62 (m, 1H), 4.52 (d, J=12.6 Hz, 1H), 4.47 (d, J=12.6 Hz, 1H), 4.31-4.15 (m, 1H), 4.07-3.94 (m, 2H), 3.57-3.47 (m, 1H), 2.57-2.36 (m, 2H), 2.25-2.09 (m, 2H), 1.89-1.64 (m, 5H), 1.63-1.50 (m, 3H), 0.09-0.02 (m, 9H).

›Example 87

(R)—N-[5-(3-Hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1215)

To a solution of 1.10 g (2.02 mmol) of (R)—N-{5-[3-(benzyloxy)-2-phenylpropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide synthesized in the similar manner as in Example 86 in 15 ml of ethanol, 326 mg of 20% palladium hydroxide/carbon [containing 50 wt % water] was added at room temperature in a nitrogen atmosphere and then, after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 3.5 hours.

After the completion of the reaction, the inside of the reaction container was replaced with a nitrogen atmosphere under reduced pressure. The reaction solution was filtered using a celite filter, subsequently the removed solid was washed with ethyl acetate, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 10:90 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (elution solvent: dichloromethane:methanol=100:0 to 96:4 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 708 mg of the title compound (yield: 77%) as a white solid.

Mass spectrum (CI, m/z): 455 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.25 & 11.82 (s, total 1H), 9.66-9.47 (m, 1H), 7.36-7.20 (m, 5H), 4.83-4.62 (m, 2H), 4.32-4.13 (m, 1H), 3.99-3.90 (m, 1H), 3.89-3.79 (m, 1H), 3.53-3.42 (m, 1H), 2.57-2.35 (m, 2H), 2.25-2.09 (m, 2H), 1.91-1.64 (m, 5H), 1.63-1.52 (m, 3H), 0.13-0.01 (m, 9H).

›Example 88

(R)—N-[5-(2-Methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1175)

To a solution of 263 mg (1.58 mmol) of (R)-2-methoxy-2-phenylacetic acid in 5 ml of dehydrated dichloromethane, 0.24 ml (2.8 mmol) of oxalyl chloride and 0.025 ml (0.32 mmol) of DMF were added in this order at 0° C. in an argon atmosphere and then stirred for 3 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure at room temperature to obtain a concentration residue.

To a solution of 300 mg (0.793 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.55 ml (3.2 mmol) of DIPEA in 5 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise at 0° C. in an argon atmosphere and then stirred at room temperature for 15 hours. Subsequently, 0.37 ml (4.0 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then stirred for 3 hours with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. All of the obtained organic layers were washed with a saturated aqueous solution of ammonium chloride and a saturated aqueous solution of sodium chloride in this order, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 35:65 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 224 mg of the title compound (yield: 62%) as a white solid.

Mass spectrum (CI, m/z): 455 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.26 & 11.86 (br s, total 1H), 9.71-9.47 (m, 1H), 7.44-7.27 (m, 5H), 4.96 (s, 1H), 4.74-4.52 (m, 1H), 4.39-4.21 (m, 1H), 3.31 (s, 3H), 2.48-2.36 (m, 2H), 2.26-2.07 (m, 2H), 1.92-1.53 (m, 8H), 0.05 (s, 9H).

›Example 89

(S)—N-[5-(2-Methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1176)

To a solution of 263 mg (1.58 mmol) of (S)-2-methoxy-2-phenylacetic acid in 5 ml of dehydrated dichloromethane, 0.24 ml (2.8 mmol) of oxalyl chloride and 0.025 ml (0.32 mmol) of DMF were added in this order at 0° C. in an argon atmosphere and then stirred for 3 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure at room temperature to obtain a concentration residue.

To a solution of 300 mg (0.793 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.55 ml (3.2 mmol) of DIPEA in 5 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise at 0° C. in an argon atmosphere and then stirred at room temperature for 15 hours. Subsequently, 0.37 ml (4.0 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then stirred for 3 hours with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. All of the obtained organic layers were washed with a saturated aqueous solution of ammonium chloride and a saturated aqueous solution of sodium chloride in this order, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 35:65 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved by adding ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 206 mg of the title compound (yield: 57%) as a white solid.

Mass spectrum (CI, m/z): 455 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.26 & 11.86 (br s, total 1H), 9.71-9.45 (m, 1H), 7.46-7.26 (m, 5H), 4.96 (s, 1H), 4.73-4.53 (m, 1H), 4.30 (br d, J=12.3 Hz, 1H), 3.31 (s, 3H), 2.47-2.36 (m, 2H), 2.24-2.11 (m, 2H), 1.89-1.53 (m, 8H), 0.05 (s, 9H).

›Example 90

N-[5-(3-Methoxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-634)

To a solution of 212 mg (1.18 mmol) of 3-methoxy-2-phenylpropanoic acid synthesized in the similar manner as in Reference Example 72 in 6 ml of dehydrated dichloromethane, 0.14 ml (1.6 mmol) of oxalyl chloride and 0.0060 ml (0.077 mmol) of dehydrated DMF were added in this order at 0° C. in a nitrogen atmosphere and then stirred for 2.5 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 156 mg (0.413 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.36 ml (2.1 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added at 0° C. in a nitrogen atmosphere and then stirred for 1.5 hours with the temperature unchanged. Subsequently, 0.23 ml (2.1 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at 0° C. and then stirred at room temperature for 2 hours.

After the completion of the reaction, the reaction solution diluted with dichloromethane was washed with a 5% aqueous potassium bisulfate solution, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with dichloromethane twice, and then, all of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (elution solvent: dichloromethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous dipotassium hydrogen phosphate solution=40:60 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, and acetonitrile was distilled off. The obtained concentration residue was subjected to extraction with ethyl acetate three times, and then, all of the obtained organic layers were washed with a saturated aqueous solution of sodium chloride, subsequently dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 101 mg of the title compound (yield: 52%) as a white solid.

Mass spectrum (CI, m/z): 469 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.50-11.61 (m, 1H), 9.57 (br s, 1H), 7.36-7.22 (m, 5H), 4.70 (d, J=12.3 Hz, 1H), 4.22 (d, J=12.3 Hz, 1H), 3.99-3.92 (m, 1H), 3.90-3.83 (m, 1H), 3.40 (dd, J=5.7, 8.8 Hz, 1H), 3.23 (s, 3H), 2.57-2.37 (m, 2H), 2.22-2.12 (m, 2H), 1.86-1.74 (m, 2H), 1.68 (s, 3H), 1.57 (s, 3H), 0.05 (s, 9H).

›Example 91

N-[5-(4-Methoxy-2-phenylbutanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1224)

To a solution of 154 mg (0.793 mmol) of 4-methoxy-2-phenylbutanoic acid synthesized in the similar manner as in Reference Example 74 in 3 ml of dehydrated dichloromethane, 0.14 ml (1.6 mmol) of oxalyl chloride and 0.0092 ml (0.12 mmol) of DMF were added in this order at 0° C. in an argon atmosphere and then stirred for 1 hour with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure at room temperature to obtain a concentration residue.

To a solution of 150 mg (0.396 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.28 ml (1.6 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise at 0° C. in an argon atmosphere and then stirred at room temperature for 3 hours. Subsequently, 0.185 ml (1.98 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then stirred for 14 hours with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. All of the obtained organic layers were washed with a saturated aqueous solution of ammonium chloride and a saturated aqueous solution of sodium chloride in this order, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 40:60 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected to preparative HPLC (column: XSelect (trade name) HSS C18, elution solvent: acetonitrile:1 mM aqueous potassium dihydrogen phosphate solution=50:50 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, and acetonitrile was distilled off. The obtained concentration residue was subjected to extraction with ethyl acetate, and all of the obtained organic layers were washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was dissolved by adding ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 78 mg of the title compound (yield: 41%) as a white solid.

Mass spectrum (CI, m/z): 483 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.24 & 11.95 (br s, total 1H), 9.78-9.46 (m, 1H), 7.39-7.18 (m, 5H), 4.79-4.57 (m, 1H), 4.24 (br d, J=12.2 Hz, 1H), 3.92-3.75 (m, 1H), 3.29-3.21 (m, 2H), 3.20 (s, 3H), 2.59-2.37 (m, 2H), 2.25-2.11 (m, 3H), 1.88-1.62 (m, 6H), 1.57 (br s, 3H), 0.05 (s, 9H).

›Example 92

(S)—N-[5-(3-Hydroxy-2-phenylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide (Compound No. III-592)

To a solution of 45.8 mg (0.0864 mmol) of (S)—N-{5-[3-(benzyloxy)-2-phenylpropanoyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclopropanecarboxamide synthesized in the similar manner as in Reference Example 75 in 1 ml of ethanol, 13.6 mg of 20% palladium hydroxide/carbon [containing 50 wt % water] was added at room temperature in a nitrogen atmosphere and then, after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 2.5 hours.

After the completion of the reaction, the inside of the reaction container was replaced with a nitrogen atmosphere under reduced pressure. The reaction solution was filtered using a celite filter, subsequently the removed solid was washed with ethyl acetate, and then, the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (elution solvent: dichloromethane:methanol=99:1 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 19 mg of the title compound (yield: 50%) as a white solid.

Mass spectrum (CI, m/z): 441 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.25 & 11.96 (br s, total 1H), 9.98-9.65 (m, 1H), 7.37-7.19 (m, 5H), 4.80-4.58 (m, 2H), 4.33-4.10 (m, 1H), 3.98-3.88 (m, 1H), 3.88-3.80 (m, 1H), 3.52-3.43 (m, 1H), 1.68 (br s, 3H), 1.57 (br s, 3H), 1.05-0.91 (m, 2H), 0.80-0.56 (m, 2H), 0.01 (s, 9H).

›Example 93

(R)—N-[5-(2-Methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclopropanecarboxamide (Compound No. III-1059)

To a solution of 182 mg (1.10 mmol) of (R)-2-methoxy-2-phenylacetic acid in 5 ml of dehydrated dichloromethane, 0.165 ml (1.92 mmol) of oxalyl chloride and 0.017 ml (0.22 mmol) of DMF were added in this order at 0° C. in an argon atmosphere and then stirred for 1 hour with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure at room temperature to obtain a concentration residue.

To a solution of 200 mg (0.549 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 46 and 0.38 ml (2.2 mmol) of DIPEA in 5 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise at 0° C. in an argon atmosphere and then stirred at room temperature for 1.5 hours. Subsequently, 0.26 ml (2.7 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then stirred for 1 hour with the temperature unchanged.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. All of the obtained organic layers were washed with a saturated aqueous solution of ammonium chloride and a saturated aqueous solution of sodium chloride in this order, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (elution solvent: 1,2-dichloroethane:methanol=97:3 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 191 mg of the title compound (yield: 79%) as a white solid.

Mass spectrum (CI, m/z): 441 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.38-11.88 (m, 1H), 9.97-9.65 (m, 1H), 7.45-7.27 (m, 5H), 4.96 (s, 1H), 4.71-4.49 (m, 1H), 4.29 (br d, J=12.8 Hz, 1H), 3.31 (s, 3H), 1.68 (br s, 3H), 1.59 (s, 3H), 1.05-0.91 (m, 2H), 0.78-0.58 (m, 2H), 0.01 (s, 9H).

›Example 94

(R)—N-{5-[2-(Difluoromethoxy)-2-phenylacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1180)

To a solution of 1.01 g (4.17 mmol) of (R)-benzyl 2-hydroxy-2-phenylacetate and 158 mg (0.83 mmol) of copper(I) iodide in 15 ml of acetonitrile, a solution of 2.2 ml (17 mmol) of 2,2-difluoro-2-(fluorosulfonyl)acetic acid in 20 ml of acetonitrile was dividedly added (2 ml each) every 5 minutes at 60° C. in an argon atmosphere and stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution allowed to cool to room temperature was concentrated under reduced pressure and diluted with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 70:30 (V/V)), and subsequently, a fraction containing the compound of interest was concentrated under reduced pressure to obtain 0.67 g of a concentration residue as a colorless oil.

To a solution of 0.67 g of the obtained concentration residue in 20 ml of methanol, 70 mg of palladium/carbon (ASCA2 (trade name), manufactured by N.E. Chemcat Corp., containing 54% water) was added in an argon atmosphere and then, after replacement with a hydrogen atmosphere under reduced pressure, stirred at room temperature for 2 hours.

After the completion of the reaction, replacement with a nitrogen atmosphere was performed, the reaction solution was filtered through celite, the solid component was washed with methanol, and then, the filtrate was concentrated under reduced pressure to obtain 0.42 g of a concentration residue as a pale yellow solid.

To a solution of 115 mg of the obtained concentration residue in 3 ml of dehydrated dichloromethane, 0.072 ml (0.82 mmol) of oxalyl chloride and 0.010 ml (0.13 mmol) of dehydrated DMF were added in this order at room temperature in an argon atmosphere and then stirred for 15 minutes with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 103 mg (0.273 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.24 ml (1.4 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added at room temperature in an argon atmosphere and then stirred for 3.5 hours with the temperature unchanged. Subsequently, 0.15 ml (1.4 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at room temperature and then stirred at room temperature for 1 hour.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, dried by adding anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, and n-hexane was added. The deposited solid was collected by filtration and dried under reduced pressure to obtain 48.1 mg of the title compound (yield: 36%) as a white solid.

Mass spectrum (CI, m/z): 491 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.30 & 11.86 (br s, total 1H), 9.67-9.51 (m, 1H), 7.48-7.37 (m, 5H), 6.83 (t, J=76.0 Hz, 1H), 5.78 (s, 1H), 4.83-4.61 (m, 1H), 4.24-4.07 (m, 1H), 2.56-2.35 (m, 2H), 2.24-2.10 (m, 2H), 1.91-1.50 (m, 8H), 0.04 (s, 9H).

›Example 95

(R)—N-[5-(2-Ethoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1188)

To a solution of 128 mg (0.710 mmol) of (R)-2-ethoxy-2-phenylacetic acid obtained in the similar manner as in Reference Example 77 in 3 ml of dehydrated dichloromethane, 0.090 ml (1.0 mmol) of oxalyl chloride and 0.010 ml (0.13 mmol) of dehydrated DMF were added in this order at 0° C. in an argon atmosphere and then stirred for 1 hour with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 112 mg (0.295 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.30 ml (1.7 mmol) of DIPEA in 3 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added at 0° C. in an argon atmosphere and then stirred for 30 minutes with the temperature unchanged. Subsequently, 0.11 ml (1.01 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at 0° C. and then stirred at room temperature for 1 hour.

After the completion of the reaction, water was added, followed by extraction with ethyl acetate. The organic layer was washed with a 5% aqueous potassium bisulfate solution and a saturated aqueous solution of sodium chloride in this order, dried by adding anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, n-hexane was added, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 69.7 mg of the title compound (yield: 50%) as a white solid.

Mass spectrum (CI, m/z): 469 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.26 & 11.85 (br s, total 1H), 9.67-9.48 (m, 1H), 7.43-7.27 (m, 5H), 5.04 (s, 1H), 4.73-4.47 (m, 1H), 4.44-4.24 (m, 1H), 3.62-3.40 (m, 2H), 2.58-2.36 (m, 2H), 2.25-2.10 (m, 2H), 1.90-1.53 (m, 8H), 1.14 (t, J=7.0 Hz, 3H), 0.05 (s, 9H).

›Example 96

(R)-1-(Ethyldimethylsilyl)-N-[5-(2-methoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]cyclobutanecarboxamide (Compound No. IV-1178)

To a solution of 107 mg (0.646 mmol) of (R)-2-methoxy-2-phenylacetic acid in 2 ml of dehydrated dichloromethane, 0.080 ml (0.93 mmol) of oxalyl chloride and 0.0050 ml (0.065 mmol) of dehydrated DMF were added in this order at 0° C. in a nitrogen atmosphere and then stirred for 3 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 117 mg (0.299 mmol) of ethyl 3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 12 and 0.21 ml (1.2 mmol) of DIPEA in 1 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added at 0° C. in a nitrogen atmosphere and then stirred for 2.5 hours with the temperature unchanged. Subsequently, 0.16 ml (1.5 mmol) of N,N-dimethylethane-1,2-diamine was added to the reaction solution at 0° C. and then stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution diluted with dichloromethane was washed with a 5% aqueous potassium bisulfate solution and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with dichloromethane twice, and then, all of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=80:20 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 115 mg of the title compound (yield: 82%) as a white solid.

Mass spectrum (CI, m/z): 469 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.26 & 11.84 (s, total 1H), 9.67-9.48 (m, 1H), 7.42-7.27 (m, 5H), 4.95 (s, 1H), 4.71-4.52 (m, 1H), 4.35-4.23 (m, 1H), 3.30 (s, 3H), 2.56-2.37 (m, 2H), 2.26-2.11 (m, 2H), 1.90-1.52 (m, 8H), 0.88 (t, J=7.8 Hz, 3H), 0.53 (q, J=7.8 Hz, 2H), 0.09-0.01 (m, 6H).

›Example 97

(R)—N-[5-(2-Cyclopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1208)

To a solution of 140 mg (0.728 mmol) of (R)-2-cyclopropoxy-2-phenylacetic acid synthesized in the similar manner as in Reference Example 86 in 2 ml of dehydrated dichloromethane, 0.006 ml (0.08 mmol) of DMF and 0.083 ml (0.95 mmol) of oxalyl chloride were added with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 150 mg (0.396 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydro pyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.350 ml (2.00 mmol) of DIPEA in 2 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 2 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with water, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 70:30 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of dehydrated dichloromethane, 0.130 ml (1.19 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 16 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate and then added to n-hexane, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 80 mg of the title compound (yield: 42%) as a white solid.

Mass spectrum (CI, m/z): 481 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.37-11.83 (m, 1H), 9.59 (br s, 1H), 7.42-7.28 (m, 5H), 5.10 (s, 1H), 4.73-4.54 (m, 1H), 4.35 (d, J=12.4 Hz, 1H), 3.40 (tt, J=3.0, 6.1 Hz, 1H), 2.59-2.37 (m, 2H), 2.24-2.12 (m, 2H), 1.90-1.74 (m, 2H), 1.70 (s, 3H), 1.61 (s, 3H), 0.69-0.53 (m, 2H), 0.51-0.39 (m, 2H), 0.05 (s, 9H).

›Example 98

(R)—N-[5-(2-Isopropoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1204)

To a solution of 165 mg (0.849 mmol) of (R)-2-isopropoxy-2-phenylacetic acid synthesized in the similar manner as in Reference Example 87 in 2 ml of dehydrated dichloromethane, 0.10 ml (1.2 mmol) of oxalyl chloride and 0.0050 ml (0.065 mmol) of dehydrated DMF were added in this order at 0° C. in an argon atmosphere and then stirred for 2.5 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure and dried under reduced pressure to obtain a concentration residue.

To a solution of 128 mg (0.338 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.30 ml (1.7 mmol) of DIPEA in 1 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added at 0° C. in an argon atmosphere and then stirred for 1.5 hours with the temperature unchanged.

After the completion of the reaction, ethyl acetate and a saturated aqueous solution of sodium bicarbonate were added to the reaction solution and stirred. After separation into an aqueous layer and an organic layer, the aqueous layer was subjected to extraction with ethyl acetate twice. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=80:20 to 60:40 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of THF, 0.15 ml (1.4 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 2 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=80:20 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 135 mg of the title compound (yield: 83%) as a white solid.

Mass spectrum (CI, m/z): 483 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.40-11.82 (m, 1H), 9.75-9.42 (m, 1H), 7.40-7.27 (m, 5H), 5.11 (s, 1H), 4.65-4.38 (m, 2H), 3.68 (spt, J=6.0 Hz, 1H), 2.47-2.35 (m, 2H), 2.23-2.09 (m, 2H), 1.87-1.71 (m, 2H), 1.67 (s, 3H), 1.61 (s, 3H), 1.16 (d, J=6.0 Hz, 3H), 1.13 (d, J=6.0 Hz, 3H), 0.04 (s, 9H).

›Example 99

(R)—N-{6,6-Dimethyl-5-[2-phenyl-2-(trifluoromethoxy)acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1184)

To a solution of 160 mg of (R)-2-phenyl-2-(trifluoromethoxy)acetic acid (containing impurities) synthesized in the similar manner as in Reference Example 89 in 2 ml of dehydrated dichloromethane, 0.083 ml (0.95 mmol) of oxalyl chloride and 0.006 ml (0.08 mmol) of DMF were added with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 150 mg (0.396 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.350 ml (2.00 mmol) of DIPEA in 2 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 2 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with water, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 70:30 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of dehydrated dichloromethane, 0.130 ml (1.19 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 2 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate and then added to n-hexane, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 97.6 mg of the title compound (yield: 48%) as a white solid.

Mass spectrum (CI, m/z): 509 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.39-11.84 (m, 1H), 9.58 (br s, 1H), 7.54-7.41 (m, 5H), 6.06 (s, 1H), 4.78 (br d, J=11.9 Hz, 1H), 4.08 (br d, J=11.9 Hz, 1H), 2.58-2.35 (m, 2H), 2.23-2.10 (m, 2H), 1.88-1.73 (m, 2H), 1.70 (s, 3H), 1.60 (s, 3H), 0.04 (s, 9H).

›Example 100

(R)—N-[6,6-Dimethyl-5-(2-phenyl-2-propoxyacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1196)

To a solution of 146 mg (0.753 mmol) of (R)-2-phenyl-2-propoxyacetic acid synthesized in the similar manner as in Reference Example 91 in 2 ml of dehydrated dichloromethane, 0.10 ml (1.2 mmol) of oxalyl chloride and 0.0050 ml (0.065 mmol) of dehydrated DMF were added in this order at 0° C. in an argon atmosphere and then stirred for 1.5 hours with the temperature unchanged.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure and dried under reduced pressure to obtain a concentration residue.

To a solution of 144 mg (0.380 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.33 ml (1.9 mmol) of DIPEA in 1 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 1 ml of dehydrated dichloromethane was added at 0° C. in an argon atmosphere and then stirred for 1.5 hours with the temperature unchanged.

After the completion of the reaction, ethyl acetate and a saturated aqueous solution of sodium bicarbonate were added to the reaction solution and stirred. After separation into an aqueous layer and an organic layer, the aqueous layer was subjected to extraction with ethyl acetate twice. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=85:15 to 60:40 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of THF, 0.17 ml (1.6 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 3 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=85:15 to 60:40 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 144 mg of the title compound (yield: 80%) as a white solid.

Mass spectrum (CI, m/z): 483 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.43-11.75 (m, 1H), 9.56 (br s, 1H), 7.43-7.27 (m, 5H), 5.03 (s, 1H), 4.71-4.47 (m, 1H), 4.39 (br d, J=12.5 Hz, 1H), 3.51-3.43 (m, 1H), 3.41-3.24 (m, 1H), 2.60-2.36 (m, 2H), 2.25-2.10 (m, 2H), 1.88-1.72 (m, 2H), 1.68 (s, 3H), 1.65-1.48 (m, 5H), 0.87 (t, J=7.4 Hz, 3H), 0.04 (s, 9H).

›Example 101

N-{5-[2-(4-Fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1427)

To a suspension of 229 mg of 2-(4-fluorophenyl)-2-methoxyacetic acid (containing impurities) synthesized in the similar manner as in Reference Example 93 in 2 ml of dehydrated dichloromethane, 0.150 ml (1.71 mmol) of oxalyl chloride and 0.011 ml (0.14 mmol) of DMF were added with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 265 mg (0.700 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.620 ml (3.55 mmol) of DIPEA in 2 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 1 hour.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with water, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 70:30 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of dehydrated dichloromethane, 0.230 ml (2.11 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 1 hour.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in dichloromethane, and then, a 5% aqueous potassium bisulfate solution was added thereto, stirred, and separated into an aqueous layer and an organic layer. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate and then added to n-hexane, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 174 mg of the title compound (yield: 53%) as a white solid.

Mass spectrum (CI, m/z): 473 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.27 & 11.91 (br s, total 1H), 9.58 (br s, 1H), 7.47-7.36 (m, 2H), 7.26-7.14 (m, 2H), 4.99 (s, 1H), 4.76-4.53 (m, 1H), 4.32 (br d, J=12.4 Hz, 1H), 3.29 (s, 3H), 2.58-2.36 (m, 2H), 2.25-2.10 (m, 2H), 1.88-1.72 (m, 2H), 1.69 (br s, 3H), 1.60 (s, 3H), 0.05 (s, 9H).

›Example 102

N-{5-[2-(3-Fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1404)

To a suspension of 146 mg of 2-(3-fluorophenyl)-2-methoxyacetic acid (containing impurities) synthesized in the similar manner as in Reference Example 96 in 2 ml of dehydrated dichloromethane, 0.080 ml (0.91 mmol) of oxalyl chloride and 0.010 ml (0.13 mmol) of DMF were added with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 200 mg (0.528 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.462 ml (2.65 mmol) of DIPEA in 2 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise with stirring at room temperature in an argon atmosphere and stirred at room temperature for 1 hour.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with water, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 70:30 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of dehydrated dichloromethane, 0.173 ml (1.59 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 16 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 187 mg of the title compound (yield: 75%) as a white solid.

Mass spectrum (CI, m/z): 473 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.40-11.81 (m, 1H), 9.60 (br s, 1H), 7.48-7.38 (m, 1H), 7.24-7.13 (m, 3H), 5.03 (s, 1H), 4.75-4.54 (m, 1H), 4.39 (br d, J=12.7 Hz, 1H), 3.32 (s, 3H), 2.59-2.36 (m, 2H), 2.24-2.10 (m, 2H), 1.88-1.72 (m, 2H), 1.69 (s, 3H), 1.60 (s, 3H), 0.05 (s, 9H).

›Example 103

(R)—N-{5-[2-(2-Fluorophenyl)-2-methoxyacetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1383)

To a suspension of 200 mg (1.09 mmol) of (R)-2-(2-fluorophenyl)-2-methoxyacetic acid synthesized in the similar manner as in Reference Example 98 in 2 ml of dehydrated dichloromethane, 0.111 ml (1.27 mmol) of oxalyl chloride and 0.010 ml (0.13 mmol) of DMF were added with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 200 mg (0.528 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.500 ml (2.86 mmol) of DIPEA in 2 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise with stirring at room temperature in an argon atmosphere and stirred at room temperature for 2 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with water, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 70:30 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of dehydrated dichloromethane, 0.173 ml (1.59 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 3 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 164 mg of the title compound (yield: 66%) as a white solid.

Mass spectrum (CI, m/z): 473 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.42-11.83 (m, 1H), 9.60 (br s, 1H), 7.46-7.34 (m, 2H), 7.27-7.18 (m, 2H), 5.22 (s, 1H), 4.75 (d, J=12.3 Hz, 1H), 4.20 (d, J=12.3 Hz, 1H), 3.32 (s, 3H), 2.58-2.37 (m, 2H), 2.25-2.11 (m, 2H), 1.88-1.73 (m, 2H), 1.70 (s, 3H), 1.60 (s, 3H), 0.05 (s, 9H).

›Example 104

N-{5-[2-Methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1546)

To a suspension of 60 mg of 2-methoxy-2-(thiophen-2-yl)acetic acid (containing impurities) synthesized in the similar manner as in Reference Example 101 in 2 ml of dehydrated dichloromethane, 0.036 ml (0.41 mmol) of oxalyl chloride and 0.005 ml (0.07 mmol) of DMF were added with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 120 mg (0.317 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.166 ml (0.950 mmol) of DIPEA in 2 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 2 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with water, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 70:30 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of dehydrated dichloromethane, 0.104 ml (0.954 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 16 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in methanol and then added to water, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 62 mg of the title compound (yield: 42%) as a white solid.

Mass spectrum (CI, m/z): 461 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.41-11.86 (m, 1H), 9.82-9.47 (m, 1H), 7.57 (dd, J=1.3, 5.0 Hz, 1H), 7.13-7.06 (m, 1H), 7.01 (dd, J=3.5, 5.0 Hz, 1H), 5.26 (s, 1H), 4.84-4.64 (m, 1H), 4.41 (br d, J=12.4 Hz, 1H), 3.28 (s, 3H), 2.58-2.37 (m, 2H), 2.26-2.10 (m, 2H), 1.89-1.73 (m, 2H), 1.70 (s, 3H), 1.62 (s, 3H), 0.06 (s, 9H).

›Example 105

(−)-N-{5-[2-Methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1548)

0.041 g (0.089 mmol) of N-{5-[2-methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide synthesized in the similar manner as in Example 104 was subjected to optical resolution preparative chromatography (column: CHIRALPAK (trade name) ID, elution solvent: n-hexane:ethanol=85:15 (V/V)), and a fraction containing an optically active form eluted first was concentrated under reduced pressure to obtain 17 mg of the title compound (yield: 41%) as a white solid.

Specific optical rotation: [α] D 20 =−51 (c=0.20, methanol).

Mass spectrum (CI, m/z): 461 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.23 (br s, 1H), 9.67 (br s, 1H), 7.57 (dd, J=1.2, 5.0 Hz, 1H), 7.13-7.06 (m, 1H), 7.01 (dd, J=3.5, 5.0 Hz, 1H), 5.26 (s, 1H), 4.74 (br d, J=12.5 Hz, 1H), 4.41 (d, J=12.5 Hz, 1H), 3.28 (s, 3H), 2.58-2.37 (m, 2H), 2.24-2.11 (m, 2H), 1.89-1.74 (m, 2H), 1.70 (s, 3H), 1.62 (s, 3H), 0.06 (s, 9H).

HPLC analysis:

Column: CHIRALPAK (trade name) ID 4.6×250 mm

Eluent: n-hexane/ethanol=85/15 (V/V)

Flow rate: 1.0 ml/min

Temperature: 40° C.

Detection wavelength: 254 nm

Retention time: 7.6 min.

Optical purity: >99% ee

›Example 106

(+)-N-{5-[2-Methoxy-2-(thiophen-2-yl)acetyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1547)

A fraction containing an optically active form eluted later in the optical resolution preparative chromatography operation of Example 105 was concentrated under reduced pressure to obtain 14 mg of the title compound (yield: 34%) as a white solid.

Specific optical rotation: [α] D 20 =+66° (c=0.20, methanol).

Mass spectrum (CI, m/z): 461 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.23 (br s, 1H), 9.66 (br s, 1H), 7.57 (dd, J=1.2, 5.0 Hz, 1H), 7.14-7.06 (m, 1H), 7.01 (dd, J=3.5, 5.0 Hz, 1H), 5.26 (s, 1H), 4.74 (br d, J=12.4 Hz, 1H), 4.41 (d, J=12.4 Hz, 1H), 3.28 (s, 3H), 2.58-2.37 (m, 2H), 2.26-2.10 (m, 2H), 1.89-1.74 (m, 2H), 1.70 (s, 3H), 1.62 (s, 3H), 0.06 (s, 9H).

HPLC analysis:

Column: CHIRALPAK (trade name) ID 4.6×250 mm

Eluent: n-hexane/ethanol=85/15 (V/V)

Flow rate: 1.0 ml/min

Temperature: 40° C.

Detection wavelength: 254 nm

Retention time: 9.7 min.

Optical purity: >99% ee

›Example 107

N-{[1-(Hydroxymethyl)cyclobutyl](phenyl)methyl}-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-718)

To a solution of a mixture of 131 mg (0.243 mmol) of 2-ethyl 5-(trichloromethyl) 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 102 and 79 mg (0.18 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate in 3 ml of dehydrated 1,4-dioxane, 0.34 ml (2.0 mmol) of DIPEA and 235 mg (1.23 mmol) of {1-[amino(phenyl)methyl]cyclobutyl}methanol synthesized in the similar manner as in Reference Example 103 were added in this order at room temperature in an argon atmosphere and then stirred at 90° C. for 1.5 hours. After standing to cool until the reaction solution becomes room temperature, 0.21 ml (1.9 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature and stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 187 mg of a white solid. The obtained solid was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous potassium dihydrogen phosphate solution=50:50 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, and acetonitrile was distilled off. The solid deposited in the course of concentration was collected by filtration, washed with water, and then dried under reduced pressure to obtain 156 mg of the title compound (yield: 70%) as a white solid.

Mass spectrum (CI, m/z): 524 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.34-11.78 (m, 1H), 9.87-9.34 (m, 1H), 7.35-7.27 (m, 4H), 7.24-7.16 (m, 1H), 6.75 (d, J=7.9 Hz, 1H), 5.49 (br s, 1H), 4.95 (d, J=7.9 Hz, 1H), 4.47-4.20 (m, 2H), 3.49-3.41 (m, 1H), 3.26-3.18 (m, 1H), 2.57-2.39 (m, 2H), 2.26-2.14 (m, 2H), 2.11-1.99 (m, 2H), 1.98-1.74 (m, 5H), 1.61 (s, 3H), 1.53 (s, 3H), 1.26-1.13 (m, 1H), 0.08 (s, 9H).

›Example 108

(R)—N-[2-(1-Hydroxycyclopropyl)-1-phenylethyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-743)

To a solution of 128 mg of (R)-1-(2-amino-2-phenylethyl)cyclopropanol (containing impurities) synthesized in the similar manner as in Reference Example 105 in 2 ml of dehydrated 1,4-dioxane, 0.26 ml (1.5 mmol) of DIPEA and 154 mg (0.349 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 were added in this order at room temperature in an argon atmosphere and then stirred at 90° C. for 2 hours. After standing to cool until the reaction solution becomes room temperature, 0.16 ml (1.5 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature and stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 40:60 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was suspended in an ethyl acetate/n-hexane mixed solvent and stirred, and then, insoluble matter was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 139 mg of the title compound (yield: 79%) as a white solid.

Mass spectrum (CI, m/z): 510 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.23 & 11.80 (br s, total 1H), 9.75-9.47 (m, 1H), 7.43-7.37 (m, 2H), 7.34-7.27 (m, 2H), 7.23-7.17 (m, 1H), 6.51-6.33 (m, 1H), 5.54-5.37 (m, 1H), 5.14-5.05 (m, 1H), 4.66-4.29 (m, 2H), 2.61-2.39 (m, 2H), 2.26-2.06 (m, 3H), 1.90-1.50 (m, 9H), 0.55-0.37 (m, 3H), 0.18-0.04 (m, 10H).

›Example 109

(R)—N-(3-Ethyl-3-Hydroxy-1-phenylpentyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-759)

To a solution of 118 mg (0.568 mmol) of (R)-1-amino-3-ethyl-1-phenylpentan-3-ol synthesized in the similar manner as in Reference Example 107 in 2 ml of dehydrated 1,4-dioxane, 0.20 ml (1.1 mmol) of DIPEA and 128 mg (0.290 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 were added in this order at room temperature in an argon atmosphere and then stirred at 90° C. for 2 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=75:25 to 40:60 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of THF, 0.13 ml (1.2 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 2 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was suspended in an ethyl acetate/n-hexane mixed solvent and stirred at room temperature, and then, insoluble matter was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 123 mg of the title compound (yield: 79%) as a white solid.

Mass spectrum (CI, m/z): 540 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.35-11.68 (m, 1H), 9.56 (br s, 1H), 7.37-7.24 (m, 4H), 7.19-7.13 (m, 1H), 6.56 (d, J=5.8 Hz, 1H), 4.91-4.81 (m, 1H), 4.54-4.31 (m, 3H), 2.58-2.41 (m, 2H), 2.26-2.13 (m, 2H), 1.95-1.73 (m, 3H), 1.63-1.55 (m, 4H), 1.53 (s, 3H), 1.49-1.33 (m, 4H), 0.82 (t, J=7.4 Hz, 3H), 0.77 (t, J=7.4 Hz, 3H), 0.09 (s, 9H).

›Example 110

(R)—N-[1-(4-Fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-939)

To a solution of 599 mg (1.36 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 3 ml of 1,4-dioxane, 134 mg of (R)-4-amino-4-(4-fluorophenyl)-2-methylbutan-2-ol (containing impurities) synthesized in the similar manner as in Reference Example 111 and 0.602 ml (3.40 mmol) of DIPEA were added in this order at room temperature under argon stream and then stirred at 100° C. for 1 hour. Subsequently, 0.318 ml (3.40 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature and stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution, followed by extraction with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride in this order, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: ethyl acetate:methanol=100:0 to 90:10 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous potassium dihydrogen phosphate solution=30:70 to 50:50 (V/V)), a fraction containing the compound of interest was concentrated under reduced pressure, and acetonitrile was distilled off, followed by extraction with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, then filtered, concentrated under reduced pressure, and dried under reduced pressure to obtain 48 mg of the title compound (yield: 8% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 530 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.77 (br s, total 1H), 9.74-9.41 (m, 1H), 7.40-7.32 (m, 2H), 7.14-7.05 (m, 2H), 6.66-6.44 (m, 1H), 4.94-4.84 (m, 1H), 4.75-4.60 (m, 1H), 4.52-4.31 (m, 2H), 2.59-2.39 (m, 2H), 2.27-2.11 (m, 2H), 2.04-1.73 (m, 3H), 1.70-1.45 (m, 7H), 1.15 (s, 3H), 1.13 (s, 3H), 0.09 (s, 9H).

›Example 111

(R)—N-[1-(3-Fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-911)

To a solution of 149 mg (0.248 mmol) of (R)-ethyl 5-{[1-(3-fluorophenyl)-3-hydroxy-3-methylbutyl]carbamoyl}-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 116 in 3 ml of dichloromethane, 0.108 ml (0.992 mmol) of N,N-dimethylethane-1,2-diamine was added in one portion with stirring at room temperature under argon stream and stirred at room temperature for 1 hour.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate twice. The organic layer was washed with a 5% aqueous potassium bisulfate solution, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 17:83 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in a small amount of ethyl acetate, and a solid was deposited by adding n-hexane. The solid was collected by filtration, washed with n-hexane, and dried under reduced pressure at 50° C. to obtain 101 mg of the title compound (yield: 77%) as a white solid.

Mass spectrum (CI, m/z): 530 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.77 (br s, total 1H), 9.71-9.47 (m, 1H), 7.37-7.26 (m, 1H), 7.22-7.11 (m, 2H), 7.02-6.92 (m, 1H), 6.65-6.51 (m, 1H), 4.95-4.87 (m, 1H), 4.76-4.60 (m, 1H), 4.55-4.35 (m, 2H), 2.57-2.40 (m, 2H), 2.27-2.12 (m, 2H), 2.03-1.74 (m, 3H), 1.66 (dd, J=3.1, 14.2 Hz, 1H), 1.59 (br s, 3H), 1.54 (br s, 3H), 1.16 (s, 3H), 1.13 (s, 3H), 0.09 (s, 9H).

›Example 112

(R)—N-[1-(2-Fluorophenyl)-3-hydroxy-3-methylbutyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-883)

To a solution of 150 mg (0.249 mmol) of (R)-ethyl 5-{[1-(2-fluorophenyl)-3-hydroxy-3-methylbutyl]carbamoyl}-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 121 in 3 ml of dichloromethane, 0.109 ml (1.00 mmol) of N,N-dimethylethane-1,2-diamine was added in one portion with stirring at room temperature under argon stream and stirred at room temperature for 1 hour.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate twice. The organic layer was washed with a 5% aqueous potassium bisulfate solution, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 17:83 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in a small amount of ethyl acetate, and a solid was deposited by adding n-hexane. The solid was collected by filtration, washed with n-hexane, and dried under reduced pressure at 50° C. to obtain 112 mg of the title compound (yield: 85%) as a white solid.

Mass spectrum (CI, m/z): 530 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.20 & 11.76 (br s, total 1H), 9.72-9.46 (m, 1H), 7.54-7.43 (m, 1H), 7.26-7.17 (m, 1H), 7.17-7.04 (m, 2H), 6.62-6.47 (m, 1H), 5.23-5.14 (m, 1H), 4.78-4.62 (m, 1H), 4.55-4.35 (m, 2H), 2.58-2.40 (m, 2H), 2.27-2.12 (m, 2H), 2.02-1.73 (m, 3H), 1.67-1.45 (m, 7H), 1.18 (s, 3H), 1.15 (s, 3H), 0.09 (s, 9H).

›Example 113

(R)—N-(5-Hydroxy-2,5-dimethylhexan-3-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-815)

To a solution of 99 mg (0.18 mmol) of (R)-ethyl 5-[(5-hydroxy-2,5-dimethylhexan-3-yl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 125 in 3 ml of dichloromethane, 0.078 ml (0.72 mmol) of N,N-dimethylethane-1,2-diamine was added in one portion with stirring at room temperature under argon stream and stirred at room temperature for 1 hour.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate twice. The organic layer was washed with a 5% aqueous potassium bisulfate solution, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 16:84 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in a small amount of ethyl acetate, and a solid was deposited by adding n-hexane. The solid was collected by filtration, washed with n-hexane, and dried under reduced pressure at 50° C. to obtain 72 mg of the title compound (yield: 84%) as a white solid.

Mass spectrum (CI, m/z): 478 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.19 & 11.81 (br s, total 1H), 9.71-9.44 (m, 1H), 5.63 (br s, 1H), 4.47-4.25 (m, 3H), 3.71-3.60 (m, 1H), 2.57-2.39 (m, 2H), 2.27-2.11 (m, 2H), 1.90-1.66 (m, 3H), 1.65-1.52 (m, 7H), 1.49-1.42 (m, 1H), 1.10 (s, 3H), 1.09 (s, 3H), 0.82 (d, J=6.8 Hz, 6H), 0.08 (s, 9H).

›Example 114

N-[1-(4-Fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-946)

To a solution of 0.745 g (1.69 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 8 ml of 1,4-dioxane, 1.47 ml (8.44 mmol) of DIPEA and 1.00 g (5.07 mmol) of 3-amino-3-(4-fluorophenyl)-2,2-dimethylpropan-1-ol synthesized in the similar manner as in Reference Example 127 were added in this order with stirring at room temperature under argon stream and stirred at 90° C. for 1.5 hours. Subsequently, the reaction solution was allowed to cool to room temperature, and then, 0.738 ml (6.78 mmol) of N,N-dimethylethane-1,2-diamine was added dropwise at room temperature and stirred at room temperature for 4 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate twice. The organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 19:81 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The concentration residue was dissolved in 60 ml of ethyl acetate and washed with 10 ml of a 5% aqueous potassium bisulfate solution three times. The organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was dissolved in a small amount of ethyl acetate, and a solid was deposited by adding n-hexane. The solid was collected by filtration, washed with n-hexane, and dried under reduced pressure at 50° C. to obtain 509 mg of the title compound (yield: 57%) as a white solid.

Mass spectrum (ESI, m/z): 530 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.80 (br s, total 1H), 9.68-9.44 (m, 1H), 7.39-7.32 (m, 2H), 7.17-7.09 (m, 2H), 6.91-6.78 (m, 1H), 5.46 (br s, 1H), 4.65 (d, J=7.9 Hz, 1H), 4.45-4.28 (m, 2H), 3.23 (dd, J=4.2, 10.6 Hz, 1H), 3.08-2.99 (m, 1H), 2.60-2.39 (m, 2H), 2.27-2.14 (m, 2H), 1.91-1.73 (m, 2H), 1.65-1.49 (m, 6H), 1.05 (s, 3H), 0.64 (s, 3H), 0.09 (s, 9H).

›Example 115

N-[1-(3-Fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-918)

To a solution of 162 mg (0.367 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 in 4 ml of 1,4-dioxane, 0.32 ml (1.9 mmol) of DIPEA and 227 mg (1.15 mmol) of 3-amino-3-(3-fluorophenyl)-2,2-dimethylpropan-1-ol synthesized in the similar manner as in Reference Example 129 were added at room temperature in an argon atmosphere and then reacted at 100° C. for 2.5 hours. After standing to cool, 0.12 ml (1.1 mmol) of N,N-dimethyl-1,2-diamine was added and stirred at room temperature for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, 20 ml of ethyl acetate was added to the residue, the organic layer after washing with 10 ml of a 5% aqueous potassium bisulfate solution, 10 ml of a saturated aqueous solution of sodium bicarbonate, and 10 ml of a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=81:19 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in a small amount of dichloromethane, then n-hexane was added, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 159 mg of the title compound (yield: 82%) as a white solid.

Mass spectrum (CI, m/z): 530 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.22 & 11.89 (br s, total 1H), 9.79-9.40 (m, 1H), 7.39-7.29 (m, 1H), 7.22-7.13 (m, 2H), 7.08-7.01 (m, 1H), 6.86 (d, J=8.0 Hz, 1H), 5.56-5.41 (m, 1H), 4.67 (d, J=8.0 Hz, 1H), 4.49-4.27 (m, 2H), 3.25 (dd, J=4.0, 10.6 Hz, 1H), 3.05 (dd, J=4.0, 10.6 Hz, 1H), 2.56-2.40 (m, 2H), 2.29-2.13 (m, 2H), 1.92-1.72 (m, 2H), 1.60 (br s, 3H), 1.52 (br s, 3H), 1.05 (s, 3H), 0.67 (s, 3H), 0.09 (s, 9H).

›Example 116

(−)-N-[1-(3-Fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-920)

0.129 g (0.244 mmol) of N-[1-(3-fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide synthesized in the similar manner as in Example 115 was subjected to optical resolution preparative chromatography (column: CHIRALPAK (trade name) ID, elution solvent: n-hexane:ethanol:methanol=95:5:1 (V/V)), and a fraction containing an optically active form eluted first was concentrated under reduced pressure to obtain 47 mg of the title compound (yield: 36%) as a white solid.

Specific optical rotation: [α] D 20 =−53° (c=0.23, methanol).

Mass spectrum (CI, m/z): 530 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.88 (br s, total 1H), 9.78-9.41 (m, 1H), 7.38-7.30 (m, 1H), 7.21-7.13 (m, 2H), 7.08-7.01 (m, 1H), 6.86 (br d, J=8.3 Hz, 1H), 5.56-5.40 (m, 1H), 4.67 (d, J=8.3 Hz, 1H), 4.47-4.30 (m, 2H), 3.25 (br dd, J=3.9, 10.5 Hz, 1H), 3.05 (br dd, J=3.9, 10.5 Hz, 1H), 2.60-2.40 (m, 2H), 2.26-2.13 (m, 2H), 1.90-1.73 (m, 2H), 1.60 (br s, 3H), 1.52 (s, 3H), 1.05 (s, 3H), 0.67 (s, 3H), 0.09 (s, 9H).

HPLC analysis:

Column: CHIRALPAK (trade name) ID 4.6×250 mm

Eluent: n-hexane/ethanol/methanol=95/5/1 (V/V)

Flow rate: 1.0 ml/min

Temperature: 40° C.

Detection wavelength: 254 nm

Retention time: 8.8 min.

Optical purity: >99% ee

›Example 117

(+)-N-[1-(3-Fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-919)

A fraction containing an optically active form eluted later in the optical resolution preparative chromatography operation of Example 116 was concentrated under reduced pressure to obtain 45 mg of the title compound (yield: 35%) as a white solid.

Specific optical rotation: [α] D 20 =+59° (c=0.22, methanol).

Mass spectrum (CI, m/z): 530 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.94 (br s, total 1H), 9.78-9.41 (m, 1H), 7.38-7.30 (m, 1H), 7.21-7.13 (m, 2H), 7.08-7.01 (m, 1H), 6.86 (br d, J=8.1 Hz, 1H), 5.56-5.39 (m, 1H), 4.67 (d, J=8.1 Hz, 1H), 4.47-4.30 (m, 2H), 3.25 (br dd, J=3.8, 10.5 Hz, 1H), 3.05 (br dd, J=3.8, 10.5 Hz, 1H), 2.59-2.40 (m, 2H), 2.27-2.13 (m, 2H), 1.90-1.73 (m, 2H), 1.60 (br s, 3H), 1.52 (s, 3H), 1.05 (s, 3H), 0.67 (s, 3H), 0.09 (s, 9H).

HPLC analysis:

Column: CHIRALPAK (trade name) ID 4.6×250 mm

Elution solvent: n-hexane/ethanol/methanol=95/5/1 (V/V)

Flow rate: 1.0 ml/min

Temperature: 40° C.

Detection wavelength: 254 nm

Retention time: 11.6 min.

Optical purity: >98% ee

›Example 118

N-[1-(2-Fluorophenyl)-3-hydroxy-2,2-dimethylpropyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-890)

To a solution of 225 mg (1.14 mmol) of 3-amino-3-(2-fluorophenyl)-2,2-dimethylpropan-1-ol synthesized in the similar manner as in Reference Example 130 in 4 ml of 1,4-dioxane, 0.32 ml (1.9 mmol) of DIPEA and 166 mg (0.376 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarbox amido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 3 were added at room temperature in an argon atmosphere and then reacted at 100° C. for 2.5 hours. After standing to cool, 0.12 ml (1.1 mmol) of N,N-dimethylethane-1,2-diamine was added and stirred at room temperature for 1 hour.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, 20 ml of ethyl acetate was added to the residue, the organic layer after washing with 10 ml of a 5% aqueous potassium bisulfate solution, 10 ml of a saturated aqueous solution of sodium bicarbonate, and 10 ml of a saturated aqueous solution of sodium chloride in this order was dried over anhydrous magnesium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=81:19 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in a small amount of dichloromethane, then n-hexane was added, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 154 mg of the title compound (yield: 77%) as a white solid.

Mass spectrum (CI, m/z): 530 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.22 & 11.87 (br s, total 1H), 9.75-9.42 (m, 1H), 7.53-7.44 (m, 1H), 7.32-7.24 (m, 1H), 7.23-7.17 (m, 1H), 7.17-7.08 (m, 1H), 6.96-6.85 (m, 1H), 5.53 (br s, 1H), 5.03 (d, J=7.9 Hz, 1H), 4.46-4.26 (m, 2H), 3.40-3.28 (m, 1H), 3.08 (dd, J=4.0, 10.5 Hz, 1H), 2.56-2.39 (m, 2H), 2.27-2.12 (m, 2H), 1.92-1.72 (m, 2H), 1.65-1.47 (m, 6H), 1.10 (s, 3H), 0.69-0.60 (m, 3H), 0.09 (s, 9H).

›Example 119

N-(1-Hydroxy-2,2,4-trimethylpentan-3-yl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-822)

To a solution of a mixture of 133 mg (0.246 mmol) of 2-ethyl 5-(trichloromethyl) 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 102 and 80 mg (0.18 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate in 3 ml of dehydrated 1,4-dioxane, 0.37 ml (2.1 mmol) of DIPEA and 189 mg (1.30 mmol) of 3-amino-2,2,4-trimethylpentan-1-ol synthesized in the similar manner as in Reference Example 132 were added in this order at room temperature in an argon atmosphere and then stirred at 90° C. for 2.5 hours. After standing to cool until the reaction solution becomes room temperature, 0.23 ml (2.1 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature and stirred for 14 hours with the temperature unchanged.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 30:70 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 107 mg of the title compound (yield: 52%) as a white solid.

Mass spectrum (CI, m/z): 478 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.42-11.70 (m, 1H), 9.86-9.33 (m, 1H), 5.48 (br d, J=9.2 Hz, 1H), 5.13-4.93 (m, 1H), 4.48-4.22 (m, 2H), 3.55-3.48 (m, 1H), 3.45 (dd, J=3.9, 10.7 Hz, 1H), 3.04 (dd, J=5.4, 10.7 Hz, 1H), 2.58-2.38 (m, 2H), 2.26-2.12 (m, 2H), 2.05-1.92 (m, 1H), 1.88-1.73 (m, 2H), 1.61 (br s, 3H), 1.59 (br s, 3H), 0.93 (s, 3H), 0.89 (d, J=6.7 Hz, 6H), 0.79 (s, 3H), 0.07 (s, 9H).

›Example 120

(R)—N-(3-Hydroxy-3-methyl-1-phenylbutyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. III-298)

To a solution of 1.53 g (4.19 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 46 in 20 ml of dehydrated dichloromethane, 2.60 ml (14.9 mmol) of DIPEA was added at room temperature in an argon atmosphere. Subsequently, a solution of 700 mg (2.36 mmol) of bis(trichloromethyl) carbonate in 5 ml of dehydrated dichloromethane was added dropwise at −78° C. and then stirred for 0.5 hours with the temperature unchanged and further for 2 hours after the temperature was raised to room temperature.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate and dichloromethane were added to the reaction solution at −78° C. and then stirred for 1.5 hours while the temperature was raised to room temperature for a while. The reaction solution was separated into an aqueous layer and an organic layer, and then, the aqueous layer was subjected to extraction with ethyl acetate twice. All of the organic layers were washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=85:15 to 75:25 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain 1.75 g of a white solid.

To a solution of 97.1 mg (0.542 mmol) of (R)-4-amino-2-methyl-4-phenylbutan-2-ol synthesized in the similar manner as in Reference Example 23 in 2 ml of dehydrated 1,4-dioxane, 0.18 ml (1.0 mmol) of DIPEA and 130 mg of a portion of the solid obtained by the operation described above were added in this order at room temperature in an argon atmosphere and then stirred at 90° C. for 1.5 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=70:30 to 30:70 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of THF, 0.12 ml (1.1 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=50:50 to 25:75 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 96 mg of the title compound (yield: 62% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 498 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.35-11.77 (m, 1H), 9.95-9.67 (m, 1H), 7.36-7.23 (m, 4H), 7.19-7.11 (m, 1H), 6.58-6.44 (m, 1H), 4.94-4.84 (m, 1H), 4.64 (br s, 1H), 4.40 (br s, 2H), 2.00-1.88 (m, 1H), 1.65 (dd, J=3.2, 14.2 Hz, 1H), 1.57 (br s, 3H), 1.52 (br s, 3H), 1.16 (s, 3H), 1.13 (s, 3H), 0.97 (br s, 2H), 0.98 (br s, 2H), 0.03 (s, 9H).

›Example 121

N-(3-Hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. III-353)

To a solution of 1.53 g (4.19 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 46 in 20 ml of dehydrated dichloromethane, 2.60 ml (14.9 mmol) of DIPEA was added at room temperature in an argon atmosphere. Subsequently, a solution of 700 mg (2.36 mmol) of bis(trichloromethyl) carbonate in 5 ml of dehydrated dichloromethane was added dropwise at −78° C. and then stirred for 0.5 hours with the temperature unchanged and further for 2 hours after the temperature was raised to room temperature.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate and dichloromethane were added to the reaction solution at −78° C. and then stirred for 1.5 hours while the temperature was raised to room temperature for a while. The reaction solution was separated into an aqueous layer and an organic layer, and then, the aqueous layer was subjected to extraction with ethyl acetate twice. All of the organic layers were washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=85:15 to 75:25 (V/V)), subsequently concentrated under reduced pressure, and dried under reduced pressure to obtain 1.75 g of a white solid.

To a solution of 109 mg (0.608 mmol) of 3-amino-2,2-dimethyl-3-phenylpropan-1-ol [synthesized according to the method described in Synthetic Communications 1994, 24 (7), 899-906] in 2 ml of dehydrated 1,4-dioxane, 0.20 ml (1.1 mmol) of DIPEA and 142 mg of a portion of the solid obtained by the operation described above were added in this order at room temperature in an argon atmosphere and then stirred at 90° C. for 2.5 hours. After standing to cool until the reaction solution becomes room temperature, 0.13 ml (1.2 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature and stirred for 2 hours with the temperature unchanged.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 40:60 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 112 mg of the title compound (yield: 66% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 498 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.40-11.84 (m, 1H), 10.11-9.58 (m, 1H), 7.37-7.26 (m, 4H), 7.25-7.18 (m, 1H), 6.85 (br d, J=8.2 Hz, 1H), 5.53-5.39 (m, 1H), 4.63 (d, J=8.2 Hz, 1H), 4.45-4.25 (m, 2H), 3.29-3.22 (m, 1H), 3.07-2.98 (m, 1H), 1.58 (s, 3H), 1.51 (s, 3H), 1.06 (s, 3H), 1.03-0.94 (m, 2H), 0.76-0.58 (m, 5H), 0.03 (s, 9H).

›Example 122

(−)-N-(3-Hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-673)

To a solution of a mixture of 545 mg (1.16 mmol) of 2-ethyl 5-(trichloromethyl) 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 102 and 329 mg (0.853 mmol) of ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate in 7 ml of dehydrated 1,4-dioxane, 1.80 ml (10.3 mmol) of DIPEA and 1.16 g (6.47 mmol) of 3-amino-2,2-dimethyl-3-phenylpropan-1-ol [synthesized according to the method described in Synthetic Communications 1994, 24 (7), 899-906] were added in this order at room temperature in an argon atmosphere and then stirred at 90° C. for 2 hours. After standing to cool until the reaction solution becomes room temperature, 0.90 ml (8.3 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature and stirred for 2.5 hours with the temperature unchanged.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with ethyl acetate three times. All of the organic layers were dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=60:40 to 40:60 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel column chromatography (DIOL silica gel, elution solvent: 1,2-dichloroethane:ethyl acetate=100:0 to 85:15 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in an ethyl acetate/ethanol mixed solvent, then n-hexane was added, and the deposited solid was collected by filtration, washed with n-hexane, and then dried under reduced pressure to obtain 802 mg of a white solid.

0.50 g of a portion of the obtained solid was subjected to optical resolution preparative chromatography (column: CHIRALPAK (trade name) ID, elution solvent: n-hexane:ethanol=90:10 (V/V)), and a fraction containing an optically active form eluted first was concentrated under reduced pressure. The obtained concentration residue was dissolved in an acetonitrile/water mixed solvent and then freeze-dried to obtain 225 mg of the title compound (yield: 35%) as a white solid.

Specific optical rotation: [α] D 20 =−66° (c=0.50, methanol).

Mass spectrum (CI, m/z): 512 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.35-11.77 (m, 1H), 9.86-9.35 (m, 1H), 7.36-7.27 (m, 4H), 7.25-7.17 (m, 1H), 6.86 (br d, J=8.2 Hz, 1H), 5.45 (br s, 1H), 4.64 (d, J=8.2 Hz, 1H), 4.46-4.30 (m, 2H), 3.45-3.23 (m, 1H), 3.06-2.99 (m, 1H), 2.58-2.40 (m, 2H), 2.26-2.14 (m, 2H), 1.90-1.73 (m, 2H), 1.60 (s, 3H), 1.52 (s, 3H), 1.06 (s, 3H), 0.64 (s, 3H), 0.09 (s, 9H).

SFC (supercritical fluid chromatography) analysis:

Column: CHIRALPAK (trade name) ID 2.1×150 mm (particle size: 3 um)

Eluent: CO 2 /methanol=90/10 (V/V)

Flow rate: 0.85 ml/min

Temperature: 40° C.

Detection wavelength: 240 nm

Retention time: 5.3 min.

Optical purity: >99% ee

›Example 123

(+)-N-(3-Hydroxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-672)

A fraction containing an optically active form eluted later in the optical resolution preparative chromatography operation of Example 122 was concentrated under reduced pressure. The obtained concentration residue was dissolved in an acetonitrile/water mixed solvent and then freeze-dried to obtain 223 mg of the title compound (yield: 35%) as a white solid.

Specific optical rotation: [α] D 20 =+60° (c=0.50, methanol).

Mass spectrum (CI, m/z): 512 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.42-11.76 (m, 1H), 9.57 (br s, 1H), 7.35-7.27 (m, 4H), 7.25-7.18 (m, 1H), 6.86 (br d, J=8.2 Hz, 1H), 5.45 (br s, 1H), 4.64 (d, J=8.2 Hz, 1H), 4.44-4.30 (m, 2H), 3.44-3.23 (m, 1H), 3.06-2.98 (m, 1H), 2.59-2.40 (m, 2H), 2.26-2.14 (m, 2H), 1.89-1.74 (m, 2H), 1.60 (s, 3H), 1.52 (s, 3H), 1.06 (s, 3H), 0.64 (s, 3H), 0.09 (s, 9H).

SFC (supercritical fluid chromatography) analysis:

Column: CHIRALPAK (trade name) ID 2.1×150 mm (particle size: 3 um)

Eluent: CO 2 /methanol=90/10 (V/V)

Flow rate: 0.85 ml/min

Temperature: 40° C.

Detection wavelength: 240 nm

Retention time: 6.5 min.

Optical purity: >99% ee

›Example 124

(R)—N-[5-(2-Butoxy-2-phenylacetyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-1-(trimethylsilyl)cyclobutanecarboxamide (Compound No. IV-1200)

To a solution of 1.65 g (5.53 mmol) of (R)-benzyl 2-butoxy-2-phenylacetate synthesized in the similar manner as in Reference Example 133 in 8 ml of methanol/8 ml of water, 300 mg (7.15 mmol) of lithium hydroxide monohydrate was added at room temperature and then reacted with stirring at room temperature for 3 hours.

After the completion of the reaction, diethyl ether was added to the reaction solution and separated into an aqueous layer and an organic layer. The aqueous layer was adjusted to pH 2 by adding 2 N hydrochloric acid, followed by extraction with ethyl acetate three times. All of the obtained organic layers were washed with saturated saline, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain 1.34 g of a concentration residue.

To a solution of 150 mg of a portion of the obtained concentration residue in 2 ml of dehydrated dichloromethane, 0.006 ml (0.08 mmol) of DMF and 0.083 ml (0.95 mmol) of oxalyl chloride were added with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 1.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 150 mg (0.396 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.350 ml (2.00 mmol) of DIPEA in 2 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 3 ml of dehydrated dichloromethane was added dropwise with stirring at 0° C. in an argon atmosphere and stirred at room temperature for 3 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with water, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 70:30 (V/V)) and subsequently concentrated under reduced pressure to obtain a concentration residue.

To a solution of the obtained concentration residue in 2 ml of dehydrated dichloromethane, 0.130 ml (1.19 mmol) of N,N-dimethylethane-1,2-diamine was added at room temperature in an argon atmosphere and then stirred at room temperature for 16 hours.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution and stirred, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated saline in this order, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=100:0 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected to preparative HPLC (column: X-Bridge (trade name) ODS, elution solvent: acetonitrile:1 mM aqueous potassium dihydrogen phosphate solution=50:50 (V/V)), and ethyl acetate and water were added to a fraction containing the compound of interest to separate an organic layer and an aqueous layer. The obtained organic layer was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate and then added to n-hexane, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 77 mg of the title compound (yield: 39%) as a white solid.

Mass spectrum (CI, m/z): 497 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.34-11.89 (m, 1H), 9.56 (br s, 1H), 7.45-7.25 (m, 5H), 5.02 (s, 1H), 4.68-4.49 (m, 1H), 4.40 (br d, J=12.7 Hz, 1H), 3.57-3.39 (m, 2H), 2.59-2.35 (m, 2H), 2.24-2.09 (m, 2H), 1.87-1.73 (m, 2H), 1.68 (s, 3H), 1.61 (s, 3H), 1.56-1.45 (m, 2H), 1.40-1.28 (m, 2H), 0.86 (t, J=7.3 Hz, 3H), 0.05 (s, 9H).

›Example 125 · 1 of 10

N-(3-Methoxy-2,2-dimethyl-1-phenylpropyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound No. IV-676)

To a solution of 131 mg (0.219 mmol) of ethyl 5-[(3-methoxy-2,2-dimethyl-1-phenylpropyl)carbamoyl]-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 137 in 3 ml of dichloromethane, 0.095 ml (0.87 mol) of N,N-dimethylethane-1,2-diamine was added in one portion with stirring at room temperature under argon stream and stirred at room temperature for 1 hour.

After the completion of the reaction, a 5% aqueous potassium bisulfate solution was added to the reaction solution, followed by extraction from the mixed solution with ethyl acetate twice. The organic layer was washed with a 5% aqueous potassium bisulfate solution, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (DIOL silica gel, elution solvent: n-hexane:ethyl acetate=70:30 to 13:87 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was dissolved in a small amount of ethyl acetate, and a solid was deposited by adding n-hexane. The solid was collected by filtration, washed with n-hexane, and dried under reduced pressure at 50° C. to obtain 62 mg of the title compound (yield: 54%) as a white solid.

Mass spectrum (CI, m/z): 526 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 12.21 & 11.76 (br s, total 1H), 9.58 (br s, 1H), 7.38-7.18 (m, 5H), 6.75-6.52 (m, 1H), 4.59 (d, J=7.7 Hz, 1H), 4.52-4.30 (m, 2H), 3.38 (s, 3H), 3.13 (d, J=9.3 Hz, 1H), 2.92 (d, J=9.3 Hz, 1H), 2.58-2.40 (m, 2H), 2.29-2.12 (m, 2H), 1.91-1.74 (m, 2H), 1.59 (br s, 3H), 1.50 (s, 3H), 1.12 (s, 3H), 0.68 (s, 3H), 0.09 (s, 9H).

Reference Example 1

1-(Trimethylsilyl)cyclobutanecarboxylic acid

To 200 ml of dehydrated THF, 214 ml (428 mmol) of 2 M lithium diisopropylamide/THF solution was added in an argon atmosphere, and then, 10.1 ml (107 mmol) of cyclobutanecarboxylic acid was added dropwise with stirring under cooling in ice water and stirred for 4 hours while the temperature was raised to room temperature for a while. Subsequently, 20 ml (116 mmol) of hexamethylphosphoric acid triamide was added, and 51 ml (490 mmol) of chlorotrimethylsilane was added dropwise with stirring while the internal temperature was kept at −60° C. or lower under cooling in a dry ice/acetone coolant, and then stirred at −78° C. for 16.5 hours.

After the completion of the reaction, 67 ml of methanol was added to the reaction solution, and 134 ml of cold water was added after the temperature was raised to 0° C. The pH was adjusted to 2.1 by adding 2 N hydrochloric acid, 268 ml of diethyl ether was added thereto and then the aqueous layer and the organic layer were separated, and the organic layer was washed with 268 ml of a saturated aqueous solution of sodium chloride. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 50 ml of a 2 N aqueous sodium hydroxide solution and 267 ml of n-hexane were added to the obtained concentration residue and then the aqueous layer and the organic layer were separated. Subsequently, the aqueous layer was adjusted to pH 2.7 by adding 1 N hydrochloric acid, and 267 ml of ethyl acetate was added to this solution and then the aqueous layer and the organic layer were separated. The obtained organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. n-Hexane was added to the obtained concentration residue and cooled in an ice water bath. The resulting solid was filtered, washed by sousing with cooled n-hexane, and then dried under reduced pressure to obtain 6.24 g of the title compound (yield: 34%) as a white solid. The filtrate was further concentrated under reduced pressure, and the obtained residue was subjected to silica gel column chromatography (elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 4.33 g of the title compound (yield: 23%) as a white solid.

Mass spectrum (CI, m/z): 173 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 11.64 (br s, 1H), 2.45-2.34 (m, 2H), 2.17-2.06 (m, 2H), 1.91-1.70 (m, 2H), 0.06 (s, 9H).

Reference Example 2

5-tert-Butyl 2-ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate

To a solution of 13.9 g (80.4 mmol) of 1-(trimethylsilyl)cyclobutanecarboxylic acid synthesized in the similar manner as in Reference Example 1 in 105 ml of dehydrated dichloromethane, 6.96 ml (81.2 mmol) of oxalyl chloride and 0.32 ml (4.14 mmol) of DMF were added dropwise in this order between −25° C. and −10° C. in an argon atmosphere and then stirred for 2 hours after the temperature was raised to 0° C. To a solution of 8.74 g (26.9 mmol) of 5-tert-butyl 2-ethyl 3-amino-6,6-dimethylpyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate [synthesized according to the method described in Journal of Medicinal Chemistry 2012, 55 (10), 4728-4739] and 23.5 ml (135 mmol) of DIPEA in 122 ml of dehydrated dichloromethane, the resulting reaction solution was added dropwise at 0° C. in an argon atmosphere and stirred at the same temperature as above for 16 hours.

After the completion of the reaction, 486 ml of a 5% aqueous potassium bisulfate solution was added to the reaction solution and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 200 ml of dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=86:14 to 53:47 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 8.30 g of the title compound (yield: 64%) as a white foam.

›Example 125 · 2 of 10

Mass spectrum (CI, m/z): 479 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 9.98 & 9.72 & 9.71 (s, total 1H), 4.50-4.37 (m, 4H), 2.53-2.43 (m, 2H), 2.32-2.07 (m, 2H), 2.02-1.72 (m, 2H), 1.65-1.55 (m, 6H), 1.51-1.42 (m, 9H), 1.38-1.31 (m, 3H), 0.10 & 0.06 & 0.01 (s, total 9H).

Reference Example 3

Ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate

To a solution of 8.30 g (17.3 mmol) of 5-tert-butyl 2-ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 2 in 81 ml of dehydrated dichloromethane, 6.0 ml (52 mmol) of 2,6-lutidine and 9.2 ml (51 mmol) of trimethylsilyl trifluoromethanesulfonate were added dropwise in this order at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, 64 ml of a saturated aqueous solution of sodium bicarbonate and 64 ml of dichloromethane were added to the reaction solution and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 72 ml of dichloromethane twice, and then, all of the obtained organic layers were washed with 72 ml of a saturated aqueous solution of sodium bicarbonate and 72 ml of a saturated aqueous solution of sodium chloride in this order, subsequently dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The operation of adding 5 ml of toluene to the obtained concentration residue and concentrating the resultant under reduced pressure was repeated five times to obtain crude ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate.

To a solution of 6.70 g of the obtained crude ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate in 235 ml of dehydrated dichloromethane, 8.8 ml (51 mmol) of DIPEA was added at room temperature in an argon atmosphere, and then, a solution of 3.79 g (12.8 mmol) of bis(trichloromethyl)carbonate in 38 ml of dehydrated dichloromethane was added dropwise at −78° C. and stirred at the same temperature as above for 3 hours. At each point in time of 1 hour, 2 hours, and 2.6 hours after the start of this reaction, 1.0 ml (5.7 mmol) of DIPEA was added thereto.

After the completion of the reaction, 150 ml of a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred while the temperature was raised to room temperature for a while. After separation into an aqueous layer and an organic layer, the aqueous layer was subjected to extraction with 130 ml of dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=78:22 to 57:43 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. n-Hexane was added to the obtained concentration residue and ultrasonicated. After cooling in a refrigerator, the deposited solid was filtered and dried under reduced pressure to obtain 3.51 g of the title compound (yield: 46% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 441 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 9.83-9.65 (m, 1H), 4.84 (s, 2H), 4.49-4.37 (m, 2H), 2.54-2.43 (m, 2H), 2.31-2.21 (m, 2H), 1.95-1.83 (m, 2H), 1.71-1.58 (m, 6H), 1.35 (t, J=7.1 Hz, 3H), 0.13-0.08 (m, 9H).

Reference Example 4

5-tert-Butyl 1-ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate

To a solution of 24.52 g (142 mmol) of 1-(trimethylsilyl)cyclobutanecarboxylic acid synthesized in the similar manner as in Reference Example 1 in 180 ml of dehydrated dichloromethane, 0.55 ml (7.1 mmol) of DMF and 12.2 ml (142 mmol) of oxalyl chloride were added dropwise at 0° C. in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure (hot water bath temperature: 30° C.) to obtain a concentration residue.

To a solution of 15.39 g (47.4 mmol) of 5-tert-butyl 1-ethyl 3-amino-6,6-dimethylpyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate [synthesized according to the method described in Journal of Medicinal Chemistry 2012, 55 (10), 4728-4739] and 40.6 ml (238 mmol) of DIPEA in 180 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 120 ml of dehydrated dichloromethane was added dropwise at 0° C. in an argon atmosphere and stirred at the same temperature as above for 20 hours.

After the completion of the reaction, the reaction solution was poured to 800 ml of a 5% aqueous potassium bisulfate solution, stirred, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 250 ml of dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=91:9 to 70:30 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 14.6 g of the title compound (yield: 64%) as a white foam.

Mass spectrum (EI, m/z): 478 [M] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 10.32-10.20 (m, 1H), 4.46-4.32 (m, 4H), 2.48-2.39 (m, 2H), 2.24-2.14 (m, 2H), 1.84-1.68 (m, 8H), 1.52-1.40 (m, 9H), 1.32 (t, J=7.1 Hz, 3H), 0.07 (s, 9H).

Reference Example 5

Ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate

To a solution of 10.02 g (20.9 mmol) of 5-tert-butyl 1-ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]pyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 4 in 100 ml of dehydrated dichloromethane, 7.26 ml (62.7 mmol) of 2,6-lutidine and 11.3 ml (62.7 mmol) of trimethylsilyl trifluoromethanesulfonate were added dropwise at 0° C. in an argon atmosphere and stirred at the same temperature as above for 1.5 hours.

›Example 125 · 3 of 10

After the completion of the reaction, 60 ml of a saturated aqueous solution of sodium bicarbonate and 60 ml of dichloromethane were added to the reaction solution. After separation into an aqueous layer and an organic layer, the aqueous layer was subjected to extraction with 60 ml of dichloromethane twice. All of the obtained organic layers were washed with 60 ml of a saturated aqueous solution of sodium bicarbonate and 60 ml of a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The operation of adding toluene to the obtained concentration residue and concentrating it under reduced pressure was repeated three times to obtain 7.43 g of the title compound (yield: 94%) as a pale yellow solid.

Mass spectrum (EI, m/z): 378 [M] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 10.03 (s, 1H), 4.37 (q, J=7.1 Hz, 2H), 3.85 (s, 2H), 2.48-2.38 (m, 2H), 2.23-2.12 (m, 2H), 1.85-1.72 (m, 2H), 1.41 (s, 6H), 1.31 (t, J=7.1 Hz, 3H), 0.06 (s, 9H).

Reference Example 6

5-tert-Butyl 2-ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate

To a solution of 1.05 g (6.63 mmol) of 1-(trimethylsilyl)cyclopropanecarboxylic acid [synthesized according to the method described in J. Org. Chem., 1982, 47 (5), 893-895] in 20 ml of dehydrated dichloromethane, 0.70 ml (8.2 mmol) of oxalyl chloride and 0.020 ml (0.26 mmol) of DMF were added at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 3 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure (hot water bath temperature: 25° C.) to obtain a concentration residue.

To a solution of the obtained concentration residue in 15 ml of dehydrated dichloromethane, 1.80 ml (10.3 mmol) of DIPEA and 839 mg (2.59 mmol) of 5-tert-butyl 2-ethyl 3-amino-6,6-dimethylpyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate [synthesized according to the method described in Journal of Medicinal Chemistry 2012, 55 (10), 4728-4739] were added at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 20.5 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 75:25 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 1.19 g of the title compound (containing impurities) as a pale yellow foam.

Mass spectrum (CI, m/z): 465 [M+1] + .

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 10.09 & 9.92 (s, total 1H), 4.70-4.46 (m, 4H), 1.72 (s, 3H), 1.65 (s, 3H), 1.54-1.44 (m, 12H), 1.15-1.07 (m, 2H), 0.84-0.78 (m, 2H), 0.17-0.07 (m, 9H).

Reference Example 7

Ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate hydrochloride

To a solution of 1.19 g of 5-tert-butyl 2-ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclopropanecarboxamido]pyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate (containing impurities) synthesized in the similar manner as in Reference Example 6 in 20 ml of ethyl acetate, 4.0 ml (16 mmol) of 4 N hydrogen chloride/ethyl acetate was added at room temperature in a nitrogen atmosphere and stirred at the same temperature as above for 6.5 hours. Then, 2.0 ml (8.0 mmol) of 4 N hydrogen chloride/ethyl acetate was added thereto and further stirred at room temperature for 14.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, and the obtained concentration residue was suspended in diisopropyl ether and stirred at room temperature. Insoluble matter was collected by filtration, and the obtained solid was washed by sousing with diisopropyl ether and then dried under reduced pressure to obtain 0.91 g of the title compound (yield: 88% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 365 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 9.99 (br s, 2H), 9.91 (s, 1H), 4.51-4.39 (m, 4H), 1.63 (s, 6H), 1.35 (t, J=7.2 Hz, 3H), 1.08 (dd, J=4.2, 6.0 Hz, 2H), 0.87 (dd, J=4.2, 6.0 Hz, 2H), 0.08 (s, 9H).

Reference Example 8

2-Methyl-2-(trimethylsilyl)propanoic acid

To 100 ml of dehydrated THF, 200 ml (400 mmol) of 2 M lithium diisopropylamide/THF solution was added in an argon atmosphere, and subsequently, 4.7 ml (51 mmol) of isobutanoic acid was added dropwise at 0° C. and then stirred at room temperature for 4 hours. 10 ml (58 mmol) of hexamethylphosphoric acid triamide was added thereto, and then, 29 ml (230 mmol) of chlorotrimethylsilane was added thereto dropwise at −78° C. and stirred for 24 hours while the temperature was gradually raised to room temperature.

After the completion of the reaction, 25 ml of methanol and 50 ml of water were added to the reaction solution. Subsequently, the solution was rendered acidic by adding 2 N hydrochloric acid, followed by extraction with diethyl ether. All of the obtained organic layers were washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was dissolved in a 2 N aqueous sodium hydroxide solution and washed with ethyl acetate. After separation into an aqueous layer and an organic layer, the aqueous layer was rendered acidic by adding 1 N hydrochloric acid, followed by extraction with ethyl acetate. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was suspended in n-hexane, and after ultrasonication, insoluble matter was collected by filtration. The filtrate was concentrated under reduced pressure, the obtained concentration residue was subjected to silica gel column chromatography (elution solvent: 1,2-dichloroethane:methanol=100:0 to 99:1 (V/V)), and a fraction containing the compound of interest and the aforementioned solid collected by filtration were combined, concentrated under reduced pressure, and dried under reduced pressure to obtain 2.66 g of the title compound (yield: 32%) as a white solid.

›Example 125 · 4 of 10

Mass spectrum (CI, m/z): 161 [M+1] + .

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 1.22 (s, 6H), 0.08 (s, 9H).

Reference Example 9

5-tert-Butyl 1-ethyl 6,6-dimethyl-3-[2-methyl-2-(trimethylsilyl)propanamido]pyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate

To a solution of 1.30 g (8.11 mmol) of 2-methyl-2-(trimethylsilyl)propanoic acid synthesized in the similar manner as in Reference Example 8 in 25 ml of dehydrated dichloromethane, 0.85 ml (9.9 mmol) of oxalyl chloride and 0.040 ml (0.52 mmol) of DMF were added in this order at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 3.5 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure (hot water bath temperature: 25° C.) to obtain a concentration residue.

To a solution of the obtained concentration residue in 15 ml of dehydrated dichloromethane, 2.30 ml (13.2 mmol) of DIPEA and 1.08 g (3.33 mmol) of 5-tert-butyl 1-ethyl 3-amino-6,6-dimethylpyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate [synthesized according to the method described in Journal of Medicinal Chemistry 2012, 55 (10), 4728-4739] were added in this order at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 17.5 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with dichloromethane three times. All of the organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=93:7 to 80:20 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 1.28 g of the title compound (yield: 82%) as a pale yellow foam.

Mass spectrum (CI, m/z): 467 [M+1] + .

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 7.87-7.74 (m, 1H), 4.60-4.47 (m, 4H), 1.84 & 1.78 (s, total 6H), 1.55-1.48 (m, 9H), 1.47 (t, J=7.2 Hz, 3H), 1.31-1.25 (m, 6H), 0.10-0.04 (m, 9H).

Reference Example 10

1-(Ethyldimethylsilyl)cyclobutanecarboxylic acid

To 200 ml of dehydrated THF, 214 ml (428 mmol) of 2 M lithium diisopropylamide/THF solution was added in an argon atmosphere, and then, 10.7 ml (112 mmol) of cyclobutanecarboxylic acid was added dropwise under cooling in ice water and stirred while the temperature was raised to room temperature for a while. Subsequently, 20 ml (120 mmol) of hexamethylphosphoric acid triamide was added. After cooling in a dry ice/ethanol coolant, 67.6 ml (485 mmol) of chloro(ethyl)dimethylsilane was added dropwise at −75° C. to −69° C. and stirred overnight at a temperature of −60° C. or lower.

After the completion of the reaction, 67 ml of methanol and subsequently 134 ml of cold water were added dropwise to the reaction solution and then brought to room temperature. 240 ml of 2 N hydrochloric acid was added for acidity (pH 2.0), and 200 ml of diethyl ether was added thereto and then the aqueous layer and the organic layer were separated. The obtained organic layer was washed with 250 ml of a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 41 ml of a 2 N aqueous sodium hydroxide solution was added to the obtained concentration residue and washed with 250 ml of n-hexane. The aqueous layer was rendered acidic (pH 2.0) again by adding 82 ml of 1 N hydrochloric acid. This solution was subjected to extraction with 250 ml of ethyl acetate, and the organic layer was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 11.7 g of the title compound (yield: 59%) as a white solid.

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 11.71 (br s, 1H), 2.44-2.33 (m, 2H), 2.19-2.08 (m, 2H), 1.91-1.73 (m, 2H), 0.92 (t, J=7.9 Hz, 3H), 0.55 (q, J=7.9 Hz, 2H), 0.05 (s, 6H).

Reference Example 11

5-tert-Butyl 2-ethyl 3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-6,6-dimethylpyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate

To a solution of 11.7 g (62.8 mmol) of 1-(ethyldimethylsilyl)cyclobutanecarboxylic acid synthesized in the similar manner as in Reference Example 10 in 81 ml of dehydrated dichloromethane, 5.3 ml (62 mmol) of oxalyl chloride and 0.24 ml (3.1 mmol) of DMF were added in this order under cooling in ice water in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure at room temperature to obtain a concentration residue.

To a solution of 6.73 g (20.7 mmol) of 5-tert-butyl 2-ethyl 3-amino-6,6-dimethylpyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate [synthesized according to the method described in Journal of Medicinal Chemistry 2012, 55 (10), 4728-4739] and 18 ml (100 mmol) of DIPEA in 94 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 5 ml of dehydrated dichloromethane was added dropwise under cooling in ice water in a nitrogen atmosphere and stirred at the same temperature as above for 16 hours.

After the completion of the reaction, 350 ml of a 5% aqueous potassium bisulfate solution was added to the reaction solution and separated into an aqueous layer and an organic layer, and then, the aqueous layer was subjected to extraction with 150 ml of dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=86:14 to 53:47 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 7.51 g of the title compound (yield: 74%) as a pale yellow oil.

›Example 125 · 5 of 10

Mass spectrum (DUIS, m/z): 493 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 9.82-9.69 (m, 1H), 4.51-4.36 (m, 4H), 2.49-2.42 (m, 2H), 2.32-2.23 (m, 2H), 1.95-1.84 (m, 2H), 1.62-1.55 (m, 6H), 1.49-1.42 (m, 9H), 1.38-1.31 (m, 3H), 0.91 (t, J=7.9 Hz, 3H), 0.57 (q, J=7.9 Hz, 2H), 0.09 (s, 6H).

Reference Example 12

Ethyl 3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate

To a solution of 7.27 g (14.8 mmol) of 5-tert-butyl 2-ethyl 3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-6,6-dimethylpyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 11 in 70 ml of dehydrated dichloromethane, 5.1 ml (44 mmol) of 2,6-lutidine and 7.8 ml (43 mmol) of trimethylsilyl trifluoromethanesulfonate were added dropwise in this order under ice cooling in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, 57 ml of a saturated aqueous solution of sodium bicarbonate and 57 ml of dichloromethane were added to the reaction solution, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 60 ml of dichloromethane twice, all of the obtained organic layers were washed with 60 ml of a saturated aqueous solution of sodium bicarbonate and 60 ml of a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous magnesium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The operation of adding toluene to the obtained concentration residue and concentrating the resultant under reduced pressure was performed five times to obtain 5.92 g of the title compound (containing impurities) as a yellow oil.

Mass spectrum (DUIS, m/z): 393 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 9.68 (s, 1H), 4.39 (q, J=7.0 Hz, 2H), 3.92 (s, 2H), 2.48-2.40 (m, 2H), 2.29-2.22 (m, 2H), 1.93-1.82 (m, 2H), 1.33 (t, J=7.0 Hz, 3H), 1.29 (s, 6H), 0.91 (t, J=8.1 Hz, 3H), 0.56 (q, J=8.1 Hz, 2H), 0.08 (s, 6H).

Reference Example 13

Ethyl 5-(chlorocarbonyl)-3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate

To a solution of 5.92 g of ethyl 3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate (containing impurities) synthesized in the similar manner as in Reference Example 12 by using 7.27 g (14.8 mmol) of 5-tert-butyl 2-ethyl 3-[1-(ethyldimethylsilyl)cyclobutanecarboxamido]-6,6-dimethylpyrrolo[3,4-c]pyrazole-2,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 11 in 200 ml of dehydrated dichloromethane, 7.3 ml (43 mmol) of DIPEA was added at room temperature in an argon atmosphere, and then, a solution of 3.24 g (10.9 mmol) of bis(trichloromethyl)carbonate in 33 ml of dehydrated dichloromethane was added dropwise at −60° C. or lower and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, 130 ml of a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the temperature was raised to room temperature for a while with stirring. After separation into an aqueous layer and an organic layer, the aqueous layer was subjected to extraction with 100 ml of dichloromethane twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=78:22 to 57:43 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. n-Hexane was added to the concentration residue and concentrated again under reduced pressure to obtain 5.13 g of the title compound (yield: 76% [2 steps]) as a white solid.

Mass spectrum (CI, m/z): 455 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 9.85-9.76 (m, 1H), 4.88-4.81 & 4.53-4.48 (m, total 2H), 4.44 (q, J=7.1 Hz, 2H), 2.55-2.44 (m, 2H), 2.35-2.24 (m, 2H), 1.96-1.85 (m, 2H), 1.69-1.61 (m, 6H), 1.34 (t, J=7.1 Hz, 3H), 0.92 (t, J=7.9 Hz, 3H), 0.58 (q, J=7.9 Hz, 2H), 0.13-0.07 (m, 6H).

Reference Example 14

2-(Ethyldimethylsilyl)-2-methylpropanoic acid

To 100 ml of dehydrated THF, 100 ml (200 mmol) of 2 M lithium diisopropylamide/THF solution was added in an argon atmosphere, and then, 4.7 ml (51 mmol) of isobutanoic acid was added dropwise at 0° C. and stirred for 4 hours after the temperature was raised to room temperature. Subsequently, 10 ml (58 mmol) of hexamethylphosphoric acid triamide was added thereto, and then, 32 ml (230 mmol) of chloro(ethyl)dimethylsilane was added thereto dropwise at −78° C. After the completion of the dropwise addition, the resultant was stirred for 1 day while the temperature was raised to room temperature for a while.

After the completion of the reaction, 25 ml of methanol and subsequently 50 ml of water were added under cooling in ice water. Then, 2 N hydrochloric acid was added for acidity, followed by extraction with diethyl ether. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. A 2 N aqueous sodium hydroxide solution was added to the concentration residue, and it was washed with ethyl acetate. Subsequently, the aqueous layer was rendered acidic by adding a 1 N aqueous hydrochloric acid solution, followed by extraction with ethyl acetate. The obtained organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: 1,2-dichloroethane:methanol=100:0 to 99:1 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 2.24 g of the title compound (yield: 25%) as a white solid.

›Example 125 · 6 of 10

Mass spectrum (CI, m/z): 175 [M+1] + .

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 11.57 (br s, 1H), 1.23 (s, 6H), 0.95 (t, J=8.0 Hz, 3H), 0.62 (q, J=8.0 Hz, 2H), 0.06 (s, 6H).

Reference Example 15

5-tert-Butyl 1-ethyl 3-[2-(ethyldimethylsilyl)-2-methylpropanamido]-6,6-dimethylpyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate

To a solution of 4.7 g (27 mmol) of 2-(ethyldimethylsilyl)-2-methylpropanoic acid synthesized in the similar manner as in Reference Example 14 in 40 ml of dehydrated dichloromethane, 2.3 ml (27 mmol) of oxalyl chloride was added dropwise at 0° C. in an argon atmosphere and stirred at the same temperature as above for 10 minutes. Subsequently, 0.10 ml (1.3 mmol) of DMF was added at 0° C. and stirred at the same temperature as above for 4 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure at room temperature to obtain a concentration residue.

To a solution of 2.9 g (8.9 mmol) of 5-tert-butyl 1-ethyl 3-amino-6,6-dimethylpyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate [synthesized according to the method described in Journal of Medicinal Chemistry 2012, 55 (10), 4728-4739] in 10 ml of dehydrated dichloromethane, a solution of the obtained concentration residue in 20 ml of dehydrated dichloromethane was added dropwise at 0° C. in an argon atmosphere, and subsequently, 7.9 ml (45 mmol) of DIPEA was added and stirred at 0° C. for 24 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=98:2 to 80:20 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 3.18 g of the title compound (yield: 74%) as a pale yellow oil.

Mass spectrum (CI, m/z): 481 [M+1] + .

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 7.88-7.73 (m, 1H), 4.62-4.46 (m, 4H), 1.87-1.75 (m, 6H), 1.55-1.41 (m, 12H), 1.31-1.26 (m, 6H), 0.99-0.88 (m, 3H), 0.66-0.53 (m, 2H), 0.09-0.02 (m, 6H).

Reference Example 16

Ethyl 3-[2-(ethyldimethylsilyl)-2-methylpropanamido]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1 (4H)-carboxylate

To a solution of 3.18 g (6.62 mmol) of 5-tert-butyl 1-ethyl 3-[2-(ethyldimethylsilyl)-2-methylpropanamido]-6,6-dimethylpyrrolo[3,4-c]pyrazole-1,5(4H,6H)-dicarboxylate synthesized in the similar manner as in Reference Example 15 in 30 ml of dehydrated dichloromethane, 2.3 ml (20 mmol) of 2,6-lutidine and 3.6 ml (20 mmol) of trimethylsilyl trifluoromethanesulfonate were added dropwise in this order at 0° C. in an argon atmosphere and stirred at the same temperature as above for 1 hour.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with dichloromethane. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. Toluene was added to the residue, and then, concentration under reduced pressure was performed to obtain 2.44 g of the title compound (yield: 97%) as a pale yellow solid.

Mass spectrum (CI, m/z): 381 [M+1] + .

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 7.77 (s, 1H), 4.50 (q, J=7.2 Hz, 2H), 4.15 (s, 2H), 1.55 (s, 6H), 1.46 (t, J=7.2 Hz, 3H), 1.32-1.25 (m, 6H), 0.93 (t, J=8.0 Hz, 3H), 0.60 (q, J=8.0 Hz, 2H), 0.05 (s, 6H).

Reference Example 17

(S)-2-[(2-Methoxypropan-2-yl)oxy]-1-phenylethanol

To a solution of 664 mg (2.63 mmol) of (S)-2-[(tert-butyldimethylsilyl)oxy]-2-phenylethanol [synthesized according to the method described in Angew. Chem. Int. Ed., 2012, 51 (31), 7825-7829] in 15 ml of dichloromethane, 0.33 ml (3.5 mmol) of 2-methoxy-1-propene and 68.3 mg (0.272 mmol) of pyridinium p-toluenesulfonate were added at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with dichloromethane twice. All of the organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=98:2 to 97:3 (V/V)), and a fraction containing (S)-3,3,8,8,9,9-hexamethyl-6-phenyl-2,4,7-trioxa-8-siladecane was concentrated under reduced pressure and dried under reduced pressure to obtain a concentration residue.

To a solution of 347 mg of the obtained concentration residue in 10 ml of THF, 428 mg (1.64 mmol) of tetrabutylammonium fluoride was added at 0° C. in a nitrogen atmosphere and stirred at the same temperature as above for 3.5 hours.

After the completion of the reaction, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution and stirred, followed by extraction with an ethyl acetate/n-hexane mixed solvent twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 85:15 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 160 mg of the title compound (yield: 29% [2 steps]) as a colorless oil.

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 7.43-7.27 (m, 5H), 4.89-4.83 (m, 1H), 3.59 (dd, J=3.2, 9.8 Hz, 1H), 3.45 (dd, J=9.0, 9.8 Hz, 1H), 3.19 (s, 3H), 2.82 (d, J=2.4 Hz, 1H), 1.38 (s, 3H), 1.37 (s, 3H).

Reference Example 18

(S)-2,5-Dioxopyrrolidin-1-yl {2-[(2-methoxypropan-2-yl)oxy]-1-phenylethyl}carbonate

›Example 125 · 7 of 10

To a solution of 157 mg (0.747 mmol) of (S)-2-[(2-methoxypropan-2-yl)oxy]-1-phenylethanol synthesized in the similar manner as in Reference Example 17 in 4 ml of dehydrated acetonitrile, 0.16 ml (1.2 mmol) of triethylamine and 233 mg (0.908 mmol) of N,N′-disuccinimidyl carbonate were added at room temperature in a nitrogen atmosphere and stirred at the same temperature as above for 6 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure. The obtained concentration residue was dissolved in ethyl acetate, and it was washed with water. After separation into an aqueous layer and an organic layer, the aqueous layer was subjected to extraction with ethyl acetate twice. All of the obtained organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=90:10 to 65:35 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 190 mg of the title compound (yield: 72%) as a colorless oil.

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 7.42-7.33 (m, 5H), 5.86 (dd, J=3.4, 8.8 Hz, 1H), 3.83 (dd, J=8.8, 11.0 Hz, 1H), 3.64 (dd, J=3.4, 11.0 Hz, 1H), 3.20 (s, 3H), 2.81 (s, 4H), 1.38 (s, 3H), 1.34 (s, 3H).

Reference Example 19

Ethyl 4-(benzyloxy)-3-phenylbutanoate

To a solution of 8.9 mg (0.023 mmol) of bis(acetonitrile)(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate in 3 ml of 1,4-dioxane/0.3 ml of water, 23 mg (0.41 mmol) of potassium hydroxide, 128 mg (1.05 mmol) of phenylboronic acid, and 120 mg (0.545 mmol) of (E)-ethyl 4-(benzyloxy)-2-butenoate [synthesized according to the method described in Tetrahedron Lett., 1982, 37, 9033-9036] were added in this order with stirring at room temperature in an argon atmosphere, stirred at the same temperature as above for 30 minutes, and then stirred at 60° C. for 6 hours.

After the completion of the reaction, water was added to the reaction solution, followed by extraction with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium chloride, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=95:5 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 160 mg of the title compound (yield: 98%) as a pale yellow oil.

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 7.36-7.18 (m, 10H), 4.45 (s, 2H), 3.97-3.89 (m, 2H), 3.59-3.52 (m, 2H), 3.39-3.33 (m, 1H), 2.81 (dd, J=6.3, 15.6 Hz, 1H), 2.59 (dd, J=8.5, 15.6 Hz, 1H), 1.04 (t, J=7.1 Hz, 3H).

Reference Example 20

Ethyl 6,6-dimethyl-5-(3-oxo-3-phenylpropanoyl)-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate and (Z)-ethyl 5-(3-hydroxy-3-phenylacryloyl)-6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate as tautomer

To a solution of 487 mg (2.39 mmol) of 3-oxo-3-phenylpropanoic acid [synthesized according to the method described in Chem. Pharm. Bull., 29 (10), 2762 (1981)] and 10 μl (0.13 mmol) of DMF in 5 ml of dehydrated dichloromethane, 205 μl (2.39 mmol) of oxalyl chloride was added dropwise with stirring at 0° C. in an argon atmosphere and stirred for 1.5 hours after the temperature was raised to room temperature.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure at room temperature to obtain a concentration residue.

To a solution of 299 mg (0.790 mmol) of ethyl 6,6-dimethyl-3-[1-(trimethylsilyl)cyclobutanecarboxamido]-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate synthesized in the similar manner as in Reference Example 84 and 0.70 ml (4.1 mmol) of DIPEA in 5 ml of 1,2-dichloroethane, a solution of the obtained concentration residue in 5 ml of 1,2-dichloroethane was added dropwise with stirring at room temperature in an argon atmosphere and stirred at the same temperature as above for 5 hours.

After the completion of the reaction, 5 ml of 2-propanol was added and stirred at room temperature for 14 hours, and then, the reaction solution was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=87:13 to 0:100 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 293 mg of the title compound (yield: 71%) (containing the tautomer) as a pale yellow solid.

Mass spectrum (DUIS, m/z): 525 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 15.71 (s, 0.3H), 9.79 (s, 0.3H), 9.75 (s, 0.7H), 8.01-7.42 (m, total 5H), 5.82 (s, 0.3H), 4.85 (s, 0.6H), 4.78 (s, 1.4H), 4.47-4.38 (m, total 2H), 4.18 (s, 1.4H), 2.57-2.41 (m, total 2H), 2.33-2.12 (m, total 2H), 1.93-1.81 (m, total 2H), 1.75 & 1.64 (s, total 6H), 1.38-1.31 (m, total 3H), 0.11 & 0.08 (s, total 9H).

Reference Example 21

(R)-Methyl 3-amino-3-phenylpropanoate hydrochloride

To a solution of 2.01 g (12.2 mmol) of (R)-3-amino-3-phenylpropanoic acid [purchased from Shanghai HC Biotech Co., Ltd.] in 100 ml of dehydrated methanol, 1.32 ml (18.2 mmol) of thionyl chloride was added dropwise with stirring at room temperature in a nitrogen atmosphere and then stirred at the same temperature as above for 24 hours. Then, the temperature was raised to 65° C., and the resultant was stirred for 9.5 hours.

After standing to cool, the reaction solution was concentrated under reduced pressure, diethyl ether was added to the obtained concentration residue and ultrasonicated, and the deposited solid was collected by filtration and dried under reduced pressure to obtain 2.55 g of the title compound (yield: 97%) as a white solid.

Mass spectrum (DUIS, m/z): 180 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 8.67 (br s, 3H), 7.57-7.50 (m, 2H), 7.45-7.36 (m, 3H), 4.58 (dd, J=6.0, 8.6 Hz, 1H), 3.35 (br s, 3H), 3.20 (dd, J=6.0, 16.3 Hz, 1H), 3.00 (dd, J=8.6, 16.3 Hz, 1H).

›Example 125 · 8 of 10

Reference Example 22

(R)-Methyl 3-phenyl-3-(2,2,2-trifluoroacetamido)propanoate

To a solution of 2.55 g (11.8 mmol) of (R)-methyl 3-amino-3-phenylpropanoate hydrochloride synthesized in the similar manner as in Reference Example 21 in 50 ml of dichloromethane, 10.5 ml (60.3 mmol) of DIPEA and 1.75 ml (12.4 mmol) of trifluoroacetic anhydride were added dropwise in this order with stirring at 0° C. in an argon atmosphere, stirred at the same temperature as above for 2 hours, and further stirred overnight at room temperature.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure. Ethyl acetate was added to the concentration residue, washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride in this order, then dried over anhydrous magnesium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: n-hexane:ethyl acetate=91:9 to 70:30 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 2.75 g of the title compound (yield: 85%) as a white solid.

Mass spectrum (DUIS, m/z): 276 [M+1] + .

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 7.80-7.64 (m, 1H), 7.39-7.25 (m, 5H), 5.46-5.39 (m, 1H), 3.65 (s, 3H), 3.00 (dd, J=5.5, 16.2 Hz, 1H), 2.93 (dd, J=5.5, 16.2 Hz, 1H).

Reference Example 23

(R)-4-Amino-2-methyl-4-phenylbutan-2-ol

To a solution of 506 mg (1.84 mmol) of (R)-methyl 3-phenyl-3-(2,2,2-trifluoroacetamido)propanoate synthesized in the similar manner as in Reference Example 22 in 5 ml of dehydrated THF, 6.60 ml (9.24 mmol) of 1.4 M methyl magnesium bromide/THF solution was added dropwise with stirring at room temperature in an argon atmosphere and stirred at room temperature for 3.5 hours.

After the completion of the reaction, 10 ml of a saturated aqueous solution of ammonium chloride was added dropwise to the reaction solution under ice cooling, brought back to room temperature, and stirred for a while. Dichloromethane and water, and further an aqueous solution of dilute sodium hydroxide were added to the reaction solution to adjust the pH of the aqueous layer to 10, followed by separation into an aqueous layer and an organic layer. The aqueous layer was subjected to extraction with dichloromethane, all of the obtained organic layers were dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing (R)-2,2,2-trifluoro-N-(3-hydroxy-3-methyl-1-phenylbutyl)acetamide was concentrated under reduced pressure to obtain a concentration residue.

To a solution of 427 mg of the obtained concentration residue in 5 ml of ethanol, 64.6 mg (1.71 mmol) of sodium borohydride was added in several divided portions at room temperature and then stirred at room temperature for 14 hours. 77.0 mg (2.04 mmol) of sodium borohydride was further added in several divided portions, stirred at room temperature for 2 hours, and then stirred at 75° C. for 2 hours.

After the completion of the reaction, the reaction solution was cooled in ice, and 10 ml of a saturated aqueous solution of ammonium chloride was added thereto dropwise and then stirred at room temperature. Dichloromethane and water were added thereto, and an aqueous solution of dilute sodium hydroxide was added thereto to adjust the pH of the aqueous layer to 10, followed by separation into an aqueous layer and an organic layer. The aqueous layer was subjected to extraction with dichloromethane, all of the obtained organic layers were dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The concentration residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 160 mg of the title compound (yield: 49%) as a colorless oil.

Mass spectrum (DUIS, m/z): 180 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 7.37-7.26 (m, 4H), 7.21-7.15 (m, 1H), 4.05 (dd, J=2.8, 10.7 Hz, 1H), 1.66 (dd, J=10.7, 14.0 Hz, 1H), 1.52 (dd, J=2.8, 14.0 Hz, 1H), 1.22 (s, 3H), 1.10 (s, 3H).

Reference Example 24

(S)-tert-Butyl [2-(difluoromethoxy)-1-phenylethyl]carbamate

To a solution of 1.00 g (4.21 mmol) of (S)-tert-butyl (2-hydroxy-1-phenylethyl)carbamate [purchased from Novo Chemy Ltd.] in 30 ml of dehydrated acetonitrile, 165 mg (0.866 mmol) of copper(I) iodide was added at room temperature in an argon atmosphere and stirred at the same temperature as above for 30 minutes. Subsequently, a solution of 0.87 ml (8.4 mmol) of 2-(fluorosulfonyl)difluoroacetic acid in 10 ml of dehydrated acetonitrile was dividedly added (1 ml each) at 45° C. over 40 minutes and stirred at the same temperature as above for 1 hour.

After the completion of the reaction, the reaction solution allowed to cool to room temperature was concentrated under reduced pressure. Water and ethyl acetate were added to the obtained concentration residue, followed by extraction from the mixed solution with ethyl acetate. The obtained organic layer was washed with water, then dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained concentration residue was subjected to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=95:5 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained concentration residue was subjected again to silica gel chromatography (elution solvent: n-hexane:ethyl acetate=95:5 to 50:50 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure and dried under reduced pressure to obtain 213 mg of the title compound (yield: 18%) as a yellow solid.

›Example 125 · 9 of 10

Mass spectrum (CI, m/z): 288 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 7.55 (d, J=8.7 Hz, 1H), 7.37-7.24 (m, 5H), 6.67 (t, J=75.9 Hz, 1H), 4.83-4.73 (m, 1H), 3.95-3.86 (m, 2H), 1.42-1.23 (m, 9H).

Reference Example 25

(S)-2-(Difluoromethoxy)-1-phenylethanamine trifluoroacetate

To a solution of 210 mg (0.731 mmol) of (S)-tert-butyl [2-(difluoromethoxy)-1-phenylethyl]carbamate synthesized in the similar manner as in Reference Example 24 in 4 ml of dehydrated dichloromethane, 1 ml of trifluoroacetic acid was added at room temperature in an argon atmosphere and stirred at the same temperature as above for 2 hours.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure and dried under reduced pressure to obtain 210 mg of the title compound (yield: 95%) as a yellow oil.

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 8.59 (br s, 3H), 7.54-7.40 (m, 5H), 6.76 (t, J=74.8 Hz, 1H), 4.70-4.59 (m, 1H), 4.19-4.11 (m, 2H).

Reference Example 26

(S)-2-Ethoxy-1-phenylethanamine

To a solution of 1.40 g (10.2 mmol) of (S)-2-amino-2-phenylethanol and 3.0 ml (15 mmol) of 1,4,7,10,13-pentaoxacyclopentadecane in 10 ml of dehydrated THF, 481 mg (11.0 mmol) of 55% sodium hydride was dividedly added with stirring at room temperature in an argon atmosphere and stirred at the same temperature as above until foaming settled. Subsequently, 0.82 ml (10 mmol) of ethyl iodide was added dropwise at room temperature and stirred at the same temperature as above for 24 hours.

After the completion of the reaction, water and diethyl ether were added to the reaction solution and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with diethyl ether, then all of the organic layers were washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 1.17 g of the title compound (yield: 69%) as a pale yellow oil.

Mass spectrum (CI, m/z): 166 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 7.39-7.33 (m, 2H), 7.33-7.25 (m, 2H), 7.25-7.19 (m, 1H), 4.01 (dd, J=4.9, 8.0 Hz, 1H), 3.53-3.35 (m, 3H), 3.28 (dd, J=8.0, 9.3 Hz, 1H), 1.82 (br s, 2H), 1.09 (t, J=7.0 Hz, 3H).

Reference Example 27

(R)-3-Methoxy-1-phenylpropan-1-amine

To a solution of 1.53 g (10.1 mmol) of (R)-3-amino-3-phenylpropan-1-ol [purchased from Ark Pharm, Inc.] and 3.0 ml (15 mmol) of 1,4,7,10,13-pentaoxacyclopentadecane in 10 ml of dehydrated THF, 473 mg (10.9 mmol) of 55% sodium hydride was dividedly added with stirring at room temperature in an argon atmosphere and stirred at the same temperature as above until foaming settled. Subsequently, 0.62 ml (10 mmol) of methyl iodide was added thereto dropwise at 0° C. and then stirred at room temperature for 17 hours.

After the completion of the reaction, water and diethyl ether were added to the reaction solution and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with diethyl ether, then all of the organic layers were washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (DNH silica gel, elution solvent: 1,2-dichloroethane:methanol=100:0 to 95:5 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 1.49 g of the title compound (yield: 89%) as a colorless oil.

Mass spectrum (CI, m/z): 166 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 7.35-7.26 (m, 4H), 7.24-7.15 (m, 1H), 3.85 (dd, J=6.4, 7.4 Hz, 1H), 3.38-3.20 (m, 2H), 3.19 (s, 3H), 1.93-1.63 (m, 4H).

Reference Example 28

2-(Benzo[d][1,3]dioxol-4-yl)-2-[(tert-butoxycarbonyl)amino]acetic acid

To a solution of 7.09 g (47.2 mmol) of benzo[d][1,3]dioxole-4-carbaldehyde in 15 ml of methanol, 67.5 ml (472 mmol) of 7 M aqueous ammonia solution/methanol solution was gradually added at room temperature and then stirred at room temperature for 18 minutes. The reaction solution was cooled in ice water, and 14.1 ml (113 mmol) of trimethylsilane carbonitrile was added dropwise. After the completion of the dropwise addition, the resultant was stirred overnight at room temperature.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To 9.30 g of the obtained concentration residue, 17 ml of acetic acid and 66.7 ml (776 mmol) of concentrated hydrochloric acid were added and stirred for 9 hours while heated to reflux.

After standing to cool, the reaction solution was concentrated under reduced pressure to obtain a concentration residue.

To 8.33 g of the obtained concentration residue, 35.2 ml (141 mmol) of a 4 N aqueous sodium hydroxide solution, 65 ml of 1,4-dioxane, and 14.7 ml (64.1 mmol) of di-tert-butyl dicarbonate were added in this order at room temperature and stirred at room temperature.

After the completion of the reaction, the reaction solution was concentrated under reduced pressure, 100 ml of dichloromethane was added thereto, and then, the pH was adjusted to 1.75 by using concentrated hydrochloric acid. Methanol was added thereto until insoluble matter was dissolved, and then the aqueous layer and the organic layer were separated. The aqueous layer was subjected to extraction with 100 ml of dichloromethane twice, all of the obtained organic layers were dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: ethyl acetate), and a fraction containing the compound of interest was concentrated under reduced pressure. The obtained residue was subjected again to silica gel column chromatography (elution solvent: ethyl acetate), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 10.22 g of the title compound (yield: 73% [3 steps]) as a black viscous liquid.

›Example 125 · 10 of 10

Mass spectrum (DUIS, m/z): 296 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 13.24-12.32 (m, 1H), 7.48 (d, J=8.5 Hz, 1H), 6.88-6.77 (m, 3H), 6.04-6.01 (m, 2H), 5.22 (d, J=8.5 Hz, 1H), 1.38 (s, 9H).

Reference Example 29

Methyl 2-(benzo[d][1,31]dioxol-4-yl)-2-[(tert-butoxycarbonyl)amino]acetate

To a solution of 3.93 g (13.3 mmol) of 2-(benzo[d][1,3]dioxol-4-yl)-2-[(tert-butoxycarbonyl)amino]acetic acid synthesized in the similar manner as in Reference Example 28 in 8 ml of DMF, 3.86 g (27.9 mmol) of potassium carbonate and 1.3 ml (21 mmol) of methyl iodide were added in this order at room temperature, stirred at the same temperature as above for 1 hour, and then left standing overnight.

After the completion of the reaction, the reaction solution was poured to 100 ml of a saturated aqueous solution of sodium chloride, and water was added until insoluble matter was dissolved, followed by extraction with toluene twice. The obtained organic layer was dried over anhydrous sodium sulfate and filtered, and then, the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (elution solvent: hexane:ethyl acetate=95:5 to 70:30 (V/V)), and a fraction containing the compound of interest was concentrated under reduced pressure to obtain 2.83 g of the title compound (yield: 69%) as a white solid.

Mass spectrum (EI, m/z): 309 [M] + .

1 H-NMR spectrum (400 MHz, CDCl 3 ) δ: 6.85-6.76 (m, 3H), 6.03-5.97 (m, 2H), 5.71-5.61 (m, 1H), 5.49-5.39 (m, 1H), 3.73 (s, 3H), 1.47-1.39 (m, 9H).

Reference Example 30

tert-Butyl [1-(benzo[d][1,3]dioxol-4-yl)-2-hydroxyethyl]carbamate

To a solution of 2.82 g (9.13 mmol) of methyl 2-(benzo[d][1,3]dioxol-4-yl)-2-[(tert-butoxycarbonyl)amino]acetate synthesized in the similar manner as in Reference Example 29 in 30 ml of dehydrated THF, 716 mg (32.9 mmol) of lithium borohydride was added under cooling in ice water and stirred at room temperature.

After the completion of the reaction, the reaction solution was poured to 150 ml of a saturated aqueous solution of ammonium chloride, followed by extraction with ethyl acetate. The obtained organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. Diethyl ether and n-hexane were added to the concentration residue, and the formed solid was filtered, washed by sousing with diethyl ether, and then dried under reduced pressure to obtain 1.54 g of the title compound (yield: 60%) as a white solid.

Mass spectrum (CI, m/z): 282 [M+1] + .

1 H-NMR spectrum (400 MHz, DMSO-d 6 ) δ: 7.13 (d, J=8.3 Hz, 1H), 6.84-6.75 (m, 3H), 6.02-5.96 (m, 2H), 4.82 (t, J=5.6 Hz, 1H), 4.74-4.64 (m, 1H), 3.54-3.40 (m, 2H), 1.37 (s, 9H).

Reference Example 31

2-Amino-2-(benzo[d][1,3]dioxol-4-yl)ethanol

To a solution of 1.04 g (3.69 mmol) of tert-butyl [1-(benzo[d][1,3]dioxol-4-yl)-2-hydroxy

›Tables in the description — 164
TABLE 1 — (I) Com-
poundCon-
No.R 1R 2R 3L 1L 2R 4L 3R 5figuration
I-1MeMeMeCH 2OPhCH 2Hracemic
I-2MeMeMeCH 2OPhCH 2H(S)-
I-3MeMeMeCH 2OPhCH 2Meracemic
I-4MeMeMeCH 2OPhCH 2Me(S)-
I-5MeMeMeCH 2OPh(CH 2 ) 2Hracemic
I-6MeMeMeCH 2OPh(CH 2 ) 2H(R)-
I-7MeMeMeCH 2OPh(CH 2 ) 2Meracemic
I-8MeMeMeCH 2OPh(CH 2 ) 2Me(R)-
I-9MeMeMeCH 2OPhC≡CCH 2Hracemic
I-10MeMeMeCH 2OPhC≡CCH 2H(S)-
I-11MeMeMeCH 2OPhC≡CCH 2Meracemic
I-12MeMeMeCH 2OPhC≡CCH 2Me(S)-
I-13MeMeMeCH 2 C(Me) 2OPhCH 2Hracemic
I-14MeMeMeCH 2 C(Me) 2OPhCH 2H(S)-
I-15MeMeMeCH 2 C(Me) 2OPhCH 2Meracemic
I-16MeMeMeCH 2 C(Me) 2OPhCH 2Me(S)-
I-17MeMeMeCH 2 C(Me) 2OPh(CH 2 ) 2Hracemic
I-18MeMeMeCH 2 C(Me) 2OPh(CH 2 ) 2H(R)-
I-19MeMeMeCH 2 C(Me) 2OPh(CH 2 ) 2Meracemic
I-20MeMeMeCH 2 C(Me) 2OPh(CH 2 ) 2Me(R)-
I-21MeMeMeCH 2 C(Me) 2OPhC≡CCH 2Hracemic
I-22MeMeMeCH 2 C(Me) 2OPhC≡CCH 2H(S)-
I-23MeMeMeCH 2 C(Me) 2OPhC≡CCH 2Meracemic
I-24MeMeMeCH 2 C(Me) 2OPhC≡CCH 2Me(S)-
I-25MeMeMeCH 2 CH═CHOPhCH 2Hracemic
I-26MeMeMeCH 2 CH═CHOPhCH 2H(S)-
I-27MeMeMeCH 2 CH═CHOPhCH 2Meracemic
I-28MeMeMeCH 2 CH═CHOPhCH 2Me(S)-
I-29MeMeMeCH 2 CH═CHOPh(CH 2 ) 2Hracemic
I-30MeMeMeCH 2 CH═CHOPh(CH 2 ) 2H(R)-
I-31MeMeMeCH 2 CH═CHOPh(CH 2 ) 2Meracemic
I-32MeMeMeCH 2 CH═CHOPh(CH 2 ) 2Me(R)-
I-33MeMeMeCH 2 CH═CHOPhC≡CCH 2Hracemic
I-34MeMeMeCH 2 CH═CHOPhC≡CCH 2H(S)-
I-35MeMeMeCH 2 CH═CHOPhC≡CCH 2Meracemic
I-36MeMeMeCH 2 CH═CHOPhC≡CCH 2Me(S)-
I-37MeMeMeCH 2 C≡COPhCH 2Hracemic
I-38MeMeMeCH 2 C≡COPhCH 2H(S)-
I-39MeMeMeCH 2 C≡COPhCH 2Meracemic
I-40MeMeMeCH 2 C≡COPhCH 2Me(S)-
I-41MeMeMeCH 2 C≡COPh(CH 2 ) 2Hracemic
I-42MeMeMeCH 2 C≡COPh(CH 2 ) 2H(R)-
I-43MeMeMeCH 2 C≡COPh(CH 2 ) 2Meracemic
I-44MeMeMeCH 2 C≡COPh(CH 2 ) 2Me(R)-
I-45MeMeMeCH 2 C≡COPhC≡CCH 2Hracemic
I-46MeMeMeCH 2 C≡COPhC≡CCH 2H(S)-
I-47MeMeMeCH 2 C≡COPhC≡CCH 2Meracemic
I-48MeMeMeCH 2 C≡COPhC≡CCH 2Me(S)-
I-49MeMeMe1,2-Cyclo-OPhCH 2Hracemic
propylene
I-50MeMeMe1,2-Cyclo-OPhCH 2H(S)-
propylene
TABLE 2 — (I)
Com-Con-
poundfigu-
No.R 1R 2R 3L 1L 2R 4L 3R 5ration
I-51MeMeMe1,2-Cyclo-OPhCH 2Meracemic
propylene
I-52MeMeMe1,2-Cyclo-OPhCH 2Me(S)-
propylene
I-53MeMeMe1,2-Cyclo-OPh(CH 2 ) 2Hracemic
propylene
I-54MeMeMe1,2-Cyclo-OPh(CH 2 ) 2H(R)-
propylene
I-55MeMeMe1,2-Cyclo-OPh(CH 2 ) 2Meracemic
propylene
I-56MeMeMe1,2-Cyclo-OPh(CH 2 ) 2Me(R)-
propylene
I-57MeMeMe1,2-Cyclo-OPhC≡CCH 2Hracemic
propylene
I-58MeMeMe1,2-Cyclo-OPhC≡CCH 2H(S)-
propylene
I-59MeMeMe1,2-Cyclo-OPhC≡CCH 2Meracemic
propylene
I-60MeMeMe1,2-Cyclo-OPhC≡CCH 2Me(S)-
propylene
I-61MeMeMe5,5-OPhCH 2Hracemic
Spiro[2.3]
hexylene
I-62MeMeMe5,5-OPhCH 2H(S)-
Spiro[2.3]
hexylene
I-63MeMeMe5,5-OPhCH 2Meracemic
Spiro[2.3]
hexylene
I-64MeMeMe5,5-OPhCH 2Me(S)-
Spiro[2.3]
hexylene
I-65MeMeMe5,5-OPh(CH 2 ) 2Hracemic
Spiro[2.3]
hexylene
I-66MeMeMe5,5-OPh(CH 2 ) 2H(R)-
Spiro[2.3]
hexylene
I-67MeMeMe5,5-OPh(CH 2 ) 2Meracemic
Spiro[2.3]
hexylene
I-68MeMeMe5,5-OPh(CH 2 ) 2Me(R)-
Spiro[2.3]
hexylene
I-69MeMeMe5,5-OPhC≡CCH 2Hracemic
Spiro[2.3]
hexylene
I-70MeMeMe5,5-OPhC≡CCH 2H(S)-
Spiro[2.3]
hexylene
I-71MeMeMe5,5-OPhC≡CCH 2Meracemic
Spiro[2.3]
hexylene
I-72MeMeMe5,5-OPhC≡CCH 2Me(S)-
Spiro[2.3]
hexylene
I-73MeMeMe4,4-Cyclo-OPhCH 2Hracemic
pentenylene
I-74MeMeMe4,4-Cyclo-OPhCH 2H(S)-
pentenylene
I-75MeMeMe4,4-Cyclo-OPhCH 2Meracemic
pentenylene
I-76MeMeMe4,4-Cyclo-OPhCH 2Me(S)-
pentenylene
I-77MeMeMe4,4-Cyclo-OPh(CH 2 ) 2Hracemic
pentenylene
I-78MeMeMe4,4-Cyclo-OPh(CH 2 ) 2H(R)-
pentenylene
I-79MeMeMe4,4-Cyclo-OPh(CH 2 ) 2Meracemic
pentenylene
I-80MeMeMe4,4-Cyclo-OPh(CH 2 ) 2Me(R)-
pentenylene
I-81MeMeMe4,4-Cyclo-OPhC≡CCH 2Hracemic
pentenylene
I-82MeMeMe4,4-Cyclo-OPhC≡CCH 2H(S)-
pentenylene
I-83MeMeMe4,4-Cyclo-OPhC≡CCH 2Meracemic
pentenylene
I-84MeMeMe4,4-Cyclo-OPhC≡CCH 2Me(S)-
pentenylene
I-85MeMeMeCH 2NHPhCH 2Hracemic
I-86MeMeMeCH 2NHPhCH 2H(S)-
I-87MeMeMeCH 2NHPhCH 2Meracemic
I-88MeMeMeCH 2NHPhCH 2Me(S)-
I-89MeMeMeCH 2NHPh(CH 2 ) 2Hracemic
I-90MeMeMeCH 2NHPh(CH 2 ) 2H(R)-
I-91MeMeMeCH 2NHPh(CH 2 ) 2Meracemic
I-92MeMeMeCH 2NHPh(CH 2 ) 2Me(R)-
I-93MeMeMeCH 2NHPhC≡CCH 2Hracemic
I-94MeMeMeCH 2NHPhC≡CCH 2H(S)-
I-95MeMeMeCH 2NHPhC≡CCH 2Meracemic
I-96MeMeMeCH 2NHPhC≡CCH 2Me(S)-
I-97MeMeMeCH 2 C(Me) 2NHPhCH 2Hracemic
I-98MeMeMeCH 2 C(Me) 2NHPhCH 2H(S)-
I-99MeMeMeCH 2 C(Me) 2NHPhCH 2Meracemic
I-100MeMeMeCH 2 C(Me) 2NHPhCH 2Me(S)-
TABLE 3 — (I)
Com-Con-
poundfigu-
No.R 1R 2R 3L 1L 2R 4L 3R 5ration
I-101MeMeMeCH 2 C(Me) 2NHPh(CH 2 ) 2Hracemic
I-102MeMeMeCH 2 C(Me) 2NHPh(CH 2 ) 2H(R)-
I-103MeMeMeCH 2 C(Me) 2NHPh(CH 2 ) 2Meracemic
I-104MeMeMeCH 2 C(Me) 2NHPh(CH 2 ) 2Me(R)-
I-105MeMeMeCH 2 C(Me) 2NHPhC≡CCH 2Hracemic
I-106MeMeMeCH 2 C(Me) 2NHPhC≡CCH 2H(S)-
I-107MeMeMeCH 2 C(Me) 2NHPhC≡CCH 2Meracemic
I-108MeMeMeCH 2 C(Me) 2NHPhC≡CCH 2Me(S)-
I-109MeMeMeCH 2 CH═CHNHPhCH 2Hracemic
I-110MeMeMeCH 2 CH═CHNHPhCH 2H(S)-
I-111MeMeMeCH 2 CH═CHNHPhCH 2Meracemic
I-112MeMeMeCH 2 CH═CHNHPhCH 2Me(S)-
I-113MeMeMeCH 2 CH═CHNHPh(CH 2 ) 2Hracemic
I-114MeMeMeCH 2 CH═CHNHPh(CH 2 ) 2H(R)-
I-115MeMeMeCH 2 CH═CHNHPh(CH 2 ) 2Meracemic
I-116MeMeMeCH 2 CH═CHNHPh(CH 2 ) 2Me(R)-
I-117MeMeMeCH 2 CH═CHNHPhC≡CCH 2Hracemic
I-118MeMeMeCH 2 CH═CHNHPhC≡CCH 2H(S)-
I-119MeMeMeCH 2 CH═CHNHPhC≡CCH 2Meracemic
I-120MeMeMeCH 2 CH═CHNHPhC≡CCH 2Me(S)-
I-121MeMeMeCH 2 C≡CNHPhCH 2Hracemic
I-122MeMeMeCH 2 C≡CNHPhCH 2H(S)-
I-123MeMeMeCH 2 C≡CNHPhCH 2Meracemic
I-124MeMeMeCH 2 C≡CNHPhCH 2Me(S)-
I-125MeMeMeCH 2 C≡CNHPh(CH 2 ) 2Hracemic
I-126MeMeMeCH 2 C≡CNHPh(CH 2 ) 2H(R)-
I-127MeMeMeCH 2 C≡CNHPh(CH 2 ) 2Meracemic
I-128MeMeMeCH 2 C≡CNHPh(CH 2 ) 2Me(R)-
I-129MeMeMeCH 2 C≡CNHPhC≡CCH 2Hracemic
I-130MeMeMeCH 2 C≡CNHPhC≡CCH 2H(S)-
I-131MeMeMeCH 2 C≡CNHPhC≡CCH 2Meracemic
I-132MeMeMeCH 2 C≡CNHPhC≡CCH 2Me(S)-
I-133MeMeMe1,2-Cyclo-NHPhCH 2Hracemic
propylene
I-134MeMeMe1,2-Cyclo-NHPhCH 2H(S)-
propylene
I-135MeMeMe1,2-Cyclo-NHPhCH 2Meracemic
propylene
I-136MeMeMe1,2-Cyclo-NHPhCH 2Me(S)-
propylene
I-137MeMeMe1,2-Cyclo-NHPh(CH 2 ) 2Hracemic
propylene
I-138MeMeMe1,2-Cyclo-NHPh(CH 2 ) 2H(R)-
propylene
I-139MeMeMe1,2-Cyclo-NHPh(CH 2 ) 2Meracemic
propylene
I-140MeMeMe1,2-Cyclo-NHPh(CH 2 ) 2Me(R)-
propylene
I-141MeMeMe1,2-Cyclo-NHPhC≡CCH 2Hracemic
propylene
I-142MeMeMe1,2-Cyclo-NHPhC≡CCH 2H(S)-
propylene
I-143MeMeMe1,2-Cyclo-NHPhC≡CCH 2Meracemic
propylene
I-144MeMeMe1,2-Cyclo-NHPhC≡CCH 2Me(S)-
propylene
I-145MeMeMe5,5-Spiro[2.3]NHPhCH 2Hracemic
hexylene
I-146MeMeMe5,5-Spiro[2.3]NHPhCH 2H(S)-
hexylene
I-147MeMeMe5,5-Spiro[2.3]NHPhCH 2Meracemic
hexylene
I-148MeMeMe5,5-Spiro[2.3]NHPhCH 2Me(S)-
hexylene
I-149MeMeMe5,5-Spiro[2.3]NHPh(CH 2 ) 2Hracemic
hexylene
I-150MeMeMe5,5-Spiro[2.3]NHPh(CH 2 ) 2H(R)-
hexylene
TABLE 4 — (I)
Com-Con-
poundfigu-
No.R 1R 2R 3L 1L 2R 4L 3R 5ration
I-151MeMeMe5,5-NHPh(CH 2 ) 2Meracemic
Spiro[2.3]
hexylene
I-152MeMeMe5,5-NHPh(CH 2 ) 2Me(R)-
Spiro[2.3]
hexylene
I-153MeMeMe5,5-NHPhC≡CCH 2Hracemic
Spiro[2.3]
hexylene
I-154MeMeMe5,5-NHPhC≡CCH 2H(S)-
Spiro[2.3]
hexylene
I-155MeMeMe5,5-NHPhC≡CCH 2Meracemic
Spiro[2.3]
hexylene
I-156MeMeMe5,5-NHPhC≡CCH 2Me(S)-
Spiro[2.3]
hexylene
I-157MeMeMe4,4-Cyclo-NHPhCH 2Hracemic
pentenylene
I-158MeMeMe4,4-Cyclo-NHPhCH 2H(S)-
pentenylene
I-159MeMeMe4,4-Cyclo-NHPhCH 2Meracemic
pentenylene
I-160MeMeMe4,4-Cyclo-NHPhCH 2Me(S)-
pentenylene
I-161MeMeMe4,4-Cyclo-NHPh(CH 2 ) 2Hracemic
pentenylene
I-162MeMeMe4,4-Cyclo-NHPh(CH 2 ) 2H(R)-
pentenylene
I-163MeMeMe4,4-Cyclo-NHPh(CH 2 ) 2Meracemic
pentenylene
I-164MeMeMe4,4-Cyclo-NHPh(CH 2 ) 2Me(R)-
pentenylene
I-165MeMeMe4,4-Cyclo-NHPhC≡CCH 2Hracemic
pentenylene
I-166MeMeMe4,4-Cyclo-NHPhC≡CCH 2H(S)-
pentenylene
I-167MeMeMe4,4-Cyclo-NHPhC≡CCH 2Meracemic
pentenylene
I-168MeMeMe4,4-Cyclo-NHPhC≡CCH 2Me(S)-
pentenylene
I-169MeMeMeCH 2CH 2PhCH 2Hracemic
I-170MeMeMeCH 2CH 2PhCH 2H(S)-
I-171MeMeMeCH 2CH 2Ph—Hracemic
I-172MeMeMeCH 2CH 2Ph—H(S)-
I-173MeMeMeCH 2CH 2PhCH 2Meracemic
I-174MeMeMeCH 2CH 2PhCH 2Me(S)-
I-175MeMeMeCH 2CH 2PhC(Me) 2Hracemic
I-176MeMeMeCH 2CH 2PhC(Me) 2H(S)-
I-177MeMeMeCH 2CH 2PhC(Me) 2Meracemic
I-178MeMeMeCH 2CH 2PhC(Me) 2Me(S)-
I-179MeMeMeCH 2CH 2Ph(CH 2 ) 2Hracemic
I-180MeMeMeCH 2CH 2Ph(CH 2 ) 2H(S)-
I-181MeMeMeCH 2CH 2Ph(CH 2 ) 2Meracemic
I-182MeMeMeCH 2CH 2Ph(CH 2 ) 2Me(S)-
I-183MeMeMeCH 2CH 2PhC≡CCH 2Hracemic
I-184MeMeMeCH 2CH 2PhC≡CCH 2H(S)-
I-185MeMeMeCH 2CH 2PhC≡CCH 2Meracemic
I-186MeMeMeCH 2CH 2PhC≡CCH 2Me(S)-
I-187MeMeMeCH 2 C(Me) 2CH 2PhCH 2Hracemic
I-188MeMeMeCH 2 C(Me) 2CH 2PhCH 2H(S)-
I-189MeMeMeCH 2 C(Me) 2CH 2Ph—Hracemic
I-190MeMeMeCH 2 C(Me) 2CH 2Ph—H(S)-
I-191MeMeMeCH 2 C(Me) 2CH 2PhCH 2Meracemic
I-192MeMeMeCH 2 C(Me) 2CH 2PhCH 2Me(S)-
I-193MeMeMeCH 2 C(Me) 2CH 2PhC(Me) 2Hracemic
I-194MeMeMeCH 2 C(Me) 2CH 2PhC(Me) 2H(S)-
I-195MeMeMeCH 2 C(Me) 2CH 2PhC(Me) 2Meracemic
I-196MeMeMeCH 2 C(Me) 2CH 2PhC(Me) 2Me(S)-
I-197MeMeMeCH 2 C(Me) 2CH 2Ph(CH 2 ) 2Hracemic
I-198MeMeMeCH 2 C(Me) 2CH 2Ph(CH 2 ) 2H(S)-
I-199MeMeMeCH 2 C(Me) 2CH 2Ph(CH 2 ) 2Meracemic
I-200MeMeMeCH 2 C(Me) 2CH 2Ph(CH 2 ) 2Me(S)-
TABLE 5 — (I)
Com-Con-
poundfigu-
No.R 1R 2R 3L 1L 2R 4L 3R 5ration
I-201MeMeMeCH 2 C(Me) 2CH 2PhC≡CCH 2Hracemic
I-202MeMeMeCH 2 C(Me) 2CH 2PhC≡CCH 2H(S)-
I-203MeMeMeCH 2 C(Me) 2CH 2PhC≡CCH 2Meracemic
I-204MeMeMeCH 2 C(Me) 2CH 2PhC≡CCH 2Me(S)-
I-205MeMeMeCH 2 CH═CHCH 2PhCH 2Hracemic
I-206MeMeMeCH 2 CH═CHCH 2PhCH 2H(S)-
I-207MeMeMeCH 2 CH═CHCH 2Ph—Hracemic
I-208MeMeMeCH 2 CH═CHCH 2Ph—H(S)-
I-209MeMeMeCH 2 CH═CHCH 2PhCH 2Meracemic
I-210MeMeMeCH 2 CH═CHCH 2PhCH 2Me(S)-
I-211MeMeMeCH 2 CH═CHCH 2PhC(Me) 2Hracemic
I-212MeMeMeCH 2 CH═CHCH 2PhC(Me) 2H(S)-
I-213MeMeMeCH 2 CH═CHCH 2PhC(Me) 2Meracemic
I-214MeMeMeCH 2 CH═CHCH 2PhC(Me) 2Me(S)-
I-215MeMeMeCH 2 CH═CHCH 2Ph(CH 2 ) 2Hracemic
I-216MeMeMeCH 2 CH═CHCH 2Ph(CH 2 ) 2H(S)-
I-217MeMeMeCH 2 CH═CHCH 2Ph(CH 2 ) 2Meracemic
I-218MeMeMeCH 2 CH═CHCH 2Ph(CH 2 ) 2Me(S)-
I-219MeMeMeCH 2 CH═CHCH 2PhC≡CCH 2Hracemic
I-220MeMeMeCH 2 CH═CHCH 2PhC≡CCH 2H(S)-
I-221MeMeMeCH 2 CH═CHCH 2PhC≡CCH 2Meracemic
I-222MeMeMeCH 2 CH═CHCH 2PhC≡CCH 2Me(S)-
I-223MeMeMeCH 2 C≡CCH 2PhCH 2Hracemic
I-224MeMeMeCH 2 C≡CCH 2PhCH 2H(S)-
I-225MeMeMeCH 2 C≡CCH 2Ph—Hracemic
I-226MeMeMeCH 2 C≡CCH 2Ph—H(S)-
I-227MeMeMeCH 2 C≡CCH 2PhCH 2Meracemic
I-228MeMeMeCH 2 C≡CCH 2PhCH 2Me(S)-
I-229MeMeMeCH 2 C≡CCH 2PhC(Me) 2Hracemic
I-230MeMeMeCH 2 C≡CCH 2PhC(Me) 2H(S)-
I-231MeMeMeCH 2 C≡CCH 2PhC(Me) 2Meracemic
I-232MeMeMeCH 2 C≡CCH 2PhC(Me) 2Me(S)-
I-233MeMeMeCH 2 C≡CCH 2Ph(CH 2 ) 2Hracemic
I-234MeMeMeCH 2 C≡CCH 2Ph(CH 2 ) 2H(S)-
I-235MeMeMeCH 2 C≡CCH 2Ph(CH 2 ) 2Meracemic
I-236MeMeMeCH 2 C≡CCH 2Ph(CH 2 ) 2Me(S)-
I-237MeMeMeCH 2 C≡CCH 2PhC≡CCH 2Hracemic
I-238MeMeMeCH 2 C≡CCH 2PhC≡CCH 2H(S)-
I-239MeMeMeCH 2 C≡CCH 2PhC≡CCH 2Meracemic
I-240MeMeMeCH 2 C≡CCH 2PhC≡CCH 2Me(S)-
I-241MeMeMe1,2-Cyclo-CH 2PhCH 2Hracemic
propylene
I-242MeMeMe1,2-Cyclo-CH 2PhCH 2H(S)-
propylene
I-243MeMeMe1,2-Cyclo-CH 2Ph—Hracemic
propylene
I-244MeMeMe1,2-Cyclo-CH 2Ph—H(S)-
propylene
I-245MeMeMe1,2-Cyclo-CH 2PhCH 2Meracemic
propylene
I-246MeMeMe1,2-Cyclo-CH 2PhCH 2Me(S)-
propylene
I-247MeMeMe1,2-Cyclo-CH 2PhC(Me) 2Hracemic
propylene
I-248MeMeMe1,2-Cyclo-CH 2PhC(Me) 2H(S)-
propylene
I-249MeMeMe1,2-Cyclo-CH 2PhC(Me) 2Meracemic
propylene
I-250MeMeMe1,2-Cyclo-CH 2PhC(Me) 2Me(S)-
propylene
TABLE 6 — (I)
Com-Con-
poundfigur-
No.R 1R 2R 3L 1L 2R 4L 3R 5ation
I-251MeMeMe1,2-Cyclo-CH 2Ph(CH 2 ) 2Hracemic
propylene
I-252MeMeMe1,2-Cyclo-CH 2Ph(CH 2 ) 2H(S)-
propylene
I-253MeMeMe1,2-Cyclo-CH 2Ph(CH 2 ) 2Meracemic
propylene
I-254MeMeMe1,2-Cyclo-CH 2Ph(CH 2 ) 2Me(S)-
propylene
I-255MeMeMe1,2-Cyclo-CH 2PhC≡CCH 2Hracemic
propylene
I-256MeMeMe1,2-Cyclo-CH 2PhC≡CCH 2H(S)-
propylene
I-257MeMeMe1,2-Cyclo-CH 2PhC≡CCH 2Meracemic
propylene
I-258MeMeMe1,2-Cyclo-CH 2PhC≡CCH 2Me(S)-
propylene
I-259MeMeMe5,5-Spiro-CH 2PhCH 2Hracemic
[2.3]hexyl-
ene
I-260MeMeMe5,5-Spiro-CH 2PhCH 2H(S)-
[2.3]hexyl-
ene
I-261MeMeMe5,5-Spiro-CH 2Ph—Hracemic
[2.3]hexyl-
ene
I-262MeMeMe5,5-Spiro-CH 2Ph—H(S)-
[2.3]hexyl-
ene
I-263MeMeMe5,5-Spiro-CH 2PhCH 2Meracemic
[2.3]hexyl-
ene
I-264MeMeMe5,5-Spiro-CH 2PhCH 2Me(S)-
[2.3]hexyl-
ene
I-265MeMeMe5,5-Spiro-CH 2PhC(Me) 2Hracemic
[2.3]hexyl-
ene
I-266MeMeMe5,5-Spiro-CH 2PhC(Me) 2H(S)-
[2.3]hexyl-
ene
I-267MeMeMe5,5-Spiro-CH 2PhC(Me) 2Meracemic
[2.3]hexyl-
ene
I-268MeMeMe5,5-Spiro-CH 2PhC(Me) 2Me(S)-
[2.3]hexyl-
ene
I-269MeMeMe5,5-Spiro-CH 2Ph(CH 2 ) 2Hracemic
[2.3]hexyl-
ene
I-270MeMeMe5,5-Spiro-CH 2Ph(CH 2 ) 2H(S)-
[2.3]hexyl-
ene
I-271MeMeMe5,5-Spiro-CH 2Ph(CH 2 ) 2Meracemic
[2.3]hexyl-
ene
I-272MeMeMe5,5-Spiro-CH 2Ph(CH 2 ) 2Me(S)-
[2.3]hexyl-
ene
I-273MeMeMe5,5-Spiro-CH 2PhC≡CCH 2Hracemic
[2.3]hexyl-
ene
I-274MeMeMe5,5-Spiro-CH 2PhC≡CCH 2H(S)-
[2.3]hexyl-
ene
I-275MeMeMe5,5-Spiro-CH 2PhC≡CCH 2Meracemic
[2.3]hexyl-
ene
I-276MeMeMe5,5-Spiro-CH 2PhC≡CCH 2Me(S)-
[2.3]hexyl-
ene
I-277MeMeMe4,4-Cyclo-CH 2PhCH 2Hracemic
pentenylene
I-278MeMeMe4,4-Cyclo-CH 2PhCH 2H(S)-
pentenylene
I-279MeMeMe4,4-Cyclo-CH 2Ph—Hracemic
pentenylene
I-280MeMeMe4,4-Cyclo-CH 2Ph—H(S)-
pentenylene
I-281MeMeMe4,4-Cyclo-CH 2PhCH 2Meracemic
pentenylene
I-282MeMeMe4,4-Cyclo-CH 2PhCH 2Me(S)-
pentenylene
I-283MeMeMe4,4-Cyclo-CH 2PhC(Me) 2Hracemic
pentenylene
I-284MeMeMe4,4-Cyclo-CH 2PhC(Me) 2H(S)-
pentenylene
I-285MeMeMe4,4-Cyclo-CH 2PhC(Me) 2Meracemic
pentenylene
I-286MeMeMe4,4-Cyclo-CH 2PhC(Me) 2Me(S)-
pentenylene
I-287MeMeMe4,4-Cyclo-CH 2Ph(CH 2 ) 2Hracemic
pentenylene
I-288MeMeMe4,4-Cyclo-CH 2Ph(CH 2 ) 2H(S)-
pentenylene
I-289MeMeMe4,4-Cyclo-CH 2Ph(CH 2 ) 2Meracemic
pentenylene
I-290MeMeMe4,4-Cyclo-CH 2Ph(CH 2 ) 2Me(S)-
pentenylene
I-291MeMeMe4,4-Cyclo-CH 2PhC≡CCH 2Hracemic
pentenylene
I-292MeMeMe4,4-Cyclo-CH 2PhC≡CCH 2H(S)-
pentenylene
I-293MeMeMe4,4-Cyclo-CH 2PhC≡CCH 2Meracemic
pentenylene
I-294MeMeMe4,4-Cyclo-CH 2PhC≡CCH 2Me(S)-
pentenylene
TABLE 7 — (I)
Com-Con-
poundfigur-
No.R 1R 2R 3L 1L 2R 4L 3R 5ation
I-295MeMeMe5,5-Spiro-NHPhCH 2 C(Me) 2Hracemic
[2.3]hexyl-
ene
I-296MeMeMe5,5-Spiro-NHPhCH 2 C(Me) 2H(R)-
[2.3]hexyl-
ene
I-297MeMeMe5,5-Spiro-NHPhCH 2 C(Me) 2Meracemic
[2.3]hexyl-
ene
I-298MeMeMe5,5-Spiro-NHPhCH 2 C(Me) 2Me(R)-
[2.3]hexyl-
ene
I-299MeMeMe5,5-Spiro-NHPhC(Me) 2 CH 2Hracemic
[2.3]hexyl-
ene
I-300MeMeMe5,5-Spiro-NHPhC(Me) 2 CH 2H(+)
[2.3]hexyl-
ene
I-301MeMeMe5,5-Spiro-NHPhC(Me) 2 CH 2H(−)
[2.3]hexyl-
ene
I-302MeMeMe5,5-Spiro-NHPhC(Me) 2 CH 2Meracemic
[2.3]hexyl-
ene
I-303MeMeMe5,5-Spiro-NHPhC(Me) 2 CH 2Me(+)
[2.3]hexyl-
ene
I-304MeMeMe5,5-Spiro-NHPhC(Me) 2 CH 2Me(−)
[2.3]hexyl-
ene
I-305MeMeMe4,4-Cyclo-NHPhCH 2 C(Me) 2Hracemic
pentenylene
I-306MeMeMe4,4-Cyclo-NHPhCH 2 C(Me) 2H(R)-
pentenylene
I-307MeMeMe4,4-Cyclo-NHPhCH 2 C(Me) 2Meracemic
pentenylene
I-308MeMeMe4,4-Cyclo-NHPhCH 2 C(Me) 2Me(R)-
pentenylene
I-309MeMeMe4,4-Cyclo-NHPhC(Me) 2 CH 2Hracemic
pentenylene
I-310MeMeMe4,4-Cyclo-NHPhC(Me) 2 CH 2H(+)
pentenylene
I-311MeMeMe4,4-Cyclo-NHPhC(Me) 2 CH 2H(−)
pentenylene
I-312MeMeMe4,4-Cyclo-NHPhC(Me) 2 CH 2Meracemic
pentenylene
I-313MeMeMe4,4-Cyclo-NHPhC(Me) 2 CH 2Me(+)
pentenylene
I-314MeMeMe4,4-Cyclo-NHPhC(Me) 2 CH 2Me(−)
pentenylene
I-315MeMeMe1,2-Cyclo-—Ph—Hracemic
propylene
I-316MeMeMe1,2-Cyclo-—Ph—H(S)-
propylene
I-317MeMeMe1,2-Cyclo-—Ph—Meracemic
propylene
I-318MeMeMe1,2-Cyclo-—Ph—Me(S)-
propylene
I-319MeMeMe5,5-Spiro-—Ph—Hracemic
[2.3]hexyl-
ene
I-320MeMeMe5,5-Spiro-—Ph—H(S)-
[2.3]hexyl-
ene
I-321MeMeMe5,5-Spiro-—Ph—Meracemic
[2.3]hexyl-
ene
I-322MeMeMe5,5-Spiro-—Ph—Me(S)-
[2.3]hexyl-
ene
I-323MeMeMe4,4-Cyclo-—Ph—Hracemic
pentenylene
I-324MeMeMe4,4-Cyclo-—Ph—H(S)-
pentenylene
I-325MeMeMe4,4-Cyclo-Ph—Meracemic
pentenylene
I-326MeMeMe4,4-Cyclo-—Ph—Me(S)-
pentenylene
I-327MeMeMe1,2-Cyclo-—PhCH 2Hracemic
propylene
I-328MeMeMe1,2-Cyclo-—PhCH 2H(S)-
propylene
I-329MeMeMe1,2-Cyclo-—PhCH 2Meracemic
propylene
I-330MeMeMe1,2-Cyclo-—PhCH 2Me(S)-
propylene
I-331MeMeMe1,2-Cyclo-—Ph(CH 2 ) 2Hracemic
propylene
I-332MeMeMe1,2-Cyclo-—Ph(CH 2 ) 2H(S)-
propylene
I-333MeMeMe1,2-Cyclo-—Ph(CH 2 ) 2Meracemic
propylene
I-334MeMeMe1,2-Cyclo-—Ph(CH 2 ) 2Me(S)-
propylene
I-335MeMeMe5,5-Spiro-—PhCH 2Hracemic
[2.3]hexyl-
ene
I-336MeMeMe5,5-Spiro-—PhCH 2H(S)-
[2.3]hexyl-
ene
I-337MeMeMe5,5-Spiro-—PhCH 2Meracemic
[2.3]hexyl-
ene
I-338MeMeMe5,5-Spiro-—PhCH 2Me(S)-
[2.3]hexyl-
ene
I-339MeMeMe5,5-Spiro-—Ph(CH 2 ) 2Hracemic
[2.3]hexyl-
ene
I-340MeMeMe5,5-Spiro-—Ph(CH 2 ) 2H(S)-
[2.3]hexyl-
ene
I-341MeMeMe5,5-Spiro-—Ph(CH 2 ) 2Meracemic
[2.3]hexyl-
ene
I-342MeMeMe5,5-Spiro-—Ph(CH 2 ) 2Me(S)-
[2.3]hexyl-
ene
I-343MeMeMe4,4-Cyclo-—PhCH 2Hracemic
pentenylene
I-344MeMeMe4,4-Cyclo-—PhCH 2H(S)-
pentenylene
I-345MeMeMe4,4-Cyclo-—PhCH 2Meracemic
pentenylene
TABLE 8 — (I)
Com-Con-
poundfigur-
No.R 1R 2R 3L 1L 2R 4L 3R 5ation
I-346MeMeMe4,4-Cyclo-—PhCH 2Me(S)-
pentenylene
I-347MeMeMe4,4-Cyclo-—Ph(CH 2 ) 2Hracemic
pentenylene
I-348MeMeMe4,4-Cyclo-—Ph(CH 2 ) 2H(S)-
pentenylene
I-349MeMeMe4,4-Cyclo-—Ph(CH 2 ) 2Meracemic
pentenylene
I-350MeMeMe4,4-Cyclo-—Ph(CH 2 ) 2Me(S)-
pentenylene
TABLE 9 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-1MeMeMeOPhCH 2Hracemic
II-2MeMeMeOPhCH 2H(S)-
II-3MeEtMeOPhCH 2Hracemic
II-4MeEtMeOPhCH 2H(S)-
II-5MeMeMeOPhCH 2Meracemic
II-6MeMeMeOPhCH 2Me(S)-
II-7MeEtMeOPhCH 2Meracemic
II-8MeEtMeOPhCH 2Me(S)-
II-9MeMeMeOPhCH 2CHF 2racemic
II-10MeMeMeOPhCH 2CHF 2(S)-
II-11MeEtMeOPhCH 2CHF 2racemic
II-12MeEtMeOPhCH 2CHF 2(S)-
II-13MeMeMeOPhCH 2Etracemic
II-14MeMeMeOPhCH 2Et(S)-
II-15MeEtMeOPhCH 2Etracemic
II-16MeEtMeOPhCH 2Et(S)-
II-17MeMeMeOPhCH 2iPrracemic
II-18MeMeMeOPhCH 2iPr(S)-
II-19MeEtMeOPhCH 2iPrracemic
II-20MeEtMeOPhCH 2iPr(S)-
II-21MeMeMeOPhCH 2cPrracemic
II-22MeMeMeOPhCH 2cPr(S)-
II-23MeEtMeOPhCH 2cPrracemic
II-24MeEtMeOPhCH 2cPr(S)-
II-25MeMeMeOPhCH 2Phracemic
II-26MeMeMeOPhCH 2Ph(S)-
II-27MeEtMeOPhCH 2Phracemic
II-28MeEtMeOPhCH 2Ph(S)-
II-29MeMeMeOPhC(Me) 2Hracemic
II-30MeMeMeOPhC(Me) 2H(S)-
II-31MeEtMeOPhC(Me) 2Hracemic
II-32MeEtMeOPhC(Me) 2H(S)-
II-33MeMeMeOPhC(Me) 2Meracemic
II-34MeMeMeOPhC(Me) 2Me(S)-
II-35MeEtMeOPhC(Me) 2Meracemic
II-36MeEtMeOPhC(Me) 2Me(S)-
II-37MeMeMeOPhC(Me) 2CHF 2racemic
II-38MeMeMeOPhC(Me) 2CHF 2(S)-
II-39MeEtMeOPhC(Me) 2CHF 2racemic
II-40MeEtMeOPhC(Me) 2CHF 2(S)-
II-41MeMeMeOPhC(Me) 2Etracemic
II-42MeMeMeOPhC(Me) 2Et(S)-
II-43MeEtMeOPhC(Me) 2Etracemic
II-44MeEtMeOPhC(Me) 2Et(S)-
II-45MeMeMeOPhC(Me) 2iPrracemic
II-46MeMeMeOPhC(Me) 2iPr(S)-
II-47MeEtMeOPhC(Me) 2iPrracemic
II-48MeEtMeOPhC(Me) 2iPr(S)-
II-49MeMeMeOPhC(Me) 2cPrracemic
II-50MeMeMeOPhC(Me) 2cPr(S)-
TABLE 10 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-51MeEtMeOPhC(Me) 2cPrracemic
II-52MeEtMeOPhC(Me) 2cPr(S)-
II-53MeMeMeOPhC(Me) 2Phracemic
II-54MeMeMeOPhC(Me) 2Ph(S)-
II-55MeEtMeOPhC(Me) 2Phracemic
II-56MeEtMeOPhC(Me) 2Ph(S)-
II-57MeMeMeOPh(CH 2 ) 2Hracemic
II-58MeMeMeOPh(CH 2 ) 2H(R)-
II-59MeEtMeOPh(CH 2 ) 2Hracemic
II-60MeEtMeOPh(CH 2 ) 2H(R)-
II-61MeMeMeOPh(CH 2 ) 2Meracemic
II-62MeMeMeOPh(CH 2 ) 2Me(R)-
II-63MeEtMeOPh(CH 2 ) 2Meracemic
II-64MeEtMeOPh(CH 2 ) 2Me(R)-
II-65MeMeMeOPh(CH 2 ) 2CHF 2racemic
II-66MeMeMeOPh(CH 2 ) 2CHF 2(R)-
II-67MeEtMeOPh(CH 2 ) 2CHF 2racemic
II-68MeEtMeOPh(CH 2 ) 2CHF 2(R)-
II-69MeMeMeOPh(CH 2 ) 2Etracemic
II-70MeMeMeOPh(CH 2 ) 2Et(R)-
II-71MeEtMeOPh(CH 2 ) 2Etracemic
II-72MeEtMeOPh(CH 2 ) 2Et(R)-
II-73MeMeMeOPh(CH 2 ) 2iPrracemic
II-74MeMeMeOPh(CH 2 ) 2iPr(R)-
II-75MeEtMeOPh(CH 2 ) 2iPrracemic
II-76MeEtMeOPh(CH 2 ) 2iPr(R)-
II-77MeMeMeOPh(CH 2 ) 2cPrracemic
II-78MeMeMeOPh(CH 2 ) 2cPr(R)-
II-79MeEtMeOPh(CH 2 ) 2cPrracemic
II-80MeEtMeOPh(CH 2 ) 2cPr(R)-
II-81MeMeMeOPh(CH 2 ) 2Phracemic
II-82MeMeMeOPh(CH 2 ) 2Ph(R)-
II-83MeEtMeOPh(CH 2 ) 2Phracemic
II-84MeEtMeOPh(CH 2 ) 2Ph(R)-
II-85MeMeMeOPhCH 2 C(Me) 2Hracemic
II-86MeMeMeOPhCH 2 C(Me) 2H(R)-
II-87MeEtMeOPhCH 2 C(Me) 2Hracemic
II-88MeEtMeOPhCH 2 C(Me) 2H(R)-
II-89MeMeMeOPhCH 2 C(Me) 2Meracemic
II-90MeMeMeOPhCH 2 C(Me) 2Me(R)-
II-91MeEtMeOPhCH 2 C(Me) 2Meracemic
II-92MeEtMeOPhCH 2 C(Me) 2Me(R)-
II-93MeMeMeOPhCH 2 C(Me) 2CHF 2racemic
II-94MeMeMeOPhCH 2 C(Me) 2CHF 2(R)-
II-95MeEtMeOPhCH 2 C(Me) 2CHF 2racemic
II-96MeEtMeOPhCH 2 C(Me) 2CHF 2(R)-
II-97MeMeMeOPhCH 2 C(Me) 2Etracemic
II-98MeMeMeOPhCH 2 C(Me) 2Et(R)-
II-99MeEtMeOPhCH 2 C(Me) 2Etracemic
II-100MeEtMeOPhCH 2 C(Me) 2Et(R)-
TABLE 11 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-101MeMeMeOPhCH 2 C(Me) 2iPrracemic
II-102MeMeMeOPhCH 2 C(Me) 2iPr(R)-
II-103MeEtMeOPhCH 2 C(Me) 2iPrracemic
II-104MeEtMeOPhCH 2 C(Me) 2iPr(R)-
II-105MeMeMeOPhCH 2 C(Me) 2cPrracemic
II-106MeMeMeOPhCH 2 C(Me) 2cPr(R)-
II-107MeEtMeOPhCH 2 C(Me) 2cPrracemic
II-108MeEtMeOPhCH 2 C(Me) 2cPr(R)-
II-109MeMeMeOPhCH 2 C(Me) 2Phracemic
II-110MeMeMeOPhCH 2 C(Me) 2Ph(R)-
II-111MeEtMeOPhCH 2 C(Me) 2Phracemic
II-112MeEtMeOPhCH 2 C(Me) 2Ph(R)-
II-113MeMeMeNHPhCH 2Hracemic
II-114MeMeMeNHPhCH 2H(S)-
II-115MeEtMeNHPhCH 2Hracemic
II-116MeEtMeNHPhCH 2H(S)-
II-117MeMeMeN(Me)PhCH 2Hracemic
II-118MeMeMeN(Me)PhCH 2H(S)-
II-119MeEtMeN(Me)PhCH 2Hracemic
II-120MeEtMeN(Me)PhCH 2H(S)-
II-121MeMeMeNHPhCH 2Meracemic
II-122MeMeMeNHPhCH 2Me(S)-
II-123MeEtMeNHPhCH 2Meracemic
II-124MeEtMeNHPhCH 2Me(S)-
II-125MeMeMeN(Me)PhCH 2Meracemic
II-126MeMeMeN(Me)PhCH 2Me(S)-
II-127MeEtMeN(Me)PhCH 2Meracemic
II-128MeEtMeN(Me)PhCH 2Me(S)-
II-129MeMeMeNHPhCH 2CHF 2racemic
II-130MeMeMeNHPhCH 2CHF 2(S)-
II-131MeEtMeNHPhCH 2CHF 2racemic
II-132MeEtMeNHPhCH 2CHF 2(S)-
II-133MeMeMeN(Me)PhCH 2CHF 2racemic
II-134MeMeMeN(Me)PhCH 2CHF 2(S)-
II-135MeEtMeN(Me)PhCH 2CHF 2racemic
II-136MeEtMeN(Me)PhCH 2CHF 2(S)-
II-137MeMeMeNHPhCH 2Etracemic
II-138MeMeMeNHPhCH 2Et(S)-
II-139MeEtMeNHPhCH 2Etracemic
II-140MeEtMeNHPhCH 2Et(S)-
II-141MeMeMeN(Me)PhCH 2Etracemic
II-142MeMeMeN(Me)PhCH 2Et(S)-
II-143MeEtMeN(Me)PhCH 2Etracemic
II-144MeEtMeN(Me)PhCH 2Et(S)-
II-145MeMeMeNHPhCH 2iPrracemic
II-146MeMeMeNHPhCH 2iPr(S)-
II-147MeEtMeNHPhCH 2iPrracemic
II-148MeEtMeNHPhCH 2iPr(S)-
II-149MeMeMeN(Me)PhCH 2iPrracemic
II-150MeMeMeN(Me)PhCH 2iPr(S)-
TABLE 12 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-151MeEtMeN(Me)PhCH 2iPrracemic
II-152MeEtMeN(Me)PhCH 2iPr(S)-
II-153MeMeMeNHPhCH 2cPrracemic
II-154MeMeMeNHPhCH 2cPr(S)-
II-155MeEtMeNHPhCH 2cPrracemic
II-156MeEtMeNHPhCH 2cPr(S)-
II-157MeMeMeN(Me)PhCH 2cPrracemic
II-158MeMeMeN(Me)PhCH 2cPr(S)-
II-159MeEtMeN(Me)PhCH 2cPrracemic
II-160MeEtMeN(Me)PhCH 2cPr(S)-
II-161MeMeMeNHPhCH 2Phracemic
II-162MeMeMeNHPhCH 2Ph(S)-
II-163MeEtMeNHPhCH 2Phracemic
II-164MeEtMeNHPhCH 2Ph(S)-
II-165MeMeMeN(Me)PhCH 2Phracemic
II-166MeMeMeN(Me)PhCH 2Ph(S)-
II-167MeEtMeN(Me)PhCH 2Phracemic
II-168MeEtMeN(Me)PhCH 2Ph(S)-
II-169MeMeMeNHPhC(Me) 2Hracemic
II-170MeMeMeNHPhC(Me) 2H(S)-
II-171MeEtMeNHPhC(Me) 2Hracemic
II-172MeEtMeNHPhC(Me) 2H(S)-
II-173MeMeMeN(Me)PhC(Me) 2Hracemic
II-174MeMeMeN(Me)PhC(Me) 2H(S)-
II-175MeEtMeN(Me)PhC(Me) 2Hracemic
II-176MeEtMeN(Me)PhC(Me) 2H(S)-
II-177MeMeMeNHPhC(Me) 2Meracemic
II-178MeMeMeNHPhC(Me) 2Me(S)-
II-179MeEtMeNHPhC(Me) 2Meracemic
II-180MeEtMeNHPhC(Me) 2Me(S)-
II-181MeMeMeN(Me)PhC(Me) 2Meracemic
II-182MeMeMeN(Me)PhC(Me) 2Me(S)-
II-183MeEtMeN(Me)PhC(Me) 2Meracemic
II-184MeEtMeN(Me)PhC(Me) 2Me(S)-
II-185MeMeMeNHPhC(Me) 2CHF 2racemic
II-186MeMeMeNHPhC(Me) 2CHF 2(S)-
II-187MeEtMeNHPhC(Me) 2CHF 2racemic
II-188MeEtMeNHPhC(Me) 2CHF 2(S)-
II-189MeMeMeN(Me)PhC(Me) 2CHF 2racemic
II-190MeMeMeN(Me)PhC(Me) 2CHF 2(S)-
II-191MeEtMeN(Me)PhC(Me) 2CHF 2racemic
II-192MeEtMeN(Me)PhC(Me) 2CHF 2(S)-
II-193MeMeMeNHPhC(Me) 2Etracemic
II-194MeMeMeNHPhC(Me) 2Et(S)-
II-195MeEtMeNHPhC(Me) 2Etracemic
II-196MeEtMeNHPhC(Me) 2Et(S)-
II-197MeMeMeN(Me)PhC(Me) 2Etracemic
II-198MeMeMeN(Me)PhC(Me) 2Et(S)-
II-199MeEtMeN(Me)PhC(Me) 2Etracemic
II-200MeEtMeN(Me)PhC(Me) 2Et(S)-
TABLE 13 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-201MeMeMeNHPhC(Me) 2iPrracemic
II-202MeMeMeNHPhC(Me) 2iPr(S)-
II-203MeEtMeNHPhC(Me) 2iPrracemic
II-204MeEtMeNHPhC(Me) 2iPr(S)-
II-205MeMeMeN(Me)PhC(Me) 2iPrracemic
II-206MeMeMeN(Me)PhC(Me) 2iPr(S)-
II-207MeEtMeN(Me)PhC(Me) 2iPrracemic
II-208MeEtMeN(Me)PhC(Me) 2iPr(S)-
II-209MeMeMeNHPhC(Me) 2cPrracemic
II-210MeMeMeNHPhC(Me) 2cPr(S)-
II-211MeEtMeNHPhC(Me) 2cPrracemic
II-212MeEtMeNHPhC(Me) 2cPr(S)-
II-213MeMeMeN(Me)PhC(Me) 2cPrracemic
II-214MeMeMeN(Me)PhC(Me) 2cPr(S)-
II-215MeEtMeN(Me)PhC(Me) 2cPrracemic
II-216MeEtMeN(Me)PhC(Me) 2cPr(S)-
II-217MeMeMeNHPhC(Me) 2Phracemic
II-218MeMeMeNHPhC(Me) 2Ph(S)-
II-219MeEtMeNHPhC(Me) 2Phracemic
II-220MeEtMeNHPhC(Me) 2Ph(S)-
II-221MeMeMeN(Me)PhC(Me) 2Phracemic
II-222MeMeMeN(Me)PhC(Me) 2Ph(S)-
II-223MeEtMeN(Me)PhC(Me) 2Phracemic
II-224MeEtMeN(Me)PhC(Me) 2Ph(S)-
II-225MeMeMeNHPh(CH 2 ) 2Hracemic
II-226MeMeMeNHPh(CH 2 ) 2H(R)-
II-227MeEtMeNHPh(CH 2 ) 2Hracemic
II-228MeEtMeNHPh(CH 2 ) 2H(R)-
II-229MeMeMeN(Me)Ph(CH 2 ) 2Hracemic
II-230MeMeMeN(Me)Ph(CH 2 ) 2H(R)-
II-231MeEtMeN(Me)Ph(CH 2 ) 2Hracemic
II-232MeEtMeN(Me)Ph(CH 2 ) 2H(R)-
II-233MeMeMeNHPh(CH 2 ) 2Meracemic
II-234MeMeMeNHPh(CH 2 ) 2Me(R)-
II-235MeEtMeNHPh(CH 2 ) 2Meracemic
II-236MeEtMeNHPh(CH 2 ) 2Me(R)-
II-237MeMeMeN(Me)Ph(CH 2 ) 2Meracemic
II-238MeMeMeN(Me)Ph(CH 2 ) 2Me(R)-
II-239MeEtMeN(Me)Ph(CH 2 ) 2Meracemic
II-240MeEtMeN(Me)Ph(CH 2 ) 2Me(R)-
II-241MeMeMeNHPh(CH 2 ) 2CHF 2racemic
II-242MeMeMeNHPh(CH 2 ) 2CHF 2(R)-
II-243MeEtMeNHPh(CH 2 ) 2CHF 2racemic
II-244MeEtMeNHPh(CH 2 ) 2CHF 2(R)-
II-245MeMeMeN(Me)Ph(CH 2 ) 2CHF 2racemic
II-246MeMeMeN(Me)Ph(CH 2 ) 2CHF 2(R)-
II-247MeEtMeN(Me)Ph(CH 2 ) 2CHF 2racemic
II-248MeEtMeN(Me)Ph(CH 2 ) 2CHF 2(R)-
II-249MeMeMeNHPh(CH 2 ) 2Etracemic
II-250MeMeMeNHPh(CH 2 ) 2Et(R)-
TABLE 14 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-251MeEtMeNHPh(CH 2 ) 2Etracemic
II-252MeEtMeNHPh(CH 2 ) 2Et(R)-
II-253MeMeMeN(Me)Ph(CH 2 ) 2Etracemic
II-254MeMeMeN(Me)Ph(CH 2 ) 2Et(R)-
II-255MeEtMeN(Me)Ph(CH 2 ) 2Etracemic
II-256MeEtMeN(Me)Ph(CH 2 ) 2Et(R)-
II-257MeMeMeNHPh(CH 2 ) 2iPrracemic
II-258MeMeMeNHPh(CH 2 ) 2iPr(R)-
II-259MeEtMeNHPh(CH 2 ) 2iPrracemic
II-260MeEtMeNHPh(CH 2 ) 2iPr(R)-
II-261MeMeMeN(Me)Ph(CH 2 ) 2iPrracemic
II-262MeMeMeN(Me)Ph(CH 2 ) 2iPr(R)-
II-263MeEtMeN(Me)Ph(CH 2 ) 2iPrracemic
II-264MeEtMeN(Me)Ph(CH 2 ) 2iPr(R)-
II-265MeMeMeNHPh(CH 2 ) 2cPrracemic
II-266MeMeMeNHPh(CH 2 ) 2cPr(R)-
II-267MeEtMeNHPh(CH 2 ) 2cPrracemic
II-268MeEtMeNHPh(CH 2 ) 2cPr(R)-
II-269MeMeMeN(Me)Ph(CH 2 ) 2cPrracemic
II-270MeMeMeN(Me)Ph(CH 2 ) 2cPr(R)-
II-271MeEtMeN(Me)Ph(CH 2 ) 2cPrracemic
II-272MeEtMeN(Me)Ph(CH 2 ) 2cPr(R)-
II-273MeMeMeNHPh(CH 2 ) 2Phracemic
II-274MeMeMeNHPh(CH 2 ) 2Ph(R)-
II-275MeEtMeNHPh(CH 2 ) 2Phracemic
II-276MeEtMeNHPh(CH 2 ) 2Ph(R)-
II-277MeMeMeN(Me)Ph(CH 2 ) 2Phracemic
II-278MeMeMeN(Me)Ph(CH 2 ) 2Ph(R)-
II-279MeEtMeN(Me)Ph(CH 2 ) 2Phracemic
II-280MeEtMeN(Me)Ph(CH 2 ) 2Ph(R)-
II-281MeMeMeNHPh(CH 2 ) 3Hracemic
II-282MeMeMeNHPh(CH 2 ) 3H(R)-
II-283MeEtMeNHPh(CH 2 ) 3Hracemic
II-284MeEtMeNHPh(CH 2 ) 3H(R)-
II-285MeMeMeN(Me)Ph(CH 2 ) 3Hracemic
II-286MeMeMeN(Me)Ph(CH 2 ) 3H(R)-
II-287MeEtMeN(Me)Ph(CH 2 ) 3Hracemic
II-288MeEtMeN(Me)Ph(CH 2 ) 3H(R)-
II-289MeMeMeNHPh(CH 2 ) 4Hracemic
II-290MeMeMeNHPh(CH 2 ) 4H(R)-
II-291MeEtMeNHPh(CH 2 ) 4Hracemic
II-292MeEtMeNHPh(CH 2 ) 4H(R)-
II-293MeMeMeN(Me)Ph(CH 2 ) 4Hracemic
II-294MeMeMeN(Me)Ph(CH 2 ) 4H(R)-
II-295MeEtMeN(Me)Ph(CH 2 ) 4Hracemic
II-296MeEtMeN(Me)Ph(CH 2 ) 4H(R)-
II-297MeMeMeNHPhCH 2 C(Me) 2Hracemic
II-298MeMeMeNHPhCH 2 C(Me) 2H(R)-
II-299MeEtMeNHPhCH 2 C(Me) 2Hracemic
II-300MeEtMeNHPhCH 2 C(Me) 2H(R)-
TABLE 15 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-301MeMeMeN(Me)PhCH 2 C(Me) 2Hracemic
II-302MeMeMeN(Me)PhCH 2 C(Me) 2H(R)-
II-303MeEtMeN(Me)PhCH 2 C(Me) 2Hracemic
II-304MeEtMeN(Me)PhCH 2 C(Me) 2H(R)-
II-305MeMeMeNHPhCH 2 C(Me) 2Meracemic
II-306MeMeMeNHPhCH 2 C(Me) 2Me(R)-
II-307MeEtMeNHPhCH 2 C(Me) 2Meracemic
II-308MeEtMeNHPhCH 2 C(Me) 2Me(R)-
II-309MeMeMeN(Me)PhCH 2 C(Me) 2Meracemic
II-310MeMeMeN(Me)PhCH 2 C(Me) 2Me(R)-
II-311MeEtMeN(Me)PhCH 2 C(Me) 2Meracemic
II-312MeEtMeN(Me)PhCH 2 C(Me) 2Me(R)-
II-313MeMeMeNHPhCH 2 C(Me) 2CHF 2racemic
II-314MeMeMeNHPhCH 2 C(Me) 2CHF 2(R)-
II-315MeEtMeNHPhCH 2 C(Me) 2CHF 2racemic
II-316MeEtMeNHPhCH 2 C(Me) 2CHF 2(R)-
II-317MeMeMeN(Me)PhCH 2 C(Me) 2CHF 2racemic
II-318MeMeMeN(Me)PhCH 2 C(Me) 2CHF 2(R)-
II-319MeEtMeN(Me)PhCH 2 C(Me) 2CHF 2racemic
II-320MeEtMeN(Me)PhCH 2 C(Me) 2CHF 2(R)-
II-321MeMeMeNHPhCH 2 C(Me) 2Etracemic
II-322MeMeMeNHPhCH 2 C(Me) 2Et(R)-
II-323MeEtMeNHPhCH 2 C(Me) 2Etracemic
II-324MeEtMeNHPhCH 2 C(Me) 2Et(R)-
II-325MeMeMeN(Me)PhCH 2 C(Me) 2Etracemic
II-326MeMeMeN(Me)PhCH 2 C(Me) 2Et(R)-
II-327MeEtMeN(Me)PhCH 2 C(Me) 2Etracemic
II-328MeEtMeN(Me)PhCH 2 C(Me) 2Et(R)-
II-329MeMeMeNHPhCH 2 C(Me) 2iPrracemic
II-330MeMeMeNHPhCH 2 C(Me) 2iPr(R)-
II-331MeEtMeNHPhCH 2 C(Me) 2iPrracemic
II-332MeEtMeNHPhCH 2 C(Me) 2iPr(R)-
II-333MeMeMeN(Me)PhCH 2 C(Me) 2iPrracemic
II-334MeMeMeN(Me)PhCH 2 C(Me) 2iPr(R)-
II-335MeEtMeN(Me)PhCH 2 C(Me) 2iPrracemic
II-336MeEtMeN(Me)PhCH 2 C(Me) 2iPr(R)-
II-337MeMeMeNHPhCH 2 C(Me) 2cPrracemic
II-338MeMeMeNHPhCH 2 C(Me) 2cPr(R)-
II-339MeEtMeNHPhCH 2 C(Me) 2cPrracemic
II-340MeEtMeNHPhCH 2 C(Me) 2cPr(R)-
II-341MeMeMeN(Me)PhCH 2 C(Me) 2cPrracemic
II-342MeMeMeN(Me)PhCH 2 C(Me) 2cPr(R)-
II-343MeEtMeN(Me)PhCH 2 C(Me) 2cPrracemic
II-344MeEtMeN(Me)PhCH 2 C(Me) 2cPr(R)-
II-345MeMeMeNHPhCH 2 C(Me) 2Phracemic
II-346MeMeMeNHPhCH 2 C(Me) 2Ph(R)-
II-347MeEtMeNHPhCH 2 C(Me) 2Phracemic
II-348MeEtMeNHPhCH 2 C(Me) 2Ph(R)-
II-349MeMeMeN(Me)PhCH 2 C(Me) 2Phracemic
II-350MeMeMeN(Me)PhCH 2 C(Me) 2Ph(R)-
TABLE 16 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-351MeEtMeN(Me)PhCH 2 C(Me) 2Phracemic
II-352MeEtMeN(Me)PhCH 2 C(Me) 2Ph(R)-
II-353MeMeMeNHPhC(Me) 2 CH 2Hracemic
II-354MeMeMeNHPhC(Me) 2 CH 2H(S)-
II-355MeEtMeNHPhC(Me) 2 CH 2Hracemic
II-356MeEtMeNHPhC(Me) 2 CH 2H(S)-
II-357MeMeMeN(Me)PhC(Me) 2 CH 2Hracemic
II-358MeMeMeN(Me)PhC(Me) 2 CH 2H(S)-
II-359MeEtMeN(Me)PhC(Me) 2 CH 2Hracemic
II-360MeEtMeN(Me)PhC(Me) 2 CH 2H(S)-
II-361MeMeMeNHPhCF 2 CH 2Hracemic
II-362MeMeMeNHPhCF 2 CH 2H(S)-
II-363MeEtMeNHPhCF 2 CH 2Hracemic
II-364MeEtMeNHPhCF 2 CH 2H(S)-
II-365MeMeMeN(Me)PhCF 2 CH 2Hracemic
II-366MeMeMeN(Me)PhCF 2 CH 2H(S)-
II-367MeEtMeN(Me)PhCF 2 CH 2Hracemic
II-368MeEtMeN(Me)PhCF 2 CH 2H(S)-
II-369MeMeMeNHPhCH═CHCH 2Hracemic
II-370MeMeMeNHPhCH═CHCH 2H(S)-
II-371MeEtMeNHPhCH═CHCH 2Hracemic
II-372MeEtMeNHPhCH═CHCH 2H(S)-
II-373MeMeMeN(Me)PhCH═CHCH 2Hracemic
II-374MeMeMeN(Me)PhCH═CHCH 2H(S)-
II-375MeEtMeN(Me)PhCH═CHCH 2Hracemic
II-376MeEtMeN(Me)PhCH═CHCH 2H(S)-
II-377MeMeMeNHPhC≡CCH 2Hracemic
II-378MeMeMeNHPhC≡CCH 2H(S)-
II-379MeEtMeNHPhC≡CCH 2Hracemic
II-380MeEtMeNHPhC≡CCH 2H(S)-
II-381MeMeMeN(Me)PhC≡CCH 2Hracemic
II-382MeMeMeN(Me)PhC≡CCH 2H(S)-
II-383MeEtMeN(Me)PhC≡CCH 2Hracemic
II-384MeEtMeN(Me)PhC≡CCH 2H(S)-
II-385MeMeMeNHPh1,1-Cyclo-Hracemic
propylene
II-386MeMeMeNHPh1,1-Cyclo-H(S)-
propylene
II-387MeEtMeNHPh1,1-Cyclo-Hracemic
propylene
II-388MeEtMeNHPh1,1-Cyclo-H(S)-
propylene
II-389MeMeMeN(Me)Ph1,1-Cyclo-Hracemic
propylene
II-390MeMeMeN(Me)Ph1,1-Cyclo-H(S)-
propylene
II-391MeEtMeN(Me)Ph1,1-Cyclo-Hracemic
propylene
II-392MeEtMeN(Me)Ph1,1-Cyclo-H(S)-
propylene
II-393MeMeMeNHPh1,2-Cyclo-Hracemic
propynylene
II-394MeMeMeNHPh1,2-Cyclo-H(S)-
propynylene
II-395MeEtMeNHPh1,2-Cyclo-Hracemic
propynylene
II-396MeEtMeNHPh1,2-Cyclo-H(S)-
propynylene
II-397MeMeMeN(Me)Ph1,2-Cyclo-Hracemic
propynylene
II-398MeMeMeN(Me)Ph1,2-Cyclo-H(S)-
propynylene
II-399MeEtMeN(Me)Ph1,2-Cyclo-Hracemic
propynylene
II-400MeEtMeN(Me)Ph1,2-Cyclo-H(S)-
propynylene
TABLE 17 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-401MeMeMeNHPhC(═O)Hracemic
II-402MeMeMeNHPhC(═O)H(S)-
II-403MeEtMeNHPhC(═O)Hracemic
II-404MeEtMeNHPhC(═O)H(S)-
II-405MeMeMeN(Me)PhC(═O)Hracemic
II-406MeMeMeN(Me)PhC(═O)H(S)-
II-407MeEtMeN(Me)PhC(═O)Hracemic
II-408MeEtMeN(Me)PhC(═O)H(S)-
II-409MeMeMeNHPhC(═O)Bnracemic
II-410MeMeMeNHPhC(═O)Bn(S)-
II-411MeEtMeNHPhC(═O)Bnracemic
II-412MeEtMeNHPhC(═O)Bn(S)-
II-413MeMeMeN(Me)PhC(═O)Bnracemic
II-414MeMeMeN(Me)PhC(═O)Bn(S)-
II-415MeEtMeN(Me)PhC(═O)Bnracemic
II-416MeEtMeN(Me)PhC(═O)Bn(S)-
II-417MeMeMeNHPhC(═O)Meracemic
II-418MeMeMeNHPhC(═O)Me(S)-
II-419MeEtMeNHPhC(═O)Meracemic
II-420MeEtMeNHPhC(═O)Me(S)-
II-421MeMeMeN(Me)PhC(═O)Meracemic
II-422MeMeMeN(Me)PhC(═O)Me(S)-
II-423MeEtMeN(Me)PhC(═O)Meracemic
II-424MeEtMeN(Me)PhC(═O)Me(S)-
II-425MeMeMeNHHCH 2H
II-426MeEtMeNHHCH 2H
II-427MeMeMeN(Me)HCH 2H
II-428MeEtMeN(Me)HCH 2H
II-429MeMeMeNHHCH(Me)H
II-430MeEtMeNHHCH(Me)H
II-431MeMeMeN(Me)HCH(Me)H
II-432MeEtMeN(Me)HCH(Me)H
II-433MeMeMeNHHCH(iPr)H
II-434MeEtMeNHHCH(iPr)H
II-435MeMeMeN(Me)HCH(iPr)H
II-436MeEtMeN(Me)HCH(iPr)H
II-437MeMeMeNHHCH(Ph)H
II-438MeEtMeNHHCH(Ph)H
II-439MeMeMeN(Me)HCH(Ph)H
II-440MeEtMeN(Me)HCH(Ph)H
II-441MeMeMeNHMeCH 2Hracemic
II-442MeMeMeNHMeCH 2H(S)-
II-443MeEtMeNHMeCH 2Hracemic
II-444MeEtMeNHMeCH 2H(S)-
II-445MeMeMeN(Me)MeCH 2Hracemic
II-446MeMeMeN(Me)MeCH 2H(S)-
II-447MeEtMeN(Me)MeCH 2Hracemic
II-448MeEtMeN(Me)MeCH 2H(S)-
II-449MeMeMeNHiPrCH 2Hracemic
II-450MeMeMeNHiPrCH 2H(S)-
TABLE 18 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-451MeEtMeNHiPrCH 2Hracemic
II-452MeEtMeNHiPrCH 2H(S)-
II-453MeMeMeN(Me)iPrCH 2Hracemic
II-454MeMeMeN(Me)iPrCH 2H(S)-
II-455MeEtMeN(Me)iPrCH 2Hracemic
II-456MeEtMeN(Me)iPrCH 2H(S)-
II-457MeMeMeNHcHexCH 2Hracemic
II-458MeMeMeNHcHexCH 2H(S)-
II-459MeEtMeNHcHexCH 2Hracemic
II-460MeEtMeNHcHexCH 2H(S)-
II-461MeMeMeN(Me)cHexCH 2Hracemic
II-462MeMeMeN(Me)cHexCH 2H(S)-
II-463MeEtMeN(Me)cHexCH 2Hracemic
II-464MeEtMeN(Me)cHexCH 2H(S)-
II-465MeMeMeNH1,3-Benzodi-CH 2Hracemic
oxol-4-yl
II-466MeMeMeNH1,3-Benzodi-CH 2H(S)-
oxol-4-yl
II-467MeEtMeNH1,3-Benzodi-CH 2Hracemic
oxol-4-yl
II-468MeEtMeNH1,3-Benzodi-CH 2H(S)-
oxol-4-yl
II-469MeMeMeN(Me)1,3-Benzodi-CH 2Hracemic
oxol-4-yl
II-470MeMeMeN(Me)1,3 -Benzodi-CH 2H(S)-
oxol-4-yl
II-471MeEtMeN(Me)1,3-Benzodi-CH 2Hracemic
oxol-4-yl
II-472MeEtMeN(Me)1,3-Benzodi-CH 2H(S)-
oxol-4-yl
II-473MeMeMeNH2-F—PhCH 2Hracemic
II-474MeMeMeNH2-F—PhCH 2H(S)-
II-475MeEtMeNH2-F—PhCH 2Hracemic
II-476MeEtMeNH2-F—PhCH 2H(S)-
II-477MeMeMeN(Me)2-F—PhCH 2Hracemic
II-478MeMeMeN(Me)2-F—PhCH 2H(S)-
II-479MeEtMeN(Me)2-F—PhCH 2Hracemic
II-480MeEtMeN(Me)2-F—PhCH 2H(S)-
II-481MeMeMeNH3-F—PhCH 2Hracemic
II-482MeMeMeNH3-F—PhCH 2H(S)-
II-483MeEtMeNH3-F—PhCH 2Hracemic
II-484MeEtMeNH3-F—PhCH 2H(S)-
II-485MeMeMeN(Me)3-F—PhCH 2Hracemic
II-486MeMeMeN(Me)3-F—PhCH 2H(S)-
II-487MeEtMeN(Me)3-F—PhCH 2Hracemic
II-488MeEtMeN(Me)3-F—PhCH 2H(S)-
II-489MeMeMeNH4-F—PhCH 2Hracemic
II-490MeMeMeNH4-F—PhCH 2H(S)-
II-491MeEtMeNH4-F—PhCH 2Hracemic
II-492MeEtMeNH4-F—PhCH 2H(S)-
II-493MeMeMeN(Me)4-F—PhCH 2Hracemic
II-494MeMeMeN(Me)4-F—PhCH 2H(S)-
II-495MeEtMeN(Me)4-F—PhCH 2Hracemic
II-496MeEtMeN(Me)4-F—PhCH 2H(S)-
II-497MeMeMeNH2-PyCH 2Hracemic
II-498MeMeMeNH2-PyCH 2H(S)-
II-499MeEtMeNH2-PyCH 2Hracemic
II-500MeEtMeNH2-PyCH 2H(S)-
TABLE 19 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-501MeMeMeN(Me)2-PyCH 2Hracemic
II-502MeMeMeN(Me)2-PyCH 2H(S)-
II-503MeEtMeN(Me)2-PyCH 2Hracemic
II-504MeEtMeN(Me)2-PyCH 2H(S)-
II-505MeMeMeNH3-PyCH 2Hracemic
II-506MeMeMeNH3-PyCH 2H(S)-
II-507MeEtMeNH3-PyCH 2Hracemic
II-508MeEtMeNH3-PyCH 2H(S)-
II-509MeMeMeN(Me)3-PyCH 2Hracemic
II-510MeMeMeN(Me)3-PyCH 2H(S)-
II-511MeEtMeN(Me)3-PyCH 2Hracemic
II-512MeEtMeN(Me)3-PyCH 2H(S)-
II-513MeMeMeNH4-PyCH 2Hracemic
II-514MeMeMeNH4-PyCH 2H(S)-
II-515MeEtMeNH4-PyCH 2Hracemic
II-516MeEtMeNH4-PyCH 2H(S)-
II-517MeMeMeN(Me)4-PyCH 2Hracemic
II-518MeMeMeN(Me)4-PyCH 2H(S)-
II-519MeEtMeN(Me)4-PyCH 2Hracemic
II-520MeEtMeN(Me)4-PyCH 2H(S)-
II-521MeMeMeCH 2PhCH 2Hracemic
II-522MeMeMeCH 2PhCH 2H(S)-
II-523MeEtMeCH 2PhCH 2Hracemic
II-524MeEtMeCH 2PhCH 2H(S)-
II-525MeMeMeCH 2Ph—Hracemic
II-526MeMeMeCH 2Ph—H(S)-
II-527MeEtMeCH 2Ph—Hracemic
II-528MeEtMeCH 2Ph—H(S)-
II-529MeMeMeCH 2PhCH 2Meracemic
II-530MeMeMeCH 2PhCH 2Me(S)-
II-531MeEtMeCH 2PhCH 2Meracemic
II-532MeEtMeCH 2PhCH 2Me(S)-
II-533MeMeMeCH 2PhC(Me) 2Hracemic
II-534MeMeMeCH 2PhC(Me) 2H(S)-
II-535MeEtMeCH 2PhC(Me) 2Hracemic
II-536MeEtMeCH 2PhC(Me) 2H(S)-
II-537MeMeMeCH 2PhC(Me) 2Meracemic
II-538MeMeMeCH 2PhC(Me) 2Me(S)-
II-539MeEtMeCH 2PhC(Me) 2Meracemic
II-540MeEtMeCH 2PhC(Me) 2Me(S)-
II-541MeMeMeCH 2Ph(CH 2 ) 2Hracemic
II-542MeMeMeCH 2Ph(CH 2 ) 2H(S)-
II-543MeEtMeCH 2Ph(CH 2 ) 2Hracemic
II-544MeEtMeCH 2Ph(CH 2 ) 2H(S)-
II-545MeMeMeCH 2Ph(CH 2 ) 2Meracemic
II-546MeMeMeCH 2Ph(CH 2 ) 2Me(S)-
II-547MeEtMeCH 2Ph(CH 2 ) 2Meracemic
II-548MeEtMeCH 2Ph(CH 2 ) 2Me(S)-
II-549MeMeMeCH 2PhCH 2 C(Me) 2Hracemic
II-550MeMeMeCH 2PhCH 2 C(Me) 2H(S)-
TABLE 20 — (II)
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-551MeEtMeCH 2PhCH 2 C(Me) 2Hracemic
II-552MeEtMeCH 2PhCH 2 C(Me) 2H(S)-
II-553MeMeMeCH 2PhCH 2 C(Me) 2Meracemic
II-554MeMeMeCH 2PhCH 2 C(Me) 2Me(S)-
II-555MeEtMeCH 2PhCH 2 C(Me) 2Meracemic
II-556MeEtMeCH 2PhCH 2 C(Me) 2MeN-
II-557MeMeMe—PhCH 2Hracemic
II-558MeMeMe—PhCH 2H(S)-
II-559MeMeMe—PhCH 2Meracemic
II-560MeMeMe—PhCH 2Me(S)-
II-561MeMeMeCH═CHPhCH 2Hracemic
II-562MeMeMeCH═CHPhCH 2H(S)-
II-563MeMeMeCH═CHPhCH 2Meracemic
II-564MeMeMeCH═CHPhCH 2Me(S)-
II-565MeMeMeC≡CPhCH 2Hracemic
II-566MeMeMeC≡CPhCH 2H(S)-
II-567MeMeMeC≡CPhCH 2Meracemic
II-568MeMeMeC≡CPhCH 2Me(S)-
II-569MeMeMe1,2-Cyclopro-PhCH 2Hracemic
pylene
II-570MeMeMe1,2-Cyclopro-PhCH 2H(S)-
pylene
II-571MeMeMe1,2-Cyclopro-PhCH 2Meracemic
pylene
II-572MeMeMe1,2-Cyclopro-PhCH 2Me(S)-
pylene
II-573MeMeMe1,2-Cyclopro-PhCH 2Hracemic
pynylene
II-574MeMeMe1,2-Cyclopro-PhCH 2H(S)-
pynylene
II-575MeMeMe1,2-Cyclopro-PhCH 2Meracemic
pynylene
II-576MeMeMe1,2-Cyclopro-PhCH 2Me(S)-
pynylene
TABLE 21 — (II) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
II-577MeMeMeOPhC(Me) 2 CH 2Hracemic
II-578MeMeMeOPhC(Me) 2 CH 2H(+)
II-579MeMeMeOPhC(Me) 2 CH 2H(−)
II-580MeEtMeOPhC(Me) 2 CH 2Hracemic
II-581MeEtMeOPhC(Me) 2 CH 2H(+)
II-582MeEtMeOPhC(Me) 2 CH 2H(−)
II-583MeMeMeOPhC(Me) 2 CH 2Meracemic
II-584MeMeMeOPhC(Me) 2 CH 2Me(+)
II-585MeMeMeOPhC(Me) 2 CH 2Me(−)
II-586MeEtMeOPhC(Me) 2 CH 2Meracemic
II-587MeEtMeOPhC(Me) 2 CH 2Me(+)
II-588MeEtMeOPhC(Me) 2 CH 2Me(−)
II-589MeMeMeOPhC(Me) 2 CH 2CHF 2racemic
II-590MeMeMeOPhC(Me) 2 CH 2CHF 2(+)
II-591MeMeMeOPhC(Me) 2 CH 2CHF 2(−)
II-592MeMeMeOPhC(Me) 2 CH 2Etracemic
II-593MeMeMeOPhC(Me) 2 CH 2Et(+)
II-594MeMeMeOPhC(Me) 2 CH 2Et(−)
II-595MeMeMeNHPhC(Me) 2 CH 2H(+)
II-596MeMeMeNHPhC(Me) 2 CH 2H(−)
II-597MeEtMeNHPhC(Me) 2 CH 2H(+)
II-598MeEtMeNHPhC(Me) 2 CH 2H(−)
II-599MeMeMeNHPhC(Me) 2 CH 2Meracemic
II-600MeMeMeNHPhC(Me) 2 CH 2Me(+)
II-601MeMeMeNHPhC(Me) 2 CH 2Me(−)
II-602MeEtMeNHPhC(Me) 2 CH 2Meracemic
II-603MeEtMeNHPhC(Me) 2 CH 2Me(+)
II-604MeEtMeNHPhC(Me) 2 CH 2Me(−)
II-605MeMeMeNHPhC(Me) 2 CH 2CHF 2racemic
II-606MeMeMeNHPhC(Me) 2 CH 2CHF 2(+)
II-607MeMeMeNHPhC(Me) 2 CH 2CHF 2(−)
II-608MeEtMeNHPhC(Me) 2 CH 2CHF 2racemic
II-609MeEtMeNHPhC(Me) 2 CH 2CHF 2(+)
II-610MeEtMeNHPhC(Me) 2 CH 2CHF 2(−)
II-611MeMeMeNHPhC(Me) 2 CH 2Etracemic
II-612MeMeMeNHPhC(Me) 2 CH 2Et(+)
II-613MeMeMeNHPhC(Me) 2 CH 2Et(−)
II-614MeEtMeNHPhC(Me) 2 CH 2Etracemic
II-615MeEtMeNHPhC(Me) 2 CH 2Et(+)
II-616MeEtMeNHPhC(Me) 2 CH 2Et(−)
II-617MeMeMeNHPhC(Me) 2 CH 2iPrracemic
II-618MeMeMeNHPhC(Me) 2 CH 2iPr(+)
II-619MeMeMeNHPhC(Me) 2 CH 2iPr(−)
II-620MeEtMeNHPhC(Me) 2 CH 2iPrracemic
II-621MeEtMeNHPhC(Me) 2 CH 2iPr(+)
II-622MeEtMeNHPhC(Me) 2 CH 2iPr(−)
II-623MeMeMeNHPhC(Me) 2 CH 2cPrracemic
II-624MeMeMeNHPhC(Me) 2 CH 2cPr(+)
II-625MeMeMeNHPhC(Me) 2 CH 2cPr(−)
II-626MeEtMeNHPhC(Me) 2 CH 2cPrracemic
TABLE 22 — (II) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-627MeEtMeNHPhC(Me) 2 CH 2cPr(+)
II-628MeEtMeNHPhC(Me) 2 CH 2cPr(−)
II-629MeMeMeNHPh1,1-Cyclopropylene-CH 2Hracemic
II-630MeMeMeNHPh1,1-Cyclopropylene-CH 2H(+)
II-631MeMeMeNHPh1,1-Cyclopropylene-CH 2H(−)
II-632MeEtMeNHPh1,1-Cyclopropylene-CH 2Hracemic
II-633MeEtMeNHPh1,1-Cyclopropylene-CH 2H(+)
II-634MeEtMeNHPh1,1-Cyclopropylene-CH 2H(−)
II-635MeMeMeNHPh1,1-Cyclopropylene-CH 2Meracemic
II-636MeMeMeNHPh1,1-Cyclopropylene-CH 2Me(+)
II-637MeMeMeNHPh1,1-Cyclopropylene-CH 2Me(−)
II-638MeEtMeNHPh1,1-Cyclopropylene-CH 2Meracemic
II-639MeEtMeNHPh1,1-Cyclopropylene-CH 2Me(+)
II-640MeEtMeNHPh1,1-Cyclopropylene-CH 2Me(−)
II-641MeMeMeNHPh1,1-Cyclobutylene-CH 2Hracemic
II-642MeMeMeNHPh1,1-Cyclobutylene-CH 2H(+)
II-643MeMeMeNHPh1,1-Cyclobutylene-CH 2H(−)
II-644MeEtMeNHPh1,1-Cyclobutylene-CH 2Hracemic
II-645MeEtMeNHPh1,1-Cyclobutylene-CH 2H(+)
II-646MeEtMeNHPh1,1-Cyclobutylene-CH 2H(−)
II-647MeMeMeNHPh1,1-Cyclobutylene-CH 2Meracemic
II-648MeMeMeNHPh1,1-Cyclobutylene-CH 2Me(+)
II-649MeMeMeNHPh1,1-Cyclobutylene-CH 2Me(−)
II-650MeEtMeNHPh1,1-Cyclobutylene-CH 2Meracemic
II-651MeEtMeNHPh1,1-Cyclobutylene-CH 2Me(+)
II-652MeEtMeNHPh1,1-Cyclobutylene-CH 2Me(−)
II-653MeMeMeNHPhC(Et) 2 CH 2Hracemic
II-654MeMeMeNHPhC(Et) 2 CH 2H(+)
II-655MeMeMeNHPhC(Et) 2 CH 2H(−)
II-656MeEtMeNHPhC(Et) 2 CH 2Hracemic
II-657MeEtMeNHPhC(Et) 2 CH 2H(+)
II-658MeEtMeNHPhC(Et) 2 CH 2H(−)
II-659MeMeMeNHPhC(Et) 2 CH 2Meracemic
II-660MeMeMeNHPhC(Et) 2 CH 2Me(+)
II-661MeMeMeNHPhC(Et) 2 CH 2Me(−)
II-662MeEtMeNHPhC(Et) 2 CH 2Meracemic
II-663MeEtMeNHPhC(Et) 2 CH 2Me(+)
II-664MeEtMeNHPhC(Et) 2 CH 2Me(−)
II-665MeMeMeNHPhCH 2 -1,1-CyclopropyleneHracemic
II-666MeMeMeNHPhCH 2 -1,1-CyclopropyleneH(R)-
II-667MeEtMeNHPhCH 2 -1,1-CyclopropyleneHracemic
II-668MeEtMeNHPhCH 2 -1,1-CyclopropyleneH(R)-
II-669MeMeMeNHPhCH 2 -1,1-CyclopropyleneMeracemic
II-670MeMeMeNHPhCH 2 -1,1-CyclopropyleneMe(R)-
II-671MeEtMeNHPhCH 2 -1,1-CyclopropyleneMeracemic
II-672MeEtMeNHPhCH 2 -1,1-CyclopropyleneMe(R)-
II-673MeMeMeNHPhCH 2 -1,1-cyclobutyleneHracemic
II-674MeMeMeNHPhCH 2 -1,1-cyclobutyleneH(R)-
II-675MeEtMeNHPhCH 2 -1,1-cyclobutyleneHracemic
II-676MeEtMeNHPhCH 2 -1,1-cyclobutyleneH(R)-
TABLE 23 — (II)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-677MeMeMeNHPhCH 2 -1,1-Meracemic
cyclobutylene
II-678MeMeMeNHPhCH 2 -1,1-Me(R)-
cyclobutylene
II-679MeEtMeNHPhCH 2 -1,1-Meracemic
cyclobutylene
II-680MeEtMeNHPhCH 2 -1,1-Me(R)-
cyclobutylene
II-681MeMeMeNHPhCH 2 C(Et) 2Hracemic
II-682MeMeMeNHPhCH 2 C(Et) 2H(R)-
II-683MeEtMeNHPhCH 2 C(Et) 2Hracemic
II-684MeEtMeNHPhCH 2 C(Et) 2H(R)-
II-685MeMeMeNHPhCH 2 C(Et) 2Meracemic
II-686MeMeMeNHPhCH 2 C(Et) 2Me(R)-
II-687MeEtMeNHPhCH 2 C(Et) 2Meracemic
II-688MeEtMeNHPhCH 2 C(Et) 2Me(R)-
II-689MeMeMeNHiPrCH 2Meracemic
II-690MeMeMeNHiPrCH 2Me(S)-
II-691MeEtMeNHiPrCH 2Meracemic
II-692MeEtMeNHiPrCH 2Me(S)-
II-693MeMeMeNHiPr(CH 2 ) 2Hracemic
II-694MeMeMeNHiPr(CH 2 ) 2H(R)-
II-695MeEtMeNHiPr(CH 2 ) 2Hracemic
II-696MeEtMeNHiPr(CH 2 ) 2H(R)-
II-697MeMeMeNHiPr(CH 2 ) 2Meracemic
II-698MeMeMeNHiPr(CH 2 ) 2Me(R)-
II-699MeEtMeNHiPr(CH 2 ) 2Meracemic
II-700MeEtMeNHiPr(CH 2 ) 2Me(R)-
II-701MeMeMeNHCF 3CH 2Hracemic
II-702MeMeMeNHCF 3CH 2H(S)-
II-703MeEtMeNHCF 3CH 2Hracemic
II-704MeEtMeNHCF 3CH 2H(S)-
II-705MeMeMeNHCH 2 OHCH 2H
II-706MeEtMeNHCH 2 OHCH 2H
II-707MeMeMeNHCH 2 OMeCH 2Hracemic
II-708MeMeMeNHCH 2 OMeCH 2H(R)-
II-709MeEtMeNHCH 2 OMeCH 2Hracemic
II-710MeEtMeNHCH 2 OMeCH 2H(R)-
II-711MeMeMeNHCH 2 PhCH 2Hracemic
II-712MeMeMeNHCH 2 PhCH 2H(R)-
II-713MeMeMeNHCH 2 PhCH 2H(S)-
II-714MeEtMeNHCH 2 PhCH 2Hracemic
II-715MeEtMeNHCH 2 PhCH 2H(S)-
II-716MeMeMeNH2-F—PhCH 2Meracemic
II-717MeMeMeNH2-F—PhCH 2Me(S)-
II-718MeEtMeNH2-F—PhCH 2Meracemic
II-719MeEtMeNH2-F—PhCH 2Me(S)-
II-720MeMeMeNH2-F—Ph(CH 2 ) 2Hracemic
II-721MeMeMeNH2-F—Ph(CH 2 ) 2H(R)-
II-722MeEtMeNH2-F—Ph(CH 2 ) 2Hracemic
II-723MeEtMeNH2-F—Ph(CH 2 ) 2H(R)-
II-724MeMeMeNH2-F—Ph(CH 2 ) 2Meracemic
II-725MeMeMeNH2-F—Ph(CH 2 ) 2Me(R)-
II-726MeEtMeNH2-F—Ph(CH 2 ) 2Meracemic
TABLE 24 — (II)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-727MeEtMeNH2-F—Ph(CH 2 ) 2Me(R)-
II-728MeMeMeNH2-F—PhCH 2 C(Me) 2Hracemic
II-729MeMeMeNH2-F—PhCH 2 C(Me) 2H(R)-
II-730MeEtMeNH2-F—PhCH 2 C(Me) 2Hracemic
II-731MeEtMeNH2-F—PhCH 2 C(Me) 2H(R)-
II-732MeMeMeNH2-F—PhCH 2 C(Me) 2Meracemic
II-733MeMeMeNH2-F—PhCH 2 C(Me) 2Me(R)-
II-734MeEtMeNH2-F—PhCH 2 C(Me) 2Meracemic
II-735MeEtMeNH2-F—PhCH 2 C(Me) 2Me(R)-
II-736MeMeMeNH2-F—PhC(Me) 2 CH 2Hracemic
II-737MeMeMeNH2-F—PhC(Me) 2 CH 2H(+)
II-738MeMeMeNH2-F—PhC(Me) 2 CH 2H(−)
II-739MeEtMeNH2-F—PhC(Me) 2 CH 2Hracemic
II-740MeEtMeNH2-F—PhC(Me) 2 CH 2H(+)
II-741MeEtMeNH2-F—PhC(Me) 2 CH 2H(−)
II-742MeMeMeNH2-F—PhC(Me) 2 CH 2Meracemic
II-743MeMeMeNH2-F—PhC(Me) 2 CH 2Me(+)
II-744MeMeMeNH2-F—PhC(Me) 2 CH 2Me(−)
II-745MeEtMeNH2-F—PhC(Me) 2 CH 2Meracemic
II-746MeEtMeNH2-F—PhC(Me) 2 CH 2Me(+)
II-747MeEtMeNH2-F—PhC(Me) 2 CH 2Me(−)
II-748MeMeMeNH3-F—Ph(CH 2 ) 2Hracemic
II-749MeMeMeNH3-F—Ph(CH 2 ) 2H(R)-
II-750MeEtMeNH3-F—Ph(CH 2 ) 2Hracemic
II-751MeEtMeNH3-F—Ph(CH 2 ) 2H(R)-
II-752MeMeMeNH3-F—Ph(CH 2 ) 2Meracemic
II-753MeMeMeNH3-F—Ph(CH 2 ) 2Me(R)-
II-754MeEtMeNH3-F—Ph(CH 2 ) 2Meracemic
II-755MeEtMeNH3-F—Ph(CH 2 ) 2Me(R)-
II-756MeMeMeNH3-F—PhCH 2 C(Me) 2Hracemic
II-757MeMeMeNH3-F—PhCH 2 C(Me) 2H(R)-
II-758MeEtMeNH3-F—PhCH 2 C(Me) 2Hracemic
II-759MeEtMeNH3-F—PhCH 2 C(Me) 2H(R)-
II-760MeMeMeNH3-F—PhCH 2 C(Me) 2Meracemic
II-761MeMeMeNH3-F—PhCH 2 C(Me) 2Me(R)-
II-762MeEtMeNH3-F—PhCH 2 C(Me) 2Meracemic
II-763MeEtMeNH3-F—PhCH 2 C(Me) 2Me(R)-
II-764MeMeMeNH3-F—PhC(Me) 2 CH 2Hracemic
II-765MeMeMeNH3-F—PhC(Me) 2 CH 2H(+)
II-766MeMeMeNH3-F—PhC(Me) 2 CH 2H(−)
II-767MeEtMeNH3-F—PhC(Me) 2 CH 2Hracemic
II-768MeEtMeNH3-F—PhC(Me) 2 CH 2H(+)
II-769MeEtMeNH3-F—PhC(Me) 2 CH 2H(−)
II-770MeMeMeNH3-F—PhC(Me) 2 CH 2Meracemic
II-771MeMeMeNH3-F—PhC(Me) 2 CH 2Me(+)
II-772MeMeMeNH3-F—PhC(Me) 2 CH 2Me(−)
II-773MeEtMeNH3-F—PhC(Me) 2 CH 2Meracemic
II-774MeEtMeNH3-F—PhC(Me) 2 CH 2Me(+)
II-775MeEtMeNH3-F—PhC(Me) 2 CH 2Me(−)
II-776MeMeMeNH4-F—Ph(CH 2 ) 2Hracemic
TABLE 25 — (II)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-777MeMeMeNH4-F—Ph(CH 2 ) 2H(R)-
II-778MeEtMeNH4-F—Ph(CH 2 ) 2Hracemic
II-779MeEtMeNH4-F—Ph(CH 2 ) 2H(R)-
II-780MeMeMeNH4-F—Ph(CH 2 ) 2Meracemic
II-781MeMeMeNH4-F—Ph(CH 2 ) 2Me(R)-
II-782MeEtMeNH4-F—Ph(CH 2 ) 2Meracemic
II-783MeEtMeNH4-F—Ph(CH 2 ) 2Me(R)-
II-784MeMeMeNH4-F—PhCH 2 C(Me) 2Hracemic
II-785MeMeMeNH4-F—PhCH 2 C(Me) 2H(R)-
II-786MeEtMeNH4-F—PhCH 2 C(Me) 2Hracemic
II-787MeEtMeNH4-F—PhCH 2 C(Me) 2H(R)-
II-788MeMeMeNH4-F—PhCH 2 C(Me) 2Meracemic
II-789MeMeMeNH4-F—PhCH 2 C(Me) 2Me(R)-
II-790MeEtMeNH4-F—PhCH 2 C(Me) 2Meracemic
II-791MeEtMeNH4-F—PhCH 2 C(Me) 2Me(R)-
II-792MeMeMeNH4-F—PhC(Me) 2 CH 2Hracemic
II-793MeMeMeNH4-F—PhC(Me) 2 CH 2H(+)
II-794MeMeMeNH4-F—PhC(Me) 2 CH 2H(−)
II-795MeEtMeNH4-F—PhC(Me) 2 CH 2Hracemic
II-796MeEtMeNH4-F—PhC(Me) 2 CH 2H(+)
II-797MeEtMeNH4-F—PhC(Me) 2 CH 2H(−)
II-798MeMeMeNH4-F—PhC(Me) 2 CH 2Meracemic
II-799MeMeMeNH4-F—PhC(Me) 2 CH 2Me(+)
II-800MeMeMeNH4-F—PhC(Me) 2 CH 2Me(−)
II-801MeEtMeNH4-F—PhC(Me) 2 CH 2Meracemic
II-802MeEtMeNH4-F—PhC(Me) 2 CH 2Me(+)
II-803MeEtMeNH4-F—PhC(Me) 2 CH 2Me(−)
II-804MeMeMeNH2-Cl—PhCH 2Hracemic
II-805MeMeMeNH2-Cl—PhCH 2H(S)-
II-806MeEtMeNH2-Cl—PhCH 2Hracemic
II-807MeEtMeNH2-Cl—PhCH 2H(S)-
II-808MeMeMeNH2-Cl—PhCH 2Meracemic
II-809MeMeMeNH2-Cl—PhCH 2Me(S)-
II-810MeEtMeNH2-Cl—PhCH 2Meracemic
II-811MeEtMeNH2-Cl—PhCH 2Me(S)-
II-812MeMeMeNH2-Cl—Ph(CH 2 ) 2Hracemic
II-813MeMeMeNH2-Cl—Ph(CH 2 ) 2H(R)-
II-814MeEtMeNH2-Cl—Ph(CH 2 ) 2Hracemic
II-815MeEtMeNH2-Cl—Ph(CH 2 ) 2H(R)-
II-816MeMeMeNH2-Cl—Ph(CH 2 ) 2Meracemic
II-817MeMeMeNH2-Cl—Ph(CH 2 ) 2Me(R)-
II-818MeEtMeNH2-Cl—Ph(CH 2 ) 2Meracemic
II-819MeEtMeNH2-Cl—Ph(CH 2 ) 2Me(R)-
II-820MeMeMeNH2-Cl—PhCH 2 C(Me) 2Hracemic
II-821MeMeMeNH2-Cl—PhCH 2 C(Me) 2H(R)-
II-822MeEtMeNH2-Cl—PhCH 2 C(Me) 2Hracemic
II-823MeEtMeNH2-Cl—PhCH 2 C(Me) 2H(R)-
II-824MeMeMeNH2-Cl—PhCH 2 C(Me) 2Meracemic
II-825MeMeMeNH2-Cl—PhCH 2 C(Me) 2Me(R)-
II-826MeEtMeNH2-Cl—PhCH 2 C(Me) 2Meracemic
TABLE 26 — (II)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-827MeEtMeNH2-Cl—PhCH 2 C(Me) 2Me(R)-
II-828MeMeMeNH2-Cl—PhC(Me) 2 CH 2Hracemic
II-829MeMeMeNH2-Cl—PhC(Me) 2 CH 2H(+)
II-830MeMeMeNH2-Cl—PhC(Me) 2 CH 2H(−)
II-831MeEtMeNH2-Cl—PhC(Me) 2 CH 2Hracemic
II-832MeEtMeNH2-Cl—PhC(Me) 2 CH 2H(+)
II-833MeEtMeNH2-Cl—PhC(Me) 2 CH 2H(−)
II-834MeMeMeNH2-Cl—PhC(Me) 2 CH 2Meracemic
II-835MeMeMeNH2-Cl—PhC(Me) 2 CH 2Me(+)
II-836MeMeMeNH2-Cl—PhC(Me) 2 CH 2Me(−)
II-837MeEtMeNH2-Cl—PhC(Me) 2 CH 2Meracemic
II-838MeEtMeNH2-Cl—PhC(Me) 2 CH 2Me(+)
II-839MeEtMeNH2-Cl—PhC(Me) 2 CH 2Me(−)
II-840MeMeMeNH3-Cl—PhCH 2Hracemic
II-841MeMeMeNH3-Cl—PhCH 2H(S)-
II-842MeEtMeNH3-Cl—PhCH 2Hracemic
II-843MeEtMeNH3-Cl—PhCH 2H(S)-
II-844MeMeMeNH3-Cl—PhCH 2Meracemic
II-845MeMeMeNH3-Cl—PhCH 2Me(S)-
II-846MeEtMeNH3-Cl—PhCH 2Meracemic
II-847MeEtMeNH3-Cl—PhCH 2Me(S)-
II-848MeMeMeNH3-Cl—Ph(CH 2 ) 2Hracemic
II-849MeMeMeNH3-Cl—Ph(CH 2 ) 2H(R)-
II-850MeEtMeNH3-Cl—Ph(CH 2 ) 2Hracemic
II-851MeEtMeNH3-Cl—Ph(CH 2 ) 2H(R)-
II-852MeMeMeNH3-Cl—Ph(CH 2 ) 2Meracemic
II-853MeMeMeNH3-Cl—Ph(CH 2 ) 2Me(R)-
II-854MeEtMeNH3-Cl—Ph(CH 2 ) 2Meracemic
II-855MeEtMeNH3-Cl—Ph(CH 2 ) 2Me(R)-
II-856MeMeMeNH3-Cl—PhCH 2 C(Me) 2Hracemic
II-857MeMeMeNH3-Cl—PhCH 2 C(Me) 2H(R)-
II-858MeEtMeNH3-Cl—PhCH 2 C(Me) 2Hracemic
II-859MeEtMeNH3-Cl—PhCH 2 C(Me) 2H(R)-
II-860MeMeMeNH3-Cl—PhCH 2 C(Me) 2Meracemic
II-861MeMeMeNH3-Cl—PhCH 2 C(Me) 2Me(R)-
II-862MeEtMeNH3-Cl—PhCH 2 C(Me) 2Meracemic
II-863MeEtMeNH3-Cl—PhCH 2 C(Me) 2Me(R)-
II-864MeMeMeNH3-Cl—PhC(Me) 2 CH 2Hracemic
II-865MeMeMeNH3-Cl—PhC(Me) 2 CH 2H(+)
II-866MeMeMeNH3-Cl—PhC(Me) 2 CH 2H(−)
II-867MeEtMeNH3-Cl—PhC(Me) 2 CH 2Hracemic
II-868MeEtMeNH3-Cl—PhC(Me) 2 CH 2H(+)
II-869MeEtMeNH3-Cl—PhC(Me) 2 CH 2H(−)
II-870MeMeMeNH3-Cl—PhC(Me) 2 CH 2Meracemic
II-871MeMeMeNH3-Cl—PhC(Me) 2 CH 2Me(+)
II-872MeMeMeNH3-Cl—PhC(Me) 2 CH 2Me(−)
II-873MeEtMeNH3-Cl—PhC(Me) 2 CH 2Meracemic
II-874MeEtMeNH3-Cl—PhC(Me) 2 CH 2Me(+)
II-875MeEtMeNH3-Cl—PhC(Me) 2 CH 2Me(−)
II-876MeMeMeNH4-Cl—PhCH 2Hracemic
TABLE 27 — (II)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-877MeMeMeNH4-Cl—PhCH 2H(S)-
II-878MeEtMeNH4-Cl—PhCH 2Hracemic
II-879MeEtMeNH4-Cl—PhCH 2H(S)-
II-880MeMeMeNH4-Cl—PhCH 2Meracemic
II-881MeMeMeNH4-Cl—PhCH 2Me(S)-
II-882MeEtMeNH4-Cl—PhCH 2Meracemic
II-883MeEtMeNH4-Cl—PhCH 2Me(S)-
II-884MeMeMeNH4-Cl—Ph(CH 2 ) 2Hracemic
II-885MeMeMeNH4-Cl—Ph(CH 2 ) 2H(R)-
II-886MeEtMeNH4-Cl—Ph(CH 2 ) 2Hracemic
II-887MeEtMeNH4-Cl—Ph(CH 2 ) 2H(R)-
II-888MeMeMeNH4-Cl—Ph(CH 2 ) 2Meracemic
II-889MeMeMeNH4-Cl—Ph(CH 2 ) 2Me(R)-
II-890MeEtMeNH4-Cl—Ph(CH 2 ) 2Meracemic
II-891MeEtMeNH4-Cl—Ph(CH 2 ) 2Me(R)-
II-892MeMeMeNH4-Cl—PhCH 2 C(Me) 2Hracemic
II-893MeMeMeNH4-Cl—PhCH 2 C(Me) 2H(R)-
II-894MeEtMeNH4-Cl—PhCH 2 C(Me) 2Hracemic
II-895MeEtMeNH4-Cl—PhCH 2 C(Me) 2H(R)-
II-896MeMeMeNH4-Cl—PhCH 2 C(Me) 2Meracemic
II-897MeMeMeNH4-Cl—PhCH 2 C(Me) 2Me(R)-
II-898MeEtMeNH4-Cl—PhCH 2 C(Me) 2Meracemic
II-899MeEtMeNH4-Cl—PhCH 2 C(Me) 2Me(R)-
II-900MeMeMeNH4-Cl—PhC(Me) 2 CH 2Hracemic
II-901MeMeMeNH4-Cl—PhC(Me) 2 CH 2H(+)
II-902MeMeMeNH4-Cl—PhC(Me) 2 CH 2H(−)
II-903MeEtMeNH4-Cl—PhC(Me) 2 CH 2Hracemic
II-904MeEtMeNH4-Cl—PhC(Me) 2 CH 2H(+)
II-905MeEtMeNH4-Cl—PhC(Me) 2 CH 2H(−)
II-906MeMeMeNH4-Cl—PhC(Me) 2 CH 2Meracemic
II-907MeMeMeNH4-Cl—PhC(Me) 2 CH 2Me(+)
II-908MeMeMeNH4-Cl—PhC(Me) 2 CH 2Me(−)
II-909MeEtMeNH4-Cl—PhC(Me) 2 CH 2Meracemic
II-910MeEtMeNH4-Cl—PhC(Me) 2 CH 2Me(+)
II-911MeEtMeNH4-Cl—PhC(Me) 2 CH 2Me(−)
II-912MeMeMeNH2-Me—PhCH 2Hracemic
II-913MeMeMeNH2-Me—PhCH 2H(S)-
II-914MeEtMeNH2-Me—PhCH 2Hracemic
II-915MeEtMeNH2-Me—PhCH 2H(S)-
II-916MeMeMeNH2-Me—PhCH 2Meracemic
II-917MeMeMeNH2-Me—PhCH 2Me(S)-
II-918MeEtMeNH2-Me—PhCH 2Meracemic
II-919MeEtMeNH2-Me—PhCH 2Me(S)-
II-920MeMeMeNH2-Me—Ph(CH 2 ) 2Hracemic
II-921MeMeMeNH2-Me—Ph(CH 2 ) 2H(R)-
II-922MeEtMeNH2-Me—Ph(CH 2 ) 2Hracemic
II-923MeEtMeNH2-Me—Ph(CH 2 ) 2H(R)-
II-924MeMeMeNH2-Me—Ph(CH 2 ) 2Meracemic
II-925MeMeMeNH2-Me—Ph(CH 2 ) 2Me(R)-
II-926MeEtMeNH2-Me—Ph(CH 2 ) 2Meracemic
TABLE 28 — (II)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-927MeEtMeNH2-Me—Ph(CH 2 ) 2Me(R)-
II-928MeMeMeNH2-Me—PhCH 2 C(Me) 2Hracemic
II-929MeMeMeNH2-Me—PhCH 2 C(Me) 2H(R)-
II-930MeEtMeNH2-Me—PhCH 2 C(Me) 2Hracemic
II-931MeEtMeNH2-Me—PhCH 2 C(Me) 2H(R)-
II-932MeMeMeNH2-Me—PhCH 2 C(Me) 2Meracemic
II-933MeMeMeNH2-Me—PhCH 2 C(Me) 2Me(R)-
II-934MeEtMeNH2-Me—PhCH 2 C(Me) 2Meracemic
II-935MeEtMeNH2-Me—PhCH 2 C(Me) 2Me(R)-
II-936MeMeMeNH2-Me—PhC(Me) 2 CH 2Hracemic
II-937MeMeMeNH2-Me—PhC(Me) 2 CH 2H(+)
II-938MeMeMeNH2-Me—PhC(Me) 2 CH 2H(−)
II-939MeEtMeNH2-Me—PhC(Me) 2 CH 2Hracemic
II-940MeEtMeNH2-Me—PhC(Me) 2 CH 2H(+)
II-941MeEtMeNH2-Me—PhC(Me) 2 CH 2H(−)
II-942MeMeMeNH2-Me—PhC(Me) 2 CH 2Meracemic
II-943MeMeMeNH2-Me—PhC(Me) 2 CH 2Me(+)
II-944MeMeMeNH2-Me—PhC(Me) 2 CH 2Me(−)
II-945MeEtMeNH2-Me—PhC(Me) 2 CH 2Meracemic
II-946MeEtMeNH2-Me—PhC(Me) 2 CH 2Me(+)
II-947MeEtMeNH2-Me—PhC(Me) 2 CH 2Me(−)
II-948MeMeMeNH3-Me—PhCH 2Hracemic
II-949MeMeMeNH3-Me—PhCH 2H(S)-
II-950MeEtMeNH3-Me—PhCH 2Hracemic
II-951MeEtMeNH3-Me—PhCH 2H(S)-
II-952MeMeMeNH3-Me—PhCH 2Meracemic
II-953MeMeMeNH3-Me—PhCH 2Me(S)-
II-954MeEtMeNH3-Me—PhCH 2Meracemic
II-955MeEtMeNH3-Me—PhCH 2Me(S)-
II-956MeMeMeNH3-Me—Ph(CH 2 ) 2Hracemic
II-957MeMeMeNH3-Me—Ph(CH 2 ) 2H(R)-
II-958MeEtMeNH3-Me—Ph(CH 2 ) 2Hracemic
II-959MeEtMeNH3-Me—Ph(CH 2 ) 2H(R)-
II-960MeMeMeNH3-Me—Ph(CH 2 ) 2Meracemic
II-961MeMeMeNH3-Me—Ph(CH 2 ) 2Me(R)-
II-962MeEtMeNH3-Me—Ph(CH 2 ) 2Meracemic
II-963MeEtMeNH3-Me—Ph(CH 2 ) 2Me(R)-
II-964MeMeMeNH3-Me—PhCH 2 C(Me) 2Hracemic
II-965MeMeMeNH3-Me—PhCH 2 C(Me) 2H(R)-
II-966MeEtMeNH3-Me—PhCH 2 C(Me) 2Hracemic
II-967MeEtMeNH3-Me—PhCH 2 C(Me) 2H(R)-
II-968MeMeMeNH3-Me—PhCH 2 C(Me) 2Meracemic
II-969MeMeMeNH3-Me—PhCH 2 C(Me) 2Me(R)-
II-970MeEtMeNH3-Me—PhCH 2 C(Me) 2Meracemic
II-971MeEtMeNH3-Me—PhCH 2 C(Me) 2Me(R)-
II-972MeMeMeNH3-Me—PhC(Me) 2 CH 2Hracemic
II-973MeMeMeNH3-Me—PhC(Me) 2 CH 2H(+)
II-974MeMeMeNH3-Me—PhC(Me) 2 CH 2H(−)
II-975MeEtMeNH3-Me—PhC(Me) 2 CH 2Hracemic
II-976MeEtMeNH3-Me—PhC(Me) 2 CH 2H(+)
TABLE 29 — (II)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-977MeEtMeNH3-Me—PhC(Me) 2 CH 2H(−)
II-978MeMeMeNH3-Me—PhC(Me) 2 CH 2Meracemic
II-979MeMeMeNH3-Me—PhC(Me) 2 CH 2Me(+)
II-980MeMeMeNH3-Me—PhC(Me) 2 CH 2Me(−)
II-981MeEtMeNH3-Me—PhC(Me) 2 CH 2Meracemic
II-982MeEtMeNH3-Me—PhC(Me) 2 CH 2Me(+)
II-983MeEtMeNH3-Me—PhC(Me) 2 CH 2Me(−)
II-984MeMeMeNH4-Me—PhCH 2Hracemic
II-985MeMeMeNH4-Me—PhCH 2H(S)-
II-986MeEtMeNH4-Me—PhCH 2Hracemic
II-987MeEtMeNH4-Me—PhCH 2H(S)-
II-988MeMeMeNH4-Me—PhCH 2Meracemic
II-989MeMeMeNH4-Me—PhCH 2Me(S)-
II-990MeEtMeNH4-Me—PhCH 2Meracemic
II-991MeEtMeNH4-Me—PhCH 2Me(S)-
II-992MeMeMeNH4-Me—Ph(CH 2 ) 2Hracemic
II-993MeMeMeNH4-Me—Ph(CH 2 ) 2H(R)-
II-994MeEtMeNH4-Me—Ph(CH 2 ) 2Hracemic
II-995MeEtMeNH4-Me—Ph(CH 2 ) 2H(R)-
II-996MeMeMeNH4-Me—Ph(CH 2 ) 2Meracemic
II-997MeMeMeNH4-Me—Ph(CH 2 ) 2Me(R)-
II-998MeEtMeNH4-Me—Ph(CH 2 ) 2Meracemic
II-999MeEtMeNH4-Me—Ph(CH 2 ) 2Me(R)-
II-1000MeMeMeNH4-Me—PhCH 2 C(Me) 2Hracemic
II-1001MeMeMeNH4-Me—PhCH 2 C(Me) 2H(R)-
II-1002MeEtMeNH4-Me—PhCH 2 C(Me) 2Hracemic
II-1003MeEtMeNH4-Me—PhCH 2 C(Me) 2H(R)-
II-1004MeMeMeNH4-Me—PhCH 2 C(Me) 2Meracemic
II-1005MeMeMeNH4-Me—PhCH 2 C(Me) 2Me(R)-
II-1006MeEtMeNH4-Me—PhCH 2 C(Me) 2Meracemic
II-1007MeEtMeNH4-Me—PhCH 2 C(Me) 2Me(R)-
II-1008MeMeMeNH4-Me—PhC(Me) 2 CH 2Hracemic
II-1009MeMeMeNH4-Me—PhC(Me) 2 CH 2H(+)
II-1010MeMeMeNH4-Me—PhC(Me) 2 CH 2H(−)
II-1011MeEtMeNH4-Me—PhC(Me) 2 CH 2Hracemic
II-1012MeEtMeNH4-Me—PhC(Me) 2 CH 2H(+)
II-1013MeEtMeNH4-Me—PhC(Me) 2 CH 2H(−)
II-1014MeMeMeNH4-Me—PhC(Me) 2 CH 2Meracemic
II-1015MeMeMeNH4-Me—PhC(Me) 2 CH 2Me(+)
II-1016MeMeMeNH4-Me—PhC(Me) 2 CH 2Me(−)
II-1017MeEtMeNH4-Me—PhC(Me) 2 CH 2Meracemic
II-1018MeEtMeNH4-Me—PhC(Me) 2 CH 2Me(+)
II-1019MeEtMeNH4-Me—PhC(Me) 2 CH 2Me(−)
II-1020MeMeMe—Ph—Hracemic
II-1021MeMeMe—Ph—H(R)-
II-1022MeEtMe—Ph—Hracemic
II-1023MeEtMe—Ph—H(R)-
II-1024MeMeMe—Ph—Meracemic
II-1025MeMeMe—Ph—Me(R)-
II-1026MeEtMe—Ph—Meracemic
TABLE 30 — (II) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
II-1027MeEtMe—Ph—Me(R)-
II-1028MeMeMe—Ph—CHF 2racemic
II-1029MeMeMe—Ph—CHF 2(R)-
II-1030MeEtMe—Ph—CHF 2racemic
II-1031MeEtMe—Ph—CHF 2(R)-
II-1032MeMeMe—Ph—CF 3racemic
II-1033MeMeMe—Ph—CF 3(R)-
II-1034MeEtMe—Ph—CF 3racemic
II-1035MeEtMe—Ph—CF 3(R)-
II-1036MeMeMe—Ph—Etracemic
II-1037MeMeMe—Ph—Et(R)-
II-1038MeEtMe—Ph—Etracemic
II-1039MeEtMe—Ph—Et(R)-
II-1040MeMeMe—Ph—CF 2 CH 3racemic
II-1041MeMeMe—Ph—CF 2 CH 3(R)-
II-1042MeEtMe—Ph—CF 2 CH 3racemic
II-1043MeEtMe—Ph—CF 2 CH 3(R)-
II-1044MeMeMe—Ph—nPrracemic
II-1045MeMeMe—Ph—nPr(R)-
II-1046MeEtMe—Ph—nPrracemic
II-1047MeEtMe—Ph—nPr(R)-
II-1048MeMeMe—Ph—nBuracemic
II-1049MeMeMe—Ph—nBu(R)-
II-1050MeEtMe—Ph—nBuracemic
II-1051MeEtMe—Ph—nBu(R)-
II-1052MeMeMe—Ph—iPrracemic
II-1053MeMeMe—Ph—iPr(R)-
II-1054MeEtMe—Ph—iPrracemic
II-1055MeEtMe—Ph—iPr(R)-
II-1056MeMeMe—Ph—cPrracemic
II-1057MeMeMe—Ph—cPr(R)-
II-1058MeEtMe—Ph—cPrracemic
II-1059MeEtMe—Ph—cPr(R)-
II-1060MeMeMe—Ph—Phracemic
II-1061MeMeMe—Ph—Ph(R)-
II-1062MeEtMe—Ph—Phracemic
II-1063MeEtMe—Ph—Ph(R)-
II-1064MeMeMe—PhCH 2CHF 2racemic
II-1065MeMeMe—PhCH 2CHF 2(S)-
II-1066MeMeMe—PhCH 2Etracemic
II-1067MeMeMe—PhCH 2Et(S)-
II-1068MeMeMe—PhCH 2Phracemic
II-1069MeMeMe—PhCH 2Ph(R)-
II-1070MeMeMe—Ph(CH 2 ) 2Hracemic
II-1071MeMeMe—Ph(CH 2 ) 2H(S)-
II-1072MeMeMe—Ph(CH 2 ) 2Meracemic
II-1073MeMeMe—Ph(CH 2 ) 2Me(S)-
II-1074MeMeMe—Ph(CH 2 ) 2CHF 2racemic
II-1075MeMeMe—Ph(CH 2 ) 2CHF 2(S)-
II-1076MeMeMe—Ph(CH 2 ) 2Etracemic
TABLE 31 — (II) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
II-1077MeMeMe—Ph(CH 2 ) 2Et(S)-
II-1078MeMeMe—H—H
II-1079MeMeMe—H—Me
II-1080MeMeMe—H—CHF 2
II-1081MeMeMe—H—CF 3
II-1082MeMeMe—H—Et
II-1083MeMeMe—H—nPr
II-1084MeMeMe—H—iPr
II-1085MeMeMe—H—cPr
II-1086MeMeMe—H—Ph
II-1087MeMeMe—Me—Hracemic
II-1088MeMeMe—Me—H(R)-
II-1089MeMeMe—Me—Meracemic
II-1090MeMeMe—Me—Me(R)-
II-1091MeMeMe—Me—CHF 2racemic
II-1092MeMeMe—Me—CHF 2(R)-
II-1093MeMeMe—Me—CF 3racemic
II-1094MeMeMe—Me—CF 3(R)-
II-1095MeMeMe—Me—Etracemic
II-1096MeMeMe—Me—Et(R)-
II-1097MeMeMe—Me—nPrracemic
II-1098MeMeMe—Me—nPr(R)-
II-1099MeMeMe—Me—iPrracemic
II-1100MeMeMe—Me—iPr(R)-
II-1101MeMeMe—Me—cPrracemic
II-1102MeMeMe—Me—cPr(R)-
II-1103MeMeMe—Me—cHexracemic
II-1104MeMeMe—Me—cHex(R)-
II-1105MeMeMe—Me—Phracemic
II-1106MeMeMe—Me—Ph(R)-
II-1107MeMeMe—Me—2-F—Phracemic
II-1108MeMeMe—Me—2-F—Ph(R)-
II-1109MeMeMe—Me—3-F—Phracemic
II-1110MeMeMe—Me—3-F—Ph(R)-
II-1111MeMeMe—Me—4-F—Phracemic
II-1112MeMeMe—Me—4-F—Ph(R)-
II-1113MeMeMe—Me—2-Cl—Phracemic
II-1114MeMeMe—Me—2-Cl—Ph(R)-
II-1115MeMeMe—Me—3-Cl—Phracemic
II-1116MeMeMe—Me—3-Cl—Ph(R)-
II-1117MeMeMe—Me—4-Cl—Phracemic
II-1118MeMeMe—Me—4-Cl—Ph(R)-
II-1119MeMeMe—Me—2-Pyracemic
II-1120MeMeMe—Me—2-Py(R)-
II-1121MeMeMe—Me—3-Pyracemic
II-1122MeMeMe—Me—3-Py(R)-
II-1123MeMeMe—Me—4-Pyracemic
II-1124MeMeMe—Me—4-Py(R)-
II-1125MeMeMe—iPr—Hracemic
II-1126MeMeMe—iPr—H(R)-
TABLE 32 — (II) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
II-1127MeMeMe—iPr—Meracemic
II-1128MeMeMe—iPr—Me(R)-
II-1129MeMeMe—iPr—CHF 2racemic
II-1130MeMeMe—iPr—CHF 2(R)-
II-1131MeMeMe—iPr—CF 3racemic
II-1132MeMeMe—iPr—CF 3(R)-
II-1133MeMeMe—iPr—Etracemic
II-1134MeMeMe—iPr—Et(R)-
II-1135MeMeMe—iPr—nPrracemic
II-1136MeMeMe—iPr—nPr(R)-
II-1137MeMeMe—iPr—iPrracemic
II-1138MeMeMe—iPr—iPr(R)-
II-1139MeMeMe—iPr—cPrracemic
II-1140MeMeMe—iPr—cPr(R)-
II-1141MeMeMe—iPr—Phracemic
II-1142MeMeMe—iPr—Ph(R)-
II-1143MeMeMe—CF 3—Hracemic
II-1144MeMeMe—CF 3—H(R)-
II-1145MeMeMe—CF 3—Meracemic
II-1146MeMeMe—CF 3—Me(R)-
II-1147MeMeMe—CF 3—CHF 2racemic
II-1148MeMeMe—CF 3—CHF 2(R)-
II-1149MeMeMe—CF 3—CF 3racemic
II-1150MeMeMe—CF 3—CF 3(R)-
II-1151MeMeMe—CF 3—Etracemic
II-1152MeMeMe—CF 3—Et(R)-
II-1153MeMeMe—CF 3—nPrracemic
II-1154MeMeMe—CF 3—nPr(R)-
II-1155MeMeMe—CF 3—iPrracemic
II-1156MeMeMe—CF 3—iPr(R)-
II-1157MeMeMe—CF 3—cPrracemic
II-1158MeMeMe—CF 3—cPr(R)-
II-1159MeMeMe—CF 3—Phracemic
II-1160MeMeMe—CF 3—Ph(R)-
II-1161MeMeMe—CH 2 OH—Hracemic
II-1162MeMeMe—CH 2 OH—H(R)-
II-1163MeMeMe—CH 2 OH—Meracemic
II-1164MeMeMe—CH 2 OH—Me(R)-
II-1165MeMeMe—CH 2 OH—CHF 2racemic
II-1166MeMeMe—CH 2 OH—CHF 2(R)-
II-1167MeMeMe—CH 2 OH—CF 3racemic
II-1168MeMeMe—CH 2 OH—CF 3(R)-
II-1169MeMeMe—CH 2 OH—Etracemic
II-1170MeMeMe—CH 2 OH—Et(R)-
II-1171MeMeMe—CH 2 OH—nPrracemic
II-1172MeMeMe—CH 2 OH—nPr(R)-
II-1173MeMeMe—CH 2 OH—iPrracemic
II-1174MeMeMe—CH 2 OH—iPr(R)-
II-1175MeMeMe—CH 2 OH—cPrracemic
II-1176MeMeMe—CH 2 OH—cPr(R)-
TABLE 33 — (II)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
II-1177MeMeMe—CH 2 OH—Phracemic
II-1178MeMeMe—CH 2 OH—Ph(R)-
II-1179MeMeMe—CH 2 OMe—Hracemic
II-1180MeMeMe—CH 2 OMe—H(R)-
II-1181MeMeMe—CH 2 OMe—Meracemic
II-1182MeMeMe—CH 2 OMe—Me(R)-
II-1183MeMeMe—CH 2 OMe—CHF 2racemic
II-1184MeMeMe—CH 2 OMe—CHF 2(R)-
II-1185MeMeMe—CH 2 OMe—CF 3racemic
II-1186MeMeMe—CH 2 OMe—CF 3(R)-
II-1187MeMeMe—CH 2 OMe—Etracemic
II-1188MeMeMe—CH 2 OMe—Et(R)-
II-1189MeMeMe—CH 2 OMe—nPrracemic
II-1190MeMeMe—CH 2 OMe—nPr(R)-
II-1191MeMeMe—CH 2 OMe—iPrracemic
II-1192MeMeMe—CH 2 OMe—iPr(R)-
II-1193MeMeMe—CH 2 OMe—cPrracemic
II-1194MeMeMe—CH 2 OMe—cPr(R)-
II-1195MeMeMe—CH 2 OMe—Phracemic
II-1196MeMeMe—CH 2 OMe—Ph(R)-
II-1197MeMeMe—CH 2 OBn—Hracemic
II-1198MeMeMe—CH 2 OBn—H(R)-
II-1199MeMeMe—CH 2 OBn—Meracemic
II-1200MeMeMe—CH 2 OBn—Me(R)-
II-1201MeMeMe—CH 2 OBn—Phracemic
II-1202MeMeMe—CH 2 OBn—Ph(R)-
II-1203MeMeMe—CH 2 NMe 2—Hracemic
II-1204MeMeMe—CH 2 NMe 2—H(R)-
II-1205MeMeMe—CH 2 NMe 2—Meracemic
II-1206MeMeMe—CH 2 NMe 2—Me(R)-
II-1207MeMeMe—CH 2 NMe 2—CHF 2racemic
II-1208MeMeMe—CH 2 NMe 2—CHF 2(R)-
II-1209MeMeMe—CH 2 NMe 2—CF 3racemic
II-1210MeMeMe—CH 2 NMe 2—CF 3(R)-
II-1211MeMeMe—CH 2 NMe 2—Etracemic
II-1212MeMeMe—CH 2 NMe 2—Et(R)-
II-1213MeMeMe—CH 2 NMe 2—nPrracemic
II-1214MeMeMe—CH 2 NMe 2—nPr(R)-
II-1215MeMeMe—CH 2 NMe 2—iPrracemic
II-1216MeMeMe—CH 2 NMe 2—iPr(R)-
II-1217MeMeMe—CH 2 NMe 2—cPrracemic
II-1218MeMeMe—CH 2 NMe 2—cPr(R)-
II-1219MeMeMe—CH 2 NMe 2—Phracemic
II-1220MeMeMe—CH 2 NMe 2—Ph(R)-
II-1221MeMeMe—CH 2 -(3,3-—Hracemic
difluoropyrrolidyl)
II-1222MeMeMe—CH 2 -(3,3-—H(R)-
difluoropyrrolidyl)
II-1223MeMeMe—CH 2 -(3,3-—Meracemic
difluoropyrrolidyl)
II-1224MeMeMe—CH 2 -(3,3-—Me(R)-
difluoropyrrolidyl)
II-1225MeMeMe—CH 2 -(3,3-—Phracemic
difluoropyrrolidyl)
II-1226MeMeMe—CH 2 -(3,3-—Ph(R)-
difluoropyrrolidyl)
TABLE 34 — (II) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
II-1227MeMeMe—2-F—Ph—Hracemic
II-1228MeMeMe—2-F—Ph—H(R)-
II-1229MeMeMe—2-F—Ph—Meracemic
II-1230MeMeMe—2-F—Ph—Me(R)-
II-1231MeMeMe—2-F—Ph—CHF 2racemic
II-1232MeMeMe—2-F—Ph—CHF 2(R)-
II-1233MeMeMe—2-F—Ph—CF 3racemic
II-1234MeMeMe—2-F—Ph—CF 3(R)-
II-1235MeMeMe—2-F—Ph—Etracemic
II-1236MeMeMe—2-F—Ph—Et(R)-
II-1237MeMeMe—2-F—Ph—nPrracemic
II-1238MeMeMe—2-F—Ph—nPr(R)-
II-1239MeMeMe—2-F—Ph—iPrracemic
II-1240MeMeMe—2-F—Ph—iPr(R)-
II-1241MeMeMe—2-F—Ph—cPrracemic
II-1242MeMeMe—2-F—Ph—cPr(R)-
II-1243MeMeMe—3-F—Ph—Hracemic
II-1244MeMeMe—3-F—Ph—H(R)-
II-1245MeMeMe—3-F—Ph—Meracemic
II-1246MeMeMe—3-F—Ph—Me(R)-
II-1247MeMeMe—3-F—Ph—CHF 2racemic
II-1248MeMeMe—3-F—Ph—CHF 2(R)-
II-1249MeMeMe—3-F—Ph—CF 3racemic
II-1250MeMeMe—3-F—Ph—CF 3(R)-
II-1251MeMeMe—3-F—Ph—Etracemic
II-1252MeMeMe—3-F—Ph—Et(R)-
II-1253MeMeMe—3-F—Ph—nPrracemic
II-1254MeMeMe—3-F—Ph—nPr(R)-
II-1255MeMeMe—3-F—Ph—iPrracemic
II-1256MeMeMe—3-F—Ph—iPr(R)-
II-1257MeMeMe—3-F—Ph—cPrracemic
II-1258MeMeMe—3-F—Ph—cPr(R)-
II-1259MeMeMe—4-F—Ph—Hracemic
II-1260MeMeMe—4-F—Ph—H(R)-
II-1261MeMeMe—4-F—Ph—Meracemic
II-1262MeMeMe—4-F—Ph—Me(R)-
II-1263MeMeMe—4-F—Ph—CHF 2racemic
II-1264MeMeMe—4-F—Ph—CHF 2(R)-
II-1265MeMeMe—4-F—Ph—CF 3racemic
II-1266MeMeMe—4-F—Ph—CF 3(R)-
II-1267MeMeMe—4-F—Ph—Etracemic
II-1268MeMeMe—4-F—Ph—Et(R)-
II-1269MeMeMe—4-F—Ph—nPrracemic
II-1270MeMeMe—4-F—Ph—nPr(R)-
II-1271MeMeMe—4-F—Ph—iPrracemic
II-1272MeMeMe—4-F—Ph—iPr(R)-
II-1273MeMeMe—4-F—Ph—cPrracemic
II-1274MeMeMe—4-F—Ph—cPr(R)-
II-1275MeMeMe—2-thienyl—Hracemic
II-1276MeMeMe—2-thienyl—H(S)-
TABLE 35 — (II) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
II-1277MeMeMe—2-thienyl—Meracemic
II-1278MeMeMe—2-thienyl—Me(S)-
II-1279MeMeMe—2-thienyl—CHF 2racemic
II-1280MeMeMe—2-thienyl—CHF 2(S)-
II-1281MeMeMe—2-thienyl—CF 3racemic
II-1282MeMeMe—2-thienyl—CF 3(S)-
II-1283MeMeMe—2-thienyl—Etracemic
II-1284MeMeMe—2-thienyl—Et(S)-
II-1285MeMeMe—2-thienyl—nPrracemic
II-1286MeMeMe—2-thienyl—nPr(S)-
II-1287MeMeMe—2-thienyl—iPrracemic
II-1288MeMeMe—2-thienyl—iPr(S)-
II-1289MeMeMe—2-thienyl—cPrracemic
II-1290MeMeMe—2-thienyl—cPr(S)-
II-1291MeMeMe—3-thienyl—Hracemic
II-1292MeMeMe—3-thienyl—H(R)-
II-1293MeMeMe—3-thienyl—Meracemic
II-1294MeMeMe—3-thienyl—Me(R)-
II-1295MeMeMe—3-thienyl—CHF 2racemic
II-1296MeMeMe—3-thienyl—CHF 2(R)-
II-1297MeMeMe—3-thienyl—CF 3racemic
II-1298MeMeMe—3-thienyl—CF 3(R)-
II-1299MeMeMe—3-thienyl—Etracemic
II-1300MeMeMe—3-thienyl—Et(R)-
II-1301MeMeMe—3-thienyl—nPrracemic
II-1302MeMeMe—3-thienyl—nPr(R)-
II-1303MeMeMe—3-thienyl—iPrracemic
II-1304MeMeMe—3-thienyl—iPr(R)-
II-1305MeMeMe—3-thienyl—cPrracemic
II-1306MeMeMe—3-thienyl—cPr(R)-
TABLE 36 — (III) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
III-1MeMeMeOPhCH 2Hracemic
III-2MeMeMeOPhCH 2H(S)-
III-3MeEtMeOPhCH 2Hracemic
III-4MeEtMeOPhCH 2H(S)-
III-5MeMeMeOPhCH 2Meracemic
III-6MeMeMeOPhCH 2Me(S)-
III-7MeEtMeOPhCH 2Meracemic
III-8MeEtMeOPhCH 2Me(S)-
III-9MeMeMeOPhCH 2CHF 2racemic
III-10MeMeMeOPhCH 2CHF 2(S)-
III-11MeEtMeOPhCH 2CHF 2racemic
III-12MeEtMeOPhCH 2CHF 2(S)-
III-13MeMeMeOPhCH 2Etracemic
III-14MeMeMeOPhCH 2Et(S)-
III-15MeEtMeOPhCH 2Etracemic
III-16MeEtMeOPhCH 2Et(S)-
III-17MeMeMeOPhCH 2iPrracemic
III-18MeMeMeOPhCH 2iPr(S)-
III-19MeEtMeOPhCH 2iPrracemic
III-20MeEtMeOPhCH 2iPr(S)-
III-21MeMeMeOPhCH 2cPrracemic
III-22MeMeMeOPhCH 2cPr(S)-
III-23MeEtMeOPhCH 2cPrracemic
III-24MeEtMeOPhCH 2cPr(S)-
III-25MeMeMeOPhCH 2Phracemic
III-26MeMeMeOPhCH 2Ph(S)-
III-27MeEtMeOPhCH 2Phracemic
III-28MeEtMeOPhCH 2Ph(S)-
III-29MeMeMeOPhC(Me) 2Hracemic
III-30MeMeMeOPhC(Me) 2H(S)-
III-31MeEtMeOPhC(Me) 2Hracemic
III-32MeEtMeOPhC(Me) 2H(S)-
III-33MeMeMeOPhC(Me) 2Meracemic
III-34MeMeMeOPhC(Me) 2Me(S)-
III-35MeEtMeOPhC(Me) 2Meracemic
III-36MeEtMeOPhC(Me) 2Me(S)-
III-37MeMeMeOPhC(Me) 2CHF 2racemic
III-38MeMeMeOPhC(Me) 2CHF 2(S)-
III-39MeEtMeOPhC(Me) 2CHF 2racemic
III-40MeEtMeOPhC(Me) 2CHF 2(S)-
III-41MeMeMeOPhC(Me) 2Etracemic
III-42MeMeMeOPhC(Me) 2Et(S)-
III-43MeEtMeOPhC(Me) 2Etracemic
III-44MeEtMeOPhC(Me) 2Et(S)-
III-45MeMeMeOPhC(Me) 2iPrracemic
III-46MeMeMeOPhC(Me) 2iPr(S)-
III-47MeEtMeOPhC(Me) 2iPrracemic
III-48MeEtMeOPhC(Me) 2iPr(S)-
III-49MeMeMeOPhC(Me) 2cPrracemic
III-50MeMeMeOPhC(Me) 2cPr(S)-
TABLE 37 — (III) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
III-51MeEtMeOPhC(Me) 2cPrracemic
III-52MeEtMeOPhC(Me) 2cPr(S)-
III-53MeMeMeOPhC(Me) 2Phracemic
III-54MeMeMeOPhC(Me) 2Ph(S)-
III-55MeEtMeOPhC(Me) 2Phracemic
III-56MeEtMeOPhC(Me) 2Ph(S)-
III-57MeMeMeOPh(CH 2 ) 2Hracemic
III-58MeMeMeOPh(CH 2 ) 2H(R)-
III-59MeEtMeOPh(CH 2 ) 2Hracemic
III-60MeEtMeOPh(CH 2 ) 2H(R)-
III-61MeMeMeOPh(CH 2 ) 2Meracemic
III-62MeMeMeOPh(CH 2 ) 2Me(R)-
III-63MeEtMeOPh(CH 2 ) 2Meracemic
III-64MeEtMeOPh(CH 2 ) 2Me(R)-
III-65MeMeMeOPh(CH 2 ) 2CHF 2racemic
III-66MeMeMeOPh(CH 2 ) 2CHF 2(R)-
III-67MeEtMeOPh(CH 2 ) 2CHF 2racemic
III-68MeEtMeOPh(CH 2 ) 2CHF 2(R)-
III-69MeMeMeOPh(CH 2 ) 2Etracemic
III-70MeMeMeOPh(CH 2 ) 2Et(R)-
III-71MeEtMeOPh(CH 2 ) 2Etracemic
III-72MeEtMeOPh(CH 2 ) 2Et(R)-
III-73MeMeMeOPh(CH 2 ) 2iPrracemic
III-74MeMeMeOPh(CH 2 ) 2iPr(R)-
III-75MeEtMeOPh(CH 2 ) 2iPrracemic
III-76MeEtMeOPh(CH 2 ) 2iPr(R)-
III-77MeMeMeOPh(CH 2 ) 2cPrracemic
III-78MeMeMeOPh(CH 2 ) 2cPr(R)-
III-79MeEtMeOPh(CH 2 ) 2cPrracemic
III-80MeEtMeOPh(CH 2 ) 2cPr(R)-
III-81MeMeMeOPh(CH 2 ) 2Phracemic
III-82MeMeMeOPh(CH 2 ) 2Ph(R)-
III-83MeEtMeOPh(CH 2 ) 2Phracemic
III-84MeEtMeOPh(CH 2 ) 2Ph(R)-
III-85MeMeMeOPhCH 2 C(Me) 2Hracemic
III-86MeMeMeOPhCH 2 C(Me) 2H(R)-
III-87MeEtMeOPhCH 2 C(Me) 2Hracemic
III-88MeEtMeOPhCH 2 C(Me) 2H(R)-
III-89MeMeMeOPhCH 2 C(Me) 2Meracemic
III-90MeMeMeOPhCH 2 C(Me) 2Me(R)-
III-91MeEtMeOPhCH 2 C(Me) 2Meracemic
III-92MeEtMeOPhCH 2 C(Me) 2Me(R)-
III-93MeMeMeOPhCH 2 C(Me) 2CHF 2racemic
III-94MeMeMeOPhCH 2 C(Me) 2CHF 2(R)-
III-95MeEtMeOPhCH 2 C(Me) 2CHF 2racemic
III-96MeEtMeOPhCH 2 C(Me) 2CHF 2(R)-
III-97MeMeMeOPhCH 2 C(Me) 2Etracemic
III-98MeMeMeOPhCH 2 C(Me) 2Et(R)-
III-99MeEtMeOPhCH 2 C(Me) 2Etracemic
III-100MeEtMeOPhCH 2 C(Me) 2Et(R)-
TABLE 38 — (III) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
III-101MeMeMeOPhCH 2 C(Me) 2iPrracemic
III-102MeMeMeOPhCH 2 C(Me) 2iPr(R)-
III-103MeEtMeOPhCH 2 C(Me) 2iPrracemic
III-104MeEtMeOPhCH 2 C(Me) 2iPr(R)-
III-105MeMeMeOPhCH 2 C(Me) 2cPrracemic
III-106MeMeMeOPhCH 2 C(Me) 2cPr(R)-
III-107MeEtMeOPhCH 2 C(Me) 2cPrracemic
III-108MeEtMeOPhCH 2 C(Me) 2cPr(R)-
III-109MeMeMeOPhCH 2 C(Me) 2Phracemic
III-110MeMeMeOPhCH 2 C(Me) 2Ph(R)-
III-111MeEtMeOPhCH 2 C(Me) 2Phracemic
III-112MeEtMeOPhCH 2 C(Me) 2Ph(R)-
III-113MeMeMeNHPhCH 2Hracemic
III-114MeMeMeNHPhCH 2H(S)-
III-115MeEtMeNHPhCH 2Hracemic
III-116MeEtMeNHPhCH 2H(S)-
III-117MeMeMeN(Me)PhCH 2Hracemic
III-118MeMeMeN(Me)PhCH 2H(S)-
III-119MeEtMeN(Me)PhCH 2Hracemic
III-120MeEtMeN(Me)PhCH 2H(S)-
III-121MeMeMeNHPhCH 2Meracemic
III-122MeMeMeNHPhCH 2Me(S)-
III-123MeEtMeNHPhCH 2Meracemic
III-124MeEtMeNHPhCH 2Me(S)-
III-125MeMeMeN(Me)PhCH 2Meracemic
III-126MeMeMeN(Me)PhCH 2Me(S)-
III-127MeEtMeN(Me)PhCH 2Meracemic
III-128MeEtMeN(Me)PhCH 2Me(S)-
III-129MeMeMeNHPhCH 2CHF 2racemic
III-130MeMeMeNHPhCH 2CHF 2(S)-
III-131MeEtMeNHPhCH 2CHF 2racemic
III-132MeEtMeNHPhCH 2CHF 2(S)-
III-133MeMeMeN(Me)PhCH 2CHF 2racemic
III-134MeMeMeN(Me)PhCH 2CHF 2(S)-
III-135MeEtMeN(Me)PhCH 2CHF 2racemic
III-136MeEtMeN(Me)PhCH 2CHF 2(S)-
III-137MeMeMeNHPhCH 2Etracemic
III-138MeMeMeNHPhCH 2Et(S)-
III-139MeEtMeNHPhCH 2Etracemic
III-140MeEtMeNHPhCH 2Et(S)-
III-141MeMeMeN(Me)PhCH 2Etracemic
III-142MeMeMeN(Me)PhCH 2Et(S)-
III-143MeEtMeN(Me)PhCH 2Etracemic
III-144MeEtMeN(Me)PhCH 2Et(S)-
III-145MeMeMeNHPhCH 2iPrracemic
III-146MeMeMeNHPhCH 2iPr(S)-
III-147MeEtMeNHPhCH 2iPrracemic
III-148MeEtMeNHPhCH 2iPr(S)-
III-149MeMeMeN(Me)PhCH 2iPrracemic
III-150MeMeMeN(Me)PhCH 2iPr(S)-
TABLE 39 — (III) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5guration
III-151MeEtMeN(Me)PhCH 2iPrracemic
III-152MeEtMeN(Me)PhCH 2iPr(S)-
III-153MeMeMeNHPhCH 2cPrracemic
III-154MeMeMeNHPhCH 2cPr(S)-
III-155MeEtMeNHPhCH 2cPrracemic
III-156MeEtMeNHPhCH 2cPr(S)-
III-157MeMeMeN(Me)PhCH 2cPrracemic
III-158MeMeMeN(Me)PhCH 2cPr(S)-
III-159MeEtMeN(Me)PhCH 2cPrracemic
III-160MeEtMeN(Me)PhCH 2cPr(S)-
III-161MeMeMeNHPhCH 2Phracemic
III-162MeMeMeNHPhCH 2Ph(S)-
III-163MeEtMeNHPhCH 2Phracemic
III-164MeEtMeNHPhCH 2Ph(S)-
III-165MeMeMeN(Me)PhCH 2Phracemic
III-166MeMeMeN(Me)PhCH 2Ph(S)-
III-167MeEtMeN(Me)PhCH 2Phracemic
III-168MeEtMeN(Me)PhCH 2Ph(S)-
III-169MeMeMeNHPhC(Me) 2Hracemic
III-170MeMeMeNHPhC(Me) 2H(S)-
III-171MeEtMeNHPhC(Me) 2Hracemic
III-172MeEtMeNHPhC(Me) 2H(S)-
III-173MeMeMeN(Me)PhC(Me) 2Hracemic
III-174MeMeMeN(Me)PhC(Me) 2H(S)-
III-175MeEtMeN(Me)PhC(Me) 2Hracemic
III-176MeEtMeN(Me)PhC(Me) 2H(S)-
III-177MeMeMeNHPhC(Me) 2Meracemic
III-178MeMeMeNHPhC(Me) 2Me(S)-
III-179MeEtMeNHPhC(Me) 2Meracemic
III-180MeEtMeNHPhC(Me) 2Me(S)-
III-181MeMeMeN(Me)PhC(Me) 2Meracemic
III-182MeMeMeN(Me)PhC(Me) 2Me(S)-
III-183MeEtMeN(Me)PhC(Me) 2Meracemic
III-184MeEtMeN(Me)PhC(Me) 2Me(S)-
III-185MeMeMeNHPhC(Me) 2CHF 2racemic
III-186MeMeMeNHPhC(Me) 2CHF 2(S)-
III-187MeEtMeNHPhC(Me) 2CHF 2racemic
III-188MeEtMeNHPhC(Me) 2CHF 2(S)-
III-189MeMeMeN(Me)PhC(Me) 2CHF 2racemic
III-190MeMeMeN(Me)PhC(Me) 2CHF 2(S)-
III-191MeEtMeN(Me)PhC(Me) 2CHF 2racemic
III-192MeEtMeN(Me)PhC(Me) 2CHF 2(S)-
III-193MeMeMeNHPhC(Me) 2Etracemic
III-194MeMeMeNHPhC(Me) 2Et(S)-
III-195MeEtMeNHPhC(Me) 2Etracemic
III-196MeEtMeNHPhC(Me) 2Et(S)-
III-197MeMeMeN(Me)PhC(Me) 2Etracemic
III-198MeMeMeN(Me)PhC(Me) 2Et(S)-
III-199MeEtMeN(Me)PhC(Me) 2Etracemic
III-200MeEtMeN(Me)PhC(Me) 2Et(S)-
TABLE 40 — (III) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
III-201MeMeMeNHPhC(Me) 2iPrracemic
III-202MeMeMeNHPhC(Me) 2iPr(S)-
III-203MeEtMeNHPhC(Me) 2iPrracemic
III-204MeEtMeNHPhC(Me) 2iPr(S)-
III-205MeMeMeN(Me)PhC(Me) 2iPrracemic
III-206MeMeMeN(Me)PhC(Me) 2iPr(S)-
III-207MeEtMeN(Me)PhC(Me) 2iPrracemic
III-208MeEtMeN(Me)PhC(Me) 2iPr(S)-
III-209MeMeMeNHPhC(Me) 2cPrracemic
III-210MeMeMeNHPhC(Me) 2cPr(S)-
III-211MeEtMeNHPhC(Me) 2cPrracemic
III-212MeEtMeNHPhC(Me) 2cPr(S)-
III-213MeMeMeN(Me)PhC(Me) 2cPrracemic
III-214MeMeMeN(Me)PhC(Me) 2cPr(S)-
III-215MeEtMeN(Me)PhC(Me) 2cPrracemic
III-216MeEtMeN(Me)PhC(Me) 2cPr(S)-
III-217MeMeMeNHPhC(Me) 2Phracemic
III-218MeMeMeNHPhC(Me) 2Ph(S)-
III-219MeEtMeNHPhC(Me) 2Phracemic
III-220MeEtMeNHPhC(Me) 2Ph(S)-
III-221MeMeMeN(Me)PhC(Me) 2Phracemic
III-222MeMeMeN(Me)PhC(Me) 2Ph(S)-
III-223MeEtMeN(Me)PhC(Me) 2Phracemic
III-224MeEtMeN(Me)PhC(Me) 2Ph(S)-
III-225MeMeMeNHPhC(Me) 2Hracemic
III-226MeMeMeNHPhC(Me) 2H(R)-
III-227MeEtMeNHPhC(Me) 2Hracemic
III-228MeEtMeNHPhC(Me) 2H(R)-
III-229MeMeMeN(Me)PhC(Me) 2Hracemic
III-230MeMeMeN(Me)PhC(Me) 2H(R)-
III-231MeEtMeN(Me)PhC(Me) 2Hracemic
III-232MeEtMeN(Me)PhC(Me) 2H(R)-
III-233MeMeMeNHPhC(Me) 2Meracemic
III-234MeMeMeNHPhC(Me) 2Me(R)-
III-235MeEtMeNHPhC(Me) 2Meracemic
III-236MeEtMeNHPhC(Me) 2Me(R)-
III-237MeMeMeN(Me)PhC(Me) 2Meracemic
III-238MeMeMeN(Me)PhC(Me) 2Me(R)-
III-239MeEtMeN(Me)PhC(Me) 2Meracemic
III-240MeEtMeN(Me)PhC(Me) 2Me(R)-
III-241MeMeMeNHPhC(Me) 2CHF 2racemic
III-242MeMeMeNHPhC(Me) 2CHF 2(R)-
III-243MeEtMeNHPhC(Me) 2CHF 2racemic
III-244MeEtMeNHPhC(Me) 2CHF 2(R)-
III-245MeMeMeN(Me)PhC(Me) 2CHF 2racemic
III-246MeMeMeN(Me)PhC(Me) 2CHF 2(R)-
III-247MeEtMeN(Me)PhC(Me) 2CHF 2racemic
III-248MeEtMeN(Me)PhC(Me) 2CHF 2(R)-
III-249MeMeMeNHPhC(Me) 2Etracemic
III-250MeMeMeNHPhC(Me) 2Et(R)-
TABLE 41 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-251MeEtMeNHPh(CH 2 ) 2Etracemic
III-252MeEtMeNHPh(CH 2 ) 2Et(R)-
III-253MeMeMeN(Me)Ph(CH 2 ) 2Etracemic
III-254MeMeMeN(Me)Ph(CH 2 ) 2Et(R)-
III-255MeEtMeN(Me)Ph(CH 2 ) 2Etracemic
III-256MeEtMeN(Me)Ph(CH 2 ) 2Et(R)-
III-257MeMeMeNHPh(CH 2 ) 2iPrracemic
III-258MeMeMeNHPh(CH 2 ) 2iPr(R)-
III-259MeEtMeNHPh(CH 2 ) 2iPrracemic
III-260MeEtMeNHPh(CH 2 ) 2iPr(R)-
III-261MeMeMeN(Me)Ph(CH 2 ) 2iPrracemic
III-262MeMeMeN(Me)Ph(CH 2 ) 2iPr(R)-
III-263MeEtMeN(Me)Ph(CH 2 ) 2iPrracemic
III-264MeEtMeN(Me)Ph(CH 2 ) 2iPr(R)-
III-265MeMeMeNHPh(CH 2 ) 2cPrracemic
III-266MeMeMeNHPh(CH 2 ) 2cPr(R)-
III-267MeEtMeNHPh(CH 2 ) 2cPrracemic
III-268MeEtMeNHPh(CH 2 ) 2cPr(R)-
III-269MeMeMeN(Me)Ph(CH 2 ) 2cPrracemic
III-270MeMeMeN(Me)Ph(CH 2 ) 2cPr(R)-
III-271MeEtMeN(Me)Ph(CH 2 ) 2cPrracemic
III-272MeEtMeN(Me)Ph(CH 2 ) 2cPr(R)-
III-273MeMeMeNHPh(CH 2 ) 2Phracemic
III-274MeMeMeNHPh(CH 2 ) 2Ph(R)-
III-275MeEtMeNHPh(CH 2 ) 2Phracemic
III-276MeEtMeNHPh(CH 2 ) 2Ph(R)-
III-277MeMeMeN(Me)Ph(CH 2 ) 2Phracemic
III-278MeMeMeN(Me)Ph(CH 2 ) 2Ph(R)-
III-279MeEtMeN(Me)Ph(CH 2 ) 2Phracemic
III-280MeEtMeN(Me)Ph(CH 2 ) 2Ph(R)-
III-281MeMeMeNHPh(CH 2 ) 3Hracemic
III-282MeMeMeNHPh(CH 2 ) 3H(R)-
III-283MeEtMeNHPh(CH 2 ) 3Hracemic
III-284MeEtMeNHPh(CH 2 ) 3H(R)-
III-285MeMeMeN(Me)Ph(CH 2 ) 3Hracemic
III-286MeMeMeN(Me)Ph(CH 2 ) 3H(R)-
III-287MeEtMeN(Me)Ph(CH 2 ) 3Hracemic
III-288MeEtMeN(Me)Ph(CH 2 ) 3H(R)-
III-289MeMeMeNHPh(CH 2 ) 4Hracemic
III-290MeMeMeNHPh(CH 2 ) 4H(R)-
III-291MeEtMeNHPh(CH 2 ) 4Hracemic
III-292MeEtMeNHPh(CH 2 ) 4H(R)-
III-293MeMeMeN(Me)Ph(CH 2 ) 4Hracemic
III-294MeMeMeN(Me)Ph(CH 2 ) 4H(R)-
III-295MeEtMeN(Me)Ph(CH 2 ) 4Hracemic
III-296MeEtMeN(Me)Ph(CH 2 ) 4H(R)-
III-297MeMeMeNHPhCH 2 C(Me) 2Hracemic
III-298MeMeMeNHPhCH 2 C(Me) 2H(R)-
III-299MeEtMeNHPhCH 2 C(Me) 2Hracemic
III-300MeEtMeNHPhCH 2 C(Me) 2H(R)-
TABLE 42 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-301MeMeMeN(Me)PhCH 2 C(Me) 2Hracemic
III-302MeMeMeN(Me)PhCH 2 C(Me) 2H(R)-
III-303MeEtMeN(Me)PhCH 2 C(Me) 2Hracemic
III-304MeEtMeN(Me)PhCH 2 C(Me) 2H(R)-
III-305MeMeMeNHPhCH 2 C(Me) 2Meracemic
III-306MeMeMeNHPhCH 2 C(Me) 2Me(R)-
III-307MeEtMeNHPhCH 2 C(Me) 2Meracemic
III-308MeEtMeNHPhCH 2 C(Me) 2Me(R)-
III-309MeMeMeN(Me)PhCH 2 C(Me) 2Meracemic
III-310MeMeMeN(Me)PhCH 2 C(Me) 2Me(R)-
III-311MeEtMeN(Me)PhCH 2 C(Me) 2Meracemic
III-312MeEtMeN(Me)PhCH 2 C(Me) 2Me(R)-
III-313MeMeMeNHPhCH 2 C(Me) 2CHF 2racemic
III-314MeMeMeNHPhCH 2 C(Me) 2CHF 2(R)-
III-315MeEtMeNHPhCH 2 C(Me) 2CHF 2racemic
III-316MeEtMeNHPhCH 2 C(Me) 2CHF 2(R)-
III-317MeMeMeN(Me)PhCH 2 C(Me) 2CHF 2racemic
III-318MeMeMeN(Me)PhCH 2 C(Me) 2CHF 2(R)-
III-319MeEtMeN(Me)PhCH 2 C(Me) 2CHF 2racemic
III-320MeEtMeN(Me)PhCH 2 C(Me) 2CHF 2(R)-
III-321MeMeMeNHPhCH 2 C(Me) 2Etracemic
III-322MeMeMeNHPhCH 2 C(Me) 2Et(R)-
III-323MeEtMeNHPhCH 2 C(Me) 2Etracemic
III-324MeEtMeNHPhCH 2 C(Me) 2Et(R)-
III-325MeMeMeN(Me)PhCH 2 C(Me) 2Etracemic
III-326MeMeMeN(Me)PhCH 2 C(Me) 2Et(R)-
III-327MeEtMeN(Me)PhCH 2 C(Me) 2Etracemic
III-328MeEtMeN(Me)PhCH 2 C(Me) 2Et(R)-
III-329MeMeMeNHPhCH 2 C(Me) 2iPrracemic
III-330MeMeMeNHPhCH 2 C(Me) 2iPr(R)-
III-331MeEtMeNHPhCH 2 C(Me) 2iPrracemic
III-332MeEtMeNHPhCH 2 C(Me) 2iPr(R)-
III-333MeMeMeN(Me)PhCH 2 C(Me) 2iPrracemic
III-334MeMeMeN(Me)PhCH 2 C(Me) 2iPr(R)-
III-335MeEtMeN(Me)PhCH 2 C(Me) 2iPrracemic
III-336MeEtMeN(Me)PhCH 2 C(Me) 2iPr(R)-
III-337MeMeMeNHPhCH 2 C(Me) 2cPrracemic
III-338MeMeMeNHPhCH 2 C(Me) 2cPr(R)-
III-339MeEtMeNHPhCH 2 C(Me) 2cPrracemic
III-340MeEtMeNHPhCH 2 C(Me) 2cPr(R)-
III-341MeMeMeN(Me)PhCH 2 C(Me) 2cPrracemic
III-342MeMeMeN(Me)PhCH 2 C(Me) 2cPr(R)-
III-343MeEtMeN(Me)PhCH 2 C(Me) 2cPrracemic
III-344MeEtMeN(Me)PhCH 2 C(Me) 2cPr(R)-
III-345MeMeMeNHPhCH 2 C(Me) 2Phracemic
III-346MeMeMeNHPhCH 2 C(Me) 2Ph(R)-
III-347MeEtMeNHPhCH 2 C(Me) 2Phracemic
III-348MeEtMeNHPhCH 2 C(Me) 2Ph(R)-
III-349MeMeMeN(Me)PhCH 2 C(Me) 2Phracemic
III-350MeMeMeN(Me)PhCH 2 C(Me) 2Ph(R)-
TABLE 43 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-351MeEtMeN(Me)PhCH 2 C(Me) 2Phracemic
III-352MeEtMeN(Me)PhCH 2 C(Me) 2Ph(R)-
III-353MeMeMeNHPhCH 2 C(Me) 2Hracemic
III-354MeMeMeNHPhCH 2 C(Me) 2H(S)-
III-355MeEtMeNHPhCH 2 C(Me) 2Hracemic
III-356MeEtMeNHPhCH 2 C(Me) 2H(S)-
III-357MeMeMeN(Me)PhCH 2 C(Me) 2Hracemic
III-358MeMeMeN(Me)PhCH 2 C(Me) 2H(S)-
III-359MeEtMeN(Me)PhCH 2 C(Me) 2Hracemic
III-360MeEtMeN(Me)PhCH 2 C(Me) 2H(S)-
III-361MeMeMeNHPhCF 2 CH 2Hracemic
III-362MeMeMeNHPhCF 2 CH 2H(S)-
III-363MeEtMeNHPhCF 2 CH 2Hracemic
III-364MeEtMeNHPhCF 2 CH 2H(S)-
III-365MeMeMeN(Me)PhCF 2 CH 2Hracemic
III-366MeMeMeN(Me)PhCF 2 CH 2H(S)-
III-367MeEtMeN(Me)PhCF 2 CH 2Hracemic
III-368MeEtMeN(Me)PhCF 2 CH 2H(S)-
III-369MeMeMeNHPhCH═CHCH 2Hracemic
III-370MeMeMeNHPhCH═CHCH 2H(S)-
III-371MeEtMeNHPhCH═CHCH 2Hracemic
III-372MeEtMeNHPhCH═CHCH 2H(S)-
III-373MeMeMeN(Me)PhCH═CHCH 2Hracemic
III-374MeMeMeN(Me)PhCH═CHCH 2H(S)-
III-375MeEtMeN(Me)PhCH═CHCH 2Hracemic
III-376MeEtMeN(Me)PhCH═CHCH 2H(S)-
III-377MeMeMeNHPhC═CCH 2Hracemic
III-378MeMeMeNHPhC═CCH 2H(S)-
III-379MeEtMeNHPhC═CCH 2Hracemic
III-380MeEtMeNHPhC═CCH 2H(S)-
III-381MeMeMeN(Me)PhC═CCH 2Hracemic
III-382MeMeMeN(Me)PhC═CCH 2H(S)-
III-383MeEtMeN(Me)PhC═CCH 2Hracemic
III-384MeEtMeN(Me)PhC═CCH 2H(S)-
III-385MeMeMeNHPh1,1-CyclopropyleneHracemic
III-386MeMeMeNHPh1,1-CyclopropyleneH(S)-
III-387MeEtMeNHPh1,1-CyclopropyleneHracemic
III-388MeEtMeNHPh1,1-CyclopropyleneH(S)-
III-389MeMeMeN(Me)Ph1,1-CyclopropyleneHracemic
III-390MeMeMeN(Me)Ph1,1-CyclopropyleneH(S)-
III-391MeEtMeN(Me)Ph1,1-CyclopropyleneHracemic
III-392MeEtMeN(Me)Ph1,1-CyclopropyleneH(S)-
III-393MeMeMeNHPh1,2-CyclopropyleneHracemic
III-394MeMeMeNHPh1,2-CyclopropyleneH(S)-
III-395MeEtMeNHPh1,2-CyclopropyleneHracemic
III-396MeEtMeNHPh1,2-CyclopropyleneH(S)-
III-397MeMeMeN(Me)Ph1,2-CyclopropyleneHracemic
III-398MeMeMeN(Me)Ph1,2-CyclopropyleneH(S)-
III-399MeEtMeN(Me)Ph1,2-CyclopropyleneHracemic
III-400MeEtMeN(Me)Ph1,2-CyclopropyleneH(S)-
TABLE 44 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-401MeMeMeNHPhC(═O)Hracemic
III-402MeMeMeNHPhC(═O)H(S)-
III-403MeEtMeNHPhC(═O)Hracemic
III-404MeEtMeNHPhC(═O)H(S)-
III-405MeMeMeN(Me)PhC(═O)Hracemic
III-406MeMeMeN(Me)PhC(═O)H(S)-
III-407MeEtMeN(Me)PhC(═O)Hracemic
III-408MeEtMeN(Me)PhC(═O)H(S)-
III-409MeMeMeNHPhC(═O)Bnracemic
III-410MeMeMeNHPhC(═O)Bn(S)-
III-411MeEtMeNHPhC(═O)Bnracemic
III-412MeEtMeNHPhC(═O)Bn(S)-
III-413MeMeMeN(Me)PhC(═O)Bnracemic
III-414MeMeMeN(Me)PhC(═O)Bn(S)-
III-415MeEtMeN(Me)PhC(═O)Bnracemic
III-416MeEtMeN(Me)PhC(═O)Bn(S)-
III-417MeMeMeNHPhC(═O)Meracemic
III-418MeMeMeNHPhC(═O)Me(S)-
III-419MeEtMeNHPhC(═O)Meracemic
III-420MeEtMeNHPhC(═O)Me(S)-
III-421MeMeMeN(Me)PhC(═O)Meracemic
III-422MeMeMeN(Me)PhC(═O)Me(S)-
III-423MeEtMeN(Me)PhC(═O)Meracemic
III-424MeEtMeN(Me)PhC(═O)Me(S)-
III-425MeMeMeNHHCH 2H
III-426MeEtMeNHHCH 2H
III-427MeMeMeN(Me)HCH 2H
III-428MeEtMeN(Me)HCH 2H
III-429MeMeMeNHHCH(Me)H
III-430MeEtMeNHHCH(Me)H
III-431MeMeMeN(Me)HCH(Me)H
III-432MeEtMeN(Me)HCH(Me)H
III-433MeMeMeNHHCH(iPr)H
III-434MeEtMeNHHCH(iPr)H
III-435MeMeMeN(Me)HCH(iPr)H
III-436MeEtMeN(Me)HCH(iPr)H
III-437MeMeMeNHHCH(Ph)H
III-438MeEtMeNHHCH(Ph)H
III-439MeMeMeN(Me)HCH(Ph)H
III-440MeEtMeN(Me)HCH(Ph)H
III-441MeMeMeNHMeCH 2Hracemic
III-442MeMeMeNHMeCH 2H(S)-
III-443MeEtMeNHMeCH 2Hracemic
III-444MeEtMeNHMeCH 2H(S)-
III-445MeMeMeN(Me)MeCH 2Hracemic
III-446MeMeMeN(Me)MeCH 2H(S)-
III-447MeEtMeN(Me)MeCH 2Hracemic
III-448MeEtMeN(Me)MeCH 2H(S)-
III-449MeMeMeNHiPrCH 2Hracemic
III-450MeMeMeNHiPrCH 2H(S)-
TABLE 45 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-451MeEtMeNHiPrCH 2Hracemic
III-452MeEtMeNHiPrCH 2H(S)-
III-453MeMeMeN(Me)iPrCH 2Hracemic
III-454MeMeMeN(Me)iPrCH 2H(S)-
III-455MeEtMeN(Me)iPrCH 2Hracemic
III-456MeEtMeN(Me)iPrCH 2H(S)-
III-457MeMeMeNHcHexCH 2Hracemic
III-458MeMeMeNHcHexCH 2H(S)-
III-459MeEtMeNHcHexCH 2Hracemic
III-460MeEtMeNHcHexCH 2H(S)-
III-461MeMeMeN(Me)cHexCH 2Hracemic
III-462MeMeMeN(Me)cHexCH 2H(S)-
III-463MeEtMeN(Me)cHexCH 2Hracemic
III-464MeEtMeN(Me)cHexCH 2H(S)-
III-465MeMeMeNH1,3-Benzodioxol-4-ylCH 2Hracemic
III-466MeMeMeNH1,3-Benzodioxol-4-ylCH 2H(S)-
III-467MeEtMeNH1,3-Benzodioxol-4-ylCH 2Hracemic
III-468MeEtMeNH1,3-Benzodioxol-4-ylCH 2H(S)-
III-469MeMeMeN(Me)1,3-Benzodioxol-4-ylCH 2Hracemic
III-470MeMeMeN(Me)1,3-Benzodioxol-4-ylCH 2H(S)-
III-471MeEtMeN(Me)1,3-Benzodioxol-4-ylCH 2Hracemic
III-472MeEtMeN(Me)1,3-Benzodioxol-4-ylCH 2H(S)-
III-473MeMeMeNH2-F-PhCH 2Hracemic
III-474MeMeMeNH2-F-PhCH 2H(S)-
III-475MeEtMeNH2-F-PhCH 2Hracemic
III-476MeEtMeNH2-F-PhCH 2H(S)-
III-477MeMeMeN(Me)2-F-PhCH 2Hracemic
III-478MeMeMeN(Me)2-F-PhCH 2H(S)-
III-479MeEtMeN(Me)2-F-PhCH 2Hracemic
III-480MeEtMeN(Me)2-F-PhCH 2H(S)-
III-481MeMeMeNH3-F-PhCH 2Hracemic
III-482MeMeMeNH3-F-PhCH 2H(S)-
III-483MeEtMeNH3-F-PhCH 2Hracemic
III-484MeEtMeNH3-F-PhCH 2H(S)-
III-485MeMeMeN(Me)3-F-PhCH 2Hracemic
III-486MeMeMeN(Me)3-F-PhCH 2H(S)-
III-487MeEtMeN(Me)3-F-PhCH 2Hracemic
III-488MeEtMeN(Me)3-F-PhCH 2H(S)-
III-489MeMeMeNH4-F-PhCH 2Hracemic
III-490MeMeMeNH4-F-PhCH 2H(S)-
III-491MeEtMeNH4-F-PhCH 2Hracemic
III-492MeEtMeNH4-F-PhCH 2H(S)-
III-493MeMeMeN(Me)4-F-PhCH 2Hracemic
III-494MeMeMeN(Me)4-F-PhCH 2H(S)-
III-495MeEtMeN(Me)4-F-PhCH 2Hracemic
III-496MeEtMeN(Me)4-F-PhCH 2H(S)-
III-497MeMeMeNH2-PyCH 2Hracemic
III-498MeMeMeNH2-PyCH 2H(S)-
III-499MeEtMeNH2-PyCH 2Hracemic
III-500MeEtMeNH2-PyCH 2H(S)-
TABLE 46 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-501MeMeMeN(Me)2-PyCH 2Hracemic
III-502MeMeMeN(Me)2-PyCH 2H(S)-
III-503MeEtMeN(Me)2-PyCH 2Hracemic
III-504MeEtMeN(Me)2-PyCH 2H(S)-
III-505MeMeMeNH3-PyCH 2Hracemic
III-506MeMeMeNH3-PyCH 2H(S)-
III-507MeEtMeNH3-PyCH 2Hracemic
III-508MeEtMeNH3-PyCH 2H(S)-
III-509MeMeMeN(Me)3-PyCH 2Hracemic
III-510MeMeMeN(Me)3-PyCH 2H(S)-
III-511MeEtMeN(Me)3-PyCH 2Hracemic
III-512MeEtMeN(Me)3-PyCH 2H(S)-
III-513MeMeMeNH4-PyCH 2Hracemic
III-514MeMeMeNH4-PyCH 2H(S)-
III-515MeEtMeNH4-PyCH 2Hracemic
III-516MeEtMeNH4-PyCH 2H(S)-
III-517MeMeMeN(Me)4-PyCH 2Hracemic
III-518MeMeMeN(Me)4-PyCH 2H(S)-
III-519MeEtMeN(Me)4-PyCH 2Hracemic
III-520MeEtMeN(Me)4-PyCH 2H(S)-
III-521MeMeMeCH 2PhCH 2Hracemic
III-522MeMeMeCH 2PhCH 2H(S)-
III-523MeEtMeCH 2PhCH 2Hracemic
III-524MeEtMeCH 2PhCH 2H(S)-
III-525MeMeMeCH 2Ph—Hracemic
III-526MeMeMeCH 2Ph—H(S)-
III-527MeEtMeCH 2Ph—Hracemic
III-528MeEtMeCH 2Ph—H(S)-
III-529MeMeMeCH 2PhCH 2Meracemic
III-530MeMeMeCH 2PhCH 2Me(S)-
III-531MeEtMeCH 2PhCH 2Meracemic
III-532MeEtMeCH 2PhCH 2Me(S)-
III-533MeMeMeCH 2PhCH 2CHF2racemic
III-534MeMeMeCH 2PhCH 2CHF2(S)-
III-535MeEtMeCH 2PhCH 2CHF2racemic
III-536MeEtMeCH 2PhCH 2CHF2(S)-
III-537MeMeMeCH 2PhCH 2Etracemic
III-538MeMeMeCH 2PhCH 2Et(S)-
III-539MeEtMeCH 2PhCH 2Etracemic
III-540MeEtMeCH 2PhCH 2Et(S)-
III-541MeMeMeCH 2PhCH 2cPrracemic
III-542MeMeMeCH 2PhCH 2cPr(S)-
III-543MeMeMeCH 2PhCH 2Phracemic
III-544MeMeMeCH 2PhCH 2Ph(S)-
III-545MeMeMeCH 2PhC(Me) 2Hracemic
III-546MeMeMeCH 2PhC(Me) 2H(S)-
III-547MeEtMeCH 2PhC(Me) 2Hracemic
III-548MeEtMeCH 2PhC(Me) 2H(S)-
III-549MeMeMeCH 2PhC(Me) 2Meracemic
III-550MeMeMeCH 2PhC(Me) 2Me(S)-
TABLE 47 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-551MeEtMeCH 2PhC(Me) 2Meracemic
III-552MeEtMeCH 2PhC(Me) 2Me(S)-
III-553MeMeMeCH 2PhC(Me) 2CHF 2racemic
III-554MeMeMeCH 2PhC(Me) 2CHF 2(S)-
III-555MeMeMeCH 2PhC(Me) 2Etracemic
III-556MeMeMeCH 2PhC(Me) 2Et(S)-
III-557MeMeMeCH 2PhC(Me) 2cPrracemic
III-558MeMeMeCH 2PhC(Me) 2cPr(S)-
III-559MeMeMeCH 2PhC(Me) 2Phracemic
III-560MeMeMeCH 2PhC(Me) 2Ph(S)-
III-561MeMeMeCH 2Ph(CH 2 ) 2Hracemic
III-562MeMeMeCH 2Ph(CH 2 ) 2H(S)-
III-563MeEtMeCH 2Ph(CH 2 ) 2Hracemic
III-564MeEtMeCH 2Ph(CH 2 ) 2H(S)-
III-565MeMeMeCH 2Ph(CH 2 ) 2Meracemic
III-566MeMeMeCH 2Ph(CH 2 ) 2Me(S)-
III-567MeMeMeCH 2Ph(CH 2 ) 2CHF 2racemic
III-568MeMeMeCH 2Ph(CH 2 ) 2CHF 2(S)-
III-569MeMeMeCH 2Ph(CH 2 ) 2Etracemic
III-570MeMeMeCH 2Ph(CH 2 ) 2Et(S)-
III-571MeMeMeCH 2Ph(CH 2 ) 2cPrracemic
III-572MeMeMeCH 2Ph(CH 2 ) 2cPr(S)-
III-573MeMeMeCH 2Ph(CH 2 ) 2Phracemic
III-574MeMeMeCH 2Ph(CH 2 ) 2Ph(S)-
III-575MeMeMeCH 2PhCH 2 C(Me) 2Hracemic
III-576MeMeMeCH 2PhCH 2 C(Me) 2H(S)-
III-577MeEtMeCH 2PhCH 2 C(Me) 2Hracemic
III-578MeEtMeCH 2PhCH 2 C(Me) 2H(S)-
III-579MeMeMeCH 2PhCH 2 C(Me) 2Meracemic
III-580MeMeMeCH 2PhCH 2 C(Me) 2Me(S)-
III-581MeEtMeCH 2PhCH 2 C(Me) 2Meracemic
III-582MeEtMeCH 2PhCH 2 C(Me) 2Me(S)-
III-583MeMeMeCH 2PhCH 2 C(Me) 2CHF 2racemic
III-584MeMeMeCH 2PhCH 2 C(Me) 2CHF 2(S)-
III-585MeMeMeCH 2PhCH 2 C(Me) 2Etracemic
III-586MeMeMeCH 2PhCH 2 C(Me) 2Et(S)-
III-587MeMeMeCH 2PhCH 2 C(Me) 2cPrracemic
III-588MeMeMeCH 2PhCH 2 C(Me) 2cPr(S)-
III-589MeMeMeCH 2PhCH 2 C(Me) 2Phracemic
III-590MeMeMeCH 2PhCH 2 C(Me) 2Ph(S)-
III-591MeMeMe—PhCH 2Hracemic
III-592MeMeMe—PhCH 2H(S)-
III-593MeMeMe—PhCH 2Meracemic
III-594MeMeMe—PhCH 2Me(S)-
III-595MeMeMeCH═CHPhCH 2Hracemic
III-596MeMeMeCH═CHPhCH 2H(S)-
III-597MeMeMeCH═CHPhCH 2Meracemic
III-598MeMeMeCH═CHPhCH 2Me(S)-
III-599MeMeMeC═CPhCH 2Hracemic
III-600MeMeMeC═CPhCH 2H(S)-
TABLE 48 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-601MeMeMeC═CPhCH 2Meracemic
III-602MeMeMeC═CPhCH 2Me(S)-
III-603MeMeMe1,2-CyclopropylenePhCH 2Hracemic
III-604MeMeMe1,2-CyclopropylenePhCH 2H(S)-
III-605MeMeMe1,2-CyclopropylenePhCH 2Meracemic
III-606MeMeMe1,2-CyclopropylenePhCH 2Me(S)-
III-607MeMeMe1,2-CyclopropylenePhCH 2Hracemic
III-608MeMeMe1,2-CyclopropylenePhCH 2H(S)-
III-609MeMeMe1,2-CyclopropylenePhCH 2Meracemic
III-610MeMeMe1,2-CyclopropylenePhCH 2Me(S)-
TABLE 49 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-611MeMeMeOPhC(Me) 2 CH 2Hracemic
III-612MeMeMeOPhC(Me) 2 CH 2H(+)
III-613MeMeMeOPhC(Me) 2 CH 2H(−)
III-614MeEtMeOPhC(Me) 2 CH 2Hracemic
III-615MeEtMeOPhC(Me) 2 CH 2H(+)
III-616MeEtMeOPhC(Me) 2 CH 2H(−)
III-617MeMeMeOPhC(Me) 2 CH 2Meracemic
III-618MeMeMeOPhC(Me) 2 CH 2Me(+)
III-619MeMeMeOPhC(Me) 2 CH 2Me(−)
III-620MeEtMeOPhC(Me) 2 CH 2Meracemic
III-621MeEtMeOPhC(Me) 2 CH 2Me(+)
III-622MeEtMeOPhC(Me) 2 CH 2Me(−)
III-623MeMeMeOPhC(Me) 2 CH 2CHF 2racemic
III-624MeMeMeOPhC(Me) 2 CH 2CHF 2(+)
III-625MeMeMeOPhC(Me) 2 CH 2CHF 2(−)
III-626MeMeMeOPhC(Me) 2 CH 2Etracemic
III-627MeMeMeOPhC(Me) 2 CH 2Et(+)
III-628MeMeMeOPhC(Me) 2 CH 2Et(−)
III-629MeMeMeNHPhC(Me) 2 CH 2H(+)
III-630MeMeMeNHPhC(Me) 2 CH 2H(−)
III-631MeEtMeNHPhC(Me) 2 CH 2H(+)
III-632MeEtMeNHPhC(Me) 2 CH 2H(−)
III-633MeMeMeNHPhC(Me) 2 CH 2Meracemic
III-634MeMeMeNHPhC(Me) 2 CH 2Me(+)
III-635MeMeMeNHPhC(Me) 2 CH 2Me(−)
III-636MeEtMeNHPhC(Me) 2 CH 2Meracemic
III-637MeEtMeNHPhC(Me) 2 CH 2Me(+)
III-638MeEtMeNHPhC(Me) 2 CH 2Me(−)
III-639MeMeMeNHPhC(Me) 2 CH 2CHF 2racemic
III-640MeMeMeNHPhC(Me) 2 CH 2CHF 2(+)
III-641MeMeMeNHPhC(Me) 2 CH 2CHF 2(−)
III-642MeEtMeNHPhC(Me) 2 CH 2CHF 2racemic
III-643MeEtMeNHPhC(Me) 2 CH 2CHF 2(+)
III-644MeEtMeNHPhC(Me) 2 CH 2CHF 2(−)
III-645MeMeMeNHPhC(Me) 2 CH 2Etracemic
III-646MeMeMeNHPhC(Me) 2 CH 2Et(+)
III-647MeMeMeNHPhC(Me) 2 CH 2Et(−)
III-648MeEtMeNHPhC(Me) 2 CH 2Etracemic
III-649MeEtMeNHPhC(Me) 2 CH 2Et(+)
III-650MeEtMeNHPhC(Me) 2 CH 2Et(−)
TABLE 50 — Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-651MeMeMeNHPhC(Me) 2 CH 2iPrracemic
III-652MeMeMeNHPhC(Me) 2 CH 2iPr(+)
III-653MeMeMeNHPhC(Me) 2 CH 2iPr(−)
III-654MeEtMeNHPhC(Me) 2 CH 2iPrracemic
III-655MeEtMeNHPhC(Me) 2 CH 2iPr(+)
III-656MeEtMeNHPhC(Me) 2 CH 2iPr(−)
III-657MeMeMeNHPhC(Me) 2 CH 2cPrracemic
III-658MeMeMeNHPhC(Me) 2 CH 2cPr(+)
III-659MeMeMeNHPhC(Me) 2 CH 2cPr(−)
III-660MeEtMeNHPhC(Me) 2 CH 2cPrracemic
III-661MeEtMeNHPhC(Me) 2 CH 2cPr(+)
III-662MeEtMeNHPhC(Me) 2 CH 2cPr(−)
III-663MeMeMeNHPh1,1-Cyclopropylene-CH 2Hracemic
III-664MeMeMeNHPh1,1-Cyclopropylene-CH 2H(+)
III-665MeMeMeNHPh1,1-Cyclopropylene-CH 2H(−)
III-666MeEtMeNHPh1,1-Cyclopropylene-CH 2Hracemic
III-667MeEtMeNHPh1,1-Cyclopropylene-CH 2H(+)
III-668MeEtMeNHPh1,1-Cyclopropylene-CH 2H(−)
III-669MeMeMeNHPh1,1-Cyclopropylene-CH 2Meracemic
III-670MeMeMeNHPh1,1-Cyclopropylene-CH 2Me(+)
III-671MeMeMeNHPh1,1-Cyclopropylene-CH 2Me(−)
III-672MeEtMeNHPh1,1-Cyclopropylene-CH 2Meracemic
III-673MeEtMeNHPh1,1-Cyclopropylene-CH 2Me(+)
III-674MeEtMeNHPh1,1-Cyclopropylene-CH 2Me(−)
III-675MeMeMeNHPh1,1-Cyclopropylene-CH 2Hracemic
III-676MeMeMeNHPh1,1-Cyclopropylene-CH 2H(+)
III-677MeMeMeNHPh1,1-Cyclopropylene-CH 2H(−)
III-678MeEtMeNHPh1,1-Cyclopropylene-CH 2Hracemic
III-679MeEtMeNHPh1,1-Cyclopropylene-CH 2H(+)
III-680MeEtMeNHPh1,1-Cyclopropylene-CH 2H(−)
III-681MeMeMeNHPh1,1-Cyclopropylene-CH 2Meracemic
III-682MeMeMeNHPh1,1-Cyclopropylene-CH 2Me(+)
III-683MeMeMeNHPh1,1-Cyclopropylene-CH 2Me(−)
III-684MeEtMeNHPh1,1-Cyclopropylene-CH 2Meracemic
III-685MeEtMeNHPh1,1-Cyclopropylene-CH 2Me(+)
III-686MeEtMeNHPh1,1-Cyclopropylene-CH 2Me(−)
III-687MeMeMeNHPhC(Et) 2 CH 2Hracemic
III-688MeMeMeNHPhC(Et) 2 CH 2H(+)
III-689MeMeMeNHPhC(Et) 2 CH 2H(−)
III-690MeEtMeNHPhC(Et) 2 CH 2Hracemic
III-691MeEtMeNHPhC(Et) 2 CH 2H(+)
III-692MeEtMeNHPhC(Et) 2 CH 2H(−)
III-693MeMeMeNHPhC(Et) 2 CH 2Meracemic
III-694MeMeMeNHPhC(Et) 2 CH 2Me(+)
III-695MeMeMeNHPhC(Et) 2 CH 2Me(−)
III-696MeEtMeNHPhC(Et) 2 CH 2Meracemic
III-697MeEtMeNHPhC(Et) 2 CH 2Me(+)
III-698MeEtMeNHPhC(Et) 2 CH 2Me(−)
III-699MeMeMeNHPhCH 2 -1,1-CyclopropyleneHracemic
III-700MeMeMeNHPhCH 2 -1,1-CyclopropyleneH(R)-
TABLE 51 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-701MeEtMeNHPhCH 2 -1,1-Cyclo-Hracemic
propylene
III-702MeEtMeNHPhCH 2 -1,1-Cyclo-H(R)-
propylene
III-703MeMeMeNHPhCH 2 -1,1-Cyclo-Meracemic
propylene
III-704MeMeMeNHPhCH 2 -1,1-Cyclo-Me(R)-
propylene
III-705MeEtMeNHPhCH 2 -1,1-Cyclo-Meracemic
propylene
III-706MeEtMeNHPhCH 2 -1,1-Cyclo-Me(R)-
propylene
III-707MeMeMeNHPhCH 2 -1,1-cyclo-Hracemic
butylene
III-708MeMeMeNHPhCH 2 -1,1-cyclo-H(R)-
butylene
III-709MeEtMeNHPhCH 2 -1,1-cyclo-Hracemic
butylene
III-710MeEtMeNHPhCH 2 -1,1-cyclo-H(R)-
butylene
III-711MeMeMeNHPhCH 2 -1,1-cyclo-Meracemic
butylene
III-712MeMeMeNHPhCH 2 -1,1-cyclo-Me(R)-
butylene
III-713MeEtMeNHPhCH 2 -1,1-cyclo-Meracemic
butylene
III-714MeEtMeNHPhCH 2 -1,1-cyclo-Me(R)-
butylene
III-715MeMeMeNHPhCH 2 C(Et) 2Hracemic
III-716MeMeMeNHPhCH 2 C(Et) 2H(R)-
III-717MeEtMeNHPhCH 2 C(Et) 2Hracemic
III-718MeEtMeNHPhCH 2 C(Et) 2H(R)-
III-719MeMeMeNHPhCH 2 C(Et) 2Meracemic
III-720MeMeMeNHPhCH 2 C(Et) 2Me(R)-
III-721MeEtMeNHPhCH 2 C(Et) 2Meracemic
III-722MeEtMeNHPhCH 2 C(Et) 2Me(R)-
III-723MeMeMeNHiPrCH 2Meracemic
III-724MeMeMeNHiPrCH 2Me(S)-
III-725MeEtMeNHiPrCH 2Meracemic
III-726MeEtMeNHiPrCH 2Me(S)-
III-727MeMeMeNHiPr(CH 2 ) 2Hracemic
III-728MeMeMeNHiPr(CH 2 ) 2H(R)-
III-729MeEtMeNHiPr(CH 2 ) 2Hracemic
III-730MeEtMeNHiPr(CH 2 ) 2H(R)-
III-731MeMeMeNHiPr(CH 2 ) 2Meracemic
III-732MeMeMeNHiPr(CH 2 ) 2Me(R)-
III-733MeEtMeNHiPr(CH 2 ) 2Meracemic
III-734MeEtMeNHiPr(CH 2 ) 2Me(R)-
III-735MeMeMeNHCF 3CH 2Hracemic
III-736MeMeMeNHCF 3CH 2H(S)-
III-737MeEtMeNHCF 3CH 2Hracemic
III-738MeEtMeNHCF 3CH 2H(S)-
III-739MeMeMeNHCH 2 OHCH 2H
III-740MeEtMeNHCH 2 OHCH 2H
III-741MeMeMeNHCH 2 OMeCH 2Hracemic
III-742MeMeMeNHCH 2 OMeCH 2H(R)-
III-743MeEtMeNHCH 2 OMeCH 2Hracemic
III-744MeEtMeNHCH 2 OMeCH 2H(R)-
III-745MeMeMeNHCH 2 PhCH 2Hracemic
III-746MeMeMeNHCH 2 PhCH 2H(R)-
III-747MeMeMeNHCH 2 PhCH 2H(S)-
III-748MeEtMeNHCH 2 PhCH 2Hracemic
III-749MeEtMeNHCH 2 PhCH 2H(S)-
III-750MeMeMeNH2-F—PhCH 2Meracemic
TABLE 52 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-751MeMeMeNH2-F—PhCH 2Me(S)-
III-752MeEtMeNH2-F—PhCH 2Meracemic
III-753MeEtMeNH2-F—PhCH 2Me(S)-
III-754MeMeMeNH2-F—Ph(CH 2 ) 2Hracemic
III-755MeMeMeNH2-F—Ph(CH 2 ) 2H(R)-
III-756MeEtMeNH2-F—Ph(CH 2 ) 2Hracemic
III-757MeEtMeNH2-F—Ph(CH 2 ) 2H(R)-
III-758MeMeMeNH2-F—Ph(CH 2 ) 2Meracemic
III-759MeMeMeNH2-F—Ph(CH 2 ) 2Me(R)-
III-760MeEtMeNH2-F—Ph(CH 2 ) 2Meracemic
III-761MeEtMeNH2-F—Ph(CH 2 ) 2Me(R)-
III-762MeMeMeNH2-F—PhCH 2 C(Me) 2Hracemic
III-763MeMeMeNH2-F—PhCH 2 C(Me) 2H(R)-
III-764MeEtMeNH2-F—PhCH 2 C(Me) 2Hracemic
III-765MeEtMeNH2-F—PhCH 2 C(Me) 2H(R)-
III-766MeMeMeNH2-F—PhCH 2 C(Me) 2Meracemic
III-767MeMeMeNH2-F—PhCH 2 C(Me) 2Me(R)-
III-768MeEtMeNH2-F—PhCH 2 C(Me) 2Meracemic
III-769MeEtMeNH2-F—PhCH 2 C(Me) 2Me(R)-
III-770MeMeMeNH2-F—PhC(Me) 2 CH 2Hracemic
III-771MeMeMeNH2-F—PhC(Me) 2 CH 2H(+)
III-772MeMeMeNH2-F—PhC(Me) 2 CH 2H(−)
III-773MeEtMeNH2-F—PhC(Me) 2 CH 2Hracemic
III-774MeEtMeNH2-F—PhC(Me) 2 CH 2H(+)
III-775MeEtMeNH2-F—PhC(Me) 2 CH 2H(−)
III-776MeMeMeNH2-F—PhC(Me) 2 CH 2Meracemic
III-777MeMeMeNH2-F—PhC(Me) 2 CH 2Me(+)
III-778MeMeMeNH2-F—PhC(Me) 2 CH 2Me(−)
III-779MeEtMeNH2-F—PhC(Me) 2 CH 2Meracemic
III-780MeEtMeNH2-F—PhC(Me) 2 CH 2Me(+)
III-781MeEtMeNH2-F—PhC(Me) 2 CH 2Me(−)
III-782MeMeMeNH2-F—Ph(CH 2 ) 2Hracemic
III-783MeMeMeNH2-F—Ph(CH 2 ) 2H(R)-
III-784MeEtMeNH2-F—Ph(CH 2 ) 2Hracemic
III-785MeEtMeNH2-F—Ph(CH 2 ) 2H(R)-
III-786MeMeMeNH2-F—Ph(CH 2 ) 2Meracemic
III-787MeMeMeNH2-F—Ph(CH 2 ) 2Me(R)-
III-788MeEtMeNH2-F—Ph(CH 2 ) 2Meracemic
III-789MeEtMeNH2-F—Ph(CH 2 ) 2Me(R)-
III-790MeMeMeNH2-F—PhCH 2 C(Me) 2Hracemic
III-791MeMeMeNH2-F—PhCH 2 C(Me) 2H(R)-
III-792MeEtMeNH2-F—PhCH 2 C(Me) 2Hracemic
III-793MeEtMeNH2-F—PhCH 2 C(Me) 2H(R)-
III-794MeMeMeNH2-F—PhCH 2 C(Me) 2Meracemic
III-795MeMeMeNH2-F—PhCH 2 C(Me) 2Me(R)-
III-796MeEtMeNH2-F—PhCH 2 C(Me) 2Meracemic
III-797MeEtMeNH2-F—PhCH2C(Me)2Me(R)-
III-798MeMeMeNH2-F—PhC(Me) 2 CH 2Hracemic
III-799MeMeMeNH2-F—PhC(Me) 2 CH 2H(+)
III-800MeMeMeNH2-F—PhC(Me) 2 CH 2H(−)
TABLE 53 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-801MeEtMeNH3-F—PhC(Me) 2 CH 2Hracemic
III-802MeEtMeNH3-F—PhC(Me) 2 CH 2H(+)
III-803MeEtMeNH3-F—PhC(Me) 2 CH 2H(−)
III-804MeMeMeNH3-F—PhC(Me) 2 CH 2Meracemic
III-805MeMeMeNH3-F—PhC(Me) 2 CH 2Me(+)
III-806MeMeMeNH3-F—PhC(Me) 2 CH 2Me(−)
III-807MeEtMeNH3-F—PhC(Me) 2 CH 2Meracemic
III-808MeEtMeNH3-F—PhC(Me) 2 CH 2Me(+)
III-809MeEtMeNH3-F—PhC(Me) 2 CH 2Me(−)
III-810MeMeMeNH4-F—Ph(CH 2 ) 2Hracemic
III-811MeMeMeNH4-F—Ph(CH 2 ) 2H(R)-
III-812MeEtMeNH4-F—Ph(CH 2 ) 2Hracemic
III-813MeEtMeNH4-F—Ph(CH 2 ) 2H(R)-
III-814MeMeMeNH4-F—Ph(CH 2 ) 2Meracemic
III-815MeMeMeNH4-F—Ph(CH 2 ) 2Me(R)-
III-816MeEtMeNH4-F—Ph(CH 2 ) 2Meracemic
III-817MeEtMeNH4-F—Ph(CH 2 ) 2Me(R)-
III-818MeMeMeNH4-F—PhCH 2 C(Me) 2Hracemic
III-819MeMeMeNH4-F—PhCH 2 C(Me) 2H(R)-
III-820MeEtMeNH4-F—PhCH 2 C(Me) 2Hracemic
III-821MeEtMeNH4-F—PhCH 2 C(Me) 2H(R)-
III-822MeMeMeNH4-F—PhCH 2 C(Me) 2Meracemic
III-823MeMeMeNH4-F—PhCH 2 C(Me) 2Me(R)-
III-824MeEtMeNH4-F—PhCH 2 C(Me) 2Meracemic
III-825MeEtMeNH4-F—PhCH 2 C(Me) 2Me(R)-
III-826MeMeMeNH4-F—PhC(Me) 2 CH 2Hracemic
III-827MeMeMeNH4-F—PhC(Me) 2 CH 2H(+)
III-828MeMeMeNH4-F—PhC(Me) 2 CH 2H(−)
III-829MeEtMeNH4-F—PhC(Me) 2 CH 2Hracemic
III-830MeEtMeNH4-F—PhC(Me) 2 CH 2H(+)
III-831MeEtMeNH4-F—PhC(Me) 2 CH 2H(−)
III-832MeMeMeNH4-F—PhC(Me) 2 CH 2Meracemic
III-833MeMeMeNH4-F—PhC(Me) 2 CH 2Me(+)
III-834MeMeMeNH4-F—PhC(Me) 2 CH 2Me(−)
III-835MeEtMeNH4-F—PhC(Me) 2 CH 2Meracemic
III-836MeEtMeNH4-F—PhC(Me) 2 CH 2Me(+)
III-837MeEtMeNH4-F—PhC(Me) 2 CH 2Me(−)
III-838MeMeMeNH2-Cl—PhCH 2Hracemic
III-839MeMeMeNH2-Cl—PhCH 2H(S)-
III-840MeEtMeNH2-Cl—PhCH 2Hracemic
III-841MeEtMeNH2-Cl—PhCH 2H(S)-
III-842MeMeMeNH2-Cl—PhCH 2Meracemic
III-843MeMeMeNH2-Cl—PhCH 2Me(S)-
III-844MeEtMeNH2-Cl—PhCH 2Meracemic
III-845MeEtMeNH2-Cl—PhCH 2Me(S)-
III-846MeMeMeNH2-Cl—Ph(CH 2 ) 2Hracemic
III-847MeMeMeNH2-Cl—Ph(CH 2 ) 2H(R)-
III-848MeEtMeNH2-Cl—Ph(CH 2 ) 2Hracemic
III-849MeEtMeNH2-Cl—Ph(CH 2 ) 2H(R)-
III-850MeMeMeNH2-Cl—Ph(CH 2 ) 2Meracemic
TABLE 54 — (IIII)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-851MeMeMeNH2-Cl—Ph(CH 2 ) 2Me(R)-
III-852MeEtMeNH2-Cl—Ph(CH 2 ) 2Meracemic
III-853MeEtMeNH2-Cl—Ph(CH 2 ) 2Me(R)-
III-854MeMeMeNH2-Cl—PhCH 2 C(Me) 2Hracemic
III-855MeMeMeNH2-Cl—PhCH 2 C(Me) 2H(R)-
III-856MeEtMeNH2-Cl—PhCH 2 C(Me) 2Hracemic
III-857MeEtMeNH2-Cl—PhCH 2 C(Me) 2H(R)-
III-858MeMeMeNH2-Cl—PhCH 2 C(Me) 2Meracemic
III-859MeMeMeNH2-Cl—PhCH 2 C(Me) 2Me(R)-
III-860MeEtMeNH2-Cl—PhCH 2 C(Me) 2Meracemic
III-861MeEtMeNH2-Cl—PhCH 2 C(Me) 2Me(R)-
III-862MeMeMeNH2-Cl—PhC(Me) 2 CH 2Hracemic
III-863MeMeMeNH2-Cl—PhC(Me) 2 CH 2H(+)
III-864MeMeMeNH2-Cl—PhC(Me) 2 CH 2H(−)
III-865MeEtMeNH2-Cl—PhC(Me) 2 CH 2Hracemic
III-866MeEtMeNH2-Cl—PhC(Me) 2 CH 2H(+)
III-867MeEtMeNH2-Cl—PhC(Me) 2 CH 2H(−)
III-868MeMeMeNH2-Cl—PhC(Me) 2 CH 2Meracemic
III-869MeMeMeNH2-Cl—PhC(Me) 2 CH 2Me(+)
III-870MeMeMeNH2-Cl—PhC(Me) 2 CH 2Me(−)
III-871MeEtMeNH2-Cl—PhC(Me) 2 CH 2Meracemic
III-872MeEtMeNH2-Cl—PhC(Me) 2 CH 2Me(+)
III-873MeEtMeNH2-Cl—PhC(Me) 2 CH 2Me(−)
III-874MeMeMeNH2-Cl—PhCH 2Hracemic
III-875MeMeMeNH2-Cl—PhCH 2H(S)-
III-876MeEtMeNH2-Cl—PhCH 2Hracemic
III-877MeEtMeNH2-Cl—PhCH 2H(S)-
III-878MeMeMeNH2-Cl—PhCH 2Meracemic
III-879MeMeMeNH2-Cl—PhCH 2Me(S)-
III-880MeEtMeNH2-Cl—PhCH 2Meracemic
III-881MeEtMeNH2-Cl—PhCH 2Me(S)-
III-882MeMeMeNH2-Cl—Ph(CH 2 ) 2Hracemic
III-883MeMeMeNH2-Cl—Ph(CH 2 ) 2H(R)-
III-884MeEtMeNH2-Cl—Ph(CH 2 ) 2Hracemic
III-885MeEtMeNH2-Cl—Ph(CH 2 ) 2H(R)-
III-886MeMeMeNH2-Cl—Ph(CH 2 ) 2Meracemic
III-887MeMeMeNH2-Cl—Ph(CH 2 ) 2Me(R)-
III-888MeEtMeNH2-Cl—Ph(CH 2 ) 2Meracemic
III-889MeEtMeNH2-Cl—Ph(CH 2 ) 2Me(R)-
III-890MeMeMeNH2-Cl—PhCH 2 C(Me) 2Hracemic
III-891MeMeMeNH2-Cl—PhCH 2 C(Me) 2H(R)-
III-892MeEtMeNH2-Cl—PhCH 2 C(Me) 2Hracemic
III-893MeEtMeNH2-Cl—PhCH 2 C(Me) 2H(R)-
III-894MeMeMeNH2-Cl—PhCH 2 C(Me) 2Meracemic
III-895MeMeMeNH2-Cl—PhCH 2 C(Me) 2Me(R)-
III-896MeEtMeNH2-Cl—PhCH 2 C(Me) 2Meracemic
III-897MeEtMeNH2-Cl—PhCH 2 C(Me) 2Me(R)-
III-898MeMeMeNH2-Cl—PhC(Me) 2 CH 2Hracemic
III-899MeMeMeNH2-Cl—PhC(Me) 2 CH 2H(+)
III-900MeMeMeNH2-Cl—PhC(Me) 2 CH 2H(−)
TABLE 55 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-901MeEtMeNH3-Cl—PhC(Me) 2 CH 2Hracemic
III-902MeEtMeNH3-Cl—PhC(Me) 2 CH 2H(+)
III-903MeEtMeNH3-Cl—PhC(Me) 2 CH 2H(−)
III-904MeMeMeNH3-Cl—PhC(Me) 2 CH 2Meracemic
III-905MeMeMeNH3-Cl—PhC(Me) 2 CH 2Me(+)
III-906MeMeMeNH3-Cl—PhC(Me) 2 CH 2Me(−)
III-907MeEtMeNH3-Cl—PhC(Me) 2 CH 2Meracemic
III-908MeEtMeNH3-Cl—PhC(Me) 2 CH 2Me(+)
III-909MeEtMeNH3-Cl—PhC(Me) 2 CH 2Me(−)
III-910MeMeMeNH3-Cl—PhCH 2Hracemic
III-911MeMeMeNH3-Cl—PhCH 2H(S)-
III-912MeEtMeNH3-Cl—PhCH 2Hracemic
III-913MeEtMeNH3-Cl—PhCH 2H(S)-
III-914MeMeMeNH3-Cl—PhCH 2Meracemic
III-915MeMeMeNH3-Cl—PhCH 2Me(S)-
III-916MeEtMeNH3-Cl—PhCH 2Meracemic
III-917MeEtMeNH3-Cl—PhCH 2Me(S)-
III-918MeMeMeNH3-Cl—Ph(CH 2 ) 2Hracemic
III-919MeMeMeNH3-Cl—Ph(CH 2 ) 2H(R)-
III-920MeEtMeNH3-Cl—Ph(CH 2 ) 2Hracemic
III-921MeEtMeNH3-Cl—Ph(CH 2 ) 2H(R)-
III-922MeMeMeNH3-Cl—Ph(CH 2 ) 2Meracemic
III-923MeMeMeNH3-Cl—Ph(CH 2 ) 2Me(R)-
III-924MeEtMeNH3-Cl—Ph(CH 2 ) 2Meracemic
III-925MeEtMeNH3-Cl—Ph(CH 2 ) 2Me(R)-
III-926MeMeMeNH3-Cl—PhCH 2 C(Me) 2Hracemic
III-927MeMeMeNH3-Cl—PhCH 2 C(Me) 2H(R)-
III-928MeEtMeNH3-Cl—PhCH 2 C(Me) 2Hracemic
III-929MeEtMeNH3-Cl—PhCH 2 C(Me) 2H(R)-
III-930MeMeMeNH3-Cl—PhCH 2 C(Me) 2Meracemic
III-931MeMeMeNH3-Cl—PhCH 2 C(Me) 2Me(R)-
III-932MeEtMeNH3-Cl—PhCH 2 C(Me) 2Meracemic
III-933MeEtMeNH3-Cl—PhCH 2 C(Me) 2Me(R)-
III-934MeMeMeNH3-Cl—PhC(Me) 2 CH 2Hracemic
III-935MeMeMeNH3-Cl—PhC(Me) 2 CH 2H(+)
III-936MeMeMeNH3-Cl—PhC(Me) 2 CH 2H(−)
III-937MeEtMeNH3-Cl—PhC(Me) 2 CH 2Hracemic
III-938MeEtMeNH3-Cl—PhC(Me) 2 CH 2H(+)
III-939MeEtMeNH3-Cl—PhC(Me) 2 CH 2H(−)
III-940MeMeMeNH3-Cl—PhC(Me) 2 CH 2Meracemic
III-941MeMeMeNH3-Cl—PhC(Me) 2 CH 2Me(+)
III-942MeMeMeNH3-Cl—PhC(Me) 2 CH 2Me(−)
III-943MeEtMeNH3-Cl—PhC(Me) 2 CH 2Meracemic
III-944MeEtMeNH3-Cl—PhC(Me) 2 CH 2Me(+)
III-945MeEtMeNH4-Cl—PhC(Me) 2 CH 2Me(−)
III-946MeMeMeNH2-Me—PhCH 2Hracemic
III-947MeMeMeNH2-Me—PhCH 2H(S)-
III-948MeEtMeNH2-Me—PhCH 2Hracemic
III-949MeEtMeNH2-Me—PhCH 2H(S)-
III-950MeMeMeNH2-Me—PhCH 2Meracemic
TABLE 56 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-951MeMeMeNH2-Me—PhCH 2Me(S)-
III-952MeEtMeNH2-Me—PhCH 2Meracemic
III-953MeEtMeNH2-Me—PhCH 2Me(S)-
III-954MeMeMeNH2-Me—Ph(CH 2 ) 2Hracemic
III-955MeMeMeNH2-Me—Ph(CH 2 ) 2H(R)-
III-956MeEtMeNH2-Me—Ph(CH 2 ) 2Hracemic
III-957MeEtMeNH2-Me—Ph(CH 2 ) 2H(R)-
III-958MeMeMeNH2-Me—Ph(CH 2 ) 2Meracemic
III-959MeMeMeNH2-Me—Ph(CH 2 ) 2Me(R)-
III-960MeEtMeNH2-Me—Ph(CH 2 ) 2Meracemic
III-961MeEtMeNH2-Me—Ph(CH 2 ) 2Me(R)-
III-962MeMeMeNH2-Me—PhCH 2 C(Me) 2Hracemic
III-963MeMeMeNH2-Me—PhCH 2 C(Me) 2H(R)-
III-964MeEtMeNH2-Me—PhCH 2 C(Me) 2Hracemic
III-965MeEtMeNH2-Me—PhCH 2 C(Me) 2H(R)-
III-966MeMeMeNH2-Me—PhCH 2 C(Me) 2Meracemic
III-967MeMeMeNH2-Me—PhCH 2 C(Me) 2Me(R)-
III-968MeEtMeNH2-Me—PhCH 2 C(Me) 2Meracemic
III-969MeEtMeNH2-Me—PhCH 2 C(Me) 2Me(R)-
III-970MeMeMeNH2-Me—PhC(Me) 2 CH 2Hracemic
III-971MeMeMeNH2-Me—PhC(Me) 2 CH 2H(+)
III-972MeMeMeNH2-Me—PhC(Me) 2 CH 2H(−)
III-973MeEtMeNH2-Me—PhC(Me) 2 CH 2Hracemic
III-974MeEtMeNH2-Me—PhC(Me) 2 CH 2H(+)
III-975MeEtMeNH2-Me—PhC(Me) 2 CH 2H(−)
III-976MeMeMeNH2-Me—PhC(Me) 2 CH 2Meracemic
III-977MeMeMeNH2-Me—PhC(Me) 2 CH 2Me(+)
III-978MeMeMeNH2-Me—PhC(Me) 2 CH 2Me(−)
III-979MeEtMeNH2-Me—PhC(Me) 2 CH 2Meracemic
III-980MeEtMeNH2-Me—PhC(Me) 2 CH 2Me(+)
III-981MeEtMeNH2-Me—PhC(Me) 2 CH 2Me(−)
III-982MeMeMeNH3-Me—PhCH 2Hracemic
III-983MeMeMeNH3-Me—PhCH 2H(S)-
III-984MeEtMeNH3-Me—PhCH 2Hracemic
III-985MeEtMeNH3-Me—PhCH 2H(S)-
III-986MeMeMeNH3-Me—PhCH 2Meracemic
III-987MeMeMeNH3-Me—PhCH 2Me(S)-
III-988MeEtMeNH3-Me—PhCH 2Meracemic
III-989MeEtMeNH3-Me—PhCH 2Me(S)-
III-990MeMeMeNH3-Me—Ph(CH 2 ) 2Hracemic
III-991MeMeMeNH3-Me—Ph(CH 2 ) 2H(R)-
III-992MeEtMeNH3-Me—Ph(CH 2 ) 2Hracemic
III-993MeEtMeNH3-Me—Ph(CH 2 ) 2H(R)-
III-994MeMeMeNH3-Me—Ph(CH 2 ) 2Meracemic
III-995MeMeMeNH3-Me—Ph(CH 2 ) 2Me(R)-
III-996MeEtMeNH3-Me—Ph(CH 2 ) 2Meracemic
III-997MeEtMeNH3-Me—Ph(CH 2 ) 2Me(R)-
III-998MeMeMeNH3-Me—PhCH 2 C(Me) 2Hracemic
III-999MeMeMeNH3-Me—PhCH 2 C(Me) 2H(R)-
III-1000MeEtMeNH3-Me—PhCH 2 C(Me) 2Hracemic
TABLE 57 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-1001MeEtMeNH3-Me—PhCH 2 C(Me) 2H(R)-
III-1002MeMeMeNH3-Me—PhCH 2 C(Me) 2Meracemic
III-1003MeMeMeNH3-Me—PhCH 2 C(Me) 2Me(R)-
III-1004MeEtMeNH3-Me—PhCH 2 C(Me) 2Meracemic
III-1005MeEtMeNH3-Me—PhCH 2 C(Me) 2Me(R)-
III-1006MeMeMeNH3-Me—PhC(Me) 2 CH 2Hracemic
III-1007MeMeMeNH3-Me—PhC(Me) 2 CH 2H(+)
III-1008MeMeMeNH3-Me—PhC(Me) 2 CH 2H(−)
III-1009MeEtMeNH3-Me—PhC(Me) 2 CH 2Hracemic
III-1010MeEtMeNH3-Me—PhC(Me) 2 CH 2H(+)
III-1011MeEtMeNH3-Me—PhC(Me) 2 CH 2H(−)
III-1012MeMeMeNH3-Me—PhC(Me) 2 CH 2Meracemic
III-1013MeMeMeNH3-Me—PhC(Me) 2 CH 2Me(+)
III-1014MeMeMeNH3-Me—PhC(Me) 2 CH 2Me(−)
III-1015MeEtMeNH3-Me—PhC(Me) 2 CH 2Meracemic
III-1016MeEtMeNH3-Me—PhC(Me) 2 CH 2Me(+)
III-1017MeEtMeNH3-Me—PhC(Me) 2 CH 2Me(−)
III-1018MeMeMeNH4-Me—PhCH 2Hracemic
III-1019MeMeMeNH4-Me—PhCH 2H(S)-
III-1020MeEtMeNH4-Me—PhCH 2Hracemic
III-1021MeEtMeNH4-Me—PhCH 2H(S)-
III-1022MeMeMeNH4-Me—PhCH 2Meracemic
III-1023MeMeMeNH4-Me—PhCH 2Me(S)-
III-1024MeEtMeNH4-Me—PhCH 2Meracemic
III-1025MeEtMeNH4-Me—PhCH 2Me(S)-
III-1026MeMeMeNH4-Me—Ph(CH 2 ) 2Hracemic
III-1027MeMeMeNH4-Me—Ph(CH 2 ) 2H(R)-
III-1028MeEtMeNH4-Me—Ph(CH 2 ) 2Hracemic
III-1029MeEtMeNH4-Me—Ph(CH 2 ) 2H(R)-
III-1030MeMeMeNH4-Me—Ph(CH 2 ) 2Meracemic
III-1031MeMeMeNH4-Me—Ph(CH 2 ) 2Me(R)-
III-1032MeEtMeNH4-Me—Ph(CH 2 ) 2Meracemic
III-1033MeEtMeNH4-Me—Ph(CH 2 ) 2Me(R)-
III-1034MeMeMeNH4-Me—PhCH 2 C(Me) 2Hracemic
III-1035MeMeMeNH4-Me—PhCH 2 C(Me) 2H(R)-
III-1036MeEtMeNH4-Me—PhCH 2 C(Me) 2Hracemic
III-1037MeEtMeNH4-Me—PhCH 2 C(Me) 2H(R)-
III-1038MeMeMeNH4-Me—PhCH 2 C(Me) 2Meracemic
III-1039MeMeMeNH4-Me—PhCH 2 C(Me) 2Me(R)-
III-1040MeEtMeNH4-Me—PhCH 2 C(Me) 2Meracemic
III-1041MeEtMeNH4-Me—PhCH 2 C(Me) 2Me(R)-
III-1042MeMeMeNH4-Me—PhC(Me) 2 CH 2Hracemic
III-1043MeMeMeNH4-Me—PhC(Me) 2 CH 2H(+)
III-1044MeMeMeNH4-Me—PhC(Me) 2 CH 2H(−)
III-1045MeEtMeNH4-Me—PhC(Me) 2 CH 2Hracemic
III-1046MeEtMeNH4-Me—PhC(Me) 2 CH 2H(+)
III-1047MeEtMeNH4-Me—PhC(Me) 2 CH 2H(−)
III-1048MeMeMeNH4-Me—PhC(Me) 2 CH 2Meracemic
III-1049MeMeMeNH4-Me—PhC(Me) 2 CH 2Me(+)
III-1050MeMeMeNH4-Me—PhC(Me) 2 CH 2Me(−)
TABLE 58 — (III) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
III-1051MeEtMeNH4-Me—PhC(Me) 2 CH 2Meracemic
III-1052MeEtMeNH4-Me—PhC(Me) 2 CH 2Me(+)
III-1053MeEtMeNH4-Me—PhC(Me) 2 CH 2Me(−)
III-1054MeMeMe—Ph—Hracemic
III-1055MeMeMe—Ph—H(R)-
III-1056MeEtMe—Ph—Hracemic
III-1057MeEtMe—Ph—H(R)-
III-1058MeMeMe—Ph—Meracemic
III-1059MeMeMe—Ph—Me(R)-
III-1060MeEtMe—Ph—Meracemic
III-1061MeEtMe—Ph—Me(R)-
III-1062MeMeMe—Ph—CHF 2racemic
III-1063MeMeMe—Ph—CHF 2(R)-
III-1064MeEtMe—Ph—CHF 2racemic
III-1065MeEtMe—Ph—CHF 2(R)-
III-1066MeMeMe—Ph—CF 3racemic
III-1067MeMeMe—Ph—CF 3(R)-
III-1068MeEtMe—Ph—CF 3racemic
III-1069MeEtMe—Ph—CF 3(R)-
III-1070MeMeMe—Ph—Etracemic
III-1071MeMeMe—Ph—Et(R)-
III-1072MeEtMe—Ph—Etracemic
III-1073MeEtMe—Ph—Et(R)-
III-1074MeMeMe—Ph—CF 2 CH 3Cracemic
III-1075MeMeMe—Ph—CF 2 CH 3(R)-
III-1076MeEtMe—Ph—CF 2 CH 3Cracemic
III-1077MeEtMe—Ph—CF 2 CH 3(R)-
III-1078MeMeMe—Ph—nPrracemic
III-1079MeMeMe—Ph—nPr(R)-
III-1080MeEtMe—Ph—nPrracemic
III-1081MeEtMe—Ph—nPr(R)-
III-1082MeMeMe—Ph—nBuracemic
III-1083MeMeMe—Ph—nBu(R)-
III-1084MeEtMe—Ph—nBuracemic
III-1085MeEtMe—Ph—nBu(R)-
III-1086MeMeMe—Ph—iPrracemic
III-1087MeMeMe—Ph—iPr(R)-
III-1088MeEtMe—Ph—iPrracemic
III-1089MeEtMe—Ph—iPr(R)-
III-1090MeMeMe—Ph—cPrracemic
III-1091MeMeMe—Ph—cPr(R)-
III-1092MeEtMe—Ph—cPrracemic
III-1093MeEtMe—Ph—cPr(R)-
III-1094MeMeMe—Ph—Phracemic
III-1095MeMeMe—Ph—Ph(R)-
III-1096MeEtMe—Ph—Phracemic
III-1097MeEtMe—Ph—Ph(R)-
III-1098MeMeMe—PhCH 2CHF 2racemic
III-1099MeMeMe—PhCH 2CHF 2(S)-
III-1100MeMeMe—PhCH 2Etracemic
TABLE 59 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-1101MeMeMe—PhCH 2Et(S)-
III-1102MeMeMe—PhCH 2Phracemic
III-1103MeMeMe—PhCH 2Ph(R)-
III-1104MeMeMe—Ph(CH 2 ) 2Hracemic
III-1105MeMeMe—Ph(CH 2 ) 2H(S)-
III-1106MeMeMe—Ph(CH 2 ) 2Meracemic
III-1107MeMeMe—Ph(CH 2 ) 2Me(S)-
III-1108MeMeMe—Ph(CH 2 ) 2CHF 2racemic
III-1109MeMeMe—Ph(CH 2 ) 2CHF 2(S)-
III-1110MeMeMe—Ph(CH 2 ) 2Etracemic
III-1111MeMeMe—Ph(CH 2 ) 2Et(S)-
III-1112MeMeMe—H—H
III-1113MeMeMe—H—Me
III-1114MeMeMe—H—CHF 2
III-1115MeMeMe—H—CF 3
III-1116MeMeMe—H—Et
III-1117MeMeMe—H—nPr
III-1118MeMeMe—H—iPr
III-1119MeMeMe—H—cPr
III-1120MeMeMe—H—Ph
III-1121MeMeMe—Me—Hracemic
III-1122MeMeMe—Me—H(R)-
III-1123MeMeMe—Me—Meracemic
III-1124MeMeMe—Me—Me(R)-
III-1125MeMeMe—Me—CHF 2racemic
III-1126MeMeMe—Me—CHF 2(R)-
III-1127MeMeMe—Me—CF 3racemic
III-1128MeMeMe—Me—CF 3(R)-
III-1129MeMeMe—Me—Etracemic
III-1130MeMeMe—Me—Et(R)-
III-1131MeMeMe—Me—nPrracemic
III-1132MeMeMe—Me—nPr(R)-
III-1133MeMeMe—Me—iPrracemic
III-1134MeMeMe—Me—iPr(R)-
III-1135MeMeMe—Me—cPrracemic
III-1136MeMeMe—Me—cPr(R)-
III-1137MeMeMe—Me—cHexracemic
III-1138MeMeMe—Me—cHex(R)-
III-1139MeMeMe—Me—Phracemic
III-1140MeMeMe—Me—Ph(R)-
III-1141MeMeMe—Me—2-F—Phracemic
III-1142MeMeMe—Me—2-F—Ph(R)-
III-1143MeMeMe—Me—3-F—Phracemic
III-1144MeMeMe—Me—3-F—Ph(R)-
III-1145MeMeMe—Me—4-F—Phracemic
III-1146MeMeMe—Me—4-F—Ph(R)-
III-1147MeMeMe—Me—2-Cl—Phracemic
III-1148MeMeMe—Me—2-Cl—Ph(R)-
III-1149MeMeMe—Me—3-Cl—Phracemic
III-1150MeMeMe—Me—3-Cl—Ph(R)-
TABLE 60 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-1151MeMeMe—Me—4-Cl—Phracemic
III-1152MeMeMe—Me—4-Cl—Ph(R)-
III-1153MeMeMe—Me—2-Pyracemic
III-1154MeMeMe—Me—2-Py(R)-
III-1155MeMeMe—Me—3-Pyracemic
III-1156MeMeMe—Me—3-Py(R)-
III-1157MeMeMe—Me—4-Pyracemic
III-1158MeMeMe—Me—4-Py(R)-
III-1159MeMeMe—iPr—Hracemic
III-1160MeMeMe—iPr—H(R)-
III-1161MeMeMe—iPr—Meracemic
III-1162MeMeMe—iPr—Me(R)-
III-1163MeMeMe—iPr—CHF 2racemic
III-1164MeMeMe—iPr—CHF 2(R)-
III-1165MeMeMe—iPr—CF 3racemic
III-1166MeMeMe—iPr—CF 3(R)-
III-1167MeMeMe—iPr—Etracemic
III-1168MeMeMe—iPr—Et(R)-
III-1169MeMeMe—iPr—nPrracemic
III-1170MeMeMe—iPr—nPr(R)-
III-1171MeMeMe—iPr—iPrracemic
III-1172MeMeMe—iPr—iPr(R)-
III-1173MeMeMe—iPr—cPrracemic
III-1174MeMeMe—iPr—cPr(R)-
III-1175MeMeMe—iPr—Phracemic
III-1176MeMeMe—iPr—Ph(R)-
III-1177MeMeMe—CF 3—Hracemic
III-1178MeMeMe—CF 3—H(R)-
III-1179MeMeMe—CF 3—Meracemic
III-1180MeMeMe—CF 3—Me(R)-
III-1181MeMeMe—CF 3—CHF 2racemic
III-1182MeMeMe—CF 3—CHF 2(R)-
III-1183MeMeMe—CF 3—CF 3racemic
III-1184MeMeMe—CF 3—CF 3(R)-
III-1185MeMeMe—CF 3—Etracemic
III-1186MeMeMe—CF 3—Et(R)-
III-1187MeMeMe—CF 3—nPrracemic
III-1188MeMeMe—CF 3—nPr(R)-
III-1189MeMeMe—CF 3—iPrracemic
III-1190MeMeMe—CF 3—iPr(R)-
III-1191MeMeMe—CF 3—cPrracemic
III-1192MeMeMe—CF 3—cPr(R)-
III-1193MeMeMe—CF 3—Phracemic
III-1194MeMeMe—CF 3—Ph(R)-
III-1195MeMeMe—CH 2 OH—Hracemic
III-1196MeMeMe—CH 2 OH—H(R)-
III-1197MeMeMe—CH 2 OH—Meracemic
III-1198MeMeMe—CH 2 OH—Me(R)-
III-1199MeMeMe—CH 2 OH—CHF 2racemic
III-1200MeMeMe—CH 2 OH—CHF 2(R)-
TABLE 61 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-1201MeMeMe—CH 2 OH—CF 3racemic
III-1202MeMeMe—CH 2 OH—CF 3(R)-
III-1203MeMeMe—CH 2 OH—Etracemic
III-1204MeMeMe—CH 2 OH—Et(R)-
III-1205MeMeMe—CH 2 OH—nPrracemic
III-1206MeMeMe—CH 2 OH—nPr(R)-
III-1207MeMeMe—CH 2 OH—iPrracemic
III-1208MeMeMe—CH 2 OH—iPr(R)-
III-1209MeMeMe—CH 2 OH—cPrracemic
III-1210MeMeMe—CH 2 OH—cPr(R)-
III-1211MeMeMe—CH 2 OH—Phracemic
III-1212MeMeMe—CH 2 OH—Ph(R)-
III-1213MeMeMe—CH 2 OMe—Hracemic
III-1214MeMeMe—CH 2 OMe—H(R)-
III-1215MeMeMe—CH 2 OMe—Meracemic
III-1216MeMeMe—CH 2 OMe—Me(R)-
III-1217MeMeMe—CH 2 OMe—CHF 2racemic
III-1218MeMeMe—CH 2 OMe—CHF 2(R)-
III-1219MeMeMe—CH 2 OMe—CF 3racemic
III-1220MeMeMe—CH 2 OMe—CF 3(R)-
III-1221MeMeMe—CH 2 OMe—Etracemic
III-1222MeMeMe—CH 2 OMe—Et(R)-
III-1223MeMeMe—CH 2 OMe—nPrracemic
III-1224MeMeMe—CH 2 OMe—nPr(R)-
III-1225MeMeMe—CH 2 OMe—iPrracemic
III-1226MeMeMe—CH 2 OMe—iPr(R)-
III-1227MeMeMe—CH 2 OMe—cPrracemic
III-1228MeMeMe—CH 2 OMe—cPr(R)-
III-1229MeMeMe—CH 2 OMe—Phracemic
III-1230MeMeMe—CH 2 OMe—Ph(R)-
III-1231MeMeMe—CH 2 OBn—Hracemic
III-1232MeMeMe—CH 2 OBn—H(R)-
III-1233MeMeMe—CH 2 OBn—Meracemic
III-1234MeMeMe—CH 2 OBn—Me(R)-
III-1235MeMeMe—CH 2 OBn—Phracemic
III-1236MeMeMe—CH 2 OBn—Ph(R)-
III-1237MeMeMe—CH 2 NMe 2—Hracemic
III-1238MeMeMe—CH 2 NMe 2—H(R)-
III-1239MeMeMe—CH 2 NMe 2—Meracemic
III-1240MeMeMe—CH 2 NMe 2—Me(R)-
III-1241MeMeMe—CH 2 NMe 2—CHF 2racemic
III-1242MeMeMe—CH 2 NMe 2—CHF 2(R)-
III-1243MeMeMe—CH 2 NMe 2—CF 3racemic
III-1244MeMeMe—CH 2 NMe 2—CF 3(R)-
III-1245MeMeMe—CH 2 NMe 2—Etracemic
III-1246MeMeMe—CH 2 NMe 2—Et(R)-
III-1247MeMeMe—CH 2 NMe 2—nPrracemic
III-1248MeMeMe—CH 2 NMe 2—nPr(R)-
III-1249MeMeMe—CH 2 NMe 2—iPrracemic
III-1250MeMeMe—CH 2 NMe 2—iPr(R)-
TABLE 62 — (III)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 5uration
III-1251MeMeMe—CH 2 NMe 2—cPrracemic
III-1252MeMeMe—CH 2 NMe 2—cPr(R)-
III-1253MeMeMe—CH 2 NMe 2—Phracemic
III-1254MeMeMe—CH 2 NMe 2—Ph(R)-
III-1255MeMeMe—CH 2 -(3,3-difluoro—Hracemic
—pyrrolidyl)—
III-1256MeMeMe—CH 2 -(3,3-difluoro—H(R)-
—pyrrolidyl)—
III-1257MeMeMe—CH 2 -(3,3-difluoro—Meracemic
—pyrrolidyl)—
III-1258MeMeMe—CH 2 -(3,3-difluoro—Me(R)-
—pyrrolidyl)—
III-1259MeMeMe—CH 2 -(3,3-difluoro—Phracemic
—pyrrolidyl)—
III-1260MeMeMe—CH 2 -(3,3-difluoro—Ph(R)-
—pyrrolidyl)—
III-1261MeMeMe—2-F—Ph—Hracemic
III-1262MeMeMe—2-F—Ph—H(R)-
III-1263MeMeMe—2-F—Ph—Meracemic
III-1264MeMeMe—2-F—Ph—Me(R)-
III-1265MeMeMe—2-F—Ph—CHF 2racemic
III-1266MeMeMe—2-F—Ph—CHF 2(R)-
III-1267MeMeMe—2-F—Ph—CF 3racemic
III-1268MeMeMe—2-F—Ph—CF 3(R)-
III-1269MeMeMe—2-F—Ph—Etracemic
III-1270MeMeMe—2-F—Ph—Et(R)-
III-1271MeMeMe—2-F—Ph—nPrracemic
III-1272MeMeMe—2-F—Ph—nPr(R)-
III-1273MeMeMe—2-F—Ph—iPrracemic
III-1274MeMeMe—2-F—Ph—iPr(R)-
III-1275MeMeMe—2-F—Ph—cPrracemic
III-1276MeMeMe—2-F—Ph—cPr(R)-
III-1277MeMeMe—2-F—Ph—Hracemic
III-1278MeMeMe—2-F—Ph—H(R)-
III-1279MeMeMe—2-F—Ph—Meracemic
III-1280MeMeMe—2-F—Ph—Me(R)-
III-1281MeMeMe—2-F—Ph—CHF 2racemic
III-1282MeMeMe—2-F—Ph—CHF 2(R)-
III-1283MeMeMe—2-F—Ph—CF 3racemic
III-1284MeMeMe—2-F—Ph—CF 3(R)-
III-1285MeMeMe—2-F—Ph—Etracemic
III-1286MeMeMe—2-F—Ph—Et(R)-
III-1287MeMeMe—2-F—Ph—nPrracemic
III-1288MeMeMe—2-F—Ph—nPr(R)-
III-1289MeMeMe—2-F—Ph—iPrracemic
III-1290MeMeMe—2-F—Ph—iPr(R)-
III-1291MeMeMe—2-F—Ph—cPrracemic
III-1292MeMeMe—2-F—Ph—cPr(R)-
III-1293MeMeMe—2-F—Ph—Hracemic
III-1294MeMeMe—2-F—Ph—H(R)-
III-1295MeMeMe—2-F—Ph—Meracemic
III-1296MeMeMe—2-F—Ph—Me(R)-
III-1297MeMeMe—2-F—Ph—CHF 2racemic
III-1298MeMeMe—2-F—Ph—CHF 2(R)-
III-1299MeMeMe—2-F—Ph—CF 3racemic
III-1300MeMeMe—2-F—Ph—CF 3(R)-
TABLE 63 — (III) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
III-1301MeMeMe—4-F—Ph—Etracemic
III-1302MeMeMe—4-F—Ph—Et(R)-
III-1303MeMeMe—4-F—Ph—nPrracemic
III-1304MeMeMe—4-F—Ph—nPr(R)-
III-1305MeMeMe—4-F—Ph—iPrracemic
III-1306MeMeMe—4-F—Ph—iPr(R)-
III-1307MeMeMe—4-F—Ph—cPrracemic
III-1308MeMeMe—4-F—Ph—cPr(R)-
III-1309MeMeMe—2-thienyl—Hracemic
III-1310MeMeMe—2-thienyl—H(S)-
III-1311MeMeMe—2-thienyl—Meracemic
III-1312MeMeMe—2-thienyl—Me(S)-
III-1313MeMeMe—2-thienyl—CHF 2racemic
III-1314MeMeMe—2-thienyl—CHF 2(S)-
III-1315MeMeMe—2-thienyl—CF 3racemic
III-1316MeMeMe—2-thienyl—CF 3(S)-
III-1317MeMeMe—2-thienyl—Etracemic
III-1318MeMeMe—2-thienyl—Et(S)-
III-1319MeMeMe—2-thienyl—nPrracemic
III-1320MeMeMe—2-thienyl—nPr(S)-
III-1321MeMeMe—2-thienyl—iPrracemic
III-1322MeMeMe—2-thienyl—iPr(S)-
III-1323MeMeMe—2-thienyl—cPrracemic
III-1324MeMeMe—2-thienyl—cPr(S)-
III-1325MeMeMe—3-thienyl—Hracemic
III-1326MeMeMe—3-thienyl—H(R)-
III-1327MeMeMe—3-thienyl—Meracemic
III-1328MeMeMe—3-thienyl—Me(R)-
III-1329MeMeMe—3-thienyl—CHF 2racemic
III-1330MeMeMe—3-thienyl—CHF 2(R)-
III-1331MeMeMe—3-thienyl—CF 3racemic
III-1332MeMeMe—3-thienyl—CF 3(R)-
III-1333MeMeMe—3-thienyl—Etracemic
III-1334MeMeMe—3-thienyl—Et(R)-
III-1335MeMeMe—3-thienyl—nPrracemic
III-1336MeMeMe—3-thienyl—nPr(R)-
III-1337MeMeMe—3-thienyl—iPrracemic
III-1338MeMeMe—3-thienyl—iPr(R)-
III-1339MeMeMe—3-thienyl—cPrracemic
III-1340MeMeMe—3-thienyl—cPr(R)-
TABLE 64 — (IV) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
IV-1MeMeMeOPhCH 2Hracemic
IV-2MeMeMeOPhCH 2H(S)-
IV-3MeEtMeOPhCH 2Hracemic
IV-4MeEtMeOPhCH 2H(S)-
IV-5MeMeMeOPhCH 2Meracemic
IV-6MeMeMeOPhCH 2Me(S)-
IV-7MeEtMeOPhCH 2Meracemic
IV-8MeEtMeOPhCH 2Me(S)-
IV-9MeMeMeOPhCH 2CHF 2racemic
IV-10MeMeMeOPhCH 2CHF 2(S)-
IV-11MeEtMeOPhCH 2CHF 2racemic
IV-12MeEtMeOPhCH 2CHF 2(S)-
IV-13MeMeMeOPhCH 2Etracemic
IV-14MeMeMeOPhCH 2Et(S)-
IV-15MeEtMeOPhCH 2Etracemic
IV-16MeEtMeOPhCH 2Et(S)-
IV-17MeMeMeOPhCH 2iPrracemic
IV-18MeMeMeOPhCH 2iPr(S)-
IV-19MeEtMeOPhCH 2iPrracemic
IV-20MeEtMeOPhCH 2iPr(S)-
IV-21MeMeMeOPhCH 2cPrracemic
IV-22MeMeMeOPhCH 2cPr(S)-
IV-23MeEtMeOPhCH 2cPrracemic
IV-24MeEtMeOPhCH 2cPr(S)-
IV-25MeMeMeOPhCH 2Phracemic
IV-26MeMeMeOPhCH 2Ph(S)-
IV-27MeEtMeOPhCH 2Phracemic
IV-28MeEtMeOPhCH 2Ph(S)-
IV-29MeMeMeOPhC(Me) 2Hracemic
IV-30MeMeMeOPhC(Me) 2H(S)-
IV-31MeEtMeOPhC(Me) 2Hracemic
IV-32MeEtMeOPhC(Me) 2H(S)-
IV-33MeMeMeOPhC(Me) 2Meracemic
IV-34MeMeMeOPhC(Me) 2Me(S)-
IV-35MeEtMeOPhC(Me) 2Meracemic
IV-36MeEtMeOPhC(Me) 2Me(S)-
IV-37MeMeMeOPhC(Me) 2CHF 2racemic
IV-38MeMeMeOPhC(Me) 2CHF 2(S)-
IV-39MeEtMeOPhC(Me) 2CHF 2racemic
IV-40MeEtMeOPhC(Me) 2CHF 2(S)-
IV-41MeMeMeOPhC(Me) 2Etracemic
IV-42MeMeMeOPhC(Me) 2Et(S)-
IV-43MeEtMeOPhC(Me) 2Etracemic
IV-44MeEtMeOPhC(Me) 2Et(S)-
IV-45MeMeMeOPhC(Me) 2iPrracemic
IV-46MeMeMeOPhC(Me) 2iPr(S)-
IV-47MeEtMeOPhC(Me) 2iPrracemic
IV-48MeEtMeOPhC(Me) 2iPr(S)-
IV-49MeMeMeOPhC(Me) 2cPrracemic
IV-50MeMeMeOPhC(Me) 2cPr(S)-
TABLE 65 — (IV) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-51MeEtMeOPhC(Me) 2cPrracemic
IV-52MeEtMeOPhC(Me) 2cPr(S)-
IV-53MeMeMeOPhC(Me) 2Phracemic
IV-54MeMeMeOPhC(Me) 2Ph(S)-
IV-55MeEtMeOPhC(Me) 2Phracemic
IV-56MeEtMeOPhC(Me) 2Ph(S)-
IV-57MeMeMeOPh(CH 2 ) 2Hracemic
IV-58MeMeMeOPh(CH 2 ) 2H(R)-
IV-59MeEtMeOPh(CH 2 ) 2Hracemic
IV-60MeEtMeOPh(CH 2 ) 2H(R)-
IV-61MeMeMeOPh(CH 2 ) 2Meracemic
IV-62MeMeMeOPh(CH 2 ) 2Me(R)-
IV-63MeEtMeOPh(CH 2 ) 2Meracemic
IV-64MeEtMeOPh(CH 2 ) 2Me(R)-
IV-65MeMeMeOPh(CH 2 ) 2CHF 2racemic
IV-66MeMeMeOPh(CH 2 ) 2CHF 2(R)-
IV-67MeEtMeOPh(CH 2 ) 2CHF 2racemic
IV-68MeEtMeOPh(CH 2 ) 2CHF 2(R)-
IV-69MeMeMeOPh(CH 2 ) 2Etracemic
IV-70MeMeMeOPh(CH 2 ) 2Et(R)-
IV-71MeEtMeOPh(CH 2 ) 2Etracemic
IV-72MeEtMeOPh(CH 2 ) 2Et(R)-
IV-73MeMeMeOPh(CH 2 ) 2iPrracemic
IV-74MeMeMeOPh(CH 2 ) 2iPr(R)-
IV-75MeEtMeOPh(CH 2 ) 2iPrracemic
IV-76MeEtMeOPh(CH 2 ) 2iPr(R)-
IV-77MeMeMeOPh(CH 2 ) 2cPrracemic
IV-78MeMeMeOPh(CH 2 ) 2cPr(R)-
IV-79MeEtMeOPh(CH 2 ) 2cPrracemic
IV-80MeEtMeOPh(CH 2 ) 2cPr(R)-
IV-81MeMeMeOPh(CH 2 ) 2Phracemic
IV-82MeMeMeOPh(CH 2 ) 2Ph(R)-
IV-83MeEtMeOPh(CH 2 ) 2Phracemic
IV-84MeEtMeOPh(CH 2 ) 2Ph(R)-
IV-85MeMeMeOPhCH 2 C(Me) 2Hracemic
IV-86MeMeMeOPhCH 2 C(Me) 2H(R)-
IV-87MeEtMeOPhCH 2 C(Me) 2Hracemic
IV-88MeEtMeOPhCH 2 C(Me) 2H(R)-
IV-89MeMeMeOPhCH 2 C(Me) 2Meracemic
IV-90MeMeMeOPhCH 2 C(Me) 2Me(R)-
IV-91MeEtMeOPhCH 2 C(Me) 2Meracemic
IV-92MeEtMeOPhCH 2 C(Me) 2Me(R)-
IV-93MeMeMeOPhCH 2 C(Me) 2CHF 2racemic
IV-94MeMeMeOPhCH 2 C(Me) 2CHF 2(R)-
IV-95MeEtMeOPhCH 2 C(Me) 2CHF 2racemic
IV-96MeEtMeOPhCH 2 C(Me) 2CHF 2(R)-
IV-97MeMeMeOPhCH 2 C(Me) 2Etracemic
IV-98MeMeMeOPhCH 2 C(Me) 2Et(R)-
IV-99MeEtMeOPhCH 2 C(Me) 2Etracemic
IV-100MeEtMeOPhCH 2 C(Me) 2Et(R)-
TABLE 66 — (IV)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-101MeMeMeOPhCH 2 C(Me) 2iPrracemic
IV-102MeMeMeOPhCH 2 C(Me) 2iPr(R)-
IV-103MeEtMeOPhCH 2 C(Me) 2iPrracemic
IV-104MeEtMeOPhCH 2 C(Me) 2iPr(R)-
IV-105MeMeMeOPhCH 2 C(Me) 2cPrracemic
IV-106MeMeMeOPhCH 2 C(Me) 2cPr(R)-
IV-107MeEtMeOPhCH 2 C(Me) 2cPrracemic
IV-108MeEtMeOPhCH 2 C(Me) 2cPr(R)-
IV-109MeMeMeOPhCH 2 C(Me) 2Phracemic
IV-110MeMeMeOPhCH 2 C(Me) 2Ph(R)-
IV-111MeEtMeOPhCH 2 C(Me) 2Phracemic
IV-112MeEtMeOPhCH 2 C(Me) 2Ph(R)-
IV-113MeMeMeNHPhCH 2Hracemic
IV-114MeMeMeNHPhCH 2H(S)-
IV-115MeMeMeNHPhCH 2H(R)-
IV-116MeEtMeNHPhCH 2Hracemic
IV-117MeEtMeNHPhCH 2H(S)-
IV-118MeMeMeN(Me)PhCH 2Hracemic
IV-119MeMeMeN(Me)PhCH 2H(S)-
IV-120MeEtMeN(Me)PhCH 2Hracemic
IV-121MeEtMeN(Me)PhCH 2H(S)-
IV-122MeMeMeNHPhCH 2Meracemic
IV-123MeMeMeNHPhCH 2Me(S)-
IV-124MeEtMeNHPhCH 2Meracemic
IV-125MeEtMeNHPhCH 2Me(S)-
IV-126MeMeMeN(Me)PhCH 2Meracemic
IV-127MeMeMeN(Me)PhCH 2Me(S)-
IV-128MeEtMeN(Me)PhCH 2Meracemic
IV-129MeEtMeN(Me)PhCH 2Me(S)-
IV-130MeMeMeNHPhCH 2CHF 2racemic
IV-131MeMeMeNHPhCH 2CHF 2(S)-
IV-132MeEtMeNHPhCH 2CHF 2racemic
IV-133MeEtMeNHPhCH 2CHF 2(S)-
IV-134MeMeMeN(Me)PhCH 2CHF 2racemic
IV-135MeMeMeN(Me)PhCH 2CHF 2(S)-
IV-136MeEtMeN(Me)PhCH 2CHF 2racemic
IV-137MeEtMeN(Me)PhCH 2CHF 2(S)-
IV-138MeMeMeNHPhCH 2Etracemic
IV-139MeMeMeNHPhCH 2Et(S)-
IV-140MeEtMeNHPhCH 2Etracemic
IV-141MeEtMeNHPhCH 2Et(S)-
IV-142MeMeMeN(Me)PhCH 2Etracemic
IV-143MeMeMeN(Me)PhCH 2Et(S)-
IV-144MeEtMeN(Me)PhCH 2Etracemic
IV-145MeEtMeN(Me)PhCH 2Et(S)-
IV-146MeMeMeNHPhCH 2iPrracemic
IV-147MeMeMeNHPhCH 2iPr(S)-
IV-148MeEtMeNHPhCH 2iPrracemic
IV-149MeEtMeNHPhCH 2iPr(S)-
IV-150MeMeMeN(Me)PhCH 2iPrracemic
TABLE 67 — (IV) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
IV-151MeMeMeN(Me)PhCH 2iPr(S)-
IV-152MeEtMeN(Me)PhCH 2iPrracemic
IV-153MeEtMeN(Me)PhCH 2iPr(S)-
IV-154MeMeMeNHPhCH 2cPrracemic
IV-155MeMeMeNHPhCH 2cPr(S)-
IV-156MeEtMeNHPhCH 2cPrracemic
IV-157MeEtMeNHPhCH 2cPr(S)-
IV-158MeMeMeN(Me)PhCH 2cPrracemic
IV-159MeMeMeN(Me)PhCH 2cPr(S)-
IV-160MeEtMeN(Me)PhCH 2cPrracemic
IV-161MeEtMeN(Me)PhCH 2cPr(S)-
IV-162MeMeMeNHPhCH 2Phracemic
IV-163MeMeMeNHPhCH 2Ph(S)-
IV-164MeEtMeNHPhCH 2Phracemic
IV-165MeEtMeNHPhCH 2Ph(S)-
IV-166MeMeMeN(Me)PhCH 2Phracemic
IV-167MeMeMeN(Me)PhCH 2Ph(S)-
IV-168MeEtMeN(Me)PhCH 2Phracemic
IV-169MeEtMeN(Me)PhCH 2Ph(S)-
IV-170MeMeMeNHPhC(Me) 2Hracemic
IV-171MeMeMeNHPhC(Me) 2H(S)-
IV-172MeEtMeNHPhC(Me) 2Hracemic
IV-173MeEtMeNHPhC(Me) 2H(S)-
IV-174MeMeMeN(Me)PhC(Me) 2Hracemic
IV-175MeMeMeN(Me)PhC(Me) 2H(S)-
IV-176MeEtMeN(Me)PhC(Me) 2Hracemic
IV-177MeEtMeN(Me)PhC(Me) 2H(S)-
IV-178MeMeMeNHPhC(Me) 2Meracemic
IV-179MeMeMeNHPhC(Me) 2Me(S)-
IV-180MeEtMeNHPhC(Me) 2Meracemic
IV-181MeEtMeNHPhC(Me) 2Me(S)-
IV-182MeMeMeN(Me)PhC(Me) 2Meracemic
IV-183MeMeMeN(Me)PhC(Me) 2Me(S)-
IV-184MeEtMeN(Me)PhC(Me) 2Meracemic
IV-185MeEtMeN(Me)PhC(Me) 2Me(S)-
IV-186MeMeMeNHPhC(Me) 2CHF 2racemic
IV-187MeMeMeNHPhC(Me) 2CHF 2(S)-
IV-188MeEtMeNHPhC(Me) 2CHF 2racemic
IV-189MeEtMeNHPhC(Me) 2CHF 2(S)-
IV-190MeMeMeN(Me)PhC(Me) 2CHF 2racemic
IV-191MeMeMeN(Me)PhC(Me) 2CHF 2(S)-
IV-192MeEtMeN(Me)PhC(Me) 2CHF 2racemic
IV-193MeEtMeN(Me)PhC(Me) 2CHF 2(S)-
IV-194MeMeMeNHPhC(Me) 2Etracemic
IV-195MeMeMeNHPhC(Me) 2Et(S)-
IV-196MeEtMeNHPhC(Me) 2Etracemic
IV-197MeEtMeNHPhC(Me) 2Et(S)-
IV-198MeMeMeN(Me)PhC(Me) 2Etracemic
IV-199MeMeMeN(Me)PhC(Me) 2Et(S)-
IV-200MeEtMeN(Me)PhC(Me) 2Etracemic
TABLE 68 — (IV) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
IV-201MeEtMeN(Me)PhC(Me) 2Et(S)-
IV-202MeMeMeNHPhC(Me) 2iPrracemic
IV-203MeMeMeNHPhC(Me) 2iPr(S)-
IV-204MeEtMeNHPhC(Me) 2iPrracemic
IV-205MeEtMeNHPhC(Me) 2iPr(S)-
IV-206MeMeMeN(Me)PhC(Me) 2iPrracemic
IV-207MeMeMeN(Me)PhC(Me) 2iPr(S)-
IV-208MeEtMeN(Me)PhC(Me) 2iPrracemic
IV-209MeEtMeN(Me)PhC(Me) 2iPr(S)-
IV-210MeMeMeNHPhC(Me) 2cPrracemic
IV-211MeMeMeNHPhC(Me) 2cPr(S)-
IV-212MeEtMeNHPhC(Me) 2cPrracemic
IV-213MeEtMeNHPhC(Me) 2cPr(S)-
IV-214MeMeMeN(Me)PhC(Me) 2cPrracemic
IV-215MeMeMeN(Me)PhC(Me) 2cPr(S)-
IV-216MeEtMeN(Me)PhC(Me) 2cPrracemic
IV-217MeEtMeN(Me)PhC(Me) 2cPr(S)-
IV-218MeMeMeNHPhC(Me) 2Phracemic
IV-219MeMeMeNHPhC(Me) 2Ph(S)-
IV-220MeEtMeNHPhC(Me) 2Phracemic
IV-221MeEtMeNHPhC(Me) 2Ph(S)-
IV-222MeMeMeN(Me)PhC(Me) 2Phracemic
IV-223MeMeMeN(Me)PhC(Me) 2Ph(S)-
IV-224MeEtMeN(Me)PhC(Me) 2Phracemic
IV-225MeEtMeN(Me)PhC(Me) 2Ph(S)-
IV-226MeMeMeNHPh(CH 2 ) 2Hracemic
IV-227MeMeMeNHPh(CH 2 ) 2H(R)-
IV-228MeEtMeNHPh(CH 2 ) 2Hracemic
IV-229MeEtMeNHPh(CH 2 ) 2H(R)-
IV-230MeMeMeN(Me)Ph(CH 2 ) 2Hracemic
IV-231MeMeMeN(Me)Ph(CH 2 ) 2H(R)-
IV-232MeEtMeN(Me)Ph(CH 2 ) 2Hracemic
IV-233MeEtMeN(Me)Ph(CH 2 ) 2H(R)-
IV-234MeMeMeNHPh(CH 2 ) 2Meracemic
IV-235MeMeMeNHPh(CH 2 ) 2Me(R)-
IV-236MeEtMeNHPh(CH 2 ) 2Meracemic
IV-237MeEtMeNHPh(CH 2 ) 2Me(R)-
IV-238MeMeMeN(Me)Ph(CH 2 ) 2Meracemic
IV-239MeMeMeN(Me)Ph(CH 2 ) 2Me(R)-
IV-240MeEtMeN(Me)Ph(CH 2 ) 2Meracemic
IV-241MeEtMeN(Me)Ph(CH 2 ) 2Me(R)-
IV-242MeMeMeNHPh(CH 2 ) 2CHF 2racemic
IV-243MeMeMeNHPh(CH 2 ) 2CHF 2(R)-
IV-244MeEtMeNHPh(CH 2 ) 2CHF 2racemic
IV-245MeEtMeNHPh(CH 2 ) 2CHF 2(R)-
IV-246MeMeMeN(Me)Ph(CH 2 ) 2CHF 2racemic
IV-247MeMeMeN(Me)Ph(CH 2 ) 2CHF 2(R)-
IV-248MeEtMeN(Me)Ph(CH 2 ) 2CHF 2racemic
IV-249MeEtMeN(Me)Ph(CH 2 ) 2CHF 2(R)-
IV-250MeMeMeNHPh(CH 2 ) 2Etracemic
TABLE 69 — (IV) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
IV-251MeMeMeNHPh(CH 2 ) 2Et(R)-
IV-252MeEtMeNHPh(CH 2 ) 2Etracemic
IV-253MeEtMeNHPh(CH 2 ) 2Et(R)-
IV-254MeMeMeN(Me)Ph(CH 2 ) 2Etracemic
IV-255MeMeMeN(Me)Ph(CH 2 ) 2Et(R)-
IV-256MeEtMeN(Me)Ph(CH 2 ) 2Etracemic
IV-257MeEtMeN(Me)Ph(CH 2 ) 2Et(R)-
IV-258MeMeMeNHPh(CH 2 ) 2iPrracemic
IV-259MeMeMeNHPh(CH 2 ) 2iPr(R)-
IV-260MeEtMeNHPh(CH 2 ) 2iPrracemic
IV-261MeEtMeNHPh(CH 2 ) 2iPr(R)-
IV-262MeMeMeN(Me)Ph(CH 2 ) 2iPrracemic
IV-263MeMeMeN(Me)Ph(CH 2 ) 2iPr(R)-
IV-264MeEtMeN(Me)Ph(CH 2 ) 2iPrracemic
IV-265MeEtMeN(Me)Ph(CH 2 ) 2iPr(R)-
IV-266MeMeMeNHPh(CH 2 ) 2cPrracemic
IV-267MeMeMeNHPh(CH 2 ) 2cPr(R)-
IV-268MeEtMeNHPh(CH 2 ) 2cPrracemic
IV-269MeEtMeNHPh(CH 2 ) 2cPr(R)-
IV-270MeMeMeN(Me)Ph(CH 2 ) 2cPrracemic
IV-271MeMeMeN(Me)Ph(CH 2 ) 2cPr(R)-
IV-272MeEtMeN(Me)Ph(CH 2 ) 2cPrracemic
IV-273MeEtMeN(Me)Ph(CH 2 ) 2cPr(R)-
IV-274MeMeMeNHPh(CH 2 ) 2Phracemic
IV-275MeMeMeNHPh(CH 2 ) 2Ph(R)-
IV-276MeEtMeNHPh(CH 2 ) 2Phracemic
IV-277MeEtMeNHPh(CH 2 ) 2Ph(R)-
IV-278MeMeMeN(Me)Ph(CH 2 ) 2Phracemic
IV-279MeMeMeN(Me)Ph(CH 2 ) 2Ph(R)-
IV-280MeEtMeN(Me)Ph(CH 2 ) 2Phracemic
IV-281MeEtMeN(Me)Ph(CH 2 ) 2Ph(R)-
IV-282MeMeMeNHPh(CH 2 ) 3Hracemic
IV-283MeMeMeNHPh(CH 2 ) 3H(R)-
IV-284MeEtMeNHPh(CH 2 ) 3Hracemic
IV-285MeEtMeNHPh(CH 2 ) 3H(R)-
IV-286MeMeMeN(Me)Ph(CH 2 ) 3Hracemic
IV-287MeMeMeN(Me)Ph(CH 2 ) 3H(R)-
IV-288MeEtMeN(Me)Ph(CH 2 ) 3Hracemic
IV-289MeEtMeN(Me)Ph(CH 2 ) 3H(R)-
IV-290MeMeMeNHPh(CH 2 ) 4Hracemic
IV-291MeMeMeNHPh(CH 2 ) 4H(R)-
IV-292MeEtMeNHPh(CH 2 ) 4Hracemic
IV-293MeEtMeNHPh(CH 2 ) 4H(R)-
IV-294MeMeMeN(Me)Ph(CH 2 ) 4Hracemic
IV-295MeMeMeN(Me)Ph(CH 2 ) 4H(R)-
IV-296MeEtMeN(Me)Ph(CH 2 ) 4Hracemic
IV-297MeEtMeN(Me)Ph(CH 2 ) 4H(R)-
IV-298MeMeMeNHPhCH 2 C(Me) 2Hracemic
IV-299MeMeMeNHPhCH 2 C(Me) 2H(R)-
IV-300MeEtMeNHPhCH 2 C(Me) 2Hracemic
TABLE 70 — (IV) Com- pound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
IV-301MeEtMeNHPhCH 2 C(Me) 2H(R)-
IV-302MeMeMeN(Me)PhCH 2 C(Me) 2Hracemic
IV-303MeMeMeN(Me)PhCH 2 C(Me) 2H(R)-
IV-304MeEtMeN(Me)PhCH 2 C(Me) 2Hracemic
IV-305MeEtMeN(Me)PhCH 2 C(Me) 2H(R)-
IV-306MeMeMeNHPhCH 2 C(Me) 2Meracemic
IV-307MeMeMeNHPhCH 2 C(Me) 2Me(R)-
IV-308MeEtMeNHPhCH 2 C(Me) 2Meracemic
IV-309MeEtMeNHPhCH 2 C(Me) 2Me(R)-
IV-310MeMeMeN(Me)PhCH 2 C(Me) 2Meracemic
IV-311MeMeMeN(Me)PhCH 2 C(Me) 2Me(R)-
IV-312MeEtMeN(Me)PhCH 2 C(Me) 2Meracemic
IV-313MeEtMeN(Me)PhCH 2 C(Me) 2Me(R)-
IV-314MeMeMeNHPhCH 2 C(Me) 2CHF 2racemic
IV-315MeMeMeNHPhCH 2 C(Me) 2CHF 2(R)-
IV-316MeEtMeNHPhCH 2 C(Me) 2CHF 2racemic
IV-317MeEtMeNHPhCH 2 C(Me) 2CHF 2(R)-
IV-318MeMeMeN(Me)PhCH 2 C(Me) 2CHF 2racemic
IV-319MeMeMeN(Me)PhCH 2 C(Me) 2CHF 2(R)-
IV-320MeEtMeN(Me)PhCH 2 C(Me) 2CHF 2racemic
IV-321MeEtMeN(Me)PhCH 2 C(Me) 2CHF 2(R)-
IV-322MeMeMeNHPhCH 2 C(Me) 2Etracemic
IV-323MeMeMeNHPhCH 2 C(Me) 2Et(R)-
IV-324MeEtMeNHPhCH 2 C(Me) 2Etracemic
IV-325MeEtMeNHPhCH 2 C(Me) 2Et(R)-
IV-326MeMeMeN(Me)PhCH 2 C(Me) 2Etracemic
IV-327MeMeMeN(Me)PhCH 2 C(Me) 2Et(R)-
IV-328MeEtMeN(Me)PhCH 2 C(Me) 2Etracemic
IV-329MeEtMeN(Me)PhCH 2 C(Me) 2Et(R)-
IV-330MeMeMeNHPhCH 2 C(Me) 2iPrracemic
IV-331MeMeMeNHPhCH 2 C(Me) 2iPr(R)-
IV-332MeEtMeNHPhCH 2 C(Me) 2iPrracemic
IV-333MeEtMeNHPhCH 2 C(Me) 2iPr(R)-
IV-334MeMeMeN(Me)PhCH 2 C(Me) 2iPrracemic
IV-335MeMeMeN(Me)PhCH 2 C(Me) 2iPr(R)-
IV-336MeEtMeN(Me)PhCH 2 C(Me) 2iPrracemic
IV-337MeEtMeN(Me)PhCH 2 C(Me) 2iPr(R)-
IV-338MeMeMeNHPhCH 2 C(Me) 2cPrracemic
IV-339MeMeMeNHPhCH 2 C(Me) 2cPr(R)-
IV-340MeEtMeNHPhCH 2 C(Me) 2cPrracemic
IV-341MeEtMeNHPhCH 2 C(Me) 2cPr(R)-
IV-342MeMeMeN(Me)PhCH 2 C(Me) 2cPrracemic
IV-343MeMeMeN(Me)PhCH 2 C(Me) 2cPr(R)-
IV-344MeEtMeN(Me)PhCH 2 C(Me) 2cPrracemic
IV-345MeEtMeN(Me)PhCH 2 C(Me) 2cPr(R)-
IV-346MeMeMeNHPhCH 2 C(Me) 2Phracemic
IV-347MeMeMeNHPhCH 2 C(Me) 2Ph(R)-
IV-348MeEtMeNHPhCH 2 C(Me) 2Phracemic
IV-349MeEtMeNHPhCH 2 C(Me) 2Ph(R)-
IV-350MeMeMeN(Me)PhCH 2 C(Me) 2Phracemic
TABLE 71 — (IV)
Com-Con-
poundfigu-
No.R 1R 2R 3L 2R 4L 3R 5ration
IV-351MeMeMeN(Me)PhCH 2 C(Me) 2Ph(R)-
IV-352MeEtMeN(Me)PhCH 2 C(Me) 2Phracemic
IV-353MeEtMeN(Me)PhCH 2 C(Me) 2Ph(R)-
IV-354MeMeMeNHPhC(Me) 2 CH 2Hracemic
IV-355MeMeMeNHPhC(Me) 2 CH 2H(S)-
IV-356MeEtMeNHPhC(Me) 2 CH 2Hracemic
IV-357MeEtMeNHPhC(Me) 2 CH 2H(S)-
IV-358MeMeMeN(Me)PhC(Me) 2 CH 2Hracemic
IV-359MeMeMeN(Me)PhC(Me) 2 CH 2H(S)-
IV-360MeEtMeN(Me)PhC(Me) 2 CH 2Hracemic
IV-361MeEtMeN(Me)PhC(Me) 2 CH 2H(S)-
IV-362MeMeMeNHPhCF 2 CH 2Hracemic
IV-363MeMeMeNHPhCF 2 CH 2H(S)-
IV-364MeEtMeNHPhCF 2 CH 2Hracemic
IV-365MeEtMeNHPhCF 2 CH 2H(S)-
IV-366MeMeMeN(Me)PhCF 2 CH 2Hracemic
IV-367MeMeMeN(Me)PhCF 2 CH 2H(S)-
IV-368MeEtMeN(Me)PhCF 2 CH 2Hracemic
IV-369MeEtMeN(Me)PhCF 2 CH 2H(S)-
IV-370MeMeMeNHPhCH═CHCH 2Hracemic
IV-371MeMeMeNHPhCH═CHCH 2H(S)-
IV-372MeEtMeNHPhCH═CHCH 2Hracemic
IV-373MeEtMeNHPhCH═CHCH 2H(S)-
IV-374MeMeMeN(Me)PhCH═CHCH 2Hracemic
IV-375MeMeMeN(Me)PhCH═CHCH 2H(S)-
IV-376MeEtMeN(Me)PhCH═CHCH 2Hracemic
IV-377MeEtMeN(Me)PhCH═CHCH 2H(S)-
IV-378MeMeMeNHPhC≡CCH 2Hracemic
IV-379MeMeMeNHPhC≡CCH 2H(S)-
IV-380MeEtMeNHPhC≡CCH 2Hracemic
IV-381MeEtMeNHPhC≡CCH 2H(S)-
IV-382MeMeMeN(Me)PhC≡CCH 2Hracemic
IV-383MeMeMeN(Me)PhC≡CCH 2H(S)-
IV-384MeEtMeN(Me)PhC≡CCH 2Hracemic
IV-385MeEtMeN(Me)PhC≡CCH 2H(S)-
IV-386MeMeMeNHPh1,1-CyclopropyleneHracemic
IV-387MeMeMeNHPh1,1-CyclopropyleneH(S)-
IV-388MeEtMeNHPh1,1-CyclopropyleneHracemic
IV-389MeEtMeNHPh1,1-CyclopropyleneH(S)-
IV-390MeMeMeN(Me)Ph1,1-CyclopropyleneHracemic
IV-391MeMeMeN(Me)Ph1,1-CyclopropyleneH(S)-
IV-392MeEtMeN(Me)Ph1,1-CyclopropyleneHracemic
IV-393MeEtMeN(Me)Ph1,1-CyclopropyleneH(S)-
IV-394MeMeMeNHPh1,2-Cyclo-Hracemic
propynylene
IV-395MeMeMeNHPh1,2-Cyclo-H(S)-
propynylene
IV-396MeEtMeNHPh1,2-Cyclo-Hracemic
propynylene
IV-397MeEtMeNHPh1,2-Cyclo-H(S)-
propynylene
IV-398MeMeMeN(Me)Ph1,2-Cyclo-Hracemic
propynylene
IV-399MeMeMeN(Me)Ph1,2-Cyclo-H(S)-
propynylene
IV-400MeEtMeN(Me)Ph1,2-Cyclo-Hracemic
propynylene
TABLE 72 — (IV)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-401MeEtMeN(Me)Ph1,2-Cyclo-H(S)-
propynylene
IV-402MeMeMeNHPhC(═O)Hracemic
IV-403MeMeMeNHPhC(═O)H(S)-
IV-404MeEtMeNHPhC(═O)Hracemic
IV-405MeEtMeNHPhC(═O)H(S)-
IV-406MeMeMeN(Me)PhC(═O)Hracemic
IV-407MeMeMeN(Me)PhC(═O)H(S)-
IV-408MeEtMeN(Me)PhC(═O)Hracemic
IV-409MeEtMeN(Me)PhC(═O)H(S)-
IV-410MeMeMeNHPhC(═O)Bnracemic
IV-411MeMeMeNHPhC(═O)Bn(S)-
IV-412MeEtMeNHPhC(═O)Bnracemic
IV-413MeEtMeNHPhC(═O)Bn(S)-
IV-414MeMeMeN(Me)PhC(═O)Bnracemic
IV-415MeMeMeN(Me)PhC(═O)Bn(S)-
IV-416MeEtMeN(Me)PhC(═O)Bnracemic
IV-417MeEtMeN(Me)PhC(═O)Bn(S)-
IV-418MeMeMeNHPhC(═O)Meracemic
IV-419MeMeMeNHPhC(═O)Me(S)-
IV-420MeEtMeNHPhC(═O)Meracemic
IV-421MeEtMeNHPhC(═O)Me(S)-
IV-422MeMeMeN(Me)PhC(═O)Meracemic
IV-423MeMeMeN(Me)PhC(═O)Me(S)-
IV-424MeEtMeN(Me)PhC(═O)Meracemic
IV-425MeEtMeN(Me)PhC(═O)Me(S)-
IV-426MeMeMeNHPhCH(Me)Hracemic
IV-427MeMeMeNHPhCH(Me)H(S)-
IV-428MeEtMeNHPhCH(Me)Hracemic
IV-429MeEtMeNHPhCH(Me)H(S)-
IV-430MeMeMeNHPhCH(iPr)Hracemic
IV-431MeMeMeNHPhCH(iPr)H(S)-
IV-432MeEtMeNHPhCH(iPr)Hracemic
IV-433MeEtMeNHPhCH(iPr)H(S)-
IV-434MeMeMeNHPhCH(Ph)Hracemic
IV-435MeMeMeNHPhCH(Ph)H(S)-
IV-436MeEtMeNHPhCH(Ph)Hracemic
IV-437MeEtMeNHPhCH(Ph)H(S)-
IV-438MeMeMeNHHCH 2H
IV-439MeEtMeNHHCH 2H
IV-440MeMeMeN(Me)HCH 2H
IV-441MeEtMeN(Me)HCH 2H
IV-442MeMeMeNHHCH(Me)H
IV-443MeEtMeNHHCH(Me)H
IV-444MeMeMeN(Me)HCH(Me)H
IV-445MeEtMeN(Me)HCH(Me)H
IV-446MeMeMeNHHCH(iPr)H
IV-447MeEtMeNHHCH(iPr)H
IV-448MeMeMeN(Me)HCH(iPr)H
IV-449MeEtMeN(Me)HCH(iPr)H
IV-450MeMeMeNHHCH(Ph)H
TABLE 73 — (IV) Compound
No.R 1R 2R 3L 2R 4L 3R 5Configuration
IV-451MeEtMeNHHCH(Ph)H
IV-452MeMeMeN(Me)HCH(Ph)H
IV-453MeEtMeN(Me)HCH(Ph)H
IV-454MeMeMeNHMeCH 2Hracemic
IV-455MeMeMeNHMeCH 2H(S)-
IV-456MeEtMeNHMeCH 2Hracemic
IV-457MeEtMeNHMeCH 2H(S)-
IV-458MeMeMeNHMeCH(Me)Hracemic
IV-459MeMeMeNHMeCH(Me)H(S)-
IV-460MeEtMeNHMeCH(Me)Hracemic
IV-461MeEtMeNHMeCH(Me)H(S)-
IV-462MeMeMeNHMeCH(iPr)Hracemic
IV-463MeMeMeNHMeCH(iPr)H(S)-
IV-464MeEtMeNHMeCH(iPr)Hracemic
IV-465MeEtMeNHMeCH(iPr)H(S)-
IV-466MeMeMeNHMeCH(Ph)Hracemic
IV-467MeMeMeNHMeCH(Ph)H(S)-
IV-468MeEtMeNHMeCH(Ph)Hracemic
IV-469MeEtMeNHMeCH(Ph)H(S)-
IV-470MeMeMeN(Me)MeCH 2Hracemic
IV-471MeMeMeN(Me)MeCH 2H(S)-
IV-472MeEtMeN(Me)MeCH 2Hracemic
IV-473MeEtMeN(Me)MeCH 2H(S)-
IV-474MeMeMeNHiPrCH 2Hracemic
IV-475MeMeMeNHiPrCH 2H(S)-
IV-476MeEtMeNHiPrCH 2Hracemic
IV-477MeEtMeNHiPrCH 2H(S)-
IV-478MeMeMeNHiPrCH(Me)Hracemic
IV-479MeMeMeNHiPrCH(Me)H(S)-
IV-480MeEtMeNHiPrCH(Me)Hracemic
IV-481MeEtMeNHiPrCH(Me)H(S)-
IV-482MeMeMeNHiPrCH(iPr)Hracemic
IV-483MeMeMeNHiPrCH(iPr)H(S)-
IV-484MeEtMeNHiPrCH(iPr)Hracemic
IV-485MeEtMeNHiPrCH(iPr)H(S)-
IV-486MeMeMeNHiPrCH(Ph)Hracemic
IV-487MeMeMeNHiPrCH(Ph)H(S)-
IV-488MeEtMeNHiPrCH(Ph)Hracemic
IV-489MeEtMeNHiPrCH(Ph)H(S)-
IV-490MeMeMeN(Me)iPrCH 2Hracemic
IV-491MeMeMeN(Me)iPrCH 2H(S)-
IV-492MeEtMeN(Me)iPrCH 2Hracemic
IV-493MeEtMeN(Me)iPrCH 2H(S)-
IV-494MeMeMeNHcHexCH 2Hracemic
IV-495MeMeMeNHcHexCH 2H(S)-
IV-496MeEtMeNHcHexCH 2Hracemic
IV-497MeEtMeNHcHexCH 2H(S)-
IV-498MeMeMeN(Me)cHexCH 2Hracemic
IV-499MeMeMeN(Me)cHexCH 2H(S)-
IV-500MeEtMeN(Me)cHexCH 2Hracemic
TABLE 74 — (IV) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-501MeEtMeN(Me)cHexCH 2H(S)-
IV-502MeMeMeNH1,3-Benzo-CH 2Hracemic
dioxol-4-yl
IV-503MeMeMeNH1,3-Benzo-CH 2H(S)-
dioxol-4-yl
IV-504MeEtMeNH1,3-Benzo-CH 2Hracemic
dioxol-4-yl
IV-505MeEtMeNH1,3-Benzo-CH 2H(S)-
dioxol-4-yl
IV-506MeMeMeN(Me)1,3-Benzo-CH 2Hracemic
dioxol-4-yl
IV-507MeMeMeN(Me)1,3-Benzo-CH 2H(S)-
dioxol-4-yl
IV-508MeEtMeN(Me)1,3-Benzo-CH 2Hracemic
dioxol-4-yl
IV-509MeEtMeN(Me)1,3-Benzo-CH 2H(S)-
dioxol-4-yl
IV-510MeMeMeNH2-F—PhCH 2Hracemic
IV-511MeMeMeNH2-F—PhCH 2H(S)-
IV-512MeEtMeNH2-F—PhCH 2Hracemic
IV-513MeEtMeNH2-F—PhCH 2H(S)-
IV-514MeMeMeN(Me)2-F—PhCH 2Hracemic
IV-515MeMeMeN(Me)2-F—PhCH 2H(S)-
IV-516MeEtMeN(Me)2-F—PhCH 2Hracemic
IV-517MeEtMeN(Me)2-F—PhCH 2H(S)-
IV-518MeMeMeNH3-F—PhCH 2Hracemic
IV-519MeMeMeNH3-F—PhCH 2H(S)-
IV-520MeEtMeNH3-F—PhCH 2Hracemic
IV-521MeEtMeNH3-F—PhCH 2H(S)-
IV-522MeMeMeN(Me)3-F—PhCH 2Hracemic
IV-523MeMeMeN(Me)3-F—PhCH 2H(S)-
IV-524MeEtMeN(Me)3-F—PhCH 2Hracemic
IV-525MeEtMeN(Me)3-F—PhCH 2H(S)-
IV-526MeMeMeNH4-F—PhCH 2Hracemic
IV-527MeMeMeNH4-F—PhCH 2H(S)-
IV-528MeEtMeNH4-F—PhCH 2Hracemic
IV-529MeEtMeNH4-F—PhCH 2H(S)-
IV-530MeMeMeN(Me)4-F—PhCH 2Hracemic
IV-531MeMeMeN(Me)4-F—PhCH 2H(S)-
IV-532MeEtMeN(Me)4-F—PhCH 2Hracemic
IV-533MeEtMeN(Me)4-F—PhCH 2H(S)-
IV-534MeMeMeNH2-PyCH 2Hracemic
IV-535MeMeMeNH2-PyCH 2H(S)-
IV-536MeEtMeNH2-PyCH 2Hracemic
IV-537MeEtMeNH2-PyCH 2H(S)-
IV-538MeMeMeN(Me)2-PyCH 2Hracemic
IV-539MeMeMeN(Me)2-PyCH 2H(S)-
IV-540MeEtMeN(Me)2-PyCH 2Hracemic
IV-541MeEtMeN(Me)2-PyCH 2H(S)-
IV-542MeMeMeNH3-PyCH 2Hracemic
IV-543MeMeMeNH3-PyCH 2H(S)-
IV-544MeEtMeNH3-PyCH 2Hracemic
IV-545MeEtMeNH3-PyCH 2H(S)-
IV-546MeMeMeN(Me)3-PyCH 2Hracemic
IV-547MeMeMeN(Me)3-PyCH 2H(S)-
IV-548MeEtMeN(Me)3-PyCH 2Hracemic
IV-549MeEtMeN(Me)3-PyCH 2H(S)-
IV-550MeMeMeNH4-PyCH 2Hracemic
TABLE 75 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-551MeMeMeNH4-PyCH 2H(S)-
IV-552MeEtMeNH4-PyCH 2Hracemic
IV-553MeEtMeNH4-PyCH 2H(S)-
IV-554MeMeMeN(Me)4-PyCH 2Hracemic
IV-555MeMeMeN(Me)4-PyCH 2H(S)-
IV-556MeEtMeN(Me)4-PyCH 2Hracemic
IV-557MeEtMeN(Me)4-PyCH 2H(S)-
IV-558MeMeMeCH 2PhCH 2Hracemic
IV-559MeMeMeCH 2PhCH 2H(S)-
IV-560MeEtMeCH 2PhCH 2Hracemic
IV-561MeEtMeCH 2PhCH 2H(S)-
IV-562MeMeMeCH 2Ph—Hracemic
IV-563MeMeMeCH 2Ph—H(S)-
IV-564MeEtMeCH 2Ph—Hracemic
IV-565MeEtMeCH 2Ph—H(S)-
IV-566MeMeMeCH 2PhCH 2Meracemic
IV-567MeMeMeCH 2PhCH 2Me(S)-
IV-568MeEtMeCH 2PhCH 2Meracemic
IV-569MeEtMeCH 2PhCH 2Me(S)-
IV-570MeMeMeCH 2PhCH 2CHF 2racemic
IV-571MeMeMeCH 2PhCH 2CHF 2(S)-
IV-572MeMeMeCH 2PhCH 2Etracemic
IV-573MeMeMeCH 2PhCH 2Et(S)-
IV-574MeEtMeCH 2PhCH 2Etracemic
IV-575MeEtMeCH 2PhCH 2Et(S)-
IV-576MeMeMeCH 2PhCH 2cPrracemic
IV-577MeMeMeCH 2PhCH 2cPr(S)-
IV-578MeEtMeCH 2PhCH 2cPrracemic
IV-579MeEtMeCH 2PhCH 2cPr(S)-
IV-580MeMeMeCH 2PhCH 2Phracemic
IV-581MeMeMeCH 2PhCH 2Ph(S)-
IV-582MeEtMeCH 2PhCH 2Phracemic
IV-583MeEtMeCH 2PhCH 2Ph(S)-
IV-584MeMeMeCH 2PhC(Me) 2Hracemic
IV-585MeMeMeCH 2PhC(Me) 2H(S)-
IV-586MeEtMeCH 2PhC(Me) 2Hracemic
IV-587MeEtMeCH 2PhC(Me) 2H(S)-
IV-588MeMeMeCH 2PhC(Me) 2Meracemic
IV-589MeMeMeCH 2PhC(Me) 2Me(S)-
IV-590MeEtMeCH 2PhC(Me) 2Meracemic
IV-591MeEtMeCH 2PhC(Me) 2Me(S)-
IV-592MeMeMeCH 2PhC(Me) 2CHF 2racemic
IV-593MeMeMeCH 2PhC(Me) 2CHF 2(S)-
IV-594MeMeMeCH 2PhC(Me) 2Etracemic
IV-595MeMeMeCH 2PhC(Me) 2Et(S)-
IV-596MeMeMeCH 2PhC(Me) 2cPrracemic
IV-597MeMeMeCH 2PhC(Me) 2cPr(S)-
IV-598MeMeMeCH 2PhC(Me) 2Phracemic
IV-599MeMeMeCH 2PhC(Me) 2Ph(S)-
IV-600MeMeMeCH 2Ph(CH 2 ) 2Hracemic
TABLE 76 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-601MeMeMeCH 2Ph(CH 2 ) 2H(S)-
IV-602MeEtMeCH 2Ph(CH 2 ) 2Hracemic
IV-603MeEtMeCH 2Ph(CH 2 ) 2H(S)-
IV-604MeMeMeCH 2Ph(CH 2 ) 2Meracemic
IV-605MeMeMeCH 2Ph(CH 2 ) 2Me(S)-
IV-606MeEtMeCH 2Ph(CH 2 ) 2Meracemic
IV-607MeEtMeCH 2Ph(CH 2 ) 2Me(S)-
IV-608MeMeMeCH 2Ph(CH 2 ) 2CHF 2racemic
IV-609MeMeMeCH 2Ph(CH 2 ) 2CHF 2(S)-
IV-610MeMeMeCH 2Ph(CH 2 ) 2Etracemic
IV-611MeMeMeCH 2Ph(CH 2 ) 2Et(S)-
IV-612MeMeMeCH 2Ph(CH 2 ) 2cPrracemic
IV-613MeMeMeCH 2Ph(CH 2 ) 2cPr(S)-
IV-614MeMeMeCH 2Ph(CH 2 ) 2Phracemic
IV-615MeMeMeCH 2Ph(CH 2 ) 2Ph(S)-
IV-616MeMeMeCH 2PhCH 2 C(Me) 2Hracemic
IV-617MeMeMeCH 2PhCH 2 C(Me) 2H(S)-
IV-618MeEtMeCH 2PhCH 2 C(Me) 2Hracemic
IV-619MeEtMeCH 2PhCH 2 C(Me) 2H(S)-
IV-620MeMeMeCH 2PhCH 2 C(Me) 2Meracemic
IV-621MeMeMeCH 2PhCH 2 C(Me) 2Me(S)-
IV-622MeEtMeCH 2PhCH 2 C(Me) 2Meracemic
IV-623MeEtMeCH 2PhCH 2 C(Me) 2Me(S)-
IV-624MeMeMeCH 2PhCH 2 C(Me) 2CHF 2racemic
IV-625MeMeMeCH 2PhCH 2 C(Me) 2CHF 2(S)-
IV-626MeMeMeCH 2PhCH 2 C(Me) 2Etracemic
IV-627MeMeMeCH 2PhCH 2 C(Me) 2Et(S)-
IV-628MeMeMeCH 2PhCH 2 C(Me) 2cPrracemic
IV-629MeMeMeCH 2PhCH 2 C(Me) 2cPr(S)-
IV-630MeMeMeCH 2PhCH 2 C(Me) 2Phracemic
IV-631MeMeMeCH 2PhCH 2 C(Me) 2Ph(S)-
IV-632MeMeMe—PhCH 2Hracemic
IV-633MeMeMe—PhCH 2H(S)-
IV-634MeMeMe—PhCH 2Meracemic
IV-635MeMeMe—PhCH 2Me(S)-
IV-636MeMeMeCH═CHPhCH 2Hracemic
IV-637MeMeMeCH═CHPhCH 2H(S)-
IV-638MeMeMeCH═CHPhCH 2Meracemic
IV-639MeMeMeCH═CHPhCH 2Me(S)-
IV-640MeMeMeC≡CPhCH 2Hracemic
IV-641MeMeMeC≡CPhCH 2H(S)-
IV-642MeMeMeC≡CPhCH 2Meracemic
IV-643MeMeMeC≡CPhCH 2Me(S)-
IV-644MeMeMe1,2-Cyclo-PhCH 2Hracemic
propylene
IV-645MeMeMe1,2-Cyclo-PhCH 2H(S)-
propylene
IV-646MeMeMe1,2-Cyclo-PhCH 2Meracemic
propylene
IV-647MeMeMe1,2-Cyclo-PhCH 2Me(S)-
propylene
IV-648MeMeMe1,2-CycloPhCH 2Hracemic
propynylene
IV-649MeMeMe1,2-Cyclo-PhCH 2H(S)-
propynylene
IV-650MeMeMe1,2-Cyclo-PhCH 2Meracemic
propynylene
IV-651MeMeMe1,2-Cyclo-PhCH 2Me(S)-
propynylene
TABLE 77 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-652MeMeMeOPhC(Me) 2 CH 2Hracemic
IV-653MeMeMeOPhC(Me) 2 CH 2H(+)
IV-654MeMeMeOPhC(Me) 2 CH 2H(−)
IV-655MeEtMeOPhC(Me) 2 CH 2Hracemic
IV-656MeEtMeOPhC(Me) 2 CH 2H(+)
IV-657MeEtMeOPhC(Me) 2 CH 2H(−)
IV-658MeMeMeOPhC(Me) 2 CH 2Meracemic
IV-659MeMeMeOPhC(Me) 2 CH 2Me(+)
IV-660MeMeMeOPhC(Me) 2 CH 2Me(−)
IV-661MeEtMeOPhC(Me) 2 CH 2Meracemic
IV-662MeEtMeOPhC(Me) 2 CH 2Me(+)
IV-663MeEtMeOPhC(Me) 2 CH 2Me(−)
IV-664MeMeMeOPhC(Me) 2 CH 2CHF 2racemic
IV-665MeMeMeOPhC(Me) 2 CH 2CHF 2(+)
IV-666MeMeMeOPhC(Me) 2 CH 2CHF 2(−)
IV-667MeMeMeOPhC(Me) 2 CH 2Etracemic
IV-668MeMeMeOPhC(Me) 2 CH 2Et(+)
IV-669MeMeMeOPhC(Me) 2 CH 2Et(−)
IV-670MeMeMeOHCH(Ph)H
IV-671MeEtMeOHCH(Ph)H
IV-672MeMeMeNHPhC(Me) 2 CH 2H(+)
IV-673MeMeMeNHPhC(Me) 2 CH 2H(−)
IV-674MeEtMeNHPhC(Me) 2 CH 2H(+)
IV-675MeEtMeNHPhC(Me) 2 CH 2H(−)
IV-676MeMeMeNHPhC(Me) 2 CH 2Meracemic
IV-677MeMeMeNHPhC(Me) 2 CH 2Me(+)
IV-678MeMeMeNHPhC(Me) 2 CH 2Me(−)
IV-679MeEtMeNHPhC(Me) 2 CH 2Meracemic
IV-680MeEtMeNHPhC(Me) 2 CH 2Me(+)
IV-681MeEtMeNHPhC(Me) 2 CH 2Me(−)
IV-682MeMeMeNHPhC(Me) 2 CH 2CHF 2racemic
IV-683MeMeMeNHPhC(Me) 2 CH 2CHF 2(+)
IV-684MeMeMeNHPhC(Me) 2 CH 2CHF 2(−)
IV-685MeEtMeNHPhC(Me) 2 CH 2CHF 2racemic
IV-686MeEtMeNHPhC(Me) 2 CH 2CHF 2(+)
IV-687MeEtMeNHPhC(Me) 2 CH 2CHF 2(−)
IV-688MeMeMeNHPhC(Me) 2 CH 2Etracemic
IV-689MeMeMeNHPhC(Me) 2 CH 2Et(+)
IV-690MeMeMeNHPhC(Me) 2 CH 2Et(−)
IV-691MeEtMeNHPhC(Me) 2 CH 2Etracemic
IV-692MeEtMeNHPhC(Me) 2 CH 2Et(+)
IV-693MeEtMeNHPhC(Me) 2 CH 2Et(−)
IV-694MeMeMeNHPhC(Me) 2 CH 2iPrracemic
IV-695MeMeMeNHPhC(Me) 2 CH 2iPr(+)
IV-696MeMeMeNHPhC(Me) 2 CH 2iPr(−)
IV-697MeEtMeNHPhC(Me) 2 CH 2iPrracemic
IV-698MeEtMeNHPhC(Me) 2 CH 2iPr(+)
IV-699MeEtMeNHPhC(Me) 2 CH 2iPr(−)
IV-700MeMeMeNHPhC(Me) 2 CH 2cPrracemic
IV-701MeMeMeNHPhC(Me) 2 CH 2cPr(+)
TABLE 78 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-702MeMeMeNHPhC(Me) 2 CH 2cPr(−)
IV-703MeEtMeNHPhC(Me) 2 CH 2cPrracemic
IV-704MeEtMeNHPhC(Me) 2 CH 2cPr(+)
IV-705MeEtMeNHPhC(Me) 2 CH 2cPr(−)
IV-706MeMeMeNHPh1,1-Cyclo-Hracemic
propylene-
CH 2
IV-707MeMeMeNHPh1,1-Cyclo-H(+)
propylene-
CH 2
IV-708MeMeMeNHPh1,1-Cyclo-H(+)
propylene-
CH 2
IV-709MeEtMeNHPh1,1-Cyclo-Hracemic
propylene-
CH 2
IV-710MeEtMeNHPh1,1-Cyclo-H(+)
propylene-
CH 2
IV-711MeEtMeNHPh1,1-Cyclo-H(−)
propylene-
CH 2
IV-712MeMeMeNHPh1,1-Cyclo-Meracemic
propylene-
CH 2
IV-713MeMeMeNHPh1,1-Cyclo-Me(+)
propylene-
CH 2
IV-714MeMeMeNHPh1,1-Cyclo-Me(−)
propylene-
CH 2
IV-715MeEtMeNHPh1,1-Cyclo-Meracemic
propylene-
CH 2
IV-716MeEtMeNHPh1,1-Cyclo-Me(+)
propylene-
CH 2
IV-717MeEtMeNHPh1,1-Cyclo-Me(−)
propylene-
CH 2
IV-718MeMeMeNHPh1,1-Cyclo-Hracemic
butylene-
CH 2
IV-719MeMeMeNHPh1,1-Cyclo-H(+)
butylene-
CH 2
IV-720MeMeMeNHPh1,1-Cyclo-H(−)
butylene-
CH 2
IV-721MeEtMeNHPh1,1-Cyclo-Hracemic
butylene-
CH 2
IV-722MeEtMeNHPh1,1-Cyclo-H(+)
butylene-
CH 2
IV-723MeEtMeNHPh1,1-Cyclo-H(−)
butylene-
CH 2
IV-724MeMeMeNHPh1,1-Cyclo-Meracemic
butylene-
CH 2
IV-725MeMeMeNHPh1,1-Cyclo-Me(+)
butylene-
CH 2
IV-726MeMeMeNHPh1,1-Cyclo-Me(−)
butylene-
CH 2
IV-727MeEtMeNHPh1,1-Cyclo-Meracemic
butylene-
CH 2
IV-728MeEtMeNHPh1,1-Cyclo-Me(+)
butylene-
CH 2
IV-729MeEtMeNHPh1,1-Cyclo-Me(−)
butylene-
CH 2
IV-730MeMeMeNHPhC(Et) 2 CH 2Hracemic
IV-731MeMeMeNHPhC(Et) 2 CH 2H(+)
IV-732MeMeMeNHPhC(Et) 2 CH 2H(−)
IV-733MeEtMeNHPhC(Et) 2 CH 2Hracemic
IV-734MeEtMeNHPhC(Et) 2 CH 2H(+)
IV-735MeEtMeNHPhC(Et) 2 CH 2H(−)
IV-736MeMeMeNHPhC(Et) 2 CH 2Meracemic
IV-737MeMeMeNHPhC(Et) 2 CH 2Me(+)
IV-738MeMeMeNHPhC(Et) 2 CH 2Me(−)
IV-739MeEtMeNHPhC(Et) 2 CH 2Meracemic
IV-740MeEtMeNHPhC(Et) 2 CH 2Me(+)
IV-741MeEtMeNHPhC(Et) 2 CH 2Me(−)
IV-742MeMeMeNHPhCH 2 -1,1-Hracemic
Cyclo-
propylene
IV-743MeMeMeNHPhCH 2 -1,1-H(R)-
Cyclo-
propylene
IV-744MeEtMeNHPhCH 2 -1,1-Hracemic
Cyclo-
propylene
IV-745MeEtMeNHPhCH 2 -1,1-H(R)-
Cyclo-
propylene
IV-746MeMeMeNHPhCH 2 -1,1-Meracemic
Cyclo-
propylene
IV-747MeMeMeNHPhCH 2 -1,1-Me(R)-
Cyclo-
propylene
IV-748MeEtMeNHPhCH 2 -1,1-Meracemic
Cyclo-
propylene
IV-749MeEtMeNHPhCH 2 -1,1-Me(R)-
Cyclo-
propylene
IV-750MeMeMeNHPhCH 2 -1,1-Hracemic
cyclo-
butylene
IV-751MeMeMeNHPhCH 2 -1,1-H(R)-
cyclo-
butylene
TABLE 79 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-752MeEtMeNHPhCH 2 -1,1-Hracemic
cyclo-
butylene
IV-753MeEtMeNHPhCH 2 -1,1-H(R)-
cyclo-
butylene
IV-754MeMeMeNHPhCH 2 -1,1-Meracemic
cyclo-
butylene
IV-755MeMeMeNHPhCH 2 -1,1-Me(R)-
cyclo-
butylene
IV-756MeEtMeNHPhCH 2 -1,1-Meracemic
cyclo-
butylene
IV-757MeEtMeNHPhCH 2 -1,1-Me(R)-
cyclo-
butylene
IV-758MeMeMeNHPhCH 2 C(Et) 2Hracemic
IV-759MeMeMeNHPhCH 2 C(Et) 2H(R)-
IV-760MeEtMeNHPhCH 2 C(Et) 2Hracemic
IV-761MeEtMeNHPhCH 2 C(Et) 2H(R)-
IV-762MeMeMeNHPhCH 2 C(Et) 2Meracemic
IV-763MeMeMeNHPhCH 2 C(Et) 2Me(R)-
IV-764MeEtMeNHPhCH 2 C(Et) 2Meracemic
IV-765MeEtMeNHPhCH 2 C(Et) 2Me(R)-
IV-766MeMeMeNHPh(R)-CH(Me)H(S)-
IV-767MeMeMeNHPh(S)-CH(Me)H(S)-
IV-768MeEtMeNHPh(R)-CH(Me)H(S)-
IV-769MeEtMeNHPh(S)-CH(Me)H(S)-
IV-770MeMeMeNHPh(R)-CH(iPr)H(S)-
IV-771MeMeMeNHPh(S)-CH(iPr)H(S)-
IV-772MeEtMeNHPh(R)-CH(iPr)H(S)-
IV-773MeEtMeNHPh(S)-CH(iPr)H(S)-
IV-774MeMeMeNHPh(R)-CH(Ph)H(S)-
IV-775MeMeMeNHPh(S)-CH(Ph)H(S)-
IV-776MeEtMeNHPh(R)-CH(Ph)H(S)-
IV-777MeEtMeNHPh(S)-CH(Ph)H(S)-
IV-778MeMeMeNHH(R)-CH(Me)H
IV-779MeMeMeNHH(S)-CH(Me)H
IV-780MeEtMeNHH(R)-CH(Me)H
IV-781MeEtMeNHH(S)-CH(Me)H
IV-782MeMeMeNHH(R)-CH(iPr)H
IV-783MeMeMeNHH(S)-CH(iPr)H
IV-784MeEtMeNHH(R)-CH(iPr)H
IV-785MeEtMeNHH(S)-CH(iPr)H
IV-786MeMeMeNHH(R)-CH(Ph)H
IV-787MeMeMeNHH(S)-CH(Ph)H
IV-788MeEtMeNHH(R)-CH(Ph)H
IV-789MeEtMeNHH(S)-CH(Ph)H
IV-790MeMeMeNHMe(R)-CH(Me)H(S)-
IV-791MeMeMeNHMe(S)-CH(Me)H(S)-
IV-792MeEtMeNHMe(R)-CH(Me)H(S)-
IV-793MeEtMeNHMe(S)-CH(Me)H(S)-
IV-794MeMeMeNHMe(R)-CH(iPr)H(S)-
IV-795MeMeMeNHMe(S)-CH(iPr)H(S)-
IV-796MeEtMeNHMe(R)-CH(iPr)H(S)-
IV-797MeEtMeNHMe(S)-CH(iPr)H(S)-
IV-798MeMeMeNHMe(R)-CH(Ph)H(S)-
IV-799MeMeMeNHMe(S)-CH(Ph)H(S)-
IV-800MeEtMeNHMe(R)-CH(Ph)H(S)-
IV-801MeEtMeNHMe(S)-CH(Ph)H(S)-
TABLE 80 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-802MeMeMeNHiPrCH 2Meracemic
IV-803MeMeMeNHiPrCH 2Me(S)-
IV-804MeEtMeNHiPrCH 2Meracemic
IV-805MeEtMeNHiPrCH 2Me(S)-
IV-806MeMeMeNHiPr(CH 2 ) 2Hracemic
IV-807MeMeMeNHiPr(CH 2 ) 2H(R)-
IV-808MeEtMeNHiPr(CH 2 ) 2Hracemic
IV-809MeEtMeNHiPr(CH 2 ) 2H(R)-
IV-810MeMeMeNHiPr(CH 2 ) 2Meracemic
IV-811MeMeMeNHiPr(CH 2 ) 2Me(R)-
IV-812MeEtMeNHiPr(CH 2 ) 2Meracemic
IV-813MeEtMeNHiPr(CH 2 ) 2Me(R)-
IV-814MeMeMeNHiPrCH 2 C(Me) 2Hracemic
IV-815MeMeMeNHiPrCH 2 C(Me) 2H(R)-
IV-816MeEtMeNHiPrCH 2 C(Me) 2Hracemic
IV-817MeEtMeNHiPrCH 2 C(Me) 2H(R)-
IV-818MeMeMeNHiPrCH 2 C(Me) 2Meracemic
IV-819MeMeMeNHiPrCH 2 C(Me) 2Me(R)-
IV-820MeEtMeNHiPrCH 2 C(Me) 2Meracemic
IV-821MeEtMeNHiPrCH 2 C(Me) 2Me(R)-
IV-822MeMeMeNHiPrC(Me) 2 CH 2Hracemic
IV-823MeMeMeNHiPrC(Me) 2 CH 2H(+)
IV-824MeMeMeNHiPrC(Me) 2 CH 2H(−)
IV-825MeEtMeNHiPrC(Me) 2 CH 2Hracemic
IV-826MeEtMeNHiPrC(Me) 2 CH 2H(+)
IV-827MeEtMeNHiPrC(Me) 2 CH 2H(−)
IV-828MeMeMeNHiPrC(Me) 2 CH 2Meracemic
IV-829MeMeMeNHiPrC(Me) 2 CH 2Me(+)
IV-830MeMeMeNHiPrC(Me) 2 CH 2Me(−)
IV-831MeEtMeNHiPrC(Me) 2 CH 2Meracemic
IV-832MeEtMeNHiPrC(Me) 2 CH 2Me(+)
IV-833MeEtMeNHiPrC(Me) 2 CH 2Me(−)
IV-834MeMeMeNHiPr(R)-CH(Me)H(S)-
IV-835MeMeMeNHiPr(S)-CH(Me)H(S)-
IV-836MeEtMeNHiPr(R)-CH(Me)H(S)-
IV-837MeEtMeNHiPr(S)-CH(Me)H(S)-
IV-838MeMeMeNHiPr(R)-CH(iPr)H(S)-
IV-839MeMeMeNHiPr(S)-CH(iPr)H(S)-
IV-840MeEtMeNHiPr(R)-CH(iPr)H(S)-
IV-841MeEtMeNHiPr(S)-CH(iPr)H(S)-
IV-842MeMeMeNHiPr(R)-CH(Ph)H(S)-
IV-843MeMeMeNHiPr(S)-CH(Ph)H(S)-
IV-844MeEtMeNHiPr(R)-CH(Ph)H(S)-
IV-845MeEtMeNHiPr(S)-CH(Ph)H(S)-
IV-846MeMeMeNHCF 3CH 2Hracemic
IV-847MeMeMeNHCF 3CH 2H(S)-
IV-848MeEtMeNHCF 3CH 2Hracemic
IV-849MeEtMeNHCF 3CH 2H(S)-
IV-850MeMeMeN(Me)CF 3CH 2Hracemic
IV-851MeMeMeN(Me)CF 3CH 2H(S)-
TABLE 81 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-852MeEtMeN(Me)CF 3CH 2Hracemic
IV-853MeEtMeN(Me)CF 3CH 2H(S)-
IV-854MeMeMeNHCH 2 OHCH 2H
IV-855MeEtMeNHCH 2 OHCH 2H
IV-856MeMeMeNHCH 2 OMeCH 2Hracemic
IV-857MeMeMeNHCH 2 OMeCH 2H(R)-
IV-858MeEtMeNHCH 2 OMeCH 2Hracemic
IV-859MeEtMeNHCH 2 OMeCH 2H(R)-
IV-860MeMeMeNHCH 2 PhCH 2Hracemic
IV-861MeMeMeNHCH 2 PhCH 2H(R)-
IV-862MeMeMeNHCH 2 PhCH 2H(S)-
IV-863MeEtMeNHCH 2 PhCH 2Hracemic
IV-864MeEtMeNHCH 2 PhCH 2H(S)-
IV-865MeMeMeN(Me)CH 2 PhCH 2Hracemic
IV-866MeMeMeN(Me)CH 2 PhCH 2H(S)-
IV-867MeEtMeN(Me)CH 2 PhCH 2Hracemic
IV-868MeEtMeN(Me)CH 2 PhCH 2H(S)-
IV-869MeMeMeNH2-F—PhCH 2Meracemic
IV-870MeMeMeNH2-F—PhCH 2Me(S)-
IV-871MeEtMeNH2-F—PhCH 2Meracemic
IV-872MeEtMeNH2-F—PhCH 2Me(S)-
IV-873MeMeMeNH2-F—Ph(CH 2 ) 2Hracemic
IV-874MeMeMeNH2-F—Ph(CH 2 ) 2H(+)-
IV-875MeMeMeNH2-F—Ph(CH 2 ) 2H(−)-
IV-876MeEtMeNH2-F—Ph(CH 2 ) 2Hracemic
IV-877MeEtMeNH2-F—Ph(CH 2 ) 2H(R)-
IV-878MeMeMeNH2-F—Ph(CH 2 ) 2Meracemic
IV-879MeMeMeNH2-F—Ph(CH 2 ) 2Me(R)-
IV-880MeEtMeNH2-F—Ph(CH 2 ) 2Meracemic
IV-881MeEtMeNH2-F—Ph(CH 2 ) 2Me(R)-
IV-882MeMeMeNH2-F—PhCH 2 C(Me) 2Hracemic
IV-883MeMeMeNH2-F—PhCH 2 C(Me) 2H(R)-
IV-884MeEtMeNH2-F—PhCH 2 C(Me) 2Hracemic
IV-885MeEtMeNH2-F—PhCH 2 C(Me) 2H(R)-
IV-886MeMeMeNH2-F—PhCH 2 C(Me) 2Meracemic
IV-887MeMeMeNH2-F—PhCH 2 C(Me) 2Me(R)-
IV-888MeEtMeNH2-F—PhCH 2 C(Me) 2Meracemic
IV-889MeEtMeNH2-F—PhCH 2 C(Me) 2Me(R)-
IV-890MeMeMeNH2-F—PhC(Me) 2 CH 2Hracemic
IV-891MeMeMeNH2-F—PhC(Me) 2 CH 2H(+)
IV-892MeMeMeNH2-F—PhC(Me) 2 CH 2H(−)
IV-893MeEtMeNH2-F—PhC(Me) 2 CH 2Hracemic
IV-894MeEtMeNH2-F—PhC(Me) 2 CH 2H(+)
IV-895MeEtMeNH2-F—PhC(Me) 2 CH 2H(−)
IV-896MeMeMeNH2-F—PhC(Me) 2 CH 2Meracemic
IV-897MeMeMeNH2-F—PhC(Me) 2 CH 2Me(+)
IV-898MeMeMeNH2-F—PhC(Me) 2 CH 2Me(−)
IV-899MeEtMeNH2-F—PhC(Me) 2 CH 2Meracemic
IV-900MeEtMeNH2-F—PhC(Me) 2 CH 2Me(+)
IV-901MeEtMeNH2-F—PhC(Me) 2 CH 2Me(−)
TABLE 82 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-902MeMeMeNH3-F—Ph(CH 2 ) 2Hracemic
IV-903MeMeMeNH3-F—Ph(CH 2 ) 2H(R)-
IV-904MeEtMeNH3-F—Ph(CH 2 ) 2Hracemic
IV-905MeEtMeNH3-F—Ph(CH 2 ) 2H(R)-
IV-906MeMeMeNH3-F—Ph(CH 2 ) 2Meracemic
IV-907MeMeMeNH3-F—Ph(CH 2 ) 2Me(R)-
IV-908MeEtMeNH3-F—Ph(CH 2 ) 2Meracemic
IV-909MeEtMeNH3-F—Ph(CH 2 ) 2Me(R)-
IV-910MeMeMeNH3-F—PhCH 2 C(Me) 2Hracemic
IV-911MeMeMeNH3-F—PhCH 2 C(Me) 2H(R)-
IV-912MeEtMeNH3-F—PhCH 2 C(Me) 2Hracemic
IV-913MeEtMeNH3-F—PhCH 2 C(Me) 2H(R)-
IV-914MeMeMeNH3-F—PhCH 2 C(Me) 2Meracemic
IV-915MeMeMeNH3-F—PhCH 2 C(Me) 2Me(R)-
IV-916MeEtMeNH3-F—PhCH 2 C(Me) 2Meracemic
IV-917MeEtMeNH3-F—PhCH 2 C(Me) 2Me(R)-
IV-918MeMeMeNH3-F—PhC(Me) 2 CH 2Hracemic
IV-919MeMeMeNH3-F—PhC(Me) 2 CH 2H(+)
IV-920MeMeMeNH3-F—PhC(Me) 2 CH 2H(−)
IV-921MeEtMeNH3-F—PhC(Me) 2 CH 2Hracemic
IV-922MeEtMeNH3-F—PhC(Me) 2 CH 2H(+)
IV-923MeEtMeNH3-F—PhC(Me) 2 CH 2H(−)
IV-924MeMeMeNH3-F—PhC(Me) 2 CH 2Meracemic
IV-925MeMeMeNH3-F—PhC(Me) 2 CH 2Me(+)
IV-926MeMeMeNH3-F—PhC(Me) 2 CH 2Me(−)
IV-927MeEtMeNH3-F—PhC(Me) 2 CH 2Meracemic
IV-928MeEtMeNH3-F—PhC(Me) 2 CH 2Me(+)
IV-929MeEtMeNH3-F—PhC(Me) 2 CH 2Me(−)
IV-930MeMeMeNH4-F—Ph(CH 2 ) 2Hracemic
IV-931MeMeMeNH4-F—Ph(CH 2 ) 2H(R)-
IV-932MeEtMeNH4-F—Ph(CH 2 ) 2Hracemic
IV-933MeEtMeNH4-F—Ph(CH 2 ) 2H(R)-
IV-934MeMeMeNH4-F—Ph(CH 2 ) 2Meracemic
IV-935MeMeMeNH4-F—Ph(CH 2 ) 2Me(R)-
IV-936MeEtMeNH4-F—Ph(CH 2 ) 2Meracemic
IV-937MeEtMeNH4-F—Ph(CH 2 ) 2Me(R)-
IV-938MeMeMeNH4-F—PhCH 2 C(Me) 2Hracemic
IV-939MeMeMeNH4-F—PhCH 2 C(Me) 2H(R)-
IV-940MeEtMeNH4-F—PhCH 2 C(Me) 2Hracemic
IV-941MeEtMeNH4-F—PhCH 2 C(Me) 2H(R)-
IV-942MeMeMeNH4-F—PhCH 2 C(Me) 2Meracemic
IV-943MeMeMeNH4-F—PhCH 2 C(Me) 2Me(R)-
IV-944MeEtMeNH4-F—PhCH 2 C(Me) 2Meracemic
IV-945MeEtMeNH4-F—PhCH 2 C(Me) 2Me(R)-
IV-946MeMeMeNH4-F—PhC(Me) 2 CH 2Hracemic
IV-947MeMeMeNH4-F—PhC(Me) 2 CH 2H(+)
IV-948MeMeMeNH4-F—PhC(Me) 2 CH 2H(−)
IV-949MeEtMeNH4-F—PhC(Me) 2 CH 2Hracemic
IV-950MeEtMeNH4-F—PhC(Me) 2 CH 2H(+)
IV-951MeEtMeNH4-F—PhC(Me) 2 CH 2H(−)
TABLE 83 — (IV)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 5tion
IV-952MeMeMeNH4-F—PhC(Me) 2 CH 2Meracemic
IV-953MeMeMeNH4-F—PhC(Me) 2 CH 2Me(+)
IV-954MeMeMeNH4-F—PhC(Me) 2 CH 2Me(−)
IV-955MeEtMeNH4-F—PhC(Me) 2 CH 2Meracemic
IV-956MeEtMeNH4-F—PhC(Me) 2 CH 2Me(+)
IV-957MeEtMeNH4-F—PhC(Me) 2 CH 2Me(−)
IV-958MeMeMeNH2-Cl—PhCH 2Hracemic
IV-959MeMeMeNH2-Cl—PhCH 2H(S)-
IV-960MeEtMeNH2-Cl—PhCH 2Hracemic
IV-961MeEtMeNH2-Cl—PhCH 2H(S)-
IV-962MeMeMeNH2-Cl—PhCH 2Meracemic
IV-963MeMeMeNH2-Cl—PhCH 2Me(S)-
IV-964MeEtMeNH2-Cl—PhCH 2Meracemic
IV-965MeEtMeNH2-Cl—PhCH 2Me(S)-
IV-966MeMeMeNH2-Cl—Ph(CH 2 ) 2Hracemic
IV-967MeMeMeNH2-Cl—Ph(CH 2 ) 2H(R)-
IV-968MeEtMeNH2-Cl—Ph(CH 2 ) 2Hracemic
IV-969MeEtMeNH2-Cl—Ph(CH 2 ) 2H(R)-
IV-970MeMeMeNH2-Cl—Ph(CH 2 ) 2Meracemic
IV-971MeMeMeNH2-Cl—Ph(CH 2 ) 2Me(R)-
IV-972MeEtMeNH2-Cl—Ph(CH 2 ) 2Meracemic
IV-973MeEtMeNH2-Cl—Ph(CH 2 ) 2Me(R)-
IV-974MeMeMeNH2-Cl—PhCH 2 C(Me) 2Hracemic
IV-975MeMeMeNH2-Cl—PhCH 2 C(Me) 2H(R)-
IV-976MeEtMeNH2-Cl—PhCH 2 C(Me) 2Hracemic
IV-977MeEtMeNH2-Cl—PhCH 2 C(Me) 2H(R)-
IV-978MeMeMeNH2-Cl—PhCH 2 C(Me) 2Meracemic
IV-979MeMeMeNH2-Cl—PhCH 2 C(Me) 2Me(R)-
IV-980MeEtMeNH2-Cl—PhCH 2 C(Me) 2Meracemic
IV-981MeEtMeNH2-Cl—PhCH 2 C(Me) 2Me(R)-
IV-982MeMeMeNH2-Cl—PhC(Me) 2 CH 2Hracemic
IV-983MeMeMeNH2-Cl—PhC(Me) 2 CH 2H(+)
IV-984MeMeMeNH2-Cl—PhC(Me) 2 CH 2H(−)
IV-985MeEtMeNH2-Cl—PhC(Me) 2 CH 2Hracemic
IV-986MeEtMeNH2-Cl—PhC(Me) 2 CH 2H(+)
IV-987MeEtMeNH2-Cl—PhC(Me) 2 CH 2H(−)
IV-988MeMeMeNH2-Cl—PhC(Me) 2 CH 2Meracemic
IV-989MeMeMeNH2-Cl—PhC(Me) 2 CH 2Me(+)
IV-990MeMeMeNH2-Cl—PhC(Me) 2 CH 2Me(−)
IV-991MeEtMeNH2-Cl—PhC(Me) 2 CH 2Meracemic
IV-992MeEtMeNH2-Cl—PhC(Me) 2 CH 2Me(+)
IV-993MeEtMeNH2-Cl—PhC(Me) 2 CH 2Me(−)
IV-994MeMeMeNH3-Cl—PhCH 2Hracemic
IV-995MeMeMeNH3-Cl—PhCH 2H(S)-
IV-996MeEtMeNH3-Cl—PhCH 2Hracemic
IV-997MeEtMeNH3-Cl—PhCH 2H(S)-
IV-998MeMeMeNH3-Cl—PhCH 2Meracemic
IV-999MeMeMeNH3-Cl—PhCH 2Me(S)-
IV-1000MeEtMeNH3-Cl—PhCH 2Meracemic
IV-1001MeEtMeNH3-Cl—PhCH 2Me(S)-
TABLE 84 — (IV) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
IV-1002MeMeMeNH3-Cl—Ph(CH 2 ) 2Hracemic
IV-1003MeMeMeNH3-Cl—Ph(CH 2 ) 2H(R)-
IV-1004MeEtMeNH3-Cl—Ph(CH 2 ) 2Hracemic
IV-1005MeEtMeNH3-Cl—Ph(CH 2 ) 2H(R)-
IV-1006MeMeMeNH3-Cl—Ph(CH 2 ) 2Meracemic
IV-1007MeMeMeNH3-Cl—Ph(CH 2 ) 2Me(R)-
IV-1008MeEtMeNH3-Cl—Ph(CH 2 ) 2Meracemic
IV-1009MeEtMeNH3-Cl—Ph(CH 2 ) 2Me(R)-
IV-1010MeMeMeNH3-Cl—PhCH 2 C(Me) 2Hracemic
IV-1011MeMeMeNH3-Cl—PhCH 2 C(Me) 2H(R)-
IV-1012MeEtMeNH3-Cl—PhCH 2 C(Me) 2Hracemic
IV-1013MeEtMeNH3-Cl—PhCH 2 C(Me) 2H(R)-
IV-1014MeMeMeNH3-Cl—PhCH 2 C(Me) 2Meracemic
IV-1015MeMeMeNH3-Cl—PhCH 2 C(Me) 2Me(R)-
IV-1016MeEtMeNH3-Cl—PhCH 2 C(Me) 2Meracemic
IV-1017MeEtMeNH3-Cl—PhCH 2 C(Me) 2Me(R)-
IV-1018MeMeMeNH3-Cl—PhC(Me) 2 CH 2Hracemic
IV-1019MeMeMeNH3-Cl—PhC(Me) 2 CH 2H(+)
IV-1020MeMeMeNH3-Cl—PhC(Me) 2 CH 2H(−)
IV-1021MeEtMeNH3-Cl—PhC(Me) 2 CH 2Hracemic
IV-1022MeEtMeNH3-Cl—PhC(Me) 2 CH 2H(+30)
IV-1023MeEtMeNH3-Cl—PhC(Me) 2 CH 2H(-)
IV-1024MeMeMeNH3-Cl—PhC(Me) 2 CH 2Meracemic
IV-1025MeMeMeNH3-Cl—PhC(Me) 2 CH 2Me(+)
IV-1026MeMeMeNH3-Cl—PhC(Me) 2 CH 2Me(−)
IV-1027MeEtMeNH3-Cl—PhC(Me) 2 CH 2Meracemic
IV-1028MeEtMeNH3-Cl—PhC(Me) 2 CH 2Me(+)
IV-1029MeEtMeNH3-Cl—PhC(Me) 2 CH 2Me(−)
IV-1030MeMeMeNH3-Cl—PhCH 2Hracemic
IV-1031MeMeMeNH3-Cl—PhCH 2H(S)-
IV-1032MeEtMeNH3-Cl—PhCH 2Hracemic
IV-1033MeEtMeNH3-Cl—PhCH 2H(S)-
IV-1034MeMeMeNH3-Cl—PhCH 2Meracemic
IV-1035MeMeMeNH3-Cl—PhCH 2Me(S)-
IV-1036MeEtMeNH3-Cl—PhCH 2Meracemic
IV-1037MeEtMeNH3-Cl—PhCH 2Me(S)-
IV-1038MeMeMeNH3-Cl—Ph(CH 2 ) 2Hracemic
IV-1039MeMeMeNH3-Cl—Ph(CH 2 ) 2H(R)-
IV-1040MeEtMeNH3-Cl—Ph(CH 2 ) 2Hracemic
IV-1041MeEtMeNH3-Cl—Ph(CH 2 ) 2H(R)-
IV-1042MeMeMeNH3-Cl—Ph(CH 2 ) 2Meracemic
IV-1043MeMeMeNH3-Cl—Ph(CH 2 ) 2Me(R)-
IV-1044MeEtMeNH3-Cl—Ph(CH 2 ) 2Meracemic
IV-1045MeEtMeNH3-Cl—Ph(CH 2 ) 2Me(R)-
IV-1046MeMeMeNH3-Cl—PhCH 2 C(Me) 2Hracemic
IV-1047MeMeMeNH3-Cl—PhCH 2 C(Me) 2H(R)-
IV-1048MeEtMeNH3-Cl—PhCH 2 C(Me) 2Hracemic
IV-1049MeEtMeNH3-Cl—PhCH 2 C(Me) 2H(R)-
IV-1050MeMeMeNH3-Cl—PhCH 2 C(Me) 2Meracemic
IV-1051MeMeMeNH3-Cl—PhCH 2 C(Me) 2Me(R)-
TABLE 85 — (IV) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
IV-1052MeEtMeNH4-Cl—PhCH 2 C(Me) 2Meracemic
IV-1053MeEtMeNH4-Cl—PhCH 2 C(Me) 2Me(R)-
IV-1054MeMeMeNH4-Cl—PhCH 2 C(Me) 2Hracemic
IV-1055MeMeMeNH4-Cl—PhCH 2 C(Me) 2H(+)
IV-1056MeMeMeNH4-Cl—PhCH 2 C(Me) 2H(−)
IV-1057MeEtMeNH4-Cl—PhCH 2 C(Me) 2Hracemic
IV-1058MeEtMeNH4-Cl—PhCH 2 C(Me) 2H(+)
IV-1059MeEtMeNH4-Cl—PhCH 2 C(Me) 2H(−)
IV-1060MeMeMeNH4-Cl—PhCH 2 C(Me) 2Meracemic
IV-1061MeMeMeNH4-Cl—PhCH 2 C(Me) 2Me(+)
IV-1062MeMeMeNH4-Cl—PhCH 2 C(Me) 2Me(−)
IV-1063MeEtMeNH4-Cl—PhCH 2 C(Me) 2Meracemic
IV-1064MeEtMeNH4-Cl—PhCH 2 C(Me) 2Me(+)
IV-1065MeEtMeNH4-Cl—PhCH 2 C(Me) 2Me(−)
IV-1066MeMeMeNH2-Me—PhCH 2Hracemic
IV-1067MeMeMeNH2-Me—PhCH 2H(S)-
IV-1068MeEtMeNH2-Me—PhCH 2Hracemic
IV-1069MeEtMeNH2-Me—PhCH 2H(S)-
IV-1070MeMeMeNH2-Me—PhCH 2Meracemic
IV-1071MeMeMeNH2-Me—PhCH 2Me(S)-
IV-1072MeEtMeNH2-Me—PhCH 2Meracemic
IV-1073MeEtMeNH2-Me—PhCH 2Me(S)-
IV-1074MeMeMeNH2-Me—Ph(CH 2 ) 2Hracemic
IV-1075MeMeMeNH2-Me—Ph(CH 2 ) 2H(R)-
IV-1076MeEtMeNH2-Me—Ph(CH 2 ) 2Hracemic
IV-1077MeEtMeNH2-Me—Ph(CH 2 ) 2H(R)-
IV-1078MeMeMeNH2-Me—Ph(CH 2 ) 2Meracemic
IV-1079MeMeMeNH2-Me—Ph(CH 2 ) 2Me(R)-
IV-1080MeEtMeNH2-Me—Ph(CH 2 ) 2Meracemic
IV-1081MeEtMeNH2-Me—Ph(CH 2 ) 2Me(R)-
IV-1082MeMeMeNH2-Me—PhCH 2 C(Me) 2Hracemic
IV-1083MeMeMeNH2-Me—PhCH 2 C(Me) 2H(R)-
IV-1084MeEtMeNH2-Me—PhCH 2 C(Me) 2Hracemic
IV-1085MeEtMeNH2-Me—PhCH 2 C(Me) 2H(R)-
IV-1086MeMeMeNH2-Me—PhCH 2 C(Me) 2Meracemic
IV-1087MeMeMeNH2-Me—PhCH 2 C(Me) 2Me(R)-
IV-1088MeEtMeNH2-Me—PhCH 2 C(Me) 2Meracemic
IV-1089MeEtMeNH2-Me—PhCH 2 C(Me) 2Me(R)-
IV-1090MeMeMeNH2-Me—PhCH 2 C(Me) 2Hracemic
IV-1091MeMeMeNH2-Me—PhCH 2 C(Me) 2H(+)
IV-1092MeMeMeNH2-Me—PhCH 2 C(Me) 2H(−)
IV-1093MeEtMeNH2-Me—PhCH 2 C(Me) 2Hracemic
IV-1094MeEtMeNH2-Me—PhCH 2 C(Me) 2H(+)
IV-1095MeEtMeNH2-Me—PhCH 2 C(Me) 2H(−)
IV-1096MeMeMeNH2-Me—PhCH 2 C(Me) 2Meracemic
IV-1097MeMeMeNH2-Me—PhCH 2 C(Me) 2Me(+)
IV-1098MeMeMeNH2-Me—PhCH 2 C(Me) 2Me(−)
IV-1099MeEtMeNH2-Me—PhCH 2 C(Me) 2Meracemic
IV-1100MeEtMeNH2-Me—PhCH 2 C(Me) 2Me(+)
IV-1101MeEtMeNH2-Me—PhCH 2 C(Me) 2Me(−)
TABLE 86 — (IV) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
IV-1102MeMeMeNH3-Me—PhCH 2Hracemic
IV-1103MeMeMeNH3-Me—PhCH 2H(S)-
IV-1104MeEtMeNH3-Me—PhCH 2Hracemic
IV-1105MeEtMeNH3-Me—PhCH 2H(S)-
IV-1106MeMeMeNH3-Me—PhCH 2Meracemic
IV-1107MeMeMeNH3-Me—PhCH 2Me(S)-
IV-1108MeEtMeNH3-Me—PhCH 2Meracemic
IV-1109MeEtMeNH3-Me—PhCH 2Me(S)-
IV-1110MeMeMeNH3-Me—Ph(CH 2 ) 2Hracemic
IV-1111MeMeMeNH3-Me—Ph(CH 2 ) 2H(R)-
IV-1112MeEtMeNH3-Me—Ph(CH 2 ) 2Hracemic
IV-1113MeEtMeNH3-Me—Ph(CH 2 ) 2H(R)-
IV-1114MeMeMeNH3-Me—Ph(CH 2 ) 2Meracemic
IV-1115MeMeMeNH3-Me—Ph(CH 2 ) 2Me(R)-
IV-1116MeEtMeNH3-Me—Ph(CH 2 ) 2Meracemic
IV-1117MeEtMeNH3-Me—Ph(CH 2 ) 2Me(R)-
IV-1118MeMeMeNH3-Me—PhCH 2 C(Me) 2Hracemic
IV-1119MeMeMeNH3-Me—PhCH 2 C(Me) 2H(R)-
IV-1120MeEtMeNH3-Me—PhCH 2 C(Me) 2Hracemic
IV-1121MeEtMeNH3-Me—PhCH 2 C(Me) 2H(R)-
IV-1122MeMeMeNH3-Me—PhCH 2 C(Me) 2Meracemic
IV-1123MeMeMeNH3-Me—PhCH 2 C(Me) 2Me(R)-
IV-1124MeEtMeNH3-Me—PhCH 2 C(Me) 2Meracemic
IV-1125MeEtMeNH3-Me—PhCH 2 C(Me) 2Me(R)-
IV-1126MeMeMeNH3-Me—PhC(Me) 2 CH 2Hracemic
IV-1127MeMeMeNH3-Me—PhC(Me) 2 CH 2H(+)
IV-1128MeMeMeNH3-Me—PhC(Me) 2 CH 2H(−)
IV-1129MeEtMeNH3-Me—PhC(Me) 2 CH 2Hracemic
IV-1130MeEtMeNH3-Me—PhC(Me) 2 CH 2H(+)
IV-1131MeEtMeNH3-Me—PhC(Me) 2 CH 2H(−)
IV-1132MeMeMeNH3-Me—PhC(Me) 2 CH 2Meracemic
IV-1133MeMeMeNH3-Me—PhC(Me) 2 CH 2Me(+)
IV-1134MeMeMeNH3-Me—PhC(Me) 2 CH 2Me(−)
IV-1135MeEtMeNH3-Me—PhC(Me) 2 CH 2Meracemic
IV-1136MeEtMeNH3-Me—PhC(Me) 2 CH 2Me(+)
IV-1137MeEtMeNH3-Me—PhC(Me) 2 CH 2Me(−)
IV-1138MeMeMeNH3-Me—PhCH 2Hracemic
IV-1139MeMeMeNH3-Me—PhCH 2H(S)-
IV-1140MeEtMeNH3-Me—PhCH 2Hracemic
IV-1141MeEtMeNH3-Me—PhCH 2H(S)-
IV-1142MeMeMeNH3-Me—PhCH 2Meracemic
IV-1143MeMeMeNH3-Me—PhCH 2Me(S)-
IV-1144MeEtMeNH3-Me—PhCH 2Meracemic
IV-1145MeEtMeNH3-Me—PhCH 2Me(S)-
IV-1146MeMeMeNH3-Me—Ph(CH 2 ) 2Hracemic
IV-1147MeMeMeNH3-Me—Ph(CH 2 ) 2H(R)-
IV-1148MeMeMeNH3-Me—Ph(CH 2 ) 2Meracemic
IV-1149MeMeMeNH3-Me—Ph(CH 2 ) 2Me(R)-
IV-1150MeMeMeNH3-Me—PhCH 2 C(Me) 2Hracemic
IV-1151MeMeMeNH3-Me—PhCH 2 C(Me) 2H(R)-
TABLE 87 — (IV) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
IV-1152MeEtMeNH4-Me—PhCH 2 C(Me) 2Hracemic
IV-1153MeEtMeNH4-Me—PhCH 2 C(Me) 2H(R)-
IV-1154MeMeMeNH4-Me—PhCH 2 C(Me) 2Meracemic
IV-1155MeMeMeNH4-Me—PhCH 2 C(Me) 2Me(R)-
IV-1156MeEtMeNH4-Me—PhCH 2 C(Me) 2Meracemic
IV-1157MeEtMeNH4-Me—PhCH 2 C(Me) 2Me(R)-
IV-1158MeMeMeNH4-Me—PhC(Me) 2 CH 2Hracemic
IV-1159MeMeMeNH4-Me—PhC(Me) 2 CH 2H(+)
IV-1160MeMeMeNH4-Me—PhC(Me) 2 CH 2H(−)
IV-1161MeEtMeNH4-Me—PhC(Me) 2 CH 2Hracemic
IV-1162MeEtMeNH4-Me—PhC(Me) 2 CH 2H(+)
IV-1163MeEtMeNH4-Me—PhC(Me) 2 CH 2H(−)
IV-1164MeMeMeNH4-Me—PhC(Me) 2 CH 2Meracemic
IV-1165MeMeMeNH4-Me—PhC(Me) 2 CH 2Me(+)
IV-1166MeMeMeNH4-Me—PhC(Me) 2 CH 2Me(−)
IV-1167MeEtMeNH4-Me—PhC(Me) 2 CH 2Meracemic
IV-1168MeEtMeNH4-Me—PhC(Me) 2 CH 2Me(+)
IV-1169MeEtMeNH4-Me—PhC(Me) 2 CH 2Me(−)
IV-1170MeMeMe—Ph—Hracemic
IV-1171MeMeMe—Ph—H(R)-
IV-1172MeEtMe—Ph—Hracemic
IV-1173MeEtMe—Ph—H(R)-
IV-1174MeMeMe—Ph—Meracemic
IV-1175MeMeMe—Ph—Me(R)-
IV-1176MeMeMe—Ph—Me(S)-
IV-1177MeEtMe—Ph—Meracemic
IV-1178MeEtMe—Ph—Me(R)-
IV-1179MeMeMe—Ph—CHF 2racemic
IV-1180MeMeMe—Ph—CHF 2(R)-
IV-1181MeEtMe—Ph—CHF 2racemic
IV-1182MeEtMe—Ph—CHF 2(R)-
IV-1183MeMeMe—Ph—CF 3racemic
IV-1184MeMeMe—Ph—CF 3(R)-
IV-1185MeEtMe—Ph—CF 3racemic
IV-1186MeEtMe—Ph—CF 3(R)-
IV-1187MeMeMe—Ph—Etracemic
IV-1188MeMeMe—Ph—Et(R)-
IV-1189MeEtMe—Ph—Etracemic
IV-1190MeEtMe—Ph—Et(R)-
IV-1191MeMeMe—Ph—CF 2 CH 3racemic
IV-1192MeMeMe—Ph—CF 2 CH 3(R)-
IV-1193MeEtMe—Ph—CF 2 CH 3racemic
IV-1194MeEtMe—Ph—CF 2 CH 3(R)-
IV-1195MeMeMe—Ph—nPrracemic
IV-1196MeMeMe—Ph—nPr(R)-
IV-1197MeEtMe—Ph—nPrracemic
IV-1198MeEtMe—Ph—nPr(R)-
IV-1199MeMeMe—Ph—nBuracemic
IV-1200MeMeMe—Ph—nBu(R)-
IV-1201MeEtMe—Ph—nBuracemic
TABLE 88 — (IV) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
IV-1202MeEtMe—Ph—nBu(R)-
IV-1203MeMeMe—Ph—iPrracemic
IV-1204MeMeMe—Ph—iPr(R)-
IV-1205MeEtMe—Ph—iPrracemic
IV-1206MeEtMe—Ph—iPr(R)-
IV-1207MeMeMe—Ph—cPrracemic
IV-1208MeMeMe—Ph—cPr(R)-
IV-1209MeEtMe—Ph—cPrracemic
IV-1210MeEtMe—Ph—cPr(R)-
IV-1211MeMeMe—Ph—Phracemic
IV-1212MeMeMe—Ph—Ph(R)-
IV-1213MeMeMe—Ph—2,2-diF-cPrracemic
IV-1214MeMeMe—Ph—2,2-diF-cPr(R)-
IV-1215MeMeMe—PhCH 2H(R)-
IV-1216MeMeMe—PhCH 2CHF 2racemic
IV-1217MeMeMe—PhCH 2CHF 2(S)-
IV-1218MeMeMe—PhCH 2Etracemic
IV-1219MeMeMe—PhCH 2Et(S)-
IV-1220MeMeMe—PhCH 2Bnracemic
IV-1221MeMeMe—PhCH 2Bn(R)-
IV-1222MeMeMe—Ph(CH 2 ) 2Hracemic
IV-1223MeMeMe—Ph(CH 2 ) 2H(S)-
IV-1224MeMeMe—Ph(CH 2 ) 2Meracemic
IV-1225MeMeMe—Ph(CH 2 ) 2Me(S)-
IV-1226MeMeMe—Ph(CH 2 ) 2CHF 2racemic
IV-1227MeMeMe—Ph(CH 2 ) 2CHF 2(S)-
IV-1228MeMeMe—Ph(CH 2 ) 2Etracemic
IV-1229MeMeMe—Ph(CH 2 ) 2Et(S)-
IV-1230MeMeMe—H—H
IV-1231MeMeMe—H—Me
IV-1232MeMeMe—H—CHF 2
IV-1233MeMeMe—H—CF 3
IV-1234MeMeMe—H—Et
IV-1235MeMeMe—H—nPr
IV-1236MeMeMe—H—iPr
IV-1237MeMeMe—H—cPr
IV-1238MeMeMe—H—Ph
IV-1239MeMeMe—Me—Hracemic
IV-1240MeMeMe—Me—H(R)-
IV-1241MeMeMe—Me—Meracemic
IV-1242MeMeMe—Me—Me(R)-
IV-1243MeMeMe—Me—CHF 2racemic
IV-1244MeMeMe—Me—CHF 2(R)-
IV-1245MeMeMe—Me—CF 3racemic
IV-1246MeMeMe—Me—CF 3(R)-
IV-1247MeMeMe—Me—Etracemic
IV-1248MeMeMe—Me—Et(R)-
IV-1249MeMeMe—Me—nPrracemic
IV-1250MeMeMe—Me—nPr(R)-
IV-1251MeMeMe—Me—iPrracemic
TABLE 89 — (IV) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
IV-1252MeMeMe—Me—iPr(R)-
IV-1253MeMeMe—Me—cPrracemic
IV-1254MeMeMe—Me—cPr(R)-
IV-1255MeMeMe—Me—cHexracemic
IV-1256MeMeMe—Me—cHex(R)-
IV-1257MeMeMe—Me—Phracemic
IV-1258MeMeMe—Me—Ph(R)-
IV-1259MeMeMe—Me—Ph(S)-
IV-1260MeMeMe—Me—2-F—Phracemic
IV-1261MeMeMe—Me—2-F—Ph(R)-
IV-1262MeMeMe—Me—2-F—Phracemic
IV-1263MeMeMe—Me—2-F—Ph(R)-
IV-1264MeMeMe—Me—2-F—Phracemic
IV-1265MeMeMe—Me—2-F—Ph(R)-
IV-1266MeMeMe—Me—2-Cl—Phracemic
IV-1267MeMeMe—Me—2-Cl—Ph(R)-
IV-1268MeMeMe—Me—2-Cl—Phracemic
IV-1269MeMeMe—Me—2-Cl—Ph(R)-
IV-1270MeMeMe—Me—2-Cl—Phracemic
IV-1271MeMeMe—Me—2-Cl—Ph(R)-
IV-1272MeMeMe—Me—2-Pyracemic
IV-1273MeMeMe—Me—2-Py(R)-
IV-1274MeMeMe—Me—3-Pyracemic
IV-1275MeMeMe—Me—3-Py(R)-
IV-1276MeMeMe—Me—4-Pyracemic
IV-1277MeMeMe—Me—4-Py(R)-
IV-1278MeMeMe—iPr—Hracemic
IV-1279MeMeMe—iPr—H(R)-
IV-1280MeMeMe—iPr—Meracemic
IV-1281MeMeMe—iPr—Me(R)-
IV-1282MeMeMe—iPr—CHF 2racemic
IV-1283MeMeMe—iPr—CHF 2(R)-
IV-1284MeMeMe—iPr—CF 3racemic
IV-1285MeMeMe—iPr—CF 3(R)-
IV-1286MeMeMe—iPr—Etracemic
IV-1287MeMeMe—iPr—Et(R)-
IV-1288MeMeMe—iPr—nPrracemic
IV-1289MeMeMe—iPr—nPr(R)-
IV-1290MeMeMe—iPr—iPrracemic
IV-1291MeMeMe—iPr—iPr(R)-
IV-1292MeMeMe—iPr—cPrracemic
IV-1293MeMeMe—iPr—cPr(R)-
IV-1294MeMeMe—iPr—Phracemic
IV-1295MeMeMe—iPr—Ph(R)-
IV-1296MeMeMe—CF 3—Hracemic
IV-1297MeMeMe—CF 3—H(R)-
IV-1298MeMeMe—CF 3—Meracemic
IV-1299MeMeMe—CF 3—Me(R)-
IV-1300MeMeMe—CF 3—CHF 2racemic
IV-1301MeMeMe—CF 3—CHF 2(R)-
TABLE 90 — (IV) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
IV-1302MeMeMe—CF 3—CF 3racemic
IV-1303MeMeMe—CF 3—CF 3(R)-
IV-1304MeMeMe—CF 3—Etracemic
IV-1305MeMeMe—CF 3—Et(R)-
IV-1306MeMeMe—CF 3—nPrracemic
IV-1307MeMeMe—CF 3—nPr(R)-
IV-1308MeMeMe—CF 3—iPrracemic
IV-1309MeMeMe—CF 3—iPr(R)-
IV-1310MeMeMe—CF 3—cPrracemic
IV-1311MeMeMe—CF 3—cPr(R)-
IV-1312MeMeMe—CF 3—Phracemic
IV-1313MeMeMe—CF 3—Ph(R)-
IV-1314MeMeMe—CH 2 OH—Hracemic
IV-1315MeMeMe—CH 2 OH—H(R)-
IV-1316MeMeMe—CH 2 OH—Meracemic
IV-1317MeMeMe—CH 2 OH—Me(R)-
IV-1318MeMeMe—CH 2 OH—CHF 2racemic
IV-1319MeMeMe—CH 2 OH—CHF 2(R)-
IV-1320MeMeMe—CH 2 OH—CF 3racemic
IV-1321MeMeMe—CH 2 OH—CF 3(R)-
IV-1322MeMeMe—CH 2 OH—Etracemic
IV-1323MeMeMe—CH 2 OH—Et(R)-
IV-1324MeMeMe—CH 2 OH—nPrracemic
IV-1325MeMeMe—CH 2 OH—nPr(R)-
IV-1326MeMeMe—CH 2 OH—iPrracemic
IV-1327MeMeMe—CH 2 OH—iPr(R)-
IV-1328MeMeMe—CH 2 OH—cPrracemic
IV-1329MeMeMe—CH 2 OH—cPr(R)-
IV-1330MeMeMe—CH 2 OH—Phracemic
IV-1331MeMeMe—CH 2 OH—Ph(R)-
IV-1332MeMeMe—CH 2 OMe—Hracemic
IV-1333MeMeMe—CH 2 OMe—H(R)-
IV-1334MeMeMe—CH 2 OMe—Meracemic
IV-1335MeMeMe—CH 2 OMe—Me(R)-
IV-1336MeMeMe—CH 2 OMe—CHF 2racemic
IV-1337MeMeMe—CH 2 OMe—CHF 2(R)-
IV-1338MeMeMe—CH 2 OMe—CF 3racemic
IV-1339MeMeMe—CH 2 OMe—CF 3(R)-
IV-1340MeMeMe—CH 2 OMe—Etracemic
IV-1341MeMeMe—CH 2 OMe—Et(R)-
IV-1342MeMeMe—CH 2 OMe—nPrracemic
IV-1343MeMeMe—CH 2 OMe—nPr(R)-
IV-1344MeMeMe—CH 2 OMe—iPrracemic
IV-1345MeMeMe—CH 2 OMe—iPr(R)-
IV-1346MeMeMe—CH 2 OMe—cPrracemic
IV-1347MeMeMe—CH 2 OMe—cPr(R)-
IV-1348MeMeMe—CH 2 OMe—Phracemic
IV-1349MeMeMe—CH 2 OMe—Ph(R)-
IV-1350MeMeMe—CH 2 OBn—Hracemic
IV-1351MeMeMe—CH 2 OBn—H(R)-
TABLE 91 — (IV) Com-
poundConfig-
No.R 1R 2R 3L 2R 4L 3R 5uration
IV-1352MeMeMe—CH 2 OBn—Meracemic
IV-1353MeMeMe—CH 2 OBn—Me(R)-
IV-1354MeMeMe—CH 2 OBn—Phracemic
IV-1355MeMeMe—CH 2 OBn—Ph(R)-
IV-1356MeMeMe—CH 2 NMe 2—Hracemic
IV-1357MeMeMe—CH 2 NMe 2—H(R)-
IV-1358MeMeMe—CH 2 NMe 2—Meracemic
IV-1359MeMeMe—CH 2 NMe 2—Me(R)-
IV-1360MeMeMe—CH 2 NMe 2—CHF 2racemic
IV-1361MeMeMe—CH 2 NMe 2—CHF 2(R)-
IV-1362MeMeMe—CH 2 NMe 2—CF 3racemic
IV-1363MeMeMe—CH 2 NMe 2—CF 3(R)-
IV-1364MeMeMe—CH 2 NMe 2—Etracemic
IV-1365MeMeMe—CH 2 NMe 2—Et(R)-
IV-1366MeMeMe—CH 2 NMe 2—nPrracemic
IV-1367MeMeMe—CH 2 NMe 2—nPr(R)-
IV-1368MeMeMe—CH 2 NMe 2—iPrracemic
IV-1369MeMeMe—CH 2 NMe 2—iPr(R)-
IV-1370MeMeMe—CH 2 NMe 2—cPrracemic
IV-1371MeMeMe—CH 2 NMe 2—cPr(R)-
IV-1372MeMeMe—CH 2 NMe 2—Phracemic
IV-1373MeMeMe—CH 2 NMe 2—Ph(R)-
IV-1374MeMeMe—CH 2 -3-(3,3-(3,—Hracemic
—pyrrolidyl)—
IV-1375MeMeMe—CH 2 -3-(3,3-(3,—H(R)-
—pyrrolidyl)—
IV-1376MeMeMe—CH 2 -3-(3,3-(3,—Meracemic
—pyrrolidyl)—
IV-1377MeMeMe—CH 2 -3-(3,3-(3,—Me(R)-
—pyrrolidyl)—
IV-1378MeMeMe—CH 2 -3-(3,3-(3,—Phracemic
—pyrrolidyl)—
IV-1379MeMeMe—CH 2 -3-(3,3-(3,—Ph(R)-
—pyrrolidyl)—
IV-1380MeMeMe—2-F—Ph—Hracemic
IV-1381MeMeMe—2-F—Ph—H(R)-
IV-1382MeMeMe—2-F—Ph—Meracemic
IV-1383MeMeMe—2-F—Ph—Me(R)-
IV-1384MeMeMe—2-F—Ph—Me(S)-
IV-1385MeMeMe—2-F—Ph—CHF 2racemic
IV-1386MeMeMe—2-F—Ph—CHF 2(R)-
IV-1387MeMeMe—2-F—Ph—CHF 2(S)-
IV-1388MeMeMe—2-F—Ph—CF 3racemic
IV-1389MeMeMe—2-F—Ph—CF 3(R)-
IV-1390MeMeMe—2-F—Ph—CF 3(S)-
IV-1391MeMeMe—2-F—Ph—Etracemic
IV-1392MeMeMe—2-F—Ph—Et(R)-
IV-1393MeMeMe—2-F—Ph—Et(S)-
IV-1394MeMeMe—2-F—Ph—nPrracemic
IV-1395MeMeMe—2-F—Ph—nPr(R)-
IV-1396MeMeMe—2-F—Ph—iPrracemic
IV-1397MeMeMe—2-F—Ph—iPr(R)-
IV-1398MeMeMe—2-F—Ph—iPr(S)-
IV-1399MeMeMe—2-F—Ph—cPrracemic
IV-1400MeMeMe—2-F—Ph—cPr(R)-
IV-1401MeMeMe—2-F—Ph—cPr(S)-
TABLE 92
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-1402MeMeMe—3-F—Ph—Hracemic
IV-1403MeMeMe—3-F—Ph—H(R)-
IV-1404MeMeMe—3-F—Ph—Meracemic
IV-1405MeMeMe—3-F—Ph—Me(R)-
IV-1406MeMeMe—3-F—Ph—Me(S)-
IV-1407MeMeMe—3-F—Ph—CHF 2racemic
IV-1408MeMeMe—3-F—Ph—CHF 2(R)-
IV-1409MeMeMe—3-F—Ph—CHF 2(S)-
IV-1410MeMeMe—3-F—Ph—CF 3racemic
IV-1411MeMeMe—3-F—Ph—CF 3(R)-
IV-1412MeMeMe—3-F—Ph—CF 3(S)-
IV-1413MeMeMe—3-F—Ph—Etracemic
IV-1414MeMeMe—3-F—Ph—Et(R)-
IV-1415MeMeMe—3-F—Ph—Et(S)-
IV-1416MeMeMe—3-F—Ph—nPrracemic
IV-1417MeMeMe—3-F—Ph—nPr(R)-
IV-1418MeMeMe—3-F—Ph—nPr(S)-
IV-1419MeMeMe—3-F—Ph—iPrracemic
IV-1420MeMeMe—3-F—Ph—iPr(R)-
IV-1421MeMeMe—3-F—Ph—iPr(S)-
IV-1422MeMeMe—3-F—Ph—cPrracemic
IV-1423MeMeMe—3-F—Ph—cPr(R)-
IV-1424MeMeMe—3-F—Ph—cPr(S)-
IV-1425MeMeMe—4-F—Ph—Hracemic
IV-1426MeMeMe—4-F—Ph—H(R)-
IV-1427MeMeMe—4-F—Ph—Meracemic
IV-1428MeMeMe—4-F—Ph—Me(R)-
IV-1429MeMeMe—4-F—Ph—Me(S)-
IV-1430MeMeMe—4-F—Ph—CHF 2racemic
IV-1431MeMeMe—4-F—Ph—CHF 2(R)-
IV-1432MeMeMe—4-F—Ph—CHF 2(S)-
IV-1433MeMeMe—4-F—Ph—CF 3racemic
IV-1434MeMeMe—4-F—Ph—CF 3(R)-
IV-1435MeMeMe—4-F—Ph—CF 3(S)-
IV-1436MeMeMe—4-F—Ph—Etracemic
IV-1437MeMeMe—4-F—Ph—Et(R)-
IV-1438MeMeMe—4-F—Ph—Et(S)-
IV-1439MeMeMe—4-F—Ph—nPrracemic
IV-1440MeMeMe—4-F—Ph—nPr(R)-
IV-1441MeMeMe—4-F—Ph—nPr(S)-
IV-1442MeMeMe—4-F—Ph—iPrracemic
IV-1443MeMeMe—4-F—Ph—iPr(R)-
IV-1444MeMeMe—4-F—Ph—iPr(S)-
IV-1445MeMeMe—4-F—Ph—cPrracemic
IV-1446MeMeMe—4-F—Ph—cPr(R)-
IV-1447MeMeMe—4-F—Ph—cPr(S)-
IV-1448MeMeMe—2-Cl—Ph—Hracemic
IV-1449MeMeMe—2-Cl—Ph—H(R)-
IV-1450MeMeMe—2-Cl—Ph—Meracemic
IV-1451MeMeMe—2-Cl—Ph—Me(R)-
TABLE 93
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-1452MeMeMe—2-Cl—Ph—CHF 2racemic
IV-1453MeMeMe—2-Cl—Ph—CHF 2(R)-
IV-1454MeMeMe—2-Cl—Ph—CF 3racemic
IV-1455MeMeMe—2-Cl—Ph—CF 3(R)-
IV-1456MeMeMe—2-Cl—Ph—Etracemic
IV-1457MeMeMe—2-Cl—Ph—Et(R)-
IV-1458MeMeMe—2-Cl—Ph—nPrracemic
IV-1459MeMeMe—2-Cl—Ph—nPr(R)-
IV-1460MeMeMe—2-Cl—Ph—iPrracemic
IV-1461MeMeMe—2-Cl—Ph—iPr(R)-
IV-1462MeMeMe—2-Cl—Ph—cPrracemic
IV-1463MeMeMe—2-Cl—Ph—cPr(R)-
IV-1464MeMeMe—3-Cl—Ph—Hracemic
IV-1465MeMeMe—3-Cl—Ph—H(R)-
IV-1466MeMeMe—3-Cl—Ph—Meracemic
IV-1467MeMeMe—3-Cl—Ph—Me(R)-
IV-1468MeMeMe—3-Cl—Ph—CHF 2racemic
IV-1469MeMeMe—3-Cl—Ph—CHF 2(R)-
IV-1470MeMeMe—3-Cl—Ph—CF 3racemic
IV-1471MeMeMe—3-Cl—Ph—CF 3(R)-
IV-1472MeMeMe—3-Cl—Ph—Etracemic
IV-1473MeMeMe—3-Cl—Ph—Et(R)-
IV-1474MeMeMe—3-Cl—Ph—nPrracemic
IV-1475MeMeMe—3-Cl—Ph—nPr(R)-
IV-1476MeMeMe—3-Cl—Ph—iPrracemic
IV-1477MeMeMe—3-Cl—Ph—iPr(R)-
IV-1478MeMeMe—3-Cl—Ph—cPrracemic
IV-1479MeMeMe—3-Cl—Ph—cPr(R)-
IV-1480MeMeMe—4-Cl—Ph—Hracemic
IV-1481MeMeMe—4-Cl—Ph—H(R)-
IV-1482MeMeMe—4-Cl—Ph—Meracemic
IV-1483MeMeMe—4-Cl—Ph—Me(R)-
IV-1484MeMeMe—4-Cl—Ph—CHF 2racemic
IV-1485MeMeMe—4-Cl—Ph—CHF 2(R)-
IV-1486MeMeMe—4-Cl—Ph—CF 3racemic
IV-1487MeMeMe—4-Cl—Ph—CF 3(R)-
IV-1488MeMeMe—4-Cl—Ph—Etracemic
IV-1489MeMeMe—4-Cl—Ph—Et(R)-
IV-1490MeMeMe—4-Cl—Ph—nPrracemic
IV-1491MeMeMe—4-Cl—Ph—nPr(R)-
IV-1492MeMeMe—4-Cl—Ph—iPrracemic
IV-1493MeMeMe—4-Cl—Ph—iPr(R)-
IV-1494MeMeMe—4-Cl—Ph—cPrracemic
IV-1495MeMeMe—4-Cl—Ph—cPr(R)-
IV-1496MeMeMe—2-Me—Ph—Hracemic
IV-1497MeMeMe—2-Me—Ph—H(R)-
IV-1498MeMeMe—2-Me—Ph—Meracemic
IV-1499MeMeMe—2-Me—Ph—Me(R)-
IV-1500MeMeMe—2-Me—Ph—CHF 2racemic
IV-1501MeMeMe—2-Me—Ph—CHF 2(R)-
TABLE 94
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-1502MeMeMe—2-Me—Ph—CF 3racemic
IV-1503MeMeMe—2-Me—Ph—CF 3(R)-
IV-1504MeMeMe—2-Me—Ph—Etracemic
IV-1505MeMeMe—2-Me—Ph—Et(R)-
IV-1506MeMeMe—2-Me—Ph—nPrracemic
IV-1507MeMeMe—2-Me—Ph—nPr(R)-
IV-1508MeMeMe—2-Me—Ph—iPrracemic
IV-1509MeMeMe—2-Me—Ph—iPr(R)-
IV-1510MeMeMe—2-Me—Ph—cPrracemic
IV-1511MeMeMe—2-Me—Ph—cPr(R)-
IV-1512MeMeMe—3-Me—Ph—Hracemic
IV-1513MeMeMe—3-Me—Ph—H(R)-
IV-1514MeMeMe—3-Me—Ph—Meracemic
IV-1515MeMeMe—3-Me—Ph—Me(R)-
IV-1516MeMeMe—3-Me—Ph—CHF 2racemic
IV-1517MeMeMe—3-Me—Ph—CHF 2(R)-
IV-1518MeMeMe—3-Me—Ph—CF 3racemic
IV-1519MeMeMe—3-Me—Ph—CF 3(R)-
IV-1520MeMeMe—3-Me—Ph—Etracemic
IV-1521MeMeMe—3-Me—Ph—Et(R)-
IV-1522MeMeMe—3-Me—Ph—nPrracemic
IV-1523MeMeMe—3-Me—Ph—nPr(R)-
IV-1524MeMeMe—3-Me—Ph—iPrracemic
IV-1525MeMeMe—3-Me—Ph—iPr(R)-
IV-1526MeMeMe—3-Me—Ph—cPrracemic
IV-1527MeMeMe—3-Me—Ph—cPr(R)-
IV-1528MeMeMe—4-Me—Ph—Hracemic
IV-1529MeMeMe—4-Me—Ph—H(R)-
IV-1530MeMeMe—4-Me—Ph—Meracemic
IV-1531MeMeMe—4-Me—Ph—Me(R)-
IV-1532MeMeMe—4-Me—Ph—CHF 2racemic
IV-1533MeMeMe—4-Me—Ph—CHF 2(R)-
IV-1534MeMeMe—4-Me—Ph—CF 3racemic
IV-1535MeMeMe—4-Me—Ph—CF 3(R)-
IV-1536MeMeMe—4-Me—Ph—Etracemic
IV-1537MeMeMe—4-Me—Ph—Et(R)-
IV-1538MeMeMe—4-Me—Ph—nPrracemic
IV-1539MeMeMe—4-Me—Ph—nPr(R)-
IV-1540MeMeMe—4-Me—Ph—iPrracemic
IV-1541MeMeMe—4-Me—Ph—iPr(R)-
IV-1542MeMeMe—4-Me—Ph—cPrracemic
IV-1543MeMeMe—4-Me—Ph—cPr(R)-
IV-1544MeMeMe—2-thienyl—Hracemic
IV-1545MeMeMe—2-thienyl—H(S)-
IV-1546MeMeMe—2-thienyl—Meracemic
IV-1547MeMeMe—2-thienyl—Me(+)-
IV-1548MeMeMe—2-thienyl—Me(−)-
IV-1549MeMeMe—2-thienyl—CHF 2racemic
IV-1550MeMeMe—2-thienyl—CHF 2(+)-
IV-1551MeMeMe—2-thienyl—CHF 2(−)-
TABLE 95
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-1552MeMeMe—2-thienyl—CF 3racemic
IV-1553MeMeMe—2-thienyl—CF 3(+)-
IV-1554MeMeMe—2-thienyl—CF 3(−)-
IV-1555MeMeMe—2-thienyl—Etracemic
IV-1556MeMeMe—2-thienyl—Et(+)-
IV-1557MeMeMe—2-thienyl—Et(−)-
IV-1558MeMeMe—2-thienyl—nPrracemic
IV-1559MeMeMe—2-thienyl—nPr(+)-
IV-1560MeMeMe—2-thienyl—nPr(−)-
IV-1561MeMeMe—2-thienyl—iPrracemic
IV-1562MeMeMe—2-thienyl—iPr(+)-
IV-1563MeMeMe—2-thienyl—iPr(−)-
IV-1564MeMeMe—2-thienyl—cPrracemic
IV-1565MeMeMe—2-thienyl—cPr(+)-
IV-1566MeMeMe—2-thienyl—cPr(−)-
IV-1567MeMeMe—3-F-2-thienyl—Hracemic
IV-1568MeMeMe—3-F-2-thienyl—H(S)-
IV-1569MeMeMe—3-F-2-thienyl—Meracemic
IV-1570MeMeMe—3-F-2-thienyl—Me(S)-
IV-1571MeMeMe—3-F-2-thienyl—CHF 2racemic
IV-1572MeMeMe—3-F-2-thienyl—CHF 2(S)-
IV-1573MeMeMe—3-F-2-thienyl—CF 3racemic
IV-1574MeMeMe—3-F-2-thienyl—CF 3(S)-
IV-1575MeMeMe—3-F-2-thienyl—Etracemic
IV-1576MeMeMe—3-F-2-thienyl—Et(S)-
IV-1577MeMeMe—3-F-2-thienyl—nPrracemic
IV-1578MeMeMe—3-F-2-thienyl—nPr(S)-
IV-1579MeMeMe—3-F-2-thienyl—iPrracemic
IV-1580MeMeMe—3-F-2-thienyl—iPr(S)-
IV-1581MeMeMe—3-F-2-thienyl—cPrracemic
IV-1582MeMeMe—3-F-2-thienyl—cPr(S)-
IV-1583MeMeMe—4-F-2-thienyl—Hracemic
IV-1584MeMeMe—4-F-2-thienyl—H(S)-
IV-1585MeMeMe—4-F-2-thienyl—Meracemic
IV-1586MeMeMe—4-F-2-thienyl—Me(S)-
IV-1587MeMeMe—4-F-2-thienyl—CHF 2racemic
IV-1588MeMeMe—4-F-2-thienyl—CHF 2(S)-
IV-1589MeMeMe—4-F-2-thienyl—CF 3racemic
IV-1590MeMeMe—4-F-2-thienyl—CF 3(S)-
IV-1591MeMeMe—4-F-2-thienyl—Etracemic
IV-1592MeMeMe—4-F-2-thienyl—Et(S)-
IV-1593MeMeMe—4-F-2-thienyl—nPrracemic
IV-1594MeMeMe—4-F-2-thienyl—nPr(S)-
IV-1595MeMeMe—4-F-2-thienyl—iPrracemic
IV-1596MeMeMe—4-F-2-thienyl—iPr(S)-
IV-1597MeMeMe—4-F-2-thienyl—cPrracemic
IV-1598MeMeMe—4-F-2-thienyl—cPr(S)-
IV-1599MeMeMe—4-F-2-thienyl—Hracemic
IV-1600MeMeMe—4-F-2-thienyl—H(S)-
IV-1601MeMeMe—4-F-2-thienyl—Meracemic
TABLE 96
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-1602MeMeMe—5-F-2-thienyl—Me(S)-
IV-1603MeMeMe—5-F-2-thienyl—CHF 2racemic
IV-1604MeMeMe—5-F-2-thienyl—CHF 2(S)-
IV-1605MeMeMe—5-F-2-thienyl—CF 3racemic
IV-1606MeMeMe—5-F-2-thienyl—CF 3(S)-
IV-1607MeMeMe—5-F-2-thienyl—Etracemic
IV-1608MeMeMe—5-F-2-thienyl—Et(S)-
IV-1609MeMeMe—5-F-2-thienyl—nPrracemic
IV-1610MeMeMe—5-F-2-thienyl—nPr(S)-
IV-1611MeMeMe—5-F-2-thienyl—iPrracemic
IV-1612MeMeMe—5-F-2-thienyl—iPr(S)-
IV-1613MeMeMe—5-F-2-thienyl—cPrracemic
IV-1614MeMeMe—5-F-2-thienyl—cPr(S)-
IV-1615MeMeMe—3-Cl-2-thienyl—Hracemic
IV-1616MeMeMe—3-Cl-2-thienyl—H(S)-
IV-1617MeMeMe—3-Cl-2-thienyl—Meracemic
IV-1618MeMeMe—3-Cl-2-thienyl—Me(S)-
IV-1619MeMeMe—3-Cl-2-thienyl—CHF 2racemic
IV-1620MeMeMe—3-Cl-2-thienyl—CHF 2(S)-
IV-1621MeMeMe—3-Cl-2-thienyl—CF 3racemic
IV-1622MeMeMe—3-Cl-2-thienyl—CF 3(S)-
IV-1623MeMeMe—3-Cl-2-thienyl—Etracemic
IV-1624MeMeMe—3-Cl-2-thienyl—Et(S)-
IV-1625MeMeMe—3-Cl-2-thienyl—nPrracemic
IV-1626MeMeMe—3-Cl-2-thienyl—nPr(S)-
IV-1627MeMeMe—3-Cl-2-thienyl—iPrracemic
IV-1628MeMeMe—3-Cl-2-thienyl—iPr(S)-
IV-1629MeMeMe—3-Cl-2-thienyl—cPrracemic
IV-1630MeMeMe—3-Cl-2-thienyl—cPr(S)-
IV-1631MeMeMe—4-Cl-2-thienyl—Hracemic
IV-1632MeMeMe—4-Cl-2-thienyl—H(S)-
IV-1633MeMeMe—4-Cl-2-thienyl—Meracemic
IV-1634MeMeMe—4-Cl-2-thienyl—Me(S)-
IV-1635MeMeMe—4-Cl-2-thienyl—CHF 2racemic
IV-1636MeMeMe—4-Cl-2-thienyl—CHF 2(S)-
IV-1637MeMeMe—4-Cl-2-thienyl—CF 3racemic
IV-1638MeMeMe—4-Cl-2-thienyl—CF 3(S)-
IV-1639MeMeMe—4-Cl-2-thienyl—Etracemic
IV-1640MeMeMe—4-Cl-2-thienyl—Et(S)-
IV-1641MeMeMe—4-Cl-2-thienyl—nPrracemic
IV-1642MeMeMe—4-Cl-2-thienyl—nPr(S)-
IV-1643MeMeMe—4-Cl-2-thienyl—iPrracemic
IV-1644MeMeMe—4-Cl-2-thienyl—iPr(S)-
IV-1645MeMeMe—4-Cl-2-thienyl—cPrracemic
IV-1646MeMeMe—4-Cl-2-thienyl—cPr(S)-
IV-1647MeMeMe—5-Cl-2-thienyl—Hracemic
IV-1648MeMeMe—5-Cl-2-thienyl—H(S)-
IV-1649MeMeMe—5-Cl-2-thienyl—Meracemic
IV-1650MeMeMe—5-Cl-2-thienyl—Me(S)-
IV-1651MeMeMe—5-Cl-2-thienyl—CHF 2racemic
TABLE 97
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-1652MeMeMe—5-Cl-2-thienyl—CHF 2(S)-
IV-1653MeMeMe—5-Cl-2-thienyl—CF 3racemic
IV-1654MeMeMe—5-Cl-2-thienyl—CF 3(S)-
IV-1655MeMeMe—5-Cl-2-thienyl—Etracemic
IV-1656MeMeMe—5-Cl-2-thienyl—Et(S)-
IV-1657MeMeMe—5-Cl-2-thienyl—nPrracemic
IV-1658MeMeMe—5-Cl-2-thienyl—nPr(S)-
IV-1659MeMeMe—5-Cl-2-thienyl—iPrracemic
IV-1660MeMeMe—5-Cl-2-thienyl—iPr(S)-
IV-1661MeMeMe—5-Cl-2-thienyl—cPrracemic
IV-1662MeMeMe—5-Cl-2-thienyl—cPr(S)-
IV-1663MeMeMe—3-Me-2-thienyl—Hracemic
IV-1664MeMeMe—3-Me-2-thienyl—H(S)-
IV-1665MeMeMe—3-Me-2-thienyl—Meracemic
IV-1666MeMeMe—3-Me-2-thienyl—Me(S)-
IV-1667MeMeMe—3-Me-2-thienyl—CHF 2racemic
IV-1668MeMeMe—3-Me-2-thienyl—CHF 2(S)-
IV-1669MeMeMe—3-Me-2-thienyl—CF 3racemic
IV-1670MeMeMe—3-Me-2-thienyl—CF 3(S)-
IV-1671MeMeMe—3-Me-2-thienyl—Etracemic
IV-1672MeMeMe—3-Me-2-thienyl—Et(S)-
IV-1673MeMeMe—3-Me-2-thienyl—nPrracemic
IV-1674MeMeMe—3-Me-2-thienyl—nPr(S)-
IV-1675MeMeMe—3-Me-2-thienyl—iPrracemic
IV-1676MeMeMe—3-Me-2-thienyl—iPr(S)-
IV-1677MeMeMe—3-Me-2-thienyl—cPrracemic
IV-1678MeMeMe—3-Me-2-thienyl—cPr(S)-
IV-1679MeMeMe—4-Me-2-thienyl—Hracemic
IV-1680MeMeMe—4-Me-2-thienyl—H(S)-
IV-1681MeMeMe—4-Me-2-thienyl—Meracemic
IV-1682MeMeMe—4-Me-2-thienyl—Me(S)-
IV-1683MeMeMe—4-Me-2-thienyl—CHF 2racemic
IV-1684MeMeMe—4-Me-2-thienyl—CHF 2(S)-
IV-1685MeMeMe—4-Me-2-thienyl—CF 3racemic
IV-1686MeMeMe—4-Me-2-thienyl—CF 3(S)-
IV-1687MeMeMe—4-Me-2-thienyl—Etracemic
IV-1688MeMeMe—4-Me-2-thienyl—Et(S)-
IV-1689MeMeMe—4-Me-2-thienyl—nPrracemic
IV-1690MeMeMe—4-Me-2-thienyl—nPr(S)-
IV-1691MeMeMe—4-Me-2-thienyl—iPrracemic
IV-1692MeMeMe—4-Me-2-thienyl—iPr(S)-
IV-1693MeMeMe—4-Me-2-thienyl—cPrracemic
IV-1694MeMeMe—4-Me-2-thienyl—cPr(S)-
IV-1695MeMeMe—5-Me-2-thienyl—Hracemic
IV-1696MeMeMe—5-Me-2-thienyl—H(S)-
IV-1697MeMeMe—5-Me-2-thienyl—Meracemic
IV-1698MeMeMe—5-Me-2-thienyl—Me(S)-
IV-1699MeMeMe—5-Me-2-thienyl—CHF 2racemic
IV-1700MeMeMe—5-Me-2-thienyl—CHF 2(S)-
IV-1701MeMeMe—5-Me-2-thienyl—CF 3racemic
TABLE 98
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 5figuration
IV-1702MeMeMe—5-Me-2 -thienyl—CF 3(S)-
IV-1703MeMeMe—5-Me-2 -thienyl—Etracemic
IV-1704MeMeMe—5-Me-2 -thienyl—Et(S)-
IV-1705MeMeMe—5-Me-2 -thienyl—nPrracemic
IV-1706MeMeMe—5-Me-2-thienyl—nPr(S)-
IV-1707MeMeMe—5-Me-2 -thienyl—iPrracemic
IV-1708MeMeMe—5-Me-2-thienyl—iPr(S)-
IV-1709MeMeMe—5-Me-2-thienyl—cPrracemic
IV-1710MeMeMe—5-Me-2-thienyl—cPr(S)-
IV-1711MeMeMe—3-thienyl—Hracemic
IV-1712MeMeMe—3-thienyl—H(R)-
IV-1713MeMeMe—3-thienyl—Meracemic
IV-1714MeMeMe—3-thienyl—Me(R)-
IV-1715MeMeMe—3-thienyl—CHF 2racemic
IV-1716MeMeMe—3-thienyl—CHF 2(R) —
IV-1717MeMeMe—3-thienyl—CF 3racemic
IV-1718MeMeMe—3-thienyl—CF 3(R) —
IV-1719MeMeMe—3-thienyl—Etracemic
IV-1720MeMeMe—3-thienyl—Et(R)-
IV-1721MeMeMe—3-thienyl—nPrracemic
IV-1722MeMeMe—3-thienyl—nPr(R)-
IV-1723MeMeMe—3-thienyl—iPrracemic
IV-1724MeMeMe—3-thienyl—iPr(R)-
IV-1725MeMeMe—3-thienyl—cPrracemic
IV-1726MeMeMe—3-thienyl—cPr(R)-
TABLE 99
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1MeMeMeOPhCH 2Meracemic
V-2MeMeMeOPhCH 2Me(S)-
V-3MeEtMeOPhCH 2Meracemic
V-4MeEtMeOPhCH 2Me(S)-
V-5MeMeMeOPhCH 2Etracemic
V-6MeMeMeOPhCH 2Et(S)-
V-7MeEtMeOPhCH 2Etracemic
V-8MeEtMeOPhCH 2Et(S)-
V-9MeMeMeOPhCH 2nPrracemic
V-10MeMeMeOPhCH 2nPr(S)-
V-11MeEtMeOPhCH 2nPrracemic
V-12MeEtMeOPhCH 2nPr(S)-
V-13MeMeMeOPhCH 2iPrracemic
V-14MeMeMeOPhCH 2iPr(S)-
V-15MeEtMeOPhCH 2iPrracemic
V-16MeEtMeOPhCH 2iPr(S)-
V-17MeMeMeOPhCH 2nBuracemic
V-18MeMeMeOPhCH 2nBu(S)-
V-19MeEtMeOPhCH 2nBuracemic
V-20MeEtMeOPhCH 2nBu(S)-
V-21MeMeMeOPhCH 2tBuracemic
V-22MeMeMeOPhCH 2tBu(S)-
V-23MeEtMeOPhCH 2tBuracemic
V-24MeEtMeOPhCH 2tBu(S)-
V-25MeMeMeOPhCH 2iBuracemic
V-26MeMeMeOPhCH 2iBu(S)-
V-27MeEtMeOPhCH 2iBuracemic
V-28MeEtMeOPhCH 2iBu(S)-
V-29MeMeMeOPhCH 2n-Heptylracemic
V-30MeMeMeOPhCH 2n-Heptyl(S)-
V-31MeEtMeOPhCH 2n-Heptylracemic
V-32MeEtMeOPhCH 2n-Heptyl(S)-
V-33MeMeMeOPhCH 2n-Undecylracemic
V-34MeMeMeOPhCH 2n-Undecyl(S)-
V-35MeEtMeOPhCH 2n-Undecylracemic
V-36MeEtMeOPhCH 2n-Undecyl(S)-
V-37MeMeMeOPhCH 2Phracemic
V-38MeMeMeOPhCH 2Ph(S)-
V-39MeEtMeOPhCH 2Phracemic
V-40MeEtMeOPhCH 2Ph(S)-
V-41MeMeMeOPhCH 2OEtracemic
V-42MeMeMeOPhCH 2OEt(S)-
V-43MeEtMeOPhCH 2OEtracemic
V-44MeEtMeOPhCH 2OEt(S)-
V-45MeMeMeOPhCH 2(CH 2 ) 2 COOHracemic
V-46MeMeMeOPhCH 2(CH 2 ) 2 COOH(S)-
V-47MeEtMeOPhCH 2(CH 2 ) 2 COOHracemic
V-48MeEtMeOPhCH 2(CH 2 ) 2 COOH(S)-
V-49MeMeMeOPhC(Me) 2Meracemic
V-50MeMeMeOPhC(Me) 2Me(S)-
TABLE 100
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-51MeEtMeOPhC(Me) 2Meracemic
V-52MeEtMeOPhC(Me) 2Me(S)-
V-53MeMeMeOPhC(Me) 2Etracemic
V-54MeMeMeOPhC(Me) 2Et(S)-
V-55MeEtMeOPhC(Me) 2Etracemic
V-56MeEtMeOPhC(Me) 2Et(S)-
V-57MeMeMeOPhC(Me) 2nPrracemic
V-58MeMeMeOPhC(Me) 2nPr(S)-
V-59MeEtMeOPhC(Me) 2nPrracemic
V-60MeEtMeOPhC(Me) 2nPr(S)-
V-61MeMeMeOPhC(Me) 2iPrracemic
V-62MeMeMeOPhC(Me) 2iPr(S)-
V-63MeEtMeOPhC(Me) 2iPrracemic
V-64MeEtMeOPhC(Me) 2iPr(S)-
V-65MeMeMeOPhC(Me) 2nBuracemic
V-66MeMeMeOPhC(Me) 2nBu(S)-
V-67MeEtMeOPhC(Me) 2nBuracemic
V-68MeEtMeOPhC(Me) 2nBu(S)-
V-69MeMeMeOPhC(Me) 2tBuracemic
V-70MeMeMeOPhC(Me) 2tBu(S)-
V-71MeEtMeOPhC(Me) 2tBuracemic
V-72MeEtMeOPhC(Me) 2tBu(S)-
V-73MeMeMeOPhC(Me) 2iBuracemic
V-74MeMeMeOPhC(Me) 2iBu(S)-
V-75MeEtMeOPhC(Me) 2iBuracemic
V-76MeEtMeOPhC(Me) 2iBu(S)-
V-77MeMeMeOPhC(Me) 2n-Heptylracemic
V-78MeMeMeOPhC(Me) 2n-Heptyl(S)-
V-79MeEtMeOPhC(Me) 2n-Heptylracemic
V-80MeEtMeOPhC(Me) 2n-Heptyl(S)-
V-81MeMeMeOPhC(Me) 2n-Undecylracemic
V-82MeMeMeOPhC(Me) 2n-Undecyl(S)-
V-83MeEtMeOPhC(Me) 2n-Undecylracemic
V-84MeEtMeOPhC(Me) 2n-Undecyl(S)-
V-85MeMeMeOPhC(Me) 2Phracemic
V-86MeMeMeOPhC(Me) 2Ph(S)-
V-87MeEtMeOPhC(Me) 2Phracemic
V-88MeEtMeOPhC(Me) 2Ph(S)-
V-89MeMeMeOPhC(Me) 2OEtracemic
V-90MeMeMeOPhC(Me) 2OEt(S)-
V-91MeEtMeOPhC(Me) 2OEtracemic
V-92MeEtMeOPhC(Me) 2OEt(S)-
V-93MeMeMeOPhC(Me) 2(CH 2 ) 2 COOHracemic
V-94MeMeMeOPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-95MeEtMeOPhC(Me) 2(CH 2 ) 2 COOHracemic
V-96MeEtMeOPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-97MeMeMeOPh(CH 2 ) 2Meracemic
V-98MeMeMeOPh(CH 2 ) 2Me(R)-
V-99MeEtMeOPh(CH 2 ) 2Meracemic
V-100MeEtMeOPh(CH 2 ) 2Me(R)-
TABLE 101
CompoundConfig-
No.R 1R 2R 3L 2R 4L 3R 6uration
V-101MeMeMeOPh(CH 2 ) 2Etracemic
V-102MeMeMeOPh(CH 2 ) 2Et(R)-
V-103MeEtMeOPh(CH 2 ) 2Etracemic
V-104MeEtMeOPh(CH 2 ) 2Et(R)-
V-105MeMeMeOPh(CH 2 ) 2nPrracemic
V-106MeMeMeOPh(CH 2 ) 2nPr(R)-
V-107MeEtMeOPh(CH 2 ) 2nPrracemic
V-108MeEtMeOPh(CH 2 ) 2nPr(R)-
V-109MeMeMeOPh(CH 2 ) 2iPrracemic
V-110MeMeMeOPh(CH 2 ) 2iPr(R)-
V-111MeEtMeOPh(CH 2 ) 2iPrracemic
V-112MeEtMeOPh(CH 2 ) 2iPr(R)-
V-113MeMeMeOPh(CH 2 ) 2nBuracemic
V-114MeMeMeOPh(CH 2 ) 2nBu(R)-
V-115MeEtMeOPh(CH 2 ) 2nBuracemic
V-116MeEtMeOPh(CH 2 ) 2nBu(R)-
V-117MeMeMeOPh(CH 2 ) 2tBuracemic
V-118MeMeMeOPh(CH 2 ) 2tBu(R)-
V-119MeEtMeOPh(CH 2 ) 2tBuracemic
V-120MeEtMeOPh(CH 2 ) 2tBu(R)-
V-121MeMeMeOPh(CH 2 ) 2iBuracemic
V-122MeMeMeOPh(CH 2 ) 2iBu(R)-
V-123MeEtMeOPh(CH 2 ) 2iBuracemic
V-124MeEtMeOPh(CH 2 ) 2iBu(R)-
V-125MeMeMeOPh(CH 2 ) 2n-Heptylracemic
V-126MeMeMeOPh(CH 2 ) 2n-Heptyl(R)-
V-127MeEtMeOPh(CH 2 ) 2n-Heptylracemic
V-128MeEtMeOPh(CH 2 ) 2n-Heptyl(R)-
V-129MeMeMeOPh(CH 2 ) 2n-Undecylracemic
V-130MeMeMeOPh(CH 2 ) 2n-Undecyl(R)-
V-131MeEtMeOPh(CH 2 ) 2n-Undecylracemic
V-132MeEtMeOPh(CH 2 ) 2n-Undecyl(R)-
V-133MeMeMeOPh(CH 2 ) 2Phracemic
V-134MeMeMeOPh(CH 2 ) 2Ph(R)-
V-135MeEtMeOPh(CH 2 ) 2Phracemic
V-136MeEtMeOPh(CH 2 ) 2Ph(R)-
V-137MeMeMeOPh(CH 2 ) 2OEtracemic
V-138MeMeMeOPh(CH 2 ) 2OEt(R)-
V-139MeEtMeOPh(CH 2 ) 2OEtracemic
V-140MeEtMeOPh(CH 2 ) 2OEt(R)-
V-141MeMeMeOPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-142MeMeMeOPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-143MeEtMeOPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-144MeEtMeOPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-145MeMeMeOPhCH 2 C(Me) 2Meracemic
V-146MeMeMeOPhCH 2 C(Me) 2Me(R)-
V-147MeEtMeOPhCH 2 C(Me) 2Meracemic
V-148MeEtMeOPhCH 2 C(Me) 2Me(R)-
V-149MeMeMeOPhCH 2 C(Me) 2Etracemic
V-150MeMeMeOPhCH 2 C(Me) 2Et(R)-
TABLE 102 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-151MeEtMeOPhCH 2 C(Me) 2Etracemic
V-152MeEtMeOPhCH 2 C(Me) 2Et(R)-
V-153MeMeMeOPhCH 2 C(Me) 2nPrracemic
V-154MeMeMeOPhCH 2 C(Me) 2nPr(R)-
V-155MeEtMeOPhCH 2 C(Me) 2nPrracemic
V-156MeEtMeOPhCH 2 C(Me) 2nPr(R)-
V-157MeMeMeOPhCH 2 C(Me) 2iPrracemic
V-158MeMeMeOPhCH 2 C(Me) 2iPr(R)-
V-159MeEtMeOPhCH 2 C(Me) 2iPrracemic
V-160MeEtMeOPhCH 2 C(Me) 2iPr(R)-
V-161MeMeMeOPhCH 2 C(Me) 2nBuracemic
V-162MeMeMeOPhCH 2 C(Me) 2nBu(R)-
V-163MeEtMeOPhCH 2 C(Me) 2nBuracemic
V-164MeEtMeOPhCH 2 C(Me) 2nBu(R)-
V-165MeMeMeOPhCH 2 C(Me) 2tBuracemic
V-166MeMeMeOPhCH 2 C(Me) 2tBu(R)-
V-167MeEtMeOPhCH 2 C(Me) 2tBuracemic
V-168MeEtMeOPhCH 2 C(Me) 2tBu(R)-
V-169MeMeMeOPhCH 2 C(Me) 2iBuracemic
V-170MeMeMeOPhCH 2 C(Me) 2iBu(R)-
V-171MeEtMeOPhCH 2 C(Me) 2iBuracemic
V-172MeEtMeOPhCH 2 C(Me) 2iBu(R)-
V-173MeMeMeOPhCH 2 C(Me) 2n-Heptylracemic
V-174MeMeMeOPhCH 2 C(Me) 2n-Heptyl(R)-
V-175MeEtMeOPhCH 2 C(Me) 2n-Heptylracemic
V-176MeEtMeOPhCH 2 C(Me) 2n-Heptyl(R)-
V-177MeMeMeOPhCH 2 C(Me) 2n-Undecylracemic
V-178MeMeMeOPhCH 2 C(Me) 2n-Undecyl(R)-
V-179MeEtMeOPhCH 2 C(Me) 2n-Undecylracemic
V-180MeEtMeOPhCH 2 C(Me) 2n-Undecyl(R)-
V-181MeMeMeOPhCH 2 C(Me) 2Phracemic
V-182MeMeMeOPhCH 2 C(Me) 2Ph(R)-
V-183MeEtMeOPhCH 2 C(Me) 2Phracemic
V-184MeEtMeOPhCH 2 C(Me) 2Ph(R)-
V-185MeMeMeOPhCH 2 C(Me) 2OEtracemic
V-186MeMeMeOPhCH 2 C(Me) 2OEt(R)-
V-187MeEtMeOPhCH 2 C(Me) 2OEtracemic
V-188MeEtMeOPhCH 2 C(Me) 2OEt(R)-
V-189MeMeMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-190MeMeMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-191MeEtMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-192MeEtMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-193MeMeMeNHPhCH 2Meracemic
V-194MeMeMeNHPhCH 2Me(S)-
V-195MeEtMeNHPhCH 2Meracemic
V-196MeEtMeNHPhCH 2Me(S)-
V-197MeMeMeNHPhCH 2Etracemic
V-198MeMeMeNHPhCH 2Et(S)-
V-199MeEtMeNHPhCH 2Etracemic
V-200MeEtMeNHPhCH 2Et(S)-
TABLE 103 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-201MeMeMeNHPhCH 2nPrracemic
V-202MeMeMeNHPhCH 2nPr(S)-
V-203MeEtMeNHPhCH 2nPrracemic
V-204MeEtMeNHPhCH 2nPr(S)-
V-205MeMeMeNHPhCH 2iPrracemic
V-206MeMeMeNHPhCH 2iPr(S)-
V-207MeEtMeNHPhCH 2iPrracemic
V-208MeEtMeNHPhCH 2iPr(S)-
V-209MeMeMeNHPhCH 2nBuracemic
V-210MeMeMeNHPhCH 2nBu(S)-
V-211MeEtMeNHPhCH 2nBuracemic
V-212MeEtMeNHPhCH 2nBu(S)-
V-213MeMeMeNHPhCH 2tBuracemic
V-214MeMeMeNHPhCH 2tBu(S)-
V-215MeEtMeNHPhCH 2tBuracemic
V-216MeEtMeNHPhCH 2tBu(S)-
V-217MeMeMeNHPhCH 2iBuracemic
V-218MeMeMeNHPhCH 2iBu(S)-
V-219MeEtMeNHPhCH 2iBuracemic
V-220MeEtMeNHPhCH 2iBu(S)-
V-221MeMeMeNHPhCH 2n-Heptylracemic
V-222MeMeMeNHPhCH 2n-Heptyl(S)-
V-223MeEtMeNHPhCH 2n-Heptylracemic
V-224MeEtMeNHPhCH 2n-Heptyl(S)-
V-225MeMeMeNHPhCH 2n-Undecylracemic
V-226MeMeMeNHPhCH 2n-Undecyl(S)-
V-227MeEtMeNHPhCH 2n-Undecylracemic
V-228MeEtMeNHPhCH 2n-Undecyl(S)-
V-229MeMeMeNHPhCH 2Phracemic
V-230MeMeMeNHPhCH 2Ph(S)-
V-231MeEtMeNHPhCH 2Phracemic
V-232MeEtMeNHPhCH 2Ph(S)-
V-233MeMeMeNHPhCH 2OEtracemic
V-234MeMeMeNHPhCH 2OEt(S)-
V-235MeEtMeNHPhCH 2OEtracemic
V-236MeEtMeNHPhCH 2OEt(S)-
V-237MeMeMeNHPhCH 2(CH 2 ) 2 COOHracemic
V-238MeMeMeNHPhCH 2(CH 2 ) 2 COOH(S)-
V-239MeEtMeNHPhCH 2(CH 2 ) 2 COOHracemic
V-240MeEtMeNHPhCH 2(CH 2 ) 2 COOH(S)-
V-241MeMeMeNHPhC(Me) 2Meracemic
V-242MeMeMeNHPhC(Me) 2Me(S)-
V-243MeEtMeNHPhC(Me) 2Meracemic
V-244MeEtMeNHPhC(Me) 2Me(S)-
V-245MeMeMeNHPhC(Me) 2Etracemic
V-246MeMeMeNHPhC(Me) 2Et(S)-
V-247MeEtMeNHPhC(Me) 2Etracemic
V-248MeEtMeNHPhC(Me) 2Et(S)-
V-249MeMeMeNHPhC(Me) 2nPrracemic
V-250MeMeMeNHPhC(Me) 2nPr(S)-
TABLE 104 — (Va) Compound
No.R 1R 2R 3L 2R 4L 3R 6Configuration
V-251MeEtMeNHPhC(Me) 2nPrracemic
V-252MeEtMeNHPhC(Me) 2nPr(S)-
V-253MeMeMeNHPhC(Me) 2iPrracemic
V-254MeMeMeNHPhC(Me) 2iPr(S)-
V-255MeEtMeNHPhC(Me) 2iPrracemic
V-256MeEtMeNHPhC(Me) 2iPr(S)-
V-257MeMeMeNHPhC(Me) 2nBuracemic
V-258MeMeMeNHPhC(Me) 2nBu(S)-
V-259MeEtMeNHPhC(Me) 2nBuracemic
V-260MeEtMeNHPhC(Me) 2nBu(S)-
V-261MeMeMeNHPhC(Me) 2tBuracemic
V-262MeMeMeNHPhC(Me) 2tBu(S)-
V-263MeEtMeNHPhC(Me) 2tBuracemic
V-264MeEtMeNHPhC(Me) 2tBu(S)-
V-265MeMeMeNHPhC(Me) 2iBuracemic
V-266MeMeMeNHPhC(Me) 2iBu(S)-
V-267MeEtMeNHPhC(Me) 2iBuracemic
V-268MeEtMeNHPhC(Me) 2iBu(S)-
V-269MeMeMeNHPhC(Me) 2n-Heptylracemic
V-270MeMeMeNHPhC(Me) 2n-Heptyl(S)-
V-271MeEtMeNHPhC(Me) 2n-Heptylracemic
V-272MeEtMeNHPhC(Me) 2n-Heptyl(S)-
V-273MeMeMeNHPhC(Me) 2n-Undecylracemic
V-274MeMeMeNHPhC(Me) 2n-Undecyl(S)-
V-275MeEtMeNHPhC(Me) 2n-Undecylracemic
V-276MeEtMeNHPhC(Me) 2n-Undecyl(S)-
V-277MeMeMeNHPhC(Me) 2Phracemic
V-278MeMeMeNHPhC(Me) 2Ph(S)-
V-279MeEtMeNHPhC(Me) 2Phracemic
V-280MeEtMeNHPhC(Me) 2Ph(S)-
V-281MeMeMeNHPhC(Me) 2OEtracemic
V-282MeMeMeNHPhC(Me) 2OEt(S)-
V-283MeEtMeNHPhC(Me) 2OEtracemic
V-284MeEtMeNHPhC(Me) 2OEt(S)-
V-285MeMeMeNHPhC(Me) 2(CH 2 ) 2 COOHracemic
V-286MeMeMeNHPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-287MeEtMeNHPhC(Me) 2(CH 2 ) 2 COOHracemic
V-288MeEtMeNHPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-289MeMeMeNHPh(CH 2 ) 2Meracemic
V-290MeMeMeNHPh(CH 2 ) 2Me(R)-
V-291MeEtMeNHPh(CH 2 ) 2Meracemic
V-292MeEtMeNHPh(CH 2 ) 2Me(R)-
V-293MeMeMeNHPh(CH 2 ) 2Etracemic
V-294MeMeMeNHPh(CH 2 ) 2Et(R)-
V-295MeEtMeNHPh(CH 2 ) 2Etracemic
V-296MeEtMeNHPh(CH 2 ) 2Et(R)-
V-297MeMeMeNHPh(CH 2 ) 2nPrracemic
V-298MeMeMeNHPh(CH 2 ) 2nPr(R)-
V-299MeEtMeNHPh(CH 2 ) 2nPrracemic
V-300MeEtMeNHPh(CH 2 ) 2nPr(R)-
TABLE 105 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-301MeMeMeNHPh(CH 2 ) 2iPrracemic
V-302MeMeMeNHPh(CH 2 ) 2iPr(R)-
V-303MeEtMeNHPh(CH 2 ) 2iPrracemic
V-304MeEtMeNHPh(CH 2 ) 2iPr(R)-
V-305MeMeMeNHPh(CH 2 ) 2nBuracemic
V-306MeMeMeNHPh(CH 2 ) 2nBu(R)-
V-307MeEtMeNHPh(CH 2 ) 2nBuracemic
V-308MeEtMeNHPh(CH 2 ) 2nBu(R)-
V-309MeMeMeNHPh(CH 2 ) 2tBuracemic
V-310MeMeMeNHPh(CH 2 ) 2tBu(R)-
V-311MeEtMeNHPh(CH 2 ) 2tBuracemic
V-312MeEtMeNHPh(CH 2 ) 2tBu(R)-
V-313MeMeMeNHPh(CH 2 ) 2iBuracemic
V-314MeMeMeNHPh(CH 2 ) 2iBu(R)-
V-315MeEtMeNHPh(CH 2 ) 2iBuracemic
V-316MeEtMeNHPh(CH 2 ) 2iBu(R)-
V-317MeMeMeNHPh(CH 2 ) 2n-Heptylracemic
V-318MeMeMeNHPh(CH 2 ) 2n-Heptyl(R)-
V-319MeEtMeNHPh(CH 2 ) 2n-Heptylracemic
V-320MeEtMeNHPh(CH 2 ) 2n-Heptyl(R)-
V-321MeMeMeNHPh(CH 2 ) 2n-Undecylracemic
V-322MeMeMeNHPh(CH 2 ) 2n-Undecyl(R)-
V-323MeEtMeNHPh(CH 2 ) 2n-Undecylracemic
V-324MeEtMeNHPh(CH 2 ) 2n-Undecyl(R)-
V-325MeMeMeNHPh(CH 2 ) 2Phracemic
V-326MeMeMeNHPh(CH 2 ) 2Ph(R)-
V-327MeEtMeNHPh(CH 2 ) 2Phracemic
V-328MeEtMeNHPh(CH 2 ) 2Ph(R)-
V-329MeMeMeNHPh(CH 2 ) 2OEtracemic
V-330MeMeMeNHPh(CH 2 ) 2OEt(R)-
V-331MeEtMeNHPh(CH 2 ) 2OEtracemic
V-332MeEtMeNHPh(CH 2 ) 2OEt(R)-
V-333MeMeMeNHPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-334MeMeMeNHPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-335MeEtMeNHPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-336MeEtMeNHPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-337MeMeMeNHPhCH 2 C(Me) 2Meracemic
V-338MeMeMeNHPhCH 2 C(Me) 2Me(R)-
V-339MeEtMeNHPhCH 2 C(Me) 2Meracemic
V-340MeEtMeNHPhCH 2 C(Me) 2Me(R)-
V-341MeMeMeNHPhCH 2 C(Me) 2Etracemic
V-342MeMeMeNHPhCH 2 C(Me) 2Et(R)-
V-343MeEtMeNHPhCH 2 C(Me) 2Etracemic
V-344MeEtMeNHPhCH 2 C(Me) 2Et(R)-
V-345MeMeMeNHPhCH 2 C(Me) 2nPrracemic
V-346MeMeMeNHPhCH 2 C(Me) 2nPr(R)-
V-347MeEtMeNHPhCH 2 C(Me) 2nPrracemic
V-348MeEtMeNHPhCH 2 C(Me) 2nPr(R)-
V-349MeMeMeNHPhCH 2 C(Me) 2iPrracemic
V-350MeMeMeNHPhCH 2 C(Me) 2iPr(R)-
TABLE 106 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-351MeEtMeNHPhCH 2 C(Me) 2iPrracemic
V-352MeEtMeNHPhCH 2 C(Me) 2iPr(R)-
V-353MeMeMeNHPhCH 2 C(Me) 2nBuracemic
V-354MeMeMeNHPhCH 2 C(Me) 2nBu(R)-
V-355MeEtMeNHPhCH 2 C(Me) 2nBuracemic
V-356MeEtMeNHPhCH 2 C(Me) 2nBu(R)-
V-357MeMeMeNHPhCH 2 C(Me) 2tBuracemic
V-358MeMeMeNHPhCH 2 C(Me) 2tBu(R)-
V-359MeEtMeNHPhCH 2 C(Me) 2tBuracemic
V-360MeEtMeNHPhCH 2 C(Me) 2tBu(R)-
V-361MeMeMeNHPhCH 2 C(Me) 2iBuracemic
V-362MeMeMeNHPhCH 2 C(Me) 2iBu(R)-
V-363MeEtMeNHPhCH 2 C(Me) 2iBuracemic
V-364MeEtMeNHPhCH 2 C(Me) 2iBu(R)-
V-365MeMeMeNHPhCH 2 C(Me) 2n-Heptylracemic
V-366MeMeMeNHPhCH 2 C(Me) 2n-Heptyl(R)-
V-367MeEtMeNHPhCH 2 C(Me) 2n-Heptylracemic
V-368MeEtMeNHPhCH 2 C(Me) 2n-Heptyl(R)-
V-369MeMeMeNHPhCH 2 C(Me) 2n-Undecylracemic
V-370MeMeMeNHPhCH 2 C(Me) 2n-Undecyl(R)-
V-371MeEtMeNHPhCH 2 C(Me) 2n-Undecylracemic
V-372MeEtMeNHPhCH 2 C(Me) 2n-Undecyl(R)-
V-373MeMeMeNHPhCH 2 C(Me) 2Phracemic
V-374MeMeMeNHPhCH 2 C(Me) 2Ph(R)-
V-375MeEtMeNHPhCH 2 C(Me) 2Phracemic
V-376MeEtMeNHPhCH 2 C(Me) 2Ph(R)-
V-377MeMeMeNHPhCH 2 C(Me) 2OEtracemic
V-378MeMeMeNHPhCH 2 C(Me) 2OEt(R)-
V-379MeEtMeNHPhCH 2 C(Me) 2OEtracemic
V-380MeEtMeNHPhCH 2 C(Me) 2OEt(R)-
V-381MeMeMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-382MeMeMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-383MeEtMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-384MeEtMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-385MeMeMeCH 2PhCH 2Meracemic
V-386MeMeMeCH 2PhCH 2Me(S)-
V-387MeEtMeCH 2PhCH 2Meracemic
V-388MeEtMeCH 2PhCH 2Me(S)-
V-389MeMeMeCH 2PhCH 2Etracemic
V-390MeMeMeCH 2PhCH 2Et(S)-
V-391MeEtMeCH 2PhCH 2Etracemic
V-392MeEtMeCH 2PhCH 2Et(S)-
V-393MeMeMeCH 2PhCH 2nPrracemic
V-394MeMeMeCH 2PhCH 2nPr(S)-
V-395MeEtMeCH 2PhCH 2nPrracemic
V-396MeEtMeCH 2PhCH 2nPr(S)-
V-397MeMeMeCH 2PhCH 2iPrracemic
V-398MeMeMeCH 2PhCH 2iPr(S)-
V-399MeEtMeCH 2PhCH 2iPrracemic
V-400MeEtMeCH 2PhCH 2iPr(S)-
TABLE 107 — (Va) Com- pound
No.R 1R 2R 3L 2R 4L 3R 6Configuration
V-401MeMeMeCH 2PhCH 2nBuracemic
V-402MeMeMeCH 2PhCH 2nBu(S)-
V-403MeEtMeCH 2PhCH 2nBuracemic
V-404MeEtMeCH 2PhCH 2nBu(S)-
V-405MeMeMeCH 2PhCH 2tBuracemic
V-406MeMeMeCH 2PhCH 2tBu(S)-
V-407MeEtMeCH 2PhCH 2tBuracemic
V-408MeEtMeCH 2PhCH 2tBu(S)-
V-409MeMeMeCH 2PhCH 2iBuracemic
V-410MeMeMeCH 2PhCH 2iBu(S)-
V-411MeEtMeCH 2PhCH 2iBuracemic
V-412MeEtMeCH 2PhCH 2iBu(S)-
V-413MeMeMeCH 2PhCH 2n-Heptylracemic
V-414MeMeMeCH 2PhCH 2n-Heptyl(S)-
V-415MeEtMeCH 2PhCH 2n-Heptylracemic
V-416MeEtMeCH 2PhCH 2n-Heptyl(S)-
V-417MeMeMeCH 2PhCH 2n-Undecylracemic
V-418MeMeMeCH 2PhCH 2n-Undecyl(S)-
V-419MeEtMeCH 2PhCH 2n-Undecylracemic
V-420MeEtMeCH 2PhCH 2n-Undecyl(S)-
V-421MeMeMeCH 2PhCH 2Phracemic
V-422MeMeMeCH 2PhCH 2Ph(S)-
V-423MeEtMeCH 2PhCH 2Phracemic
V-424MeEtMeCH 2PhCH 2Ph(S)-
V-425MeMeMeCH 2PhCH 2OEtracemic
V-426MeMeMeCH 2PhCH 2OEt(S)-
V-427MeEtMeCH 2PhCH 2OEtracemic
V-428MeEtMeCH 2PhCH 2OEt(S)-
V-429MeMeMeCH 2PhCH 2(CH 2 ) 2 COOHracemic
V-430MeMeMeCH 2PhCH 2(CH 2 ) 2 COOH(S)-
V-431MeEtMeCH 2PhCH 2(CH 2 ) 2 COOHracemic
V-432MeEtMeCH 2PhCH 2(CH 2 ) 2 COOH(S)-
V-433MeMeMeCH 2Ph—Meracemic
V-434MeMeMeCH 2Ph—Me(S)-
V-435MeEtMeCH 2Ph—Meracemic
V-436MeEtMeCH 2Ph—Me(S)-
V-437MeMeMeCH 2Ph—Etracemic
V-438MeMeMeCH 2Ph—Et(S)-
V-439MeEtMeCH 2Ph—Etracemic
V-440MeEtMeCH 2Ph—Et(S)-
V-441MeMeMeCH 2Ph—nPrracemic
V-442MeMeMeCH 2Ph—nPr(S)-
V-443MeEtMeCH 2Ph—nPrracemic
V-444MeEtMeCH 2Ph—nPr(S)-
V-445MeMeMeCH 2Ph—iPrracemic
V-446MeMeMeCH 2Ph—iPr(S)-
V-447MeEtMeCH 2Ph—iPrracemic
V-448MeEtMeCH 2Ph—iPr(S)-
V-449MeMeMeCH 2Ph—nBuracemic
V-450MeMeMeCH 2Ph—nBu(S)-
TABLE 108 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-451MeEtMeCH 2Ph—nBuracemic
V-452MeEtMeCH 2Ph—nBu(S)-
V-453MeMeMeCH 2Ph—tBuracemic
V-454MeMeMeCH 2Ph—tBu(S)-
V-455MeEtMeCH 2Ph—tBuracemic
V-456MeEtMeCH 2Ph—tBu(S)-
V-457MeMeMeCH 2Ph—iBuracemic
V-458MeMeMeCH 2Ph—iBu(S)-
V-459MeEtMeCH 2Ph—iBuracemic
V-460MeEtMeCH 2Ph—iBu(S)-
V-461MeMeMeCH 2Ph—n-Heptylracemic
V-462MeMeMeCH 2Ph—n-Heptyl(S)-
V-463MeEtMeCH 2Ph—n-Heptylracemic
V-464MeEtMeCH 2Ph—n-Heptyl(S)-
V-465MeMeMeCH 2Ph—n-Undecylracemic
V-466MeMeMeCH 2Ph—n-Undecyl(S)-
V-467MeEtMeCH 2Ph—n-Undecylracemic
V-468MeEtMeCH 2Ph—n-Undecyl(S)-
V-469MeMeMeCH 2Ph—Phracemic
V-470MeMeMeCH 2Ph—Ph(S)-
V-471MeEtMeCH 2Ph—Phracemic
V-472MeEtMeCH 2Ph—Ph(S)-
V-473MeMeMeCH 2Ph—OEtracemic
V-474MeMeMeCH 2Ph—OEt(S)-
V-475MeEtMeCH 2Ph—OEtracemic
V-476MeEtMeCH 2Ph—OEt(S)-
V-477MeMeMeCH 2Ph—(CH 2 ) 2 COOHracemic
V-478MeMeMeCH 2Ph—(CH 2 ) 2 COOH(S)-
V-479MeEtMeCH 2Ph—(CH 2 ) 2 COOHracemic
V-480MeEtMeCH 2Ph—(CH 2 ) 2 COOH(S)-
V-481MeMeMeCH 2PhC(Me) 2Meracemic
V-482MeMeMeCH 2PhC(Me) 2Me(S)-
V-483MeEtMeCH 2PhC(Me) 2Meracemic
V-484MeEtMeCH 2PhC(Me) 2Me(S)-
V-485MeMeMeCH 2PhC(Me) 2Etracemic
V-486MeMeMeCH 2PhC(Me) 2Et(S)-
V-487MeEtMeCH 2PhC(Me) 2Etracemic
V-488MeEtMeCH 2PhC(Me) 2Et(S)-
V-489MeMeMeCH 2PhC(Me) 2nPrracemic
V-490MeMeMeCH 2PhC(Me) 2nPr(S)-
V-491MeEtMeCH 2PhC(Me) 2nPrracemic
V-492MeEtMeCH 2PhC(Me) 2nPr(S)-
V-493MeMeMeCH 2PhC(Me) 2iPrracemic
V-494MeMeMeCH 2PhC(Me) 2iPr(S)-
V-495MeEtMeCH 2PhC(Me) 2iPrracemic
V-496MeEtMeCH 2PhC(Me) 2iPr(S)-
V-497MeMeMeCH 2PhC(Me) 2nBuracemic
V-498MeMeMeCH 2PhC(Me) 2nBu(S)-
V-499MeEtMeCH 2PhC(Me) 2nBuracemic
V-500MeEtMeCH 2PhC(Me) 2nBu(S)-
TABLE 109 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-501MeMeMeCH 2PhC(Me) 2tBuracemic
V-502MeMeMeCH 2PhC(Me) 2tBu(S)-
V-503MeEtMeCH 2PhC(Me) 2tBuracemic
V-504MeEtMeCH 2PhC(Me) 2tBu(S)-
V-505MeMeMeCH 2PhC(Me) 2iBuracemic
V-506MeMeMeCH 2PhC(Me) 2iBu(S)-
V-507MeEtMeCH 2PhC(Me) 2iBuracemic
V-508MeEtMeCH 2PhC(Me) 2iBu(S)-
V-509MeMeMeCH 2PhC(Me) 2n-Heptylracemic
V-510MeMeMeCH 2PhC(Me) 2n-Heptyl(S)-
V-511MeEtMeCH 2PhC(Me) 2n-Heptylracemic
V-512MeEtMeCH 2PhC(Me) 2n-Heptyl(S)-
V-513MeMeMeCH 2PhC(Me) 2n-Undecylracemic
V-514MeMeMeCH 2PhC(Me) 2n-Undecyl(S)-
V-515MeEtMeCH 2PhC(Me) 2n-Undecylracemic
V-516MeEtMeCH 2PhC(Me) 2n-Undecyl(S)-
V-517MeMeMeCH 2PhC(Me) 2Phracemic
V-518MeMeMeCH 2PhC(Me) 2Ph(S)-
V-519MeEtMeCH 2PhC(Me) 2Phracemic
V-520MeEtMeCH 2PhC(Me) 2Ph(S)-
V-521MeMeMeCH 2PhC(Me) 2OEtracemic
V-522MeMeMeCH 2PhC(Me) 2OEt(S)-
V-523MeEtMeCH 2PhC(Me) 2OEtracemic
V-524MeEtMeCH 2PhC(Me) 2OEt(S)-
V-525MeMeMeCH 2PhC(Me) 2(CH 2 ) 2 COOHracemic
V-526MeMeMeCH 2PhC(Me) 2(CH 2 ) 2 COOH(S)-
V-527MeEtMeCH 2PhC(Me) 2(CH 2 ) 2 COOHracemic
V-528MeEtMeCH 2PhC(Me) 2(CH 2 ) 2 COOH(S)-
V-529MeMeMeCH 2Ph(CH 2 ) 2Meracemic
V-530MeMeMeCH 2Ph(CH 2 ) 2Me(S)-
V-531MeEtMeCH 2Ph(CH 2 ) 2Meracemic
V-532MeEtMeCH 2Ph(CH 2 ) 2Me(S)-
V-533MeMeMeCH 2Ph(CH 2 ) 2Etracemic
V-534MeMeMeCH 2Ph(CH 2 ) 2Et(S)-
V-535MeEtMeCH 2Ph(CH 2 ) 2Etracemic
V-536MeEtMeCH 2Ph(CH 2 ) 2Et(S)-
V-537MeMeMeCH 2Ph(CH 2 ) 2nPrracemic
V-538MeMeMeCH 2Ph(CH 2 ) 2nPr(S)-
V-539MeEtMeCH 2Ph(CH 2 ) 2nPrracemic
V-540MeEtMeCH 2Ph(CH 2 ) 2nPr(S)-
V-541MeMeMeCH 2Ph(CH 2 ) 2iPrracemic
V-542MeMeMeCH 2Ph(CH 2 ) 2iPr(S)-
V-543MeEtMeCH 2Ph(CH 2 ) 2iPrracemic
V-544MeEtMeCH 2Ph(CH 2 ) 2iPr(S)-
V-545MeMeMeCH 2Ph(CH 2 ) 2nBuracemic
V-546MeMeMeCH 2Ph(CH 2 ) 2nBu(S)-
V-547MeEtMeCH 2Ph(CH 2 ) 2nBuracemic
V-548MeEtMeCH 2Ph(CH 2 ) 2nBu(S)-
V-549MeMeMeCH 2Ph(CH 2 ) 2tBuracemic
V-550MeMeMeCH 2Ph(CH 2 ) 2tBu(S)-
TABLE 110 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-551MeEtMeCH 2Ph(CH 2 ) 2tBuracemic
V-552MeEtMeCH 2Ph(CH 2 ) 2tBu(S)-
V-553MeMeMeCH 2Ph(CH 2 ) 2iBuracemic
V-554MeMeMeCH 2Ph(CH 2 ) 2iBu(S)-
V-555MeEtMeCH 2Ph(CH 2 ) 2iBuracemic
V-556MeEtMeCH 2Ph(CH 2 ) 2iBu(S)-
V-557MeMeMeCH 2Ph(CH 2 ) 2n-Heptylracemic
V-558MeMeMeCH 2Ph(CH 2 ) 2n-Heptyl(S)-
V-559MeEtMeCH 2Ph(CH 2 ) 2n-Heptylracemic
V-560MeEtMeCH 2Ph(CH 2 ) 2n-Heptyl(S)-
V-561MeMeMeCH 2Ph(CH 2 ) 2n-Undecylracemic
V-562MeMeMeCH 2Ph(CH 2 ) 2n-Undecyl(S)-
V-563MeEtMeCH 2Ph(CH 2 ) 2n-Undecylracemic
V-564MeEtMeCH 2Ph(CH 2 ) 2n-Undecyl(S)-
V-565MeMeMeCH 2Ph(CH 2 ) 2Phracemic
V-566MeMeMeCH 2Ph(CH 2 ) 2Ph(S)-
V-567MeEtMeCH 2Ph(CH 2 ) 2Phracemic
V-568MeEtMeCH 2Ph(CH 2 ) 2Ph(S)-
V-569MeMeMeCH 2Ph(CH 2 ) 2OEtracemic
V-570MeMeMeCH 2Ph(CH 2 ) 2OEt(S)-
V-571MeEtMeCH 2Ph(CH 2 ) 2OEtracemic
V-572MeEtMeCH 2Ph(CH 2 ) 2OEt(S)-
V-573MeMeMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-574MeMeMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOH(S)-
V-575MeEtMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-576MeEtMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOH(S)-
V-577MeMeMeCH 2PhCH 2 C(Me) 2Meracemic
V-578MeMeMeCH 2PhCH 2 C(Me) 2Me(S)-
V-579MeEtMeCH 2PhCH 2 C(Me) 2Meracemic
V-580MeEtMeCH 2PhCH 2 C(Me) 2Me(S)-
V-581MeMeMeCH 2PhCH 2 C(Me) 2Etracemic
V-582MeMeMeCH 2PhCH 2 C(Me) 2Et(S)-
V-583MeEtMeCH 2PhCH 2 C(Me) 2Etracemic
V-584MeEtMeCH 2PhCH 2 C(Me) 2Et(S)-
V-585MeMeMeCH 2PhCH 2 C(Me) 2nPrracemic
V-586MeMeMeCH 2PhCH 2 C(Me) 2nPr(S)-
V-587MeEtMeCH 2PhCH 2 C(Me) 2nPrracemic
V-588MeEtMeCH 2PhCH 2 C(Me) 2nPr(S)-
V-589MeMeMeCH 2PhCH 2 C(Me) 2iPrracemic
V-590MeMeMeCH 2PhCH 2 C(Me) 2iPr(S)-
V-591MeEtMeCH 2PhCH 2 C(Me) 2iPrracemic
V-592MeEtMeCH 2PhCH 2 C(Me) 2iPr(S)-
V-593MeMeMeCH 2PhCH 2 C(Me) 2nBuracemic
V-594MeMeMeCH 2PhCH 2 C(Me) 2nBu(S)-
V-595MeEtMeCH 2PhCH 2 C(Me) 2nBuracemic
V-596MeEtMeCH 2PhCH 2 C(Me) 2nBu(S)-
V-597MeMeMeCH 2PhCH 2 C(Me) 2tBuracemic
V-598MeMeMeCH 2PhCH 2 C(Me) 2tBu(S)-
V-599MeEtMeCH 2PhCH 2 C(Me) 2tBuracemic
V-600MeEtMeCH 2PhCH 2 C(Me) 2tBu(S)-
TABLE 111 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-601MeMeMeCH 2PhCH 2 C(Me) 2iBuracemic
V-602MeMeMeCH 2PhCH 2 C(Me) 2iBu(S)-
V-603MeEtMeCH 2PhCH 2 C(Me) 2iBuracemic
V-604MeEtMeCH 2PhCH 2 C(Me) 2iBu(S)-
V-605MeMeMeCH 2PhCH 2 C(Me) 2n-Heptylracemic
V-606MeMeMeCH 2PhCH 2 C(Me) 2n-Heptyl(S)-
V-607MeEtMeCH 2PhCH 2 C(Me) 2n-Heptylracemic
V-608MeEtMeCH 2PhCH 2 C(Me) 2n-Heptyl(S)-
V-609MeMeMeCH 2PhCH 2 C(Me) 2n-Undecylracemic
V-610MeMeMeCH 2PhCH 2 C(Me) 2n-Undecyl(S)-
V-611MeEtMeCH 2PhCH 2 C(Me) 2n-Undecylracemic
V-612MeEtMeCH 2PhCH 2 C(Me) 2n-Undecyl(S)-
V-613MeMeMeCH 2PhCH 2 C(Me) 2Phracemic
V-614MeMeMeCH 2PhCH 2 C(Me) 2Ph(S)-
V-615MeEtMeCH 2PhCH 2 C(Me) 2Phracemic
V-616MeEtMeCH 2PhCH 2 C(Me) 2Ph(S)-
V-617MeMeMeCH 2PhCH 2 C(Me) 2OEtracemic
V-618MeMeMeCH 2PhCH 2 C(Me) 2OEt(S)-
V-619MeEtMeCH 2PhCH 2 C(Me) 2OEtracemic
V-620MeEtMeCH 2PhCH 2 C(Me) 2OEt(S)-
V-621MeMeMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-622MeMeMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOH(S)-
V-623MeEtMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-624MeEtMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOH(S)-
TABLE 112 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-1884MeMeMe—Ph—Meracemic
V-1885MeMeMe—Ph—Me(R)-
V-1886MeEtMe—Ph—Meracemic
V-1887MeEtMe—Ph—Me(R)-
V-1888MeMeMe—Ph—Etracemic
V-1889MeMeMe—Ph—Et(R)-
V-1890MeEtMe—Ph—Etracemic
V-1891MeEtMe—Ph—Et(R)-
V-1892MeMeMe—Ph—nPrracemic
V-1893MeMeMe—Ph—nPr(R)-
V-1894MeEtMe—Ph—nPrracemic
V-1895MeEtMe—Ph—nPr(R)-
V-1896MeMeMe—Ph—iPrracemic
V-1897MeMeMe—Ph—iPr(R)-
V-1898MeEtMe—Ph—iPrracemic
V-1899MeEtMe—Ph—iPr(R)-
V-1900MeMeMe—Ph—nBuracemic
V-1901MeMeMe—Ph—nBu(R)-
V-1902MeEtMe—Ph—nBuracemic
V-1903MeEtMe—Ph—nBu(R)-
V-1904MeMeMe—Ph—tBuracemic
V-1905MeMeMe—Ph—tBu(R)-
V-1906MeEtMe—Ph—tBuracemic
V-1907MeEtMe—Ph—tBu(R)-
V-1908MeMeMe—Ph—iBuracemic
V-1909MeMeMe—Ph—iBu(R)-
V-1910MeEtMe—Ph—iBuracemic
V-1911MeEtMe—Ph—iBu(R)-
V-1912MeMeMe—Ph—n-Heptylracemic
V-1913MeMeMe—Ph—n-Heptyl(R)-
V-1914MeEtMe—Ph—n-Heptylracemic
V-1915MeEtMe—Ph—n-Heptyl(R)-
V-1916MeMeMe—Ph—n-Undecylracemic
V-1917MeMeMe—Ph—n-Undecyl(R)-
V-1918MeEtMe—Ph—n-Undecylracemic
V-1919MeEtMe—Ph—n-Undecyl(R)-
V-1920MeMeMe—Ph—OEtracemic
V-1921MeMeMe—Ph—OEt(R)-
V-1922MeEtMe—Ph—OEtracemic
V-1923MeEtMe—Ph—OEt(R)-
V-1924MeMeMe—Ph—(CH 2 ) 2 COONaracemic
V-1925MeMeMe—Ph—(CH 2 ) 2 COONa(R)-
V-1926MeEtMe—Ph—(CH 2 ) 2 COONaracemic
V-1927MeEtMe—Ph—(CH 2 ) 2 COONa(R)-
V-1928MeMeMe—PhCH 2Meracemic
V-1929MeMeMe—PhCH 2Me(S)-
V-1930MeEtMe—PhCH 2Meracemic
V-1931MeEtMe—PhCH 2Me(S)-
V-1932MeMeMe—PhCH 2Etracemic
V-1933MeMeMe—PhCH 2Et(S)-
TABLE 113 — (Va)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-1934MeEtMe—PhCH 2Etracemic
V-1935MeEtMe—PhCH 2Et(S)-
V-1936MeMeMe—PhCH 2nPrracemic
V-1937MeMeMe—PhCH 2nPr(S)-
V-1938MeEtMe—PhCH 2nPrracemic
V-1939MeEtMe—PhCH 2nPr(S)-
V-1940MeMeMe—PhCH 2iPrracemic
V-1941MeMeMe—PhCH 2iPr(S)-
V-1942MeEtMe—PhCH 2iPrracemic
V-1943MeEtMe—PhCH 2iPr(S)-
V-1944MeMeMe—PhCH 2nBuracemic
V-1945MeMeMe—PhCH 2nBu(S)-
V-1946MeEtMe—PhCH 2nBuracemic
V-1947MeEtMe—PhCH 2nBu(S)-
V-1948MeMeMe—PhCH 2tBuracemic
V-1949MeMeMe—PhCH 2tBu(S)-
V-1950MeEtMe—PhCH 2tBuracemic
V-1951MeEtMe—PhCH 2tBu(S)-
V-1952MeMeMe—PhCH 2iBuracemic
V-1953MeMeMe—PhCH 2iBu(S)-
V-1954MeEtMe—PhCH 2iBuracemic
V-1955MeEtMe—PhCH 2iBu(S)-
V-1956MeMeMe—PhCH 2n-Heptylracemic
V-1957MeMeMe—PhCH 2n-Heptyl(S)-
V-1958MeEtMe—PhCH 2n-Heptylracemic
V-1959MeEtMe—PhCH 2n-Heptyl(S)-
V-1960MeMeMe—PhCH 2n-Undecylracemic
V-1961MeMeMe—PhCH 2n-Undecyl(S)-
V-1962MeEtMe—PhCH 2n-Undecylracemic
V-1963MeEtMe—PhCH 2n-Undecyl(S)-
V-1964MeMeMe—PhCH 2OEtracemic
V-1965MeMeMe—PhCH 2OEt(S)-
V-1966MeEtMe—PhCH 2OEtracemic
V-1967MeEtMe—PhCH 2OEt(S)-
V-1968MeMeMe—PhCH 2(CH 2 ) 2 COONaracemic
V-1969MeMeMe—PhCH 2(CH 2 ) 2 COONa(S)-
V-1970MeEtMe—PhCH 2(CH 2 ) 2 COONaracemic
V-1971MeEtMe—PhCH 2(CH 2 ) 2 COONa(S)-
TABLE 114 — (Vb) Com-
poundConfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-625MeMeMeOPhCH 2Meracemic
V-626MeMeMeOPhCH 2Me(S)-
V-627MeEtMeOPhCH 2Meracemic
V-628MeEtMeOPhCH 2Me(S)-
V-629MeMeMeOPhCH 2Etracemic
V-630MeMeMeOPhCH 2Et(S)-
V-631MeEtMeOPhCH 2Etracemic
V-632MeEtMeOPhCH 2Et(S)-
V-633MeMeMeOPhCH 2nPrracemic
V-634MeMeMeOPhCH 2nPr(S)-
V-635MeEtMeOPhCH 2nPrracemic
V-636MeEtMeOPhCH 2nPr(S)-
V-637MeMeMeOPhCH 2iPrracemic
V-638MeMeMeOPhCH 2iPr(S)-
V-639MeEtMeOPhCH 2iPrracemic
V-640MeEtMeOPhCH 2iPr(S)-
V-641MeMeMeOPhCH 2nBuracemic
V-642MeMeMeOPhCH 2nBu(S)-
V-643MeEtMeOPhCH 2nBuracemic
V-644MeEtMeOPhCH 2nBu(S)-
V-645MeMeMeOPhCH 2tBuracemic
V-646MeMeMeOPhCH 2tBu(S)-
V-647MeEtMeOPhCH 2tBuracemic
V-648MeEtMeOPhCH 2tBu(S)-
V-649MeMeMeOPhCH 2iBuracemic
V-650MeMeMeOPhCH 2iBu(S)-
V-651MeEtMeOPhCH 2iBuracemic
V-652MeEtMeOPhCH 2iBu(S)-
V-653MeMeMeOPhCH 2n-Heptylracemic
V-654MeMeMeOPhCH 2n-Heptyl(S)-
V-655MeEtMeOPhCH 2n-Heptylracemic
V-656MeEtMeOPhCH 2n-Heptyl(S)-
V-657MeMeMeOPhCH 2n-Undecylracemic
V-658MeMeMeOPhCH 2n-Undecyl(S)-
V-659MeEtMeOPhCH 2n-Undecylracemic
V-660MeEtMeOPhCH 2n-Undecyl(S)-
V-661MeMeMeOPhCH 2Phracemic
V-662MeMeMeOPhCH 2Ph(S)-
V-663MeEtMeOPhCH 2Phracemic
V-664MeEtMeOPhCH 2Ph(S)-
V-665MeMeMeOPhCH 2OEtracemic
V-666MeMeMeOPhCH 2OEt(S)-
V-667MeEtMeOPhCH 2OEtracemic
V-668MeEtMeOPhCH 2OEt(S)-
V-669MeMeMeOPhCH 2(CH 2 ) 2 COOHracemic
V-670MeMeMeOPhCH 2(CH 2 ) 2 COOH(S)-
V-671MeEtMeOPhCH 2(CH 2 ) 2 COOHracemic
V-672MeEtMeOPhCH 2(CH 2 ) 2 COOH(S)-
V-673MeMeMeOPhC(Me) 2Meracemic
V-674MeMeMeOPhC(Me) 2Me(S)-
V-675MeEtMeOPhC(Me) 2Meracemic
TABLE 115 — (Vb) Com-
poundConfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-676MeEtMeOPhC(Me) 2Me(S)-
V-677MeMeMeOPhC(Me) 2Etracemic
V-678MeMeMeOPhC(Me) 2Et(S)-
V-679MeEtMeOPhC(Me) 2Etracemic
V-680MeEtMeOPhC(Me) 2Et(S)-
V-681MeMeMeOPhC(Me) 2nPrracemic
V-682MeMeMeOPhC(Me) 2nPr(S)-
V-683MeEtMeOPhC(Me) 2nPrracemic
V-684MeEtMeOPhC(Me) 2nPr(S)-
V-685MeMeMeOPhC(Me) 2iPrracemic
V-686MeMeMeOPhC(Me) 2iPr(S)-
V-687MeEtMeOPhC(Me) 2iPrracemic
V-688MeEtMeOPhC(Me) 2iPr(S)-
V-689MeMeMeOPhC(Me) 2nBuracemic
V-690MeMeMeOPhC(Me) 2nBu(S)-
V-691MeEtMeOPhC(Me) 2nBuracemic
V-692MeEtMeOPhC(Me) 2nBu(S)-
V-693MeMeMeOPhC(Me) 2tBuracemic
V-694MeMeMeOPhC(Me) 2tBu(S)-
V-695MeEtMeOPhC(Me) 2tBuracemic
V-696MeEtMeOPhC(Me) 2tBu(S)-
V-697MeMeMeOPhC(Me) 2iBuracemic
V-698MeMeMeOPhC(Me) 2iBu(S)-
V-699MeEtMeOPhC(Me) 2iBuracemic
V-700MeEtMeOPhC(Me) 2iBu(S)-
V-701MeMeMeOPhC(Me) 2n-Heptylracemic
V-702MeMeMeOPhC(Me) 2n-Heptyl(S)-
V-703MeEtMeOPhC(Me) 2n-Heptylracemic
V-704MeEtMeOPhC(Me) 2n-Heptyl(S)-
V-705MeMeMeOPhC(Me) 2n-Undecylracemic
V-706MeMeMeOPhC(Me) 2n-Undecyl(S)-
V-707MeEtMeOPhC(Me) 2n-Undecylracemic
V-708MeEtMeOPhC(Me) 2n-Undecyl(S)-
V-709MeMeMeOPhC(Me) 2Phracemic
V-710MeMeMeOPhC(Me) 2Ph(S)-
V-711MeEtMeOPhC(Me) 2Phracemic
V-712MeEtMeOPhC(Me) 2Ph(S)-
V-713MeMeMeOPhC(Me) 2OEtracemic
V-714MeMeMeOPhC(Me) 2OEt(S)-
V-715MeEtMeOPhC(Me) 2OEtracemic
V-716MeEtMeOPhC(Me) 2OEt(S)-
V-717MeMeMeOPhC(Me) 2(CH 2 ) 2 COOHracemic
V-718MeMeMeOPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-719MeEtMeOPhC(Me) 2(CH 2 ) 2 COOHracemic
V-720MeEtMeOPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-721MeMeMeOPh(CH 2 ) 2Meracemic
V-722MeMeMeOPh(CH 2 ) 2Me(R)-
V-723MeEtMeOPh(CH 2 ) 2Meracemic
V-724MeEtMeOPh(CH 2 ) 2Me(R)-
V-725MeMeMeOPh(CH 2 ) 2Etracemic
TABLE 116 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-726MeMeMeOPh(CH 2 ) 2Et(R)-
V-727MeEtMeOPh(CH 2 ) 2Etracemic
V-728MeEtMeOPh(CH 2 ) 2Et(R)-
V-729MeMeMeOPh(CH 2 ) 2nPrracemic
V-730MeMeMeOPh(CH 2 ) 2nPr(R)-
V-731MeEtMeOPh(CH 2 ) 2nPrracemic
V-732MeEtMeOPh(CH 2 ) 2nPr(R)-
V-733MeMeMeOPh(CH 2 ) 2iPrracemic
V-734MeMeMeOPh(CH 2 ) 2iPr(R)-
V-735MeEtMeOPh(CH 2 ) 2iPrracemic
V-736MeEtMeOPh(CH 2 ) 2iPr(R)-
V-737MeMeMeOPh(CH 2 ) 2nBuracemic
V-738MeMeMeOPh(CH 2 ) 2nBu(R)-
V-739MeEtMeOPh(CH 2 ) 2nBuracemic
V-740MeEtMeOPh(CH 2 ) 2nBu(R)-
V-741MeMeMeOPh(CH 2 ) 2tBuracemic
V-742MeMeMeOPh(CH 2 ) 2tBu(R)-
V-743MeEtMeOPh(CH 2 ) 2tBuracemic
V-744MeEtMeOPh(CH 2 ) 2tBu(R)-
V-745MeMeMeOPh(CH 2 ) 2iBuracemic
V-746MeMeMeOPh(CH 2 ) 2iBu(R)-
V-747MeEtMeOPh(CH 2 ) 2iBuracemic
V-748MeEtMeOPh(CH 2 ) 2iBu(R)-
V-749MeMeMeOPh(CH 2 ) 2n-Heptylracemic
V-750MeMeMeOPh(CH 2 ) 2n-Heptyl(R)-
V-751MeEtMeOPh(CH 2 ) 2n-Heptylracemic
V-752MeEtMeOPh(CH 2 ) 2n-Heptyl(R)-
V-753MeMeMeOPh(CH 2 ) 2n-Undecylracemic
V-754MeMeMeOPh(CH 2 ) 2n-Undecyl(R)-
V-755MeEtMeOPh(CH 2 ) 2n-Undecylracemic
V-756MeEtMeOPh(CH 2 ) 2n-Undecyl(R)-
V-757MeMeMeOPh(CH 2 ) 2Phracemic
V-758MeMeMeOPh(CH 2 ) 2Ph(R)-
V-759MeEtMeOPh(CH 2 ) 2Phracemic
V-760MeEtMeOPh(CH 2 ) 2Ph(R)-
V-761MeMeMeOPh(CH 2 ) 2OEtracemic
V-762MeMeMeOPh(CH 2 ) 2OEt(R)-
V-763MeEtMeOPh(CH 2 ) 2OEtracemic
V-764MeEtMeOPh(CH 2 ) 2OEt(R)-
V-765MeMeMeOPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-766MeMeMeOPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-767MeEtMeOPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-768MeEtMeOPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-769MeMeMeOPhCH 2 C(Me) 2Meracemic
V-770MeMeMeOPhCH 2 C(Me) 2Me(R)-
V-771MeEtMeOPhCH 2 C(Me) 2Meracemic
V-772MeEtMeOPhCH 2 C(Me) 2Me(R)-
V-773MeMeMeOPhCH 2 C(Me) 2Etracemic
V-774MeMeMeOPhCH 2 C(Me) 2Et(R)-
V-775MeEtMeOPhCH 2 C(Me) 2Etracemic
TABLE 117 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-776MeEtMeOPhCH 2 C(Me) 2Et(R)-
V-777MeMeMeOPhCH 2 C(Me) 2nPrracemic
V-778MeMeMeOPhCH 2 C(Me) 2nPr(R)-
V-779MeEtMeOPhCH 2 C(Me) 2nPrracemic
V-780MeEtMeOPhCH 2 C(Me) 2nPr(R)-
V-781MeMeMeOPhCH 2 C(Me) 2iPrracemic
V-782MeMeMeOPhCH 2 C(Me) 2iPr(R)-
V-783MeEtMeOPhCH 2 C(Me) 2iPrracemic
V-784MeEtMeOPhCH 2 C(Me) 2iPr(R)-
V-785MeMeMeOPhCH 2 C(Me) 2nBuracemic
V-786MeMeMeOPhCH 2 C(Me) 2nBu(R)-
V-787MeEtMeOPhCH 2 C(Me) 2nBuracemic
V-788MeEtMeOPhCH 2 C(Me) 2nBu(R)-
V-789MeMeMeOPhCH 2 C(Me) 2tBuracemic
V-790MeMeMeOPhCH 2 C(Me) 2tBu(R)-
V-791MeEtMeOPhCH 2 C(Me) 2tBuracemic
V-792MeEtMeOPhCH 2 C(Me) 2tBu(R)-
V-793MeMeMeOPhCH 2 C(Me) 2iBuracemic
V-794MeMeMeOPhCH 2 C(Me) 2iBu(R)-
V-795MeEtMeOPhCH 2 C(Me) 2iBuracemic
V-796MeEtMeOPhCH 2 C(Me) 2iBu(R)-
V-797MeMeMeOPhCH 2 C(Me) 2n-Heptylracemic
V-798MeMeMeOPhCH 2 C(Me) 2n-Heptyl(R)-
V-799MeEtMeOPhCH 2 C(Me) 2n-Heptylracemic
V-800MeEtMeOPhCH 2 C(Me) 2n-Heptyl(R)-
V-801MeMeMeOPhCH 2 C(Me) 2n-Undecylracemic
V-802MeMeMeOPhCH 2 C(Me) 2n-Undecyl(R)-
V-803MeEtMeOPhCH 2 C(Me) 2n-Undecylracemic
V-804MeEtMeOPhCH 2 C(Me) 2n-Undecyl(R)-
V-805MeMeMeOPhCH 2 C(Me) 2Phracemic
V-806MeMeMeOPhCH 2 C(Me) 2Ph(R)-
V-807MeEtMeOPhCH 2 C(Me) 2Phracemic
V-808MeEtMeOPhCH 2 C(Me) 2Ph(R)-
V-809MeMeMeOPhCH 2 C(Me) 2OEtracemic
V-810MeMeMeOPhCH 2 C(Me) 2OEt(R)-
V-811MeEtMeOPhCH 2 C(Me) 2OEtracemic
V-812MeEtMeOPhCH 2 C(Me) 2OEt(R)-
V-813MeMeMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-814MeMeMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-815MeEtMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-816MeEtMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-817MeMeMeNHPhCH 2Meracemic
V-818MeMeMeNHPhCH 2Me(S)-
V-819MeEtMeNHPhCH 2Meracemic
V-820MeEtMeNHPhCH 2Me(S)-
V-821MeMeMeNHPhCH 2Etracemic
V-822MeMeMeNHPhCH 2Et(S)-
V-823MeEtMeNHPhCH 2Etracemic
V-824MeEtMeNHPhCH 2Et(S)-
V-825MeMeMeNHPhCH 2nPrracemic
TABLE 118 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-826MeMeMeNHPhCH 2nPr(S)-
V-827MeEtMeNHPhCH 2nPrracemic
V-828MeEtMeNHPhCH 2nPr(S)-
V-829MeMeMeNHPhCH 2iPrracemic
V-830MeMeMeNHPhCH 2iPr(S)-
V-831MeEtMeNHPhCH 2iPrracemic
V-832MeEtMeNHPhCH 2iPr(S)-
V-833MeMeMeNHPhCH 2nBuracemic
V-834MeMeMeNHPhCH 2nBu(S)-
V-835MeEtMeNHPhCH 2nBuracemic
V-836MeEtMeNHPhCH 2nBu(S)-
V-837MeMeMeNHPhCH 2tBuracemic
V-838MeMeMeNHPhCH 2tBu(S)-
V-839MeEtMeNHPhCH 2tBuracemic
V-840MeEtMeNHPhCH 2tBu(S)-
V-841MeMeMeNHPhCH 2iBuracemic
V-842MeMeMeNHPhCH 2iBu(S)-
V-843MeEtMeNHPhCH 2iBuracemic
V-844MeEtMeNHPhCH 2iBu(S)-
V-845MeMeMeNHPhCH 2n-Heptylracemic
V-846MeMeMeNHPhCH 2n-Heptyl(S)-
V-847MeEtMeNHPhCH 2n-Heptylracemic
V-848MeEtMeNHPhCH 2n-Heptyl(S)-
V-849MeMeMeNHPhCH 2n-Undecylracemic
V-850MeMeMeNHPhCH 2n-Undecyl(S)-
V-851MeEtMeNHPhCH 2n-Undecylracemic
V-852MeEtMeNHPhCH 2n-Undecyl(S)-
V-853MeMeMeNHPhCH 2Phracemic
V-854MeMeMeNHPhCH 2Ph(S)-
V-855MeEtMeNHPhCH 2Phracemic
V-856MeEtMeNHPhCH 2Ph(S)-
V-857MeMeMeNHPhCH 2OEtracemic
V-858MeMeMeNHPhCH 2OEt(S)-
V-859MeEtMeNHPhCH 2OEtracemic
V-860MeEtMeNHPhCH 2OEt(S)-
V-861MeMeMeNHPhCH 2(CH 2 ) 2 COOHracemic
V-862MeMeMeNHPhCH 2(CH 2 ) 2 COOH(S)-
V-863MeEtMeNHPhCH 2(CH 2 ) 2 COOHracemic
V-864MeEtMeNHPhCH 2(CH 2 ) 2 COOH(S)-
V-865MeMeMeNHPhC(Me) 2Meracemic
V-866MeMeMeNHPhC(Me) 2Me(S)-
V-867MeEtMeNHPhC(Me) 2Meracemic
V-868MeEtMeNHPhC(Me) 2Me(S)-
V-869MeMeMeNHPhC(Me) 2Etracemic
V-870MeMeMeNHPhC(Me) 2Et(S)-
V-871MeEtMeNHPhC(Me) 2Etracemic
V-872MeEtMeNHPhC(Me) 2Et(S)-
V-873MeMeMeNHPhC(Me) 2nPrracemic
V-874MeMeMeNHPhC(Me) 2nPr(S)-
V-875MeEtMeNHPhC(Me) 2nPrracemic
TABLE 119 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-876MeEtMeNHPhC(Me) 2nPr(S)-
V-877MeMeMeNHPhC(Me) 2iPrracemic
V-878MeMeMeNHPhC(Me) 2iPr(S)-
V-879MeEtMeNHPhC(Me) 2iPrracemic
V-880MeEtMeNHPhC(Me) 2iPr(S)-
V-881MeMeMeNHPhC(Me) 2nBuracemic
V-882MeMeMeNHPhC(Me) 2nBu(S)-
V-883MeEtMeNHPhC(Me) 2nBuracemic
V-884MeEtMeNHPhC(Me) 2nBu(S)-
V-885MeMeMeNHPhC(Me) 2tBuracemic
V-886MeMeMeNHPhC(Me) 2tBu(S)-
V-887MeEtMeNHPhC(Me) 2tBuracemic
V-888MeEtMeNHPhC(Me) 2tBu(S)-
V-889MeMeMeNHPhC(Me) 2iBuracemic
V-890MeMeMeNHPhC(Me) 2iBu(S)-
V-891MeEtMeNHPhC(Me) 2iBuracemic
V-892MeEtMeNHPhC(Me) 2iBu(S)-
V-893MeMeMeNHPhC(Me) 2n-Heptylracemic
V-894MeMeMeNHPhC(Me) 2n-Heptyl(S)-
V-895MeEtMeNHPhC(Me) 2n-Heptylracemic
V-896MeEtMeNHPhC(Me) 2n-Heptyl(S)-
V-897MeMeMeNHPhC(Me) 2n-Undecylracemic
V-898MeMeMeNHPhC(Me) 2n-Undecyl(S)-
V-899MeEtMeNHPhC(Me) 2n-Undecylracemic
V-900MeEtMeNHPhC(Me) 2n-Undecyl(S)-
V-901MeMeMeNHPhC(Me) 2Phracemic
V-902MeMeMeNHPhC(Me) 2Ph(S)-
V-903MeEtMeNHPhC(Me) 2Phracemic
V-904MeEtMeNHPhC(Me) 2Ph(S)-
V-905MeMeMeNHPhC(Me) 2OEtracemic
V-906MeMeMeNHPhC(Me) 2OEt(S)-
V-907MeEtMeNHPhC(Me) 2OEtracemic
V-908MeEtMeNHPhC(Me) 2OEt(S)-
V-909MeMeMeNHPhC(Me) 2(CH 2 ) 2 COOHracemic
V-910MeMeMeNHPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-911MeEtMeNHPhC(Me) 2(CH 2 ) 2 COOHracemic
V-912MeEtMeNHPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-913MeMeMeNHPh(CH 2 ) 2Meracemic
V-914MeMeMeNHPh(CH 2 ) 2Me(R)-
V-915MeEtMeNHPh(CH 2 ) 2Meracemic
V-916MeEtMeNHPh(CH 2 ) 2Me(R)-
V-917MeMeMeNHPh(CH 2 ) 2Etracemic
V-918MeMeMeNHPh(CH 2 ) 2Et(R)-
V-919MeEtMeNHPh(CH 2 ) 2Etracemic
V-920MeEtMeNHPh(CH 2 ) 2Et(R)-
V-921MeMeMeNHPh(CH 2 ) 2nPrracemic
V-922MeMeMeNHPh(CH 2 ) 2nPr(R)-
V-923MeEtMeNHPh(CH 2 ) 2nPrracemic
V-924MeEtMeNHPh(CH 2 ) 2nPr(R)-
V-925MeMeMeNHPh(CH 2 ) 2iPrracemic
TABLE 120 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-926MeMeMeNHPh(CH 2 ) 2iPr(R)-
V-927MeEtMeNHPh(CH 2 ) 2iPrracemic
V-928MeEtMeNHPh(CH 2 ) 2iPr(R)-
V-929MeMeMeNHPh(CH 2 ) 2nBuracemic
V-930MeMeMeNHPh(CH 2 ) 2nBu(R)-
V-931MeEtMeNHPh(CH 2 ) 2nBuracemic
V-932MeEtMeNHPh(CH 2 ) 2nBu(R)-
V-933MeMeMeNHPh(CH 2 ) 2tBuracemic
V-934MeMeMeNHPh(CH 2 ) 2tBu(R)-
V-935MeEtMeNHPh(CH 2 ) 2tBuracemic
V-936MeEtMeNHPh(CH 2 ) 2tBu(R)-
V-937MeMeMeNHPh(CH 2 ) 2iBuracemic
V-938MeMeMeNHPh(CH 2 ) 2iBu(R)-
V-939MeEtMeNHPh(CH 2 ) 2iBuracemic
V-940MeEtMeNHPh(CH 2 ) 2iBu(R)-
V-941MeMeMeNHPh(CH 2 ) 2n-Heptylracemic
V-942MeMeMeNHPh(CH 2 ) 2n-Heptyl(R)-
V-943MeEtMeNHPh(CH 2 ) 2n-Heptylracemic
V-944MeEtMeNHPh(CH 2 ) 2n-Heptyl(R)-
V-945MeMeMeNHPh(CH 2 ) 2n-Undecylracemic
V-946MeMeMeNHPh(CH 2 ) 2n-Undecyl(R)-
V-947MeEtMeNHPh(CH 2 ) 2n-Undecylracemic
V-948MeEtMeNHPh(CH 2 ) 2n-Undecyl(R)-
V-949MeMeMeNHPh(CH 2 ) 2Phracemic
V-950MeMeMeNHPh(CH 2 ) 2Ph(R)-
V-951MeEtMeNHPh(CH 2 ) 2Phracemic
V-952MeEtMeNHPh(CH 2 ) 2Ph(R)-
V-953MeMeMeNHPh(CH 2 ) 2OEtracemic
V-954MeMeMeNHPh(CH 2 ) 2OEt(R)-
V-955MeEtMeNHPh(CH 2 ) 2OEtracemic
V-956MeEtMeNHPh(CH 2 ) 2OEt(R)-
V-957MeMeMeNHPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-958MeMeMeNHPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-959MeEtMeNHPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-960MeEtMeNHPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-961MeMeMeNHPhCH 2 C(Me) 2Meracemic
V-962MeMeMeNHPhCH 2 C(Me) 2Me(R)-
V-963MeEtMeNHPhCH 2 C(Me) 2Meracemic
V-964MeEtMeNHPhCH 2 C(Me) 2Me(R)-
V-965MeMeMeNHPhCH 2 C(Me) 2Etracemic
V-966MeMeMeNHPhCH 2 C(Me) 2Et(R)-
V-967MeEtMeNHPhCH 2 C(Me) 2Etracemic
V-968MeEtMeNHPhCH 2 C(Me) 2Et(R)-
V-969MeMeMeNHPhCH 2 C(Me) 2nPrracemic
V-970MeMeMeNHPhCH 2 C(Me) 2nPr(R)-
V-971MeEtMeNHPhCH 2 C(Me) 2nPrracemic
V-972MeEtMeNHPhCH 2 C(Me) 2nPr(R)-
V-973MeMeMeNHPhCH 2 C(Me) 2iPrracemic
V-974MeMeMeNHPhCH 2 C(Me) 2iPr(R)-
V-975MeEtMeNHPhCH 2 C(Me) 2iPrracemic
TABLE 121 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-976MeEtMeNHPhCH 2 C(Me) 2iPr(R)-
V-977MeMeMeNHPhCH 2 C(Me) 2nBuracemic
V-978MeMeMeNHPhCH 2 C(Me) 2nBu(R)-
V-979MeEtMeNHPhCH 2 C(Me) 2nBuracemic
V-980MeEtMeNHPhCH 2 C(Me) 2nBu(R)-
V-981MeMeMeNHPhCH 2 C(Me) 2tBuracemic
V-982MeMeMeNHPhCH 2 C(Me) 2tBu(R)-
V-983MeEtMeNHPhCH 2 C(Me) 2tBuracemic
V-984MeEtMeNHPhCH 2 C(Me) 2tBu(R)-
V-985MeMeMeNHPhCH 2 C(Me) 2iBuracemic
V-986MeMeMeNHPhCH 2 C(Me) 2iBu(R)-
V-987MeEtMeNHPhCH 2 C(Me) 2iBuracemic
V-988MeEtMeNHPhCH 2 C(Me) 2iBu(R)-
V-989MeMeMeNHPhCH 2 C(Me) 2n-Heptylracemic
V-990MeMeMeNHPhCH 2 C(Me) 2n-Heptyl(R)-
V-991MeEtMeNHPhCH 2 C(Me) 2n-Heptylracemic
V-992MeEtMeNHPhCH 2 C(Me) 2n-Heptyl(R)-
V-993MeMeMeNHPhCH 2 C(Me) 2n-Undecylracemic
V-994MeMeMeNHPhCH 2 C(Me) 2n-Undecyl(R)-
V-995MeEtMeNHPhCH 2 C(Me) 2n-Undecylracemic
V-996MeEtMeNHPhCH 2 C(Me) 2n-Undecyl(R)-
V-997MeMeMeNHPhCH 2 C(Me) 2Phracemic
V-998MeMeMeNHPhCH 2 C(Me) 2Ph(R)-
V-999MeEtMeNHPhCH 2 C(Me) 2Phracemic
V-1000MeEtMeNHPhCH 2 C(Me) 2Ph(R)-
V-1001MeMeMeNHPhCH 2 C(Me) 2OEtracemic
V-1002MeMeMeNHPhCH 2 C(Me) 2OEt(R)-
V-1003MeEtMeNHPhCH 2 C(Me) 2OEtracemic
V-1004MeEtMeNHPhCH 2 C(Me) 2OEt(R)-
V-1005MeMeMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1006MeMeMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-1007MeEtMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1008MeEtMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-1009MeMeMeCH 2PhCH 2Meracemic
V-1010MeMeMeCH 2PhCH 2Me(S)-
V-1011MeEtMeCH 2PhCH 2Meracemic
V-1012MeEtMeCH 2PhCH 2Me(S)-
V-1013MeMeMeCH 2PhCH 2Etracemic
V-1014MeMeMeCH 2PhCH 2Et(S)-
V-1015MeEtMeCH 2PhCH 2Etracemic
V-1016MeEtMeCH 2PhCH 2Et(S)-
V-1017MeMeMeCH 2PhCH 2nPrracemic
V-1018MeMeMeCH 2PhCH 2nPr(S)-
V-1019MeEtMeCH 2PhCH 2nPrracemic
V-1020MeEtMeCH 2PhCH 2nPr(S)-
V-1021MeMeMeCH 2PhCH 2iPrracemic
V-1022MeMeMeCH 2PhCH 2iPr(S)-
V-1023MeEtMeCH 2PhCH 2iPrracemic
V-1024MeEtMeCH 2PhCH 2iPr(S)-
V-1025MeMeMeCH 2PhCH 2nBuracemic
TABLE 122 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-1026MeMeMeCH 2PhCH 2nBu(S)-
V-1027MeEtMeCH 2PhCH 2nBuracemic
V-1028MeEtMeCH 2PhCH 2nBu(S)-
V-1029MeMeMeCH 2PhCH 2tBuracemic
V-1030MeMeMeCH 2PhCH 2tBu(S)-
V-1031MeEtMeCH 2PhCH 2tBuracemic
V-1032MeEtMeCH 2PhCH 2tBu(S)-
V-1033MeMeMeCH 2PhCH 2iBuracemic
V-1034MeMeMeCH 2PhCH 2iBu(S)-
V-1035MeEtMeCH 2PhCH 2iBuracemic
V-1036MeEtMeCH 2PhCH 2iBu(S)-
V-1037MeMeMeCH 2PhCH 2n-Heptylracemic
V-1038MeMeMeCH 2PhCH 2n-Heptyl(S)-
V-1039MeEtMeCH 2PhCH 2n-Heptylracemic
V-1040MeEtMeCH 2PhCH 2n-Heptyl(S)-
V-1041MeMeMeCH 2PhCH 2n-Undecylracemic
V-1042MeMeMeCH 2PhCH 2n-Undecyl(S)-
V-1043MeEtMeCH 2PhCH 2n-Undecylracemic
V-1044MeEtMeCH 2PhCH 2n-Undecyl(S)-
V-1045MeMeMeCH 2PhCH 2Phracemic
V-1046MeMeMeCH 2PhCH 2Ph(S)-
V-1047MeEtMeCH 2PhCH 2Phracemic
V-1048MeEtMeCH 2PhCH 2Ph(S)-
V-1049MeMeMeCH 2PhCH 2OEtracemic
V-1050MeMeMeCH 2PhCH 2OEt(S)-
V-1051MeEtMeCH 2PhCH 2OEtracemic
V-1052MeEtMeCH 2PhCH 2OEt(S)-
V-1053MeMeMeCH 2PhCH 2(CH 2 ) 2 COOHracemic
V-1054MeMeMeCH 2PhCH 2(CH 2 ) 2 COOH(S)-
V-1055MeEtMeCH 2PhCH 2(CH 2 ) 2 COOHracemic
V-1056MeEtMeCH 2PhCH 2(CH 2 ) 2 COOH(S)-
V-1057MeMeMeCH 2Ph—Meracemic
V-1058MeMeMeCH 2Ph—Me(S)-
V-1059MeEtMeCH 2Ph—Meracemic
V-1060MeEtMeCH 2Ph—Me(S)-
V-1061MeMeMeCH 2Ph—Etracemic
V-1062MeMeMeCH 2Ph—Et(S)-
V-1063MeEtMeCH 2Ph—Etracemic
V-1064MeEtMeCH 2Ph—Et(S)-
V-1065MeMeMeCH 2Ph—nPrracemic
V-1066MeMeMeCH 2Ph—nPr(S)-
V-1067MeEtMeCH 2Ph—nPrracemic
V-1068MeEtMeCH 2Ph—nPr(S)-
V-1069MeMeMeCH 2Ph—iPrracemic
V-1070MeMeMeCH 2Ph—iPr(S)-
V-1071MeEtMeCH 2Ph—iPrracemic
V-1072MeEtMeCH 2Ph—iPr(S)-
V-1073MeMeMeCH 2Ph—nBuracemic
V-1074MeMeMeCH 2Ph—nBu(S)-
V-1075MeEtMeCH 2Ph—nBuracemic
TABLE 123 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-1076MeEtMeCH 2Ph—nBu(S)-
V-1077MeMeMeCH 2Ph—tBuracemic
V-1078MeMeMeCH 2Ph—tBu(S)-
V-1079MeEtMeCH 2Ph—tBuracemic
V-1080MeEtMeCH 2Ph—tBu(S)-
V-1081MeMeMeCH 2Ph—iBuracemic
V-1082MeMeMeCH 2Ph—iBu(S)-
V-1083MeEtMeCH 2Ph—iBuracemic
V-1084MeEtMeCH 2Ph—iBu(S)-
V-1085MeMeMeCH 2Ph—n-Heptylracemic
V-1086MeMeMeCH 2Ph—n-Heptyl(S)-
V-1087MeEtMeCH 2Ph—n-Heptylracemic
V-1088MeEtMeCH 2Ph—n-Heptyl(S)-
V-1089MeMeMeCH 2Ph—n-Undecylracemic
V-1090MeMeMeCH 2Ph—n-Undecyl(S)-
V-1091MeEtMeCH 2Ph—n-Undecylracemic
V-1092MeEtMeCH 2Ph—n-Undecyl(S)-
V-1093MeMeMeCH 2Ph—Phracemic
V-1094MeMeMeCH 2Ph—Ph(S)-
V-1095MeEtMeCH 2Ph—Phracemic
V-1096MeEtMeCH 2Ph—Ph(S)-
V-1097MeMeMeCH 2Ph—OEtracemic
V-1098MeMeMeCH 2Ph—OEt(S)-
V-1099MeEtMeCH 2Ph—OEtracemic
V-1100MeEtMeCH 2Ph—OEt(S)-
V-1101MeMeMeCH 2Ph—(CH 2 ) 2 COOHracemic
V-1102MeMeMeCH 2Ph—(CH 2 ) 2 COOH(S)-
V-1103MeEtMeCH 2Ph—(CH 2 ) 2 COOHracemic
V-1104MeEtMeCH 2Ph—(CH 2 ) 2 COOH(S)-
V-1105MeMeMeCH 2PhC(Me) 2Meracemic
V-1106MeMeMeCH 2PhC(Me) 2Me(S)-
V-1107MeEtMeCH 2PhC(Me) 2Meracemic
V-1108MeEtMeCH 2PhC(Me) 2Me(S)-
V-1109MeMeMeCH 2PhC(Me) 2Etracemic
V-1110MeMeMeCH 2PhC(Me) 2Et(S)-
V-1111MeEtMeCH 2PhC(Me) 2Etracemic
V-1112MeEtMeCH 2PhC(Me) 2Et(S)-
V-1113MeMeMeCH 2PhC(Me) 2nPrracemic
V-1114MeMeMeCH 2PhC(Me) 2nPr(S)-
V-1115MeEtMeCH 2PhC(Me) 2nPrracemic
V-1116MeEtMeCH 2PhC(Me) 2nPr(S)-
V-1117MeMeMeCH 2PhC(Me) 2iPrracemic
V-1118MeMeMeCH 2PhC(Me) 2iPr(S)-
V-1119MeEtMeCH 2PhC(Me) 2iPrracemic
V-1120MeEtMeCH 2PhC(Me) 2iPr(S)-
V-1121MeMeMeCH 2PhC(Me) 2nBuracemic
V-1122MeMeMeCH 2PhC(Me) 2nBu(S)-
V-1123MeEtMeCH 2PhC(Me) 2nBuracemic
V-1124MeEtMeCH 2PhC(Me) 2nBu(S)-
V-1125MeMeMeCH 2PhC(Me) 2tBuracemic
TABLE 124 — (Vb)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1126MeMeMeCH 2PhC(Me) 2tBu(S)-
V-1127MeEtMeCH 2PhC(Me) 2tBuracemic
V-1128MeEtMeCH 2PhC(Me) 2tBu(S)-
V-1129MeMeMeCH 2PhC(Me) 2iBuracemic
V-1130MeMeMeCH 2PhC(Me) 2iBu(S)-
V-1131MeEtMeCH 2PhC(Me) 2iBuracemic
V-1132MeEtMeCH 2PhC(Me) 2iBu(S)-
V-1133MeMeMeCH 2PhC(Me) 2n-Heptylracemic
V-1134MeMeMeCH 2PhC(Me) 2n-Heptyl(S)-
V-1135MeEtMeCH 2PhC(Me) 2n-Heptylracemic
V-1136MeEtMeCH 2PhC(Me) 2n-Heptyl(S)-
V-1137MeMeMeCH 2PhC(Me) 2n-Undecylracemic
V-1138MeMeMeCH 2PhC(Me) 2n-Undecyl(S)-
V-1139MeEtMeCH 2PhC(Me) 2n-Undecylracemic
V-1140MeEtMeCH 2PhC(Me) 2n-Undecyl(S)-
V-1141MeMeMeCH 2PhC(Me) 2Phracemic
V-1142MeMeMeCH 2PhC(Me) 2Ph(S)-
V-1143MeEtMeCH 2PhC(Me) 2Phracemic
V-1144MeEtMeCH 2PhC(Me) 2Ph(S)-
V-1145MeMeMeCH 2PhC(Me) 2OEtracemic
V-1146MeMeMeCH 2PhC(Me) 2OEt(S)-
V-1147MeEtMeCH 2PhC(Me) 2OEtracemic
V-1148MeEtMeCH 2PhC(Me) 2OEt(S)-
V-1149MeMeMeCH 2PhC(Me) 2(CH 2 ) 2 COOHracemic
V-1150MeMeMeCH 2PhC(Me) 2(CH 2 ) 2 COOH(S)-
V-1151MeEtMeCH 2PhC(Me) 2(CH 2 ) 2 COOHracemic
V-1152MeEtMeCH 2PhC(Me) 2(CH 2 ) 2 COOH(S)-
V-1153MeMeMeCH 2Ph(CH 2 ) 2Meracemic
V-1154MeMeMeCH 2Ph(CH 2 ) 2Me(S)-
V-1155MeEtMeCH 2Ph(CH 2 ) 2Meracemic
V-1156MeEtMeCH 2Ph(CH 2 ) 2Me(S)-
V-1157MeMeMeCH 2Ph(CH 2 ) 2Etracemic
V-1158MeMeMeCH 2Ph(CH 2 ) 2Et(S)-
V-1159MeEtMeCH 2Ph(CH 2 ) 2Etracemic
V-1160MeEtMeCH 2Ph(CH 2 ) 2Et(S)-
V-1161MeMeMeCH 2Ph(CH 2 ) 2nPrracemic
V-1162MeMeMeCH 2Ph(CH 2 ) 2nPr(S)-
V-1163MeEtMeCH 2Ph(CH 2 ) 2nPrracemic
V-1164MeEtMeCH 2Ph(CH 2 ) 2nPr(S)-
V-1165MeMeMeCH 2Ph(CH 2 ) 2iPrracemic
V-1166MeMeMeCH 2Ph(CH 2 ) 2iPr(S)-
V-1167MeEtMeCH 2Ph(CH 2 ) 2iPrracemic
V-1168MeEtMeCH 2Ph(CH 2 ) 2iPr(S)-
V-1169MeMeMeCH 2Ph(CH 2 ) 2nBuracemic
V-1170MeMeMeCH 2Ph(CH 2 ) 2nBu(S)-
V-1171MeEtMeCH 2Ph(CH 2 ) 2nBuracemic
V-1172MeEtMeCH 2Ph(CH 2 ) 2nBu(S)-
V-1173MeMeMeCH 2Ph(CH 2 ) 2tBuracemic
V-1174MeMeMeCH 2Ph(CH 2 ) 2tBu(S)-
V-1175MeEtMeCH 2Ph(CH 2 ) 2tBuracemic
TABLE 125 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-1176MeEtMeCH 2Ph(CH 2 ) 2tBu(S)-
V-1177MeMeMeCH 2Ph(CH 2 ) 2iBuracemic
V-1178MeMeMeCH 2Ph(CH 2 ) 2iBu(S)-
V-1179MeEtMeCH 2Ph(CH 2 ) 2iBuracemic
V-1180MeEtMeCH 2Ph(CH 2 ) 2iBu(S)-
V-1181MeMeMeCH 2Ph(CH 2 ) 2n-Heptylracemic
V-1182MeMeMeCH 2Ph(CH 2 ) 2n-Heptyl(S)-
V-1183MeEtMeCH 2Ph(CH 2 ) 2n-Heptylracemic
V-1184MeEtMeCH 2Ph(CH 2 ) 2n-Heptyl(S)-
V-1185MeMeMeCH 2Ph(CH 2 ) 2n-Undecylracemic
V-1186MeMeMeCH 2Ph(CH 2 ) 2n-Undecyl(S)-
V-1187MeEtMeCH 2Ph(CH 2 ) 2n-Undecylracemic
V-1188MeEtMeCH 2Ph(CH 2 ) 2n-Undecyl(S)-
V-1189MeMeMeCH 2Ph(CH 2 ) 2Phracemic
V-1190MeMeMeCH 2Ph(CH 2 ) 2Ph(S)-
V-1191MeEtMeCH 2Ph(CH 2 ) 2Phracemic
V-1192MeEtMeCH 2Ph(CH 2 ) 2Ph(S)-
V-1193MeMeMeCH 2Ph(CH 2 ) 2OEtracemic
V-1194MeMeMeCH 2Ph(CH 2 ) 2OEt(S)-
V-1195MeEtMeCH 2Ph(CH 2 ) 2OEtracemic
V-1196MeEtMeCH 2Ph(CH 2 ) 2OEt(S)-
V-1197MeMeMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-1198MeMeMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOH(S)-
V-1199MeEtMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-1200MeEtMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOH(S)-
V-1201MeMeMeCH 2PhCH 2 C(Me) 2Meracemic
V-1202MeMeMeCH 2PhCH 2 C(Me) 2Me(S)-
V-1203MeEtMeCH 2PhCH 2 C(Me) 2Meracemic
V-1204MeEtMeCH 2PhCH 2 C(Me) 2Me(S)-
V-1205MeMeMeCH 2PhCH 2 C(Me) 2Etracemic
V-1206MeMeMeCH 2PhCH 2 C(Me) 2Et(S)-
V-1207MeEtMeCH 2PhCH 2 C(Me) 2Etracemic
V-1208MeEtMeCH 2PhCH 2 C(Me) 2Et(S)-
V-1209MeMeMeCH 2PhCH 2 C(Me) 2nPrracemic
V-1210MeMeMeCH 2PhCH 2 C(Me) 2nPr(S)-
V-1211MeEtMeCH 2PhCH 2 C(Me) 2nPrracemic
V-1212MeEtMeCH 2PhCH 2 C(Me) 2nPr(S)-
V-1213MeMeMeCH 2PhCH 2 C(Me) 2iPrracemic
V-1214MeMeMeCH 2PhCH 2 C(Me) 2iPr(S)-
V-1215MeEtMeCH 2PhCH 2 C(Me) 2iPrracemic
V-1216MeEtMeCH 2PhCH 2 C(Me) 2iPr(S)-
V-1217MeMeMeCH 2PhCH 2 C(Me) 2nBuracemic
V-1218MeMeMeCH 2PhCH 2 C(Me) 2nBu(S)-
V-1219MeEtMeCH 2PhCH 2 C(Me) 2nBuracemic
V-1220MeEtMeCH 2PhCH 2 C(Me) 2nBu(S)-
V-1221MeMeMeCH 2PhCH 2 C(Me) 2tBuracemic
V-1222MeMeMeCH 2PhCH 2 C(Me) 2tBu(S)-
V-1223MeEtMeCH 2PhCH 2 C(Me) 2tBuracemic
V-1224MeEtMeCH 2PhCH 2 C(Me) 2tBu(S)-
V-1225MeMeMeCH 2PhCH 2 C(Me) 2iBuracemic
TABLE 126 — (Vb)
Com-Con-
poundfigura-
No.R 1R 2R 3L 2R 4L 3R 6tion
V-1226MeMeMeCH 2PhCH 2 C(Me) 2iBu(S)-
V-1227MeEtMeCH 2PhCH 2 C(Me) 2iBuracemic
V-1228MeEtMeCH 2PhCH 2 C(Me) 2iBu(S)-
V-1229MeMeMeCH 2PhCH 2 C(Me) 2n-Heptylracemic
V-1230MeMeMeCH 2PhCH 2 C(Me) 2n-Heptyl(S)-
V-1231MeEtMeCH 2PhCH 2 C(Me) 2n-Heptylracemic
V-1232MeEtMeCH 2PhCH 2 C(Me) 2n-Heptyl(S)-
V-1233MeMeMeCH 2PhCH 2 C(Me) 2n-Undecylracemic
V-1234MeMeMeCH 2PhCH 2 C(Me) 2n-Undecyl(S)-
V-1235MeEtMeCH 2PhCH 2 C(Me) 2n-Undecylracemic
V-1236MeEtMeCH 2PhCH 2 C(Me) 2n-Undecyl(S)-
V-1237MeMeMeCH 2PhCH 2 C(Me) 2Phracemic
V-1238MeMeMeCH 2PhCH 2 C(Me) 2Ph(S)-
V-1239MeEtMeCH 2PhCH 2 C(Me) 2Phracemic
V-1240MeEtMeCH 2PhCH 2 C(Me) 2Ph(S)-
V-1241MeMeMeCH 2PhCH 2 C(Me) 2OEtracemic
V-1242MeMeMeCH 2PhCH 2 C(Me) 2OEt(S)-
V-1243MeEtMeCH 2PhCH 2 C(Me) 2OEtracemic
V-1244MeEtMeCH 2PhCH 2 C(Me) 2OEt(S)-
V-1245MeMeMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1246MeMeMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOH(S)-
V-1247MeEtMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1248MeEtMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOH(S)-
TABLE 127 — (Vb)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1972MeMeMe—Ph—Meracemic
V-1973MeMeMe—Ph—Me(R)-
V-1974MeEtMe—Ph—Meracemic
V-1975MeEtMe—Ph—Me(R)-
V-1976MeMeMe—Ph—Etracemic
V-1977MeMeMe—Ph—Et(R)-
V-1978MeEtMe—Ph—Etracemic
V-1979MeEtMe—Ph—Et(R)-
V-1980MeMeMe—Ph—nPrracemic
V-1981MeMeMe—Ph—nPr(R)-
V-1982MeEtMe—Ph—nPrracemic
V-1983MeEtMe—Ph—nPr(R)-
V-1984MeMeMe—Ph—iPrracemic
V-1985MeMeMe—Ph—iPr(R)-
V-1986MeEtMe—Ph—iPrracemic
V-1987MeEtMe—Ph—iPr(R)-
V-1988MeMeMe—Ph—nBuracemic
V-1989MeMeMe—Ph—nBu(R)-
V-1990MeEtMe—Ph—nBuracemic
V-1991MeEtMe—Ph—nBu(R)-
V-1992MeMeMe—Ph—tBuracemic
V-1993MeMeMe—Ph—tBu(R)-
V-1994MeEtMe—Ph—tBuracemic
V-1995MeEtMe—Ph—tBu(R)-
V-1996MeMeMe—Ph—iBuracemic
V-1997MeMeMe—Ph—iBu(R)-
V-1998MeEtMe—Ph—iBuracemic
V-1999MeEtMe—Ph—iBu(R)-
V-2000MeMeMe—Ph—n-Heptylracemic
V-2001MeMeMe—Ph—n-Heptyl(R)-
V-2002MeEtMe—Ph—n-Heptylracemic
V-2003MeEtMe—Ph—n-Heptyl(R)-
V-2004MeMeMe—Ph—n-Undecylracemic
V-2005MeMeMe—Ph—n-Undecyl(R)-
V-2006MeEtMe—Ph—n-Undecylracemic
V-2007MeEtMe—Ph—n-Undecyl(R)-
V-2008MeMeMe—Ph—OEtracemic
V-2009MeMeMe—Ph—OEt(R)-
V-2010MeEtMe—Ph—OEtracemic
V-2011MeEtMe—Ph—OEt(R)-
V-2012MeMeMe—Ph—(CH 2 ) 2 COONaracemic
V-2013MeMeMe—Ph—(CH 2 ) 2 COONa(R)-
V-2014MeEtMe—Ph—(CH 2 ) 2 COONaracemic
V-2015MeEtMe—Ph—(CH 2 ) 2 COONa(R)-
V-2016MeMeMe—PhCH 2Meracemic
V-2017MeMeMe—PhCH 2Me(S)-
V-2018MeEtMe—PhCH 2Meracemic
V-2019MeEtMe—PhCH 2Me(S)-
V-2020MeMeMe—PhCH 2Etracemic
V-2021MeMeMe—PhCH 2Et(S)-
TABLE 128 — (Vb)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-2022MeEtMe—PhCH 2Etracemic
V-2023MeEtMe—PhCH 2Et(S)-
V-2024MeMeMe—PhCH 2nPrracemic
V-2025MeMeMe—PhCH 2nPr(S)-
V-2026MeEtMe—PhCH 2nPrracemic
V-2027MeEtMe—PhCH 2nPr(S)-
V-2028MeMeMe—PhCH 2iPrracemic
V-2029MeMeMe—PhCH 2iPr(S)-
V-2030MeEtMe—PhCH 2iPrracemic
V-2031MeEtMe—PhCH 2iPr(S)-
V-2032MeMeMe—PhCH 2nBuracemic
V-2033MeMeMe—PhCH 2nBu(S)-
V-2034MeEtMe—PhCH 2nBuracemic
V-2035MeEtMe—PhCH 2nBu(S)-
V-2036MeMeMe—PhCH 2tBuracemic
V-2037MeMeMe—PhCH 2tBu(S)-
V-2038MeEtMe—PhCH 2tBuracemic
V-2039MeEtMe—PhCH 2tBu(S)-
V-2040MeMeMe—PhCH 2iBuracemic
V-2041MeMeMe—PhCH 2iBu(S)-
V-2042MeEtMe—PhCH 2iBuracemic
V-2043MeEtMe—PhCH 2iBu(S)-
V-2044MeMeMe—PhCH 2n-Heptylracemic
V-2045MeMeMe—PhCH 2n-Heptyl(S)-
V-2046MeEtMe—PhCH 2n-Heptylracemic
V-2047MeEtMe—PhCH 2n-Heptyl(S)-
V-2048MeMeMe—PhCH 2n-Undecylracemic
V-2049MeMeMe—PhCH 2n-Undecyl(S)-
V-2050MeEtMe—PhCH 2n-Undecylracemic
V-2051MeEtMe—PhCH 2n-Undecyl(S)-
V-2052MeMeMe—PhCH 2OEtracemic
V-2053MeMeMe—PhCH 2OEt(S)-
V-2054MeEtMe—PhCH 2OEtracemic
V-2055MeEtMe—PhCH 2OEt(S)-
V-2056MeMeMe—PhCH 2(CH 2 ) 2 COONaracemic
V-2057MeMeMe—PhCH 2(CH 2 ) 2 COONa(S)-
V-2058MeEtMe—PhCH 2(CH 2 ) 2 COONaracemic
V-2059MeEtMe—PhCH 2(CH 2 ) 2 COONa(S)-
TABLE 129 — (Vc)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1249MeMeMeOPhCH 2Meracemic
V-1250MeMeMeOPhCH 2Me(S)-
V-1251MeEtMeOPhCH 2Meracemic
V-1252MeEtMeOPhCH 2Me(S)-
V-1253MeMeMeOPhCH 2Etracemic
V-1254MeMeMeOPhCH 2Et(S)-
V-1255MeEtMeOPhCH 2Etracemic
V-1256MeEtMeOPhCH 2Et(S)-
V-1257MeMeMeOPhCH 2nPrracemic
V-1258MeMeMeOPhCH 2nPr(S)-
V-1259MeEtMeOPhCH 2nPrracemic
V-1260MeEtMeOPhCH 2nPr(S)-
V-1261MeMeMeOPhCH 2iPrracemic
V-1262MeMeMeOPhCH 2iPr(S)-
V-1263MeEtMeOPhCH 2iPrracemic
V-1264MeEtMeOPhCH 2iPr(S)-
V-1265MeMeMeOPhCH 2nBuracemic
V-1266MeMeMeOPhCH 2nBu(S)-
V-1267MeEtMeOPhCH 2nBuracemic
V-1268MeEtMeOPhCH 2nBu(S)-
V-1269MeMeMeOPhCH 2tBuracemic
V-1270MeMeMeOPhCH 2tBu(S)-
V-1271MeEtMeOPhCH 2tBuracemic
V-1272MeEtMeOPhCH 2tBu(S)-
V-1273MeMeMeOPhCH 2iBuracemic
V-1274MeMeMeOPhCH 2iBu(S)-
V-1275MeEtMeOPhCH 2iBuracemic
V-1276MeEtMeOPhCH 2iBu(S)-
V-1277MeMeMeOPhCH 2n-Heptylracemic
V-1278MeMeMeOPhCH 2n-Heptyl(S)-
V-1279MeEtMeOPhCH 2n-Heptylracemic
V-1280MeEtMeOPhCH 2n-Heptyl(S)-
V-1281MeMeMeOPhCH 2n-Undecylracemic
V-1282MeMeMeOPhCH 2n-Undecyl(S)-
V-1283MeEtMeOPhCH 2n-Undecylracemic
V-1284MeEtMeOPhCH 2n-Undecyl(S)-
V-1285MeMeMeOPhCH 2Phracemic
V-1286MeMeMeOPhCH 2Ph(S)-
V-1287MeEtMeOPhCH 2Phracemic
V-1288MeEtMeOPhCH 2Ph(S)-
V-1289MeMeMeOPhCH 2OEtracemic
V-1290MeMeMeOPhCH 2OEt(S)-
V-1291MeEtMeOPhCH 2OEtracemic
V-1292MeEtMeOPhCH 2OEt(S)-
V-1293MeMeMeOPhCH 2(CH 2 ) 2 COOHracemic
V-1294MeMeMeOPhCH 2(CH 2 ) 2 COOH(S)-
V-1295MeEtMeOPhCH 2(CH 2 ) 2 COOHracemic
V-1296MeEtMeOPhCH 2(CH 2 ) 2 COOH(S)-
V-1297MeMeMeOPhC(Me) 2Meracemic
V-1298MeMeMeOPhC(Me) 2Me(S)-
TABLE 130 — (Vc)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1299MeEtMeOPhC(Me) 2Meracemic
V-1300MeEtMeOPhC(Me) 2Me(S)-
V-1301MeMeMeOPhC(Me) 2Etracemic
V-1302MeMeMeOPhC(Me) 2Et(S)-
V-1303MeEtMeOPhC(Me) 2Etracemic
V-1304MeEtMeOPhC(Me) 2Et(S)-
V-1305MeMeMeOPhC(Me) 2nPrracemic
V-1306MeMeMeOPhC(Me) 2nPr(S)-
V-1307MeEtMeOPhC(Me) 2nPrracemic
V-1308MeEtMeOPhC(Me) 2nPr(S)-
V-1309MeMeMeOPhC(Me) 2iPrracemic
V-1310MeMeMeOPhC(Me) 2iPr(S)-
V-1311MeEtMeOPhC(Me) 2iPrracemic
V-1312MeEtMeOPhC(Me) 2iPr(S)-
V-1313MeMeMeOPhC(Me) 2nBuracemic
V-1314MeMeMeOPhC(Me) 2nBu(S)-
V-1315MeEtMeOPhC(Me) 2nBuracemic
V-1316MeEtMeOPhC(Me) 2nBu(S)-
V-1317MeMeMeOPhC(Me) 2tBuracemic
V-1318MeMeMeOPhC(Me) 2tBu(S)-
V-1319MeEtMeOPhC(Me) 2tBuracemic
V-1320MeEtMeOPhC(Me) 2tBu(S)-
V-1321MeMeMeOPhC(Me) 2iBuracemic
V-1322MeMeMeOPhC(Me) 2iBu(S)-
V-1323MeEtMeOPhC(Me) 2iBuracemic
V-1324MeEtMeOPhC(Me) 2iBu(S)-
V-1325MeMeMeOPhC(Me) 2n-Heptylracemic
V-1326MeMeMeOPhC(Me) 2n-Heptyl(S)-
V-1327MeEtMeOPhC(Me) 2n-Heptylracemic
V-1328MeEtMeOPhC(Me) 2n-Heptyl(S)-
V-1329MeMeMeOPhC(Me) 2n-Undecylracemic
V-1330MeMeMeOPhC(Me) 2n-Undecyl(S)-
V-1331MeEtMeOPhC(Me) 2n-Undecylracemic
V-1332MeEtMeOPhC(Me) 2n-Undecyl(S)-
V-1333MeMeMeOPhC(Me) 2Phracemic
V-1334MeMeMeOPhC(Me) 2Ph(S)-
V-1335MeEtMeOPhC(Me) 2Phracemic
V-1336MeEtMeOPhC(Me) 2Ph(S)-
V-1337MeMeMeOPhC(Me) 2OEtracemic
V-1338MeMeMeOPhC(Me) 2OEt(S)-
V-1339MeEtMeOPhC(Me) 2OEtracemic
V-1340MeEtMeOPhC(Me) 2OEt(S)-
V-1341MeMeMeOPhC(Me) 2(CH 2 ) 2 COOHracemic
V-1342MeMeMeOPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-1343MeEtMeOPhC(Me) 2(CH 2 ) 2 COOHracemic
V-1344MeEtMeOPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-1345MeMeMeOPh(CH 2 ) 2Meracemic
V-1346MeMeMeOPh(CH 2 ) 2Me(R)-
V-1347MeEtMeOPh(CH 2 ) 2Meracemic
V-1348MeEtMeOPh(CH 2 ) 2Me(R)-
TABLE 131 — (Vc) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1349MeMeMeOPh(CH 2 ) 2Etracemic
V-1350MeMeMeOPh(CH 2 ) 2Et(R)-
V-1351MeEtMeOPh(CH 2 ) 2Etracemic
V-1352MeEtMeOPh(CH 2 ) 2Et(R)-
V-1353MeMeMeOPh(CH 2 ) 2nPrracemic
V-1354MeMeMeOPh(CH 2 ) 2nPr(R)-
V-1355MeEtMeOPh(CH 2 ) 2nPrracemic
V-1356MeEtMeOPh(CH 2 ) 2nPr(R)-
V-1357MeMeMeOPh(CH 2 ) 2iPrracemic
V-1358MeMeMeOPh(CH 2 ) 2iPr(R)-
V-1359MeEtMeOPh(CH 2 ) 2iPrracemic
V-1360MeEtMeOPh(CH 2 ) 2iPr(R)-
V-1361MeMeMeOPh(CH 2 ) 2nBuracemic
V-1362MeMeMeOPh(CH 2 ) 2nBu(R)-
V-1363MeEtMeOPh(CH 2 ) 2nBuracemic
V-1364MeEtMeOPh(CH 2 ) 2nBu(R)-
V-1365MeMeMeOPh(CH 2 ) 2tBuracemic
V-1366MeMeMeOPh(CH 2 ) 2tBu(R)-
V-1367MeEtMeOPh(CH 2 ) 2tBuracemic
V-1368MeEtMeOPh(CH 2 ) 2tBu(R)-
V-1369MeMeMeOPh(CH 2 ) 2iBuracemic
V-1370MeMeMeOPh(CH 2 ) 2iBu(R)-
V-1371MeEtMeOPh(CH 2 ) 2iBuracemic
V-1372MeEtMeOPh(CH 2 ) 2iBu(R)-
V-1373MeMeMeOPh(CH 2 ) 2n-Heptylracemic
V-1374MeMeMeOPh(CH 2 ) 2n-Heptyl(R)-
V-1375MeEtMeOPh(CH 2 ) 2n-Heptylracemic
V-1376MeEtMeOPh(CH 2 ) 2n-Heptyl(R)-
V-1377MeMeMeOPh(CH 2 ) 2n-Undecylracemic
V-1378MeMeMeOPh(CH 2 ) 2n-Undecyl(R)-
V-1379MeEtMeOPh(CH 2 ) 2n-Undecylracemic
V-1380MeEtMeOPh(CH 2 ) 2n-Undecyl(R)-
V-1381MeMeMeOPh(CH 2 ) 2Phracemic
V-1382MeMeMeOPh(CH 2 ) 2Ph(R)-
V-1383MeEtMeOPh(CH 2 ) 2Phracemic
V-1384MeEtMeOPh(CH 2 ) 2Ph(R)-
V-1385MeMeMeOPh(CH 2 ) 2OEtracemic
V-1386MeMeMeOPh(CH 2 ) 2OEt(R)-
V-1387MeEtMeOPh(CH 2 ) 2OEtracemic
V-1388MeEtMeOPh(CH 2 ) 2OEt(R)-
V-1389MeMeMeOPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-1390MeMeMeOPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-1391MeEtMeOPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-1392MeEtMeOPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-1393MeMeMeOPhCH 2 C(Me) 2Meracemic
V-1394MeMeMeOPhCH 2 C(Me) 2Me(R)-
V-1395MeEtMeOPhCH 2 C(Me) 2Meracemic
V-1396MeEtMeOPhCH 2 C(Me) 2Me(R)-
V-1397MeMeMeOPhCH 2 C(Me) 2Etracemic
V-1398MeMeMeOPhCH 2 C(Me) 2Et(R)-
TABLE 132 — (Vc) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1399MeEtMeOPhCH 2 C(Me) 2Etracemic
V-1400MeEtMeOPhCH 2 C(Me) 2Et(R)-
V-1401MeMeMeOPhCH 2 C(Me) 2nPrracemic
V-1402MeMeMeOPhCH 2 C(Me) 2nPr(R)-
V-1403MeEtMeOPhCH 2 C(Me) 2nPrracemic
V-1404MeEtMeOPhCH 2 C(Me) 2nPr(R)-
V-1405MeMeMeOPhCH 2 C(Me) 2iPrracemic
V-1406MeMeMeOPhCH 2 C(Me) 2iPr(R)-
V-1407MeEtMeOPhCH 2 C(Me) 2iPrracemic
V-1408MeEtMeOPhCH 2 C(Me) 2iPr(R)-
V-1409MeMeMeOPhCH 2 C(Me) 2nBuracemic
V-1410MeMeMeOPhCH 2 C(Me) 2nBu(R)-
V-1411MeEtMeOPhCH 2 C(Me) 2nBuracemic
V-1412MeEtMeOPhCH 2 C(Me) 2nBu(R)-
V-1413MeMeMeOPhCH 2 C(Me) 2tBuracemic
V-1414MeMeMeOPhCH 2 C(Me) 2tBu(R)-
V-1415MeEtMeOPhCH 2 C(Me) 2tBuracemic
V-1416MeEtMeOPhCH 2 C(Me) 2tBu(R)-
V-1417MeMeMeOPhCH 2 C(Me) 2iBuracemic
V-1418MeMeMeOPhCH 2 C(Me) 2iBu(R)-
V-1419MeEtMeOPhCH 2 C(Me) 2iBuracemic
V-1420MeEtMeOPhCH 2 C(Me) 2iBu(R)-
V-1421MeMeMeOPhCH 2 C(Me) 2n-Heptylracemic
V-1422MeMeMeOPhCH 2 C(Me) 2n-Heptyl(R)-
V-1423MeEtMeOPhCH 2 C(Me) 2n-Heptylracemic
V-1424MeEtMeOPhCH 2 C(Me) 2n-Heptyl(R)-
V-1425MeMeMeOPhCH 2 C(Me) 2n-Undecylracemic
V-1426MeMeMeOPhCH 2 C(Me) 2n-Undecyl(R)-
V-1427MeEtMeOPhCH 2 C(Me) 2n-Undecylracemic
V-1428MeEtMeOPhCH 2 C(Me) 2n-Undecyl(R)-
V-1429MeMeMeOPhCH 2 C(Me) 2Phracemic
V-1430MeMeMeOPhCH 2 C(Me) 2Ph(R)-
V-1431MeEtMeOPhCH 2 C(Me) 2Phracemic
V-1432MeEtMeOPhCH 2 C(Me) 2Ph(R)-
V-1433MeMeMeOPhCH 2 C(Me) 2OEtracemic
V-1434MeMeMeOPhCH 2 C(Me) 2OEt(R)-
V-1435MeEtMeOPhCH 2 C(Me) 2OEtracemic
V-1436MeEtMeOPhCH 2 C(Me) 2OEt(R)-
V-1437MeMeMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1438MeMeMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-1439MeEtMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1440MeEtMeOPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-1441MeMeMeNHPhCH 2Meracemic
V-1442MeMeMeNHPhCH 2Me(S)-
V-1443MeEtMeNHPhCH 2Meracemic
V-1444MeEtMeNHPhCH 2Me(S)-
V-1445MeMeMeNHPhCH 2Etracemic
V-1446MeMeMeNHPhCH 2Et(S)-
V-1447MeEtMeNHPhCH 2Etracemic
V-1448MeEtMeNHPhCH 2Et(S)-
TABLE 133 — (Vc)
CompoundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1449MeMeMeNHPhCH 2nPrracemic
V-1450MeMeMeNHPhCH 2nPr(S)-
V-1451MeEtMeNHPhCH 2nPrracemic
V-1452MeEtMeNHPhCH 2nPr(S)-
V-1453MeMeMeNHPhCH 2iPrracemic
V-1454MeMeMeNHPhCH 2iPr(S)-
V-1455MeEtMeNHPhCH 2iPrracemic
V-1456MeEtMeNHPhCH 2iPr(S)-
V-1457MeMeMeNHPhCH 2nBuracemic
V-1458MeMeMeNHPhCH 2nBu(S)-
V-1459MeEtMeNHPhCH 2nBuracemic
V-1460MeEtMeNHPhCH 2nBu(S)-
V-1461MeMeMeNHPhCH 2tBuracemic
V-1462MeMeMeNHPhCH 2tBu(S)-
V-1463MeEtMeNHPhCH 2tBuracemic
V-1464MeEtMeNHPhCH 2tBu(S)-
V-1465MeMeMeNHPhCH 2iBuracemic
V-1466MeMeMeNHPhCH 2iBu(S)-
V-1467MeEtMeNHPhCH 2iBuracemic
V-1468MeEtMeNHPhCH 2iBu(S)-
V-1469MeMeMeNHPhCH 2n-Heptylracemic
V-1470MeMeMeNHPhCH 2n-Heptyl(S)-
V-1471MeEtMeNHPhCH 2n-Heptylracemic
V-1472MeEtMeNHPhCH 2n-Heptyl(S)-
V-1473MeMeMeNHPhCH 2n-Undecylracemic
V-1474MeMeMeNHPhCH 2n-Undecyl(S)-
V-1475MeEtMeNHPhCH 2n-Undecylracemic
V-1476MeEtMeNHPhCH 2n-Undecyl(S)-
V-1477MeMeMeNHPhCH 2n-Pentadecylracemic
V-1478MeMeMeNHPhCH 2n-Pentadecyl(S)-
V-1479MeEtMeNHPhCH 2n-Pentadecylracemic
V-1480MeEtMeNHPhCH 2n-Pentadecyl(S)-
V-1481MeMeMeNHPhCH 2Phracemic
V-1482MeMeMeNHPhCH 2Ph(S)-
V-1483MeEtMeNHPhCH 2Phracemic
V-1484MeEtMeNHPhCH 2Ph(S)-
V-1485MeMeMeNHPhCH 2OEtracemic
V-1486MeMeMeNHPhCH 2OEt(S)-
V-1487MeEtMeNHPhCH 2OEtracemic
V-1488MeEtMeNHPhCH 2OEt(S)-
V-1489MeMeMeNHPhCH 2(CH 2 ) 2 COOHracemic
V-1490MeMeMeNHPhCH 2(CH 2 ) 2 COOH(S)-
V-1491MeEtMeNHPhCH 2(CH 2 ) 2 COOHracemic
V-1492MeEtMeNHPhCH 2(CH 2 ) 2 COOH(S)-
V-1493MeMeMeNHPhCH 2Hracemic
V-1494MeMeMeNHPhCH 2H(S)-
V-1495MeEtMeNHPhCH 2Hracemic
V-1496MeEtMeNHPhCH 2H(S)-
V-1497MeMeMeNHPhCH 2(5-Methyl-2-oxo-racemic
1,3-dioxol-4-
yl)methoxy
V-1498MeMeMeNHPhCH 2(5-Methyl-2-oxo-(S)-
1,3-dioxol-4-
yl)methoxy
TABLE 134 — (Vc) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1499MeEtMeNHPhCH 2(5-Methyl-2-oxo-racemic
1,3-dioxol-4-yl)
methoxy
V-1500MeEtMeNHPhCH 2(5-Methyl-2-oxo-(S)-
1,3-dioxol-4-yl)
methoxy
V-1501MeMeMeNHPhC(Me) 2Me(S)-
V-1502MeEtMeNHPhC(Me) 2Meracemic
V-1503MeEtMeNHPhC(Me) 2Me(S)-
V-1504MeMeMeNHPhC(Me) 2Etracemic
V-1505MeMeMeNHPhC(Me) 2Et(S)-
V-1506MeEtMeNHPhC(Me) 2Etracemic
V-1507MeEtMeNHPhC(Me) 2Et(S)-
V-1508MeMeMeNHPhC(Me) 2nPrracemic
V-1509MeMeMeNHPhC(Me) 2nPr(S)-
V-1510MeEtMeNHPhC(Me) 2nPrracemic
V-1511MeEtMeNHPhC(Me) 2nPr(S)-
V-1512MeMeMeNHPhC(Me) 2iPrracemic
V-1513MeMeMeNHPhC(Me) 2iPr(S)-
V-1514MeEtMeNHPhC(Me) 2iPrracemic
V-1515MeEtMeNHPhC(Me) 2iPr(S)-
V-1516MeMeMeNHPhC(Me) 2nBuracemic
V-1517MeMeMeNHPhC(Me) 2nBu(S)-
V-1518MeEtMeNHPhC(Me) 2nBuracemic
V-1519MeEtMeNHPhC(Me) 2nBu(S)-
V-1520MeMeMeNHPhC(Me) 2tBuracemic
V-1521MeMeMeNHPhC(Me) 2tBu(S)-
V-1522MeEtMeNHPhC(Me) 2tBuracemic
V-1523MeEtMeNHPhC(Me) 2tBu(S)-
V-1524MeMeMeNHPhC(Me) 2iBuracemic
V-1525MeMeMeNHPhC(Me) 2iBu(S)-
V-1526MeEtMeNHPhC(Me) 2iBuracemic
V-1527MeEtMeNHPhC(Me) 2iBu(S)-
V-1528MeMeMeNHPhC(Me) 2n-Heptylracemic
V-1529MeMeMeNHPhC(Me) 2n-Heptyl(S)-
V-1530MeEtMeNHPhC(Me) 2n-Heptylracemic
V-1531MeEtMeNHPhC(Me) 2n-Heptyl(S)-
V-1532MeMeMeNHPhC(Me) 2n-Undecylracemic
V-1533MeMeMeNHPhC(Me) 2n-Undecyl(S)-
V-1534MeEtMeNHPhC(Me) 2n-Undecylracemic
V-1535MeEtMeNHPhC(Me) 2n-Undecyl(S)-
V-1536MeMeMeNHPhC(Me) 2Phracemic
V-1537MeMeMeNHPhC(Me) 2Ph(S)-
V-1538MeEtMeNHPhC(Me) 2Phracemic
V-1539MeEtMeNHPhC(Me) 2Ph(S)-
V-1540MeMeMeNHPhC(Me) 2OEtracemic
V-1541MeMeMeNHPhC(Me) 2OEt(S)-
V-1542MeEtMeNHPhC(Me) 2OEtracemic
V-1543MeEtMeNHPhC(Me) 2OEt(S)-
V-1544MeMeMeNHPhC(Me) 2(CH 2 ) 2 COOHracemic
V-1545MeMeMeNHPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-1546MeEtMeNHPhC(Me) 2(CH 2 ) 2 COOHracemic
V-1547MeEtMeNHPhC(Me) 2(CH 2 ) 2 COOH(S)-
V-1548MeMeMeNHPh(CH 2 ) 2Meracemic
TABLE 135 — (Vc) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 6figuration
V-1549MeMeMeNHPh(CH 2 ) 2Me(R)-
V-1550MeEtMeNHPh(CH 2 ) 2Meracemic
V-1551MeEtMeNHPh(CH 2 ) 2Me(R)-
V-1552MeMeMeNHPh(CH 2 ) 2Etracemic
V-1553MeMeMeNHPh(CH 2 ) 2Et(R)-
V-1554MeEtMeNHPh(CH 2 ) 2Etracemic
V-1555MeEtMeNHPh(CH 2 ) 2Et(R)-
V-1556MeMeMeNHPh(CH 2 ) 2nPrracemic
V-1557MeMeMeNHPh(CH 2 ) 2nPr(R)-
V-1558MeEtMeNHPh(CH 2 ) 2nPrracemic
V-1559MeEtMeNHPh(CH 2 ) 2nPr(R)-
V-1560MeMeMeNHPh(CH 2 ) 2iPrracemic
V-1561MeMeMeNHPh(CH 2 ) 2iPr(R)-
V-1562MeEtMeNHPh(CH 2 ) 2iPrracemic
V-1563MeEtMeNHPh(CH 2 ) 2iPr(R)-
V-1564MeMeMeNHPh(CH 2 ) 2nBuracemic
V-1565MeMeMeNHPh(CH 2 ) 2nBu(R)-
V-1566MeEtMeNHPh(CH 2 ) 2nBuracemic
V-1567MeEtMeNHPh(CH 2 ) 2nBu(R)-
V-1568MeMeMeNHPh(CH 2 ) 2tBuracemic
V-1569MeMeMeNHPh(CH 2 ) 2tBu(R)-
V-1570MeEtMeNHPh(CH 2 ) 2tBuracemic
V-1571MeEtMeNHPh(CH 2 ) 2tBu(R)-
V-1572MeMeMeNHPh(CH 2 ) 2iBuracemic
V-1573MeMeMeNHPh(CH 2 ) 2iBu(R)-
V-1574MeEtMeNHPh(CH 2 ) 2iBuracemic
V-1575MeEtMeNHPh(CH 2 ) 2iBu(R)-
V-1576MeMeMeNHPh(CH 2 ) 2n-Heptylracemic
V-1577MeMeMeNHPh(CH 2 ) 2n-Heptyl(R)-
V-1578MeEtMeNHPh(CH 2 ) 2n-Heptylracemic
V-1579MeEtMeNHPh(CH 2 ) 2n-Heptyl(R)-
V-1580MeMeMeNHPh(CH 2 ) 2n-Undecylracemic
V-1581MeMeMeNHPh(CH 2 ) 2n-Undecyl(R)-
V-1582MeEtMeNHPh(CH 2 ) 2n-Undecylracemic
V-1583MeEtMeNHPh(CH 2 ) 2n-Undecyl(R)-
V-1584MeMeMeNHPh(CH 2 ) 2Phracemic
V-1585MeMeMeNHPh(CH 2 ) 2Ph(R)-
V-1586MeEtMeNHPh(CH 2 ) 2Phracemic
V-1587MeEtMeNHPh(CH 2 ) 2Ph(R)-
V-1588MeMeMeNHPh(CH 2 ) 2OEtracemic
V-1589MeMeMeNHPh(CH 2 ) 2OEt(R)-
V-1590MeEtMeNHPh(CH 2 ) 2OEtracemic
V-1591MeEtMeNHPh(CH 2 ) 2OEt(R)-
V-1592MeMeMeNHPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-1593MeMeMeNHPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-1594MeEtMeNHPh(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-1595MeEtMeNHPh(CH 2 ) 2(CH 2 ) 2 COOH(R)-
V-1596MeMeMeNHPhCH 2 C(Me) 2Meracemic
V-1597MeMeMeNHPhCH 2 C(Me) 2Me(R)-
V-1598MeEtMeNHPhCH 2 C(Me) 2Meracemic
TABLE 136 — (Vc)
Com-Con-
poundfigu-
No.R 1R 2R 3L 2R 4L 3R 6ration
V-1599MeEtMeNHPhCH 2 C(Me) 2Me(R)-
V-1600MeMeMeNHPhCH 2 C(Me) 2Etracemic
V-1601MeMeMeNHPhCH 2 C(Me) 2Et(R)-
V-1602MeEtMeNHPhCH 2 C(Me) 2Etracemic
V-1603MeEtMeNHPhCH 2 C(Me) 2Et(R)-
V-1604MeMeMeNHPhCH 2 C(Me) 2nPrracemic
V-1605MeMeMeNHPhCH 2 C(Me) 2nPr(R)-
V-1606MeEtMeNHPhCH 2 C(Me) 2nPrracemic
V-1607MeEtMeNHPhCH 2 C(Me) 2nPr(R)-
V-1608MeMeMeNHPhCH 2 C(Me) 2iPrracemic
V-1609MeMeMeNHPhCH 2 C(Me) 2iPr(R)-
V-1610MeEtMeNHPhCH 2 C(Me) 2iPrracemic
V-1611MeEtMeNHPhCH 2 C(Me) 2iPr(R)-
V-1612MeMeMeNHPhCH 2 C(Me) 2nBuracemic
V-1613MeMeMeNHPhCH 2 C(Me) 2nBu(R)-
V-1614MeEtMeNHPhCH 2 C(Me) 2nBuracemic
V-1615MeEtMeNHPhCH 2 C(Me) 2nBu(R)-
V-1616MeMeMeNHPhCH 2 C(Me) 2tBuracemic
V-1617MeMeMeNHPhCH 2 C(Me) 2tBu(R)-
V-1618MeEtMeNHPhCH 2 C(Me) 2tBuracemic
V-1619MeEtMeNHPhCH 2 C(Me) 2tBu(R)-
V-1620MeMeMeNHPhCH 2 C(Me) 2iBuracemic
V-1621MeMeMeNHPhCH 2 C(Me) 2iBu(R)-
V-1622MeEtMeNHPhCH 2 C(Me) 2iBuracemic
V-1623MeEtMeNHPhCH 2 C(Me) 2iBu(R)-
V-1624MeMeMeNHPhCH 2 C(Me) 2n-Heptylracemic
V-1625MeMeMeNHPhCH 2 C(Me) 2n-Heptyl(R)-
V-1626MeEtMeNHPhCH 2 C(Me) 2n-Heptylracemic
V-1627MeEtMeNHPhCH 2 C(Me) 2n-Heptyl(R)-
V-1628MeMeMeNHPhCH 2 C(Me) 2n-Undecylracemic
V-1629MeMeMeNHPhCH 2 C(Me) 2n-Undecyl(R)-
V-1630MeEtMeNHPhCH 2 C(Me) 2n-Undecylracemic
V-1631MeEtMeNHPhCH 2 C(Me) 2n-Undecyl(R)-
V-1632MeMeMeNHPhCH 2 C(Me) 2Phracemic
V-1633MeMeMeNHPhCH 2 C(Me) 2Ph(R)-
V-1634MeEtMeNHPhCH 2 C(Me) 2Phracemic
V-1635MeEtMeNHPhCH 2 C(Me) 2Ph(R)-
V-1636MeMeMeNHPhCH 2 C(Me) 2OEtracemic
V-1637MeMeMeNHPhCH 2 C(Me) 2OEt(R)-
V-1638MeEtMeNHPhCH 2 C(Me) 2OEtracemic
V-1639MeEtMeNHPhCH 2 C(Me) 2OEt(R)-
V-1640MeMeMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1641MeMeMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-1642MeEtMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1643MeEtMeNHPhCH 2 C(Me) 2(CH 2 ) 2 COOH(R)-
V-1644MeMeMeCH 2PhCH 2Meracemic
V-1645MeMeMeCH 2PhCH 2Me(S)-
V-1646MeEtMeCH 2PhCH 2Meracemic
V-1647MeEtMeCH 2PhCH 2Me(S)-
V-1648MeMeMeCH 2PhCH 2Etracemic
TABLE 137 — (Vc) Compound
No.R 1R 2R 3L 2R 4L 3R 6Configuration
V-1649MeMeMeCH 2PhCH 2Et(S)-
V-1650MeEtMeCH 2PhCH 2Etracemic
V-1651MeEtMeCH 2PhCH 2Et(S)-
V-1652MeMeMeCH 2PhCH 2nPrracemic
V-1653MeMeMeCH 2PhCH 2nPr(S)-
V-1654MeEtMeCH 2PhCH 2nPrracemic
V-1655MeEtMeCH 2PhCH 2nPr(S)-
V-1656MeMeMeCH 2PhCH 2iPrracemic
V-1657MeMeMeCH 2PhCH 2iPr(S)-
V-1658MeEtMeCH 2PhCH 2iPrracemic
V-1659MeEtMeCH 2PhCH 2iPr(S)-
V-1660MeMeMeCH 2PhCH 2nBuracemic
V-1661MeMeMeCH 2PhCH 2nBu(S)-
V-1662MeEtMeCH 2PhCH 2nBuracemic
V-1663MeEtMeCH 2PhCH 2nBu(S)-
V-1664MeMeMeCH 2PhCH 2tBuracemic
V-1665MeMeMeCH 2PhCH 2tBu(S)-
V-1666MeEtMeCH 2PhCH 2tBuracemic
V-1667MeEtMeCH 2PhCH 2tBu(S)-
V-1668MeMeMeCH 2PhCH 2iBuracemic
V-1669MeMeMeCH 2PhCH 2iBu(S)-
V-1670MeEtMeCH 2PhCH 2iBuracemic
V-1671MeEtMeCH 2PhCH 2iBu(S)-
V-1672MeMeMeCH 2PhCH 2n-Heptylracemic
V-1673MeMeMeCH 2PhCH 2n-Heptyl(S)-
V-1674MeEtMeCH 2PhCH 2n-Heptylracemic
V-1675MeEtMeCH 2PhCH 2n-Heptyl(S)-
V-1676MeMeMeCH 2PhCH 2n-Undecylracemic
V-1677MeMeMeCH 2PhCH 2n-Undecyl(S)-
V-1678MeEtMeCH 2PhCH 2n-Undecylracemic
V-1679MeEtMeCH 2PhCH 2n-Undecyl(S)-
V-1680MeMeMeCH 2PhCH 2Phracemic
V-1681MeMeMeCH 2PhCH 2Ph(S)-
V-1682MeEtMeCH 2PhCH 2Phracemic
V-1683MeEtMeCH 2PhCH 2Ph(S)-
V-1684MeMeMeCH 2PhCH 2OEtracemic
V-1685MeMeMeCH 2PhCH 2OEt(S)-
V-1686MeEtMeCH 2PhCH 2OEtracemic
V-1687MeEtMeCH 2PhCH 2OEt(S)-
V-1688MeMeMeCH 2PhCH 2(CH 2 ) 2 COOHracemic
V-1689MeMeMeCH 2PhCH 2(CH 2 ) 2 COOH(S)-
V-1690MeEtMeCH 2PhCH 2(CH 2 ) 2 COOHracemic
V-1691MeEtMeCH 2PhCH 2(CH 2 ) 2 COOH(S)-
V-1692MeMeMeCH 2Ph—Meracemic
V-1693MeMeMeCH 2Ph—Me(S)-
V-1694MeEtMeCH 2Ph—Meracemic
V-1695MeEtMeCH 2Ph—Me(S)-
V-1696MeMeMeCH 2Ph—Etracemic
V-1697MeMeMeCH 2Ph—Et(S)-
V-1698MeEtMeCH 2Ph—Etracemic
TABLE 138 — (Vc) Com- pound
No.R 1R 2R 3L 2R 4L 3R 6Configuration
V-1699MeEtMeCH 2Ph—Et(S)-
V-1700MeMeMeCH 2Ph—nPrracemic
V-1701MeMeMeCH 2Ph—nPr(S)-
V-1702MeEtMeCH 2Ph—nPrracemic
V-1703MeEtMeCH 2Ph—nPr(S)-
V-1704MeMeMeCH 2Ph—iPrracemic
V-1705MeMeMeCH 2Ph—iPr(S)-
V-1706MeEtMeCH 2Ph—iPrracemic
V-1707MeEtMeCH 2Ph—iPr(S)-
V-1708MeMeMeCH 2Ph—nBuracemic
V-1709MeMeMeCH 2Ph—nBu(S)-
V-1710MeEtMeCH 2Ph—nBuracemic
V-1711MeEtMeCH 2Ph—nBu(S)-
V-1712MeMeMeCH 2Ph—tBuracemic
V-1713MeMeMeCH 2Ph—tBu(S)-
V-1714MeEtMeCH 2Ph—tBuracemic
V-1715MeEtMeCH 2Ph—tBu(S)-
V-1716MeMeMeCH 2Ph—iBuracemic
V-1717MeMeMeCH 2Ph—iBu(S)-
V-1718MeEtMeCH 2Ph—iBuracemic
V-1719MeEtMeCH 2Ph—iBu(S)-
V-1720MeMeMeCH 2Ph—n-Heptylracemic
V-1721MeMeMeCH 2Ph—n-Heptyl(S)-
V-1722MeEtMeCH 2Ph—n-Heptylracemic
V-1723MeEtMeCH 2Ph—n-Heptyl(S)-
V-1724MeMeMeCH 2Ph—n-Undecylracemic
V-1725MeMeMeCH 2Ph—n-Undecyl(S)-
V-1726MeEtMeCH 2Ph—n-Undecylracemic
V-1727MeEtMeCH 2Ph—n-Undecyl(S)-
V-1728MeMeMeCH 2Ph—Phracemic
V-1729MeMeMeCH 2Ph—Ph(S)-
V-1730MeEtMeCH 2Ph—Phracemic
V-1731MeEtMeCH 2Ph—Ph(S)-
V-1732MeMeMeCH 2Ph—OEtracemic
V-1733MeMeMeCH 2Ph—OEt(S)-
V-1734MeEtMeCH 2Ph—OEtracemic
V-1735MeEtMeCH 2Ph—OEt(S)-
V-1736MeMeMeCH 2Ph—(CH 2 ) 2 COOHracemic
V-1737MeMeMeCH 2Ph—(CH 2 ) 2 COOH(S)-
V-1738MeEtMeCH 2Ph—(CH 2 ) 2 COOHracemic
V-1739MeEtMeCH 2Ph—(CH 2 ) 2 COOH(S)-
V-1740MeMeMeCH 2PhC(Me) 2Meracemic
V-1741MeMeMeCH 2PhC(Me) 2Me(S)-
V-1742MeEtMeCH 2PhC(Me) 2Meracemic
V-1743MeEtMeCH 2PhC(Me) 2Me(S)-
V-1744MeMeMeCH 2PhC(Me) 2Etracemic
V-1745MeMeMeCH 2PhC(Me) 2Et(S)-
V-1746MeEtMeCH 2PhC(Me) 2Etracemic
V-1747MeEtMeCH 2PhC(Me) 2Et(S)-
V-1748MeMeMeCH 2PhC(Me) 2nPrracemic
TABLE 139 — (Vc) Com- pound
No.R 1R 2R 3L 2R 4L 3R 6Configuration
V-1749MeMeMeCH 2PhC(Me) 2nPr(S)-
V-1750MeEtMeCH 2PhC(Me) 2nPrracemic
V-1751MeEtMeCH 2PhC(Me) 2nPr(S)-
V-1752MeMeMeCH 2PhC(Me) 2iPrracemic
V-1753MeMeMeCH 2PhC(Me) 2iPr(S)-
V-1754MeEtMeCH 2PhC(Me) 2iPrracemic
V-1755MeEtMeCH 2PhC(Me) 2iPr(S)-
V-1756MeMeMeCH 2PhC(Me) 2nBuracemic
V-1757MeMeMeCH 2PhC(Me) 2nBu(S)-
V-1758MeEtMeCH 2PhC(Me) 2nBuracemic
V-1759MeEtMeCH 2PhC(Me) 2nBu(S)-
V-1760MeMeMeCH 2PhC(Me) 2tBuracemic
V-1761MeMeMeCH 2PhC(Me) 2tBu(S)-
V-1762MeEtMeCH 2PhC(Me) 2tBuracemic
V-1763MeEtMeCH 2PhC(Me) 2tBu(S)-
V-1764MeMeMeCH 2PhC(Me) 2iBuracemic
V-1765MeMeMeCH 2PhC(Me) 2iBu(S)-
V-1766MeEtMeCH 2PhC(Me) 2iBuracemic
V-1767MeEtMeCH 2PhC(Me) 2iBu(S)-
V-1768MeMeMeCH 2PhC(Me) 2n-Heptylracemic
V-1769MeMeMeCH 2PhC(Me) 2n-Heptyl(S)-
V-1770MeEtMeCH 2PhC(Me) 2n-Heptylracemic
V-1771MeEtMeCH 2PhC(Me) 2n-Heptyl(S)-
V-1772MeMeMeCH 2PhC(Me) 2n-Undecylracemic
V-1773MeMeMeCH 2PhC(Me) 2n-Undecyl(S)-
V-1774MeEtMeCH 2PhC(Me) 2n-Undecylracemic
V-1775MeEtMeCH 2PhC(Me) 2n-Undecyl(S)-
V-1776MeMeMeCH 2PhC(Me) 2Phracemic
V-1777MeMeMeCH 2PhC(Me) 2Ph(S)-
V-1778MeEtMeCH 2PhC(Me) 2Phracemic
V-1779MeEtMeCH 2PhC(Me) 2Ph(S)-
V-1780MeMeMeCH 2PhC(Me) 2OEtracemic
V-1781MeMeMeCH 2PhC(Me) 2OEt(S)-
V-1782MeEtMeCH 2PhC(Me) 2OEtracemic
V-1783MeEtMeCH 2PhC(Me) 2OEt(S)-
V-1784MeMeMeCH 2PhC(Me) 2(CH 2 ) 2 COOHracemic
V-1785MeMeMeCH 2PhC(Me) 2(CH 2 ) 2 COOH(S)-
V-1786MeEtMeCH 2PhC(Me) 2(CH 2 ) 2 COOHracemic
V-1787MeEtMeCH 2PhC(Me) 2(CH 2 ) 2 COOH(S)-
V-1788MeMeMeCH 2Ph(CH 2 ) 2Meracemic
V-1789MeMeMeCH 2Ph(CH 2 ) 2Me(S)-
V-1790MeEtMeCH 2Ph(CH 2 ) 2Meracemic
V-1791MeEtMeCH 2Ph(CH 2 ) 2Me(S)-
V-1792MeMeMeCH 2Ph(CH 2 ) 2Etracemic
V-1793MeMeMeCH 2Ph(CH 2 ) 2Et(S)-
V-1794MeEtMeCH 2Ph(CH 2 ) 2Etracemic
V-1795MeEtMeCH 2Ph(CH 2 ) 2Et(S)-
V-1796MeMeMeCH 2Ph(CH 2 ) 2nPrracemic
V-1797MeMeMeCH 2Ph(CH 2 ) 2nPr(S)-
V-1798MeEtMeCH 2Ph(CH 2 ) 2nPrracemic
TABLE 140 — (Vc)
Com-Con-
poundfigu-
No.R 1R 2R 3L 2R 4L 3R 6ration
V-1799MeEtMeCH 2Ph(CH 2 ) 2nPr(S)-
V-1800MeMeMeCH 2Ph(CH 2 ) 2iPrracemic
V-1801MeMeMeCH 2Ph(CH 2 ) 2iPr(S)-
V-1802MeEtMeCH 2Ph(CH 2 ) 2iPrracemic
V-1803MeEtMeCH 2Ph(CH 2 ) 2iPr(S)-
V-1804MeMeMeCH 2Ph(CH 2 ) 2nBuracemic
V-1805MeMeMeCH 2Ph(CH 2 ) 2nBu(S)-
V-1806MeEtMeCH 2Ph(CH 2 ) 2nBuracemic
V-1807MeEtMeCH 2Ph(CH 2 ) 2nBu(S)-
V-1808MeMeMeCH 2Ph(CH 2 ) 2tBuracemic
V-1809MeMeMeCH 2Ph(CH 2 ) 2tBu(S)-
V-1810MeEtMeCH 2Ph(CH 2 ) 2tBuracemic
V-1811MeEtMeCH 2Ph(CH 2 ) 2tBu(S)-
V-1812MeMeMeCH 2Ph(CH 2 ) 2iBuracemic
V-1813MeMeMeCH 2Ph(CH 2 ) 2iBu(S)-
V-1814MeEtMeCH 2Ph(CH 2 ) 2iBuracemic
V-1815MeEtMeCH 2Ph(CH 2 ) 2iBu(S)-
V-1816MeMeMeCH 2Ph(CH 2 ) 2n-Heptylracemic
V-1817MeMeMeCH 2Ph(CH 2 ) 2n-Heptyl(S)-
V-1818MeEtMeCH 2Ph(CH 2 ) 2n-Heptylracemic
V-1819MeEtMeCH 2Ph(CH 2 ) 2n-Heptyl(S)-
V-1820MeMeMeCH 2Ph(CH 2 ) 2n-Undecylracemic
V-1821MeMeMeCH 2Ph(CH 2 ) 2n-Undecyl(S)-
V-1822MeEtMeCH 2Ph(CH 2 ) 2n-Undecylracemic
V-1823MeEtMeCH 2Ph(CH 2 ) 2n-Undecyl(S)-
V-1824MeMeMeCH 2Ph(CH 2 ) 2Phracemic
V-1825MeMeMeCH 2Ph(CH 2 ) 2Ph(S)-
V-1826MeEtMeCH 2Ph(CH 2 ) 2Phracemic
V-1827MeEtMeCH 2Ph(CH 2 ) 2Ph(S)-
V-1828MeMeMeCH 2Ph(CH 2 ) 2OEtracemic
V-1829MeMeMeCH 2Ph(CH 2 ) 2OEt(S)-
V-1830MeEtMeCH 2Ph(CH 2 ) 2OEtracemic
V-1831MeEtMeCH 2Ph(CH 2 ) 2OEt(S)-
V-1832MeMeMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-1833MeMeMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOH(S)-
V-1834MeEtMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOHracemic
V-1835MeEtMeCH 2Ph(CH 2 ) 2(CH 2 ) 2 COOH(S)-
V-1836MeMeMeCH 2PhCH 2 C(Me) 2Meracemic
V-1837MeMeMeCH 2PhCH 2 C(Me) 2Me(S)-
V-1838MeEtMeCH 2PhCH 2 C(Me) 2Meracemic
V-1839MeEtMeCH 2PhCH 2 C(Me) 2Me(S)-
V-1840MeMeMeCH 2PhCH 2 C(Me) 2Etracemic
V-1841MeMeMeCH 2PhCH 2 C(Me) 2Et(S)-
V-1842MeEtMeCH 2PhCH 2 C(Me) 2Etracemic
V-1843MeEtMeCH 2PhCH 2 C(Me) 2Et(S)-
V-1844MeMeMeCH 2PhCH 2 C(Me) 2nPrracemic
V-1845MeMeMeCH 2PhCH 2 C(Me) 2nPr(S)-
V-1846MeEtMeCH 2PhCH 2 C(Me) 2nPrracemic
V-1847MeEtMeCH 2PhCH 2 C(Me) 2nPr(S)-
V-1848MeMeMeCH 2PhCH 2 C(Me) 2iPrracemic
TABLE 141 — (Vc)
Com-Con-
poundfigu-
No.R 1R 2R 3L 2R 4L 3R 6ration
V-1849MeMeMeCH 2PhCH 2 C(Me) 2iPr(S)-
V-1850MeEtMeCH 2PhCH 2 C(Me) 2iPrracemic
V-1851MeEtMeCH 2PhCH 2 C(Me) 2iPr(S)-
V-1852MeMeMeCH 2PhCH 2 C(Me) 2nBuracemic
V-1853MeMeMeCH 2PhCH 2 C(Me) 2nBu(S)-
V-1854MeEtMeCH 2PhCH 2 C(Me) 2nBuracemic
V-1855MeEtMeCH 2PhCH 2 C(Me) 2nBu(S)-
V-1856MeMeMeCH 2PhCH 2 C(Me) 2tBuracemic
V-1857MeMeMeCH 2PhCH 2 C(Me) 2tBu(S)-
V-1858MeEtMeCH 2PhCH 2 C(Me) 2tBuracemic
V-1859MeEtMeCH 2PhCH 2 C(Me) 2tBu(S)-
V-1860MeMeMeCH 2PhCH 2 C(Me) 2iBuracemic
V-1861MeMeMeCH 2PhCH 2 C(Me) 2iBu(S)-
V-1862MeEtMeCH 2PhCH 2 C(Me) 2iBuracemic
V-1863MeEtMeCH 2PhCH 2 C(Me) 2iBu(S)-
V-1864MeMeMeCH 2PhCH 2 C(Me) 2n-Heptylracemic
V-1865MeMeMeCH 2PhCH 2 C(Me) 2n-Heptyl(S)-
V-1866MeEtMeCH 2PhCH 2 C(Me) 2n-Heptylracemic
V-1867MeEtMeCH 2PhCH 2 C(Me) 2n-Heptyl(S)-
V-1868MeMeMeCH 2PhCH 2 C(Me) 2n-Undecylracemic
V-1869MeMeMeCH 2PhCH 2 C(Me) 2n-Undecyl(S)-
V-1870MeEtMeCH 2PhCH 2 C(Me) 2n-Undecylracemic
V-1871MeEtMeCH 2PhCH 2 C(Me) 2n-Undecyl(S)-
V-1872MeMeMeCH 2PhCH 2 C(Me) 2Phracemic
V-1873MeMeMeCH 2PhCH 2 C(Me) 2Ph(S)-
V-1874MeEtMeCH 2PhCH 2 C(Me) 2Phracemic
V-1875MeEtMeCH 2PhCH 2 C(Me) 2Ph(S)-
V-1876MeMeMeCH 2PhCH 2 C(Me) 2OEtracemic
V-1877MeMeMeCH 2PhCH 2 C(Me) 2OEt(S)-
V-1878MeEtMeCH 2PhCH 2 C(Me) 2OEtracemic
V-1879MeEtMeCH 2PhCH 2 C(Me) 2OEt(S)-
V-1880MeMeMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1881MeMeMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOH(S)-
V-1882MeEtMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOHracemic
V-1883MeEtMeCH 2PhCH 2 C(Me) 2(CH 2 ) 2 COOH(S)-
TABLE 142 — (Vc) Com- pound
No.R 1R 2R 3L 2R 4L 3R 6Configuration
V-2060MeMeMe—Ph—Meracemic
V-2061MeMeMe—Ph—Me(R)-
V-2062MeEtMe—Ph—Meracemic
V-2063MeEtMe—Ph—Me(R)-
V-2064MeMeMe—Ph—Etracemic
V-2065MeMeMe—Ph—Et(R)-
V-2066MeEtMe—Ph—Etracemic
V-2067MeEtMe—Ph—Et(R)-
V-2068MeMeMe—Ph—nPrracemic
V-2069MeMeMe—Ph—nPr(R)-
V-2070MeEtMe—Ph—nPrracemic
V-2071MeEtMe—Ph—nPr(R)-
V-2072MeMeMe—Ph—iPrracemic
V-2073MeMeMe—Ph—iPr(R)-
V-2074MeEtMe—Ph—iPrracemic
V-2075MeEtMe—Ph—iPr(R)-
V-2076MeMeMe—Ph—nBuracemic
V-2077MeMeMe—Ph—nBu(R)-
V-2078MeEtMe—Ph—nBuracemic
V-2079MeEtMe—Ph—nBu(R)-
V-2080MeMeMe—Ph—tBuracemic
V-2081MeMeMe—Ph—tBu(R)-
V-2082MeEtMe—Ph—tBuracemic
V-2083MeEtMe—Ph—tBu(R)-
V-2084MeMeMe—Ph—iBuracemic
V-2085MeMeMe—Ph—iBu(R)-
V-2086MeEtMe—Ph—iBuracemic
V-2087MeEtMe—Ph—iBu(R)-
V-2088MeMeMe—Ph—n-Heptylracemic
V-2089MeMeMe—Ph—n-Heptyl(R)-
V-2090MeEtMe—Ph—n-Heptylracemic
V-2091MeEtMe—Ph—n-Heptyl(R)-
V-2092MeMeMe—Ph—n-Undecylracemic
V-2093MeMeMe—Ph—n-Undecyl(R)-
V-2094MeEtMe—Ph—n-Undecylracemic
V-2095MeEtMe—Ph—n-Undecyl(R)-
V-2096MeMeMe—Ph—OEtracemic
V-2097MeMeMe—Ph—OEt(R)-
V-2098MeEtMe—Ph—OEtracemic
V-2099MeEtMe—Ph—OEt(R)-
V-2100MeMeMe—Ph—(CH 2 ) 2 COONaracemic
V-2101MeMeMe—Ph—(CH 2 ) 2 COONa(R)-
V-2102MeEtMe—Ph—(CH 2 ) 2 COONaracemic
V-2103MeEtMe—Ph—(CH 2 ) 2 COONa(R)-
V-2104MeMeMe—PhCH 2Meracemic
V-2105MeMeMe—PhCH 2Me(S)-
V-2106MeEtMe—PhCH 2Meracemic
V-2107MeEtMe—PhCH 2Me(S)-
V-2108MeMeMe—PhCH 2Etracemic
V-2109MeMeMe—PhCH 2Et(S)-
TABLE 143 — (Vc) Com- pound
No.R 1R 2R 3L 2R 4L 3R 6Configuration
V-2110MeEtMe—PhCH 2Etracemic
V-2111MeEtMe—PhCH 2Et(S)-
V-2112MeMeMe—PhCH 2nPrracemic
V-2113MeMeMe—PhCH 2nPr(S)-
V-2114MeEtMe—PhCH 2nPrracemic
V-2115MeEtMe—PhCH 2nPr(S)-
V-2116MeMeMe—PhCH 2iPrracemic
V-2117MeMeMe—PhCH 2iPr(S)-
V-2118MeEtMe—PhCH 2iPrracemic
V-2119MeEtMe—PhCH 2iPr(S)-
V-2120MeMeMe—PhCH 2nBuracemic
V-2121MeMeMe—PhCH 2nBu(S)-
V-2122MeEtMe—PhCH 2nBuracemic
V-2123MeEtMe—PhCH 2nBu(S)-
V-2124MeMeMe—PhCH 2tBuracemic
V-2125MeMeMe—PhCH 2tBu(S)-
V-2126MeEtMe—PhCH 2tBuracemic
V-2127MeEtMe—PhCH 2tBu(S)-
V-2128MeMeMe—PhCH 2iBuracemic
V-2129MeMeMe—PhCH 2iBu(S)-
V-2130MeEtMe—PhCH 2iBuracemic
V-2131MeEtMe—PhCH 2iBu(S)-
V-2132MeMeMe—PhCH 2n-Heptylracemic
V-2133MeMeMe—PhCH 2n-Heptyl(S)-
V-2134MeEtMe—PhCH 2n-Heptylracemic
V-2135MeEtMe—PhCH 2n-Heptyl(S)-
V-2136MeMeMe—PhCH 2n-Undecylracemic
V-2137MeMeMe—PhCH 2n-Undecyl(S)-
V-2138MeEtMe—PhCH 2n-Undecylracemic
V-2139MeEtMe—PhCH 2n-Undecyl(S)-
V-2140MeMeMe—PhCH 2OEtracemic
V-2141MeMeMe—PhCH 2OEt(S)-
V-2142MeEtMe—PhCH 2OEtracemic
V-2143MeEtMe—PhCH 2OEt(S)-
V-2144MeMeMe—PhCH 2(CH 2 ) 2 COONaracemic
V-2145MeMeMe—PhCH 2(CH 2 ) 2 COONa(S)-
V-2146MeEtMe—PhCH 2(CH 2 ) 2 COONaracemic
V-2147MeEtMe—PhCH 2(CH 2 ) 2 COONa(S)-
TABLE 144 — (VIa) Compound
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7Configuration
VI-1MeMeMeOPhCH 2HHMeracemic
VI-2MeMeMeOPhCH 2HHMe(S)-
VI-3MeMeMeOPhCH 2MeHMeracemic
VI-4MeMeMeOPhCH 2MeHMe(S)-
VI-5MeMeMeOPhCH 2HMeMeracemic
VI-6MeMeMeOPhCH 2HMeMe(S)-
VI-7MeMeMeOPhCH 2MeMeMeracemic
VI-8MeMeMeOPhCH 2MeMeMe(S)-
VI-9MeEtMeOPhCH 2HHMeracemic
VI-10MeEtMeOPhCH 2HHMe(S)-
VI-11MeEtMeOPhCH 2MeHMeracemic
VI-12MeEtMeOPhCH 2MeHMe(S)-
VT-13MeEtMeOPhCH 2HMeMeracemic
VI-14MeEtMeOPhCH 2HMeMe(S)-
VI-15MeEtMeOPhCH 2MeMeMeracemic
VI-16MeEtMeOPhCH 2MeMeMe(S)-
VI-17MeMeMeOPhCH 2HHEtracemic
VI-18MeMeMeOPhCH 2HHEt(S)-
VI-19MeMeMeOPhCH 2MeHEtracemic
VI-20MeMeMeOPhCH 2MeHEt(S)-
VI-21MeMeMeOPhCH 2HMeEtracemic
VI-22MeMeMeOPhCH 2HMeEt(S)-
VI-23MeMeMeOPhCH 2MeMeEtracemic
VI-24MeMeMeOPhCH 2MeMeEt(S)-
VI-25MeEtMeOPhCH 2HHEtracemic
VI-26MeEtMeOPhCH 2HHEt(S)-
VI-27MeEtMeOPhCH 2MeHEtracemic
VI-28MeEtMeOPhCH 2MeHEt(S)-
VI-29MeEtMeOPhCH 2HMeEtracemic
VI-30MeEtMeOPhCH 2HMeEt(S)-
VI-31MeEtMeOPhCH 2MeMeEtracemic
VI-32MeEtMeOPhCH 2MeMeEt(S)-
VI-33MeMeMeNHPhCH 2HHMeracemic
VI-34MeMeMeNHPhCH 2HHMe(S)-
VI-35MeMeMeNHPhCH 2MeHMeracemic
VI-36MeMeMeNHPhCH 2MeHMe(S)-
VI-37MeMeMeNHPhCH 2HMeMeracemic
VI-38MeMeMeNHPhCH 2HMeMe(S)-
VI-39MeMeMeNHPhCH 2MeMeMeracemic
VI-40MeMeMeNHPhCH 2MeMeMe(S)-
VI-41MeEtMeNHPhCH 2HHMeracemic
VI-42MeEtMeNHPhCH 2HHMe(S)-
VI-43MeEtMeNHPhCH 2MeHMeracemic
VI-44MeEtMeNHPhCH 2MeHMe(S)-
VI-45MeEtMeNHPhCH 2HMeMeracemic
VI-46MeEtMeNHPhCH 2HMeMe(S)-
VI-47MeEtMeNHPhCH 2MeMeMeracemic
VI-48MeEtMeNHPhCH 2MeMeMe(S)-
VI-49MeMeMeNHPhCH 2HHEtracemic
VI-50MeMeMeNHPhCH 2HHEt(S)-
TABLE 145 — (VIa)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-51MeMeMeNHPhCH 2MeHEtracemic
VI-52MeMeMeNHPhCH 2MeHEt(S)-
VI-53MeMeMeNHPhCH 2HMeEtracemic
VI-54MeMeMeNHPhCH 2HMeEt(S)-
VI-55MeMeMeNHPhCH 2MeMeEtracemic
VI-56MeMeMeNHPhCH 2MeMeEt(S)-
VI-57MeEtMeNHPhCH 2HHEtracemic
VI-58MeEtMeNHPhCH 2HHEt(S)-
VI-59MeEtMeNHPhCH 2MeHEtracemic
VI-60MeEtMeNHPhCH 2MeHEt(S)-
VI-61MeEtMeNHPhCH 2HMeEtracemic
VI-62MeEtMeNHPhCH 2HMeEt(S)-
VI-63MeEtMeNHPhCH 2MeMeEtracemic
VI-64MeEtMeNHPhCH 2MeMeEt(S)-
VI-65MeMeMeNHPhCH 2HHC(═O)Meracemic
VI-66MeMeMeNHPhCH 2HHC(═O)Me(S)-
VI-67MeMeMeNHPhCH 2MeHC(═O)Meracemic
VI-68MeMeMeNHPhCH 2MeHC(═O)Me(S)-
VI-69MeMeMeNHPhCH 2HMeC(═O)Meracemic
VI-70MeMeMeNHPhCH 2HMeC(═O)Me(S)-
VI-71MeMeMeNHPhCH 2MeMeC(═O)Meracemic
VI-72MeMeMeNHPhCH 2MeMeC(═O)Me(S)-
VI-73MeEtMeNHPhCH 2HHC(═O)Meracemic
VI-74MeEtMeNHPhCH 2HHC(═O)Me(S)-
VI-75MeEtMeNHPhCH 2MeHC(═O)Meracemic
VI-76MeEtMeNHPhCH 2MeHC(═O)Me(S)-
VI-77MeEtMeNHPhCH 2HMeC(═O)Meracemic
VI-78MeEtMeNHPhCH 2HMeC(═O)Me(S)-
VI-79MeEtMeNHPhCH 2MeMeC(═O)Meracemic
VI-80MeEtMeNHPhCH 2MeMeC(═O)Me(S)-
VI-81MeMeMeNHPhCH 2HHC(═O)Etracemic
VI-82MeMeMeNHPhCH 2HHC(═O)Et(S)-
VI-83MeMeMeNHPhCH 2MeHC(═O)Etracemic
VI-84MeMeMeNHPhCH 2MeHC(═O)Et(S)-
VI-85MeMeMeNHPhCH 2HMeC(═O)Etracemic
VI-86MeMeMeNHPhCH 2HMeC(═O)Et(S)-
VI-87MeMeMeNHPhCH 2MeMeC(═O)Etracemic
VI-88MeMeMeNHPhCH 2MeMeC(═O)Et(S)-
VI-89MeEtMeNHPhCH 2HHC(═O)Etracemic
VI-90MeEtMeNHPhCH 2HHC(═O)Et(S)-
VI-91MeEtMeNHPhCH 2MeHC(═O)Etracemic
VI-92MeEtMeNHPhCH 2MeHC(═O)Et(S)-
VI-93MeEtMeNHPhCH 2HMeC(═O)Etracemic
VI-94MeEtMeNHPhCH 2HMeC(═O)Et(S)-
VI-95MeEtMeNHPhCH 2MeMeC(═O)Etracemic
VI-96MeEtMeNHPhCH 2MeMeC(═O)Et(S)-
VI-97MeMeMeNHPhCH 2HHC(═O)tBuracemic
VI-98MeMeMeNHPhCH 2HHC(═O)tBu(S)-
VI-99MeMeMeNHPhCH 2MeHC(═O)tBuracemic
VI-100MeMeMeNHPhCH 2MeHC(═O)tBu(S)-
TABLE 146 — (VIa)
Compound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7Configuration
VI-101MeMeMeNHPhCH 2HMeC(═O)tBuracemic
VI-102MeMeMeNHPhCH 2HMeC(═O)tBu(S)-
VI-103MeMeMeNHPhCH 2MeMeC(═O)tBuracemic
VI-104MeMeMeNHPhCH 2MeMeC(═O)tBu(S)-
VI-105MeEtMeNHPhCH 2HHC(═O)tBuracemic
VI-106MeEtMeNHPhCH 2HHC(═O)tBu(S)-
VI-107MeEtMeNHPhCH 2MeHC(═O)tBuracemic
VI-108MeEtMeNHPhCH 2MeHC(═O)tBu(S)-
VI-109MeEtMeNHPhCH 2HMeC(═O)tBuracemic
VI-110MeEtMeNHPhCH 2HMeC(═O)tBu(S)-
VI-111MeEtMeNHPhCH 2MeMeC(═O)tBuracemic
VI-112MeEtMeNHPhCH 2MeMeC(═O)tBu(S)-
VI-113MeMeMeNHPhCH 2HHC(═O)OEtracemic
VI-114MeMeMeNHPhCH 2HHC(═O)OEt(S)-
VI-115MeMeMeNHPhCH 2MeHC(═O)OEtracemic
VI-116MeMeMeNHPhCH 2MeHC(═O)OEt(S)-
VI-117MeMeMeNHPhCH 2HMeC(═O)OEtracemic
VI-118MeMeMeNHPhCH 2HMeC(═O)OEt(S)-
VI-119MeMeMeNHPhCH 2MeMeC(═O)OEtracemic
VI-120MeMeMeNHPhCH 2MeMeC(═O)OEt(S)-
VI-121MeEtMeNHPhCH 2HHC(═O)OEtracemic
VI-122MeEtMeNHPhCH 2HHC(═O)OEt(S)-
VI-123MeEtMeNHPhCH 2MeHC(═O)OEtracemic
VI-124MeEtMeNHPhCH 2MeHC(═O)OEt(S)-
VI-125MeEtMeNHPhCH 2HMeC(═O)OEtracemic
VI-126MeEtMeNHPhCH 2HMeC(═O)OEt(S)-
VI-127MeEtMeNHPhCH 2MeMeC(═O)OEtracemic
VI-128MeEtMeNHPhCH 2MeMeC(═O)OEt(S)-
VI-129MeMeMeNHPhCH 2HHC(═O)OcHexracemic
VI-130MeMeMeNHPhCH 2HHC(═O)OcHex(S)-
VI-131MeMeMeNHPhCH 2MeHC(═O)OcHexracemic
VI-132MeMeMeNHPhCH 2MeHC(═O)OcHex(S)-
VI-133MeMeMeNHPhCH 2HMeC(═O)OcHexcracemic
VI-134MeMeMeNHPhCH 2HMeC(═O)OcHex(S)-
VI-135MeMeMeNHPhCH 2MeMeC(═O)OcHexracemic
VI-136MeMeMeNHPhCH 2MeMeC(═O)OcHex(S)-
VI-137MeEtMeNHPhCH 2HHC(═O)OcHexracemic
VI-138MeEtMeNHPhCH 2HHC(═O)OcHex(S)-
VI-139MeEtMeNHPhCH 2MeHC(═O)OcHexracemic
VI-140MeEtMeNHPhCH 2MeHC(═O)OcHex(S)-
VI-141MeEtMeNHPhCH 2HMeC(═O)OcHexracemic
VI-142MeEtMeNHPhCH 2HMeC(═O)OcHex(S)-
VI-143MeEtMeNHPhCH 2MeMeC(═O)OcHexracemic
VI-144MeEtMeNHPhCH 2MeMeC(═O)OcHex(S)-
VI-145MeMeMeCH 2PhCH 2HHMeracemic
VI-146MeMeMeCH 2PhCH 2HHMe(S)-
VI-147MeMeMeCH 2PhCH 2MeHMeracemic
VI-148MeMeMeCH 2PhCH 2MeHMe(S)-
VI-149MeMeMeCH 2PhCH 2HMeMeracemic
VI-150MeMeMeCH 2PhCH 2HMeMe(S)-
TABLE 147 — (VIa)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-151MeMeMeCH2PhCH 2MeMeMeracemic
VI-152MeMeMeCH2PhCH 2MeMeMe(S)-
VI-153MeEtMeCH2PhCH 2HHMeracemic
VI-154MeEtMeCH2PhCH 2HHMe(S)-
VI-155MeEtMeCH2PhCH 2MeHMeracemic
VI-156MeEtMeCH2PhCH 2MeHMe(S)-
VI-157MeEtMeCH2PhCH 2HMeMeracemic
VI-158MeEtMeCH2PhCH 2HMeMe(S)-
VI-159MeEtMeCH2PhCH 2MeMeMeracemic
VI-160MeEtMeCH2PhCH 2MeMeMe(S)-
VI-161MeMeMeCH2PhCH 2HHEtracemic
VI-162MeMeMeCH2PhCH 2HHEt(S)-
VI-163MeMeMeCH2PhCH 2MeHEtracemic
VI-164MeMeMeCH2PhCH 2MeHEt(S)-
VI-165MeMeMeCH2PhCH 2HMeEtracemic
VI-166MeMeMeCH2PhCH 2HMeEt(S)-
VI-167MeMeMeCH2PhCH 2MeMeEtracemic
VI-168MeMeMeCH2PhCH 2MeMeEt(S)-
VI-169MeEtMeCH2PhCH 2HHEtracemic
VI-170MeEtMeCH2PhCH 2HHEt(S)-
VI-171MeEtMeCH2PhCH 2MeHEtracemic
VI-172MeEtMeCH2PhCH 2MeHEt(S)-
VI-173MeEtMeCH2PhCH 2HMeEtracemic
VI-174MeEtMeCH2PhCH 2HMeEt(S)-
VI-175MeEtMeCH2PhCH 2MeMeEtracemic
VI-176MeEtMeCH2PhCH 2MeMeEt(S)-
TABLE 148 — (VIa)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-553MeMeMeNHPh(CH 2 ) 2HHMeracemic
VI-554MeMeMeNHPh(CH 2 ) 2HHMe(R)-
VI-555MeMeMeNHPh(CH 2 ) 2MeHMeracemic
VI-556MeMeMeNHPh(CH 2 ) 2MeHMe(R)-
VI-557MeMeMeNHPh(CH 2 ) 2HMeMeracemic
VI-558MeMeMeNHPh(CH 2 ) 2HMeMe(R)-
VI-559MeMeMeNHPh(CH 2 ) 2MeMeMeracemic
VI-560MeMeMeNHPh(CH 2 ) 2MeMeMe(R)-
VI-561MeEtMeNHPh(CH 2 ) 2HHMeracemic
VI-562MeEtMeNHPh(CH 2 ) 2HHMe(R)-
VI-563MeEtMeNHPh(CH 2 ) 2MeHMeracemic
VI-564MeEtMeNHPh(CH 2 ) 2MeHMe(R)-
VI-565MeEtMeNHPh(CH 2 ) 2HMeMeracemic
VI-566MeEtMeNHPh(CH 2 ) 2HMeMe(R)-
VI-567MeEtMeNHPh(CH 2 ) 2MeMeMeracemic
VI-568MeEtMeNHPh(CH 2 ) 2MeMeMe(R)-
VI-569MeMeMeNHPh(CH 2 ) 2HHC(═O)Meracemic
VI-570MeMeMeNHPh(CH 2 ) 2HHC(═O)Me(R)-
VI-571MeMeMeNHPh(CH 2 ) 2MeHC(═O)Meracemic
VI-572MeMeMeNHPh(CH 2 ) 2MeHC(═O)Me(R)-
VI-573MeMeMeNHPh(CH 2 ) 2HMeC(═O)Meracemic
VI-574MeMeMeNHPh(CH 2 ) 2HMeC(═O)Me(R)-
VI-575MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Meracemic
VI-576MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Me(R)-
VI-577MeEtMeNHPh(CH 2 ) 2HHC(═O)Meracemic
VI-578MeEtMeNHPh(CH 2 ) 2HHC(═O)Me(R)-
VI-579MeEtMeNHPh(CH 2 ) 2MeHC(═O)Meracemic
VI-580MeEtMeNHPh(CH 2 ) 2MeHC(═O)Me(R)-
VI-581MeEtMeNHPh(CH 2 ) 2HMeC(═O)Meracemic
VI-582MeEtMeNHPh(CH 2 ) 2HMeC(═O)Me(R)-
VI-583MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Meracemic
VI-584MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Me(R)-
VI-585MeMeMeNHPh(CH 2 ) 2HHC(═O)Etracemic
VI-586MeMeMeNHPh(CH 2 ) 2HHC(═O)Et(R)-
VI-587MeMeMeNHPh(CH 2 ) 2MeHC(═O)Etracemic
VI-588MeMeMeNHPh(CH 2 ) 2MeHC(═O)Et(R)-
VI-589MeMeMeNHPh(CH 2 ) 2HMeC(═O)Etracemic
VI-590MeMeMeNHPh(CH 2 ) 2HMeC(═O)Et(R)-
VI-591MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Etracemic
VI-592MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Et(R)-
VI-593MeEtMeNHPh(CH 2 ) 2HHC(═O)Etracemic
VI-594MeEtMeNHPh(CH 2 ) 2HHC(═O)Et(R)-
VI-595MeEtMeNHPh(CH 2 ) 2MeHC(═O)Etracemic
VI-596MeEtMeNHPh(CH 2 ) 2MeHC(═O)Et(R)-
VI-597MeEtMeNHPh(CH 2 ) 2HMeC(═O)Etracemic
VI-598MeEtMeNHPh(CH 2 ) 2HMeC(═O)Et(R)-
VI-599MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Etracemic
VI-600MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Et(R)-
VI-601MeMeMe—Ph—HHMeracemic
VI-602MeMeMe—Ph—HHMe(R)-
VI-603MeMeMe—Ph—MeHMeracemic
TABLE 149 — (VIa)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-604MeMeMe—Ph—MeHMe(R)-
VI-605MeMeMe—Ph—HMeMeracemic
VI-606MeMeMe—Ph—HMeMe(R)-
VI-607MeMeMe—Ph—MeMeMeracemic
VI-608MeMeMe—Ph—MeMeMe(R)-
VI-609MeEtMe—Ph—HHMeracemic
VI-610MeEtMe—Ph—HHMe(R)-
VI-611MeEtMe—Ph—MeHMeracemic
VI-612MeEtMe—Ph—MeHMe(R)-
VI-613MeEtMe—Ph—HMeMeracemic
VI-614MeEtMe—Ph—HMeMe(R)-
VI-615MeEtMe—Ph—MeMeMeracemic
VI-616MeEtMe—Ph—MeMeMe(R)-
VI-617MeMeMe—Ph—HHC(═O)Meracemic
VI-618MeMeMe—Ph—HHC(═O)Me(R)-
VI-619MeMeMe—Ph—MeHC(═O)Meracemic
VI-620MeMeMe—Ph—MeHC(═O)Me(R)-
VI-621MeMeMe—Ph—HMeC(═O)Meracemic
VI-622MeMeMe—Ph—HMeC(═O)Me(R)-
VI-623MeMeMe—Ph—MeMeC(═O)Meracemic
VI-624MeMeMe—Ph—MeMeC(═O)Me(R)-
VI-625MeEtMe—Ph—HHC(═O)Meracemic
VI-626MeEtMe—Ph—HHC(═O)Me(R)-
VI-627MeEtMe—Ph—MeHC(═O)Meracemic
VI-628MeEtMe—Ph—MeHC(═O)Me(R)-
VI-629MeEtMe—Ph—HMeC(═O)Meracemic
VI-630MeEtMe—Ph—HMeC(═O)Me(R)-
VI-631MeEtMe—Ph—MeMeC(═O)Meracemic
VI-632MeEtMe—Ph—MeMeC(═O)Me(R)-
VI-633MeMeMe—Ph—HHC(═O)Etracemic
VI-634MeMeMe—Ph—HHC(═O)Et(R)-
VI-635MeMeMe—Ph—MeHC(═O)Etracemic
VI-636MeMeMe—Ph—MeHC(═O)Et(R)-
VI-637MeMeMe—Ph—HMeC(═O)Etracemic
VI-638MeMeMe—Ph—HMeC(═O)Et(R)-
VI-639MeMeMe—Ph—MeMeC(═O)Etracemic
VI-640MeMeMe—Ph—MeMeC(═O)Et(R)-
VI-641MeEtMe—Ph—HHC(═O)Etracemic
VI-642MeEtMe—Ph—HHC(═O)Et(R)-
VI-643MeEtMe—Ph—MeHC(═O)Etracemic
VI-644MeEtMe—Ph—MeHC(═O)Et(R)-
VI-645MeEtMe—Ph—HMeC(═O)Etracemic
VI-646MeEtMe—Ph—HMeC(═O)Et(R)-
VI-647MeEtMe—Ph—MeMeC(═O)Etracemic
VI-648MeEtMe—Ph—MeMeC(═O)Et(R)-
VI-649MeMeMe—PhCH 2HHMeracemic
VI-650MeMeMe—PhCH 2HHMe(S)-
VI-651MeMeMe—PhCH 2MeHMeracemic
VI-652MeMeMe—PhCH 2MeHMe(S)-
VI-653MeMeMe—PhCH 2HMeMeracemic
TABLE 15 — (VIa)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-654MeMeMe—PhCH 2HMeMe(S)-
VI-655MeMeMe—PhCH 2MeMeMeracemic
VI-656MeMeMe—PhCH 2MeMeMe(S)-
VI-657MeEtMe—PhCH 2HHMeracemic
VI-658MeEtMe—PhCH 2HHMe(S)-
VI-659MeEtMe—PhCH 2MeHMeracemic
VI-660MeEtMe—PhCH 2MeHMe(S)-
VI-661MeEtMe—PhCH 2HMeMeracemic
VI-662MeEtMe—PhCH 2HMeMe(S)-
VI-663MeEtMe—PhCH 2MeMeMeracemic
VI-664MeEtMe—PhCH 2MeMeMe(S)-
VI-665MeMeMe—PhCH 2HHC(═O)Meracemic
VI-666MeMeMe—PhCH 2HHC(═O)Me(S)-
VI-667MeMeMe—PhCH 2MeHC(═O)Meracemic
VI-668MeMeMe—PhCH 2MeHC(═O)Me(S)-
VI-669MeMeMe—PhCH 2HMeC(═O)Meracemic
VI-670MeMeMe—PhCH 2HMeC(═O)Me(S)-
VI-671MeMeMe—PhCH 2MeMeC(═O)Meracemic
VI-672MeMeMe—PhCH 2MeMeC(═O)Me(S)-
VI-673MeEtMe—PhCH 2HHC(═O)Meracemic
VI-674MeEtMe—PhCH 2HHC(═O)Me(S)-
VI-675MeEtMe—PhCH 2MeHC(═O)Meracemic
VI-676MeEtMe—PhCH 2MeHC(═O)Me(S)-
VI-677MeEtMe—PhCH 2HMeC(═O)Meracemic
VI-678MeEtMe—PhCH 2HMeC(═O)Me(S)-
VI-679MeEtMe—PhCH 2MeMeC(═O)Meracemic
VI-680MeEtMe—PhCH 2MeMeC(═O)Me(S)-
VI-681MeMeMe—PhCH 2HHC(═O)Etracemic
VI-682MeMeMe—PhCH 2HHC(═O)Et(S)-
VI-683MeMeMe—PhCH 2MeHC(═O)Etracemic
VI-684MeMeMe—PhCH 2MeHC(═O)Et(S)-
VI-685MeMeMe—PhCH 2HMeC(═O)Etracemic
VI-686MeMeMe—PhCH 2HMeC(═O)Et(S)-
VI-687MeMeMe—PhCH 2MeMeC(═O)Etracemic
VI-688MeMeMe—PhCH 2MeMeC(═O)Et(S)-
VI-689MeEtMe—PhCH 2HHC(═O)Etracemic
VI-690MeEtMe—PhCH 2HHC(═O)Et(S)-
VI-691MeEtMe—PhCH 2MeHC(═O)Etracemic
VI-692MeEtMe—PhCH 2MeHC(═O)Et(S)-
VI-693MeEtMe—PhCH 2HMeC(═O)Etracemic
VI-694MeEtMe—PhCH 2HMeC(═O)Et(S)-
VI-695MeEtMe—PhCH 2MeMeC(═O)Etracemic
VI-696MeEtMe—PhCH 2MeMeC(═O)Et(S)-
TABLE 151 — (VIb)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-177MeMeMeOPhCH 2HHMeracemic
VI-178MeMeMeOPhCH 2HHMe(S)-
VI-179MeMeMeOPhCH 2MeHMeracemic
VI-180MeMeMeOPhCH 2MeHMe(S)-
VI-181MeMeMeOPhCH 2HMeMeracemic
VI-182MeMeMeOPhCH 2HMeMe(S)-
VI-183MeMeMeOPhCH 2MeMeMeracemic
VI-184MeMeMeOPhCH 2MeMeMe(S)-
VI-185MeEtMeOPhCH 2HHMeracemic
VI-186MeEtMeOPhCH 2HHMe(S)-
VI-187MeEtMeOPhCH 2MeHMeracemic
VI-188MeEtMeOPhCH 2MeHMe(S)-
VI-189MeEtMeOPhCH 2HMeMeracemic
VI-190MeEtMeOPhCH 2HMeMe(S)-
VI-191MeEtMeOPhCH 2MeMeMeracemic
VI-192MeEtMeOPhCH 2MeMeMe(S)-
VI-193MeMeMeOPhCH 2HHEtracemic
VI-194MeMeMeOPhCH 2HHEt(S)-
VI-195MeMeMeOPhCH 2MeHEtracemic
VI-196MeMeMeOPhCH 2MeHEt(S)-
VI-197MeMeMeOPhCH 2HMeEtracemic
VI-198MeMeMeOPhCH 2HMeEt(S)-
VI-199MeMeMeOPhCH 2MeMeEtracemic
VI-200MeMeMeOPhCH 2MeMeEt(S)-
VI-201MeEtMeOPhCH 2HHEtracemic
VI-202MeEtMeOPhCH 2HHEt(S)-
VI-203MeEtMeOPhCH 2MeHEtracemic
VI-204MeEtMeOPhCH 2MeHEt(S)-
VI-205MeEtMeOPhCH 2HMeEtracemic
VI-206MeEtMeOPhCH 2HMeEt(S)-
VI-207MeEtMeOPhCH 2MeMeEtracemic
VI-208MeEtMeOPhCH 2MeMeEt(S)-
VI-209MeMeMeNHPhCH 2HHMeracemic
VI-210MeMeMeNHPhCH 2HHMe(S)-
VI-211MeMeMeNHPhCH 2MeHMeracemic
VI-212MeMeMeNHPhCH 2MeHMe(S)-
VI-213MeMeMeNHPhCH 2HMeMeracemic
VI-214MeMeMeNHPhCH 2HMeMe(S)-
VI-215MeMeMeNHPhCH 2MeMeMeracemic
VI-216MeMeMeNHPhCH 2MeMeMe(S)-
VI-217MeEtMeNHPhCH 2HHMeracemic
VI-218MeEtMeNHPhCH 2HHMe(S)-
VI-219MeEtMeNHPhCH 2MeHMeracemic
VI-220MeEtMeNHPhCH 2MeHMe(S)-
VI-221MeEtMeNHPhCH 2HMeMeracemic
VI-222MeEtMeNHPhCH 2HMeMe(S)-
VI-223MeEtMeNHPhCH 2MeMeMeracemic
VI-224MeEtMeNHPhCH 2MeMeMe(S)-
VI-225MeMeMeNHPhCH 2HHEtracemic
VI-226MeMeMeNHPhCH 2HHEt(S)-
TABLE 152 — (VIb)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-227MeMeMeNHPhCH 2MeHEtracemic
VI-228MeMeMeNHPhCH 2MeHEt(S)-
VI-229MeMeMeNHPhCH 2HMeEtracemic
VI-230MeMeMeNHPhCH 2HMeEt(S)-
VI-231MeMeMeNHPhCH 2MeMeEtracemic
VI-232MeMeMeNHPhCH 2MeMeEt(S)-
VI-233MeEtMeNHPhCH 2HHEtracemic
VI-234MeEtMeNHPhCH 2HHEt(S)-
VI-235MeEtMeNHPhCH 2MeHEtracemic
VI-236MeEtMeNHPhCH 2MeHEt(S)-
VI-237MeEtMeNHPhCH 2HMeEtracemic
VI-238MeEtMeNHPhCH 2HMeEt(S)-
VI-239MeEtMeNHPhCH 2MeMeEtracemic
VI-240MeEtMeNHPhCH 2MeMeEt(S)-
VI-241MeMeMeNHPhCH 2HHC(═O)Meracemic
VI-242MeMeMeNHPhCH 2HHC(═O)Me(S)-
VI-243MeMeMeNHPhCH 2MeHC(═O)Meracemic
VI-244MeMeMeNHPhCH 2MeHC(═O)Me(S)-
VI-245MeMeMeNHPhCH 2HMeC(═O)Meracemic
VI-246MeMeMeNHPhCH 2HMeC(═O)Me(S)-
VI-247MeMeMeNHPhCH 2MeMeC(═O)Meracemic
VI-248MeMeMeNHPhCH 2MeMeC(═O)Me(S)-
VI-249MeEtMeNHPhCH 2HHC(═O)Meracemic
VI-250MeEtMeNHPhCH 2HHC(═O)Me(S)-
VI-251MeEtMeNHPhCH 2MeHC(═O)Meracemic
VI-252MeEtMeNHPhCH 2MeHC(═O)Me(S)-
VI-253MeEtMeNHPhCH 2HMeC(═O)Meracemic
VI-254MeEtMeNHPhCH 2HMeC(═O)Me(S)-
VI-255MeEtMeNHPhCH 2MeMeC(═O)Meracemic
VI-256MeEtMeNHPhCH 2MeMeC(═O)Me(S)-
VI-257MeMeMeNHPhCH 2HHC(═O)Etracemic
VI-258MeMeMeNHPhCH 2HHC(═O)Et(S)-
VI-259MeMeMeNHPhCH 2MeHC(═O)Etracemic
VI-260MeMeMeNHPhCH 2MeHC(═O)Et(S)-
VI-261MeMeMeNHPhCH 2HMeC(═O)Etracemic
VI-262MeMeMeNHPhCH 2HMeC(═O)Et(S)-
VI-263MeMeMeNHPhCH 2MeMeC(═O)Etracemic
VI-264MeMeMeNHPhCH 2MeMeC(═O)Et(S)-
VI-265MeEtMeNHPhCH 2HHC(═O)Etracemic
VI-266MeEtMeNHPhCH 2HHC(═O)Et(S)-
VI-267MeEtMeNHPhCH 2MeHC(═O)Etracemic
VI-268MeEtMeNHPhCH 2MeHC(═O)Et(S)-
VI-269MeEtMeNHPhCH 2HMeC(═O)Etracemic
VI-270MeEtMeNHPhCH 2HMeC(═O)Et(S)-
VI-271MeEtMeNHPhCH 2MeMeC(═O)Etracemic
VI-272MeEtMeNHPhCH 2MeMeC(═O)Et(S)-
VI-273MeMeMeNHPhCH 2HHC(═O)tBuracemic
VI-274MeMeMeNHPhCH 2HHC(═O)tBu(S)-
VI-275MeMeMeNHPhCH 2MeHC(═O)tBuracemic
VI-276MeMeMeNHPhCH 2MeHC(═O)tBu(S)-
TABLE 153 — (VIb)
Compound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7Configuration
VI-277MeMeMeNHPhCH 2HMeC(═O)tBuracemic
VI-278MeMeMeNHPhCH 2HMeC(═O)tBu(S)-
VI-279MeMeMeNHPhCH 2MeMeC(═O)tBuracemic
VI-280MeMeMeNHPhCH 2MeMeC(═O)tBu(S)-
VI-281MeEtMeNHPhCH 2HHC(═O)tBuracemic
VI-282MeEtMeNHPhCH 2HHC(═O)tBu(S)-
VI-283MeEtMeNHPhCH 2MeHC(═O)tBuracemic
VI-284MeEtMeNHPhCH 2MeHC(═O)tBu(S)-
VI-285MeEtMeNHPhCH 2HMeC(═O)tBuracemic
VI-286MeEtMeNHPhCH 2HMeC(═O)tBu(S)-
VI-287MeEtMeNHPhCH 2MeMeC(═O)tBuracemic
VI-288MeEtMeNHPhCH 2MeMeC(═O)tBu(S)-
VI-289MeMeMeNHPhCH 2HHC(═O)OEtracemic
VI-290MeMeMeNHPhCH 2HHC(═O)OEt(S)-
VI-291MeMeMeNHPhCH 2MeHC(═O)OEtracemic
VI-292MeMeMeNHPhCH 2MeHC(═O)OEt(S)-
VI-293MeMeMeNHPhCH 2HMeC(═O)OEtracemic
VI-294MeMeMeNHPhCH 2HMeC(═O)OEt(S)-
VI-295MeMeMeNHPhCH 2MeMeC(═O)OEtracemic
VI-296MeMeMeNHPhCH 2MeMeC(═O)OEt(S)-
VI-297MeEtMeNHPhCH 2HHC(═O)OEtracemic
VI-298MeEtMeNHPhCH 2HHC(═O)OEt(S)-
VI-299MeEtMeNHPhCH 2MeHC(═O)OEtracemic
VI-300MeEtMeNHPhCH 2MeHC(═O)OEt(S)-
VI-301MeEtMeNHPhCH 2HMeC(═O)OEtracemic
VI-302MeEtMeNHPhCH 2HMeC(═O)OEt(S)-
VI-303MeEtMeNHPhCH 2MeMeC(═O)OEtracemic
VI-304MeEtMeNHPhCH 2MeMeC(═O)OEt(S)-
VI-305MeMeMeNHPhCH 2HHC(═O)OcHexracemic
VI-306MeMeMeNHPhCH 2HHC(═O)OcHex(S)-
VI-307MeMeMeNHPhCH 2MeHC(═O)OcHexHracemic
VI-308MeMeMeNHPhCH 2MeHC(═O)OcHex(S)-
VI-309MeMeMeNHPhCH 2HMeC(═O)OcHexracemic
VI-310MeMeMeNHPhCH 2HMeC(═O)OcHex(S)-
VI-311MeMeMeNHPhCH 2MeMeC(═O)OcHexracemic
VI-312MeMeMeNHPhCH 2MeMeC(═O)OcHex(S)-
VI-313MeEtMeNHPhCH 2HHC(═O)OcHexracemic
VI-314MeEtMeNHPhCH 2HHC(═O)OcHex(S)-
VI-315MeEtMeNHPhCH 2MeHC(═O)OcHexracemic
VI-316MeEtMeNHPhCH 2MeHC(═O)OcHex(S)-
VI-317MeEtMeNHPhCH 2HMeC(═O)OcHexracemic
VI-318MeEtMeNHPhCH 2HMeC(═O)OcHex(S)-
VI-319MeEtMeNHPhCH 2MeMeC(═O)OcHexracemic
VI-320MeEtMeNHPhCH 2MeMeC(═O)OcHex(S)-
VI-321MeMeMeCH 2PhCH 2HHMeracemic
VI-322MeMeMeCH 2PhCH 2HHMe(S)-
VI-323MeMeMeCH 2PhCH 2MeHMeracemic
VI-324MeMeMeCH 2PhCH 2MeHMe(S)-
VI-325MeMeMeCH 2PhCH 2HMeMeracemic
VI-326MeMeMeCH 2PhCH 2HMeMe(S)-
TABLE 154 — (VIb)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-327MeMeMeCH 2PhCH 2MeMeMeracemic
VI-328MeMeMeCH 2PhCH 2MeMeMe(S)-
VI-329MeEtMeCH 2PhCH 2HHMeracemic
VI-330MeEtMeCH 2PhCH 2HHMe(S)-
VI-331MeEtMeCH 2PhCH 2MeHMeracemic
VI-332MeEtMeCH 2PhCH 2MeHMe(S)-
VI-333MeEtMeCH 2PhCH 2HMeMeracemic
VI-334MeEtMeCH 2PhCH 2HMeMe(S)-
VI-335MeEtMeCH 2PhCH 2MeMeMeracemic
VI-336MeEtMeCH 2PhCH 2MeMeMe(S)-
VI-337MeMeMeCH 2PhCH 2HHEtracemic
VI-338MeMeMeCH 2PhCH 2HHEt(S)-
VI-339MeMeMeCH 2PhCH 2MeHEtracemic
VI-340MeMeMeCH 2PhCH 2MeHEt(S)-
VI-341MeMeMeCH 2PhCH 2HMeEtracemic
VI-342MeMeMeCH 2PhCH 2HMeEt(S)-
VI-343MeMeMeCH 2PhCH 2MeMeEtracemic
VI-344MeMeMeCH 2PhCH 2MeMeEt(S)-
VI-345MeEtMeCH 2PhCH 2HHEtracemic
VI-346MeEtMeCH 2PhCH 2HHEt(S)-
VI-347MeEtMeCH 2PhCH 2MeHEtracemic
VI-348MeEtMeCH 2PhCH 2MeHEt(S)-
VI-349MeEtMeCH 2PhCH 2HMeEtracemic
VI-350MeEtMeCH 2PhCH 2HMeEt(S)-
VI-351MeEtMeCH 2PhCH 2MeMeEtracemic
VI-352MeEtMeCH 2PhCH 2MeMeEt(S)-
TABLE 155 — (VIb)
Com-Config-
pound No.R 1R 2R 3L 2R 4L 3R 8R 9R 7uration
VI-697MeMeMeNHPh(CH 2 ) 2HHMeracemic
VI-698MeMeMeNHPh(CH 2 ) 2HHMe(R)-
VI-699MeMeMeNHPh(CH 2 ) 2MeHMeracemic
VI-700MeMeMeNHPh(CH 2 ) 2MeHMe(R)-
VI-701MeMeMeNHPh(CH 2 ) 2HMeMeracemic
VI-702MeMeMeNHPh(CH 2 ) 2HMeMe(R)-
VI-703MeMeMeNHPh(CH 2 ) 2MeMeMeracemic
VI-704MeMeMeNHPh(CH 2 ) 2MeMeMe(R)-
VI-705MeEtMeNHPh(CH 2 ) 2HHMeracemic
VI-706MeEtMeNHPh(CH 2 ) 2HHMe(R)-
VI-707MeEtMeNHPh(CH 2 ) 2MeHMeracemic
VI-708MeEtMeNHPh(CH 2 ) 2MeHMe(R)-
VI-709MeEtMeNHPh(CH 2 ) 2HMeMeracemic
VI-710MeEtMeNHPh(CH 2 ) 2HMeMe(R)-
VI-711MeEtMeNHPh(CH 2 ) 2MeMeMeracemic
VI-712MeEtMeNHPh(CH 2 ) 2MeMeMe(R)-
VI-713MeMeMeNHPh(CH 2 ) 2HHC(═O)Meracemic
VI-714MeMeMeNHPh(CH 2 ) 2HHC(═O)Me(R)-
VI-715MeMeMeNHPh(CH 2 ) 2MeHC(═O)Meracemic
VI-716MeMeMeNHPh(CH 2 ) 2MeHC(═O)Me(R)-
VI-717MeMeMeNHPh(CH 2 ) 2HMeC(═O)Meracemic
VI-718MeMeMeNHPh(CH 2 ) 2HMeC(═O)Me(R)-
VI-719MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Meracemic
VI-720MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Me(R)-
VI-721MeEtMeNHPh(CH 2 ) 2HHC(═O)Meracemic
VI-722MeEtMeNHPh(CH 2 ) 2HHC(═O)Me(R)-
VI-723MeEtMeNHPh(CH 2 ) 2MeHC(═O)Meracemic
VI-724MeEtMeNHPh(CH 2 ) 2MeHC(═O)Me(R)-
VI-725MeEtMeNHPh(CH 2 ) 2HMeC(═O)Meracemic
VI-726MeEtMeNHPh(CH 2 ) 2HMeC(═O)Me(R)-
VI-727MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Meracemic
VI-728MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Me(R)-
VI-729MeMeMeNHPh(CH 2 ) 2HHC(═O)Etracemic
VI-730MeMeMeNHPh(CH 2 ) 2HHC(═O)Et(R)-
VI-731MeMeMeNHPh(CH 2 ) 2MeHC(═O)Etracemic
VI-732MeMeMeNHPh(CH 2 ) 2MeHC(═O)Et(R)-
VI-733MeMeMeNHPh(CH 2 ) 2HMeC(═O)Etracemic
VI-734MeMeMeNHPh(CH 2 ) 2HMeC(═O)Et(R)-
VI-735MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Etracemic
VI-736MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Et(R)-
VI-737MeEtMeNHPh(CH 2 ) 2HHC(═O)Etracemic
VI-738MeEtMeNHPh(CH 2 ) 2HHC(═O)Et(R)-
VI-739MeEtMeNHPh(CH 2 ) 2MeHC(═O)Etracemic
VI-740MeEtMeNHPh(CH 2 ) 2MeHC(═O)Et(R)-
VI-741MeEtMeNHPh(CH 2 ) 2HMeC(═O)Etracemic
VI-742MeEtMeNHPh(CH 2 ) 2HMeC(═O)Et(R)-
VI-743MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Etracemic
VI-744MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Et(R)-
VI-745MeMeMe—Ph—HHMeracemic
VI-746MeMeMe—Ph—HHMe(R)-
TABLE 156 — (VIb) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7figuration
VI-747MeMeMe—Ph—MeHMeracemic
VI-748MeMeMe—Ph—MeHMe(R)-
VI-749MeMeMe—Ph—HMeMeracemic
VI-750MeMeMe—Ph—HMeMe(R)-
VI-751MeMeMe—Ph—MeMeMeracemic
VI-752MeMeMe—Ph—MeMeMe(R)-
VI-753MeEtMe—Ph—HHMeracemic
VI-754MeEtMe—Ph—HHMe(R)-
VI-755MeEtMe—Ph—MeHMeracemic
VI-756MeEtMe—Ph—MeHMe(R)-
VI-757MeEtMe—Ph—HMeMeracemic
VI-758MeEtMe—Ph—HMeMe(R)-
VI-759MeEtMe—Ph—MeMeMeracemic
VI-760MeEtMe—Ph—MeMeMe(R)-
VI-761MeMeMe—Ph—HHC(═O)Meracemic
VI-762MeMeMe—Ph—HHC(═O)Me(R)-
VI-763MeMeMe—Ph—MeHC(═O)Meracemic
VI-764MeMeMe—Ph—MeHC(═O)Me(R)-
VI-765MeMeMe—Ph—HMeC(═O)Meracemic
VI-766MeMeMe—Ph—HMeC(═O)Me(R)-
VI-767MeMeMe—Ph—MeMeC(═O)Meracemic
VI-768MeMeMe—Ph—MeMeC(═O)Me(R)-
VI-769MeEtMe—Ph—HHC(═O)Meracemic
VI-770MeEtMe—Ph—HHC(═O)Me(R)-
VI-771MeEtMe—Ph—MeHC(═O)Meracemic
VI-772MeEtMe—Ph—MeHC(═O)Me(R)-
VI-773MeEtMe—Ph—HMeC(═O)Meracemic
VI-774MeEtMe—Ph—HMeC(═O)Me(R)-
VI-775MeEtMe—Ph—MeMeC(═O)Meracemic
VI-776MeEtMe—Ph—MeMeC(═O)Me(R)-
VI-777MeMeMe—Ph—HHC(═O)Etracemic
VI-778MeMeMe—Ph—HHC(═O)Et(R)-
VI-779MeMeMe—Ph—MeHC(═O)Etracemic
VI-780MeMeMe—Ph—MeHC(═O)Et(R)-
VI-781MeMeMe—Ph—HMeC(═O)Etracemic
VI-782MeMeMe—Ph—HMeC(═O)Et(R)-
VI-783MeMeMe—Ph—MeMeC(═O)Etracemic
VI-784MeMeMe—Ph—MeMeC(═O)Et(R)-
VI-785MeEtMe—Ph—HHC(═O)Etracemic
VI-786MeEtMe—Ph—HHC(═O)Et(R)-
VI-787MeEtMe—Ph—MeHC(═O)Etracemic
VI-788MeEtMe—Ph—MeHC(═O)Et(R)-
VI-789MeEtMe—Ph—HMeC(═O)Etracemic
VI-790MeEtMe—Ph—HMeC(═O)Et(R)-
VI-791MeEtMe—Ph—MeMeC(═O)Etracemic
VI-792MeEtMe—Ph—MeMeC(═O)Et(R)-
VI-793MeMeMe—PhCH 2HHMeracemic
VI-794MeMeMe—PhCH 2HHMe(S)-
VI-795MeMeMe—PhCH 2MeHMeracemic
VI-796MeMeMe—PhCH 2MeHMe(S)-
TABLE 157 — (VIb) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7figuration
VI-797MeMeMe—PhCH 2HMeMeracemic
VI-798MeMeMe—PhCH 2HMeMe(S)-
VI-799MeMeMe—PhCH 2MeMeMeracemic
VI-800MeMeMe—PhCH 2MeMeMe(S)-
VI-801MeEtMe—PhCH 2HHMeracemic
VI-802MeEtMe—PhCH 2HHMe(S)-
VI-803MeEtMe—PhCH 2MeHMeracemic
VI-804MeEtMe—PhCH 2MeHMe(S)-
VI-805MeEtMe—PhCH 2HMeMeracemic
VI-806MeEtMe—PhCH 2HMeMe(S)-
VI-807MeEtMe—PhCH 2MeMeMeracemic
VI-808MeEtMe—PhCH 2MeMeMe(S)-
VI-809MeMeMe—PhCH 2HHC(═O)Meracemic
VI-810MeMeMe—PhCH 2HHC(═O)Me(S)-
VI-811MeMeMe—PhCH 2MeHC(═O)Meracemic
VI-812MeMeMe—PhCH 2MeHC(═O)Me(S)-
VI-813MeMeMe—PhCH 2HMeC(═O)Meracemic
VI-814MeMeMe—PhCH 2HMeC(═O)Me(S)-
VI-815MeMeMe—PhCH 2MeMeC(═O)Meracemic
VI-816MeMeMe—PhCH 2MeMeC(═O)Me(S)-
VI-817MeEtMe—PhCH 2HHC(═O)Meracemic
VI-818MeEtMe—PhCH 2HHC(═O)Me(S)-
VI-819MeEtMe—PhCH 2MeHC(═O)Meracemic
VI-820MeEtMe—PhCH 2MeHC(═O)Me(S)-
VI-821MeEtMe—PhCH 2HMeC(═O)Meracemic
VI-822MeEtMe—PhCH 2HMeC(═O)Me(S)-
VI-823MeEtMe—PhCH 2MeMeC(═O)Meracemic
VI-824MeEtMe—PhCH 2MeMeC(═O)Me(S)-
VI-825MeMeMe—PhCH 2HHC(═O)Etracemic
VI-826MeMeMe—PhCH 2HHC(═O)Et(S)-
VI-827MeMeMe—PhCH 2MeHC(═O)Etracemic
VI-828MeMeMe—PhCH 2MeHC(═O)Et(S)-
VI-829MeMeMe—PhCH 2HMeC(═O)Etracemic
VI-830MeMeMe—PhCH 2HMeC(═O)Et(S)-
VI-831MeMeMe—PhCH 2MeMeC(═O)Etracemic
VI-832MeMeMe—PhCH 2MeMeC(═O)Et(S)-
VI-833MeEtMe—PhCH 2HHC(═O)Etracemic
VI-834MeEtMe—PhCH 2HHC(═O)Et(S)-
VI-835MeEtMe—PhCH 2MeHC(═O)Etracemic
VI-836MeEtMe—PhCH 2MeHC(═O)Et(S)-
VI-837MeEtMe—PhCH 2HMeC(═O)Etracemic
VI-838MeEtMe—PhCH 2HMeC(═O)Et(S)-
VI-839MeEtMe—PhCH 2MeMeC(═O)Etracemic
VI-840MeEtMe—PhCH 2MeMeC(═O)Et(S)-
TABLE 158 — (VIc) Compound
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7Configuration
VI-353MeMeMeOPhCH 2HHMeracemic
VI-354MeMeMeOPhCH 2HHMe(S)-
VI-355MeMeMeOPhCH 2MeHMeracemic
VI-356MeMeMeOPhCH 2MeHMe(S)-
VI-357MeMeMeOPhCH 2HMeMeracemic
VI-358MeMeMeOPhCH 2HMeMe(S)-
VI-359MeMeMeOPhCH 2MeMeMeracemic
VI-360MeMeMeOPhCH 2MeMeMe(S)-
VI-361MeEtMeOPhCH 2HHMeracemic
VI-362MeEtMeOPhCH 2HHMe(S)-
VI-363MeEtMeOPhCH 2MeHMeracemic
VI-364MeEtMeOPhCH 2MeHMe(S)-
VI-365MeEtMeOPhCH 2HMeMeracemic
VI-366MeEtMeOPhCH 2HMeMe(S)-
VI-367MeEtMeOPhCH 2MeMeMeracemic
VI-368MeEtMeOPhCH 2MeMeMe(S)-
VI-369MeMeMeOPhCH 2HHEtracemic
VI-370MeMeMeOPhCH 2HHEt(S)-
VI-371MeMeMeOPhCH 2MeHEtracemic
VI-372MeMeMeOPhCH 2MeHEt(S)-
VI-373MeMeMeOPhCH 2HMeEtracemic
VI-374MeMeMeOPhCH 2HMeEt(S)-
VI-375MeMeMeOPhCH 2MeMeEtracemic
VI-376MeMeMeOPhCH 2MeMeEt(S)-
VI-377MeEtMeOPhCH 2HHEtracemic
VI-378MeEtMeOPhCH 2HHEt(S)-
VI-379MeEtMeOPhCH 2MeHEtracemic
VI-380MeEtMeOPhCH 2MeHEt(S)-
VI-381MeEtMeOPhCH 2HMeEtracemic
VI-382MeEtMeOPhCH 2HMeEt(S)-
VI-383MeEtMeOPhCH 2MeMeEtracemic
VI-384MeEtMeOPhCH 2MeMeEt(S)-
VI-385MeMeMeNHPhCH 2HHMeracemic
VI-386MeMeMeNHPhCH 2HHMe(S)-
VI-387MeMeMeNHPhCH 2MeHMeracemic
VI-388MeMeMeNHPhCH 2MeHMe(S)-
VI-389MeMeMeNHPhCH 2HMeMeracemic
VI-390MeMeMeNHPhCH 2HMeMe(S)-
VI-391MeMeMeNHPhCH 2MeMeMeracemic
VI-392MeMeMeNHPhCH 2MeMeMe(S)-
VI-393MeEtMeNHPhCH 2HHMeracemic
VI-394MeEtMeNHPhCH 2HHMe(S)-
VI-395MeEtMeNHPhCH 2MeHMeracemic
VI-396MeEtMeNHPhCH 2MeHMe(S)-
VI-397MeEtMeNHPhCH 2HMeMeracemic
VI-398MeEtMeNHPhCH 2HMeMe(S)-
VI-399MeEtMeNHPhCH 2MeMeMeracemic
VI-400MeEtMeNHPhCH 2MeMeMe(S)-
VI-401MeMeMeNHPhCH 2HHEtracemic
VI-402MeMeMeNHPhCH 2HHEt(S)-
TABLE 159 — (VIc)
Com-Con-
poundfigu-
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7ration
VI-403MeMeMeNHPhCH 2MeHEtracemic
VI-404MeMeMeNHPhCH 2MeHEt(S)-
VI-405MeMeMeNHPhCH 2HMeEtracemic
VI-406MeMeMeNHPhCH 2HMeEt(S)-
VI-407MeMeMeNHPhCH 2MeMeEtracemic
VI-408MeMeMeNHPhCH 2MeMeEt(S)-
VI-409MeEtMeNHPhCH 2HHEtracemic
VI-410MeEtMeNHPhCH 2HHEt(S)-
VI-411MeEtMeNHPhCH 2MeHEtracemic
VI-412MeEtMeNHPhCH 2MeHEt(S)-
VI-413MeEtMeNHPhCH 2HMeEtracemic
VI-414MeEtMeNHPhCH 2HMeEt(S)-
VI-415MeEtMeNHPhCH 2MeMeEtracemic
VI-416MeEtMeNHPhCH 2MeMeEt(S)-
VI-417MeMeMeNHPhCH 2HH(5-Methyl-2-racemic
oxo-1,3-
dioxol-4-yl)
methyl
VI-418MeMeMeNHPhCH 2HH(5-Methyl-2-(S)-
oxo-1,3-
dioxol-4-yl)
methyl
VI-419MeMeMeNHPhCH 2MeH(5-Methyl-2-racemic
oxo-1,3-
dioxol-4-yl)
methyl
VI-420MeMeMeNHPhCH 2MeH(5-Methyl-2-(S)-
oxo-1,3-
dioxol-4-yl)
methyl
VI-421MeMeMeNHPhCH 2HMe(5-Methyl-2-racemic
oxo-1,3-
dioxol-4-yl)
methyl
VI-422MeMeMeNHPhCH 2HMe(5-Methyl-2-(S)-
oxo-1,3-
dioxol-4-yl)
methyl
VI-423MeMeMeNHPhCH 2MeMe(5-Methyl-2-racemic
oxo-1,3-
dioxol-4-yl)
methyl
VI-424MeMeMeNHPhCH 2MeMe(5-Methyl-2-(S)-
oxo-1,3-
dioxol-4-yl)
methyl
VI-425MeMeMeNHPhCH 2HHC(═O)Hracemic
VI-426MeMeMeNHPhCH 2HHC(═O)H(S)-
VI-427MeMeMeNHPhCH 2MeHC(═O)Hracemic
VI-428MeMeMeNHPhCH 2MeHC(═O)H(S)-
VI-429MeMeMeNHPhCH 2HMeC(═O)Hracemic
VI-430MeMeMeNHPhCH 2HMeC(═O)H(S)-
VI-431MeMeMeNHPhCH 2MeMeC(═O)Hracemic
VI-432MeMeMeNHPhCH 2MeMeC(═O)H(S)-
VI-433MeEtMeNHPhCH 2HHC(═O)Hracemic
VI-434MeEtMeNHPhCH 2HHC(═O)H(S)-
VI-435MeEtMeNHPhCH 2MeHC(═O)Hracemic
VI-436MeEtMeNHPhCH 2MeHC(═O)H(S)-
VI-437MeEtMeNHPhCH 2HMeC(═O)Hracemic
VI-438MeEtMeNHPhCH 2HMeC(═O)H(S)-
VI-439MeEtMeNHPhCH 2MeMeC(═O)Hracemic
VI-440MeEtMeNHPhCH 2MeMeC(═O)H(S)-
VI-441MeMeMeNHPhCH 2HHC(═O)Meracemic
VI-442MeMeMeNHPhCH 2HHC(═O)Me(S)-
VI-443MeMeMeNHPhCH 2MeHC(═O)Meracemic
VI-444MeMeMeNHPhCH 2MeHC(═O)Me(S)-
VI-445MeMeMeNHPhCH 2HMeC(═O)Meracemic
VI-446MeMeMeNHPhCH 2HMeC(═O)Me(S)-
VI-447MeMeMeNHPhCH 2MeMeC(═O)Meracemic
VI-448MeMeMeNHPhCH 2MeMeC(═O)Me(S)-
VI-449MeEtMeNHPhCH 2HHC(═O)Meracemic
VI-450MeEtMeNHPhCH 2HHC(═O)Me(S)-
VI-451MeEtMeNHPhCH 2MeHC(═O)Meracemic
VI-452MeEtMeNHPhCH 2MeHC(═O)Me(S)-
TABLE 160 — (VIc) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7figuration
VI-453MeEtMeNHPhCH 2HMeC(═O)Meracemic
VI-454MeEtMeNHPhCH 2HMeC(═O)Me(S)-
VI-455MeEtMeNHPhCH 2MeMeC(═O)Meracemic
VI-456MeEtMeNHPhCH 2MeMeC(═O)Me(S)-
VI-457MeMeMeNHPhCH 2HHC(═O)Etracemic
VI-458MeMeMeNHPhCH 2HHC(═O)Et(S)-
VI-459MeMeMeNHPhCH 2MeHC(═O)Etracemic
VI-460MeMeMeNHPhCH 2MeHC(═O)Et(S)-
VI-461MeMeMeNHPhCH 2HMeC(═O)Etracemic
VI-462MeMeMeNHPhCH 2HMeC(═O)Et(S)-
VI-463MeMeMeNHPhCH 2MeMeC(═O)Etracemic
VI-464MeMeMeNHPhCH 2MeMeC(═O)Et(S)-
VI-465MeEtMeNHPhCH 2HHC(═O)Etracemic
VI-466MeEtMeNHPhCH 2HHC(═O)Et(S)-
VI-467MeEtMeNHPhCH 2MeHC(═O)Etracemic
VI-468MeEtMeNHPhCH 2MeHC(═O)Et(S)-
VI-469MeEtMeNHPhCH 2HMeC(═O)Etracemic
VI-470MeEtMeNHPhCH 2HMeC(═O)Et(S)-
VI-471MeEtMeNHPhCH 2MeMeC(═O)Etracemic
VI-472MeEtMeNHPhCH 2MeMeC(═O)Et(S)-
VI-473MeMeMeNHPhCH 2HHC(═O)tBuracemic
VI-474MeMeMeNHPhCH 2HHC(═O)tBu(S)-
VI-475MeMeMeNHPhCH 2MeHC(═O)tBuracemic
VI-476MeMeMeNHPhCH 2MeHC(═O)tBu(S)-
VI-477MeMeMeNHPhCH 2HMeC(═O)tBuracemic
VI-478MeMeMeNHPhCH 2HMeC(═O)tBu(S)-
VI-479MeMeMeNHPhCH 2MeMeC(═O)tBuracemic
VI-480MeMeMeNHPhCH 2MeMeC(═O)tBu(S)-
VI-481MeEtMeNHPhCH 2HHC(═O)tBuracemic
VI-482MeEtMeNHPhCH 2HHC(═O)tBu(S)-
VI-483MeEtMeNHPhCH 2MeHC(═O)tBuracemic
VI-484MeEtMeNHPhCH 2MeHC(═O)tBu(S)-
VI-485MeEtMeNHPhCH 2HMeC(═O)tBuracemic
VI-486MeEtMeNHPhCH 2HMeC(═O)tBu(S)-
VI-487MeEtMeNHPhCH 2MeMeC(═O)tBuracemic
VI-488MeEtMeNHPhCH 2MeMeC(═O)tBu(S)-
VI-489MeMeMeNHPhCH 2HHC(═O)OEtracemic
VI-490MeMeMeNHPhCH 2HHC(═O)OEt(S)-
VI-491MeMeMeNHPhCH 2MeHC(═O)OEtracemic
VI-492MeMeMeNHPhCH 2MeHC(═O)OEt(S)-
VI-493MeMeMeNHPhCH 2HMeC(═O)OEtracemic
VI-494MeMeMeNHPhCH 2HMeC(═O)OEt(S)-
VI-495MeMeMeNHPhCH 2MeMeC(═O)OEtracemic
VI-496MeMeMeNHPhCH 2MeMeC(═O)OEt(S)-
VI-497MeEtMeNHPhCH 2HHC(═O)OEtracemic
VI-498MeEtMeNHPhCH 2HHC(═O)OEt(S)-
VI-499MeEtMeNHPhCH 2MeHC(═O)OEtracemic
VI-500MeEtMeNHPhCH 2MeHC(═O)OEt(S)-
VI-501MeEtMeNHPhCH 2HMeC(═O)OEtracemic
VI-502MeEtMeNHPhCH 2HMeC(═O)OEt(S)-
TABLE 161 — (VIc)
Com-Con-
poundfigu-
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7ration
VI-503MeEtMeNHPhCH 2MeMeC(═O)OEtracemic
VI-504MeEtMeNHPhCH 2MeMeC(═O)OEt(S)-
VI-505MeMeMeNHPhCH 2HHC(═O)Ocracemic
Hex
VI-506MeMeMeNHPhCH 2HHC(═O)Oc(S)-
Hex
VI-507MeMeMeNHPhCH 2MeHC(═O)Ocracemic
Hex
VI-508MeMeMeNHPhCH 2MeHC(═O)OcS)-
Hex
VI-509MeMeMeNHPhCH 2HMeC(═O)Ocracemic
Hex
VI-510MeMeMeNHPhCH 2HMeC(═O)Oc(S)-
Hex
VI-511MeMeMeNHPhCH 2MeMeC(═O)Ocracemic
Hex
VI-512MeMeMeNHPhCH 2MeMeC(═O)Oc(S)-
Hex
VI-513MeEtMeNHPhCH 2HHC(═O)Ocracemic
Hex
VI-514MeEtMeNHPhCH 2HHC(═O)Oc(S)-
Hex
VI-515MeEtMeNHPhCH 2MeHC(═O)Ocracemic
Hex
VI-516MeEtMeNHPhCH 2MeHC(═O)Oc(S)-
Hex
VI-517MeEtMeNHPhCH 2HMeC(═O)Ocracemic
Hex
VI-518MeEtMeNHPhCH 2HMeC(═O)Oc(S)-
Hex
VI-519MeEtMeNHPhCH 2MeMeC(═O)Ocracemic
Hex
VI-520MeEtMeNHPhCH 2MeMeC(═O)Oc(S)-
Hex
VI-521MeMeMeCH 2PhCH 2HHMeracemic
VI-522MeMeMeCH 2PhCH 2HHMe(S)-
VI-523MeMeMeCH 2PhCH 2MeHMeracemic
VI-524MeMeMeCH 2PhCH 2MeHMe(S)-
VI-525MeMeMeCH 2PhCH 2HMeMeracemic
VI-526MeMeMeCH 2PhCH 2HMeMe(S)-
VI-527MeMeMeCH 2PhCH 2MeMeMeracemic
VI-528MeMeMeCH 2PhCH 2MeMeMe(S)-
VI-529MeEtMeCH 2PhCH 2HHMeracemic
VI-530MeEtMeCH 2PhCH 2HHMe(S)-
VI-531MeEtMeCH 2PhCH 2MeHMeracemic
VI-532MeEtMeCH 2PhCH 2MeHMe(S)-
VI-533MeEtMeCH 2PhCH 2HMeMeracemic
VI-534MeEtMeCH 2PhCH 2HMeMe(S)-
VI-535MeEtMeCH 2PhCH 2MeMeMeracemic
VI-536MeEtMeCH 2PhCH 2MeMeMe(S)-
VI-537MeMeMeCH 2PhCH 2HHEtracemic
VI-538MeMeMeCH 2PhCH 2HHEt(S)-
VI-539MeMeMeCH 2PhCH 2MeHEtracemic
VI-540MeMeMeCH 2PhCH 2MeHEt(S)-
VI-541MeMeMeCH 2PhCH 2HMeEtracemic
VI-542MeMeMeCH 2PhCH 2HMeEt(S)-
VI-543MeMeMeCH 2PhCH 2MeMeEtracemic
VI-544MeMeMeCH 2PhCH 2MeMeEt(S)-
VI-545MeEtMeCH 2PhCH 2HHEtracemic
VI-546MeEtMeCH 2PhCH 2HHEt(S)-
VI-547MeEtMeCH 2PhCH 2MeHEtracemic
VI-548MeEtMeCH 2PhCH 2MeHEt(S)-
VI-549MeEtMeCH 2PhCH 2HMeEtracemic
VI-550MeEtMeCH 2PhCH 2HMeEt(S)-
VI-551MeEtMeCH 2PhCH 2MeMeEtracemic
VI-552MeEtMeCH 2PhCH 2MeMeEt(S)-
TABLE 162 — (VIc)
Com-Con-
poundfigu-
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7ration
VI-841MeMeMeNHPh(CH 2 ) 2HHMeracemic
VI-842MeMeMeNHPh(CH 2 ) 2HHMe(R)-
VI-843MeMeMeNHPh(CH 2 ) 2MeHMeracemic
VI-844MeMeMeNHPh(CH 2 ) 2MeHMe(R)-
VI-845MeMeMeNHPh(CH 2 ) 2HMeMeracemic
VI-846MeMeMeNHPh(CH 2 ) 2HMeMe(R)-
VI-847MeMeMeNHPh(CH 2 ) 2MeMeMeracemic
VI-848MeMeMeNHPh(CH 2 ) 2MeMeMe(R)-
VI-849MeEtMeNHPh(CH 2 ) 2HHMeracemic
VI-850MeEtMeNHPh(CH 2 ) 2HHMe(R)-
VI-851MeEtMeNHPh(CH 2 ) 2MeHMeracemic
VI-852MeEtMeNHPh(CH 2 ) 2MeHMe(R)-
VI-853MeEtMeNHPh(CH 2 ) 2HMeMeracemic
VI-854MeEtMeNHPh(CH 2 ) 2HMeMe(R)-
VI-855MeEtMeNHPh(CH 2 ) 2MeMeMeracemic
VI-856MeEtMeNHPh(CH 2 ) 2MeMeMe(R)-
VI-857MeMeMeNHPh(CH 2 ) 2HHC(═O)Meracemic
VI-858MeMeMeNHPh(CH 2 ) 2HHC(═O)Me(R)-
VI-859MeMeMeNHPh(CH 2 ) 2MeHC(═O)Meracemic
VI-860MeMeMeNHPh(CH 2 ) 2MeHC(═O)Me(R)-
VI-861MeMeMeNHPh(CH 2 ) 2HMeC(═O)Meracemic
VI-862MeMeMeNHPh(CH 2 ) 2HMeC(═O)Me(R)-
VI-863MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Meracemic
VI-864MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Me(R)-
VI-865MeEtMeNHPh(CH 2 ) 2HHC(═O)Meracemic
VI-866MeEtMeNHPh(CH 2 ) 2HHC(═O)Me(R)-
VI-867MeEtMeNHPh(CH 2 ) 2MeHC(═O)Meracemic
VI-868MeEtMeNHPh(CH 2 ) 2MeHC(═O)Me(R)-
VI-869MeEtMeNHPh(CH 2 ) 2HMeC(═O)Meracemic
VI-870MeEtMeNHPh(CH 2 ) 2HMeC(═O)Me(R)-
VI-871MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Meracemic
VI-872MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Me(R)-
VI-873MeMeMeNHPh(CH 2 ) 2HHC(═O)Etracemic
VI-874MeMeMeNHPh(CH 2 ) 2HHC(═O)Et(R)-
VI-875MeMeMeNHPh(CH 2 ) 2MeHC(═O)Etracemic
VI-876MeMeMeNHPh(CH 2 ) 2MeHC(═O)Et(R)-
VI-877MeMeMeNHPh(CH 2 ) 2HMeC(═O)Etracemic
VI-878MeMeMeNHPh(CH 2 ) 2HMeC(═O)Et(R)-
VI-879MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Etracemic
VI-880MeMeMeNHPh(CH 2 ) 2MeMeC(═O)Et(R)-
VI-881MeEtMeNHPh(CH 2 ) 2HHC(═O)Etracemic
VI-882MeEtMeNHPh(CH 2 ) 2HHC(═O)Et(R)-
VI-883MeEtMeNHPh(CH 2 ) 2MeHC(═O)Etracemic
VI-884MeEtMeNHPh(CH 2 ) 2MeHC(═O)Et(R)-
VI-885MeEtMeNHPh(CH 2 ) 2HMeC(═O)Etracemic
VI-886MeEtMeNHPh(CH 2 ) 2HMeC(═O)Et(R)-
VI-887MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Etracemic
VI-888MeEtMeNHPh(CH 2 ) 2MeMeC(═O)Et(R)-
VI-889MeMeMe—Ph—HHMeracemic
VI-890MeMeMe—Ph—HHMe(R)-
TABLE 163 — (VIc) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7figuration
VI-891MeMeMe—Ph—MeHMeracemic
VI-892MeMeMe—Ph—MeHMe(R)-
VI-893MeMeMe—Ph—HMeMeracemic
VI-894MeMeMe—Ph—HMeMe(R)-
VI-895MeMeMe—Ph—MeMeMeracemic
VI-896MeMeMe—Ph—MeMeMe(R)-
VI-897MeEtMe—Ph—HHMeracemic
VI-898MeEtMe—Ph—HHMe(R)-
VI-899MeEtMe—Ph—MeHMeracemic
VI-900MeEtMe—Ph—MeHMe(R)-
VI-901MeEtMe—Ph—HMeMeracemic
VI-902MeEtMe—Ph—HMeMe(R)-
VI-903MeEtMe—Ph—MeMeMeracemic
VI-904MeEtMe—Ph—MeMeMe(R)-
VI-905MeMeMe—Ph—HHC(═O)Meracemic
VI-906MeMeMe—Ph—HHC(═O)Me(R)-
VI-907MeMeMe—Ph—MeHC(═O)Meracemic
VI-908MeMeMe—Ph—MeHC(═O)Me(R)-
VI-909MeMeMe—Ph—HMeC(═O)Meracemic
VI-910MeMeMe—Ph—HMeC(═O)Me(R)-
VI-911MeMeMe—Ph—MeMeC(═O)Meracemic
VI-912MeMeMe—Ph—MeMeC(═O)Me(R)-
VI-913MeEtMe—Ph—HHC(═O)Meracemic
VI-914MeEtMe—Ph—HHC(═O)Me(R)-
VI-915MeEtMe—Ph—MeHC(═O)Meracemic
VI-916MeEtMe—Ph—MeHC(═O)Me(R)-
VI-917MeEtMe—Ph—HMeC(═O)Meracemic
VI-918MeEtMe—Ph—HMeC(═O)Me(R)-
VI-919MeEtMe—Ph—MeMeC(═O)Meracemic
VI-920MeEtMe—Ph—MeMeC(═O)Me(R)-
VI-921MeMeMe—Ph—HHC(═O)Etracemic
VI-922MeMeMe—Ph—HHC(═O)Et(R)-
VI-923MeMeMe—Ph—MeHC(═O)Etracemic
VI-924MeMeMe—Ph—MeHC(═O)Et(R)-
VI-925MeMeMe—Ph—HMeC(═O)Etracemic
VI-926MeMeMe—Ph—HMeC(═O)Et(R)-
VI-927MeMeMe—Ph—MeMeC(═O)Etracemic
VI-928MeMeMe—Ph—MeMeC(═O)Et(R)-
VI-929MeEtMe—Ph—HHC(═O)Etracemic
VI-930MeEtMe—Ph—HHC(═O)Et(R)-
VI-931MeEtMe—Ph—MeHC(═O)Etracemic
VI-932MeEtMe—Ph—MeHC(═O)Et(R)-
VI-933MeEtMe—Ph—HMeC(═O)Etracemic
VI-934MeEtMe—Ph—HMeC(═O)Et(R)-
VI-935MeEtMe—Ph—MeMeC(═O)Etracemic
VI-936MeEtMe—Ph—MeMeC(═O)Et(R)-
VI-937MeMeMe—PhCH 2HHMeracemic
VI-938MeMeMe—PhCH 2HHMe(S)-
VI-939MeMeMe—PhCH 2MeHMeracemic
VI-940MeMeMe—PhCH 2MeHMe(S)-
TABLE 164 — (VIc) Com-
poundCon-
No.R 1R 2R 3L 2R 4L 3R 8R 9R 7figuration
VI-941MeMeMe—PhCH 2HMeMeracemic
VI-942MeMeMe—PhCH 2HMeMe(S)-
VI-943MeMeMe—PhCH 2MeMeMeracemic
VI-944MeMeMe—PhCH 2MeMeMe(S)-
VI-945MeEtMe—PhCH 2HHMeracemic
VI-946MeEtMe—PhCH 2HHMe(S)-
VI-947MeEtMe—PhCH 2MeHMeracemic
VI-948MeEtMe—PhCH 2MeHMe(S)-
VI-949MeEtMe—PhCH 2HMeMeracemic
VI-950MeEtMe—PhCH 2HMeMe(S)-
VI-951MeEtMe—PhCH 2MeMeMeracemic
VI-952MeEtMe—PhCH 2MeMeMe(S)-
VI-953MeMeMe—PhCH 2HHC(═O)Meracemic
VI-954MeMeMe—PhCH 2HHC(═O)Me(S)-
VI-955MeMeMe—PhCH 2MeHC(═O)Meracemic
VI-956MeMeMe—PhCH 2MeHC(═O)Me(S)-
VI-957MeMeMe—PhCH 2HMeC(═O)Meracemic
VI-958MeMeMe—PhCH 2HMeC(═O)Me(S)-
VI-959MeMeMe—PhCH 2MeMeC(═O)Meracemic
VI-960MeMeMe—PhCH 2MeMeC(═O)Me(S)-
VI-961MeEtMe—PhCH 2HHC(═O)Meracemic
VI-962MeEtMe—PhCH 2HHC(═O)Me(S)-
VI-963MeEtMe—PhCH 2MeHC(═O)Meracemic
VI-964MeEtMe—PhCH 2MeHC(═O)Me(S)-
VI-965MeEtMe—PhCH 2HMeC(═O)Meracemic
VI-966MeEtMe—PhCH 2HMeC(═O)Me(S)-
VI-967MeEtMe—PhCH 2MeMeC(═O)Meracemic
VI-968MeEtMe—PhCH 2MeMeC(═O)Me(S)-
VI-969MeMeMe—PhCH 2HHC(═O)Etracemic
VI-970MeMeMe—PhCH 2HHC(═O)Et(S)-
VI-971MeMeMe—PhCH 2MeHC(═O)Etracemic
VI-972MeMeMe—PhCH 2MeHC(═O)Et(S)-
VI-973MeMeMe—PhCH 2HMeC(═O)Etracemic
VI-974MeMeMe—PhCH 2HMeC(═O)Et(S)-
VI-975MeMeMe—PhCH 2MeMeC(═O)Etracemic
VI-976MeMeMe—PhCH 2MeMeC(═O)Et(S)-
VI-977MeEtMe—PhCH 2HHC(═O)Etracemic
VI-978MeEtMe—PhCH 2HHC(═O)Et(S)-
VI-979MeEtMe—PhCH 2MeHC(═O)Etracemic
VI-980MeEtMe—PhCH 2MeHC(═O)Et(S)-
VI-981MeEtMe—PhCH 2HMeC(═O)Etracemic
VI-982MeEtMe—PhCH 2HMeC(═O)Et(S)-
VI-983MeEtMe—PhCH 2MeMeC(═O)Etracemic
VI-984MeEtMe—PhCH 2MeMeC(═O)Et(S)-
description truncated at 500,000 characters. 1 of 153 part labels are ours — the grant heads the rest
Stored text is truncated at the source; the tail of the description is not held.

Claims as granted

1 claim

Log in to read the claims of this application.

Log in to unlock

Classifications

3 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K31/695
Section C — Chemistry; metallurgy
  • C07F7/10
  • C07D487/04

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomOct 2018Jan 2019Apr 2019Jul 2019Oct 2019Jan 2020Apr 2020Jul 2020Oct 2020Jan 2021Apr 2021USPTOApplicantRestriction requirementNon-final rejectionResponse after non-finalFinal rejectionResponse after final
USPTOApplicanthover for detail · click to open
Pendency
2.4 y
889 days filing → grant
Office actions
2
after a restriction
Responses
2
no RCE
Interviews
1
examiner interview summaries
Examiner
Amanda L. Aguirre
art unit 1626 · TC 1600
Citations: 56 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom20242026202820302032203420362038Owner 1
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock